Source file signed link, expires in 15 minutes
Extracted text 286
Page 1
Page 2
2 Tema
Theme
Engage to Perform
“Engage to Perform” merefleksikan komitmen PT PT Bundamedik Tbk’s (BMHS or the Company)
Bundamedik Tbk (BMHS atau Perseroan) untuk commitment to continuously strengthening
terus memperkuat keterlibatan (engagement) engagement across all elements of the healthcare
seluruh elemen dalam ekosistem layanan kesehatan ecosystem in order to deliver superior and
guna menghadirkan kinerja yang unggul dan sustainable performance. BMHS believes that true
berkelanjutan. BMHS meyakini bahwa performa performance excellence is measured not solely by
terbaik tidak hanya diukur dari capaian finansial, financial achievements, but also by service quality,
tetapi dari kualitas layanan, inovasi berkelanjutan, continuous innovation, and the trust built with
serta kepercayaan yang terbangun dengan pasien, patients, medical professionals, partners, and other
tenaga medis, mitra, dan pemangku kepentingan stakeholders.
lainnya.
Sepanjang 2025, BMHS memperkuat sinergi Center Throughout 2025, BMHS will strengthen the
of Excellence (CoE) sebagai fondasi layanan kesehatan synergy the Center of Excellence (CoE) as the
terintegrasi di setiap fase kehidupan. BMHS juga foundation of integrated healthcare services across
memperluas akses layanan melalui peluncuran every stage of life. BMHS is also expanding access
Bunda Homecare memanfaatkan kendaraan listrik to services through the launch of Bunda Homecare,
yang mendukung efisiensi sekaligus menekan emisi, which utilizes electric vehicles to enhance efficiency
serta kehadiran Bunda Clinic MRT Dukuh Atas while reducing emissions, as well as the opening
sebagai klinik pertama di pusat transportasi publik. of Bunda Clinic MRT Dukuh Atas as the first
Kedua layanan ini mendukung peningkatan akses Clinic in a public transportation hub. These two
layanan kesehatan, serta peningkatan layanan services support improved access to healthcare,
vaksinasi dan wellness. Di sisi kapabilitas klinis, as well as enhanced vaccination and wellness
BMHS terus meningkatkan kapasitas dan kualitas services. On the clinical capabilities front, BMHS
layanan melalui penguatan fasilitas NICU dengan continues to improve service capacity and quality
program Family Integrated CARE (FICARE), penerapan by strengthening NICU facilities through the Family
teknologi Preimplantation Genetic Screening (PGS) Integrated CARE (FICARE) program, implementing
dan Time Lapse Embryo Monitoring di Morula IVF Preimplantation Genetic Screening (PGS) and Time
Indonesia, pengembangan layanan transplantasi Lapse Embryo Monitoring at Morula IVF Indonesia,
ginjal, serta implementasi operasi minimal invasif the development of kidney transplant services, and
berbasis robotic surgery system. Sejak 2012, BMHS the implementation of minimally invasive surgeries
juga berperan sebagai pionir dalam pengembangan using robotic surgery systems. Since 2012, BMHS
bedah robotik, termasuk memperkenalkan robotic has also served as a pioneer in the development of
skin sparing mastectomy pertama di Asia Tenggara robotic surgery, including the introduction of the
pada 2025. first robotic skin sparing mastectomy in Southeast
Asia in 2025.
Keterlibatan juga diwujudkan melalui transformasi Engagement is further demonstrated through digital
digital berbasis OneBunda, yang menyempurnakan transformation initiatives driven by OneBunda,
patient journey secara menyeluruh, serta penguatan which enhance and integrate the overall patient
kompetensi tenaga medis dan keperawatan melalui journey, alongside structured and continuous
program pelatihan yang terstruktur. Dengan competency development programs for medical and
membangun budaya kolaboratif dan berorientasi nursing professionals. By fostering a collaborative,
mutu, BMHS memastikan setiap insan organisasi quality-driven culture, BMHS ensures that every
berkontribusi optimal dalam memberikan layanan individual within the organization contributes
terbaik. PT Bundamedik Tbk menegaskan perannya optimally to delivering excellent healthcare services.
sebagai mitra kesehatan terpercaya yang tidak hanya Through this commitment, PT Bundamedik Tbk
merawat kehidupan hari ini, tetapi juga membangun reaffirms its role as a trusted healthcare partner—
fondasi layanan kesehatan yang adaptif, inovatif, dan one that not only cares for lives today but also builds
berkelanjutan untuk masa depan, sejalan dengan an adaptive, innovative, and sustainable healthcare
semangat Engange to Perform. foundation for the future, in line with the spirit of
Engage to Perform.
Page 3
Kesinambungan Tema | Theme Continuity
Laporan Tahunan
Annual Report 3
2024 2023
PT Bundamedik Tbk hadir sebagai solusi layanan Memasuki usia ke-50 tahun, PT Bundamedik Tbk
kesehatan yang menyeluruh dengan fokus pada telah bertransformasi dalam memajukan ekosistem
kesejahteraan fisik, mental, dan sosial seluruh layanan kesehatan yang unggul, yang berorientasi
anggota keluarga. Dengan pendekatan holistik, kami pada pemenuhan kebutuhan dan kepuasan pelanggan.
mendampingi setiap anggota keluarga dalam tiap tahap Secara progresif, BMHS terus bertumbuh dan
kehidupan, mulai dari calon bayi, ibu, anak, dewasa, beradaptasi untuk memberikan layanan kesehatan
hingga lanjut usia. PT Bundamedik Tbk memperkuat berkualitas, yang didukung pengalaman, keahlian,
pendekatan ini dengan meningkatkan pelayanan dan kepedulian setiap personelnya. Dengan semangat
untuk kenyamanan pasien melalui optimalisasi layanan compassion, competence, collaboration, create innovation,
kesehatan, inovasi digital, serta fasilitas kesehatan dan change agility, BMHS berupaya memberikan
yang unggul dan terintegrasi. Berpusat pada pasien, layanan kesehatan terintegrasi, yang memperhatikan
setiap individu adalah bagian dari keluarga kami. keseimbangan lingkungan, sosial, dan tata kelola untuk
Bersama kami menciptakan keluarga yang sehat mewujudkan pertumbuhan bisnis yang berkelanjutan.
untuk terus tumbuh dan berkembang di seluruh aspek
kehidupan.
PT Bundamedik Tbk provides comprehensive health Entering its 50th year, PT Bundamedik Tbk has
service solutions with a focus on the physical, mental, transformed in advancing an excellent healthcare
and social well-being of all family members. By following ecosystem, oriented towards meeting customer needs
a holistic approach, we accompany you at every stage and satisfaction. Progressively, BMHS continues to
of your life, from embryo, mothers, children, adults, to grow and adapt to provide quality healthcare services,
elderly. PT Bundamedik Tbk strengthens this approach supported by the experience, expertise, and care of
by increasing patient comfort through optimizing each of its personnel. With the spirit of compassion,
health services, digital innovation, and superior and competence, collaboration, create innovation, and
integrated health services and facilities. Patient- change agility, BMHS strives to provide integrated
centered means we treat each individual as part of our health services, which pay attention to environmental,
family so that a shared well-being can be created for social and governance balance to realize sustainable
healthy families to continue to grow and develop in all business growth.
aspects of their lives.
Pernyataan | Disclaimer
PT Bundamedik Tbk menyampaikan Laporan Tahunan 2025 yang menggambarkan tujuan, rencana, strategi, kebijakan, serta kinerja
Perseroan. Seluruh data dan informasi telah melalui proses verifikasi untuk menjamin keakuratan penyajiannya. Meski demikian,
laporan ini juga memuat pernyataan yang bersifat forward-looking statement, yang berisi target, prospek, proyeksi, serta ekspektasi
atas kinerja operasional dan kondisi usaha di masa mendatang. Pernyataan tersebut memiliki risiko dan ketidakpastian, sehingga
hasil aktual dapat berbeda secara material dari yang diproyeksikan. Oleh karena itu, Perseroan tidak dapat menjamin bahwa segala
langkah yang disampaikan dalam laporan ini akan menghasilkan capaian sesuai harapan.
PT Bundamedik Tbk would like to present its 2025 Annual Report, which outlines the Company’s objectives, plans, strategies,
policies, and performance. All data and information disclosed in this report has undergone a verification process to ensure its
accuracy. This report also contains forward-looking statements, including targets, prospects, projections, and expectations regarding
future operational performance and business conditions. These statements are subject to risks and uncertainties, and actual results
may differ materially from those projected. Therefore, the Company cannot guarantee that the initiatives and actions described in
this report will achieve the expected outcomes.
Page 4
4 Ikhtisar Kinerja
Performance Highlights
Daftar Isi
Table of Contents Profil Dewan Komisaris
50
Board of Commissioners Profiles
Profil Direksi
Board of Directors Profiles
58
Sumber Daya Manusia
Human Capital
62
Kilas Kinerja
Performance Overview
6 Manajemen Mutu
Quality Management
68
Ikhtisar Kinerja Keuangan
Financial Performance Highlights
6 Komposisi Pemegang Saham
Shareholders Composition
68
Ikhtisar Kinerja Operasional
Operational Performance Highlights
8 Informasi Pemegang Saham Utama dan
Pengendali
Informasi Saham Information on Majority and Controlling
69
Shares Information
8 Shareholders
Aksi Korporasi Struktur Grup
Corporate Action
9 Group Structure
70
Penghentian Sementara Perdagangan Saham Entitas Anak dan Perusahaan Asosiasi
dan/atau Penghapusan Pencatatan Saham Subsidiaries and Associated Companies
71
Temporary Suspension of Stock Trading/
9
Shares Delisting Kronologi Pencatatan Saham dan Efek
Lainnya
Peristiwa Penting Chronology of Share and Other Securities
72
Significant Event
10 Listing
Penghargaan Kantor Akuntan Publik
Awards
13 Public Accounting Firm
73
Sertifikasi Lembaga Profesi Penunjang Pasar Modal
14
Certifications Capital Market Supporting Professional 73
Institutions
Laporan Manajemen
Management Report
17 Analisis dan Pembahasan
Manajemen
Laporan Dewan Komisaris
17 Management Discussion and
74
Board of Commissioners Report
Laporan Direksi Analysis
Board of Directors Report
22
Tinjauan Perekonomian
Economic Overview
75
Profil Perusahaan
Company Profile
28 Tinjauan Sektor Kesehatan
Health Sector Overview
76
Identitas Perusahaan
28 Tinjauan Operasi per Segmen Usaha
Company Identity
Operational Overview per Business Segment
78
Sekilas Perusahaan
28 Kinerja Keuangan
Company Overview
Financial Performance
83
Jejak Langkah
Milestones
32 Laporan Laba Rugi dan Penghasilan
Komprehensif Lain
Visi, Misi, dan Nilai Perusahaan Statement of Profit and Loss and Other
85
Vision, Mission and Values of the Company
34 Comprehensive Income
Kegiatan Usaha Kemampuan Membayar Utang
Business Activities
36 Solvency
87
Layanan Kesehatan Struktur Modal
Healthcare Services
36 Capital Structure
88
Pusat Keunggulan Ikatan yang Material untuk Investasi Barang
Center of Excellence
39 Modal
Material Commitments for Capital Goods
89
Wilayah Operasional Investment
Operational Area
45
Investasi Barang Modal yang Direalisasikan
Daftar Rumah Sakit, Klinik, dan Laboratorium pada Tahun Buku Terakhir
List of Hospitals, Clinics, and Laboratories
46 89
Capital Goods Investment Realized in the Last
Struktur Organisasi Fiscal Year
Organizational Structure
48
Informasi dan Fakta Material Setelah Tanggal
Keanggotaan Asosiasi Laporan Akuntan
49 Material Information and Facts Occurring
90
Membership in Associations
After the Date of the Accountant’s Report
Page 5
Laporan Tahunan
Annual Report 5
Prospek Usaha Sistem Pengendalian Internal
Business Prospects
90 Internal Control System
148
Target dan Realisasi 2025 Sistem Manajemen Risiko
Targets and Realization in 2025
91 Risk Management System
149
Proyeksi 2026 Perkara Hukum, Sanksi Administratif, dan
2026 Projection
92 Finansial
Legal Cases, Administrative and Financial
154
Aspek Pemasaran Sanctions
Marketing Aspects
93
Kode Etik
Kebijakan Dividen Code of Ethics
156
Dividend Policy
95
Program Kepemilikan Saham oleh Karyawan
Realisasi Penggunaan Dana Hasil Penawaran dan/atau Manajemen
Umum 96 Employees and/or Management Share
157
Realized Use of Public Offering Funds Ownership Program
Informasi Material Mengenai Investasi, Kebijakan Pengungkapan Kepemilikan Saham
Ekspansi, Divestasi, Penggabungan/ Perusahaan oleh Dewan Komisaris dan/atau
Peleburan Usaha, Akuisisi, Restrukturisasi Direksi 158
Utang/Modal, Transaksi Afiliasi, yang Memiliki Board of Commissioners and/or Board of
Benturan Kepentingan Directors Share Ownership Disclosure Policy
Material Information Regarding Investments,
96
Expansion, Divestment, Business Merger/ Sistem Pelaporan Pelanggaran
Consolidation, Acquisition, Debt/Capital Whistleblowing System
159
Restructuring, Affiliated Transactions with
Conflicts of Interest Kebijakan Antikorupsi
Anti-Corruption Policy
161
Perubahan Peraturan Perundang-Undangan
pada Tahun Buku Penerapan Pedoman Tata Kelola Perusahaan
Changes in Laws and Regulations during the
97 Terbuka
Implementation of Public Company
162
Financial Year
Governance Guidelines
Perubahan Kebijakan Akuntansi
Changes in Accounting Policies
98 Penerapan Pedoman Umum Governansi
Korporat Indonesia (PUGKI) 2021
Governansi Korporat Implementation of the 2021 General 165
Corporate Governance
100 Guidelines for Indonesian Corporate
Governance (PUGKI)
Governansi Korporat yang Baik
Good Corporate Governance
101 Tanggung Jawab Sosial dan
Rapat Umum Pemegang Saham (RUPS)
Lingkungan 166
General Meeting of Shareholders (GMS)
104 Corporate Social Responsibility
Dewan Komisaris
109
Surat Pernyataan Anggota Dewan
The Board of Commissioners
Komisaris dan Direksi tentang
Direksi
115 Tanggung Jawab atas Laporan
The Board of Directors
Tahunan 2025 PT Bundamedik Tbk
Nominasi dan Remunerasi Direksi dan Dewan
Komisaris
Statement Letter of the Board 168
Board of Commissioners and Board of
121 of Commissioners and Board of
Directors Nomination and Remuneration Directors regarding Responsibility
Hubungan Afiliasi (Dewan Komisaris, Direksi, for the PT Bundamedik Tbk 2025
dan Pemegang Saham)
Annual Report
Affiliated Relationships (Board of 122
Commissioners, Board of Directors and Referensi SEOJK 16/
Shareholders)
SEOJK.04/2021 tentang Bentuk
Komite Audit
Audit Committee
123 dan Isi Laporan Tahunan Emiten
atau Perusahaan Publik
Komite Nominasi dan Remunerasi
130 Reference to SEOJK 16/
170
Nomination and Remuneration Committee
SEOJK.04/2021 regarding the Form
Komite GCG dan Manajemen Risiko
GCG and Risk Management Committee
135 and Content of the Annual Report of
Sekretaris Perusahaan Issuers or Public Companies
Corporate Secretary
140
Laporan Keuangan
Unit Internal Audit Financial Statements
185
Internal Audit Unit
143
Page 6
6 Kilas Kinerja
Performance Overview
Kilas Kinerja
Performance Overview
Ikhtisar Kinerja Keuangan dalam Rupiah penuh, kecuali dinyatakan lain
Financial Performance Highlights in Rupiah, unless stated otherwise
Keterangan 2025 2024 2023 Description
Laporan Laba Rugi dan Penghasilan Komprehensif Lain | Statement of Profit or Loss and Other Comprehensive Income
Pendapatan 1.614.340.771.512 1.554.685.010.336 1.488.197.483.371 Revenue
Laba Kotor 744.492.466.110 707.137.015.492 695.812.877.111 Gross Profit
Laba Tahun Berjalan 29.673.142.533 18.895.784.267 16.229.428.848 Profit for the Year
Total Profit for the Year
Jumlah Laba Tahun Berjalan yang Dapat Diatribusikan kepada:
Attributable to:
- Pemilik Entitas Induk 12.418.961.321 11.943.515.324 7.461.134.368 - Owner of the Parent Entity
- Kepentingan
17.254.181.212 6.952.268.943 8.768.294.480 - Non-controlling Interest
Nonpengendali
Laba Komprehensif Tahun Comprehensive Profit for
262.811.720.441 14.863.779.224 17.310.835.203
Berjalan the Year
Total Comprehensive Profit
Jumlah Laba Komprehensif yang Dapat Diatribusikan kepada:
Attributable to:
- Pemilik Entitas Induk 242.065.731.168 9.192.171.847 8.951.231.339 - Owner of the Parent Entity
- Kepentingan
20.745.989.273 5.671.607.377 8.359.603.864 - Non-controlling Interest
Nonpengendali
Laba Per Saham Dasar dari Basic Earnings Per Share
Laba Tahun Berjalan yang of Profit for the Year
1,4 1,4 0,9
Dapat Diatribusikan kepada Attributable to Owner of the
Pemilik Entitas Induk Parent Entity
Laporan Posisi Keuangan | Statement of Financial Position
Jumlah Aset 4.016.429.435.143 3.446.360.903.748 3.083.162.034.448 Total Assets
Jumlah Liabilitas 1.621.922.418.632 1.298.625.219.027 1.283.126.125.996 Total Liabilities
Jumlah Ekuitas 2.394.507.016.511 2.147.735.684.721 1.800.035.908.452 Total Equity
Rasio Keuangan (%) | Financial Ratios (%)
Rasio Laba terhadap Aset 0,7 0,5 0,5 Return on Assets
Rasio Laba terhadap Ekuitas 1,2 0,9 0,9 Return on Equity
Rasio Laba terhadap Penjualan
1,8 1,2 1,1 Profit to Net Sales Ratio
Bersih
Rasio Lancar 162,2 191,6 152,6 Current Ratio
Rasio Liabilitas terhadap
67,7 60,5 71,3 Liabilities to Equity Ratio
Ekuitas
Rasio Liabilitas terhadap Liabilities to Total Assets
40,4 37,7 41,6
Jumlah Aset Ratio
Laporan Arus Kas | Statement of Cash Flow
Arus Kas Bersih Diperoleh dari Net Cash Flow Provided by
250.621.859.694 33.979.487.371 51.438.728.484
Aktivitas Operasi Operating Activities
Arus Kas Bersih Digunakan Net Cash Flow Used in
(217.412.095.335) (245.291.393.404) (212.221.540.575)
untuk Aktivitas Investasi Investing Activities
Arus Kas Bersih Diperoleh dari Net Cash Flow Provided by
10.042.921.475 372.585.952.682 153.563.150.624
Aktivitas Pendanaan Financing Activities
Cash and Cash Equivalents
Kas dan Setara Kas Awal Tahun 783.332.056.074 622.058.009.425 629.277.670.892
at the Beginning of the Year
Kas dan Setara Kas Akhir Cash and Cash Equivalents
826.584.741.908 783.332.056.074 622.058.009.425
Tahun at the End of the Year
Page 7
Laporan Tahunan
Annual Report 7
Pendapatan | Revenue Jumlah Aset | Total Assets
dalam miliar rupiah | in billion Rupiah dalam miliar rupiah | in billion Rupiah
4.016,43
3.446,36
3.083,16
1.614,34
1.554,68
1.488,20
2025 2024 2023 2025 2024 2023
Laba Tahun Berjalan Laba Komprehensif Tahun Berjalan
Profit of the Year Comprehensive Income for the Year
dalam miliar rupiah | in billion Rupiah dalam miliar rupiah | in billion Rupiah
262,81
29,67
18,90
17,31
16,23
14,86
2025 2024 2023 2025 2024 2023
Page 8
8 Kilas Kinerja
Performance Overview
Ikhtisar Kinerja Operasional | Operational Performance Highlights
Rawat Jalan | Outpatient Rawat Inap | Inpatient
606.814 619.010 570.828 47.778 47.011 42.500
2025 2024 2023 2025 2024 2023
Informasi Saham
Shares Information
Sejak 6 Juli 2021, PT Bundamedik Tbk mencatatkan Since 6 July 2021, PT Bundamedik Tbk has been listed
sahamnya pada Bursa Efek Indonesia (BEI) dengan kode on the Indonesia Stock Exchange (IDX) under the stock
saham BMHS. Berikut informasi kinerja saham BMHS code BMHS. The following shows quarterly information
triwulanan tahun 2024-2025: on BMHS share performance for the period 2024–
2025:
Tertinggi Penutup Volume Jumlah Saham Kapitalisasi Pasar
Terendah
Triwulan (Rp) (Rp) Transaksi Beredar (Rp)
(Rp)
Quarterly Highest Closing Transaction Number of Shares Market
Lowest (IDR)
(IDR) (IDR) Volume Outstanding Capitalization (IDR)
2025
I 274 206 228 81.138.000 8.603.416.176 1.961.578.888.128
II 252 197 206 78.898.400 8.603.416.176 1.772.303.732.256
III 208 162 168 268.328.900 8.603.416.176 1.445.373.917.568
IV 238 143 190 1.156.521.800 8.603.416.176 1.634.649.073.440
2024
I 360 298 346 51.990.100 8.603.416.176 2.976.781.996.896
II 350 240 350 32.622.300 8.603.416.176 3.011.195.661.600
III 318 272 300 111.452.000 8.603.416.176 2.581.024.852.800
IV 292 236 290 100.660.300 8.603.416.176 2.494.990.691.040
Page 9
Laporan Tahunan
Annual Report 9
Grafik Pergerakan Harga Saham dan Volume Perdagangan Saham
Share Price Movement and Share Trading Volume
Aksi Korporasi Corporate Action
Selama 2025, BMHS melakukan aksi korporasi berupa In 2025, BMHS carried out a corporate action during the
pembagian dividen, pelaksanaan Management and year comprised dividend distributions, the Management
Employee Stock Option Program (MESOP), dan and Employee Stock Option Program (MESOP), and the
pengambilalihan saham pada entitas anak. Seluruh acquisition of shares in subsidiaries. Comprehensive
informasi mengenai aksi korporasi tersebut disajikan information on these corporate actions is disclosed
pada Bab Analisis dan Pembahasan Manajemen serta in the Management’s Discussion and Analysis and
Governansi Korporat dalam Laporan Tahunan ini. Corporate Governance sections of this Annual Report.
Penghentian Sementara Perdagangan Saham dan/ Temporary Suspension of Stock Trading/Shares
atau Pembatalan Pencatatan Saham Delisting
Selama 2025, BMHS tidak mendapatkan sanksi During 2025, BMHS did not receive any sanctions in
penghentian sementara perdagangan saham maupun the form of temporary suspension of share trading or
penghapusan pencatatan saham di BEI. delisting on the Indonesia Stock Exchange.
Page 10
10 Kilas Kinerja
Performance Overview
Peristiwa Penting | Significant Event
Januari | January
Penandatanganan Nota Kesepahaman dengan Institut Pertanian Bogor untuk bekerja sama di bidang pendidikan,
15th penelitian, dan pengabdian masyarakat dengan fokus memperkuat pengembangan sumber daya manusia (SDM), riset biomedis,
serta program kesehatan berbasis kolaborasi akademik.
Signing of a Memorandum of Understanding with Institut Pertanian Bogor to collaborate in the fields of education, research, and
community service, with a focus on strengthening human capital development, biomedical research, and collaborative academic-
based health programs.
Pelaksanaan Corporate Social Responsibility (CSR) Perseroan yaitu pemberian donasi berupa makanan, popok, perlengkapan
23th anak, obat, dan alat kesehatan hingga perlengkapan ibadah kepada kurang lebih 1.800 orang atau sekitar 600 Kepala Keluarga
yang merupakan korban kebakaran di Gempol, Jakarta Pusat.
The Company’s CSR activities involved providing donations in the form of food, diapers, children’s supplies, medicines, medical
equipment, and worship items to approximately 1,800 individuals, or around 600 households, who were affected by a fire in
Gempol, Central Jakarta.
Februari | February
Pelaksanaan CSR Perseroan berupa pemberian vaksin influenza gratis dan pemeriksaan kesehatan dasar kepada lebih dari 60
5th pekerja rentan di kawasan Marunda bersama RSU Citra Harapan.
The Company’s CSR activities, included the provision of free influenza vaccinations and basic health check-ups for more than 60
vulnerable workers in the Marunda area in collaboration with Citra Harapan Hospital.
Pelaksanaan CSR Perseroan berupa pemberian edukasi dan pemeriksaan USG gratis kepada Komunitas Ibu di Ciputat bersama
21th RSIA Bunda Ciputat.
The Company’s CSR activities, included the provision of education and free ultrasound (USG) examinations for a community of
mothers in Ciputat in collaboration with Bunda Ciputat Women and Children Hospital.
Maret | March
HUT BMHS ke-52.
27th BMHS’s 52nd anniversary.
April
Pelaksanaan CSR Perseroan berupa edukasi deteksi dini kanker serviks dan pemeriksaan HPV-DNA untuk komunitas Ibu di
10th Ciputat bersama RSIA Bunda Ciputat.
The Company’s CSR activities, included education on early detection of cervical cancer and HPV-DNA screening for a community
of mothers in Ciputat in collaboration with Bunda Ciputat Women and Children Hospital.
Peresmian Bunda Executive Clinic di RSU Bunda Padang.
25th Inaugurating the Bunda Executive Clinic at Bunda Padang Hospital.
Pelaksanaan CSR Perseroan berupa khitanan massal untuk anak-anak, serta edukasi deteksi dini kanker serviks dan pemeriksaan
26th HPV-DNA bagi Komunitas Ibu di RSU Bunda Padang.
The Company’s CSR implementation in the form of a mass circumcision program for children, along with education on early
detection of cervical cancer and HPV-DNA screening for the Mothers’ Community at Bunda Padang Hospital.
Pelaksanaan CSR Perseroan berupa khitanan massal untuk anak-anak di RSIA Bunda Jakarta.
27th The Company’s CSR implementation in the form of a mass circumcision program for children at Bunda Jakarta Women and
Children Hospital.
Mei | May
Pelaksanaan CSR Perseroan berupa khitanan massal untuk anak-anak di RSU Bunda Jakarta.
3rd The Company’s CSR implementation in the form of a mass circumcision program for children at Bunda Jakarta Hospital.
Page 11
Laporan Tahunan
Annual Report 11
Pelaksanaan CSR Perseroan berupa khitanan massal untuk anak-anak, serta edukasi deteksi dini kanker serviks dan pemeriksaan
4th HPV-DNA bagi Komunitas Ibu di RSU Bunda Margonda.
The Company’s CSR implementation in the form of a mass circumcision program for children, along with education on early
detection of cervical cancer and HPV-DNA screening for the Mothers’ Community at Bunda Margonda Hospital.
Pelaksanaan CSR Perseroan berupa edukasi deteksi dini kanker serviks dan pemeriksaan HPV-DNA bagi Komunitas Ibu di RSIA
5th Az Zahra Palembang.
The Company’s CSR implementation in the form of education on early detection of cervical cancer and HPV-DNA screening for
the Mothers’ Community at Az Zahra Palembang Women and Children Hospital.
Pelaksanaan CSR Perseroan berupa edukasi deteksi dini kanker serviks dan pemeriksaan HPV-DNA bagi Komunitas Ibu di RSU
6th Citra Harapan.
The Company’s CSR implementation in the form of education on early detection of cervical cancer and HPV-DNA screening for
the Mothers’ Community at Citra Harapan Hospital.
Pelaksanaan CSR Perseroan berupa khitanan massal untuk anak-anak di RSU Citra Harapan.
8th The Company’s CSR implementation in the form of a mass circumcision program for children at Citra Harapan Hospitaly.
Pelaksanaan CSR Perseroan berupa edukasi deteksi dini kanker serviks dan pemeriksaan HPV-DNA bagi Komunitas Ibu di RSIA
9th Bunda Denpasar.
The Company’s CSR implementation in the form of education on early detection of cervical cancer and HPV-DNA screening for
the Mothers’ Community at Bunda Denpasar Women and Children Hospital.
Pelaksanaan Rapat Umum Pemegang Saham Tahunan (RUPST) PT Bundamedik Tbk Tahun Buku 2024.
15th Annual General Meeting of Shareholders (AGMS) of PT Bundamedik Tbk for the 2024 financial year.
Pelaksanaan CSR Perseroan berupa edukasi deteksi dini kanker serviks dan pemeriksaan HPV-DNA bagi Komunitas Perempuan
18th di RSIA Bunda Jakarta dan RSU Bunda Jakarta.
The Company’s CSR implementation in the form of education on early detection of cervical cancer and HPV-DNA screening for
the Women’s Community at Bunda Jakarta Women and Children Hospital and Bunda Jakarta Hospital.
Pelaksanaan Health Convention & Expo (HealthConEx) 2025, termasuk simposium dan seminar kesehatan serta peluncuran
24th Bunda Homecare.
Holding of the Health Convention & Expo (HealthConEx) 2025, including health symposiums and seminars, as well as the official
launch of Bunda Homecare.
Pelaksanaan CSR Perseroan berupa edukasi dan pemeriksaan kesehatan bagi anak usia TK dan SD dari 45 sekolah di wilayah
28th Depok.
The Company’s CSR implementation in the form of health education and health screenings for kindergarten and elementary
school children from 45 schools in the Depok area.
Juni | June
Pelaksanaan CSR Perseroan berupa pemeriksaan kesehatan gratis bagi masyarakat Jakarta di Rusunawa Rawa Bebek dalam
20th rangka HUT ke-498 Kota Jakarta.
The Company’s CSR implementation in the form of free health screenings for the Jakarta community at Rusunawa Rawa Bebek in
celebration of the 498th Anniversary of the City of Jakarta.
Pelaksanaan CSR Perseroan berupa khitanan massal untuk anak-anak di RSIA Bunda Jakarta.
22th The Company’s CSR implementation in the form of a mass circumcision program for children at Bunda Jakarta Women and
Children Hospital.
Page 12
12 Kilas Kinerja
Performance Overview
Pelaksanaan CSR Perseroan berupa khitanan massal untuk anak-anak di RSU Citra Harapan.
26th The Company’s CSR implementation in the form of a mass circumcision program for children at Citra Harapan Hospital.
Juli | July
Pelaksanaan CSR Perseroan berupa khitanan massal untuk anak-anak di RSU Citra Harapan.
5th The Company’s CSR implementation in the form of a mass circumcision program for children at Citra Harapan Hospital.
Agustus | August
Pelaksanaan Rapat Umum Pemegang Saham Luar Biasa (RUPSLB) PT Bundamedik Tbk.
7th Holding an Extraordinary General Meeting of Shareholders (EGMS) of PT Bundamedik Tbk.
Pelaksanaan CSR Perseroan melalui edukasi kesehatan untuk anak usia sekolah dasar dan tenaga pendidik di wilayah Palembang,
22th Sumatera Selatan bersama RSIA Az Zahra Palembang.
Implementation of the Company’s CSR program through health education for elementary school children and educators in
Palembang, South Sumatra, with Az Zahra Palembang Women and Children Hospital..
September | September
Pelaksanaan kegiatan Bunda Maternity Academia, kelas “Kehamilan Sehat & Prenatal Yoga” di RSIA Bunda Jakarta.
6th Implementation of Bunda Maternity Academia activities, “Healthy Pregnancy & Prenatal Yoga” class at Bunda Jakarta Women
and Children Hospital.
Pelaksanaan kegiatan Health Talk dengan tema “Deteksi Dini Penyakit Jantung” dalam rangka World di RS Citra Harapan dalam
10th rangka memperingati World Heart Day 2025.
Implementation of Health Talk activities with the theme “Early Detection of Heart Disease” at Citra Harapan Hospital in
commemoration of World Heart Day 2025.
Pelaksanaan kegiatan Health Talk & Mini MCU dengan tema “Chronic Disease & Lifestyle Management” di RSU Bunda Margonda.
12th The implementation of the Health Talk & Mini MCU activity with the theme “Chronic Disease & Lifestyle Management” at Bunda
Margonda Hospital.
Pelaksanaan kegiatan talkshow interaktif oleh RSIA Az Zahra bersama TVRI Sumatra Selatan dengan tema, “Kehamilan Ektopik
17th Terganggu (KET)”.
The implementation of an interactive talk show by Az Zahra Palembang Women and Children Hospital together with TVRI South
Sumatra with the theme, “Complicated Ectopic Pregnancy (KET)”.
Oktober | October
Pengenalan prosedur robotic skin sparing mastectomy pertama di Asia Tenggara oleh RSU Bunda Jakarta.
10th Introduction of the first robotic skin sparing mastectomy procedure in Southeast Asia by Bunda Jakarta Hospital.
Pelaksanaan CSR Perseroan melalui edukasi deteksi dini kanker serviks dan pemeriksaan HPV-DNA gratis untuk komunitas
11th wanita di Surabaya bersama dengan RSIA Pusura Tegalsari dan PT Diagnos Laboratorium Utama Tbk.
Implementation of the Company’s CSR program through cervical cancer and free HPV-DNA screening for the Women Community
in Surabaya, in collaboration with Pusura Tegalsari Women and Children Hospital and PT Diagnos Laboratorium
Utama Tbk.
Peresmian Bunda Clinic MRT Dukuh Atas oleh Bapak Pramono Anung, Gubernur DKI Jakarta.
22th inaugurating the Bunda Clinic MRT Dukuh Atas by Mr. Pramono Anung, Governor of DKI Jakarta.
November
Pelaksanaan Public Expose Tahunan PT Bundamedik Tbk.
26th Holding a Annual Public Expose of PT Bundamedik Tbk.
Page 13
Laporan Tahunan
Annual Report 13
Desember | December
Pelaksanaan CSR Perseroan melalui edukasi pemilahan sampah, penanaman tanaman, dan pemeriksaan kesehatan
11th gratis di SMPN 2 Denpasar bersama dengan RSIA Bunda Denpasar dan Dinas Lingkungan Hidup Kota Denpasar.
Implementation of the Company’s CSR program through waste segregation, tree planting, and free health screening
at SMPN 2 Denpasar in collaboration with Bunda Denpasar Women and Children Hospital and the Denpasar City
Environmental Agency.
Pelaksanaan CSR Perseroan melalui edukasi kesehatan bertajuk Dokter Kecil Andalan Bunda untuk anak – anak
11th Sekolah Dasar (SD) di Menteng, Jakarta Pusat bersama RSU Bunda Jakarta dan RSIA Bunda Jakarta.
Implementation of the Company’s CSR program through health education under the “Dokter Kecil Andalan Bunda”
program for elementary school students in Menteng, Central Jakarta, in collaboration with Bunda Jakarta Hospital
and Bunda Jakarta Women and Children Hospital.
Pelaksanaan CSR Perseroan melalui inisiatif Cegah Stunting Dimulai Dari 1000 Hari Pertama Kehidupan (HPK)
16th untuk para ibu hamil, kader, dan bidan di Kecamatan Bungus, Padang, Sumatera Barat. Inisiatif ini merupakan bagian
dari rangkaian Program Cegah Stunting PT Bundamedik Tbk yang dilaksanakan di Kelurahan Bungus untuk periode
2025-2027.
Implementation of the Comapny’s CSR program through holding the “Preventing Stunting from the First 1,000
Days of Life” initiative for pregnant women, community health cadres, and midwives in Bungus Sub-district, Padang,
West Sumatra. This initiative forms part of PT Bundamedik Tbk’s Stunting Prevention Program implemented in
Bungus Urban Village for the 2025–2027 period.
Pelaksanaan CSR Perseroan melalui pemeriksaan kesehatan gratis dalam Rangkaian Pesta Rakyat Alumni IPB
20th Pulang Kampus (PRA IPK) 2025 berkolaborasi dengan Bunda Homecare.
Implementation of the Company’s CSR program through free health screenings as part of the Alumni of Institut
Pertanian Bogor Homecoming People’s Festival (PRA IPK) 2025 in collaboration with Bunda Homecare.
Penghargaan | Awards
Tanggal Unit Terkait Pemberi Penghargaan Deskripsi
Date Unit Involved Award-giver Description
Capaian Implementasi Standar Layanan Teknologi
BPJS Kesehatan Informasi dan Keamanan Informasi
6 Januari 2025 RSU Bunda Padang
Healthcare and Social Achievements in the Implementation of Information
January 6, 2025 Bunda Padang Hospital
Security Agency Technology and Information Security Service
Standards
25 Januari 2025 RSU Bunda Jakarta Power One - Agency Appreciation for Support & Participation "One Day
January 25, 2025 Bunda Jakarta Hospital Prudential Seminar"
2 Mei 2025 RSU Citra Harapan Certificate of Appreciation on the Achievement of
Shell Project
May 2, 2025 Citra Harapan Hospital 2.000.000 LTI Free Man - Hours
Penghargaan Terbaik ke- 2, FKRTL dengan KINERJA
RSIA Az Zahra Palembang
BPJS Kesehatan TERBAIK, Semester 1 Tahun 2025. Tingkat Kantor
11 Juni 2025 Az Zahra Palembang
Healthcare and Social Cabang Palembang
June 11, 2025 Women and Children
Security Agency Second-Best Award for Top Performance (FKRTL),
Hospital
First Semester of 2025, Palembang Branch Level
1 Agustus 2025 RSU Citra Harapan Certificate of Appreciation on the Achievement of
Shell Project
August 1, 2025 Citra Harapan Hospital 3.000.000 LTI Free Man - Hours
Piagam Penghargaan atas Kegiatan Pemantauan
RSIA Az Zahra Palembang Komite Akreditasi Rumah dan Evaluasi mutu Pelayanan Rumah Sakit Paska
26 Agustus 2025 Az Zahra Palembang Sakit (KARS) Akreditasi
August 26, 2025 Women and Children Hospital Accreditation Certificate of Appreciation for Participation in Post-
Hospital Committee (KARS) Accreditation Hospital Service Quality Monitoring
and Evaluation Activities
Partisipasi Kegiatan Coaching Layanan TBC di RS
15 September Kepala Dinas Kesehatan
Kota Depok bulan Juni
2025 RSU Bunda Margonda Kota Depok
Participation in Tuberculosis (TB) Service Coaching
September 15, Bunda Margonda Hospital Head of the Depok City
Activities at Hospitals in Depok City during the
2025 Health Office
period of June
Page 14
14 Kilas Kinerja
Performance Overview
Tanggal Unit Terkait Pemberi Penghargaan Deskripsi
Date Unit Involved Award-giver Description
Komite Akreditasi Rumah Piagam Penghargaan Atas Pemantauan dan Evaluasi
29 Oktober 2025 RSU Citra Harapan Sakit (KARS) Mutu Pelayanan Rumah Sakit Pasca Akreditasi
October 29, 2025 Citra Harapan Hospital Hospital Accreditation Certificate of Appreciation for Post-Accreditation
Committee (KARS) Hospital Service Quality Monitoring and Evaluation
Terbaik 1 Faskes Terbaik Kategori RS dalam
Pelayanan Imunisasi dan Penginputan ke dalam
1 November Walikota Depok & Dinas
Aplikasi Sehat Indonesiaku (ASIK)
2025 RSU Bunda Margonda Kesehatan Kota Depok
First Place Award as the Best Healthcare Facility
November 1, Bunda Margonda Hospital Mayor of Depok City &
in the Hospital Category for Excellence in
2025 Depok City Health Office
Immunization Services and Data Entry into the Sehat
Indonesiaku Application (ASIK)
10 November
2025 RSU Bunda Jakarta Appreciation for Contribution as Allianz Blue Eagle
Allianz
November 10, Bunda Jakarta Hospital Network
2025
28 November
2025 RSU Bunda Padang Apresiasi Mitra Kerja Tahun 2025
Bank Indonesia
November 28, Bunda Padang Hospital Partner Appreciation Award 2025
2025
RSU Bunda Jakarta
BRI Life Appreciation for Participant "Healthtalk"
Bunda Jakarta Hospital
5 Desember Keamanan Rumah Sakit dalam Implementasi
2025 Integrasi Sistem Antrean Online, Integrasi Sistem
December 5, BPJS Kesehatan Klaim, Implementasi E-SEP Fingerprint & Frista
RSU Bunda Padang
2025 Healthcare and Social Hospital Security Excellence in the Implementation
Bunda Padang Hospital
Security Agency of Online Queue System Integration, Claims System
Integration, and the Implementation of E-SEP,
Fingerprint, and Frista Systems
9 Desember
RSIA Bunda Denpasar
2025
Bunda Denpasar Women Garda Medika 3rd Best Provider Indonesia Timur
December 9,
and Children Hospital
2025
Penghargaan Bintang 3, Implementasi Integrasi
Sistem Antrean Online Sistem Klaim, Implementasi
15 Desember RSIA Az Zahra Palembang sistem Klaim, Implementasi E-SEP & Fingerprint /
BPJS Kesehatan
2025 Az Zahra Palembang Frista
Healthcare and Social
December 15, Women and Children Three-Star Award for the Implementation of
Security Agency
2025 Hospital Online Queue System Integration, Claims System
Integration, and the Implementation of E-SEP and
Fingerprint/Frista Systems
Sertifikasi | Certification
Australian Council on Masa Berlaku | Validity Period
20 Maret 2025 – 19 Maret 2028
Healthcare Standard (ACHS) March 20, 2025 – March 19, 2028
RSU Bunda Jakarta dan RSIA Bunda Jakarta telah memperoleh sertifikasi atas pemenuhan standar akreditasi internasional 7th
Evaluation and Quality Improvement Program (EQuIP7). Standar akreditasi diberikan kepada organisasi perawatan kesehatan
yang telah menerapkan proses dan prosedur dengan standar internasional serta mengevaluasi hasil untuk program peningkatan
kualitas berkelanjutan.
Bunda Jakarta Hospital and Bunda Jakarta Women and Children Hospital obtained certification for meeting the international
accreditation standards of the 7th Evaluation and Quality Improvement Program (EQuIP7). The accreditation standard is given
to health care organizations that have implemented processes and procedures with international standards and evaluated the
results for continuous quality improvement programs.
Page 15
Laporan Tahunan
Annual Report 15
Komite Akreditasi
Rumah Sakit (KARS)
Sebanyak 9 Rumah Sakit Grup Bunda memperoleh sertifikasi akreditasi Paripurna sebagai salah satu bentuk komitmen BMHS
untuk senantiasa memberikan layanan yang berkualitas, sesuai standar, dan berorientasi pada keselamatan pasien.
9 Bunda Group Hospitals obtained their Paripurna accreditation certification as a form of BMHS’s commitment to always
providing quality services, according to standards, and oriented towards patient safety.
Masa Berlaku | Validity Period
• RSIA Bunda Jakarta (07 Maret 2023 - 20 Februari 2027) • Bunda Jakarta Women and Children Hospital (March 7,
2023 - February 20, 2027)
• RSU Bunda Jakarta (08 Mei 2023 - 12 Maret 2027) • Bunda Jakarta Hospital (May 8, 2023 - March 12, 2027)
• RSU Bunda Margonda (12 Juni 2023 - 24 Januari 2027) • Bunda Margonda Hospital (June 12, 2023 - January 24,
2027)
• RSU Bunda Padang (22 Februari 2023 - 31 Januari 2027) • Bunda Padang Hospital (February 22, 2023 - January 31,
2027)
• RSIA Bunda Ciputat (20 Maret 2023 - 27 Februari 2027) • Bunda Ciputat Women and Children Hospital (March 20,
2023 - February 27, 2027)
• RSIA Az-Zahra Palembang (8 Februari 2023 - 24 Januari • Az-Zahra Palembang Women and Children Hospital
2027) (February 8, 2023 - January 24, 2027)
• RSU Citra Harapan (20 Maret 2023 - 5 Maret 2027) • Citra Harapan Hospital (March 20, 2023 - March 5, 2027)
• RSIA Bunda Denpasar (16 Februari 2024 - 8 Januari 2028) • Bunda Denpasar Women and Children Hospital (February
16, 2024 - January 8, 2028)
• RSIA Pusura Tegalsari (21 Juni 2024 - 26 Mei 2028) • Pusura Tegalsari Women and Children Hospital (June 21,
2024-May 26,2028)
Reproductive Technology Accreditation Committee (RTAC)
Sebanyak 2 klinik fertilitas, yaitu Morula IVF Surabaya dan Morula IVF Jakarta, memperoleh akreditasi dari Reproductive
Technology Accreditation Committee (RTAC) sebagai wujud komitmen Perseroan untuk senantiasa menghadirkan layanan
reproduksi berbantu yang berkualitas, sesuai standar internasional, dan berorientasi pada keselamatan pasien.
Two fertility clinics Morula IVF Surabaya and Morula IVF Jakarta have received accreditation from the Reproductive Technology
Accreditation Committee (RTAC), reflecting the Company’s commitment to consistently providing high-quality assisted
reproductive services that meet international standards and prioritize patient safety.
Masa Berlaku | Validity Period
• Morula IVF Surabaya (18 Desember 2025 - 31 Desember • Morula IVF Surabaya (December 18, 2025-December 31,
2026) 2026)
• Morula IVF Jakarta (18 Desember 2025 - 31 Desember • Morula IVF Jakarta (December 18, 2025-December 31,
2026) 2026)
Page 16
16 Kilas Kinerja
Performance Overview
ISO 9001:2015 TÜV Rheinland
PT Diagnos Laboratorium Utama Tbk memperoleh sertifikasi ISO 9001:2015 sebagai pengakuan atas penerapan sistem
manajemen mutu yang konsisten dan terstandar untuk manajemen, administrasi, dan penyediaan layanan laboratorium klinis.
PT Diagnos Laboratorium Utama Tbk obtained ISO 9001:2015 certification in recognition of its consistent and standardized
implementation of a quality management system for the management, administration, and delivery of clinical laboratory services.
Masa Berlaku | Validity Period
PT Diagnos Laboratorium Utama Tbk Jakarta, Denpasar, Padang, dan Tangerang (06 November 2025- 05 November 2028)
PT Diagnos Laboratorium Utama Tbk – Jakarta, Denpasar, Padang, and Tangerang (November 6, 2025 to November 5, 2028)
ISO 45001:2018 TÜV Rheinland
PT Diagnos Laboratorium Utama Tbk memperoleh sertifikasi ISO 45001:2018 sebagai bentuk pengakuan atas penerapan
sistem manajemen keselamatan dan kesehatan kerja yang terintegrasi untuk manajemen, administrasi, dan penyediaan layanan
laboratorium klinis.
PT Diagnos Laboratorium Utama Tbk obtained ISO 45001:2018 certification in recognition of its implementation of an integrated
occupational health and safety management system covering the management, administration, and delivery of clinical laboratory
services.
Masa Berlaku | Validity Period
PT Diagnos Laboratorium Utama Tbk Jakarta, Denpasar, Padang, dan Tangerang (06 November 2025- 05 November 2028)
PT Diagnos Laboratorium Utama Tbk – Jakarta, Denpasar, Padang, and Tangerang (November 6, 2025 to November 5, 2028)
TÜV Rheinland: ISO 15189:2012
PT Diagnos Laboratorium Utama Tbk memperoleh sertifikasi ISO 15189:2012 sebagai bentuk pengakuan atas penerapan sistem
manajemen mutu dan kompetensi laboratorium medis dalam pengelolaan, administrasi, dan penyediaan layanan laboratorium
klinis.
PT Diagnos Laboratorium Utama Tbk obtained ISO 15189:2012 certification in recognition of its implementation of a quality
management system and medical laboratory competence in the management, administration, and delivery of clinical laboratory
services.
Masa Berlaku | Validity Period
PT Diagnos Laboratorium Utama Tbk (22 Februari 2027)
PT Diagnos Laboratorium Utama Tbk (February 22, 2027)
Page 17
Laporan Tahunan
Annual Report 17
Laporan Dewan Komisaris
Board of Commissioners Report
“Dewan Komisaris mendukung arah kebijakan yang inovatif, termasuk
pendekatan yang lebih selektif dan berorientasi jangka panjang, di
antaranya penerapan teknologi bedah robotik generasi kedua yang mampu
mendukung penguatan layanan kesehatan ibu dan anak”.
“The Board of Commissioners supports the innovative policy
direction, including the more selective and long-term oriented approach, such
as the introduction of second-generation robotic surgery technology capable
of strengthening women and children health services.”
Ivan Rizal Sini
Komisaris Utama
President Commissioner
Pemangku kepentingan yang kami hormati, Dear stakeholders,
Tahun 2025 merupakan periode yang menunjukkan 2025 marked a period that demonstrated
kesiapan PT Bundamedik Tbk untuk melangkah lebih PT Bundamedik Tbk’s readiness to take more
progresif dengan bertumpu pada fondasi tata kelola progressive steps, thanks to an increasingly robust
internal yang semakin kokoh. Dewan Komisaris internal governance foundation. The Board of
mendukung peningkatan sumber daya manusia (SDM), Commissioners supports the development in human
tata kelola, serta disiplin pengelolaan keuangan capital (HC), governance, and the disciplined financial
yang dilakukan dalam beberapa tahun terakhir telah management implemented over the past few years
membentuk dasar yang solid untuk menjaga stabilitas has laid a solid foundation for maintaining stability
sekaligus mendorong akselerasi kinerja secara terukur. while driving measurable performance growth. The
Keterlibatan aktif seluruh elemen BMHS menjadi kunci active involvement of all elements of BMHS is key
dalam mentransformasikan kesiapan internal menjadi to transforming internal readiness into sustainable
performa yang berkelanjutan. performance.
Penilaian terhadap Kinerja Direksi Board of Directors’ Performance Assessment
Dewan Komisaris menilai bahwa sepanjang 2025 Direksi The Board of Commissioners believe that throughout
telah mengelola BMHS secara adaptif dan berhati-hati di 2025, the Board of Directors has managed BMHS
tengah dinamika industri layanan kesehatan, khususnya adaptively and prudently despite the dynamics of the
terkait perubahan pola pembiayaan melalui BPJS healthcare services industry, particularly concerning
dan asuransi. Respons strategis melalui penyesuaian changes in financing patterns through BPJS and
clinical pathway, efisiensi operasional, serta penguatan insurance. Strategic responses by adjusting to clinical
pengendalian keuangan dan tata kelola menjadi faktor pathways, operational efficiency, and the strengthening
penting dalam menjaga stabilitas kinerja BMHS. of financial controls and governance have been critical
factors in maintaining BMHS’s performance stability.
Page 18
18 Kilas Kinerja
Performance Overview
Dewan Komisaris mengapresiasi fokus Direksi The Board of Commissioners commends the Board of
dalam memperkuat kapasitas internal, termasuk Directors for strengthening internal capacity, including
pengembangan SDM dan penetapan tujuh area prioritas. human capital development and for establishing seven
Dewan Komisaris mencermati adanya pengelolaan priority areas. The Board of Commissioners have seen
SDM yang lebih terstruktur, peningkatan kompetensi more structured human capital management, enhanced
tenaga medis dan nonmedis, upaya membangun competencies among medical and non-medical staff,
pemahaman sistem rumah sakit, pengelolaan risiko, efforts to build an understanding of hospital systems,
literasi keuangan, efisiensi, dan layanan di tingkat risk management, financial literacy, efficiency, and
operasional. Pendekatan ini dinilai relevan, mengingat service delivery at the operational level. This approach
layanan kesehatan tidak hanya ditentukan oleh aspek is deemed relevant, given that healthcare services are
klinis, tetapi juga oleh kesiapan SDM dalam menjaga not only determined by clinical aspects but also by the
mutu, keselamatan pasien, dan stabilitas operasional. readiness of human capital to maintain quality, patient
safety, and operational stability.
Dari sisi keuangan, Perseroan merealisasikan From a financial perspective, BMHS generated revenue
pendapatan sebesar Rp1.614,34 miliar dan of IDR 1,614.34 billion and reported a 57% year-
mencatatkan pertumbuhan laba bersih 57% year-on- on-year (YoY) increase in net profit compared to the
year (YoY) dibandingkan tahun sebelumnya. Dewan previous year. The Board of Commissioners also noted
Komisaris mencermati adanya perbaikan dalam improvements in cash flow management discipline
disiplin pengelolaan arus kas dan efisiensi operasional, and operational efficiency, as well as strengthening in
serta penguatan sistem dan tata kelola keuangan. financial systems and governance. These efforts form
Upaya tersebut menjadi dasar penting dalam menjaga a crucial foundation for maintaining the Company’s
ketahanan Perseroan, serta memberikan ruang bagi resilience and creating room for future investment
keberlanjutan investasi ke depan. sustainability.
Pada sisi strategi layanan, Dewan Komisaris juga menilai In terms of service strategy, the Board of
bahwa Direksi konsisten menjaga fokus BMHS pada Commissioners also noted that the Board of Directors
layanan kesehatan ibu dan anak sebagai kekuatan utama has consistently maintained BMHS’s focus on women
bisnis. Konsistensi ini tidak hanya tercermin dalam and children health services as its core business strength.
arah layanan, tetapi juga dalam kesiapan sumber daya This consistency is reflected not only in the direction
dan sistem untuk menangani layanan dengan tingkat of services but also in the readiness of resources and
kompleksitas yang lebih tinggi, termasuk kehamilan systems to handle services of a higher complexity,
berisiko dan perawatan neonatal. Fokus yang terjaga ini including high-risk pregnancies and neonatal care. This
dinilai sebagai keunggulan kompetitif yang relevan dan sustained focus is viewed as a relevant competitive
sejalan dengan karakter, serta pengalaman BMHS. advantage that aligns with BMHS’s character and
experience.
Dalam hal inovasi dan optimalisasi aset, Dewan With regard to innovation and asset optimization,
Komisaris mencermati bahwa Direksi mengarahkan the Board of Commissioners notes that the Board of
BMHS pada pendekatan yang lebih selektif dan Directors is steering BMHS toward a more selective
berorientasi jangka panjang. Dewan Komisaris menilai and long-term-oriented approach. The Board of
investasi belanja modal pada teknologi bedah robotik Commissioners’ assessment is that capital expenditure
generasi kedua mampu mendukung penguatan layanan investments in second-generation robotic surgery
kesehatan ibu dan anak. Selain itu, investasi yang technology can support the strengthening of women
dilakukan juga mampu memperluas kapasitas layanan and children healthcare services. Additionally, these
untuk prosedur urologi, kardiovaskular, serta tindakan investments can expand service capacity for urological,
bedah lanjutan dengan tingkat kompleksitas yang lebih cardiovascular procedures, and advanced surgical
tinggi. Demikian halnya dengan optimalisasi aset pada interventions with higher levels of complexity. The same
lima rumah sakit yang dimiliki dan investasi pada sistem applies to asset optimization at the five hospitals owned
Page 19
Laporan Tahunan
Annual Report 19
pendukung seperti ERP. Keseluruhan langkah tersebut by BMHS and investments in support systems such as
Dewan Komisaris pandang sebagai fondasi penting ERP. The Board of Commissioners view these steps as
untuk meningkatkan kualitas layanan dan mendukung a crucial foundation for improving service quality and
pengambilan keputusan yang lebih cepat dan berbasis supporting faster, data driven decision making, while
data, dengan tetap menjaga prinsip kehati-hatian maintaining the the principle of financial prudence.
finansial.
Secara keseluruhan, Dewan Komisaris menilai kinerja Overall, the Board of Commissioners has assessed that
Direksi pada 2025 berada pada arah yang tepat. the Board of Directors’ performance in 2025 was on the
Penguatan fundamental serta sinergi seluruh elemen right track. Strengthening the foundation and fostering
dalam ekosistem BMHS memberikan dasar yang lebih synergy among all elements BMHS’s ecosystem provides
kokoh bagi BMHS untuk menjaga stabilitas, sekaligus a stronger foundation for BMHS to maintain stability
mempersiapkan langkah akselerasi secara terukur while preparing for measured acceleration moving
ke depan. Dewan Komisaris memandang bahwa forward. The Board of Commissioners believes that the
keberlanjutan kinerja BMHS akan sangat ditentukan sustainability of BMHS’s performance will be largely
oleh konsistensi Direksi dalam menjaga keseimbangan determined by the Board of Directors’ consistency in
antara adaptivitas, kehati-hatian, dan fokus jangka maintaining a balance between adaptability, prudence,
panjang. and long-term focus.
Pengawasan Dewan Komisaris dalam Implementasi Board of Commissioners Supervision of the Strategy
Strategi Implementation
Dewan Komisaris menjalankan fungsi pengawasan The Board of Commissioners performs its supervisory
melalui komite pendukung dan keterlibatan aktif dalam function through supporting committees and active
pembahasan berkala bersama Direksi, baik melalui participation in regular discussions with the Board of
rapat internal maupun rapat gabungan. Secara rutin, Directors, in both internal meetings and joint meetings.
Dewan Komisaris menelaah laporan manajemen dan On a routine basis, the Board of Commissioners reviews
meminta penjelasan dari Direksi terkait isu-isu yang management reports and seeks clarification from the
dinilai material dalam pengelolaan BMHS, termasuk Board of Directors regarding issues deemed material
kesesuaian implementasi strategi dengan Rencana in BMHS’s management, including the alignment of
Kerja dan Anggaran Perusahaan (RKAP). strategy implementation with BMHS’s Work Plan and
Budget (RKAP).
Dalam pelaksanaannya, Dewan Komisaris The Board of Commissioners has provided a number
menyampaikan sejumlah arahan dan rekomendasi of directives and recommendations to the Board of
kepada Direksi, antara lain penguatan fundamental, Directors, including strengthening fundamentals,
meningkatkan ketahanan merespons dinamika industri, improving, enhancing resilience in responding to
menjaga disiplin finansial dalam pengendalian biaya industry dynamics, maintaining financial discipline in
operasional, serta mengoptimalkan aset eksisting controlling operational costs, and optimizing existing
sebagai dasar bagi akselerasi yang berkelanjutan. assets as a foundation for sustainable acceleration.
Dewan Komisaris juga mendorong Direksi untuk terus The Board of Commissioners also encouraged the
memperkuat kapasitas SDM melalui pengembangan Board of Directors to continue strengthening human
kompetensi yang terukur, menjaga konsistensi fokus capital capacity through measurable competency
layanan ibu dan anak, kesiapan menangani kompleksitas development, maintaining a consistent focus on
klinis yang lebih tinggi, serta memastikan tata kelola women and children services, ensuring readiness
dan pengawasan risiko diterapkan secara merata hingga to handle higher clinical complexities, and ensuring
ke tingkat anak usaha. Rekomendasi tersebut akan that governance and risk supervision were uniformly
dipantau tindak lanjutnya sebagai bagian dari proses applied down to the subsidiary level. The follow-up on
pengawasan Dewan Komisaris. these recommendations will be monitored as part of the
Board of Commissioners’ supervisory process.
Page 20
20 Kilas Kinerja
Performance Overview
Pandangan terhadap Prospek Usaha Business Prospects Outlook
Dewan Komisaris memandang prospek industri The Board of Commissioners views the prospects for
layanan kesehatan nasional tetap positif, khususnya the national healthcare industry as remaining positive,
pada segmen layanan kesehatan ibu dan anak. Dewan particularly in the women and children healthcare
Komisaris menilai bahwa ke depan, fokus pada segment. The Board of Commissioners believes that
layanan kesehatan ibu dan anak tetap relevan dan going forward, the focus on women and children
konsisten dengan pengalaman BMHS selama lebih healthcare remains relevant and consistent with
dari lima dekade. Kekuatan historis di bidang fertilitas, BMHS’s experience spanning more than five decades.
kesinambungan layanan ibu dan anak, kemampuan Historical strengths in the fields of fertility, continuity of
menangani kehamilan berisiko tinggi, hingga kapasitas women and children care, the ability to manage high-risk
Neonatal Intensive Care Unit (NICU) dalam menangani pregnancies, and the capacity of the Neonatal Intensive
kasus kompleks pada bayi baru lahir menjadi keunggulan Care Unit (NICU) to handle complex cases in newborns
bersaing yang terbaik. Dewan Komisaris menilai BMHS constitute BMHS’s strongest competitive advantages.
memiliki modal kapabilitas yang kuat untuk menjaga The Board of Commissioners assessment is that BMHS
fokus tersebut, baik dari sisi sumber daya manusia, possesses the robust capabilities to maintain this focus,
sistem manajemen, maupun pengalaman operasional. both in terms of human capital, management systems,
and operational experience.
Meski demikian, Dewan Komisaris memberikan arahan Nevertheless, the Board of Commissioners has
tentang perlunya penguatan kompetensi tenaga medis provided guidance on the need to strengthen
dan keperawatan secara terstruktur dan terukur, sejalan the medical and nursing staff competencies in a
dengan peningkatan kompleksitas layanan dan tuntutan structured and measurable manner, in line with the
keselamatan pasien. Dewan Komisaris mendorong agar increasing complexity of services and patient safety
program pelatihan, fellowship, serta pengembangan requirements. The Board of Commissioners encourages
sertifikasi perlu dilakukan secara konsisten sehingga consistent implementation of training programs,
peningkatan kompetensi yang benar-benar mendukung fellowships, and certification development so that
mutu klinis dan keberlanjutan model bisnis BMHS. competency developments genuinely support BMHS’s
Dewan Komisaris juga memandang peran BMHS clinical quality and sustainable business model.
sebagai pusat pendidikan dan pengembangan tenaga The Board of Commissioners also views BMHS’s
kesehatan yang perlu terus diperkuat sebagai bagian role as a center for education and development of
dari strategi jangka panjang. healthcare personnel as one that must be continuously
strengthened as part of the long-term strategy.
Pandangan atas Penerapan Tata Kelola View on Corporate Governance Implementation
Dewan Komisaris memandang bahwa Perseroan terus The Board of Commissioners believe that the Company
memperkuat kualitas penerapan tata kelola korporat is continuing to strengthen the quality of its corporate
secara lebih matang dan terstruktur. Penerapan tata governance implementation in a more mature and
kelola tidak hanya difokuskan secara internal, tetapi structured manner. The governance implementation
juga dampak eksternal, etika bisnis serta perhatian is not only focused internally but also on external
terhadap integrasi aspek lingkungan, sosial, dan tata impacts, including business ethics and attention to the
kelola (LST). Dewan Komisaris mencermati penguatan integration of the environmental, social, and governance
kualitas ini sebagai langkah penting bagi fundamental (ESG) aspects. The Board of Commissioners view is that
kinerja BMHS. this improvement in quality is a crucial step for BMHS’s
fundamental performance.
Page 21
Laporan Tahunan
Annual Report 21
Dewan Komisaris menjalankan pengawasan The Board of Commissioners supervises corporate
terhadap governansi, didukung Komite Audit, Komite governance, supported by the Audit Committee, the
Nominasi dan Remunerasi, serta Komite GCG dan Nomination and Remuneration Committee, and the
Manajemen Risiko. Pada 2025, Dewan Komisaris GCG and Risk Management Committee. Throughout
melakukan sejumlah penyesuaian pada struktur 2025, the Board of Commissioners made a number of
komite di bawah Dewan Komisaris guna memastikan adjustments to the structure of the committees under
efektivitas fungsi pengawasan. Melalui komite the Board of Commissioners to ensure the effectiveness
pendukung, Dewan Komisaris memastikan BMHS telah of the supervision functions. Through these supporting
memiliki kecukupan pengendalian internal dan sistem committees, the Board of Commissioners can ensure
manajemen risiko, baik secara umum maupun secara that BMHS has adequate internal controls and risk
spesifik di bidang medis, finansial, dan operasional, management systems, both generally and specifically
yang melekat dalam operasional bisnis. Kolaborasi in the medical, financial, and operational fields, which
yang konstruktif antara Dewan Komisaris, Direksi, dan are integral to business operations. This constructive
komite pendukung Dewan Komisaris berperan penting collaboration, plays a crucial role in strengthening
dalam memperkuat praktik governansi, menciptakan governance practices and fostering a healthy balance
keseimbangan yang sehat antara fungsi pengawasan between supervision and management function, and
dan pengelolaan, serta memastikan keselarasan ensuring that BMHS’s management practices are in
pengelolaan BMHS dengan kepatuhan terhadap compliance with regulations.
regulasi.
Apresiasi dan Penutup Appreciation and Closing Remarks
Dewan Komisaris mengucapkan terima kasih kepada The Board of Commissioners would like to express
seluruh pemangku kepentingan atas dukungan its gratitude to all stakeholders for their support of
yang diberikan kepada PT Bundamedik Tbk. Dewan PT Bundamedik Tbk. The Board of Commissioners
Komisaris memberikan apresiasi kepada seluruh insan appreciates the effort made by all employees of
BMHS atas keterlibatan, sinergi, dedikasi, dan semangat BMHS for their engagement, synergy, dedication, and
untuk memberikan layanan kesehatan berkualitas enthusiasm in providing quality healthcare services,
yang terefleksi dalam performa kinerja 2025. Dengan which was reflected in the 2025 performance results.
kolaborasi dan fondasi yang semakin kuat, Dewan Through this collaboration and an increasingly
Komisaris yakin bahwa BMHS terus dapat melanjutkan stronger foundation, the Board of Commissioners
kinerja secara adaptif, resilien, dan berkelanjutan. is confident that BMHS will continue to perform
adaptively and resiliently, and sustainable manner.
Jakarta, April 2026
Atas Nama Dewan Komisaris, | On behalf of the Board of Commissioners,
Ivan Rizal Sini
Komisaris Utama
President Commissioner
Page 22
22 Kilas Kinerja
Performance Overview
Laporan Direksi
Board of Directors Report
“Patient journey merupakan pengalaman yang mendasar dan sangat penting
yang menjadi perhatian kami di BMHS. Untuk itu, BMHS terus melakukan
penyelarasan alur layanan di seluruh jaringan, mengembangkan inovasi,
serta meningkatkan layanan yang lebih mudah diakses masyarakat.”
“The patient’s journey is a fundamental experience and a top priority for
us at BMHS. To that end, BMHS continues to streamline service processes
across its network, develop innovations, and enhance services to make them
more accessible to the public.”
Agus Heru Darjono
Direktur Utama
President Director
Pemangku kepentingan yang kami hormati, Dear stakeholders,
Sepanjang 2025, Direksi fokus pada pengelolaan dan Throughout 2025, the Board of Directors focused
penguatan fundamental atas mutu layanan sebagai on managing and strengthening the fundamentals of
dasar pertumbuhan yang sehat dan berkelanjutan. service quality as the foundation for healthy and
Berpegang pada nilai “people first and profit will follow”, sustainable growth. Adhering to the value of “people
BMHS membangun ekosistem layanan kesehatan first and profit will follow,” BMHS built a healthcare
melalui kesiapan, keterlibatan, dan integritas sumber ecosystem through the readiness, engagement, and
daya manusia (SDM). Bagi Direksi, konsistensi integrity of its human capital (HC). For the Board of
keterlibatan dan sinergi di seluruh ekosistem Directors, consistent engagement and synergy across
BMHS merupakan kunci dalam menjalankan strategi BMHS’s entire ecosystem are key to executing our
dan menerjemahkannya menjadi kinerja yang terukur. strategy and translating it into measurable performance.
Strategi dan Analisis Kinerja Strategy and Performance Analysis
BMHS terus memperkuat ekosistem layanan kesehatan BMHS continues to strengthen its healthcare service
dengan mengintegrasikan jaringan rumah sakit (RS) ecosystem by integrating the Bunda Group hospital
Bunda Group, Morula IVF Indonesia, laboratorium network, Morula IVF Indonesia, Diagnos laboratories,
Diagnos, dan unit usaha lainnya dalam satu sistem and other business units into a single, fully integrated
yang saling terintegrasi. Secara konsisten, Direksi system. Consistently, the Board of Directors continues
melanjutkan strategi peningkatan fondasi bisnis the strategy of strengthening the business foundation
dengan memperkuat kapabilitas layanan holistik by enhancing holistic service capabilities that support
yang mendampingi kebutuhan kesehatan keluarga di family health needs at different life stages. The Board
berbagai tahap kehidupan. Direksi menetapkan tujuh of Directors have established seven key priorities:
prioritas utama, yaitu Center of Excellence, peningkatan Centers of Excellence; enhancing women and children
layanan spesialis dan subspesialis kesehatan ibu health specialist and subspecialist services; improving
dan anak, penyempurnaan manajemen dokter, physician management; standardizing and enhancing
standardisasi dan peningkatan patient journey, the patient journey; expanding hospital capacity;
perluasan kapasitas RS, optimalisasi pemanfaatan aset, optimizing asset utilization; and cost efficiency.
serta efisiensi biaya.
Penguatan layanan Center of Excellence serta The strengthening of Center of Excellence services
peningkatan layanan spesialis dan subspesialis and the enhancement of women and children health
kesehatan ibu dan anak dilakukan dengan specialist and subspecialist services are achieved by
Page 23
Laporan Tahunan
Annual Report 23
memperdalam kapabilitas klinis. Beberapa di deepening clinical capabilities. These include enhancing
antaranya yaitu melalui kelengkapan fasilitas the Neonatal Intensive Care Unit (NICU) facilities
Neonatal Intensive Care Unit (NICU) dan pendekatan and the Family Integrated CARE (FICARE) approach,
Family Integrated CARE (FICARE), pengembangan and developing assisted reproductive services, as
layanan reproduksi berbantu, serta layanan well as transplantation and further enhanced by the
transplantasi dan diperkuat dengan adanya generasi introduction of second-generation robotic surgery. the
kedua bedah robotik. Direksi meyakini bahwa Board of Directors believe that long-term competitive
keunggulan kompetitif jangka panjang dapat lebih advantage can be better sustained through the
terjaga melalui pembangunan kapabilitas dan development of capabilities and innovations that are
inovasi yang mendalam, terintegrasi, dan relevan in-depth, integrated, and relevant to patient needs. To
dengan kebutuhan pasien. Untuk menyempurnakan improve physician management, the Board of Directors
manajemen dokter, Direksi melakukan penyesuaian are adjusting the clinical governance and structured
tata kelola klinis dan pengembangan kompetensi development of medical staff competencies. BMHS is
tenaga medis yang terstruktur. BMHS membangun building a clinical learning system to ensure physician
sistem pembelajaran klinis untuk memastikan kesiapan readiness, maintain service quality, and ensure patient
dokter, menjaga mutu layanan, dan keselamatan safety through relevant fellowship programs.
pasien melalui program fellowship yang relevan.
Pada standardisasi dan peningkatan patient journey, For standardizing and improving the patient journey,
BMHS melakukan penyelarasan alur layanan di seluruh BMHS is aligning service workflows across the entire
jaringan, serta pengembangan layanan yang lebih network and developing services that are more
mudah diakses masyarakat. Peluncuran Bunda Clinic accessible to the public. The launch of Bunda Clinic MRT
MRT Dukuh Atas dan pengembangan Bunda Homecare Dukuh Atas and the development of Bunda Homecare
merupakan bagian dari upaya memperluas akses are part of our efforts to expand access to integrated
layanan yang terintegrasi dalam jaringan BMHS. services within BMHS’s network.
Sementara itu, perluasan kapasitas RS dan optimalisasi While, hospital capacity expansion and asset
pemanfaatan aset dilakukan dengan memastikan utilization optimization are being carried out by
kesiapan operasional maupun relevansi terhadap ensuring operational readiness and alignment with
kebutuhan pasar. BMHS telah memulai inisiatif market needs. BMHS has initiated these efforts at five
tersebut pada lima RS dalam ekosistemnya sejak hospitals within its ecosystem since October 2025,
Oktober 2025, yang diproyeksikan tuntas dalam 2-3 and they are projected to be completed over the
tahun ke depan. Dalam hal efisiensi biaya, BMHS next 2–3 years. For cost efficiencies, BMHS is
melakukan restrukturisasi struktur keuangan melalui restructuring its financial structure through disciplined
disiplin pengendalian biaya, optimalisasi sumber daya, cost controls, resource optimization, and enhanced
serta penguatan digitalisasi melalui sistem Enterprise digitalization via the Enterprise Resource Planning
Resource Planning (ERP). Dengan ERP, BMHS (ERP) system. Through ERP, BMHS will strengthen
memperkuat integrasi data dan kualitas pengambilan its data integration and the quality of decision-
keputusan, serta tetap mengedepankan pelindungan making, while prioritizing patient data protection and
data pasien dan keamanan informasi. information security.
BMHS juga melakukan penyesuaian struktur organisasi BMHS is also adjusting its organizational structure
dan memperkuat kapasitas SDM guna menjaga and strengthening human capital capacity to ensure
kesinambungan operasional dan kualitas pengelolaan operational continuity and management quality
di seluruh unit layanan. Direksi melakukan peningkatan across all service units. the Board of Directors are
kompetensi, penyempurnaan sistem pengembangan developing competencies, refining talent development
talenta dan retensi tenaga medis, serta membangun and medical staff retention systems, and fostering
keterlibatan karyawan melalui internalisasi budaya employee engagement through the internalization of
5C dan kebijakan kerja yang mendukung kontinuitas the 5C culture and work policies that support service
layanan dan kinerja. continuity and performance.
Page 24
24 Kilas Kinerja
Performance Overview
Sepanjang 2025, BMHS mampu menjaga kekuatan Throughout 2025, BMHS was able to maintain the
layanan utama ibu dan anak, sekaligus meningkatkan strength of its core women and children services
kontribusi layanan spesialis lainnya. Aktivitas while increasing its contribution of other specialist
layanan rumah sakit menunjukkan peningkatan services. Hospital service activities showed an increase
volume rawat inap dan tindakan bedah. Morula IVF inpatient and surgical procedure volumes. Morula IVF
Indonesia mencatat pertumbuhan pada fresh cycle dan Indonesia recorded growth in fresh cycle and revenue,
pendapatan, demikian halnya dengan Diagnos, as did Diagnos, which demonstrated volume growth
yang menunjukkan pertumbuhan volume melalui through group synergies and corporate projects. The
sinergi grup dan proyek korporasi. Penguatan strengthening of Centers of Excellence and complex
Center of Excellence dan layanan kompleks, seperti services, such as kidney transplants and minimally
transplantasi ginjal dan tindakan bedah minimal invasive surgical procedures based on robotic surgery,
invasif berbasis robotic surgery, semakin memperkuat further reinforced BMHS’s differentiation and public
diferensiasi dan kepercayaan masyarakat trust. Improvements in service quality and patient
terhadap BMHS. Peningkatan kualitas layanan dan experience were also reflected in higher Net Promoter
pengalaman pasien juga tercermin dalam perbaikan Scores (NPS) and digital service ratings.
Net Promoter Score (NPS) dan rating layanan digital.
Dari sisi keuangan, Direksi mencatat perbaikan From a financial perspective, the Board of Directors
kualitas kinerja keuangan, terutama pada semester II noted an improvement in financial performance,
2025. Pendapatan usaha sebesar Rp1.614,34 miliar, particularly in the second half of 2025. Operating
meningkat 4% dibandingkan 2024 yang sebesar revenue amounted to IDR 1,614.34 billion, an increase
Rp1.554,69 miliar. Perbaikan margin tercermin pada of 4% compared to IDR 1,554.69 billion in 2024. This
peningkatan 4% YoY Gross Profit dan EBITDA margin improvement in margins was reflected in higher 4%
mencapai 15%. Capaian tersebut menunjukkan YoY Gross Profit and EBITDA margin reaching 15%.
perbaikan payor mix, optimalisasi aset, efektivitas These achievements were the result of improvements
pengendalian biaya, serta optimalisasi struktur in the payer mix, asset optimization, cost control
biaya layanan, tanpa mengurangi kualitas pelayanan effectiveness, and optimization of the service cost
kepada pasien. Digitalisasi dan integrasi data turut structure, without compromising the quality of patient
mendukung pengambilan keputusan berbasis care. Digitalization and data integration further
informasi, memperkuat struktur keuangan, dan menjaga supported data driven decision making strengthened
arus kas tetap sehat di tengah kebutuhan investasi pada the financial structure, and maintained a healthy
layanan medis berkompleksitas tinggi. cash flow despite the need for investment in high-
complexity medical services.
Direksi juga menyampaikan capaian positif dalam The Board of Directors also reported positive
meningkatkan kapasitas dan stabilitas. Pemahaman achievements in enhancing capacity and stability.
budaya kerja 5C meningkat sebesar 12%, disertai Understanding of the 5C work culture increased by
tingkat perputaran karyawan pada periode pelaporan 12%, accompanied by a significant decrease in employee
menurun cukup signifikan dari 17,7% pada tahun 2024 turnover during the reporting period from 17.7% in 2024
menjadi 13,3%. Selain itu, perbaikan pada stabilitas to 13.3%. Additionally, improvements in the stability of
tenaga medis dan kesiapan talenta, diikuti dengan medical staff and talent readiness were accompanied
penguatan sistem pengembangan kompetensi dan by strengthening of the competency development and
kepemimpinan. Capaian ini memperkuat peran SDM leadership systems. These achievements reinforce the
sebagai fondasi mutu layanan dan keberlanjutan kinerja role of HR as the foundation of service quality and the
BMHS. sustainability of BMHS’s performance.
Peran dan Proses yang dilakukan Direksi Board of Directors’ Role and Processes
Direksi berperan aktif dalam merumuskan dan The Board of Directors plays an active role in
mengarahkan implementasi strategi BMHS. formulating and guiding BMHS’s strategy
Penyusunan kebijakan strategis dilakukan dengan implementation. Strategic policy formulation is
prinsip kehati-hatian, mempertimbangkan dinamika conducted using a prudential principle, taking into
Page 25
Laporan Tahunan
Annual Report 25
regulasi, kondisi industri, serta kesiapan internal, account regulatory dynamics, industry conditions, and
khususnya dari sisi SDM dan struktur biaya. internal readiness, particularly regarding human capital
and cost structure.
Direksi melakukan pemantauan kinerja secara The Board of Directors conduct regular performance
berkala melalui indikator kinerja utama, evaluasi monitoring through key performance indicators,
operasional dan keuangan, serta penyesuaian kebijakan operational and financial evaluations, and responsive
secara responsif. Langkah tersebut dilakukan untuk policy adjustments. These steps are taken to ensure
memastikan efektivitas implementasi strategi the effectiveness of strategy implementation and to
serta menjaga fleksibilitas BMHS dalam merespons maintain BMHS’s flexibility in responding to changes
perubahan lingkungan usaha. Direksi juga mendorong in the business environment. The Board of Directors
keterlibatan seluruh manajemen dan insan BMHS also encourage the involvement of all management and
melalui budaya kerja dan pemanfaatan sistem dan employees through a work culture and the use of digital
platform digital untuk mendukung pengambilan systems and platforms to support data driven decision
keputusan berbasis data. making.
Perbandingan Target dan Realisasi Comparison of Targets and Realization
Pada 2025, kinerja Perseroan menunjukkan dinamika In 2025, the Company’s performance showed
sepanjang tahun, khususnya pada semester I yang fluctuations throughout the year, particularly in the
dipengaruhi oleh perubahan regulasi serta proses first half, which was affected by regulatory changes and
konsolidasi operasional. Memasuki semester II, kinerja operational consolidation. Entering the second half,
mulai menunjukkan perbaikan yang tercermin dari performance began to improve, as reflected in increased
peningkatan pendapatan dan volume layanan, termasuk revenue and service volumes, including inpatient care,
rawat inap, tindakan bedah, utilisasi tempat tidur, serta surgical procedures, bed occupancy, and contributions
kontribusi layanan spesialis non-obgyn dan pediatri. from non-obgyn and pediatric specialist services.
Perseroan terus menjalankan inisiatif peningkatan The Company continues to implement initiatives to
kapasitas tempat tidur sebagai bagian dari optimalisasi increase bed capacity as part of its asset optimization
aset. Implementasi dilakukan secara bertahap, dengan efforts. Implementation is being carried out in
kontribusi yang diharapkan semakin terlihat terhadap phases, with the expected contributions becoming
pertumbuhan kinerja pada periode mendatang. increasingly evident in performance growth in the
Sementera dari sisi profitabilitas, kinerja BMHS coming periods. Meanwhile, in terms of profitability,
menunjukkan penguatan yang solid, tercermin pada BMHS’s performance shows solid improvement,
perbaikan margin laba kotor dan EBITDA. Secara reflected in the improvement of gross profit margins
keseluruhan, BMHS mencatatkan pertumbuhan dua and EBITDA. Overall, BMHS recorded double-digit
digit pada laba bersih dibandingkan tahun sebelumnya, growth in net profit compared to the previous year, in
sejalan dengan peningkatan pendapatan. Pencapaian ini line with increased revenue. This achievement reflects
mencerminkan keberhasilan BMHS dalam memperbaiki BMHS’s success in improving margins, strengthening
margin, memperkuat struktur biaya, meningkatkan cost structure, increasing the contribution of services
kontribusi layanan di luar ibu dan anak, serta menjaga beyond women and children care, and maintaining the
stabilitas tenaga medis dan retensi sumber daya stability of medical staff and human resource retention.
manusia.
Tantangan dan Kebijakan Mengatasi Tantangan Challenges and Policies to Address Challenges
Direksi menghadapi beberapa tantangan dalam The Board of Directors dealt several challenges in
mengelola BMHS sepanjang 2025. Dinamika kebijakan managing BMHS throughout 2025. The dynamics of
pembiayaan kesehatan, baik dari Jaminan Kesehatan healthcare financing policies, both from the National
Nasional (JKN) maupun asuransi memengaruhi pola Health Insurance (JKN) and private insurance,
rujukan, struktur pendapatan, serta tekanan biaya influenced referral patterns, revenue structure, and
di sejumlah unit rumah sakit. Tantangan lain adalah cost pressures in several hospital units. Another
meningkatnya kompleksitas kebutuhan dan kebutuhan challenge was the increasing complexity of patient
Page 26
26 Kilas Kinerja
Performance Overview
pasien, yang menuntut kesiapan layanan klinis yang needs and demands, which required higher clinical
lebih tinggi dan konsistensi mutu layanan. Selain itu service readiness and consistent service quality.
terdapat keterbatasan ketersediaan SDM, khususnya Additionally, there were limitations in the availability
tenaga medis dan dokter spesialis. of human capital, particularly competent medical staff
and specialists.
Direksi merespons tantangan tersebut dengan The Board of Directors is addressing these
berbagai pendekatan. Direksi melakukan penyesuaian challenges through a number of approaches.
operasional melalui disiplin biaya, evaluasi The Board of Directors are implementing
struktur layanan, serta pengelolaan pasien, tanpa operational adjustments through cost discipline,
mengesampingkan prinsip inklusivitas layanan. Direksi service structure evaluation, and patient management,
juga memperkuat kapabilitas klinis pada layanan without compromising the principle of service
prioritas, menyamakan standar patient journey, serta inclusivity. The Board of Directors are also
memastikan kesiapan sistem dan tim medis di seluruh strengthening clinical capabilities in priority services,
jaringan. Pada sisi SDM, Direksi fokus pada pengelolaan standardizing the patient journey, and ensuring the
talenta dan hubungan jangka panjang dengan tenaga readiness of systems and medical teams across the
medis melalui pengembangan kompetensi, sistem entire network. On the human capital side, the Board
pembelajaran klinis, serta penguatan tata kelola klinis. of Directors are focusing on talent management and
long-term relationships with medical staff through
competency development, clinical learning systems,
and the strengthening of clinical governance.
Prospek Usaha Business Outlook
Industri layanan kesehatan Indonesia tetap prospektif, Indonesia’s healthcare industry remains promising,
sesuai posisinya sebagai sektor prioritas untuk given its position as a priority sector for supporting
mendukung kehidupan. Perubahan demografi dan life. Demographic shifts and growing public health
kesadaran kesehatan masyarakat turut membentuk awareness are shaping the industry’s future outlook.
prospek industri ke depan. Pertumbuhan keluarga The growth of young families, the rising prevalence
muda, meningkatnya prevalensi penyakit kronis, of chronic diseases, and the expanding elderly
serta bertambahnya populasi usia lanjut mendorong population are driving the need for more integrated and
kebutuhan layanan kesehatan yang lebih terintegrasi trustworthy healthcare services.
dan terpercaya.
Prospek usaha ke depan bertumpu pada kemampuan Future business prospects hinge on the ability to
menghadirkan layanan dalam satu ekosistem disertai deliver services within a single ecosystem supported
dengan kehadiran teknologi. Menjawab prospek by technology. To respond to these prospects, the
tersebut, Direksi menempatkan layanan ibu dan anak Board of Directors are prioritizing women and children
serta pengembangan layanan medis kompleks sebagai health services and the development of complex
prioritas pendorong pertumbuhan. Selain itu, BMHS medical services as key drivers for growth. Additionally,
akan melakukan ekspansi yang terukur dan berbasis BMHS will pursue measured expansion based on
kesiapan internal, menyeimbangkan penguatan internal readiness, balancing the strengthening of
fundamental, disiplin struktur biaya, penyiapan SDM, fundamentals, cost structure discipline, human capital
pemanfaatan teknologi medis presisi, serta tetap development, the use of precision medical technology,
konsisten memperdalam fokus layanan ibu dan anak and will be consistently deepening our focus on women
melalui subspesialis. and children services through subspecialists.
Penerapan Governansi Governance Implementation
Direksi menempatkan governansi sebagai kerangka The Board of Directors sees governance as the
kerja dalam mengambil keputusan, mengelola framework for decision-making, risk management, and
risiko, dan menjaga integritas yang berbasis maintaining integrity based on public trust. The ethical
kepercayaan publik. Prinsip perilaku beretika, conduct, transparency, and accountability principles
transparansi, dan akuntabilitas diterapkan di seluruh are applied throughout BMHS’s ecosystem, and the
Page 27
Laporan Tahunan
Annual Report 27
ekosistem BMHS. Direksi memastikan penerapan Board of Directors ensure the corporate governance
governansi korporat dan aspek LST sebagai satu and ESG aspects are applied in an integrated whole
kesatuan terintegrasi dalam pengelolaan BMHS. in the management of BMHS. Through the “IBU” ESG
Melalui kerangka LST “IBU”, BMHS mewujudkan framework, BMHS applies sustainable governance,
governansi keberlanjutan, antara lain dengan which includes strengthening internal control systems
memperkuat sistem pengendalian internal dan and risk management; efficient and responsible
manajemen risiko; praktik operasional yang efisien dan operational practices; and a commitment to maintaining
bertanggung jawab; serta komitmen menjaga mutu service quality, patient safety, and public trust. In
layanan, keselamatan pasien, dan kepercayaan publik. practice, BMHS applies an anti-corruption system
Pada praktiknya, BMHS melakukan implementasi through the application of a strict code of ethics, the
sistem antikorupsi melalui penerapan kode etik yang requirement for all partners and employees to sign
ketat, kewajiban penandatanganan pakta integritas integrity pacts, and clear separation of functions to
bagi seluruh mitra dan SDM, serta pemisahan fungsi avoid potential conflicts of interest.
yang jelas untuk menghindari potensi benturan
kepentingan.
BMHS terus menyempurnakan penerapan governansi BMHS continues to refine its corporate governance
korporat, salah satunya dengan asesmen governansi practices, including its external governance assessments
secara eksternal dengan mengacu pada prinsip dan based on the principles and recommendations
rekomendasi Pedoman Umum Governansi Korporat of the Indonesian Corporate Governance
Indonesia. Pada 2025, Perseroan melakukan Code. In 2025, the Company’s conducted an
pengukuran penerapan GCG dengan eksternal assesor assessment of our corporate governance
sesuai dengan indikator Pedoman Umum Governansi implementation with an external assessor in
Korporat Indonesia (PUGKI) dengan skor 96,3 accordance with the indicators of the Indonesian
dengan kategori Sangat Baik serta Asean Corporate General Corporate Governance Guidelines (PUGKI),
Governance Scorecard (ACGS) dengan skor 106,50 achieving a score of 96.3 and a rating of Very Good, as
dengan kategori Leadership in Corporate Governance. well as the ASEAN Corporate Governance Scorecard
Asesmen ini merupakan sarana evaluasi yang (ACGS), achieving a score of 106.50 and a rating of
independen untuk mengidentifikasi area perbaikan dan Leadership in Corporate Governance. This assessment
pertumbuhan masa depan. serves as an independent evaluation tool to identify
areas for improvement and future growth.
Penutup dan Apresiasi Closing and Appreciation
Direksi menyampaikan apresiasi dan terima kasih The Board of Directors would like to express our
kepada seluruh pemangku kepentingan atas appreciation and gratitude to all stakeholders for the
kepercayaan dan dukungan yang diberikan kepada trust and support extended to PT Bundamedik Tbk
PT Bundamedik Tbk sepanjang 2025. Direksi percaya throughout 2025. The Board of Directors believe that
keterlibatan dan kolaborasi yang terbangun di seluruh this engagement and collaboration fostered across
ekosistem BMHS menjadi fondasi utama dalam BMHS’s entire ecosystem will serve as the primary
mewujudkan kinerja selanjutnya, sejalan dengan foundation for achieving future performance, in line
semangat Engage to Perform. with the spirit of Engage to Perform.
Jakarta, April 2026
Atas Nama Direksi | On behalf of the Board of Directors
Agus Heru Darjono
Direktur Utama
President Director
Page 28
28 Profil Perusahaan
Company Profile
Profil Perusahaan
Company Profile
Identitas Perusahaan
Company Identity
PT Bundamedik Tbk
Nama Perusahaan
BMHS tidak melakukan perubahan nama hingga akhir tahun 2025.
Company Name
BMHS did not change its name during 2025.
Bidang Usaha Aktivitas rumah sakit swasta.
Business Field Activities of private hospitals.
Tanggal Pendirian 13 April 1978
Date of Establishment April 13, 1978
Akta Pendirian BMHS Terbatas No. 21 tanggal 13 April 1978, yang
Dasar Hukum Pendirian dibuat di hadapan Adlan Yulizar, S.H., Notaris di Jakarta.
Legal Basis of Establishment Deed of Establishment as a Limited Liability Company No. 21 dated
April 13, 1978, made before Adlan Yulizar, S.H., Notary in Jakarta.
Modal Dasar
Rp400.000.000.000
Authorized Capital
Modal Ditempatkan dan Disetor
Penuh Rp172.068.323.520
Issued and Fully Deposited Capital
Kode Saham
BMHS
Share Code
PT Bundamedik Tbk
Jl. Teuku Cik Ditiro No. 28 Menteng, Jakarta 10350 –Indonesia
Nomor Telepon: (021) 3192-3344/(021) 3190-5915
Situs web: www.bmhs.co.id
Alamat Email: corsec@bmhs.co.id
Address
BMHS tidak memiliki kantor cabang/perwakilan sampai dengan
akhir 2025.
BMHS did not have any branch/representative offices until the end
of 2025.
Sekilas Perusahaan
Company Overview
Berawal dari klinik bersalin yang didirikan oleh dr. Starting as a maternity clinic established by dr. Rizal Sini,
Rizal Sini, Sp. OG pada 1961, PT Bundamedik Tbk Sp.OG, in 1961, PT Bundamedik Tbk grew and evolved
tumbuh dan berkembang hingga diresmikan sebagai until it was officially established as Rumah Sakit Bersalin
Rumah Sakit Bersalin Bunda pada 27 Maret 1973. Bunda on March 27, 1973. Subsequently, through the
Selanjutnya, melalui Akta Pendirian BMHS Terbatas No. Deed of Establishment of a Limited Liability Company
21 tanggal 13 April 1978, Rumah Sakit Bersalin Bunda No. 21 dated 13 April 1978, Rumah Sakit Bersalin
dikukuhkan badan hukumnya sebagai PT Bundamedik, Bunda was legally incorporated as PT Bundamedik and
dan memperoleh pengesahan Kementerian Kehakiman obtained approval from the Ministry of Justice based
Page 29
Laporan Tahunan
Annual Report 29
melalui Surat Keputusan No. YA.5/160/18 tanggal on Decree No. YA.5/160/18 dated September 28, 1978,
28 September 1978, serta diumumkan dalam Berita and was later announced in the State Gazette of the
Negara Republik Indonesia No. 555 tanggal 3 Juni 1988. Republic of Indonesia No. 555 dated 3 June 1988.
Seiring meningkatnya kepercayaan dan kebutuhan In line with increasing public trust and growing
masyarakat, PT Bundamedik Tbk memperluas healthcare needs, PT Bundamedik Tbk expanded its
layanannya dan mendirikan berbagai anak perusahaan services and established subsidiaries focusing on
yang berfokus di layanan kesehatan, penunjang medis, healthcare services, medical support services, as well as
serta sektor pendukung seperti perhotelan, medical supporting sectors such as hospitality, medical tourism,
tourism, dan konsultasi manajemen. Keseluruhan and management consulting. These services—ranging
layanan tersebut, mulai dari rumah sakit, klinik, from hospitals, clinics, fertility centers, and laboratories
pusat fertilitas, laboratorium, hingga layanan to other supporting services—were integrated to
penunjang lainnya; saling terintegrasi sehingga form a comprehensive and interconnected BMHS
membentuk ekosistem BMHS yang lengkap dan saling ecosystem. Innovation served as the foundation for
mendukung. Inovasi menjadi fondasi pertumbuhan BMHS’s growth, including the provision of robotic-
BMHS, termasuk penyediaan operasi minimal assisted minimally invasive surgery, the adoption of
invasif berbasis robotik, penerapan teknologi Preimplantation Genetic Screening and Time-Lapse
Preimplantation Genetic Screening (PGS) dan Time Lapse Embryo Monitoring technologies through Morula IVF
Embryo Monitoring melalui Morula IVF Indonesia, Indonesia, development of kidney transplant services,
transplantasi ginjal, robotic skin sparing mastectomy, dan robotic skin sparing mastectomy, and enhancement
Neonatal Intensive Care Unit (NICU) dengan program of Neonatal Intensive Care Unit services through the
the Family Integrated CARE (FICARE) untuk mendukung Family Integrated CARE (FICARE) program to support
keterlibatan orang tua dalam perawatan bayi prematur parental involvement in the care of premature babies
dan meningkatkan keberhasilan menyusui. and increase breastfeeding success.
Momentum pertumbuhan ini kemudian diperkuat This growth momentum was further strengthened by
dengan pencatatan saham BMHS di Bursa Efek BMHS’s listing on the Indonesia Stock Exchange in
Indonesia pada 2021, yang mendukung penguatan 2021, which supported capital strengthening and the
permodalan dan ekspansi ekosistem layanan kesehatan expansion of its healthcare services ecosystem through
melalui akuisisi sejumlah rumah sakit. Selanjutnya, the acquisition of several hospitals. Subsequently,
BMHS melakukan peningkatan kapasitas, integrasi BMHS enhanced its capacity, integrated services, and
layanan, dan standardisasi operasional dalam jaringan standardized operations across the BMHS network.
BMHS. Transformasi digital dilaksanakan secara Digital transformation has been implemented in stages,
bertahap, termasuk pengembangan platform One including the development of the OneBunda platform
Bunda sebagai sistem integrasi layanan dan informasi as an integrated service and patient information system
pasien di seluruh ekosistem. BMHS juga memastikan across the ecosystem. BMHS also ensures compliance
pemenuhan standar akreditasi nasional dan with national and international accreditation standards
internasional guna menjaga mutu layanan. to maintain service quality.
Secara organisasi, BMHS terus memperkuat Organizationally, BMHS continued to strengthen
governansi korporat melalui penyempurnaan kebijakan, its corporate governance through the refinement of
peningkatan efektivitas pengawasan, serta perbaikan policies, enhanced supervisory effectiveness, and
proses pengendalian internal dan manajemen risiko. improvements in internal control and risk management
Integrasi prinsip-prinsip keberlanjutan ke dalam processes. The integration of sustainability principles
proses bisnis terus dilakukan dengan menerapkan into business processes remains a priority, and is
aspek Kerangka Kerja Lingkungan, Sosial, dan Tata implemented through the Environmental, Social, and
Kelola (LST) “IBU” yang menjadi pilar keberlanjutan Governance (ESG) Framework “IBU”, which serves as
BMHS. Melalui kerangka ini, BMHS memastikan bahwa BMHS’s sustainability pillar. Through this framework,
setiap keputusan strategis, operasional, dan pelayanan BMHS ensures that all strategic, operational, and
tetap berorientasi pada praktik bisnis yang bertanggung service-related decisions are aligned with responsible
Page 30
30 Profil Perusahaan
Company Profile
jawab, pengelolaan dampak lingkungan yang lebih baik, business practices, improved environmental impact
serta peningkatan kualitas pelayanan dan keselamatan management, and continuous enhancement of service
pasien. quality and patient safety.
Penguatan Centers of Excellence terus dilakukan melalui The strengthening of the Centers of Excellence continues
pengembangan teknologi medis, penyempurnaan through the development of medical technologies, the
prosedur, dan peningkatan kompetensi tenaga refinement of clinical procedures, and the enhancement
kesehatan. Implementasi bedah robotik generasi of healthcare professionals’ competencies. The second-
kedua ini menghadirkan presisi lebih tinggi, minimal generation robotic surgery has delivered greater
invasif, dengan pemulihan yang lebih cepat bagi pasien. precision advantages and expanded the range of
Di bidang uro-nefrologi, BMHS mencatatkan tingkat minimally invasive treatment options for patients. In
keberhasilan sangat baik untuk transplantasi ginjal. the field of uro-nephrology, BMHS has achieved a very
Selain itu, BMHS juga menjadi pionir inovasi robotik strong success rate in kidney transplant procedures.
skin sparing mastectomy di Asia Tenggara dan memberi In addition, BMHS has pioneered robotic skin sparing
pendekatan perawatan yang lebih aman serta estetis mastectomy in Southeast Asia, offering a safer and
bagi pasien kanker payudara. Pada entitas anak, Morula more aesthetically favorable treatment approach for
IVF Indonesia mengembangkan inovasi fertilitas seperti breast cancer patients. At the subsidiary level, Morula
Preimplantation Genetic Testing for Aneuploidy (PGT-A), IVF Indonesia has advanced fertility innovations such
sementara Diagnos memperkuat layanan diagnostik as Preimplantation Genetic Testing for Aneuploidy
melalui peluncuran Smart MCU Report berbasis AI, (PGT-A), while Diagnos has strengthened diagnostic
yang memungkinkan deteksi risiko kesehatan secara services through the launch of an AI-based Smart MCU
lebih akurat dan komprehensif. Report, enabling more accurate and comprehensive
health risk detection.
Enam pilar Investment Highlights menggambarkan The six pillars of the Investment Highlights describes
arah strategis BMHS dalam memperkuat daya saing BMHS’s strategic direction in strengthening its
dan menciptakan nilai jangka panjang bagi pemangku competitiveness and creating long-term value for
kepentingan. stakeholders.
Strategic Ecosystem Healthcare Synergy
01
Fokus dalam membangun ekosistem layanan Focusing on the development of an integrated
kesehatan yang terintegrasi dengan sinergi healthcare services ecosystem through strong
seluruh jaringannya yang mencakup seluruh fase synergy across the entire network, covering all
kehidupan. stages of life.
Organization Fundamental Improvement
02
Mencerminkan upaya BMHS untuk terus Reflecting BMHS’s ongoing efforts to strengthen
memperkuat fondasi organisasi melalui its organizational foundation by fostering a
pembentukan lingkungan kerja yang sehat, healthy work environment, to develop future
pengembangan kepemimpinan masa depan leaders through talent management programs,
melalui program manajemen talenta, serta and to ensure equal opportunities for all
penerapan peluang yang setara bagi seluruh employees to grow and assume leadership roles.
karyawan untuk berkarier dan memimpin. Upaya These fundamental improvements are also
peningkatan fundamental ini turut tercermin reflected in a lower employee turnover rate and
dari membaiknya tingkat turnover karyawan dan the strengthened implementation of the ESG
penguatan implementasi Kerangka Kerja LST di Framework across all units and subsidiaries.
seluruh unit dan anak usaha.
Page 31
Laporan Tahunan
Annual Report 31
Customer Perception & Trust
03
Menekankan pentingnya persepsi dan kepercayaan Emphasizing the importance of customer
pelanggan. BMHS terus menyempurnakan perception and trust. BMHS continuously
patient journey melalui OneBunda dan penguatan enhances the patient journey through OneBunda
kompetensi sumber daya manusia melalui program and strengthens the competencies of human
pelatihan yang terstruktur. Upaya ini berdampak capital through structured training programs.
pada peningkatan mutu layanan dan capaian indeks These efforts contribute to improved service
kepuasan pelanggan. quality and higher customer satisfaction index
achievements.
Strengthen Center of Excellence (CoE) of Women & Children
04
Fokus BMHS untuk terus memperkuat Center of Underscoring BMHS’s focus on
Excellence (CoE) layanan ibu dan anak, yang menjadi continuously enhancing its Women and Children
kompetensi inti dan diferensiasi utamanya. BMHS Centers of Excellence, which represent its core
meluncurkan layanan Bunda Homecare, layanan competencies and key differentiators. BMHS
kunjungan medis langsung ke tempat pasien, has launched Bunda Homecare, a medical home-
yang menyediakan vaksinasi dan pemeriksaan visit service providing vaccinations and health
kesehatan. Selain itu, kapasitas dan kualitas screenings. In addition, service capacity and quality
layanan juga ditingkatkan termasuk penguatan are further enhanced, including the strengthening
dan penambahan fasilitas NICU bagi bayi baru lahir and expanding NICU facilities for newborns
dengan kondisi khusus. requiring specialized care.
Leading Healthcare Innovation through Centers of Excellence
05
Menunjukkan langkah strategis penguatan Demonstrating strategic initiatives to strengthen
Center of Excellence (CoE) dalam kepemimpinan Centers of Excellence (CoE) as leaders in
inovasi layanan kesehatan di Indonesia dengan healthcare innovation in Indonesia by introducing
menghadirkan teknologi dan prosedur medis internationally standardized medical technologies
berstandar internasional. and procedures.
Maximizing Current Asset Utilisation
06
Memastikan bahwa setiap aset yang dimiliki BMHS Ensuring that all Company assets deliver optimal
memberikan kinerja optimal melalui efisiensi performance through operational efficiency,
operasional, peningkatan kapasitas layanan, serta increased service capacity, and optimized
optimalisasi pemanfaatan fasilitas dan jaringan utilization of facilities and the broader PT
ekosistem PT Bundamedik Tbk. Bundamedik Tbk ecosystem network.
Page 32
32 Profil Perusahaan
Company Profile
Jejak
Langkah
Milestones
1970 2015
1973 2006 2010
dr. Rizal Sini, Sp.OG mendirikan BMHS melakukan BMHS mendirikan anak
Rumah Sakit Bersalin Bunda di perubahan nama Klinik perusahaan bernama PT Prima
Jakarta. Fertilitas Morula (KFM) Dental Medika.
dr. Rizal Sini, Sp.OG established menjadi Morula IVF BMHS established a subsidiary
Rumah Sakit Bersalin Bunda in Jakarta. called PT Prima Dental
Jakarta. BMHS changed the name Medika.
of Morula Fertility Clinic
(KFM) to Morula IVF
Jakarta.
1978 2012
• Rumah Sakit Bersalin Bunda resmi • BMHS mendirikan anak perusahaan
menjadi usaha pelayanan rumah sakit bernama PT Morula Indonesia,
berbadan hukum dengan pendirian 2007 PT Visiscan Indonesia, dan PT Sasana
PT Bundamedik. Mitra Bunda.
BMHS mendirikan perusahaan
• Kerja sama dengan Queen Elizabeth • RS Bunda Group menjadi rumah sakit
asosiasi bernama
Hospital dan University of Adelaide, pertama yang melaksanakan operasi
PT Diagnos Laboratorium Utama.
Australia. dengan teknologi bedah robotik (robotic
BMHS established an associated
• Rumah Sakit Bersalin Bunda officially surgery) untuk operasi invasif minimal.
company called
became a legal entity hospital service • BMHS established subsidiaries called PT
PT Diagnos Laboratorium Utama.
business with the establishment of Morula Indonesia, PT Visiscan Indonesia,
PT Bundamedik. and PT Sasana Mitra Bunda.
• Collaborated with Queen Elizabeth • RS Bunda Group became the first hospital
Hospital and University of Adelaide,
Australia. 2008 to perform surgeries using surgical
technology robotic surgery for minimally
RSU Bunda Margonda mulai invasive surgery.
beroperasi.
1995 Bunda Margonda Hospital
started operating.
• BMHS mendirikan anak perusahaan 2013
bernama PT Bunda Minang Citra. • BMHS mengelola 3 klinik fertilitas
• Rumah Sakit Umum Bunda Padang di bawah Morula IVF Indonesia yang
mulai beroperasi. terletak di Padang, Margonda, dan
• BMHS established a subsidiary Surabaya.
called PT Bunda Minang Citra.
• RSIA Citra Ananda mulai beroperasi.
• Rumah Sakit Umum Bunda Padang
• BMHS manages 3 fertility clinics under
began operations.
Morula IVF Indonesia located in Padang,
Margonda and Surabaya.
• Citra Ananda Women and Children
Hospital began operations.
1997
• BMHS mengoperasikan
Klinik IVF pertama.
2015
• BMHS mendirikan Klinik Morula IVF Indonesia menjadi klinik
Fertilitas Morula (KFM). IVF pertama untuk memperkenalkan
• BMHS operated its first Preimplantation Genetic Screening (PGS).
IVF Clinic. Morula IVF Indonesia became the first IVF
• BMHS established Klinik clinic to introduce Preimplantation Genetic
Fertilitas Morula (KFM). Screening (PGS).
Page 33
Laporan Tahunan
Annual Report 33
2016 2025
2016 2018 2022
• BMHS mendirikan anak Morula IVF Indonesia • BMHS melakukan akuisisi atas RSU Citra Harapan, RSJP
perusahaan bernama PT Bunda mengelola klinik IVF di Paramarta Bandung, dan RSIA Pusura Tegalsari.
Medika Wisesa. Tangerang dan Yogyakarta. • BMHS mendirikan anak perusahaan dengan nama PT Bunda
• Morula IVF Indonesia mengelola Morula IVF Indonesia managed Graha Properti.
klinik fertilitas di RS Melinda 2 IVF clinics in Tangerang and • BMHS melakukan penambahan jumlah kepemilikan saham
Bandung. Yogyakarta. di PT Diagnos Laboratorium Utama Tbk menjadi mayoritas
• Morula IVF Indonesia sebesar 41,20%.
memperkenalkan teknologi • BMHS acquired Citra Harapan Hospital, RSJP Paramarta
baru yaitu Time Lapse Embryo 2019 Bandung, and Pusura Tegalsari Women and Children
Monitoring System. Grand Opening Klinik BIC Vida, Hospital.
• Morula IVF Jakarta diakreditasi Laboratorium Klinik Diagnos • BMHS established a subsidiary called PT Bunda Graha
oleh The Reproductive Ciputat & Klinik Onkologi RSU Properti.
Technology Accreditation Bunda Jakarta. • BMHS increased its share ownership in PT Diagnos
Committee (RTAC) – Fertility Grand Opening of BIC Vida Laboratorium Utama Tbk to a majority of 41.20%.
Society of Australia. Clinic, Ciputat Diagnos Clinic
• BMHS established a subsidiary Laboratory & Oncology Clinic
called PT Bunda Medika Wisesa. Bunda Jakarta Hospital.
2023
• Morula IVF Indonesia managed • BMHS meresmikan RSIA Bunda Denpasar.
a fertility clinic at RS Melinda 2 • Hari jadi BMHS ke-50 tahun.
Bandung. 2020 • Peluncuran “OneBunda”, platform digital yang menyatukan
• Morula IVF Indonesia Grand Opening Laboratorium rangkaian layanan kesehatan dalam ekosistem BMHS.
introduced new technology, Klinik Diagnos Padang. • BMHS inaugurated Bunda Denpasar Women and Children Hospital.
namely the Time Lapse Embryo Grand Opening of Diagnos • BMHS’s 50th anniversary.
Monitoring System. Clinical Laboratory Padang. • Launch of “OneBunda”, a digital platform that brings together a
• Morula IVF Jakarta was range of health services in BMHS’s ecosystem.
accredited by The Reproductive
Technology Accreditation 2021
Committee (RTAC) – Fertility • BMHS melakukan Penawaran
Society of Australia. Umum Perdana pada 6 Juli 2021 2024
dengan kode saham BMHS. • Transplantasi ginjal pertama di RSU Bunda Jakarta.
• BMHS mendirikan PT Bunda Medika • Kolaborasi Morula IVF Indonesia dengan Jinxin Life Asia
Dewata. Healthcare Investment Group Pte. Ltd.
• BMHS melakukan akuisisi atas PT • The first kidney transplant at Bunda Hospital Jakarta.
Pintu Ilmu, pemilik dan pengelola • Morula IVF Indonesia collaboration with Jinxin Life Asia
2017 RSIA Az Zahra Palembang. Healthcare Investment Group Pte. Ltd.
• BMHS mendirikan anak • Perubahan nama RSIA Citra Ananda
perusahaan bernama PT BMHS
Diklat Indonesia dan PT Bunda •
menjadi RSIA Bunda Ciputat.
Perubahan nama RSU BMC Padang 2025
Global Pharma. menjadi RSU Bunda Padang.
• • Peresmian Bunda Executive Clinic di RSU Bunda
• Morula IVF Indonesia mengelola BMHS conducted an Initial Public
klinik IVF di Makassar dan Offering on July 6, 2021 under the Padang.
Pontianak. stock code BMHS. • Peluncuran Bunda Homecare.
• Morula IVF Indonesia • BMHS established PT Bunda • Peresmian Bunda Clinic MRT Dukuh Atas, klinik
beroperasi dengan entitas Medika Dewata.
pertama BMHS di pusat transportasi publik.
sendiri. • BMHS acquired PT Pintu Ilmu,
• BMHS established subsidiaries owner and manager of Az Zahra • Akuisisi Rumah Sakit Ibu dan Anak Pusura Tegalsari
called PT BMHS Diklat Palembang Women and Children dari PT Morula Indonesia ke PT Bundamedik Tbk.
Indonesia and PT Bunda Global Hospital. • Inauguration of Bunda Executive Clinic at Bunda
Pharma. • Name change of Citra Ananda Padang Hospital.
• Morula IVF Indonesia managed Women and Children Hospital
to Bunda Ciputat Women and
• Launch of Bunda Homecare.
IVF clinics in Makassar and
Pontianak. Children Hospital. • Inauguration of Bunda Clinic MRT Dukuh Atas, BMHS’s
• Morula IVF Indonesia operated • Name change of BMC Padang first clinic located within a public transportation hub.
as its own entity. Hospital to Bunda Padang • Acquisition of Rumah Sakit Ibu dan Anak Pusura
Hospital.
Tegalsari from PT Morula Indonesia by PT Bundamedik
Tbk.
Page 34
34 Profil Perusahaan
Company Profile
Visi, Misi, dan Nilai
Perusahaan
Vision, Mission, and
Values of the Company
Visi Nilai Perusahaan Misi
Company Values
Vision Mission
PT Bundamedik Tbk menjadi 1. Terus berkembang dalam
grup penyedia layanan penyediaan layanan kesehatan
kesehatan terdepan yang yang memiliki kekhususan.
paling bernilai dan inovatif di 2. Memiliki efisiensi yang tinggi
Indonesia. dalam bisnis dan investasi.
3. Memiliki sumber daya manusia
PT Bundamedik Tbk to
become the most valuable and yang bermotivasi tinggi dan
innovative leading healthcare produktif.
group in Indonesia. 4. Mengembangkan ekspansi
bisnis yang inovatif di bawah
BMHS 5C payung layanan kesehatan.
1. Continually developing in very
specific healthcare services.
2. Having high efficiency in
business and investment.
3. Having highly motivated and
productive human resources.
4. Developing innovative
business expansion under one
umbrella of healthcare.
Page 35
Laporan Tahunan
Annual Report 35
Nilai-Nilai Perusahaan
Corporate Values
BMHS 5C ditetapkan sebagai nilai dan budaya BMHS. BMHS 5C values have been established as BMHS’s
Nilai - nilai ini mengokohkan 9 indikator perilaku untuk core values and culture. These values underpin nine
menciptakan individu BMHS yang unggul, berkualitas, behavioral indicators designed to foster outstanding,
serta memiliki kompetensi dan karakter yang baik. high-caliber employees who possess strong
competencies and good character.
Compassion Change Agility
Compassion Change Agility
Kesadaran welas-asih dalam bentuk empati dan Cerdas dan tangkas dalam menghadapi setiap tantangan
simpati yang diwujudkan dalam pelayanan tulus secara dan perubahan.
berkesinambungan untuk mendorong setiap individu Smart and agile in facing every challenge and change.
bertumbuh-kembang menjadi lebih baik.
Compassion awareness in the manner of empathy and
sympathy expressed in sincere service on an ongoing basis
to encourage each individual to grow and develop for the
better. Collaboration
Integrity Collaboration
Jujur dan dapat dipercaya dalam setiap tindakan, setia Berpikir terbuka, berkomunikasi secara efektif, dan
pada etika profesi dan etika bisnis yang sejalan dengan membangun kerja sama sinergis.
nilai-nilai organisasi. Open-minded, communicate effectively, and build
Honest and trustworthy in every action, loyal to synergistic partnerships.
professional and business ethics in accordance with
Communication
organizational values.
Berpikir terbuka, bersikap sopan, menyampaikan ide dan
Ownership gagasan secara efektif untuk membangun komitmen dan
Memiliki inisiatif, mandiri, tekun, bertanggung jawab, setia hubungan baik.
pada profesi dan Perusahaan. Open-minded, polite, communicate ideas effectively to
Have the initiative, be independent, diligent, responsible, build commitment and rapport.expectations to increase
loyal to the profession and the Company. customers loyalty.
Teamwork
Menghargai perbedaan, bekerja sama secara efektif,
membangun tim, dan mengelola konflik secara produktif.
Competence Value differences, work together effectively, build teams,
and manage conflict productively.
Competence
Mampu memimpin diri sendiri dalam memberikan yang
terbaik dan terus belajar untuk meningkatkan kemampuan.
Able to lead oneself in giving the best and continue to learn
to improve one’s abilities. Create Innovation
Service Excellence Create Innovation
Mampu memberikan layanan di atas harapan yang Proaktif melakukan perbaikan berkelanjutan, berani
diinginkan dalam meningkatkan loyalitas pelanggan. menyampaikan ide-ide baru yang kreatif dan inovatif.
Able to provide services above and beyond the desired Proactively carry out continuous improvements, dare to
expectations to increase customers loyalty. deliver new creative and innovative ideas.
Leadership
Mampu menjadi teladan, memimpin diri sendiri dan orang
lain, serta menciptakan kader.
Able to be a role model, lead oneself and others, and create
cadres.
Result with Quality
Engage to
Menguasai pekerjaan dalam bidangnya dengan
mengedepankan produktivitas dan hasil yang berkualitas.
Work mastery in one’s field through prioritizing
productivity and highquality results.
Perform
Page 36
36 Profil Perusahaan
Company Profile
Kegiatan Usaha
Business Activities
Berdasarkan Pasal 3 Anggaran Dasar PT Bundamedik Based on Article 3 of the Articles of Association of PT
Tbk, yang dimuat dalam Akta Pernyataan Keputusan Bundamedik Tbk, as set forth in the Deed of Statement
Rapat Perubahan Anggaran Dasar Nomor 77 tanggal 19 of Meeting Resolutions concerning Amendments to
Juni 2023, BMHS menjalankan kegiatan usaha utama the Articles of Association No. 77 dated 19 June 2023,
aktivitas rumah sakit swasta serta dapat melaksanakan BMHS carries out its principal business activities in the
kegiatan usaha penunjang, sebagai berikut: field of private hospital operations and also carry out
supporting business activities that include:
1. Membantu pemerintah dalam membina, memupuk, 1. Assisting the Government in developing, cultivating,
dan memelihara kesehatan rakyat dan meningkatkan and maintaining people’d health and improving the
kesejahteraan sosial masyarakat pada umumnya; general social welfare in general;
2. Mendirikan dan menyelenggarakan rumah sakit- 2. Establishing and operating complete and modern
rumah sakit yang lengkap dan modern dan usaha lain hospitals and other related businesses; and
yang ada hubungannya dengan itu; dan
3. Menjalankan usaha yang berkaitan dengan poin 1 3. Carrying out business activities related to points
dan 2 di atas, baik langsung maupun tidak langsung (1) and (2) above, either directly or indirectly, as
asal tidak bertentangan dengan undang-undang dan/ long as it dows not conflict with applicable laws and
atau ketentuan yang berlaku. regulations.
Layanan Kesehatan Healthcare Services
BMHS menyediakan layanan kesehatan holistik yang BMHS provides holistic healthcare services covering
mencakup seluruh fase siklus kehidupan “From Embryo the entire life cycle, “from embryo throughout life.”
Throughout Life”. Dengan pendekatan yang humanis dan With a humanistic and patient-centered approach,
berpusat pada pasien, BMHS menghadirkan pengalaman BMHS delivers a care experience that is comfortable,
layanan yang nyaman, empatik, dan mendukung proses empathetic, and supportive for optimal recovery. Based
pemulihan secara optimal. Sejalan dengan filosofi on the philosophy of “Because Family Matters,” BMHS
“Because Family Matters”, BMHS menyediakan berbagai offers a wide range of services and facilities designed
layanan dan fasilitas yang dirancang untuk memenuhi to meet the healthcare needs of every family member
kebutuhan kesehatan setiap anggota keluarga dalam within a single, integrated healthcare ecosystem.
satu ekosistem layanan yang terpadu.
Page 37
Laporan Tahunan
Annual Report 37
Speciality
Hospital IVF Clinic Diagnostic Lab Medical
Evacuation
Hospitals
Pharmacy
BIC Medical Medical Training
Clinics Tourism Dental Clinics Program &
Research
Ibu & Anak Genomik Reproduksi
Women & Children Reproductive Genomics
Produk Fertilitas
Fertility Products
Gaya Hidup Nutri Genomik
Lifestyle Nutri Genomics
Produk TRB
ART Products
Umum (Dewasa - Geriatri) Onko Genomik
General (Adult - Geriatric) Onco Genomics
Page 38
38 Profil Perusahaan
Company Profile
Layanan kesehatan dalam ekosistem Bundamedik Healthcare services within the Bundamedik Healthcare
Healthcare Systems (BMHS) mencakup: Systems (BMHS) ecosystem include:
Bunda Clinic MRT Dukuh Atas
RS Bunda Group
BMHS mengelola Klinik Pratama yang menyediakan
Menyediakan pelayanan kesehatan Women’s Health,
konsultasi dokter umum, layanan vaksinasi, Immune
Pediatric, Robotic Surgery, Oncology Center, Digestive Center,
booster, Medical Check Up, dan kefarmasian.
Cardiovascular Center, Orthopedic Center, Urology Center,
Brain & Spine Center yang didukung teknologi medis BMHS operates a primary care clinic that offers general
modern. Saat ini BMHS mengoperasikan 5 rumah sakit ibu practitioner consultations, vaccination services, immune
dan anak, 4 rumah sakit umum, dan 1 rumah sakit jantung boosters, medical checkups, and pharmacy services.
dan pembuluh darah.
Provides health services including Women’s Health,
Pediatric, Robotic Surgery, Oncology Center, Digestive
Center, Cardiovascular Center, Orthopedic Center, Urology
Center, Brain & Spine Center supported by modern medical
technology. Currently, BMHS operates 5 woman and child
hospitals, 4 general hospitals, and 1 cardiovascular hospital. Laboratorium Diagnos
Menyediakan layanan laboratorium berkualitas tinggi dan
andal, mencakup Clinical Laboratory, Genomics Laboratory
(NIPT, PGT-A, PGT-M, Circle DNA), Diagnos Homecare,
panel pemeriksaan SARS-Cov-2, pemeriksaan patologi
anatomi, pemeriksaan mikrobiologi, dan layanan riset
diagnos.
Morula IVF Indonesia
Provides high quality and reliable laboratory services,
Mengelola klinik fertilitas yang menyediakan layanan including Clinical Laboratory, Genomics Laboratory (NIPT,
bayi tabung (IVF), inseminasi buatan, laparoskopi, MESA, PGT-A, PGT-M, Circle DNA), Diagnos Homecare, SARS-
PESA, TESA & TESE, ovulasi induksi, PGT-A, tracking Cov-2 examination, anatomical pathology examinations,
cycle, dan inkubator VIP. Saat ini Morula IVF Indonesia microbiology examinations, and diagnostic research
mengoperasikan 11 Klinik Morula IVF. services.
Manages fertility clinics that provide in vitro fertilization
(IVF), artificial insemination, laparoscopy, MESA, PESA,
TESA & TESE, ovulation induction, PGT-A, cycle tracking,
and VIP incubator services. Currently, Morula IVF
Indonesia operates 11 Morula IVF Clinics.
Emergency Response (ER)
Menyediakan layanan kegawatdaruratan berupa
evakuasi medis untuk pasien kritis menggunakan mode
transportasi darat, udara dan laut, dengan dukungan tim
medis profesional. ER juga menyediakan layanan neonatal
Bunda Global Pharma & children, emergency transport, emergency ambulance,
Menyediakan layanan distribusi farmasi dan alat kesehatan, commercial stretcher service, dan layanan medis lainnya
yang telah memiliki izin operasional serta memiliki sertifikat seperti: medical escort, medical team on site, serta first aid
Cara Distribusi Obat yang Baik (CDOB) dan Cara Distribusi and emergency training, serta pengiriman kargo jenazah.
Alat Kesehatan yang Baik (CDAKB). Provides emergency services including medical evacuations
Provides pharmaceutical and medical device distribution for critical patients, supported by professional medical
services that have operational permits and have certificates teams via land, air and sea transportation. In addition, ER
of Good Drug Distribution Practices (CDOB) and Good also provides neonatal & children emergency transport
Medical Device Distribution Practices (CDAKB). services, emergency ambulances, commercial stretcher
service, and other services such as: home care, medical
escorts, on site medical teams, coronavirus disease, first aid
and emergency training, as well as repatriation of mortal.
Page 39
Laporan Tahunan
Annual Report 39
Prima Dental Medika
BMHS Diklat Indonesia
Menyediakan layanan pemeliharaan kesehatan gigi, dengan
Menyediakan program pendidikan dan pengembangan
berbagai inovasi dan pengembangan fasilitas layanan.
keterampilan tenaga kesehatan, baik soft skill maupun hard
Prima Dental Medika beroperasi di RSU Bunda Jakarta.
skill training, yang dapat diakses secara daring maupun
luring. Program pelatihan yang disediakan antara lain Provides dental healthcare services with innovations and
pelatihan Basic Trauma Cardiac Life Support (BTCLS), continuous development of service facilities. Prima Dental
Advanced Cardiac Life Support (ACLS), Perawat Anestesi, Medika operates at Bunda Jakarta Hospital.
Preceptorship, Asesor, Laparoskopi, dan Babysitter.
Provides education and skills development programs for
healthcare professionals, covering both soft skills and Indonesian Medical
hard skills training, delivered through online and offline Tourism Board (IMTB)
modalities. The training programs offered include Basic
Trauma Cardiac Life Support (BTCLS), Advanced Cardiac Berada di bawah naungan PT Bunda Medika Wisesa
Life Support (ACLS), Anesthesia Nursing, Preceptorship, (BMW), IMBT memfasilitasi dan mempromosikan industri
Assessor training, Laparoscopy, and Babysitter training. perjalanan kesehatan tidak hanya di ekosistem BMHS tapi
juga di Indonesia dan internasional.
Operating under PT Bunda Medika Wisesa (BMW), IMBT
facilitates and promotes the medical tourism industry not
only within the BMHS’s ecosystem but also in Indonesia
and internationally.
Sasana Mitra Bunda (SMB )
Sasana Mitra Bunda atau lebih dikenal sebagai Bunda
Neuro Center, menyediakan layanan kesehatan pelayanan
fisioterapi, mencakup tindakan konsultasi, edukasi,
asesmen, diagnosis, perencanaan, intervensi, evaluasi, dan Daima Norwood Menteng
revaluasi. Beroperasi di RSU Bunda Jakarta, Bunda Neuro Menyediakan layanan penunjang akomodasi pasien yang
Center menangani general fisioterapi, okupasi terapi, terapi berasal dari luar Jakarta. Daima Norwood Menteng
wicara, neuro rehabilitasi stroke, scoliosis center, sensori bergerak di bidang perhotelan, berlokasi di Menteng,
integrasi, serta baby massage & gym. Jakarta Pusat, dengan kepemilikan berada di bawah PT
Sasana Mitra Bunda, also known as Bunda Neuro Center, Bunda Medika Wisesa (BMW).
provides physiotherapy healthcare services, encompassing Provides accommodation support services for patients
consultations, education, assessment, diagnosis, planning, from outside Jakarta. Daima Norwood Menteng operates
intervention, evaluation, and re-evaluation. Operating in the hospitality sector and is located in Menteng, Central
at Bunda Jakarta Hospital, Bunda Neuro Center delivers Jakarta, with ownership under PT Bunda Medika Wisesa
general physiotherapy, occupational therapy, speech (BMW).
therapy, neuro-rehabilitation for stroke, scoliosis center
services, sensory integration, as well as baby massage and
gym services.
Pusat Keunggulan Center of Excellence
BMHS mengembangkan pusat keunggulan untuk BMHS has developed Centers of Excellence to deliver
memberikan layanan kesehatan yang lebih terfokus more focused and specialized healthcare services
dan mendalam pada bidang penyakit atau prosedur in specific disease areas or medical procedures. In
tertentu. Melalui pusat keunggulan, pasien these Centers of Excellence, patients gain access
memperoleh akses kepada tim multidisiplin dan to multidisciplinary teams and dedicated medical
teknologi medis yang spesifik sehingga hasil perawatan technologies, enabling more optimal treatment
lebih optimal. Pusat keunggulan dilengkapi dengan outcomes. Each Center of Excellence is equipped
peralatan medis dan teknologi kedokteran modern, serta with advanced medical equipment and modern
didukung oleh tenaga medis yang ahli, berpengalaman, medical technologies, and is supported by competent,
serta memiliki keterampilan khusus dalam memberikan and experienced healthcare professionals who are
pelayanan kesehatan kepada setiap pasien. committed to providing high-quality and compassionate
specific skills for every patient.
Page 40
40 Profil Perusahaan
Company Profile
Women’s Health Center Pediatric’s Health Center
Women’s Health Center Pediatric Health Center
Melalui Women’s Health Center, kami mendampingi setiap Melalui Pediatric Health Center, kami memberikan perawatan
langkah dengan perawatan menyeluruh untuk mendukung khusus untuk menjaga kesehatan dan tumbuh kembang optimal
kehamilan yang sehat dan persiapan persalinan yang optimal. sejak hari-hari pertama kehidupan.
Pusat pelayanan kesehatan perempuan, mulai Pusat pelayanan kesehatan anak secara komprehensif
dari remaja yang memasuki masa pubertas hingga dari bayi hingga remaja, mencakup program skrining,
perempuan pasca menopause, mencakup pemeriksaan vaksinasi anak lengkap, endoskopi, bronkoskopi
rutin seperti persiapan kehamilan, pemeriksaan anak, NICU, PICU, bedah anak, serta minimal invasive
kandungan, konsultasi deteksi dini, vaksinasi, diagnosis development care. Layanan ini didukung oleh berbagai
dan penanganan berbagai gangguan kesehatan organ dokter spesialis anak dan subspesialis, termasuk paru,
reproduksi. Layanan ini didukung oleh dokter spesialis ginjal, tumbuh kembang, hemato-onkologi, nutrisi dan
dan subspesialis yang berpengalaman serta dilengkapi metabolik, infeksi tropis, gastrohepatologi, digestive,
metode dan fasilitas terkini seperti minimal invasive imaging, jantung, saraf dan endokrin.
surgery, laparoskopi, onko-ginekologi, hingga prosedur
ginekologi robotik. A comprehensive pediatric healthcare center
serving patients from infancy through adolescence,
A women’s healthcare center providing comprehensive offering screening programs, a full range of childhood
care from adolescence through post-menopause, vaccinations, endoscopy, pediatric bronchoscopy,
encompassing routine services such as preconception NICU, PICU, pediatric surgery, and minimally
care, gynecological examinations, early detection invasive developmental care. These services are
consultations, vaccination, as well as the diagnosis and supported by a wide range of pediatric specialists and
management of various reproductive health conditions. subspecialists, including pulmonology, nephrology,
These services are supported by experienced specialists growth and development, hematology-oncology,
and sub-specialists equipped with the latest methods nutrition and metabolism, tropical infectious diseases,
and facilities, including minimally invasive surgery, gastroenterology and hepatology, gastroenterology,
laparoscopy, gynecologic oncology, and robotic-assisted radiology, cardiology, neurology, and endocrinology.
gynecologic procedures.
Page 41
Laporan Tahunan
Annual Report 41
Advanced Robotic Minimal
Invasive Surgery (ARMIS) RSM Oncology Center
Advanced Robotic Minimal RSM Oncology
Invasive Surgery Center
Menghadirkan tindakan bedah yang akurat, minim sayatan, dan Melalui RSM Oncology Center, kami menghadirkan perawatan
mendukung pemulihan yang lebih optimal bagi pasien. yang penuh empati untuk mendukung hidup yang tetap aktif
dan bermakna.
Robotic Surgery merupakan teknologi medis untuk Pusat pelayanan onkologi (kanker) terdepan yang
melakukan operasi dengan tingkat presisi dan akurasi menyediakan layanan onkologi komprehensif dan
yang lebih tinggi, risiko komplikasi yang lebih rendah berkualitas tinggi melalui pemeriksaan diagnostik dan
dan pemulihan lebih cepat dengan mengurangi genomik (materi DNA) tingkat lanjut, termasuk bedah
atau menghilangkan trauma jaringan yang biasanya onkologi baik open surgery maupun minimal invasive atau
didapatkan pada operasi terbuka. Teknologi ini robotik, kemoterapi, radiasi, perawatan paliatif, serta
memungkinkan tindakan kompleks ditangani lebih aman rehabilitasi pasien kanker.
dan efektif. RS Bunda merupakan rumah sakit pelopor
di Indonesia yang memiliki layanan bedah robotik. A leading oncology (cancer) center providing
Layanan Operasi Robotic meliputi operasi Robotic comprehensive, high-quality oncology services through
kebidanan dan kandungan, Operasi Robotic Urology advanced diagnostic and genomic (DNA) testing,
misalnya pengangkatan prostat, Operasi Robotic Bedah including oncological surgery both open surgery and
Digestif dan Operasi Robotic Kasus Keganasan/Tumor minimally invasive or robotic procedures chemotherapy,
misal Robotic Mastectomy pada kasus tumor payudara, radiation therapy, palliative care, and rehabilitation for
Robotic THT, dan Robotic untuk layanan Digestive. cancer patients.
Robotic surgery is a medical technology that enables
surgical procedures to be performed with higher
precision and accuracy, lower risk of complications,
and faster recovery by reducing or eliminating tissue
trauma typically associated with open surgery. This
technology allows complex procedures to be carried
out more safely and effectively. Bunda Hospital is a
pioneer in Indonesia to offer robotic surgery services.
obotic surgery services include robotic obstetric and
gynecological surgery, robotic urological surgery (such
as prostate removal), robotic digestive surgery, and
robotic surgery for malignant tumors (such as robotic
mastectomy for breast cancer), robotic ENT surgery,
and robotic procedures for digestive conditions.
Page 42
42 Profil Perusahaan
Company Profile
Uro-Nefrology Center Digestive Center
Uro-Nephrology Digestive Center
Center
Melalui Uro-Nephrology Center, kami menghadirkan perawatan Melalui Digestive Center, kami membantu menjaga kesehatan
menyeluruh untuk menjaga fungsi ginjal tetap optimal dalam pencernaan agar tetap optimal, mendukung tubuh tetap
mendukung aktivitas sehari-hari. produktif dan bertenaga sepanjang hari.
Pusat pelayanan kesehatan yang menangani beragam Bunda Digestive Center memiliki tim Dokter yang
masalah ginjal (nefrologi) serta saluran kemih dan sudah berpengalaman dalam menangani berbagai
system urinaria (urologi), termasuk kanker prostat, penyakit pada saluran pencernaan seperti radang
disfungsi ereksi, infertilitas, transplantasi ginjal dan lambung, GERD, radang usus besar, masalah hati dan
prosedur bedah robotik urologi, serta layanan Dialysis pankreas, batu empedu, sampai dengan kasus tumor
Center, Kidney Stone Treatment (PCNL, ESWL, URS, atau kanker. Digestive Center menyediakan perawatan
TURP). Layanan ini didukung tim profesor urologi komprehensif untuk saluran pencernaan dengan
dengan kompetensi tinggi dan pengalaman luas, serta melibatkan dokter ahli gastroentero-hepatologi,
aktif berkontribusi dalam penelitian dan pengembangan endoscopy, bedah digestif serta dokter onkologi melalui
di bidang urologi. pemeriksaan lanjutan, prosedur unggulan dan bedah
minimal invasive.
A healthcare center specializing in a wide range of
kidney conditions (nephrology) as well as urinary Bunda Digestive Center is staffed by experienced
tract and urinary system issues (urology), including physicians specializing in the management of digestive
prostate cancer, erectile dysfunction, infertility, kidney system disorders, such as gastritis, gastroesophageal
transplants, and robotic urological surgery, as well as reflux disease (GERD), colitis, liver and pancreatic
Dialysis Center services and kidney stone treatment disorders, gallstones, as well as tumor and cancer
(PCNL, ESWL, URS, TURP). These services are supported cases. The Digestive Center provides comprehensive
by a team of highly competent and experienced urology gastrointestinal care through the involvement of
professors who actively contribute to research and gastroenterology-hepatology specialists, endoscopists,
development in the field of urology. digestive surgeons, and oncologists, supported
by advanced diagnostics, leading procedures, and
minimally invasive surgical techniques.
Page 43
Laporan Tahunan
Annual Report 43
Bunda Orthopedic Nurturing
Experience (BONE) Brain & Spine Center
Orthopedic Center Brain & Spine Center
Bunda Orthopedic Nurturing Experience (BONE) menghadirkan Brain & Spine Center mendukung kesehatan otak dan tulang
perawatan menyeluruh untuk menjaga kekuatan dan belakang agar Anda tetap fokus, kuat, dan seimbang dalam
kenyamanan tubuh dalam setiap aktivitas. aktivitas harian
Pusat pelayanan ortopedi dengan cakupan layanan Pusat pelayanan yang memberikan perawatan
diagnosis, pengobatan, dan rehabilitasi berbagai kondisi komprehensif untuk berbagai kondisi otak dan
muskuloskeletal (sistem gerak), termasuk tulang, sendi, saraf, dengan fokus pada diagnosis yang akurat dan
otot, ligamen dan struktur terkait lainnya. Berbagai penatalaksanaan medis yang tepat. Layanan yang
metode penanganan tersedia, mulai dari rekonstruksi tersedia mencakup penanganan trauma atau cedera
hingga tindakan minimal invasive surgery, untuk kepala (head injury), saraf terjepit, nyeri kronis,
memastikan hasil perawatan yang optimal bagi pasien parkinson, epilepsi, hidrosefalus, aneurisma serebral,
dari diagnosis hingga rehabilitasi. stroke, serta penyakit neurodegeneratif dan kelainan
neurologis lainnya dengan pendekatan yang terintegrasi
A comprehensive orthopedic service center providing dan berbasis praktik klinis terkini.
diagnostic, treatment, and rehabilitation services for
a wide range of musculoskeletal conditions, including A specialized center delivering comprehensive care for
disorders of the bones, joints, muscles, ligaments, a broad spectrum of brain and neurological conditions,
and other related structures. A variety of treatment with a strong emphasis on accurate diagnosis and
approaches are available, ranging from reconstructive appropriate medical management. Services include
procedures to minimally invasive surgery, ensuring the treatment of head trauma or head injuries, nerve
optimal patient outcomes from diagnosis through compression, chronic pain, Parkinson’s disease, epilepsy,
rehabilitation. hydrocephalus, cerebral aneurysms, stroke, as well as
neurodegenerative diseases and other neurological
disorders, utilizing an integrated approach aligned with
the latest clinical practices.
Page 44
44 Profil Perusahaan
Company Profile
Bunda Homecare: Vaccination
Cardiovascular Center & Wellness Center
Homecare Services
Home Care memberikan akses layanan kesehatan langsung di
rumah, dengan rasa aman dan nyaman dalam setiap langkah
perawatan.
Pusat pelayanan penanganan berbagai masalah jantung Pusat pelayanan kesehatan yang dirancang untuk
secara komprehensif, dengan dukungan tim medis memberikan vaksinasi dan pemeriksaan kesehatan
terbaik yang terdiri dari ahli kardiologi, perawat, dan langsung di rumah atau tempat pasien berada. Layanan
tenaga kesehatan profesional. Cardiovascular Center ini merupakan bagian dari inovasi layanan kesehatan
dilengkapi teknologi terkini, termasuk CT Scan dan preventif yang lebih nyaman, personal dan mudah
Cath Lab untuk berbagai pemeriksaan diagnostik, tes diakses. Berbagai metode penanganan tersedia, mulai
jantung, hingga tindakan medis dan bedah toraks sesuai dari vaksinasi dan imunisasi (anak maupun dewasa),
kebutuhan pasien. skrining preventif, pelayanan wellness dan konsultasi
kesehatan dasar serta pendampingan tenaga medis
A cardiovascular service center providing profesional.
comprehensive management of various heart
conditions, supported by a highly qualified medical team A healthcare service center designed to deliver
comprising cardiologists, nurses, and other healthcare vaccinations and health screening services directly
professionals. The Cardiovascular Center is equipped at patients’ homes or designated locations. This
with advanced medical technologies, including CT Scan service is part of a preventive healthcare innovation
and Cardiac Catheterization Laboratory (Cath Lab), that offers greater convenience, personalization, and
to support diagnostic examinations, cardiac testing, accessibility. A range of services is provided, including
as well as medical and thoracic surgical interventions vaccinations and immunizations for children and
tailored to patient needs. adults, preventive screenings, wellness services, basic
health consultations, and professional medical support
delivered by qualified healthcare personnel.
Page 45
Laporan Tahunan
Annual Report 45
Wilayah Operasional
Operational Area
PT Bundamedik Tbk terus mengembangkan ekosistem PT Bundamedik Tbk continues to expand its healthcare
pelayanannya. Per 31 Desember 2025, wilayah service ecosystem. As of December 31, 2025, BMHS’s
operasional BMHS telah menjangkau sebagian besar operational area covered most regions of Indonesia
Indonesia melalui 10 rumah sakit, 1 klinik, 11 klinik through a network of 10 hospitals, 1 clinic, 11 IVF
IVF, 96 Jaringan Klinik Fertilitas Indonesia (KFI), 37 clinics, 96 Klinik Fertilitas Indonesia (KFI) Networks, 37
laboratorium, serta lebih dari 3.000 Klinik Pintar. laboratories, and more than 3,000 Klinik Pintar.
Wilayah Operasional
Operational Areas
BATAM
PEKANBARU TANGERANG SELATAN PONTIANAK MAKASSAR
TANGERANG
JAKARTA
BEKASI
PADANG SURABAYA
DEPOK
PALEMBANG
DENPASAR
BANDUNG
YOGYAKARTA
10 11 37 >3.000 96
Rumah Sakit Klinik IVF Laboratorium Klinik Pintar Jaringan Klinik
Fertilitas Indonesia
Hospitals IVF Clinics Laboratories Klinik Pintar (KFI)
+ 1 Klinik | Clinic Fertility Clinics
Network (KFI)
Page 46
46 Profil Perusahaan
Company Profile
Daftar Rumah Sakit, Klinik, dan Laboratorium
List of Hospitals, Clinics, and Laboratories
Rumah Sakit Hospital
1 Rumah Sakit Ibu dan Anak Bunda Jakarta Bunda Jakarta Women and Children Hospital
2 Rumah Sakit Umum Bunda Jakarta Bunda Jakarta Hospital
3 Rumah Sakit Umum Bunda Margonda Margonda Hospital
4 Rumah Sakit Umum Bunda Padang Bunda Padang Hospital
5 Rumah Sakit Ibu dan Anak Bunda Ciputat Bunda Ciputat Women and Children Hospital
6 Rumah Sakit Ibu dan Anak Az Zahra Palembang Az Zahra Palembang Women and Children Hospital
7 Rumah Sakit Umum Citra Harapan Citra Harapan Hospital
8 Rumah Sakit Ibu dan Anak Pusura Tegalsari Pusura Tegalsari Women and Children Hospital
9 Rumah Sakit Jantung dan Pembuluh Darah Paramarta Paramarta Cardiovascular Hospital
10 Rumah Sakit Ibu dan Anak Bunda Denpasar Bunda Denpasar Women and Children Hospital
Klinik Clinic
1. Bunda Clinic MRT Dukuh Atas Bunda Clinic MRT Dukuh Atas
Klinik Bayi Tabung IVF Clinic
Morula IVF Jakarta (Bunda Jakarta Women and Children
1 Morula IVF Jakarta (RSIA Bunda Jakarta)
Hospital)
2 Morula IVF Padang (RSU Bunda Padang) Morula IVF Padang (Bunda Jakarta Hospital)
3 Morula IVF Margonda (RSU Bunda Margonda) Morula IVF Margonda (Bunda Margonda Hospital)
4 Morula IVF Surabaya (National Hospital) Morula IVF Surabaya (National Hospital)
5 Morula IVF Makassar (Rumah Sakit Sentosa) Morula IVF Makassar (Sentosa Hospital)
Morula IVF Pontianak (Rumah Sakit Anugerah Bunda
6 Morula IVF Pontianak (Anugerah Bunda Khatulistiwa Hospital)
Khatulistiwa)
7 Morula IVF Tangerang (Rumah Sakit Mentari) Morula IVF Tangerang (Mentari Hospital)
8 Morula IVF Yogyakarta (Rumah Sakit JIH) Morula IVF Yogyakarta (JIH Hospital)
Morula IVF Ciputat (Bunda Ciputat Women and Children
9 Morula IVF Ciputat (RSIA Bunda Ciputat)
Hospital)
10 Morula IVF Melinda Bandung (Rumah Sakit Melinda 2) Morula IVF Melinda Bandung (Melinda 2 Hospital)
Morula IVF Denpasar (Bunda Denpasar Women and Children
11 Morula IVF Denpasar (RSIA Bunda Denpasar)
Hospital)
Laboratorium Klinik Clinical Laboratory
Diagnos Cabang Diagnos Branches
1 Ciputat Mandiri Ciputat Mandiri
2 Denpasar Mandiri Denpasar Mandiri
3 Padang Mandiri Padang Mandiri
4 Makassar Mandiri Makassar Mandiri
5 Batam Mandiri Batam Mandiri
Diagnos Outlet Diagnos Outlet
1 Rumah Sakit Ibu dan Anak Bunda Jakarta Bunda Jakarta Women and Children Hospital
2 Rumah Sakit Umum Citra Harapan Citra Harapan Hospital
3 Rumah Sakit Umum Bunda Margonda Margonda Hospital
4 Rumah Sakit Ibu dan Anak Bunda Ciputat Bunda Ciputat Women and Children Hospital
5 Rumah Sakit Umum Grha Bhakti Medika Klungkung Grha Bhakti Medika Klungkung Hospital
6 Rumah Sakit Ibu dan Anak Bunda Denpasar Bunda Denpasar Women and Children Hospital
7 Rumah Sakit Ibu dan Anak Budhi Mulia Pekanbaru Budhi Mulia Pekanbaru Women and Children Hospital
Page 47
Laporan Tahunan
Annual Report 47
Laboratorium Klinik Clinical Laboratory
8 Rumah Sakit Ibu dan Anak Az Zahra Palembang Az Zahra Palembang Women and Children Hospital
9 Klinik Kizuna Jakarta Kizuna Jakarta Clinic
10 RS Amanah Mahmudah Brebes Amanah Mahmudah Brebes Hospital
11 Rumah Sakit Jantung dan Pembuluh Darah Paramarta Paramarta Cardiovascular Hospital
12 Klinik Nyeri BPRC Bandung BPRC Bandung Pain Clinic
13 Rumah Sakit Ibu dan Anak Pusura Tegalsari Pusua Tegalsari Women and Children Hospital
Collection Point (CP)
1 Morula IVF Margonda Morula IVF Margonda
2 BIC Vida Bekasi BIC Vida Bekasi
3 Klinik Ovarya Ovarya Clinic
4 Medens Medical Center Medens Medical Center
5 Klinik Takenoko Denpasar Takenoko Denpasar Clinic
6 Nusadua Denpasar (Crea Premium Office) Nusadua Denpasar (Crea Premium Office)
7 Klinik PLN Medika PLN Medika Clinic
8 Rumah Sakit Ibu dan Anak Sentosa Morula Sentosa Morula Women and Children Hospital
9 Klinik dr. Farabi Dr. Farabi Clinic
10 Klinik Ayani Ayani Clinic
11 Klinik Fame Fame Clinic
12 Klinik Desani Desani Clinic
13 Klinik Gading Gading Clinic
14 Okayeni Medical Care Okayeni Medical Care
15 Laboratorium Analisa Analysis Laboratory
16 Klinik Utama Permata HSO Permata HSO Main Clinic
17 Klinik BPRC BPRC Clinic
18 Morula IVF Jakarta Morula IVF Jakarta
19 Rumah Sakit Umum Bunda Jakarta Bunda Jakarta Hospital
Page 48
48 Profil Perusahaan
Company Profile
Struktur Organisasi
Organizational Structure
General Meeting of
Shareholders
Board of Commissioner
Committees
• Audit
• Remuneration &
Compensation
• GCG & Risk Management
• Investment
President Director
Corporate Strategic Committees
Planning & Investor
• Procurement
Relation
Corporate Internal Audit Corporate Secretary
Project
Management Office
President Director
Chief Comm.
Chief Financial Chief Human Chief Digital & Chief MNQ President Director PT Diagnos
& Biz. Dev
Officer Capital Officer Tech. Officer Officer PT Morula Indonesia Laboratorium Utama
Officer
Tbk
Corp Government Hosp. Director
Hosp. Director Hosp. Director Hosp. Director Hosp. Director
Relations & Market RSU Bunda
RSIA Bunda Jakarta RSU Bunda Jakarta RSU Citra Harapan RSU Bunda Padang
Access Margonda
Hosp. Hosp. Director Hosp. Director Hosp. Director Corp Facility Corporate Head of PT
Director RSIA RSIA Bunda RSIA Pusura RSIA Az Zahra Emerging*
Management Asset Bunda Global
Bunda Ciputat Denpasar Tegalsari Palembang Business Units
& GA & Procurement Pharma
* IMTB & ER , BDI & IRSI, SMB, Prima
Dental Medika, Bunda Medika Clinic
Page 49
Laporan Tahunan
Annual Report 49
Keanggotaan Asosiasi
Association Memberships
BMHS bergabung dalam beberapa asosiasi atau BMHS is a member of several associations and
organisasi untuk berbagi informasi terbaru terkait organizations to gain access to the latest information on
perkembangan industri pelayanan kesehatan dan developments in the healthcare services industry and
teknologi medis, perubahan regulasi kesehatan dan medical technology, changes in healthcare and capital
pasar modal serta isu strategis lainnya yang relevan market regulations, as well as other strategic issues
dengan bisnis. relevant to its business.
Perhimpunan Rumah Sakit Asosiasi Rumah Sakit Swasta Persatuan Pemilik Rumah Sakit
Seluruh Indonesia Indonesia Swasta Nasional
Indonesian Hospital Association Association of Indonesian Private National Association of Private
Hospitals Hospital Owners
Ikatan Rumah Sakit Jakarta Asosiasi Emiten Indonesia Indonesia Corporate
Metropolitan Indonesian Public Listed Secretary Association
Jakarta Metropolitan Companies Association
Hospital Association
RSJP Paramarta bergabung dalam
keanggotaan Federasi Rumah Perhimpunan Fertilisasi In Vitro
Sakit Internasional (IHF) Indonesia
RSJP Paramarta joined as a Indonesian Society for In Vitro
member of the International Fertilization (PERFITRI)
Hospital Federation (IHF)
Page 50
50 Profil Perusahaan
Company Profile
Profil Dewan Komisaris
Board of Commissioners Profiles
Sepanjang 2025, komposisi Dewan Komisaris BMHS In 2025, the composition of BMHS’s Board of
mengalami perubahan untuk mendukung peningkatan Commissioners underwent changes to enhance the
efektivitas fungsi pengawasannya. Perubahan effectiveness of its supervisory function. These changes
komposisi Dewan Komisaris telah mendapat were approved by the shareholders at the Extraordinary
persetujuan pemegang saham melalui Rapat Umum General Meeting of Shareholders (EGMS) held on
Pemegang Saham Luar Biasa (RUPSLB) pada 7 Agustus August 7, 2025.
2025.
Komposisi Dewan Komisaris
Board of Commissioners Composition
Dewan Komisaris 1 Januari – 7 Agustus 2025 7 Agustus – 31 Desember 2025
Board of Commissioners January 1 – August 7, 2025 August 7 – December 31, 2025
Komisaris Utama
Ivan Rizal Sini Ivan Rizal Sini
President Commissioner
Wakil Komisaris Utama - Komisaris
Independen
Wishnutama Kusubandio -
Vice President Commissioner -
Independent Commissioner
Wakil Komisaris Utama
- Shubhasish Chattoraj
Vice President Commissioner
Komisaris Mesha Rizal Sini
Mesha Rizal Sini
Commissioner Sunata Tjiterosampurno
Komisaris Independen Retno L.P. Marsudi Retno L.P. Marsudi
Independent Commissioner Arianti Anaya Arianti Anaya
Page 51
Laporan Tahunan
Annual Report 51
Ivan Rizal Sini
Komisaris Utama
President Commissioner
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 53 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau diangkat pertama kali menjadi Komisaris Utama He was first appointed as President Commissioner
berdasarkan Akta No. 200 tanggal 25 Juni 2013. based on Deed No.200 dated June 25, 2013.
Beliau memperoleh gelar Sarjana Kedokteran dari He obtained a Bachelor of Medicine degree from
Universitas Indonesia (1996), lulus kualifikasi OBGYN Universitas Indonesia (1996), passed the OBGYN
di Member of Royal Australian and NZ College of qualification at a Member of the Royal Australian
Obstetricians and Gynecologists Melbourne (2001), and NZ College of Obstetricians and Gynecologists
lulus kualifikasi OBGYN di Fellow of Royal Australian and Melbourne (2001), passed the OBGYN qualification
NZ College of Obstetricians and Gynecologists (2004), as a Fellow of the Royal Australian and NZ College of
gelar Diploma in Reproductive Medicine dari University Obstetricians and Gynecologists (2004), has a Diploma
of Western Sydney (2005), gelar Spesialis Obstetri & in Reproductive Medicine from the University of
Ginekologi (SpOG) dari Universitas Indonesia (2006), Western Sydney (2005), and a Specialist in Obstetrics
dan gelar Master of Minimally Invasive Surgery (MMIS) & Gynecology (SpOG) from the Universitas Indonesia
dari University of Adelaide (2013). Beliau juga meraih (2006), and a Master of Minimally Invasive Surgery
gelar Doktor pada Fakultas Kedokteran Universitas (MMIS) from the University of Adelaide (2013). Also
Indonesia (2021). obtained a Doctorate degree at the Faculty of Medicine,
Universitas Indonesia (2021).
Beliau memulai karier di Women’s and Children’s He started his career at the Women’s and Children’s
Hospital Adelaide sebagai Resident Medical Officer Hospital Adelaide as Resident Medical Officer (1997),
(1997) dan Specialist Registrar (1998–1999). and Specialist Registrar (1998-1999). Furthermore, and
Selanjutnya, beliau menjabat sebagai Senior Specialist served as Senior Specialist Registrar at Lyell McEwin
Registrar di Lyell McEwin Hospital Adelaide (2000), Hospital Adelaide (2000), Registrar Flying Doctor at
Registrar Flying Doctor di Mount Gambier Hospital Mount Gambier Hospital and Oncology Registrar at
dan Oncology Registrar di Royal Adelaide Hospital Royal Adelaide Hospital (2001), Gynecology Surgery
(2001), Gynecology Surgery Senior Registrar di The Senior Registrar at The Queen Elizabeth Hospital
Queen Elizabeth Hospital Adelaide (2002), Fellow di Adelaide (2002), Fellow in Reproductive Medicine
Reproductive Medicine Repromed (2003), Research Repromed (2003), Research staff at the Department
staff di Department of O&G University of Adelaide of O&G University of Adelaide (2003-present), Head of
(2003–sekarang), Head of Clinician di Repromed Clinician at Repromed Darwin IVF Center (2004-2005),
Darwin IVF Center (2004–2005), serta O&G Consultant and O&G Consultant at Royal Darwin Hospital (2004-
di Royal Darwin Hospital (2004–2005). Karier beliau di 2005). His career at BMHS includes being the Person
BMHS antara lain sebagai Penanggung Jawab Klinik BIC in Charge of the BIC Morula IVF Jakarta Clinic (2005-
Morula IVF Jakarta (2005–2013), dan Direktur Bunda 2013), and Director of Bunda Margonda Hospital
Margonda Hospital (2006–2010). (2006-2010).
Page 52
52 Profil Perusahaan
Company Profile
Saat ini, beliau memiliki rangkap jabatan sebagai Currently holds concurrent positions as Registered
Registered Medical Practitioner in Australia (sejak Medical Practitioner in Australia (since 1997),
1997), Obstetrician & Gynecologist di Bunda Hospital Obstetrician & Gynecologist at Bunda Hospital Group
Group (sejak 2005), Direktur Utama PT Bunda (since 2005), President Director of PT Bunda Investama
Investama Indonesia (sejak 2014), Komisaris Utama Indonesia (since 2014), President Commissioner of PT
PT Diagnos Laboratorium Utama Tbk, Direktur Utama Diagnos Laboratorium Utama Tbk, President Director
PT Morula Indonesia, Komisaris Utama PT Daima of PT Morula Indonesia, President Commissioner of PT
Citra Prima (sejak 2018), Dekan Fakultas Kedokteran Daima Citra Prima (since 2018), Dean of the Faculty
IPB (sejak 2024), dan Ketua Kolegium Obstetri dan of Medicine of IPB (since 2024), and Chairman of the
Ginekologi (sejak 2024). Collegium of Obstetrics and Gynecology (since 2024).
Shubhasish Chattoraj
Wakil Komisaris Utama
Vice President Commissioner
Warga Negara India | Indian Citizen
Usia | Age: 41 tahun/years
Domisili | Domicile: Singapura | Singapore
Beliau menjabat sebagai Wakil Presiden Komisaris He has served as Vice President Commissioner pursuant
berdasarkan Akta No. 41 tanggal 7 Agustus 2025. to Deed No. 41 dated 7 August 2025.
Beliau meraih gelar Sarjana Teknologi (Honours) dari He holds a Bachelor of Technology (Honours) degree
Institut Teknologi India (IIT) Kharagpur dan Program from the Indian Institute of Technology (IIT) Kharagpur
Pascasarjana Manajemen dari Sekolah Bisnis India (ISB) and a Postgraduate Programme in Management from
Hyderabad. the Indian School of Business (ISB), Hyderabad.
Beliau adalah seorang profesional investasi senior di He is a senior investment professional specializing in
bidang Merger dan Akuisisi, Strategi, dan Operasional Mergers and Acquisitions, Strategy, and Operations,
dengan pengalaman lebih dari 14 tahun di industri ilmu with more than 14 years of experience across the life
hayati, teknologi medis, dan layanan kesehatan. sciences, medical technology, and healthcare services
industries.
Saat ini, Beliau memiliki rangkap jabatan sebagai Currently, he concurrently serves as a Principal at Ares
Principal di Ares Asia dan bertanggung jawab atas Asia and has been responsible for leading private equity
kepemimpinan investasi private equity di sektor investments in the healthcare sector across various
kesehatan di berbagai pasar Asia sejak 2024. Asian markets since 2024.
Page 53
Laporan Tahunan
Annual Report 53
Mesha Rizal Sini
Komisaris
Commissioner
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 52 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Komisaris berdasarkan Akta He currently serves as Commissioner based on Deed
No. 159 tanggal 30 Mei 2024. No. 159 dated May 30, 2024.
Beliau memperoleh gelar Sarjana Teknik Mesin He obtained a Bachelor’s degree in Mechanical
dari Universitas Trisakti (1996) dan gelar Master of Engineering from Universitas Trisakti (1996) and
Engineering Science dari University of New South a Master of Engineering Science degree from the
Wales, Australia (1999). University of New South Wales, Australia (1999).
Beliau memulai karier di PT Omedata Electric Gajah He started his career at PT Omedata Electric Gajah
Tunggal Group sebagai Account Manager (1997–1999), Tunggal Group as Account Manager (1997-1999), PT
PT Bunda Global Pertama sebagai Direktur (2004– Bunda Global Pertama as Director (2004-2014), CV
2014), CV Buana Sejahtera sebagai Direktur (2007– Buana Sejahtera as Director (2007-2012), PT Timur
2012), PT Timur Prima Utama sebagai Direktur (2008– Prima Utama as Director (2008-2012), PT Tenaga Satu
2012), PT Tenaga Satu Persada sebagai Komisaris Persada as Commissioner (2012-2018), and President
(2012–2018), serta Direktur Utama BMHS (2021–Mei Director of BMHS (2021–May 2024).
2024).
Saat ini, beliau memiliki rangkap jabatan sebagai Currently holds concurrent positions as President
Komisaris Utama PT Tenaga Prima Persada (sejak Commissioner of PT Tenaga Prima Persada (since
2006), Direktur Utama PT Diagnos Laboratorium 2006), President Director of PT Diagnos Laboratorium
Utama Tbk (2007-2025), Direktur PT Diagnos Utama Tbk (2007–2025), Director of PT Diagnos
Laboratorium Utama Tbk (sejak 2025), Komisaris PT Laboratorium Utama Tbk (since 2025), Commissioner
Prima Satu Persada (sejak 2013), Komisaris PT Bunda of PT Prima Satu Persada (since 2013), Commissioner of
Investama Indonesia dan Direktur Utama PT Agung PT Bunda Investama Indonesia and President Director
Multi Berjaya (sejak 2014), Komisaris PT Morula of PT Agung Multi Berjaya (since 2014), Commissioner
Indonesia (sejak 2016), Direktur Utama PT Vizitrip of PT Morula Indonesia (since 2016), President
Global Tour dan Komisaris Utama PT Bunda Minang Director of PT Vizitrip Global Tour and President
Citra (sejak 2024), Komisaris Utama PT Bunda Ipiti Commissioner of PT Bunda Minang Citra (since 2024),
Investama, Komisaris Utama PT BMHS Diklat Indonesia President Commissioner of PT Bunda Ipiti Investama,
(sejak 2024), Komisaris PT CRM Bangun Persada, President Commissioner of PT BMHS Diklat Indonesia
Direktur PT Daima Citra Prima, Persero Komanditer (since 2024), Commissioner of PT CRM Bangun
CV Bunda Lenen Utama. Beliau juga menjabat sebagai Persada, Director of PT Daima Citra Prima, Persero
Ketua Yayasan Yayasan Daima Indonesia, Komisaris Commander CV Bunda Lenen Utama. Currently, also
Utama PT Bunda Medika Wisesa, Komisaris Utama serves as Chairman of the Yayasan Daima Indonesia,
PT Citra Ananda, Komisaris PT Brandina Kuliner President Commissioner of PT Bunda Medika
Utama, Komisaris Utama PT Bunda Global Pharma Wisesa, President Commissioner of PT Citra Ananda,
dan Komisaris Utama PT Moosa Genetika Farmindo Commissioner of PT Brandina Kuliner Utama,
(sejak 2019). Selain itu, rangkap jabatan beliau sebagai President Commissioner of PT Bunda Global Pharma
Komisaris Utama PT Bunda Medika Bekasi, Komisaris and President Commissioner of PT Moosa Genetika
Page 54
54 Profil Perusahaan
Company Profile
Utama PT Bunda Medika Dewata, Komisaris PT Bunda Farmindo (since 2019). Also holds concurrent positions
Medika Klinik dan Komisaris Utama PT Pintu Ilmu, serta as President Commissioner of PT Bunda Medika Bekasi,
Komisaris Utama PT Jolin Sapta Medika, dan Komisaris President Commissioner of PT Bunda Medika Dewata,
Utama PT Bunda Graha Properti (sejak 2024). President Commissioner of PT Bunda Medika Klinik
and President Commissioner of PT Pintu Ilmu , as well as
President Commissioner of PT Jolin Sapta Medika and
President Commissioner of PT Bunda Graha Properti
(since 2024).
Retno L.P. Marsudi
Komisaris Independen | Independent Commissioner
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 63 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Komisaris Independen She currently serves as Independent Commissioner
berdasarkan Akta No. 206 Tanggal 20 Desember 2024. based on Deed No. 206 dated December 20, 2024.
Beliau meraih gelar sarjana S1 Ilmu Hubungan She obtained a bachelor’s degree in International
Internasional dari Universitas Gadjah Mada, Yogyakarta Relations from Universitas Gadjah Mada, Yogyakarta in
(1985), dan mengambil beberapa program studi lain, 1985, and took several other study programs, including
yaitu “European Union Law” di Haagse Hogeschool, Den “European Union Law” at Haagse Hogeschool, Den
Haag dan “Human Rights Studies” di Universitas Oslo. Haag and “Human Rights Studies” at the University of
Oslo.
Beliau adalah profesional dan diplomat senior yang She is a seasoned professional and senior diplomat
berpengalaman dalam hubungan internasional, with extensive experience in international relations.
Menteri Luar Negeri perempuan pertama Indonesia She served as Indonesia’s first female Minister of
(2014–2024), dengan perhatian besar terhadap isu Foreign Affairs (2014–2024), with a strong focus on
perdamaian, kemanusiaan, kesehatan, pemberdayaan peacebuilding, humanitarian affairs, health, women’s
perempuan dan perlindungan anak. empowerment, and child protection.
Sebelumnya, beliau bergabung dengan Kementerian Previously, she served at the Ministry of Foreign Affairs
Luar Negeri Indonesia, yakni di Kedutaan Besar of the Republic of Indonesia, including postings at the
Republik Indonesia (KBRI) di Canberra, Australia Indonesian Embassy in Canberra, Australia (1990–
(1990–1994), KBRI Den Haag, Belanda (1997–2001). 1994), and the Indonesian Embassy in The Hague,
Beliau kemudian ditunjuk sebagai Direktur Kerja Sama the Netherlands (1997–2001). She was subsequently
Intra dan Antar Kawasan Amerika dan Eropa (2001– appointed Director for Intra- and Inter-Regional
2003), Direktur Eropa Barat (2003–2005), dan Duta Cooperation for the Americas and Europe (2001–
Besar Indonesia untuk Norwegia dan Islandia (2005– 2003), Director for Western Europe (2003–2005),
2008), Direktur Jenderal Urusan Amerika dan Eropa Ambassador of the Republic of Indonesia to Norway
(2008–2012), Duta Besar Indonesia untuk Kerajaan and Iceland (2005–2008), Director General for the
Belanda (2012–2014). Americas and Europe (2008–2012), and Ambassador
of the Republic of Indonesia to the Kingdom of the
Netherlands (2012–2014).
Page 55
Laporan Tahunan
Annual Report 55
Beliau memiliki rangkap jabatan sebagai Direktur Non Currently holds concurrent positions as Independent
-Eksekutif Independen Gurin Energy Pte Ltd (Sejak Non-Executive Director of Gurin Energy Pte. Ltd. (since
2024), Utusan Khusus Sekjen PBB (Sejak 2023), serta 2024), Special Envoy of the United Nations Secretary-
Komisaris Independen PT Vale Indonesia Tbk dan XL General (since 2023), and Independent Commissioner
Smart (Sejak 2025). of PT Vale Indonesia Tbk and XL Smart (since 2025).
Arianti Anaya
Komisaris Independen
Independent Commissioner
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 61 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Komisaris Independen She currently serves as Independent Commissioner
berdasarkan Akta No. 206 Tanggal 20 Desember 2024. based on Deed No. 206 dated December 20, 2024.
Beliau meraih gelar Sarjana Kedokteran Gigi (1983– She obtained a Bachelor of Dentistry degree (1983-
1988), dan Magister Ilmu Kesehatan Masyarakat 1988), and a Master of Public Health Science degree
(2003–2005), dari Universitas Indonesia, Jakarta. (2003-2005), from Universitas Indonesia, Jakarta.
Beliau bergabung dengan Kementerian Kesehatan She joined the Indonesian Ministry of Health, and has
Indonesia, dan menduduki sejumlah jabatan, di held a number of positions, including: involvement in
antaranya: terlibat dalam Indonesia National Single the Indonesia National Single Window (INSW) in (2008-
Window (INSW) pada (2008–2019), Direktur Bina 2019), Director of Production and Distribution of
Produksi dan Distribusi Alat Kesehatan (2012–2015), Medical Devices (2012-2015), Director of Assessment
Direktur Penilaian Alat Kesehatan dan Perbekalan of Medical Devices and Household Health Supplies
Kesehatan Rumah Tangga (2016–2018), Sekretaris (2016-2018), Secretary of the General of Pharmacy
Direktorat Jenderal Kefarmasian dan Alat Kesehatan and Medical Devices Directorate (2018-2021), Acting
(2018–2021), Plt. Direktur Jenderal Kefarmasian dan Director General of Pharmaceuticals and Medical
Alat Kesehatan (2021), Dewan Pengawas di RSUP Prof. Devices (2021), Supervisory Board at RSUP Prof. Dr.
dr. I.G. Ng. Ngoerah dan RSPI Sulianti Saroso (2021– I.G. Ng. Ngoerah and RSPI Sulianti Saroso (2021-2022),
2022), anggota Dewan Komisaris di PT Bio Farma member of the Board of Commissioners at PT Bio Farma
(Persero) (2024), Direktur Jenderal Tenaga Kesehatan (Persero) until August 2024, Director General of Health
(2021–2024), Dewan Pengawas di LAMPT–Kes dan Workers (2021-2024), Supervisory Board at LAMPT-
sebagai Wakil Ketua Komite Bersama Kemdikbudristek Kes and Deputy Chairman of the Joint Committee
–Kemkes (2022–2024). of the Ministry of Education, Culture, Research and
Technology - Ministry of Health (2022- 2024).
Beliau memiliki rangkap jabatan sebagai Ketua Konsil Currently holds concurrent positions as the Chairman
Kesehatan Indonesia (sejak Oktober 2024) dan sebagai of the Indonesian Health Council (since October 2024)
Anggota Dewan Komisaris PT Pertamina Bina Medika and as Commissioner of PT Pertamina Bina Medika IHC
IHC (sejak Agustus 2024). (since August 2024).
Page 56
56 Profil Perusahaan
Company Profile
BMHS mengucapkan terima kasih dan memberikan BMHS would like to express its sincere gratitude and
penghargaan setinggi–tingginya atas dedikasi, highest appreciation for the dedication, time, and
waktu serta sumbangsih tenaga dan pikiran Bapak valuable contributions of Mr. Wishnutama Kusubandio
Wishnutama Kusubandio dan Bapak Sunata and Mr. Sunata Tjiterosampurno during their tenure as
Tjiterosampurno selama menjabat sebagai Dewan Members of BMHS’s Board of Commissioners.
Komisaris BMHS.
Wishnutama Kusubandio
Wakil Komisaris Utama & Komisaris Independen
Vice President Commissioner & Independent Commissioner
(Menjabat 1 April 2021–7 Agustus 2025) | (In office April 1, 2021–August 7, 2025)
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 55 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Wakil Komisaris Utama He currently served as Vice President Commissioner as
sekaligus Komisaris Independen berdasarkan Akta No well as Independent Commissioner based on Deed No.
5 tanggal 1 April 2021. 5 dated April 1, 2021.
Beliau lulus Coursework in Communication and Navy He passed Coursework in Communication and Navy
Reserve Officers Training Corps (ROTC) di Military Reserve Officers Training Corps (ROTC) at the Military
College of Vermont, Norwich University, Vermont College of Vermont, Norwich University, Vermont
(1992), lulus Coursework in Television Production di (1992), passed Coursework in Television Production
Emerson College (1994), lulus Communication Degree at Emerson College (1994), passed Communication
di Mount Ida College, Massachusetts (1994), lulus Degree at Mount Ida College, Massachusetts (1994),
GE Management Development Institute’s GE South graduated from the GE Management Development
East Asia Executive Program di Crotonville, New York Institute’s GE South East Asia Executive Program in
(2008), dan lulus Harvard Business School Competing Crotonville, New York (2008), and graduated from
in the Age of Digital Platforms di Harvard University Harvard Business School Competing in the Age of
(2021). Digital Platforms at Harvard University (2021).
Beliau memulai karier di WHDH–TV, INC., a CBS He started his career at WHDH-TV, INC., as a CBS Affiliate
Affiliate sebagai Assistant Director on Air Promotion as Assistant Director on Air Promotion (1993-1994),
(1993–1994), kemudian di Indosiar sebagai Supervisor then at Indosiar as Supervisor on Air Promotion (1994-
on Air Promotion (1994–1995), sebagai Producer 1995), as Producer Director (1995- 1997), as Executive
Director (1995–1997), sebagai Executive Producer Producer (1997-1998), as non- Drama Section Head
(1997–1998), sebagai non–Drama Section Head (1998-1999), and as Production Manager (1999-2001).
(1998–1999), dan sebagai Production Manager (1999– Subsequently, had a career at Trans TV as Production &
2001). Selanjutnya beliau berkarier di Trans TV sebagai Facilities Division Head (2001-2004), Chief Operating
Production & Facilities Division Head (2001–2004), Officer (2004-2006), Vice President Director/Chief
Chief Operating Officer (2004–2006), Wakil Direktur Operating Officer (2006- 2008), President Director/
Utama/Chief Operating Officer (2006–2008), Direktur Chief Executive Officer (2006-2008), and at Trans 7
Utama/Chief Executive Officer (2006–2008), dan as President Director/ Chief Executive Officer (2008-
di Trans 7 sebagai Direktur Utama/Chief Executive 2012). Then served at Detik.com as Director (2011-
Officer (2008–2012). Karier Beliau selanjutnya di 2012), NET TV as Main Director (2012-2019) and as
Page 57
Laporan Tahunan
Annual Report 57
Detik.com sebagai Direktur (2011–2012), NET TV Main Commissioner (2019), 2018 Asian Games as
sebagai Direktur Utama (2012–2019) dan sebagai Director of Ceremonies and Events (2016-2017), Asian
Komisaris Utama (2019), Asian Games 2018 sebagai Television Awards as Advisory Board (2016-2019), OCC
Director of Ceremonies and Events (2016–2017), Asian Asian Games 2018 as Creative Director (2017-2018),
Television Awards sebagai Advisory Board (2016– Kumparan as Commissioner (2017-2019), Indonesian
2019), OCC Asian Games 2018 sebagai Creative National Television Association as General Chairman
Director (2017–2018), Kumparan sebagai Komisaris (2017- 2019), Tokopedia as Commissioner (2019), as
(2017–2019), Asosiasi Televisi Nasional Indonesia well as Telkomsel as Chairman of the Board and GoTo
sebagai Ketua Umum (2017–2019), Tokopedia sebagai Gojek Tokopedia as a Board Member (since 2021). He
Komisaris (2019), serta Telkomsel sebagai Komisaris is the Minister of Tourism and Creative Economy and
Utama dan GoTo Gojek Tokopedia sebagai Komisaris Head of the Tourism and Creative Economy Agency of
(sejak 2021). Beliau adalah Menteri Pariwisata dan the Republic of Indonesia at the Advanced Indonesia
Ekonomi Kreatif dan Kepala Badan Pariwisata dan Cabinet (2019-2020).
Ekonomi Kreatif Republik Indonesia pada Kabinet
Indonesia Maju (2019–2020).
Sunata Tjiterosampurno
Komisaris | Commisioner
(Menjabat 21 Juli 2022-7 Agustus 2025) | (In office July 21, 2022–August 7, 2025)
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 53 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Komisaris berdasarkan Akta He serves as Commissioner based on Deed No. 131
Notaris Nomor 131 Tanggal 21 Juli 2022. dated July 21, 2022.
Beliau meraih gelar Bachelor of Business Administration He obtained a Bachelor of Business Administration
dari University of Wisconsin (1995), Madison dan from the University of Wisconsin-Madison (1995) and a
Master in Finance dari London Business School (2002). Master in Finance from London Business School (2002).
Beliau memulai karier di Lippo Securities–SBC Warburg He started his career at Lippo Securities-SBC Warburg
sebagai Assistant Vice President Riset Ekuitas (1995– as Assistant Vice President of Equity Research (1995-
1998), dilanjutkan di Boston Consulting Group Jakarta 1998), continued at Boston Consulting Group Jakarta as
sebagai Konsultan (1998–2004), dan PT Danareksa a Consultant (1998- 2004), and PT Danareksa Sekuritas
Sekuritas sebagai Direktur Investment Banking (2004– as Director of Investment Banking (2004-2006). His
2006). Karier beliau selanjutnya antara lain Komisaris subsequent career included Commissioner of PT Bank
PT Bank Tabungan Pensiunan Nasional Tbk (2008– Tabungan Pensiunan Nasional Tbk (2008-January
Januari 2015), Komisaris PT Delta Dunia Makmur Tbk 2015), Commissioner of PT Delta Dunia Makmur Tbk
(Juni 2011–Juni 2022), Komisaris Utama PT Bukit (June 2011-June 2022), and President Commissioner
Makmur Mandiri Utama (2010–2021), Komisaris of PT Bukit Makmur Mandiri Utama (2010-2021).
PT Trimegah Sekuritas (sejak November 2013), dan Currently holds concurrent positions as Commissioner
Komisaris PT BFI Finance Indonesia Tbk (sejak 2015). of PT Trimegah Sekuritas (since November 2013), and
Commissioner of PT BFI Finance Indonesia Tbk (since
2015).
Page 58
58 Profil Perusahaan
Company Profile
Profil Direksi
Board of Directors Profiles
Sepanjang 2025, komposisi Direksi BMHS tidak Throughout 2025, there were no changes to the
mengalami perubahan. composition of BMHS’s Board of Directors.
Komposisi Direksi
Composition of the Board of Directors
Direksi 1 Januari – 31 Desember 2025
Director Januari 1 – December 31 2025
Direktur Utama
Agus Heru Darjono
President Director
Direktur
Cuncun Wijaya
Director
Direktur
Emilia Rouli
Director
Page 59
Laporan Tahunan
Annual Report 59
Agus Heru Darjono
Direktur Utama
President Director
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 55 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Direktur Utama berdasarkan He currently serves as President Director based on
Akta No. 159 tanggal 30 Mei 2024. Deed No. 159 dated May 30, 2024.
Beliau memperoleh gelar Sarjana Ekonomi dari Sekolah He obtained a Bachelor of Economics degree
Tinggi Ilmu Ekonomi (STIE) Pengembangan Bisnis from Sekolah Tinggi Ilmu Ekonomi (STIE) Business
dan Manajemen (PBM) pada tahun 2001, Magister Development and Management (PBM) in 2001, a
Management dari PPM School of Management Jakarta Master of Management Degree from IPB School of
pada tahun 2005, dan Doktor dari IPB University School Management Jakarta in 2005, and a Doctorate from IPB
of Business pada tahun 2019. University School of Business in 2019.
Beliau memulai karier profesionalnya di PT Pfizer He started his professional career at PT Pfizer Indonesia
Indonesia dengan posisi terakhir sebagai Direktur (1990-2012) with his last position as Director. His
(1990–2012), Direktur PT Merck Sharp and Dohme career history includes: Director of PT Merck Sharp
(2012–2014), Direktur PT Darya Varia Laboratoria– and Dohme (2012-2014), Director of PT Darya Varia
Unilab (2014–2017), Presiden Direktur PT Metro Laboratoria-Unilab (2014-2017), President Director
Drug Indonesia–Zuellig Group (2017–2018), Chief PT of PT Metro Drug Indonesia- Zuellig Group (2017-
Anugerah Pharmindo Lestari–Zuellig Pharma (2018– 2018), Chief of PT Anugerah Pharmindo Lestari-Zuellig
2019), Vice President PT Bernofarm Group (2020– Pharma (2018-2019), Vice President of PT Bernofarm
2021), Direktur di PT Darya–Varia Laboratoria (2021– Group (2020-2021), Director at PT Darya-Varia
2023), dan Presiden Direktur PT Indofarma (Persero) Laboratoria (2021-2023), and President Director of PT
Tbk (2023–2024). Indofarma (Persero) Tbk (2023-2024).
Beliau memiliki rangkap jabatan sebagai Direktur He has concurrent positions as Director of PT Bunda
PT Bunda Global Pharma, Direktur PT BMHS Diklat Global Pharma, Director of PT BMHS Diklat Indonesia,
Indonesia, Direktur PT Citra Ananda, Direktur PT Bunda Director of PT Citra Ananda, Director of PT Bunda
Medika Dewata, Wakil Direktur Utama PT Morula Medika Dewata, Vice President Director of PT Morula
Indonesia, Direktur PT Pintu Ilmu, Direktur PT Bunda Indonesia, Director of PT Pintu Ilmu, Director of PT
Minang Citra, Direktur PT Jolin Sapta Medika, Direktur Bunda Minang Citra, Director of PT Jolin Sapta Medika,
PT Prima Dental Medika, Direktur PT Emergency Director of PT Prima Dental Medika, Director of PT
Response Indonesia, Direktur PT Bunda Medika Wisesa, Emergency Response Indonesia, Director of PT Bunda
Direktur PT Bunda Medika Klinik, Direktur PT Bunda Medika Wisesa, Director of PT Bunda Medika Klinik,
Graha Properti, Komisaris PT Diagnos Laboratorium Director of PT Bunda Graha Properti, Commissioner of
Utama Tbk, Direktur Sasana Mitra Bunda dan PT PT Diagnos Laboratorium Utama Tbk, Director Sasana
Bunda Medika Bekasi serta Direktur Utama PT Medika Mitra Bunda and PT Bunda Medika Bekasi also the
Sejahtera Bersama. President Director of PT Medika Sejahtera Bersama.
Page 60
60 Profil Perusahaan
Company Profile
Cuncun Wijaya
Direktur Keuangan
Chief Financial Officer
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 48 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Direktur Keuangan He currently serves as Director based on Deed No. 131
berdasarkan Akta No. 131 Tanggal 21 Juli 2022. dated July 21, 2022.
Beliau meraih gelar Bachelor of Economic dari He obtained a Bachelor of Economics degree from
Universitas Katolik Atma Jaya Jakarta (1999) dan Universitas Katolik Atma Jaya, Jakarta (1999) and a
Magister Finance dari Universitas Pelita Harapan Masters in Finance degree from Universitas Pelita
Jakarta (2011). Harapan, Jakarta (2011).
Beliau merupakan profesional di bidang akuntansi dan He has served as a professional in accounting and
keuangan dengan pengalaman lebih dari 15 tahun di finance with more than 15 years of experience in various
berbagai industri. Karier beliau antara lain Investor industries. His career includes Investor Relations
Relation Officer PT Kalbe Farma Tbk (2000–2002), Officer at PT Kalbe Farma Tbk (2000-2002), Finance
Finance and Accounting Manager PT Honoris Industry and Accounting Manager at PT Honoris Industry (2004-
(2004–2012), Head of Investor Relation, Corporate 2012), Head of Investor Relations, Corporate Secretary,
Secretary, Finance Director PT Modernland Realty Tbk Finance Director at PT Modernland Realty Tbk (2012-
(2012–2018), Chief Financial Officer (CFO) di Eatwell 2018), Chief Financial Officer (CFO) at Eatwell Culinary
Culinary (2018–2019) dan Aryaduta Hotel Group (2018-2019) and at Aryaduta Hotel Group (2020-
(2020–2021). 2021).
Beliau rangkap jabatan sebagai Direktur PT Medika He has held the position of Director at PT Medika
Sejahtera Bersama sejak Februari 2025. Sejahtera Bersama since February 2025.
Page 61
Laporan Tahunan
Annual Report 61
Emilia Rouli
Direktur Sumber Daya Manusia
Chief Human Capital Officer
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 55 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Direktur Sumber Daya Manusia She currently serves as Human Capital Director based
berdasarkan Akta No. 131 Tanggal 21 Juli 2022. on Deed No. 131 dated July 21, 2022.
Beliau lulus dari Fakultas Bisnis Asian Institute of She graduated from the Faculty of Business of the Asian
Management, Filipina (2008). Institute of Management, Philippines (2008).
Beliau memulai karier di Pfizer Pharmaceuticals & She started her career at Pfizer Pharmaceuticals &
Wyeth Nutrition dengan posisi terakhir sebagai Senior Wyeth Nutrition with the last position as Senior HR
HR Business Partner (2001–2011), dilanjutkan di Business Partner (2001-2011), continued at PT Metro
PT Metro Drug Indonesia sebagai Head of Human Drug Indonesia as Head of Human Resources (2011-
Resources (2011–2014) dan PT Lafarge Cement 2014) and PT Lafarge Cement Indonesia as Vice
Indonesia sebagai Vice President OD & Transformation President OD & Transformation (2014-2016). Then
(2014–2016), PT Holcim Indonesia Tbk sebagai Head had a career at PT Holcim Indonesia Tbk as Head of
of Talent & Performance Management dan sebagai Talent & Performance Management and Regional L&D
Regional L&D Manajer untuk Kawasan Asia Pasifik, Manager for the Asia Pacific region based in Singapore
berbasis di Singapura (2017–2019), serta di PT Sodexo (2017-2019), and at PT Sodexo Indonesia as Director of
Indonesia sebagai Direktur Sumber Daya Manusia Human Resources (2019-2021).
(2019–2021).
Beliau tidak memiliki rangkap jabatan baik di dalam She does not hold any concurrent positions either inside
maupun di luar BMHS. or outside BMHS.
Page 62
62 Profil Perusahaan
Company Profile
Informasi mengenai hubungan afiliasi anggota Information concerning the affiliated relationships
Dewan Komisaris dan Direksi disampaikan pada Bab of the members of the Board of Commissioners and
Governansi Korporat Laporan Tahunan ini. the Board of Directors can be found in the Corporate
Governance Chapter of this Annual Report.
Sumber Daya Manusia
Human Capital
Sumber daya manusia (SDM) memegang peranan Human capital (HC) plays a vital role in determining
penting dalam menentukan kualitas layanan kesehatan. the quality of healthcare services. Competent and
SDM yang kompeten, berpengalaman, dan memiliki experienced HC with a high level of patient-centered
kepedulian tinggi terhadap pasien merupakan pilar care make up the main pillar supporting BMHS’s
utama yang menopang kinerja BMHS sepanjang performance throughout its journey. BMHS places
perjalanannya. BMHS menempatkan pengelolaan SDM HC management as one of its strategic priorities
sebagai salah satu prioritas strategis dalam memperkuat to strengthen organizational fundamentals.
fundamental organisasi. Internalisasi nilai “Create Internalization of the values “Create Innovation,
Innovation, Compassion, Competence, Collaboration, dan Compassion, Competence, Collaboration, and
Change Agility (5C)” terus dilakukan untuk menciptakan Change Agility (5C)” continues to be implemented to
lingkungan kerja yang sehat, adaptif, dan kolaboratif. foster a healthy, adaptive, and collaborative working
Melalui penguatan nilai 5C, BMHS membangun environment. Through the reinforcement of the 5C
kompetensi dan karakter karyawan, serta mendorong values, BMHS develops employee competencies
profesionalisme dan empati dalam setiap interaksi and character, while promoting professionalism and
dengan pasien. empathy in every interaction with patients.
Untuk memastikan pengelolaan SDM berjalan konsisten To ensure consistent and well-directed HC management,
dan terarah, BMHS menerapkan serangkaian langkah BMHS has instigated a series of strategic initiatives
strategis yang mencakup seluruh siklus kerja karyawan, covering the entire employee lifecycle, including
mulai dari proses rekrutmen, orientasi, pengembangan recruitment, orientation, competency development,
kompetensi, manajemen talenta dan suksesi, talent and succession management, performance
penilaian kinerja, pengelolaan karier, keterlibatan dan appraisal, career management, employee engagement
kesejahteraan karyawan, serta retensi dan manajemen and well-being, as well as retention and turnover
turnover. management.
Pada 2025, jumlah karyawan BMHS adalah 3.191 orang. In 2025, BMHS employed 3,191 personnel. The
Keberagaman komposisi karyawan mencerminkan diversity of the workforce composition reflects an
struktur SDM yang inklusif dan mampu mendukung inclusive HC structure that is well positioned to support
kebutuhan layanan kesehatan yang dinamis. the dynamic needs of healthcare services.
Komposisi Karyawan Berdasarkan Jenis Kelamin
Employee Composition by Gender
Gender 2025 2024 2023
Pria | Male 750 779 787
Wanita | Female 2.441 2.455 2.369
Jumlah | Total 3.191 3.234 3.156
Page 63
Laporan Tahunan
Annual Report 63
Komposisi Karyawan Berdasarkan Jabatan dan Jenis Kelamin
Employee Composition by Position Level and Gender
2025 2024
Level Jabatan
Position Level Pria Wanita Pria Wanita
Total Total
Male Female Male Female
Entry-level 510 2.053 2.563 529 2.108 2.637
Mid-level 190 349 539 193 307 500
Senior-level 25 30 55 38 35 73
Executive-level 25 9 34 19 5 24
Total 750 2.441 3.191 779 2.455 3.234
Keterangan | Note
Pada tahun 2023, jumlah karyawan berdasarkan jabatan dibagi berdasarkan Komisaris 5; Direktur 5; Head Division 58; Departement Head &
Specialist 164; Unit Head & Jr. Specialist 346; Staf Lainnya 2.361; Dokter Umum 194 dengan total 3.133 karyawan.
In 2023, BMHS’s workforce by position level consisted of 5 Commissioners, 5 Directors, 58 Division Heads, 164 Department Heads and Specialists,
346 Unit Heads and Junior Specialists, 2,361 Other Staff, and 194 General Practitioners, bringing the total number of employees to 3,133.
Komposisi Karyawan Berdasarkan Tingkat Pendidikan dan Jenis Kelamin
Employee Composition by Education Level and Gender
2025 2024
Tingkat Pendidikan
Education Level Pria Pria Wanita
Wanita Female Total Total
Male Male Female
SMA dan Sederajat
High School and 167 102 269 192 113 305
Equivalent
Diploma 162 950 1.112 172 1.013 1.185
Strata 1
356 1.278 1.634 360 1.223 1.583
Bachelor's Degree
Pascasarjana
65 111 176 55 106 161
Postgraduate
Total 750 2.441 3.191 779 2.455 3.234
Keterangan | Note
Pada tahun 2023, karyawan berdasarkan pendidikan tingkat SMA dan sederajat berjumlah 343; Diploma berjumlah 1.262; Strata 1 berjumlah 1.414;
Pascasarjana berjumlah 137 dengan total keseluruhan 3.156 karyawan.
In 2023, BMHS’s employees by education level consisted of 343 employees with senior high school or equivalent qualifications, 1,262 diploma
holders, 1,414 employees holding a bachelor’s degree, and 137 employees with postgraduate degrees, bringing the total number of employees to
3,156 employees.
Komposisi Karyawan Berdasarkan Kelompok Usia dan Jenis Kelamin
Employee Composition Based on Age Group and Gender
Rentang Usia 2025 2024
Age Group Pria Wanita Pria Wanita
(tahun/years) Total Total
Male Female Male Female
<25 29 173 202 41 239 280
≥25 s.d. ≤35 424 1.519 1.943 436 1.552 1.988
≥35 s.d. ≤45 214 550 764 218 482 700
≥45 s.d. ≤60 81 191 272 82 175 255
≥ 60 2 8 10 2 7 9
Total 750 2.441 3.191 779 2.455 3.234
Keterangan | Note
Pada tahun 2023, karyawan berdasarkan kelompok usia <25 tahun sebanyak 402; 26-45 tahun sebanyak 2.499; 46-55 tahun sebanyak 231; >55
tahun sebanyak 24 dengan total 3.156 karyawan.
In 2023, employees based on age group consisted of <25 years old - 402; 26-45 years old - 2,499; 46-55 years old - 231; >55 years old - 24 bringing
the total number of employees to 3,156 employees.
Page 64
64 Profil Perusahaan
Company Profile
Komposisi Karyawan Berdasarkan Status Ketenagakerjaan dan Wilayah Kerja 2025
Composition Based on Employment Status and Work Area in 2025
Pegawai Tetap Pegawai Tidak Tetap
Total
Lokasi Permanent Contract
Location Pria Wanita Pria Wanita Pria Wanita
Male Female Male Female Male Female
Jakarta 183 528 183 403 366 931
Bekasi 15 65 28 120 43 185
Depok 43 229 56 153 99 382
Tangerang Selatan 8 46 21 78 29 124
Palembang 4 13 19 91 23 104
Padang 51 284 32 138 83 422
Denpasar 46 107 10 38 56 145
Yogyakarta 3 5 3 11 6 16
Surabaya 3 6 11 49 14 55
Makassar 1 6 13 31 14 37
Bandung 1 5 4 12 5 17
Brebes 0 0 1 6 1 6
Pekanbaru 0 3 1 2 1 5
Batam 2 1 9 10 11 11
Total 360 1.298 391 1.142 751 2.440
Keterangan | Note
Pada tahun 2024, jumlah karyawan tetap laki-laki sebanyak 338 dan perempuan 1.241, sementara jumlah karyawan tidak tetap laki-laki sebanyak 441
dan perempuan 1.214.
In 2024, the number of permanent employees consisted of 338 male and 1,241 female employees, while non-permanent employees comprised 441
male and 1,214 female employees.
Keahlian dan Kompetensi Qualifications and Competency
BMHS memastikan seluruh karyawan telah memiliki BMHS ensures that all employees have certification
sertifikasi sesuai bidang tugasnya. Pada 2024 dan 2023, relevant to their field of work. In 2024 and 2023,
radiologi telah memiliki beberapa sertifikat di antaranya radiology has several certifications, including medical
fisikawan medis, kemudian di farmasi mempunyai physicists, while pharmacy has Total Parenteral
sertifikat Total Parenteral Nutrition (TPN) dan farmasi Nutrition (TPN) and chemotherapy pharmacy
kemoterapi, serta di bidang keperawatan telah certifications, and nursing has certifications in cath lab
tersertifikasi pelatihan cath lab, kemoterapi, hemodilisa, training, chemotherapy, hemodilysis, anesthesia, NICU,
penata anestesi, NICU, PICU, ICU, dan kamar bedah. PICU, ICU, and operating rooms. For 2025, several
Untuk 2025, beberapa sertifikasi yang telah dijalankan certifications have been implemented, including:
yaitu meliputi:
Jumlah Karyawan
Tugas Perizinan Number of Employees
Duties Licensing
2025
Sertifikat Fisikawan Medis | Medical Physicist Certificate 5
Radiologi | Radiology
Sertifikat Petugas Proteksi Radiasi 8
Sertifikat TPN | TPN Certificate 5
Farmasi | Pharmacy
Sertifikat Farmasi Kemoterapi | Chemotherapy Pharmacy Certificate 3
Page 65
Laporan Tahunan
Annual Report 65
Jumlah Karyawan
Tugas Perizinan Number of Employees
Duties Licensing
2025
Sertifikat Pelatihan Cath Lab | Cath Lab Training Certificate 2
Sertifikat Kemoterapi | Chemotherapy Certificate 2
Sertifikat Hemodialisa | Hemodialysis Certificate 20
Sertifikat ICU
27
ICU Certificate
Sertifikat Kamar Bedah
45
Operating Room Certificate
Sertifikat BTCLS
565
BTCLS Certificate
Sertifikat Keperawatan Neonatus Level 2
23
Level 2 Neonatal Nursing Certificate
Sertifikat PONEK
10
PONEK Certificate
Sertifikat Resusitasi Neonatus
127
Neonatal Resuscitation Certificate
Keperawatan | Nursing
Sertifikat ACLS
76
ACLS Certificate
Sertifikat Asuhan Persalinan Normal (APN)
51
Normal Childbirth Care (APN) Certificate
Sertifikat Komite Keperawatan
3
Nursing Committee Certificate
Sertifikat Manajemen Kepala Ruang
6
Head of Room Management Certificate
Sertifikat Mentoring/ preceptorship
3
Mentoring/Preceptorship Certificate
Sertifikat TOT dan atau TPK
6
TOT and/or TPK Certificate
Sertifikat Perawat Anestesi
17
Anesthesia Nurse Certificate
Sertifikat NICU PICU
76
NICU PICU Certificate
Sertifikat ATCLS
55
ATCLS Certificate
Sertifikat K3RS
17
K3RS Certificate
Sertifikat ATLS Dokter
3
ATLS Doctor Certificate
Medis dan Penunjang Sertifikat ACLS Dokter
11
Medical and Support Services ACLS Doctor Certificate
Sertifikasi Hiperkes
7
Hiperkes Certification
Sertifikat APN
10
APN Certificate
Sertifikasi IPCN
1
IPCN Certification
BMHS menyediakan layanan kesehatan holistik dengan BMHS provides holistic healthcare services supported
didukung oleh tenaga medis profesional, mulai dari by professional medical personnel, ranging from general
dokter umum, dokter spesialis dan sub spesialis, hingga practitioners, specialist and sub-specialist doctors to
professor yang tersebar pada: professors, in the following areas:
Page 66
66 Profil Perusahaan
Company Profile
Profesor Spesialis Sub-Spesialis
Professor Specialist Sub-Specialist
2025 2024 2023 2025 2024 2023 2025 2024 2023
RSIA Bunda Jakarta
Bunda Jakarta Women and Children 5 6 8 41 47 42 34 34 36
Hospital
RSU Bunda Jakarta
5 6 5 70 68 71 38 37 37
Bunda Jakarta Hospital
RSU Bunda Margonda
0 0 3 77 63 90 17 23 17
Bunda Margonda Hospital
RSU Bunda Padang
1 1 3 59 10 61 26 9 9
Bunda Padang Hosipital
RSIA Bunda Ciputat
Bunda Ciputat Women and Children 1 1 3 22 19 24 1 2 3
Hospital
RSIA Az Zahra Palembang
Az Zahra Palembang Women and 0 0 3 21 13 13 2 3 2
Children Hospital
RSU Citra Harapan
0 0 3 45 34 37 0 4 3
Citra Harapan Hospital
RSIA Pusura Tegalsari
Pusura Tegalsari Women and Children 0 0 3 12 18 3 3 4 3
Hospital
RSIA Bunda Denpasar
Bunda Denpasar Women and Children 0 0 3 22 21 20 4 4 3
Hospital
BIC Vida Bekasi 0 0 0 4 3 3 0 0 0
Bunda Clinic MRT Dukuh Atas 0 - - 0 - - 0 - -
Morula Indonesia 4 4 4 97 92 90 34 33 30
Diagnos Laboratorium 1 1 0 31 23 14 6 2 1
Keterangan | Note
• Bunda Clinic MRT Dukuh Atas dibuka pada September 2025 | Bunda Clinic MRT Dukuh Atas open in September 2025
• BIC Vida Bekasi tutup di akhir 2025 | BIC Vida Bekasi close at the end of 2025
Pengembangan Kompetensi Competency Development
Program pengembangan kompetensi dilaksanakan Competency development programs are implemented
secara komprehensif, mencakup pengembangan comprehensively, encompassing the enhancement
keterampilan, pengetahuan, dan sikap. Pada 2025, of skills, knowledge, and attitudes. In 2025, BMHS
BMHS telah menyelenggarakan lebih dari 1.656 organized more than 1,656 training programs, including
program pelatihan, mencakup penguatan kompetensi capacity building in NICU and PICU, medical ethics
NICU dan PICU, etika medis dan patient care, surgical and patient care, surgical excellence, as well as other
excellence, serta sejumlah pelatihan teknis lainnya yang technical trainings strategically designed to enhance
dirancang secara strategis untuk meningkatkan kualitas nursing quality and clinical standards across the BMHS
keperawatan dan standar klinis di seluruh jaringan network.
BMHS.
Top 30 Pelatihan Hard Skill | Top 30 Hard Skills Training Courses
1 Simulasi APAR Fire Extinguisher Simulation
Sosialisasi Limbah B3 dan Pengelolaan B3, Penanggulangan Training on Hazardous Waste and Hazardous Materials Management,
2 Bencana, Utilitas Gedung, Keamanan dan Keselamatan Alat Disaster Response, Building Utilities, and Medical Equipment Safety and
Medis Security
Sosialisasi Budaya Keselamatan Pasien dan Pencegahan
3 Training on Patient Safety Culture and Infection Prevention and Control
Pengendalian Infeksi
4 Sosialisasi Pengelolaan Etika dan Hukum RS Citra Harapan Training on Ethics and Legal Management at Citra Harapan Hospital
5 DRK DRK
6 Sosialisasi Akun Satu Sehat Training on the Satu Sehat Account
Pencegahan Penanggulangan Kebakaran & Simulasi Bencana
7 Fire Prevention & Fire Disaster Simulation
Kebakaran
8 Orientasi Umum General Orientation
9 Sosialisasi Greeting & Grooming Greeting & Grooming Awareness Session
Page 67
Laporan Tahunan
Annual Report 67
Top 30 Pelatihan Hard Skill | Top 30 Hard Skills Training Courses
Re-Sosialisasi Assesment-Kredensial, Mutu Profesi dan Etik- Re-Awareness Session on Assessment-Credentials, Professional Quality,
10
Disiplin Profesi dan pelatihan Service Excellence Professional Ethics & Discipline, and Service Excellence Training
11 Simulasi Proteksi Kebakaran Fire Protection Simulation
12 Sosialisasi K3RS Hospital Occupational Safety and Health (K3RS) Awareness Session
13 Sosialisasi ESG ESG Socialization
14 Etik & Caring Keperawatan Nursing Ethics & Caring
15 Manajemen Nyeri & Askep 3S Pain Management & 3S Nursing Care
16 Pelatihan Dasar Microsoft Office Basic Microsoft Office Training
17 Pelatihan PPI Dasar Basic Infection Prevention and Control (IPC) Training
18 Sosialisasi Hourly Rounding dan Nursing Care Socialization of Hourly Rounds and Nursing Care
19 Etik dan Caring Keperawatan Nursing Ethics & Caring
Sosialisasi Budaya Keselamatan Pasien dan Pencegahan Socialization of Patient Safety Culture and Infection Prevention and
20
Pengendalian Infeksi (PPI) Control (IPC)
21 Pelatihan Bantuan Hidup Dasar Penunjang Medis & Non Medis Basic Life Support Training for Medical & Non-Medical Personnel
22 Pelatihan Tanggap Darurat Kebakaran Fire Emergency Response Training
23 Pelatihan Awareness K3RS Periode Mei 2025 K3RS Awareness Training for May 2025
24 Pelatihan Skill Lab Transfusi Darah Blood Transfusion Skills Lab Training
25 12 KDK 12 KDK
26 Pelatihan Managemen Laktasi Lactation Management Training
27 Pelatihan Manual Handling Periode Maret 2025 Manual Handling Training for March 2025
28 Workshop EMR (SIRS Teramedik) Workshop EMR (SIRS Teramedik)
29 Patient Centered Communication Skills Patient Centered Communication Skills
30 Pelatihan Kode Emergency Periode Mei 2025 Pelatihan Kode Emergency Periode Mei 2025
Top 30 Pelatihan Soft Skill | Top 30 Soft Skills Training Courses
1 Beauty Class Beauty Class
2 Pemaparan Target 2025 dan Kedisiplinan Karyawan Presentation of the 2025 Goals and Employee Discipline
3 Know Your Self With DISC Know Your Self With DISC
4 Growth Mindset : Positive Thinking Growth Mindset : Positive Thinking
Meningkatkan Mindfulness dan Membangun Peer Support di
5 Promoting Mindfulness and Building Peer Support in the Hospital Setting
Lingkungan Rumah Sakit
6 Sosialisasi Pedoman Grooming Rollout of Grooming Guidelines
7 Basic Communication Skills Basic Communication Skills
8 GCG Awareness GCG Awareness
5C Talks : Stronger Together: Membangun Kolaborasi yang
9 5C Talks : Stronger Together: Membangun Kolaborasi yang Berdampak
Berdampak
10 5C Talks : From Ideas to Impact in Everyday Work 5C Talks : From Ideas to Impact in Everyday Work
11 5C Talks : Embracing Changes With Agility 5C Talks : Embracing Changes With Agility
12 Sosialisasi Mini Assesment 5C Socialization of Mini 5C Assessment
13 Sosialisasi Culture Book Socialization of the Culture Book
14 Sosialisasi 6 Sasaran Keselamatan Pasien Socialization of the 6 Patient Safety Goals
15 Sosialisasi Kamus Kompetensi PT Bundamedik Socialization of the PT Bundamedik Competency Dictionary
16 Refreshment : Values Driven Excellence with 5C Refreshment : Values Driven Excellence with 5C
17 Embracing Changes With Agility Embracing Changes With Agility
18 5C Talk : From Ideas to Impact in Everyday Work 5C Talk : From Ideas to Impact in Everyday Work
Pelatihan Komunikasi Efektif Verbal Melalui Telepon Periode Training on Effective Verbal Communication Over the Phone (June 2025
19
Juni 2025 Session)
20 Pencegahan Infeksi dan Sasaran Keselamatan Pasien Infection Prevention and Patient Safety Goals
21 Sosialisasi Akun Satu Sehat Introduction to the Satu Sehat Account
22 Sosialisasi Do & Dont Introduction to Dos and Don’ts
23 Handling Complaint Keperawatan Handling Nursing Complaints
24 5C Corporate Values 5C Corporate Values
25 5C Talks From Ideas to Impact in Everyday Work 5C Talks From Ideas to Impact in Everyday Work
26 5C Refreshment 5C Refreshment
Page 68
68 Profil Perusahaan
Company Profile
Top 30 Pelatihan Soft Skill | Top 30 Soft Skills Training Courses
27 Komunikasi Efektif & Pelayanan Prima Rumah Sakit Effective Communication & Excellent Hospital Care
28 Service Excellence Service Excellence
29 Productivity Management Productivity Management
30 Grooming and Greeting Grooming and Greeting
Manajemen Mutu Quality Management
BMHS menerapkan sistem manajemen mutu untuk BMHS applies a quality management system to ensure
memastikan setiap produk dan layanan kesehatan all healthcare products and services meet established
memenuhi standar kualitas. Seluruh proses dijalankan quality standards. All processes are carried out in
berdasarkan prosedur operasi standar (SOP) yang accordance with standard operating procedures (SOPs)
disusun selaras dengan proses bisnis, ketentuan aligned with BMHS’s business processes, regulatory
regulasi, dan tujuan strategis BMHS. Penerapan requirements, and strategic objectives. Quality
manajemen mutu bertujuan memberikan pelayanan management aims to deliver healthcare services that
kesehatan yang aman, efektif, efisien, dan berpusat are safe, effective, efficient, and patient-centered.
pada pasien.
RSU Bunda Jakarta dan RSIA Bunda Jakarta Bunda Jakarta Hospital and Bunda Jakarta Women and
telah meraih akreditasi 6th Evaluation and Quality Children Hospital have obtained the 6th Evaluation and
Improvement Program (EQuIP6) dari Australian Quality Improvement Program (EQuIP6) accreditation
Council on Healthcare Standards (ACHS). Di bidang from the Australian Council on Healthcare Standards
layanan fertilitas, Morula IVF Indonesia telah (ACHS). In the field of fertility services, Morula
memperoleh sertifikasi Reproductive Technology IVF Indonesia has received certification from the
Accreditation Committee (RTAC) dari Fertility Society Reproductive Technology Accreditation Committee
of Australia. Selain itu, seluruh rumah sakit di bawah (RTAC) of the Fertility Society of Australia. In addition,
BMHS telah menyelesaikan akreditasi sesuai Standar all Company hospitals have completed accreditation in
Akreditasi Kementerian Kesehatan (STARKES). Dengan accordance with the Ministry of Health Accreditation
pencapaian tersebut, Rumah Sakit Bunda Group Standards (STARKES). Through these achievements,
menegaskan komitmennya untuk terus menghadirkan the Bunda Hospital Group reaffirms its commitment
layanan yang berkualitas, selaras dengan standar to continuously delivering high-quality healthcare
terbaik, dan selalu mengutamakan keselamatan pasien. services aligned with best practices and patient safety
as top priorities.
Komposisi Pemegang Saham
Shareholders Composition
Pemegang Saham Berdasarkan Persentase Kepemilikan
Shareholders Based on Ownership Percentage
1 Januari 2025 31 Desember 2025
January 1, 2025 December 31, 2025
Nama Pemegang Saham
Name of Shareholder Kepemilikan Saham (%) Kepemilikan Saham (%)
Jumlah Saham Jumlah Saham
Ownership Percentage Ownership Percentage
Number of Shares Number of Shares
(%) (%)
Pemegang Saham dengan kepemilikan saham >5% | Shareholders with share ownership >5%
PT Bunda Investama Indonesia 4.935.430.900 57,37 4.935.430.900 57,37
Masyarakat | Public 2.466.534.276 28,66 2.466.534.276 28,66
Pemegang Saham dengan kepemilikan saham <5% | Shareholders with share ownership <5%
Ivan Rizal Sini 278.600.000 3,24 278.600.000 3,24
Mesha Rizal Sini 278.600.000 3,24 278.600.000 3,24
Rito Alam Rizal Sini 278.600.000 3,24 278.600.000 3,24
Renobulan Rizal Sini Suheimi 207.786.000 2,42 207.786.000 2,42
Ietje Ika Rizal Sini 157.865.000 1,83 157.865.000 1,83
Jumlah I Total 8.603.416.176 100,00 8.603.416.176 100,00
Page 69
Laporan Tahunan
Annual Report 69
Kepemilikan Saham Anggota Dewan Komisaris dan Board of Commissioners and Board of Directors Share
Direksi Ownership
Seluruh anggota Direksi tidak memiliki saham No members of the Board of Directors hold any shares in
BMHS, baik secara langsung maupun tidak langsung. BMHS, either directly or indirectly. Certain members of
Sementara itu, terdapat anggota Dewan Komisaris the Board of Commissioners, however, have direct and
dengan kepemilikan langsung dan tidak langsung atas indirect shareholdings in BMHS. Notwithstanding this,
saham BMHS. Meski demikian, BMHS memastikan BMHS ensures that all Independent Commissioners
seluruh Komisaris Independen tidak memiliki saham remain free from any share ownership that may affect
BMHS yang dapat memengaruhi independensinya, their independence, as stipulated in POJK No. 33/
sebagaimana diatur dalam POJK 33/POJK.04/2014. POJK.04/2014.
Kepemilikan Saham Langsung Anggota Dewan Komisaris
Board of Commissioners Share Ownership
1 Januari 2025 31 Desember 2025
January 1, 2025 December 31, 2025
Nama Jabatan Jumlah Kepemilikan Jumlah Kepemilikan
No
Name Position Saham Saham (%) Saham Saham (%)
Number of Ownership Number of Ownership
Shares Percentage (%) Shares Percentage (%)
Komisaris Utama
1 Ivan Rizal Sini 278.600.000 3,24 278.600.000 3,24
President Commissioner
Komisaris
2 Mesha Rizal Sini 278.600.000 3,24 278.600.000 3,24
Commissioner
Komposisi Pemegang Saham BMHS Berdasarkan Jenis Kepemilikan Saham
Shareholder Composition by Type of Share Ownership
Kelompok Pemegang Saham Jumlah Saham Kepemilikan Saham (%)
No
Group of Shareholders Number of Shares Share Ownership (%)
1 Institusi Lokal | Local Institutions 5.531.733.700 64,30
2 Individu Lokal | Local Individuals 1.859.391.600 21,61
3 Institusi Asing | Foreign Institutions 1.209.250.776 14,06
4 Individu Asing | Foreign Individuals 3.040.100 0,04
Jumlah | Total 8.603.416.176 100,00
Informasi Pemegang Saham Utama dan Pengendali Majority and Controlling Shareholders Information
Pihak pengendali dan pemilik manfaat akhir (ultimate BMHS’s controlling party and ultimate beneficial owner
beneficial owner) dari BMHS adalah Bapak Ivan Rizal is Mr. Ivan Rizal Sini, who holds a direct share ownership
Sini, dengan persentase kepemilikan saham langsung of 3.24%.
sebesar 3,24%.
Renobulan
PT Bunda Investama Ivan Rizal Mesha Rizal Rito Alam Ietje Ika Rizal Masyarakat
Rizal Sini
Indonesia Sini Sini Rizal Sini Sini Public
Suhelmi
57,37% 3,24% 3,24% 3,24% 2,42% 1,83% 28,66%
Page 70
70 Profil Perusahaan
Company Profile
Struktur Grup
Group Structure
Renobulan
Mesha Rizal Ietje Ika Ivan Rito Alam
Rizal Sini
Sini Rizal Sini Rizal Sini Rizal Sini
Suhelmi
PT Bunda
Investama
Indonesia
57,37% 2,42% 3,24% 1,83% 3,24% 3,24% Jinxin Life Asia
PT Bunda Ipiti Healthcare
PT BUNDAMEDIK TBK
Investama Investment
Group Pte. Ltd.
22,75%
PT
47,25%
10% 90%
30%
10% Morula
PT Visiscan Indonesia Indonesia
PT Emergency
60%
30%
Response
Indonesia
60% 98,01% 51%
PT Morula IVF PT Morula IVF PT Morula IVF
Surabaya Bandung 13,33%
Makassar
86,67%
PT BMHS Diklat 0,02%
10%
90%
PT Prima Dental
Indonesia Medika
PT Bunda 99% 60% 70%
35%
65%
Global Pharma
PT Morula IVF PT Morula IVF PT Morula IVF
1%
Padang Pontianak Yogyakarta PT Daima Citra
Prima
PT Bunda
60%
40%
Minang Citra
40% 60% 98% 10%
PT Empi PT Bunda Medika
90%
PT Diagnos PT Morula IVF PT Morula IVF
60%
40%
38,8%
41,2%
Pharma Wisesa
Laboratorium Pekanbaru Margonda
Sejahtera
Utama Tbk
2%
PT Sasana Husada
Citra Medika
99,992%
PT Citra
60%
40%
Ananda PT Medika
0,008%
Sejahtera 35%
Bersama PT Sasana
65%
PT Bunda Mitra Bunda
99%
1%
Medika Dewata
PT Bunda
99%
35%
1%
90%
Medika Bekasi
PT Morula PT Global
Sekawan
5%
5%
Bunda
Dewata Kreasi
99,32%
0,68%
PT Pintu Ilmu
PT Bunda
99%
1%
Medika Klinik 5%
PT Morula Bunda
90%
5%
Internasional
PT Bunda
99%
1%
Graha Properti
Pemegang Saham | Shareholder
PT Jolin Sapta
99%
1%
Medika PT Bundamedik Tbk Renobulan Rizal PT Daima Citra Prima
Sini Suhelmi,
PT Morula Indonesia Mesha Rizal Sini, PT Sasana Husada
Ietje Ika Rizal Sini, Citra Medika
PT Bunda Investama Ivan Rizal Sini,
Indonesia Rito Alam Rizal Jinxin Life Asia Healthcare
SIni Investment
Ivan Rizal Sini Group Pte. Ltd.
PT Diagnos
PT Bunda Laboratorium PT Bunda Ipiti
Minang Citra Utama Tbk Investama
Page 71
Laporan Tahunan
Annual Report 71
Entitas Anak dan Perusahaan Asosiasi
Subsidiaries and Associated Company
Total Aset per 31-
Kepemilikan Saham
Status Operasi Des- 2025
Nama BMHS (%) Bidang Usaha Lokasi
Operational (Rp)
Name Share Ownership by Type of Operations Location
Status Total Assets as of
BMHS (%)
Dec 31, 2025 (IDR)
Entitas Anak Langsung I Subsidiaries
Distributor Obat dan Alat
PT Bunda Global Kesehatan
65,00 61.280.117.861 Depok
Pharma (BGP) Distributor of Drugs and
Medical Equipment
Penyediaan jasa
PT Emergency
ambulans
Response Indonesia 60,00 5.578.020.212
Provision of ambulance
(ERI)
services
Beroperasi
Pendidikan Kesehatan Operational
PT BMHS Diklat
90,00 Swasta 2.010.605.086
Indonesia (BDI)
Private Health Education
Konsultan Manajemen
Layanan Teknologi
PT Morula Indonesia Reproduksi Berbantu
47,25 900.118.399.281
(MI) Management Consultant
for Reproductive
Technology Services
Tidak
Konsultan Manajemen Beroperasi
PT Visiscan Layanan USG Secara
90,00 4.509.592.372
Indonesia (VI) Management Consultant Komersial
Jakarta
for USG Services Not Operating
Commercially
Konsultan Manajemen
Layanan Klinik Fisioterapi
PT Sasana Mitra
65,00 Management Consultant 4.713.711.484
Bunda (SMB)
for Physiotherapy Clinic
Services
Hotel, Medical Tourism,
dan Konsultasi
PT Bunda Medika Manajemen
90,00 18.241.667.258
Wisesa (BMW) Management Consulting
for Hotel and Medical
Tourism
Konsultan Manajemen Beroperasi
PT Prima Dental Layanan Klinik Gigi Operational
86,67 3.082.030.552
Medika (PDM) Management Consultant
for Dental Clinic Services
PT Bunda Minang
40,00 231.210.371.243 Padang
Citra (BMC)
PT Citra Ananda Tangerang
40,00 58.490.188.196
(CA) Selatan
Aktivitas Rumah Sakit
PT Bunda Medika Swasta
99,00 63.762.315.316 Jakarta
Dewata (BMD) Private Hospital
PT Pintu Ilmu 99,00 Activities 76.862.409.548 Palembang
Belum
Beroperasi
PT Bunda Medika Secara
99,00 2.514.700.148 Bekasi
Bekasi Komersial
Not Operating
Commercially
Aktivitas Pelayanan
PT Diagnos
Penunjang Kesehatan Beroperasi
Laboratorium 41,20 318.672.105.755 Jakarta
Healthcare Support Operational
Utama Tbk
Service Activities
Page 72
72 Profil Perusahaan
Company Profile
Total Aset per 31-
Kepemilikan Saham
Status Operasi Des- 2025
Nama BMHS (%) Bidang Usaha Lokasi
Operational (Rp)
Name Share Ownership by Type of Operations Location
Status Total Assets as of
BMHS (%)
Dec 31, 2025 (IDR)
Belum
Beroperasi
PT Bunda Graha Properti Secara
99,00 272.099.324.873 Jakarta
Properti Property Komersial
Not Operating
Commercially
Aktivitas Rumah Sakit
PT Jolin Sapta Swasta Beroperasi
99,00 60.218.945.242 Bekasi
Medika Private Hospital Operational
Activities
PT Bunda Medika Klinik Beroperasi
99,00 13.548.792.969 Jakarta
Klinik Clinic Operational
Aktivitas Rumah Sakit
PT Medika Sejahtera Swasta Beroperasi
99,99 90.589.811.495 Surabaya
Bersama Private Hospital Operational
Activities
Entitas Anak Tidak Langsung (Melalui MI) I Indirect Subsidiaries (Via MI)
PT Morula IVF
24,10 10.124.858.840 Bandung
Bandung (MIB)
PT Morula IVF
37,80 28.127.500.628 Makassar
Makassar (MIMK) Beroperasi
PT Morula IVF Operational
28,35 32.176.983.717 Depok
Margonda (MIMG)
PT Morula IVF
46,78 Aktivitas Konsultan 15.456.979.394 Padang
Padang (MIPD)
Manajemen
Management Consulting Belum
PT Morula IVF
18,90 Activities Beroperasi 4.000.000.000 Pekanbaru
Pekanbaru (MIPB)
Not Operating
PT Morula IVF
28,35 11.753.618.823 Pontianak
Pontianak (MIPA)
PT Morula IVF
46,31 86.105.190.428 Surabaya
Surabaya (MIS)
PT Morula IVF Beroperasi
33,08 Operational 31.810.135.061 Yogyakarta
Yogyakarta (MIY)
Perdagangan Besar Obat,
PT Empi Pharma Farmasi untuk Manusia
46,31 49.571.012.347 Jakarta
Sejahtera (EPS) Wholesale Medicine,
Pharmacy for Humans
Aktivitas Rumah Sakit
Belum
PT Morula Bunda Swasta
47,53 Beroperasi 102.447.761.368 Bali
Dewata Private Hospital
Not Operating
Activities
Kronologi Pencatatan Saham dan Efek Lainnya
Chronology of Share and Other Securities Listing
Pada 6 Juli 2021, BMHS melaksanakan penawaran On July 6, 2021, BMHS conducted its initial public
umum perdana dengan nilai nominal saham Rp20 offering with a nominal share value of Rp20 per share
dan harga penawaran Rp340, sekaligus melakukan and an offering price of Rp340 per share, accompanied
Page 73
Laporan Tahunan
Annual Report 73
pencatatan saham pendiri dan konversi obligasi. by the listing of founder shares and the conversion
Hingga 31 Desember 2025, BMHS belum melakukan of bonds. As of December 31, 2025, BMHS has not
penawaran saham maupun menerbitkan efek lainnya. conducted any additional share offerings nor issued
Laporan ini tidak mengungkapkan informasi mengenai any other securities. Accordingly, this report does not
pencatatan efek lainnya. disclose any information regarding the listing of other
securities.
Jenis Pencatatan | Type of Recording Saham | Shares
Saham Perdana @ Rp340 | Initial Shares @ IDR 340 682.000.000
Pencatatan saham pendiri (company listing) I Listing of founder shares (company listing) 7.500.000.000
Konversi obligasi | Bond conversions 421.416.176
Jumlah Saham |Total Shares 8.603.416.176
Kantor Akuntan Publik (KAP)
Public Accounting Firm
BMHS menunjuk Kantor Akuntan Publik (KAP) BMHS appointed Public Accounting Firm Tanubrata
Tanubrata Sutanto Fahmi Bambang & Rekan, member Sutanto Fahmi Bambang & Rekan, a member of BDO
of BDO International Limited untuk melakukan jasa International Limited, to provide independent audit
audit independen terhadap laporan keuangan tahunan services for BMHS’s annual financial statements for the
BMHS tahun buku 2025. Penunjukan ini telah mendapat 2025 financial year. This appointment was approved
persetujuan pemegang saham dalam Rapat Umum by the shareholders at the Annual General Meeting of
Pemegang Saham Tahunan (RUPST) pada 15 Mei 2025. Shareholders (AGMS) held on May 15, 2025.
Nama Kantor Akuntan Publik KAP Tanubrata Sutanto Fahmi Bambang & Rekan
Name of Public Accounting Firm Member of BDO International Limited
Alamat Treasury Tower 11th Floor, Suite H District 8, SCBD Lot 28 Jl. Jenderal Sudirman Kav 52-
Adress 53, Jakarta 12190
Nama Akuntan Publik
Susanto Bong, SE, Ak, CPA, CA
Name of Public Accountant
Jasa Audit Laporan Keuangan dan tidak menyediakan jasa non-audit lainnya.
Service Financial Statement Audit and did not provide other non-audit services.
Periode Penugasan
2025
Assignment Period
Komisi Rp672.000.000 (termasuk pajak)
Commission IDR 672,000,000 (including tax)
Lembaga Profesi Penunjang Pasar Modal
Capital Market Supporting Profesional Institutions
Biro Administrasi Efek Penjamin Pelaksana Konsultan Hukum
Securities Administration Emisi Efek Legal Consultant
Bureau Managing Underwriter
Makes & Partners Law Firm
PT Datindo Entrycom PT Ciptadana Sekuritas
Menara Batavia
Jl. Hayam Wuruk No. 28 Asia Plaza Asia Office
Jl. K.H. Mas Mansyur Kav. 126
Jakarta 10120 Park Unit 2 Jl. Jend.
Jakarta 10220
Sudirman Kav. 59
Jakarta 12190
Page 74
74 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Analisis dan Pembahasan
Manajemen
Management Discussion and
Analysis
Page 75
Laporan Tahunan
Annual Report 75
Memasuki 2025, BMHS melanjutkan pengembangan Entering 2025, BMHS continued its development of
arah usaha yang berfokus pada layanan kesehatan its business direction, focusing on holistic and relevant
keluarga secara holistik dan relevan di berbagai family health services across the different stages of life.
tahap kehidupan. Seiring perkembangan kebutuhan In line with the communities’ evolving needs, BMHS
masyarakat, BMHS menghadirkan akses layanan yang provided services that were increasingly accessible and
semakin dekat dan mudah dijangkau. Kehadiran layanan easy to reach. The availability of health services outside
kesehatan di luar rumah sakit, penguatan layanan hospitals, the strengthening of preventive services, and
preventif, serta integrasi aspek keberlanjutan dalam the integration of sustainability aspects into operations
operasional melengkapi ekosistem layanan kesehatan complemented BMHS’s health service ecosystem.
BMHS.
Tinjauan Perekonomian
Economic Overview
Kondisi makroekonomi Indonesia sepanjang 2025 Indonesia’s macroeconomic conditions throughout
menunjukkan ketahanan di tengah dinamika ekonomi 2025 showed resilience despite the global economic
global. Pertumbuhan ekonomi nasional tetap terjaga, dynamics. National economic growth remained stable,
dengan Produk Domestik Bruto (PDB) tumbuh sebesar with Gross Domestic Product (GDP) growing by 5.11%
5,11% YoY, didukung oleh konsumsi domestik dan (y-on-y), supported by domestic consumption and
kinerja berbagai sektor usaha. Inflasi yang relatif the performance in several business sectors. Inflation
terkendali, tercatat 2,92% YoY, turut menopang was relatively under control, and stood at 2.92%
stabilitas daya beli masyarakat dan aktivitas ekonomi (y-on-y), which helped support the stability of people’s
secara keseluruhan. purchasing power and overall economic activity.
Secara sektoral, kinerja antar lapangan usaha Sectorally, the performance of the business fields
menunjukkan dinamika yang beragam. Sejumlah sektor showed varying dynamics. A number of service
jasa mencatatkan pertumbuhan yang relatif tinggi, sectors recorded relatively high growth, including
termasuk sektor informasi dan komunikasi, sejalan the information and communication sector, in line
dengan peningkatan layanan digital dan aktivitas with the increase in digital services and information
berbasis teknologi informasi. Sementara sektor jasa technology-based activities. While, the health and
kesehatan dan kegiatan sosial tumbuh sebesar 5,59% social services sector grew by 5.59% (y-on-y), reflecting
YoY, mencerminkan karakter sektor kesehatan sebagai the nature of the health sector as an essential sector
sektor esensial dengan permintaan yang relatif stabil with relatively stable and sustainable demand. Stable
dan berkelanjutan. Kondisi makroekonomi yang stabil, macroeconomic conditions, supported by controlled
didukung oleh inflasi yang terkendali dan kebijakan inflation and prudent monetary policy, created a
moneter yang prudent, membentuk lingkungan usaha business environment conducive to the sustainability
yang kondusif bagi keberlanjutan dan pengembangan and development of the health services sector.
sektor layanan kesehatan.
Page 76
76 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Tinjauan Sektor Kesehatan
Health Sector Overview
Industri layanan kesehatan di Indonesia terus The healthcare industry in Indonesia continued to
berkembang seiring meningkatnya kebutuhan grow in line with the increasing demand for quality,
masyarakat terhadap layanan kesehatan yang integrated, and accessible healthcare services.
berkualitas, terintegrasi, dan mudah diakses. The demand for healthcare services was becoming
Permintaan layanan kesehatan semakin beragam, more diverse, influenced by clinical needs, service
dipengaruhi oleh kebutuhan klinis, preferensi preferences, and patient financing schemes. This led to
layanan, serta skema pembiayaan pasien. Hal tersebut a growth in service models, ranging from basic services
mendorong tumbuhnya berbagai model layanan, to specialized and value-added services. As an essential
mulai dari layanan dasar hingga layanan spesialistik sector, the dynamics of service demand was also
dan bernilai tambah. Sebagai sektor esensial, influenced by increasing awareness of preventive and
dinamika permintaan layanan juga dipengaruhi oleh reproductive health, as well as the need for specialized
meningkatnya kesadaran terhadap kesehatan preventif and subspecialized services, thus requiring flexibility in
dan reproduksi, serta kebutuhan layanan spesialistik service models and consistency in clinical quality from
dan subspesialistik, sehingga menuntut fleksibilitas healthcare providers.
model layanan serta konsistensi kualitas klinis dari
penyedia layanan kesehatan.
Dari sisi kebijakan dan pembiayaan, sektor kesehatan In terms of policies and financing, the health sector
tetap menjadi prioritas nasional. Pemerintah remained a national priority. The government allocated
mengalokasikan anggaran kesehatan sebesar Rp218,5 a health budget of IDR 218.5 trillion in the 2025 State
triliun dalam APBN 2025, yang antara lain digunakan Budget, to be used, among other areas, to support the
untuk mendukung keberlangsungan pembiayaan sustainability of health service financing through the
layanan kesehatan melalui program Jaminan Kesehatan National Health Insurance (JKN) program, including
Nasional (JKN), termasuk pembayaran iuran bagi premium payments for Premium Assistance Recipients
peserta Penerima Bantuan Iuran (PBI). Mekanisme ini (PBI). This mechanism was one of the main ways of
menjadi salah satu jalur utama penyaluran pembiayaan channeling public financing into the health service
publik ke dalam sistem layanan kesehatan, sekaligus system, while also providing real financial support for
memberikan dukungan pembiayaan yang nyata bagi health care facilities in serving patients with varied
fasilitas pelayanan kesehatan dalam melayani pasien financial backgrounds.
dengan berbagai latar belakang pembiayaan.
Layanan kesehatan ibu dan anak menunjukkan Women and children health services showed
perbaikan dari sisi akses. Profil Statistik Kesehatan improvement in terms of access. The 2025 Health
2025 mencatat 93,95% persalinan dilakukan di Statistics Profile noted that 93.95% of deliveries were
fasilitas kesehatan, 97,35% persalinan ditolong oleh carried out in health facilities, 97.35% of which were
tenaga kesehatan, serta cakupan jaminan kesehatan assisted by health workers, and health insurance
balita yang telah melampaui 80%. Meski demikian, coverage for toddlers exceeded 80%. However, health
indikator hasil kesehatan masih memerlukan perhatian outcome indicators still required ongoing attention,
berkelanjutan, antara lain prevalensi bayi dengan berat including the prevalence of low birth weight babies
badan lahir rendah sebesar 13,95%, kondisi kesehatan at 13.95%, the health status of women aged 15–49
perempuan usia 15–49 tahun, serta angka kematian ibu years, and the estimated maternal mortality rate, which
yang diperkirakan masih berada di kisaran 170–180 per remained in the range of 170–180 per 100,000 live
100.000 kelahiran hidup dan angka kematian neonatal births, and the neonatal mortality rate of around 9 per
sekitar 9 per 1.000 kelahiran hidup. Kondisi tersebut 1,000 live births. These conditions underscored the
menegaskan pentingnya penguatan layanan maternal importance of strengthening quality and integrated
dan neonatal yang berkualitas dan terintegrasi. maternal and neonatal services.
Page 77
Laporan Tahunan
Annual Report 77
Keseluruhan dinamika tersebut menuntut penyedia These dynamics required healthcare providers manage
layanan kesehatan mampu mengelola keberagaman the diversity of patient needs, the complexity of clinical
kebutuhan pasien, kompleksitas layanan klinis, services, and the variety of financing schemes in a
serta variasi skema pembiayaan secara seimbang. balanced manner. Integrated, quality-oriented, and
Pengelolaan layanan kesehatan yang terintegrasi, adaptive healthcare service management became
berorientasi pada kualitas, dan adaptif terhadap an important factor in maintaining operational
perubahan kebutuhan pasar, menjadi faktor penting sustainability.
dalam menjaga keberlanjutan operasional.
Dalam menjawab dinamika kebutuhan layanan In response to the dynamics of healthcare needs, BMHS
kesehatan, BMHS mengembangkan portofolio layanan developed a service portfolio that covered healthcare
yang mencakup perawatan kesehatan dan peningkatan and quality of life improvement at different stages
kualitas hidup di berbagai tahap kehidupan. Dengan of life. Supported by professional medical personnel
didukung oleh tenaga medis profesional serta and the use of healthcare technology, BMHS provided
pemanfaatan teknologi kesehatan, BMHS menyediakan holistic family care, which addressed women and
holistic family care, yang menangani kesehatan ibu children health, fertility, and healthcare services for
dan anak, fertilitas, serta layanan kesehatan untuk adults and the elderly.
kelompok usia dewasa dan lanjut usia.
Sebagai bagian dari pengembangan layanan, BMHS As part of its service development, BMHS continued
terus memperkuat layanan kesehatan ibu dan anak to strengthen its women and children health services,
yang menjadi salah satu fokus pengembangan pusat which are the focuses of its center of excellence
keunggulan. BMHS juga melengkapi layanan klinis development. BMHS also complemented its clinical
dengan dukungan akses layanan kesehatan berbasis services with the support of digital-based healthcare
digital, termasuk telemedis, telekonsultasi, dan sistem services, including telemedicine, teleconsultation, and
penjadwalan melalui platform OneBunda. Selain itu, scheduling systems through the OneBunda platform.
kemitraan dengan Klinik Pintar dan Klinik Fertilitas In addition, partnerships with Klinik Pintar and Klinik
Indonesia turut mendukung perluasan akses layanan Fertilitas Indonesia also supported the expansion of
kesehatan digital bagi masyarakat. digital healthcare services for the community.
Pada 2025, BMHS mengembangkan Bunda Homecare. In 2025, BMHS developed Bunda Homecare as a direct
Layanan ini dihadirkan sebagai layanan kunjungan medical visit service to the patient’s location, which
medis langsung ke tempat pasien, yang menyediakan provided vaccinations and health checks, while still
vaksinasi dan pemeriksaan kesehatan, dengan tetap prioritizing medical standards and patient safety. Also,
mengedepankan standar medis dan keselamatan through Bunda Clinic MRT Dukuh Atas, a healthcare
pasien. Selain itu, melalui Bunda Clinic MRT Dukuh Atas, facility located near community transportation hubs,
fasilitas layanan kesehatan yang berlokasi dekat dengan BMHS developed more accessible basic and preventive
pusat mobilitas masyarakat, BMHS mengembangkan healthcare services, integrated with referral services to
layanan kesehatan dasar dan preventif yang lebih hospitals within BMHS’s network.
mudah dijangkau, serta terintegrasi dengan layanan
rujukan ke rumah sakit dalam jaringan BMHS.
Untuk meningkatkan layanan yang komprehensif, To improve its comprehensive services, BMHS has
BMHS telah menjadi pelopor dalam perawatan become a pioneer in neonatal care with 31 NICU beds
neonatal dengan memiliki 31 tempat tidur NICU as a continuing and sustainable care unit for high-risk
sebagai unit perawatan lanjutan dan berkelanjutan newborns. BMHS also has a Family Integrated Care
bagi bayi baru lahir yang berisiko tinggi. BMHS juga (FICARE) program to support parental involvement
memiliki program Family Integrated Care (FICARE) in the care of premature babies, and to increase
yang diterapkan untuk mendukung keterlibatan orang breastfeeding success.
tua dalam perawatan bayi prematur dan meningkatkan
keberhasilan menyusui.
Page 78
78 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Berbagai inovasi tanpa henti terus memperkuat Innovations continued to strengthen BMHS’s position
posisi BMHS sebagai pemimpin industri kesehatan as a leader in the Indonesian healthcare industry while
di Indonesia sekaligus menegaskan komitmen BMHS reaffirming BMHS’s commitment to patient-centered
terhadap inovasi yang berpusat pada pasien dan innovation and long-term quality of life improvement.
peningkatan kualitas hidup jangka panjang. Sebagai As a pioneer in robotic surgery since 2012, BMHS
pionir dalam bedah robotik sejak 2012, BMHS successfully performed the first robotic skin sparing
berhasil melakukan robotic skin sparing mastectomy mastectomy in Southeast Asia. BMHS also successfully
pertama di Asia Tenggara. Selain itu, BMHS juga sukses performed six kidney transplant procedures with a
melaksanakan enam prosedur transplantasi ginjal 100% success rate. The development of these services
dengan tingkat keberhasilan 100%. Pengembangan reflects BMHS’s service model adjustment to the need
berbagai layanan ini mencerminkan penyesuaian model for holistic and sustainable health access.
layanan BMHS terhadap kebutuhan akses kesehatan
yang holistik dan berkelanjutan.
Tinjauan Operasi Per Segmen Usaha
Operational Review by Business Segment
BMHS menjalankan kegiatan usaha melalui portofolio BMHS conducts its business activities through an
layanan kesehatan yang terintegrasi, mencakup layanan integrated healthcare service portfolio, covering
preventif, kuratif, dan rehabilitatif, melalui layanan preventive, curative, and rehabilitative services,
klinis inti, layanan spesialistik, serta layanan penunjang through core clinical services, specialist services,
kesehatan. Segmentasi usaha ini mencerminkan struktur and supporting healthcare services. This business
operasional BMHS dalam menjawab kebutuhan layanan segmentation reflects BMHS’s operational structure
kesehatan yang beragam di berbagai tahap kehidupan. in responding to diverse healthcare needs at different
stages of life.
Sepanjang 2025, pengelolaan operasional BMHS In 2025, BMHS’s operational management was directed
diarahkan pada penguatan layanan inti, peningkatan at strengthening its core services, enhancing centers
pusat keunggulan, serta optimalisasi kinerja unit usaha of excellence, and optimizing the performance of
dalam ekosistem BMHS. Investasi dan perluasan usaha business units within BMHS’s ecosystem. Investments
dilakukan secara selektif dengan tetap memperhatikan and business expansion were carried out selectively
prinsip kehati-hatian, guna menjaga keberlanjutan while maintaining the prudential principle so as to
usaha dan pertumbuhan jangka panjang. BMHS maintain business sustainability and long-term growth.
mengoptimalkan pemanfaatan aset yang dimiliki BMHS optimized the use of its assets by increasing the
melalui peningkatan kapasitas dan kualitas layanan capacity and quality of hospital services, as well as by
rumah sakit, serta memanfaatkan kemitraan strategis using strategic partnerships as one of the approaches
sebagai salah satu pendekatan untuk memperluas to expanding services without significantly increasing
layanan tanpa meningkatkan eksposur risiko investasi investment risk exposure.
secara signifikan.
Page 79
Laporan Tahunan
Annual Report 79
Fokus dan Inisiatif Strategis Operasional Strategic Focus and Operational Initiatives
BMHS menempatkan penciptaan nilai jangka panjang BMHS views long-term value creation as the main
sebagai landasan utama dalam penetapan arah foundation in determining its strategic direction.
strategis. BMHS membangun kerangka pengembangan BMHS has built a business development framework
usaha melalui penguatan sinergi ekosistem layanan by strengthening the synergy of its healthcare
kesehatan, peningkatan fondasi organisasi, serta ecosystem, improving the organizational foundation,
penguatan kepercayaan pasien sebagai pengguna and strengthening patient trust as service users.
layanan. Pengembangan difokuskan pada penguatan Development is focused on strengthening women
layanan kesehatan ibu dan anak sebagai kompetensi and children health services as the core competency,
inti, peningkatan layanan spesialistik berbasis Center improving Center of Excellence-based specialist
of Excellence, serta optimalisasi pemanfaatan aset services, and optimizing the use of existing assets and
dan kapasitas layanan yang telah dimiliki. Kerangka service capacity. This business development framework
pengembangan usaha tersebut menjadi dasar dalam forms the basis for assessing investment opportunities,
menilai peluang investasi, pengembangan layanan, dan service development, and sustainable management of
pengelolaan operasional BMHS secara berkelanjutan. BMHS’s operations.
Sejalan dengan arah tersebut, BMHS menetapkan In line with this direction, BMHS established key
key priority initiatives yang menjadi fokus pengelolaan priority initiatives as the focus for business
usaha sepanjang 2025, meliputi penguatan layanan management throughout 2025, which included
Center of Excellence; peningkatan layanan spesialis strengthening Center of Excellence services; improving
dan subspesialis kesehatan ibu dan anak; penerapan specialist and subspecialist women and children health
shared services; penyempurnaan sistem manajemen services; implementing shared services; improving the
dokter; standarisasi patient journey; penguatan dan doctor management system; standardizing the patient
pengoptimalan rumah sakit salah satunya melalui journey; strengthening and optimizing hospitals, which
konsolidasi RSIA Pusura Tegalsari, sehingga terdapat included the consolidation of Pusura Tegalsari Women
penambahan kapasitas tempat tidur yang dimiliki and Children Hospital, thereby increasing BMHS’s
BMHS; serta konsolidasi unit usaha berskala kecil bed capacity; and consolidating small-scale business
agar lebih terstruktur dan efisien. Inisiatif-inisiatif units to make them more structured and efficient.
ini menjadi landasan operasional dalam mendukung These initiatives formed the operational foundation
konsistensi kualitas layanan, efisiensi operasional, dan for supporting BMHS’s consistency of service quality,
tata kelola usaha BMHS. operational efficiency, and corporate governance.
1 2 3
2025
Key Priority Focus on
Improving Doctor
One Menteng Strengthening
Initiatives Women & Children
Management
4 5 6 7
Enhancing Hospital Asset Cost
Customer Journey Expansion Utilization Optimization
Page 80
80 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Analisis Operasional per Segmen Usaha Operational Analysis by Business Segment
BMHS mengelola kegiatan operasional melalui delapan BMHS manages its operations via eight main service
titik akses layanan utama, yang mencerminkan jalur access points that reflect the patient entry points into
masuk pasien ke dalam ekosistem layanan kesehatan BMHS’s healthcare ecosystem. These access points
BMHS. Titik akses ini mencakup layanan kesehatan ibu include women and children health services, emergency
dan anak, layanan gawat darurat, rawat jalan, rawat services, outpatient care, inpatient care, Center of
inap, layanan Center of Excellence, layanan teknologi Excellence services, assisted reproductive technology
reproduksi berbantu, layanan laboratorium klinik, serta services, clinical laboratory services, and referral
layanan rujukan. services.
1. Layanan Ibu dan Anak 1. Women and children Services
Menjadi fondasi operasional dan kontributor utama As the operational foundation and a major
terhadap kinerja keuangan BMHS, mencakup contributor to BMHS’s financial performance,
layanan obstetri dan ginekologi (OBGYN), termasuk these services include obstetrics and gynecology
layanan fetomaternal, klinik fertilitas, ginekologi (OBGYN), including fetomaternal services, fertility
onkologi dan uroginekologi, serta layanan kesehatan clinics, gynecological oncology and urogynecology,
anak (pediatri). as well as pediatric services.
2. Layanan Gawat Darurat 2. Emergency Services
Berperan sebagai titik akses utama bagi pasien Serves as the main point of access for patients
dengan kondisi klinis akut yang membutuhkan with acute clinical conditions requiring immediate
tindakan medis segera. Fasilitas ini dilengkapi medical attention. This facility is equipped with
dengan peralatan medis untuk penanganan medical equipment for emergency treatment and
kegawatdaruratan dan pemantauan kondisi pasien, patient monitoring, and is supported by ambulance
serta didukung oleh layanan ambulans guna services to assist in patient stabilization and referral.
mendukung proses stabilisasi dan rujukan pasien.
3. Layanan Rawat Jalan 3. Outpatient Services
Mencakup konsultasi medis, asuhan keperawatan, Includes medical consultations, nursing care, and
serta berbagai tindakan medis nonrawat inap yang non-inpatient medical procedures provided by
diberikan oleh dokter umum, dokter spesialis, general practitioners, specialists, nurses, and other
perawat, dan tenaga medis profesional lainnya. medical professionals. Through these services,
Melalui layanan ini, pasien juga dapat mengakses patients gain access to supporting services such as
layanan penunjang seperti laboratorium, radiologi, laboratories, radiology, physiotherapy, and other
fisioterapi, dan layanan diagnostik lainnya guna diagnostic services to support the examination,
mendukung proses pemeriksaan, pengobatan, dan treatment, and monitoring of their health conditions.
pemantauan kondisi kesehatan.
4. Layanan Rawat Inap 4. Inpatient Services
Disediakan bagi pasien yang memerlukan perawatan . Provided for patients requiring further treatment,
lanjutan, baik sebagai tindak lanjut dari layanan either as a follow-up to outpatient services or due
rawat jalan maupun akibat kondisi kegawat to emergencies and accidents. Service performance
daruratan dan kecelakaan. Kinerja layanan is influenced by several factors, including length
dipengaruhi oleh beberapa faktor, antara lain of stay, type of room used, complexity of medical
lama perawatan, jenis kamar yang digunakan, procedures, and patient financing group.
kompleksitas tindakan medis, serta kelompok
pembiayaan pasien.
5. Layanan Center of Excellence (CoE) 5. Center of Excellence Services (CoE)
Layanan spesialistik dan subspesialistik yang Specialist and subspecialist services that focus on
berfokus pada bidang medis tertentu, mencakup specific medical fields, including the Women’s Health
Women’s Health Center, Pediatric Center, Robotic Center, Pediatric Center, Robotic Minimally Invasive
Minimally Invasive Surgery (ARMIS), Oncology Center, Surgery (ARMIS), Oncology Center, Digestive
Digestive Center, Cardiovascular Center, Brain & Spine Center, Cardiovascular Center, Brain & Spine Center,
Center, Urology Center, Bunda Orthopedic Nurturing Urology Center, Bunda Orthopedic Nurturing
Experience (BONE), serta layanan Gastro-Hepato Experience (BONE), and Gastro-Hepato Endoscopy
Page 81
Laporan Tahunan
Annual Report 81
Endoscopy. Layanan CoE didukung oleh tim medis services. CoE services are supported by a team of
yang kompeten dan tersertifikasi, serta fasilitas dan competent and certified medical professionals, as
teknologi medis yang disesuaikan dengan kebutuhan well as medical facilities and technology tailored to
layanan spesialistik. the requirements for specialized services.
6. Layanan Teknologi Reproduksi Berbantu 6. Assisted Reproductive Technology Services
Melalui Morula IVF Indonesia (MI), BMHS Through Morula Indonesia (MI), BMHS provides
menyediakan layanan teknologi reproduksi berbantu assisted reproductive technology services as
sebagai bagian dari layanan kesehatan ibu. Layanan part of its maternal health services. Available
yang tersedia mencakup in-vitro fertilization, egg services include in-vitro fertilization, egg banking,
banking, inseminasi, preimplantation genetic testing insemination, preimplantation genetic testing
(PGT-A), serta prosedur pendukung lainnya. Layanan (PGT-A), and other supporting procedures. These
ini ditujukan bagi pasien dengan kebutuhan fertilitas services are intended for patients with specific
tertentu dan dikelola secara terintegrasi dengan fertility needs and are managed in an integrated
layanan kesehatan ibu dan anak dalam ekosistem manner with women and children health services
BMHS. within BMHS’s ecosystem.
7. Layanan Laboratorium Klinik 7. Clinical Laboratory Services
Melalui PT Diagnos Laboratorium Utama Tbk Through PT Diagnos Laboratorium Utama Tbk
(DGNS), BMHS menyediakan layanan laboratorium (DGNS), BMHS provides clinical laboratory services
klinik sebagai layanan penunjang medis. Layanan as part of its medical support services. These services
ini mencakup pemeriksaan laboratorium klinik dan include clinical and genomic laboratory testing,
genomik, layanan pemeriksaan di rumah (homecare), home care services, and diagnostic testing panels.
serta berbagai panel pemeriksaan diagnostik. Laboratory services are supported by automated
Layanan laboratorium didukung oleh sistem analysis systems and technologies designed to
analisis otomatis dan teknologi yang dirancang support the accuracy and reliability of the test
untuk mendukung akurasi dan keandalan hasil results.
pemeriksaan.
8. Layanan Rujukan 8. Referral Services
BMHS menyediakan layanan rujukan bagi pasien BMHS provides referral services for patients
yang memerlukan penanganan medis lanjutan atau requiring further medical treatment or care with a
perawatan dengan tingkat kompleksitas yang lebih higher level of complexity. Referral patients come
tinggi. Pasien rujukan berasal dari rumah sakit from other hospitals, doctors, and other health care
lain, dokter, maupun fasilitas pelayanan kesehatan facilities.
lainnya.
Kinerja Operasional per Segmen Usaha Operational Performance by Business Segment
Secara operasional, BMHS mencatat pertumbuhan Operationally, BMHS recorded a growth in a number
pada sejumlah indikator utama. Jumlah rawat inap of key indicators. The number of inpatient admissions
menunjukkan peningkatan dibandingkan tahun increased compared to the previous year, reaching
sebelumnya, yakni 47.778, dibandingkan 2024 yaitu 47,778, up from 47,011 in 2024. Meanwhile, the
47.011, Adapun jumlah kunjungan pasien rawat number of outpatient visits in 2025 totaled 606,814,
jalan sepanjang 2025 mencapai 606.814, menurun a decrease from 2024. In line with the growth in the
dibandingkan 2024. Sejalan dengan pertumbuhan number of patients, the number of inpatient days also
jumlah pasien, jumlah hari rawat inap juga meningkat increased by 2%, from 123,534 days to 125,981 days.
sebesar 2%, dari 123.534 hari menjadi 125.981 hari. The number of surgical procedures performed grew by
Jumlah tindakan bedah yang dilakukan bertumbuh 10% 10% to 16,381 procedures.
menjadi 16.381 tindakan.
Kapasitas tempat tidur dikelola secara optimal dengan Bed capacity was managed optimally with a focus
fokus pada tingkat hunian dan kualitas layanan. Pada on occupancy rates and service quality. For assisted
layanan teknologi reproduksi berbantu dan layanan reproductive technology and laboratory services,
Page 82
82 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
laboratorium, kinerja operasional mencerminkan operational performance reflects the selective and
karakter masing-masing layanan, baik yang bersifat volume-based characteristics of each service. IVF
selektif maupun yang berbasis volume pemeriksaan. Cycles (Morula IVF) services dencreased by 1% with
Layanan bayi tabung IVF Cycles (Morula IVF) a total of 4,878 cycles. Diagnos showed significant
mengalami penurunan sebesar 1% dengan jumlah tes growth of 11%.
sebanyak 4.878 cycles. Diagnos sendiri menunjukkan
pertumbuhan signifikan sebesar 11%.
Kinerja Operasional per Segmen Usaha
Operational Performance per Business Segment
Peningkatan
Tahun
Segmen Usaha Satuan (Penurunan)
Year
Business Segment Unit Increase (Decrease)
2025 2024 Nilai | Value %
Rawat Jalan | Outpatients Pasien 606.814 619.010 (12.196) (2)
Rawat Inap | Inpatients Patients 47.778 47.011 767 2
Hari
Jumlah Hari Rawat Inap | Number of Hospitalization Days 125.981 123.534 2.447 2
Days
Tindakan
Tindakan Bedah | Surgery Medical 16.381 14.949 1.432 10
procedure
Kapasitas Tempat Tidur | Bed Capacity Unit 601 576* 25 4
Bayi Tabung | IVF Siklus | Cycles 4.878 4.942 (64) (1)
Tes Laboratorium | Laboratory Tests Tes | Test 957.447 865.650* 91.797 11
Keterangan I Notes:
*) Perubahan cakupan perhitungan
*)Changes in the scope of the calculation
Profitabilitas per Segmen Usaha Profitability by Business Segment
BMHS menyusun kinerja per segmen usaha BMHS’s business segment performance is based on
berdasarkan standar akuntansi yang berlaku, yaitu applicable accounting standards, namely PSAK 5
PSAK 5 tentang Segmen Operasi. Pengelompokan for Operating Segments. The business activities are
aktivitas usaha dalam segmen pelayanan kesehatan grouped into the healthcare segment as the main
sebagai segmen utama serta segmen pendukung segment and other segments as supporting segments,
sebagai lainnya, dengan eliminasi mencerminkan with eliminations reflecting adjustments to inter-entity
penyesuaian atas transaksi antar entitas dalam grup. transactions within the group.
Profitabilitas per Segmen Usaha
Profitability per Business Segment
Peningkatan Laba Tahun Berjalan Peningkatan
Pendapatan (Rp miliar) (Penurunan) (Rp miliar) (Penurunan)
Segmen Usaha Revenue (IDR billion) Increase Profit for the Year Increase
Business Segment (Decrease) (IDR billion) (Decrease)
2025 2024 % 2025 2024 %
Pelayanan Kesehatan | Health Services 1.662,42 1.645,71 1,02 18,19 25,60 28,95
Lainnya | Others 211,18 175,35 20,43 (4,80) (8,93) 4,80
Eliminasi | Elimination (259,26) (266,37) (2,74) 16,28 2,22 633,33
Jumlah | Total 1.614,34 1.554,69 3,84 29,67 18,90 56,98
Page 83
Laporan Tahunan
Annual Report 83
Pada 2025, segmen pelayanan kesehatan mencatatkan In 2025, the healthcare segment recorded revenue
pendapatan sebesar Rp1.662,42 miliar, mengalami of IDR 1,662.42 billion, an increase compared to
peningkatan apabila dibandingkan dengan 2024 IDR 1,645.71 billion in 2024. While, total profit for the
sebesar Rp1.645,71 miliar. Sementara total laba current year amounted to IDR 29.67 billion, an increase
tahun berjalan sebesar Rp29,67 miliar, mengalami compared to IDR 18.90 billion in 2024.
peningkatan dibandingkan dengan 2024 sebesar
Rp18,90 miliar.
Kinerja Keuangan
Financial Performance
Sepanjang 2025, BMHS memprioritaskan During 2025, BMHS prioritized prudent
pengelolaan keuangan secara prudent guna financial management to support smooth operations,
mendukung kelancaran operasional, fleksibilitas financial flexibility, and long-term business
keuangan, serta keberlanjutan usaha dalam sustainability. EBITDA reached IDR 242 billion, a
jangka panjang. EBITDA tercatat sebesar Rp242 increased of 9% compared to the previous year’s
miliar, meningkat 9% apabila dibandingkan IDR 222 billion. The increase in the scale of operational
tahun sebelumnya yang sebesar Rp222 miliar. activities was reflected in the strengthening of the
Peningkatan skala aktivitas operasional overall financial position, which was managed while
tercermin pada penguatan posisi keuangan secara maintaining a balance between funding requirements
keseluruhan, yang dikelola dengan tetap menjaga and capital structure.
keseimbangan antara kebutuhan pendanaan dan
struktur permodalan.
Aset Assets
Pada 2025, BMHS mencatat peningkatan jumlah aset In 2025, BMHS recorded a 16.54% increase in assets
sebesar 16,54% menjadi Rp4.016,43 miliar apabila that reached IDR 4.016.43 billion compared to the
dibandingkan dengan periode sebelumnya yang previous period of IDR 3,446.36 billion. This asset
sebesar Rp3.446,36 miliar. Pertumbuhan aset tersebut increase was due to an increase in current assets of
didukung oleh peningkatan aset lancar, yang tercatat IDR 1,210.24 billion, up 11.15% compared to 2024’s
sebesar Rp1.210,24 miliar, naik 11,15% dari 2024 IDR 1,088.88 billion. The increase in current assets was
yang sebesar Rp1.088,88 miliar. Kenaikan aset lancar mainly due to an increase in cash and cash equivalents,
terutama berasal dari peningkatan kas dan setara kas, accounts receivable, and inventories related to
piutang usaha, serta persediaan yang terkait dengan BMHS’s health service operations. Non-current assets
operasional layanan kesehatan BMHS. Aset tidak lancar reached IDR 2,806.19 billion, an increase of 19.03%
tercatat sebesar Rp2.806,19 miliar, naik 19,03% dari compared to IDR 2,357.48 billion in 2024. The non-
2024 yang tercatat sebesar Rp2.357,48 miliar. Struktur current assets were dominated by fixed assets and
aset tidak lancar didominasi oleh aset tetap dan aset right-of-use assets that supported BMHS’s operational
hak-guna yang mendukung kegiatan operasional BMHS. activities. Overall, BMHS’s asset structure showed a
Secara keseluruhan, struktur aset BMHS menunjukkan healthy condition, with a composition that supported
kondisi yang sehat, dengan komposisi yang mendukung operational continuity, financial flexibility, and business
kelangsungan operasional, fleksibilitas keuangan, dan development.
pengembangan usaha.
Page 84
84 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Jumlah Aset dalam Rupiah penuh, kecuali dinyatakan lain
Total Assets in full Rupiah, unless otherwise stated
Tahun Peningkatan (Penurunan)
Keterangan Year Increase (Decrease)
Description
2025 2024 Nilai | Value %
Aset Lancar | Current Assets 1.210.239.116.384 1.088.880.785.952 121.358.330.432 11,15
Aset Tidak Lancar | Non-Current Assets 2.806.190.318.759 2.357.480.117.796 448.710.200.963 19,03
Jumlah Aset | Total Assets 4.016.429.435.143 3.446.360.903.748 570.068.531.395 16,54
Sementara liabilitas jangka panjang tercatat naik While, long-term liabilities increased by 19.94% to
sebesar 19,94% menjadi Rp875,84 miliar, apabila IDR 875.84 billion, compared to IDR 730.21 billion
dibandingkan dengan periode sebelumnya yang the previous period. This was mainly due to BMHS has
sebesar Rp730,21 miliar. Hal ini terutama disebabkan drawn down a loan facility from Bank Mandiri, which is
oleh BMHS melakukan pencairan fasilitas pinjaman allocated to finance capital expenditures (CAPEX) and
dari Bank Mandiri yang dialokasikan untuk pembiayaan to meet long-term lease commitments (exceeding one
investasi barang modal (Capital Expenditure/CAPEX), year) for medical equipment and land/buildings. This
serta memenuhi komitmen sewa jangka panjang strategic move was taken to strengthen the healthcare
(lebih dari satu tahun) atas peralatan medis dan ecosystem more comprehensively, which is expected
lahan/bangunan. Langkah strategis ini diambil untuk to have a positive impact on financial performance and
memperkuat ekosistem layanan kesehatan secara lebih reinforce BMHS’s business sustainability in the future.
komprehensif, yang diharapkan memberikan dampak
positif terhadap kinerja keuangan serta memperkuat
keberlangsungan usaha BMHS di masa mendatang.
Jumlah Liabilitas dalam Rupiah penuh, kecuali dinyatakan lain
Total Liabilities in full Rupiah, unless otherwise stated
Tahun Peningkatan (Penurunan)
Keterangan Year Increase (Decrease)
Description
2025 2024 Nilai | Value %
Liabilitas Jangka Pendek | Current Liabilities 746.084.870.999 568.415.968.476 177.668.902.523 31,26
Liabilitas Jangka Panjang | Long-Term Liabilities 875.837.547.633 730.209.250.551 145.628.297.082 19,94
Jumlah Liabilitas | Total Liabilities 1.621.922.418.632 1.298.625.219.027 323.297.199.605 24,90
Ekuitas Equity
Sejalan dengan posisi aset dan likuiditas, posisi ekuitas In line with the position in the assets and liquidity, equity
juga mengalami perubahan, yang mencerminkan also changed, reflecting the business performance
akumulasi kinerja usaha serta pengelolaan struktur and capital structure management. In 2025, BMHS
permodalan. Pada 2025, BMHS mencatatkan recorded an increase in equity of IDR 246.77 million,
peningkatan jumlah ekuitas sebesar Rp246,77 juta atau or 11.49% to IDR 2,394.51 billion, compared to
setara dengan 11,49% menjadi Rp2.394,51 miliar, jika IDR 2,147.74 billion in 2024. The was mainly due to
dibandingkan periode 2024 yang sebesar Rp2.147,74 driven by solid net profit growth, which directly
miliar. Perubahan jumlah ekuitas terutama disebabkan strengthens the capital structure to support sustained
oleh pertumbuhan laba bersih yang solid, yang secara expansion. The increasingly robust equity structure by
langsung memperkuat struktur permodalan untuk 2025 is the result of synergies between cost efficiency
mendukung ekspansi berkelanjutan. Struktur ekuitas and revenue growth across all BMHS business units.
yang semakin kuat pada 2025 merupakan hasil
dari sinergi antara efisiensi biaya dan pertumbuhan
pendapatan di seluruh unit bisnis BMHS.
Page 85
Laporan Tahunan
Annual Report 85
Jumlah Ekuitas dalam Rupiah penuh, kecuali dinyatakan lain
Total Equity in full Rupiah, unless otherwise stated
Tahun Peningkatan (Penurunan)
Keterangan Year Increase (Decrease)
Description
2025 2024 Nilai | Value %
Jumlah ekuitas yang dapat diatribusikan kepada | Total equity attributable to
Pemilik entitas induk
1.949.914.193.558 1.713.479.286.013 236.434.907.545 13,80
Owner of the parent entity
Kepentingan non pengendali
444.592.822.953 434.256.398.708 10.336.424.245 2,38
Non-controlling interests
Jumlah Ekuitas | Total Equity 2.394.507.016.511 2.147.735.684.721 246.771.331.790 11,49
Laporan Laba Rugi dan Penghasilan Komprehensif Lain
Statement of Profit and Loss and Other Comprehensive Income
Pada sisi kinerja laba rugi, BMHS mencatatkan In terms of profit and loss performance, BMHS recorded
pendapatan sebesar Rp1.614,34 miliar, naik 3,84%, revenue of IDR 1,614.34 billion, an increase of 3.84%,
apabila dibandingkan dengan periode 2024 yang compared to IDR 1,554.69 billion in 2024 . This increase
sebesar Rp1.554,69 miliar. Peningkatan pendapatan in revenue was due to the improvement in BMHS’s
sejalan dengan peningkatan kinerja operasional BMHS. operational performance.
Sejalan dengan tingkat aktivitas operasional, beban In line with its operational activities, cost of revenue
pokok pendapatan naik 2,63% dari tahun 2024, increased 2.63% from 2024, thereby impacting profit
sehingga berdampak pada laba periode berjalan. for the current period.
Laba tahun berjalan tercatat sebesar Rp29,67 miliar, Profit for the current year was 29.67 billion, an increase
naik 57,04% dari 2024 yang sebesar Rp18,90 miliar. of 57.04% compared to IDR 18.90 billion in 2024. While,
Sementara laba/rugi komprehensif lain tercatat sebesar other comprehensive income/loss was IDR 233.14
Rp233,14 miliar pada periode pelaporan, mengalami billion in the reporting period due to fluctuations
fluktuasi yang terutama berasal dari penyesuaian pos mainly from adjustments to non-operating items,
non-operasional, yang pada akhirnya memengaruhi which ultimately affected BMHS’s total comprehensive
total laba (rugi) komprehensif BMHS dibandingkan income (loss) compared to the previous period. Overall,
periode sebelumnya. Secara keseluruhan, BMHS BMHS recorded an increase in comprehensive income
mencatatkan kenaikan laba komprehensif tahun for the current year of IDR 262.81 billion in 2025.
berjalan menjadi Rp262,81 miliar pada 2025.
Laba Rugi dan Penghasilan Komprehensif Lain dalam Rupiah penuh, kecuali dinyatakan lain
Profit or Loss and Other Comprehensive Income in full Rupiah, unless otherwise stated
Tahun Peningkatan (Penurunan)
Keterangan Year Increase (Decrease)
Description
2025 2024 Nilai | Value %
Pendapatan Usaha
1.614.340.771.512 1.554.685.010.336 59.655.761.176 3,84
Operating Revenue
Beban Pokok Pendapatan
(869.848.305.402) (847.547.994.844) 22.300.310.558 2,63
Cost of Revenue
Page 86
86 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Tahun Peningkatan (Penurunan)
Keterangan Year Increase (Decrease)
Description
2025 2024 Nilai | Value %
Laba Tahun Berjalan
29.673.142.533 18.895.784.267 10.777.358.266 57,04
Profit for the Year
Penghasilan/(Rugi) Komprehensif Lain
233.138.577.908 (4.032.005.043) 237.170.582.951 5.882
Other Comprehensive Income/(Loss)
Laba Komprehensif Tahun Berjalan
262.811.720.441 14.863.779.224 247.947.941.217 1.668
Comprehensive Profit for the Year
Laporan Arus Kas Statement of Cash Flow
Sepanjang 2025, BMHS mengelola arus kas secara In 2025, BMHS managed its cash flow in a disciplined
disiplin untuk mendukung keberlangsungan manner to support its operational continuity and
operasional dan kebutuhan pengembangan usaha. Arus business development needs. Cash flow from operating
kas dari aktivitas operasional menjadi sumber utama activities became the main source of funding, while
pendanaan, sementara pengeluaran investasi dilakukan investment expenditures were carried out selectively
secara selektif dan pendanaan dikelola secara terukur and funding was managed in a measured manner to
guna menjaga kecukupan likuiditas. Pendekatan ini maintain sufficient liquidity. This approach enabled
memungkinkan BMHS menjaga keseimbangan antara BMHS to maintain a balance between operational
kebutuhan operasional, investasi, dan stabilitas posisi needs, investment, and cash position stability until the
kas hingga akhir periode pelaporan. end of the reporting period.
Pada akhir periode pelaporan, BMHS mencatat By the end of the reporting period, BMHS recorded net
kas bersih yang diperoleh dari aktivitas operasi cash flow from operating activities of IDR 250.62 billion
sebesar Rp250,62 miliar, yang utamanya berasal mainly from customer payments of IDR 1,611.13 billion.
dari penerimaan pembayaran pelanggan sebesar While, cash used for operating activities amounting to
Rp1.611,13 miliar. Sementara kas yang digunakan IDR 860.62 billion, and was mainly used for payments
untuk aktivitas operasi terutama digunakan untuk to suppliers and operating expenses. The total net
pembayaran kepada pemasok dan beban usaha, cash used for investing activities of IDR 217.41 billion
yakni sebesar Rp860,62 miliar. Jumlah kas bersih was mainly used for the acquisition of fixed assets
yang digunakan aktivitas investasi sebesar Rp217,41 amounting to IDR 218.91 billion. The net cash from
miliar, terutama digunakan untuk perolehan aset financing activities amounted to IDR 10.04 billion and
tetap sebesar Rp218,91 miliar. Adapun jumlah kas mainly came from drawdown of bank loans.
bersih yang diperoleh dari aktivitas pendanaan adalah
Rp10,04 miliar, terutama berasal dari penerimaan
pinjaman bank.
Arus Kas dalam Rupiah penuh, kecuali dinyatakan lain
Cash Flow in full Rupiah, unless otherwise stated
Tahun Peningkatan (Penurunan)
Keterangan Year Increase (Decrease)
Description
2025 2024 Nilai | Value %
Arus Kas Bersih dari Aktivitas Operasi
250.621.859.694 33.979.487.371 216.642.372.323 637,57
Net Cash Flow from Operating Activities
Arus Kas Bersih dari Aktivitas Investasi
(217.412.095.335) (245.291.393.404) (27.879.298.069) (11,37)
Net Cash Flow from Investing Activities
Page 87
Laporan Tahunan
Annual Report 87
Tahun Peningkatan (Penurunan)
Keterangan Year Increase (Decrease)
Description
2025 2024 Nilai | Value %
Arus Kas Bersih dari Aktivitas Pendanaan
10.042.921.475 372.585.952.682 (362.543.031.207) (97,30)
Net Cash Flow from Financing Activities
Kas dan Setara Kas Awal Tahun
Cash and Cash Equivalents at the Beginning 783.332.056.074 622.058.009.425 161.274.046.649 25,93
of the Year
Kas dan Setara Kas Akhir Tahun
Cash and Cash Equivalents at the End of the 826.584.741.908 783.332.056.074 43.252.685.834 5,52
Year
Kemampuan Membayar Utang
Solvency
BMHS mengelola kewajiban keuangan secara disiplin BMHS manages its financial obligations with discipline
dan memenuhi pembayaran sesuai dengan ketentuan and fulfills all payments in accordance with the terms
yang disepakati bersama pihak perbankan maupun agreed with banking institutions and business partners.
mitra usaha. Secara berkala, BMHS memantau On a regular basis, BMHS monitors its liquidity and
kondisi likuiditas dan solvabilitas untuk memastikan solvency positions to ensure its ability to meet both
kemampuan dalam memenuhi kewajiban keuangan short-term and long-term financial obligations. At the
jangka pendek dan jangka panjang. Pada akhir end of the reporting period, the current ratio stood at
periode pelaporan, rasio lancar tercatat sebesar 1,62, 1.62, while the liabilities to assets ratio was 0.40, and the
sementara rasio liabilitas terhadap aset sebesar 0,40, liabilities-to-equity ratio was 0.68. These ratios reflect
dan rasio liabilitas terhadap ekuitas sebesar 0,68. Rasio prudent financial structure management and support
ini mencerminkan pengelolaan struktur keuangan BMHS’s capacity to meet its financial obligations.
secara prudent dan mendukung kapasitas BMHS dalam
memenuhi kewajiban keuangannya.
Rasio Keuangan | Financial Ratios 2025 2024
Rasio Likuiditas | Liquidity Ratio
Rasio Lancar | Current Ratio 1,62 1,92
Rasio Solvabilitas | Solvency Ratio
Liabilitas terhadap Ekuitas | Liabilities to Equity 0,68 0,60
Liabilitas terhadap Aset | Liabilities to Assets 0,40 0,38
Tingkat Kolektibilitas Piutang Receivables Collectibility Level
BMHS melakukan pemantauan piutang usaha BMHS monitors trade receivables by taking into
dengan memperhatikan profil pelanggan dan umur account customer profiles and the aging of receivables.
piutang. Secara struktur, piutang usaha didominasi Structurally, trade receivables are predominantly
oleh pelanggan korporasi, perusahaan asuransi, derived from corporate customers, insurance
dan penyedia layanan pembayaran, yang secara companies, and payment service providers, which
karakteristik memiliki siklus penagihan tersendiri. characteristically have specific billing and collection
cycles.
Page 88
88 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
BMHS mengelola piutang secara aktif melalui BMHS actively manages receivables through systematic
proses penagihan dan evaluasi risiko kredit, serta collection processes and credit risk assessments,
membentuk cadangan penurunan nilai piutang yang and establishes adequate allowances for impairment
memadai guna mengantisipasi potensi penurunan nilai. to anticipate potential losses. As an indicator of
Sebagai indikator tingkat kolektibilitas piutang, BMHS receivables collectability, BMHS applies the Days Sales
menggunakan rasio Days Sales Outstanding (DSO), yang Outstanding (DSO) ratio, calculated by comparing net
dihitung dengan membandingkan piutang usaha bersih trade receivables to sales during the reporting period.
terhadap penjualan selama periode berjalan.
Tingkat Kolektibilitas Piutang
Receivables Collectibility Level
Keterangan | Description Satuan | Unit 2025 2024
Piutang Usaha – Bersih | Trade Receivables – Net Rp Miliar 161,94 144,71
Penjualan | Sales IDR Billion 1.614,34 1.554,69
Kolektibilitas Piutang | Receivables Collectibility Hari | Days 35 30
Struktur Modal
Capital Structure
BMHS mengelola struktur modal secara terukur BMHS manages its capital structure in a measured
dengan memperhatikan keseimbangan antara sumber manner by maintaining an appropriate balance
pendanaan yang berasal dari liabilitas dan ekuitas. between funding sourced from liabilities and equity.
Pendekatan ini ditujukan untuk menjaga fleksibilitas This approach is aimed at preserving financial flexibility,
keuangan, mendukung kebutuhan operasional dan supporting operational and investment requirements,
investasi, serta mengelola risiko keuangan secara and prudently managing financial risks. At the end of the
cermat. Pada akhir periode pelaporan, struktur reporting period, BMHS’s capital structure reflected a
permodalan BMHS mencerminkan basis permodalan relatively strong capital base to support the business
yang relatif kuat dalam mendukung kegiatan usaha, activities, with equity as the predominant source of
dengan dominasi bersumber dari ekuitas. funding.
Komposisi Struktur Modal dalam Rupiah penuh, kecuali dinyatakan lain
Capital Structure Composition in full Rupiah, unless otherwise stated
Struktur Modal | Capital Structure 2025 % 2024 %
Jumlah Liabilitas | Total Liabilities 1.621.922.418.632 40,38 1.298.625.219.027 37,68
Jumlah Ekuitas | Total Equity 2.394.507.016.511 59,62 2.147.735.684.721 63,32
Jumlah Liabilitas dan Ekuitas
4.016.429.435.143 100,00 3.446.360.903.748 100,00
Total Liabilities and Equity
Kebijakan Manajemen atas Struktur Modal Capital Structure Management Policy
Manajemen menetapkan kebijakan struktur modal Management established its capital structure policy
dengan dasar mempertimbangkan karakteristik usaha by taking into account the nature of BMHS’s business
sebagai penyedia layanan kesehatan yang bersifat padat as a capital-intensive healthcare service provider that
modal, yang membutuhkan kesinambungan operasional, requires operational continuity and stable medium to
serta stabilitas pendanaan jangka menengah dan long-term funding. To optimize the capital structure,
panjang. Dalam mengoptimalkan struktur permodalan, Management considers the operational funding
Page 89
Laporan Tahunan
Annual Report 89
Manajemen memperhatikan antara lain kebutuhan requirements, capital expenditure plans, cash flow
pendanaan operasional, rencana belanja modal, profil profiles, funding market conditions, and the level of
arus kas, kondisi pasar pendanaan, serta tingkat risiko risk deemed acceptable. Capital structure management
yang dapat diterima. Pengelolaan struktur modal is carried out through continuous monitoring of the
dilakukan melalui pemantauan rasio liabilitas terhadap liabilities-to-equity ratio and other relevant ratios as
ekuitas dan rasio terkait lainnya sebagai indikator indicators of capital adequacy and funding capacity. The
kecukupan permodalan dan kapasitas pendanaan. use of liabilities is directed selectively to supporting
Penggunaan liabilitas diarahkan untuk mendukung business operations and investments, while equity
kegiatan usaha dan investasi secara selektif, sementara remains the primary pillar for maintaining financial
ekuitas tetap menjadi penopang utama dalam menjaga stability.
stabilitas keuangan.
Ikatan yang Material untuk Investasi Barang Modal
Material Commitments for Capital Goods Investments
Pada 2025, BMHS tidak melaksanakan ikatan yang In 2025, BMHS did not commit to any material
material untuk investasi barang modal. commitments for capital expenditures.
Investasi Barang Modal yang Direalisasikan pada
Tahun Buku Terakhir
Capital Goods Investments Realized in the Last Financial Year
Sejalan dengan inisiatif optimalisasi pemanfaatan In line with the initiatives to optimize the use of existing
aset dan kapasitas layanan yang telah dimiliki, BMHS assets and service capacity, BMHS adopted a prudential
mengarahkan investasi belanja modal secara hati- approach to capital expenditure. In 2025, BMHS
hati. BMHS mengalokasikan belanja modal (capital allocated capital expenditure of IDR 315 billion. Of
expenditure) sebesar Rp315 miliar pada 2025. Dari this amount, realized capital investments totaled IDR
jumlah tersebut, realisasi investasi barang modal 219 billion, which was used for the development and
tercatat sebesar Rp219 miliar, yang digunakan untuk expansion of hospital facilities, the addition and renewal
pengembangan dan perluasan fasilitas rumah sakit, of medical equipment, as well as the enhancement of
penambahan serta pembaruan peralatan medis, supporting operational infrastructure across BMHS’s
serta peningkatan sarana dan prasarana penunjang hospital network.
operasional di jaringan rumah sakit BMHS.
Investasi barang modal tersebut ditujukan untuk These capital investments were aimed at strengthening
mendukung kesiapan infrastruktur operasional the operational infrastructure readiness and aligning
dan penyesuaian kapasitas layanan seiring dengan service capacity with evolving business needs. Capital
kebutuhan usaha. Pendanaan belanja modal bersumber expenditure was funded through a combination of
dari kombinasi arus kas operasional dan sumber operating cash flows and other financing sources in
pendanaan lainnya sesuai dengan kebijakan keuangan accordance with BMHS’s financial policies.
BMHS.
Page 90
90 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Informasi dan Fakta Material Setelah Tanggal Laporan Akuntan
Material Information and Facts Occurring After the Date of the Accountant’s
Report
Tidak terdapat informasi dan fakta material yang terjadi There were no material events or facts occurring after
setelah tanggal laporan Akuntan 31 Desember 2025 the date of the Auditor’s Report as of December 31,
sampai dengan tanggal penyampaian Laporan Tahunan 2025 up to the date of submission of the 2025 Annual
2025 yang dapat memengaruhi kondisi keuangan, Report that had a material impact on BMHS’s financial
kinerja, maupun tata kelola BMHS . condition, performance, or governance.
Prospek Usaha
Business Prospects
Kondisi ekonomi nasional diproyeksikan tumbuh National economic conditions are projected to grow
stabil pada kisaran 5% di 2026, di tengah dinamika steadily by around 5% in 2026 amid the ongoing global
dan ketidakpastian global. Dari sisi kebijakan, sektor dynamics and uncertainties. From a policy perspective,
kesehatan tetap menjadi salah satu prioritas nasional. the healthcare sector remains one of the national
Hal ini tercermin dalam alokasi APBN yang signifikan priorities, as reflected in the significant allocation of the
untuk penguatan pembiayaan kesehatan, termasuk State Budget to strengthen healthcare financing. This
mendukung keberlanjutan program JKN, peningkatan included support for the sustainability of the National
layanan kesehatan primer dan rujukan, serta penguatan Health Insurance (JKN) program, enhancement
kualitas dan akses layanan kesehatan. Dukungan of primary and referral healthcare services, and
kebijakan ini menciptakan lingkungan yang kondusif improvements in the quality and accessibility of
bagi pertumbuhan industri layanan kesehatan, termasuk healthcare services. Such a policy supports the creation
bagi peran rumah sakit swasta dalam melengkapi of a conducive environment for the growth of the
kapasitas sistem kesehatan nasional. healthcare services industry, including the role of
private hospitals in complementing the capacity of the
national healthcare system.
Sebagai sektor yang bersifat esensial dan relatif As an essential sector that is relatively resilient to
tidak sensitif terhadap siklus ekonomi, permintaan economic cycles, demand for healthcare services is
terhadap layanan kesehatan diperkirakan tetap expected to remain stable, particularly for services
terjaga, khususnya pada layanan dengan kebutuhan with ongoing clinical needs and higher value-added
klinis yang bersifat berkelanjutan dan bernilai tambah. characteristics. Demand for women and child health
Permintaan terhadap layanan kesehatan ibu dan anak, services, specialist and sub-specialist care, as well as
layanan spesialistik dan subspesialistik, serta layanan diagnostic services, is projected to continue growing in
diagnostik diproyeksikan tetap tumbuh seiring line with demographic changes, rising health awareness,
perubahan demografi, peningkatan kesadaran and increasing demand for more complex healthcare
kesehatan, dan kebutuhan layanan dengan kompleksitas services.
yang lebih tinggi.
Dalam konteks tersebut, BMHS berada pada posisi In this context, BMHS is well positioned to respond to
yang relevan untuk merespons perkembangan pasar, market developments, in line with the characteristics
sejalan dengan karakteristik portofolio layanannya. of its service portfolio. By optimizing the existing
Melalui optimalisasi fasilitas rumah sakit yang telah hospital facilities, BMHS continues to enhance its
beroperasi, BMHS meningkatkan kapasitas layanan service capacity and network coverage. Development
dan jaringannya. Fokus pengembangan diarahkan efforts are focused on high-complexity services based
Page 91
Laporan Tahunan
Annual Report 91
pada layanan dengan kompleksitas tinggi yang berbasis on Centers of Excellence, medical innovations, and
Center of Excellence, inovasi medis, dan teknologi robotik, robotic technology, while consistently strengthening
dengan tetap melakukan penguatan pada layanan ibu women and children health services as BMHS’s key
dan anak yang menjadi diferensiasi BMHS. differentiation.
Selain penguatan layanan rumah sakit, BMHS juga Other than its hospital-based services, BMHS has
melihat peluang pertumbuhan melalui pengembangan also identified growth opportunities through the
ekosistem layanan kesehatan yang saling terhubung, development of an integrated healthcare ecosystem,
mencakup layanan teknologi reproduksi berbantu, which includes assisted reproductive technology
layanan laboratorium, layanan kesehatan di luar services, laboratory services, out-of-hospital healthcare
rumah sakit, layanan rujukan dan wisata medis, services, referral services and medical tourism, as
serta dukungan layanan berbasis teknologi digital. well as digital health–based support services. Synergy
Sinergi antarunit usaha dipandang sebagai faktor among business units is viewed as a critical factor
penting dalam memperluas jangkauan layanan, in expanding service reach, improving continuity of
meningkatkan kesinambungan perawatan pasien, patient care, and optimizing the use of existing assets
serta mengoptimalkan pemanfaatan aset dan kapasitas and service capacity.
layanan yang telah dimiliki.
Target dan Realisasi 2025
Target and Realization in 2025
BMHS menetapkan target kinerja 2025 BMHS established its 2025 performance targets based
berdasarkan asumsi proyeksi pendapatan, beban on assumptions for projected revenue, cost of revenue,
pokok pendapatan, beban usaha, serta pajak, dengan operating expenses, and taxation, taking into account
mempertimbangkan kondisi industri dan kapasitas industry conditions and BMHS’s operational capacity.
operasional BMHS. Dalam industri layanan kesehatan, In the healthcare services industry, performance
realisasi kinerja dipengaruhi oleh berbagai faktor realization was influenced by operational factors,
operasional, seperti volume kunjungan pasien, including patient visit volumes, the level of medical
tingkat kompleksitas kasus medis, dan kondisi case complexity, and emergency conditions, all of which
kegawatdaruratan, yang bersifat dinamis sepanjang were dynamic throughout the reporting period.
periode berjalan.
Pada 2025, BMHS mencatatkan pendapatan sebesar In 2025, BMHS recorded revenue of IDR 1,614.34
Rp1.614,34 miliar, atau meningkat 4% dari tahun trillion, representing a 4% increase from the previous
sebelumnya. Sementara itu, laba tahun berjalan year. Meanwhile, net income for the year stood at IDR
tercatat sebesar Rp29,67 miliar, naik 57% YoY, sejalan 29.67 billion, up 57% YoY, in line with the double-digit
dengan target pertumbuhan laba bersih dua digit net profit growth target set at the beginning of the year.
yang telah ditetapkan di awal tahun. Dari sisi struktur From a capital structure perspective, BMHS considers
modal, BMHS menilai bahwa komposisi permodalan its capitalization to be balanced and appropriate to
yang dimiliki berada pada tingkat yang seimbang dan support its operational needs, so no adjustments were
sesuai dengan kebutuhan operasional sehingga tidak made during the year to the capital structure targets.
dilakukan penyesuaian target struktur modal sepanjang
tahun berjalan.
Page 92
92 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Proyeksi 2026
2026 Projections
BMHS telah menetapkan target dan proyeksi kinerja BMHS has set its 2026 performance targets and
2026 sebagai bagian dari Rencana Kerja dan Anggaran projections in BMHS’s Work Plan and Budget (RKAP).
BMHS (RKAP). Proyeksi tersebut disusun berdasarkan These projections were prepared based on assumptions
asumsi pendapatan, beban pokok pendapatan, beban regarding revenue, cost of revenue, operating expenses,
usaha, dan pajak, dengan mempertimbangkan dinamika and taxation, taking into account developments in
industri layanan kesehatan serta kapasitas dan kesiapan the healthcare services industry as well as BMHS’s
operasional BMHS. operational capacity and readiness.
BMHS menargetkan pertumbuhan kinerja keuangan BMHS targets sustainable financial performance
yang berkelanjutan, termasuk pada pendapatan, growth, including increases in revenue, EBITDA, and
EBITDA, dan laba bersih, yang meningkat dibandingkan net profit compared to the 2025 realization. From a
realisasi 2025. Dari sisi struktur permodalan, BMHS capital structure perspective, BMHS does not plan to
tidak merencanakan perubahan kebijakan yang make any significant changes in its funding policy and
signifikan dan akan tetap menjaga struktur modal yang will continue to maintain a healthy and balanced capital
sehat dan seimbang. Selain itu, BMHS menargetkan rasio structure. In addition, BMHS will target a dividend
pembayaran dividen dengan tetap mempertimbangkan payout ratio while continuing to consider its financial
kinerja keuangan, kebutuhan pendanaan operasional, performance, operational funding requirements, and
serta keberlanjutan usaha. long-term business sustainability.
Target dan proyeksi tersebut disusun dengan These targets and projections have been calculated
pendekatan yang terukur serta mempertimbangkan using a measured approach, with due consideration
kinerja historis dan perkembangan permintaan layanan given to historical performance and trends in
kesehatan, dan senantiasa dievaluasi secara berkala healthcare service demand, and are subject to periodic
guna menjaga keselarasan antara rencana kinerja, evaluation to ensure alignment between performance
kondisi operasional, dan dinamika lingkungan usaha. plans, operational conditions, and the evolving business
environment.
Page 93
Laporan Tahunan
Annual Report 93
Aspek Pemasaran
Marketing Aspects
Persepsi dan Kepercayaan Pelanggan Customer Perception & Trust
BMHS memandang persepsi dan kepercayaan pasien BMHS considers patient perception and trust to be
sebagai fondasi penting dalam menjaga keberlanjutan fundamental to its long-term business sustainability.
usaha. Untuk itu, BMHS secara konsisten melakukan To achieve this, BMHS consistently enhances service
penyempurnaan kualitas layanan melalui pendekatan quality through a continuous improvement approach,
continuous improvement yang berfokus pada keunggulan focusing on service excellence across both clinical and
layanan, baik pada aspek klinis dan nonklinis, di seluruh non-clinical aspects at all patient touchpoints.
titik interaksi dengan pasien.
Sejalan dengan upaya tersebut, BMHS juga terus In line with these efforts, BMHS has continued to
menyempurnakan patient journey untuk memastikan refine the patient journey to ensure more structured,
proses layanan yang lebih terstruktur, mudah diakses, accessible, and patient-aligned service processes
dan selaras dengan kebutuhan pasien pada setiap at every stage of care. This approach is expected to
tahapan perawatan. Pendekatan ini diharapkan dapat strengthen patient trust, enhance loyalty, and support
memperkuat kepercayaan pasien, meningkatkan BMHS’s reputation as a family-oriented healthcare
loyalitas, serta mendukung reputasi BMHS sebagai provider committed to quality and patient safety.
penyedia layanan kesehatan keluarga yang berorientasi
pada kualitas dan keselamatan pasien.
Strategi Pemasaran Marketing Strategy
Dalam pelaksanaannya, BMHS menerapkan sejumlah For its implementation, BMHS applies the following
pendekatan pemasaran sebagai berikut: marketing approaches:
1. Digitalisasi akses layanan melalui pengembangan 1. Digitalizing service access by developing the
platform OneBunda, yang menyediakan fitur OneBunda platform, which provides appointment
janji temu, telekonsultasi, pemesanan layanan scheduling, teleconsultation, laboratory service
laboratorium, serta penyampaian hasil pemeriksaan ordering, and electronic delivery of test results. The
secara elektronik. Platform ini juga dilengkapi platform also contains digital pregnancy and child
dengan buku kehamilan dan vaksinasi anak digital, vaccination records, as well as loyalty programs to
serta program loyalitas untuk meningkatkan enhance patient engagement.
keterlibatan pasien.
2. Peningkatan literasi dan edukasi kesehatan, 2. Enhancing health literacy and education, by
dengan memperkenalkan layanan yang tersedia introducing existing and new services through
maupun layanan baru melalui seminar, health talk, seminars, health talks, educational outreach
penyuluhan, serta konten edukatif di situs web dan programs, and educational content via BMHS’s
media sosial BMHS. website and social media channels.
3. Penguatan kualitas layanan dan kepercayaan 3. Strengthening service quality and market trust,
pasar, melalui pemenuhan dan pembaruan standar through compliance with and continuous renewal of
akreditasi rumah sakit serta sertifikasi tenaga hospital accreditation standards and medical staff
medis. certifications.
Page 94
94 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
4. Pengembangan Center of Excellence (CoE) dengan 4. Developing Centers of Excellence (CoE) by ensuring
memastikan ketersediaan dokter dan tenaga medis the availability of competent physicians and medical
yang kompeten sesuai Product of Excellence (PoE) professionals aligned with each hospital’s Product of
masing-masing rumah sakit, didukung oleh pelatihan Excellence (PoE), supported by continuous training
dan pendidikan berkelanjutan, serta pengelolaan and education, as well as responsible management of
citra layanan dan profesional medis secara service and medical professional branding.
bertanggung jawab.
5. Perluasan jaringan dan kemitraan strategis, antara 5. Expanding networks and strategic partnerships,
lain melalui kerja sama dengan Klinik Pintar melalui including collaboration with Klinik Pintar through
aplikasi Bunda Pintar, kolaborasi dengan klinik the Bunda Pintar application, partnerships with local
OBGYN lokal dalam jaringan Klinik Fertilitas OBGYN clinics within the Klinik Fertilitas Indonesia
Indonesia (KFI), serta integrasi layanan laboratorium (KFI) network, and integration of Diagnos laboratory
Diagnos dan layanan farmasi BGP untuk services and BGP pharmacy services to strengthen
memperkuat kesinambungan layanan. continuity of care.
6. Pengembangan jaringan layanan, baik rumah sakit 6. Selectively expanding its service networks in
maupun klinik, secara selektif di berbagai wilayah hospitals and clinics, across the regions to address
untuk menjangkau kebutuhan layanan kesehatan broader community healthcare needs, including
masyarakat yang lebih luas, termasuk melakukan partnerships with healthcare institutions, insurance
kemitraan dengan institusi kesehatan, asuransi, providers, and referral partners, to expand the
dan mitra rujukan, guna memperluas basis pasien, patient base, including patients from outside service
termasuk pasien dari luar wilayah layanan yang areas requiring specific medical care.
membutuhkan perawatan medis tertentu.
Pangsa Pasar Market Share
BMHS memiliki posisi yang kuat pada segmen layanan BMHS holds a strong position in the women
kesehatan ibu dan anak serta layanan teknologi and children health segment as well as assisted
reproduksi berbantu. Melalui unit usaha Morula IVF reproductive technology services. Through the, Morula
Indonesia, BMHS merupakan salah satu penyedia IVF Indonesia, business unit, BMHS has become one
layanan fertilitas terkemuka di Indonesia, dengan of the leading fertility service providers in Indonesia,
jaringan layanan yang luas dan reputasi klinis yang telah supported by its extensive service network and a
dikenal di pasar. Keunggulan tersebut didukung oleh well-established clinical reputation in the market. This
pengalaman operasional, kompetensi tenaga medis, competitive strength is supported by its operational
serta integrasi layanan penunjang dalam ekosistem experience, highly competent medical professionals,
BMHS. and the integration of supporting services within
BMHS’s ecosystem.
Di luar layanan fertilitas, penguatan layanan ibu Other than fertility services, the strengthening of
dan anak serta pengembangan Center of Excellence women and children healthcare services and the
menjadi landasan utama BMHS dalam menjaga dan development of Centers of Excellence form the core
memperluas pangsa pasar secara berkelanjutan. foundation for BMHS in maintaining and sustainably
Pengembangan layanan berbasis Center of Excellence expanding its market share. The Center of Excellence–
juga didukung oleh pemanfaatan teknologi medis based services development is supported by the
canggih, termasuk teknologi bedah robotik generasi adoption of advanced medical technologies, including
terbaru, yang memperkuat daya tarik layanan the latest generation of robotic surgery, which enhances
spesialistik dan bernilai tinggi, khususnya pada the attractiveness of high-value specialist services,
prosedur dengan kompleksitas tinggi, serta mendukung particularly for complex procedures, and reinforces
peran BMHS pada segmen layanan kesehatan rujukan BMHS’s role in referral-based healthcare services
berbasis keunggulan klinis. driven by clinical excellence.
Page 95
Laporan Tahunan
Annual Report 95
BMHS terus melakukan inisiatif pemasaran yang BMHS continues to instigate measured marketing
terukur untuk mengoptimalkan keunggulan layanan, initiatives to optimize service strengths, broaden
memperluas jangkauan pasien, serta menyesuaikan patient reach, and align its marketing strategies with the
strategi pemasaran dengan dinamika kebutuhan layanan evolving dynamics of healthcare demand and diverse
kesehatan dan skema pembiayaan yang beragam. healthcare financing schemes.
Kebijakan Dividen
Dividend Policy
BMHS menetapkan kebijakan dividen dengan mengacu BMHS’s dividend policy refers to the the provisions
pada ketentuan Anggaran Dasar serta Undang- in its Articles of Association and Law No. 40 of 2007
Undang Nomor 40 Tahun 2007 tentang BMHS concerning Limited Liability Companies. Dividend
Terbatas. Pembagian dividen dapat dilakukan dengan distribution may be carried out provided BMHS has
ketentuan BMHS memiliki saldo laba yang mencukupi, sufficient retained earnings, up to a maximum of
dengan sebanyak-banyaknya 30% dari laba tahun 30% of net profit for the year after setting aide the
berjalan setelah dilakukan penyisihan cadangan wajib. mandatory statutory reserve. The determination of
Penetapan penggunaan laba bersih, termasuk besaran the appropriation of net profit, including the amount
cadangan wajib dan dividen yang akan dibagikan allocated to the statutory reserve and dividends to be
kepada pemegang saham, diputuskan melalui Rapat distributed to shareholders, is decided through the
Umum Pemegang Saham (RUPS). General Meeting of Shareholders (GMS).
Pembayaran Dividen Dividend Payments
Sesuai hasil keputusan RUPS Tahunan 15 Mei Based on a resolution in the Annual General Meeting of
2025, BMHS membagikan dividen tunai kepada Shareholders held on May 15, 2025, BMHS distributed
Pemegang Saham sebesar Rp0,65 per saham, yang cash dividends to its shareholders amounting to IDR
berasal dari laba bersih konsolidasian tahun buku 2024, 0.65 per share, derived from the consolidated net profit
dengan total nilai dividen sebesar Rp5.592.220.514. for the 2024 financial year, for a total dividend amount
Informasi mengenai riwayat pembayaran dividen of IDR 5,592,220,514 BMHS’s dividend payment
BMHS dalam lima tahun terakhir disajikan sebagai history over the last five years is as follows:
berikut:
Jumlah Pembayaran
Persentase Laba Dividen per Saham Dividen Bruto Tanggal Pembayaran
Tahun Buku
Percentage of Profit Dividend per Share Total Gross Dividend Dividen
Financial Year
(%) (Rp) Payments Dividend Payment Date
(Rp)
28 Juni 2021
2020 21,96 130 19.500.000.000
June 28, 2021
24 Agustus 2022
2021 10,26 2,55712 22.000.000.000
August 24, 2022
21 Juli 2023
2022 15,51 1,5 12.905.124.264
July 21, 2023
3 Juli 2024
2023 64,57 0,56 4.817.913.058
July 3, 2024
18 Juni 2025
2024 46,8 0,65 5.592.220.514
June 18, 2025
Page 96
96 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Realisasi Penggunaan Dana Hasil Penawaran Umum
Use of Public Offering Proceeds Realization
BMHS telah merealisasikan seluruh dana yang BMHS used all proceeds from its initial public offering in
diperoleh dari penawaran saham perdana sesuai accordance with the stated use of proceeds as disclosed
dengan tujuan penggunaan dana yang diungkapkan in the prospectus. Up to the end of 2025, BMHS did not
dalam dokumen prospektus. Sampai akhir 2025, BMHS conduct any additional public offerings; therefore, this
tidak melaksanakan penawaran umum lainnya sehingga report does not disclose the realization of the use of
laporan ini tidak mengungkapkan realisasi penggunaan proceeds from other public offerings.
dana hasil penawaran umum.
Informasi Material Mengenai Investasi, Ekspansi, Divestasi,
Penggabungan/ Peleburan Usaha, Akuisisi, Restrukturisasi
Utang/Modal, Transaksi Material, Transaksi Afiliasi, dan
Transaksi Benturan Kepentingan
Material Information Regarding Investments, Expansions, Divestments,
Mergers/Consolidations, Acquisitions, Debt/Capital Restructuring, Material
Transactions, Affiliated Transactions, and Conflict of Interest Transactions
BMHS melakukan transaksi afiliasi dalam rangka BMHS has affiliated transactions to support its
mendukung kegiatan operasional dan pengembangan operational activities and business development. These
usaha. Transaksi afiliasi tersebut merupakan bagian dari affiliated transactions form part of BMHS’s business
kegiatan usaha BMHS yang dijalankan dalam rangka activities carried out to generate operating revenue
menghasilkan pendapatan usaha dan dilaksanakan and are conducted on a routine, recurring, and/or
secara rutin, berulang, dan/atau berkelanjutan. Seluruh ongoing basis. All affiliated transactions are executed in
transaksi afiliasi dilaksanakan sesuai dengan praktik accordance with generally accepted business practices
bisnis yang berlaku umum serta memenuhi prinsip and comply with the arm’s length principle.
kewajaran (arm’s length principle).
Untuk memastikan kewajaran transaksi, BMHS To ensure the fairness of such transactions, BMHS
telah menunjuk pihak independen guna melakukan appointed an independent party to conduct a fairness
penilaian sesuai dengan ketentuan POJK No. 42/ assessment in accordance with POJK No. 42/
POJK.04/2020 tentang Transaksi Afiliasi dan Transaksi POJK.04/2020 concerning Affiliated Transactions and
Benturan Kepentingan. Direksi menyatakan bahwa Conflict of Interest Transactions. The Board of Directors
transaksi afiliasi telah melalui prosedur yang memadai stated that the affiliated transactions had undergone
dan dilaksanakan secara wajar, dengan pengawasan adequate procedures and were carried out fairly, under
dari Dewan Komisaris dan Komite Audit. Informasi the supervision of the Board of Commissioners and the
mengenai transaksi afiliasi dan transaksi material Audit Committee. Information concerning affiliated
tersebut telah diungkapkan dalam laporan keuangan transactions and material transactions were disclosed
tahunan BMHS, khususnya pada Catatan atas Laporan in BMHS’s annual financial statements, particularly
Keuangan terkait transaksi pihak berelasi. in the Notes to the Financial Statements relating to
related party transactions.
Page 97
Laporan Tahunan
Annual Report 97
BMHS juga telah menyampaikan keterbukaan informasi BMHS also submitted information disclosures related to
atas transaksi afiliasi dan transaksi material kepada affiliated transactions and material transactions to the
Otoritas dan Bursa Efek Indonesia. Informasi tersebut, relevant authorities and the Indonesia Stock Exchange.
termasuk penilaian kewajaran dari pihak independen Such information, including the independent fairness
serta pernyataan tanggung jawab Direksi dan Dewan opinion and the statements of responsibility from the
Komisaris, dapat diakses melalui situs web Bursa Efek Board of Directors and the Board of Commissioners,
Indonesia. is accessible through the Indonesia Stock Exchange
website.
1. Pada tanggal 31 Januari 2025, BMHS telah 1. On 31 January 2025, BMHS conducted an affiliated
melakukan transaksi afiliasi berupa pengambilalihan transaction in the form of the acquisition of 99.99%
99,99% saham PT Medika Sejahtera Bersama (MSB) of the shares of PT Medika Sejahtera Bersama (MSB)
dari PT Morula Indonesia (MI), dengan nilai transaksi from PT Morula Indonesia (MI), for a transaction
sebesar Rp38,99 miliar. MI adalah entitas anak value of IDR 38.99 billion. MI is a subsidiary of
BMHS, dan MSB adalah entitas anak MI. Transaksi BMHS, and MSB is a subsidiary of MI. This
ini dilakukan dalam rangka memperkuat integrasi transaction was carried out to strengthen the
layanan kesehatan ibu dan anak serta memperluas integration of women and children health services
sinergi usaha dalam ekosistem BMHS. Transaksi and to expand business synergies within BMHS’s
tersebut tidak mengandung benturan kepentingan ecosystem. This transaction did not involve any
dan tidak memerlukan persetujuan Rapat Umum conflict of interest and did not require approval from
Pemegang Saham Independen. an Independent General Meeting of Shareholders.
Perubahan Peraturan Perundang-Undangan pada Tahun Buku
Changes in Laws and Regulations during the Financial Year
Pada 2025, Pemerintah menerbitkan sejumlah regulasi In 2025, the Government issued several regulations
yang relevan dengan operasional bisnis BMHS, antara relevant to BMHS’s business operations, including the
lain: following:
1. Peraturan Menteri Kesehatan No. 11 Tahun 2025 1. Minister of Health Regulation No. 11 of 2025
tentang Standar Kegiatan Usaha dan Standar concerning Business Activity Standards and
Produk/Jasa pada Penyelenggaraan Perizinan Product/Service Standards for Risk-Based Business
Berusaha Berbasis Risiko Subsektor Kesehatan. Licensing in the Health Subsector. For BMHS, this
Bagi BMHS, peraturan ini meningkatkan kepastian regulation increases certainty and transparency in
dan transparansi proses perizinan, sekaligus menjadi the licensing process and serves as a reference for
acuan dalam menjaga konsistensi standar layanan maintaining consistency in service standards and
dan kepatuhan operasional. operational compliance.
2. Surat Edaran Otoritas Jasa Keuangan No. 7/ 2. Financial Services Authority (OJK) Circular Letter
SEOJK.05/2025 tentang Penyelenggaraan No. 7/SEOJK.05/2025 concerning Health Insurance
Produk Asuransi Kesehatan. Bagi BMHS, Products. For BMHS, the co-payment policies for
penerapan kebijakan co-payment pada produk health insurance products may affect patterns of
asuransi kesehatan berpotensi memengaruhi pola service utilization and therefore requires attention
pemanfaatan layanan, sehingga perlu menjadi in risk management.
perhatian dalam pengelolaan risiko.
3. Peraturan Pemerintah Nomor 28 Tahun 2025 3. Government Regulation No. 28 of 2025 concerning
tentang Penyelenggaraan Perizinan Berusaha Risk-Based Business Licensing.
Berbasis Risiko.
Page 98
98 Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
4. Keputusan Direktur Jenderal Kesehatan Lanjutan 4. Director General of Advanced Health Services
Nomor HK.02.02/D/4072/2025 Tentang Decree No. HK.02.02/D/4072/2025 concerning
Pengelolaan Pengaduan Mutu Pelayanan Kesehatan the Management of Healthcare Service Quality
di Fasilitas Pelayanan Kesehatan Tingkat Lanjut. Complaints at Advanced-Level Healthcare Facilities.
5. Peraturan Kepala Badan Pusat Statistik Nomor 5. Head of Statistics Indonesia (BPS) Regulation No.
7 Tahun 2025 Tentang Klasifikasi Baku Lapangan 7 of 2025 concerning the Indonesian Standard
Usaha Indonesia. Industrial Classification (KBLI).
6. Peraturan Menteri Hukum Nomor 2 Tahun 2025 6. Minister of Law Regulation No. 2 of 2025
tentang Verifikasi dan Pengawasan Pemilik Manfaat concerning the Verification and Supervision of
Korporasi. Beneficial Owners of Corporations.
7. Peraturan Menteri Hukum Nomor 49 Tahun 2025 7. Minister of Law Regulation No. 49 of 2025
tentang Syarat dan Tata Cara Pendirian, Perubahan concerning the Requirements and Procedures for
dan Pembubaran Badan Hukum BMHS Terbatas. the Establishment, Amendment, and Dissolution of
Limited Liability Companies.
8. Permenkes Nomor 13 Tahun 2025 mengatur tentang 8. Minister of Health Regulation No. 13 of 2025
Pengelolaan Sumber Daya Manusia Kesehatan. concerning the Management of Healthcare Human
Resources.
BMHS senantiasa memperhatikan kepatuhan terhadap BMHS consistently ensures compliance with all
peraturan perundang-undangan yang berlaku. Dalam applicable laws and regulations. In practice, BMHS
pelaksanaannya, BMHS melakukan penelaahan serta conducts reviews and applies necessary adjustments
penyesuaian yang diperlukan untuk memastikan to align its business practices with newly issued
kesesuaian praktik usaha dengan penetapan atau or amended regulations. Based on the evaluations
perubahan regulasi yang berlaku. Berdasarkan hasil conducted, as of the end of the reporting period, these
evaluasi, hingga akhir periode pelaporan, penerapan regulations did not have a material impact on BMHS’s
regulasi tersebut tidak berdampak material terhadap financial performance or financial position.
kinerja keuangan maupun posisi keuangan BMHS.
Perubahan Kebijakan Akuntansi
Changes in Accounting Policies
BMHS menyusun laporan keuangan dengan mengacu BMHS prepares its financial statements in accordance
pada Standar Akuntansi Keuangan yang berlaku di with the Financial Accounting Standards applicable
Indonesia, termasuk Pernyataan Standar Akuntansi in Indonesia, which includes Statements of Financial
Keuangan (PSAK) dan Interpretasi Standar Akuntansi Accounting Standards (PSAK) and Interpretations of
Keuangan (ISAK) yang diterbitkan oleh Dewan Standar Financial Accounting Standards (ISAK) issued by the
Akuntansi Keuangan Ikatan Akuntan Indonesia, serta Financial Accounting Standards Board of the Indonesian
ketentuan penyajian dan pengungkapan laporan Institute of Accountants, as well as the presentation
keuangan yang ditetapkan oleh Otoritas Jasa Keuangan. and disclosure requirements for financial statements
PSAK dan amendemen PSAK berikut efektif berlaku 1 stipulated by the Financial Services Authority (OJK).
Januari 2025. Penerapan amendemen tersebut tidak The following PSAK and PSAK amendments became
mengakibatkan perubahan yang material terhadap effective as of January 1, 2025, but did not result in any
kebijakan akuntansi maupun penyajian laporan material changes to BMHS’s accounting policies or the
keuangan BMHS. presentation of its financial statements.
Page 99
Laporan Tahunan
Annual Report 99
Pernyataan Standar Akuntansi Keuangan (PSAK) Tentang
Statement of Financial Accounting Standards (PSAK) Subject
Kontrak Asuransi
PSAK 117
Insurance Contracts
Amandemen PSAK 232 Instrumen Keuangan: Penyajian – Informasi Komparatif
Amendment to PSAK 232 Financial Instruments: Presentation – Comparative Information
Pengaruh Perubahan Kurs Valuta Asing – Kekurangan Ketertukaran
Amandemen PSAK 221
The Effects of Changes in Foreign Exchange Rates – Lack of
Amendment to PSAK 221
Exchangeability
Page 100
100 Ikhtisar Kinerja
Performance Highlights
Governansi Korporat
Corporate Governance
Page 101
Laporan Tahunan
Annual Report 101
Governansi Korporat yang Baik
Good Corporate Governance
BMHS menjalankan kegiatan usaha dengan BMHS conducts its business activities based on the
berlandaskan prinsip transparansi, akuntabilitas, principles of transparency, accountability, responsibility,
responsibilitas, independensi, serta kewajaran dan independence, fairness, and equality. Good corporate
kesetaraan. Penerapan governansi korporat yang baik governance (GCG) implementation is the fundamental
menjadi landasan fundamental dalam pengambilan basis for decision-making, risk management, control,
keputusan, pengelolaan risiko, pengendalian, serta and efforts to build and maintain stakeholder trust.
upaya untuk membangun dan menjaga kepercayaan To strengthen these practices, BMHS has adopted the
pemangku kepentingan. Untuk memperkuat praktik Indonesian Corporate Governance Guidelines (PUGKI)
tersebut, BMHS mengadopsi Pedoman Umum into its Governance Guidelines, which provides
Governansi Korporat Indonesia (PUGKI) ke dalam comprehensive guidance based on ethical behavior,
Pedoman Tata Kelola, yang memberikan panduan accountability, transparency, and sustainability.
komprehensif berbasis perilaku beretika, akuntabilitas,
transparansi, dan keberlanjutan.
Praktik governansi korporat tidak hanya diterapkan Good corporate governance (GCG) practices are
pada struktur organisasi dan mekanisme pengawasan, not only applied to organizational structures and
tetapi juga terintegrasi dalam pengelolaan sumber supervisory mechanisms, but are also integrated
daya manusia, pengembangan kepemimpinan, serta into human capital (HC) management, leadership
pembentukan budaya kerja yang berintegritas. development, and the formation of a culture of integrity.
Lebih lanjut, BMHS juga mengintegrasikan kerangka Furthermore, BMHS also integrates an environmental,
kerja lingkungan, sosial dan tata kelola (LST) sebagai social and governance (ESG) framework as a reference
acuan dalam pengelolaan usaha, guna memastikan in business management to ensure long-term business
keberlanjutan usaha jangka panjang. BMHS sustainability. BMHS has established a corporate
menetapkan struktur governansi korporat dengan governance structure with a clear division of roles,
pembagian peran, tugas, dan tanggung jawab yang jelas duties, and responsibilities among BMHS’s organs in
di antara organ perusahaan sesuai dengan ketentuan accordance with applicable laws and regulations.
peraturan perundang-undangan yang berlaku.
Struktur Governansi Korporat | Corporate Governance Structure
General Meeting of
Shareholders
Board of Commissioner Committees
• Audit
• Remuneration &
Compensation
• GCG & Risk Management
President Director • Investment
Corporate Strategic Committees
Planning & Investor
Relation • Procurement
Corporate Internal Audit Corporate Secretary
Project
Management Office
Page 102
102 Governansi Korporat
Corporate Governance
Kerangka Kerja Governansi Korporat
Corporate Governance Framework
Komitmen | Commitment
Fondasi untuk melaksanakan Governansi Korporat The foundation for implementing Corporate
secara terencana sistemik, dan berkelanjutan, sesuai Governance in a planned, systematic, and sustainable
karakteristik dan proses bisnis Perusahaan. manner, in accordance with the characteristics and
business processes of the Company.
Struktur | Structure
Struktur organisasi yang telah mengadopsi mekanisme An organizational structure that has adopted a check
check and balance, mengeliminasi benturan and balance mechanism, eliminating conflicts of interest
kepentingan dan potensi terjadinya fraud. and the potential for fraud.
Proses | Process
Proses pengambilan keputusan/kebijakan berlandaskan Decision-making/policy-making processes based
prinsip-prinsip Governansi Korporat yang disepakati on agreed-upon corporate governance principles in
sesuai dengan karakteristik dan proses bisnis line with the Company characteristics and business
Perusahaan. processes.
Hasil | Outcome
Implementasi prinsip-prinsip Governansi Korporat Implementation of Corporate Governance principles
saat berinteraksi, agar mendapatkan dukungan penuh when interacting with stakeholders to gain their full
stakeholder. support.
Page 103
Laporan Tahunan
Annual Report 103
Kebijakan Governansi Korporat
Corporate Governance Policy
Dalam menerapkan Governansi Korporat, Perusahaan In implementing Corporate Governance activities,
memiliki berbagai kebijakan/pedoman dalam BMHS has various policies/guidelines in carrying out
menjalankan fungsi dan tugasnya yang disebut its functions and duties, referred to as the Governance
dengan Governance Soft Structure yaitu: Pedoman Tata Soft Structure, namely: Governance Guidelines,
Kelola, Kode Etik, Piagam Direksi, Piagam Dewan Code of Ethics, Board of Directors Charter, Board of
Komisaris, Hospital by Laws dan Pedoman teknis Commissioners Charter, Hospital Bylaws, and other
lainnya. technical guidelines.
Prinsip Pelaksanaan Governansi Korporat
Principles of Corporate Governance Implementation
Etika | Ethics
PT Bundamedik Tbk senantiasa mengedepankan PT Bundamedik Tbk consistently prioritizes honesty,
kejujuran, memperlakukan semua pihak dengan treats all parties with respect, fulfills its commitments,
hormat (respect), memenuhi komitmen, membangun and builds and upholds moral values and trust
serta menjaga nilai-nilai moral dan kepercayaan consistently. The implementation of ethical principles
secara konsisten. Pelaksanaan prinsip Etika di PT at PT Bundamedik Tbk includes the annual signing of an
Bundamedik Tbk yaitu mencakup penandatanganan Integrity Pact by all employees and the establishment
Pakta Integritas setiap tahun oleh seluruh Karyawan of a Quality Committee at the hospital that evaluates
dan memiliki Komite Mutu di Rumah Sakit yang quality indicators on a monthly basis.
melakukan evaluasi indikator mutu setiap bulan.
Transparansi | Transparency
PT Bundamedik Tbk menyediakan informasi yang PT Bundamedik Tbk provides material and relevant
material dan relevan dengan cara yang mudah diakses information in a manner that is easily accessible and
dan dipahami oleh pemangku kepentingan. Pelaksanaan understandable to stakeholders. The implementation
prinsip Transparansi di PT Bundamedik Tbk yaitu of the principle of Transparency at PT Bundamedik Tbk
pelaksanaan pelaporan kepada Otoritas Jasa Keuangan, includes reporting to the Financial Service Authority,
pemutakhiran informasi website serta penyusunan updating website information, and preparing Annual
Laporan Tahunan dan Laporan Keberlanjutan. Reports and Sustainability Reports.
Akuntabilitas I Accountability
PT Bundamedik Tbk dapat mempertanggungjawabkan PT Bundamedik Tbk is accountable for its performance
kinerjanya secara transparan dan wajar dengan in a transparent and fair manner while taking into
tetap memperhitungkan kepentingan pemegang account the interests of shareholders and stakeholders.
saham dan pemangku kepentingan. Pelaksanaan The implementation of the principle of Accountability
prinsip Akuntabilitas di PT Bundamedik at PT Bundamedik Tbk includes the availability of
Tbk yaitu tersedianya Organ Perusahaan corporate organs that serve as a check and balance with
yang bersifat check and balance dengan tugas dan their respective duties and responsibilities, and the
tanggung jawab masing-masing fungsi dan pelaksanaan regular evaluation of KPIs.
evaluasi KPI secara regular.
Page 104
104 Governansi Korporat
Corporate Governance
Keberlanjutan I Sustainability
PT Bundamedik Tbk mematuhi peraturan perundang- PT Bundamedik Tbk complies with laws and regulations
undangan serta berkomitmen melaksanakan tanggung jawab and is committed to fulfilling its responsibilities to the
terhadap masyarakat dan lingkungan agar berkontribusi community and the environment in order to contribute
pada pembangunan berkelanjutan melalui kerjasama dengan to sustainable development through cooperation with all
semua pemangku kepentingan terkait. Pelaksanaan prinsip relevant stakeholders. The implementation of the principle
Keberlanjutan di PT Bundamedik Tbk yaitu tersedianya of Sustainability at PT Bundamedik Tbk is reflected in the
Roadmap ESG, pengelolaan SDM melalui pelatihan dan availability of an ESG Roadmap, human resource management
pengembangan karyawan, dokter, dan perawat dan through training and development of employees, doctors, and
penyusunan konsolidasi risiko BMHS Group. nurses, and the consolidation of BMHS Group risks.
Rapat Umum Pemegang Saham
General Meeting of Shareholders
Rapat Umum Pemegang Saham (RUPS) merupakan The General Meeting of Shareholders (GMS)
representasi pemegang saham yang menjadi organ represents shareholders and is the highest authority
tertinggi dalam struktur tata kelola. RUPS memiliki in the governance structure. The GMS has powers
wewenang yang tidak diberikan kepada Direksi not granted to the Board of Directors or the Board of
maupun Dewan Komisaris sesuai ketentuan Undang- Commissioners in accordance with the provisions of
Undang dan/atau anggaran dasar. Melalui RUPS, the Laws and/or the Articles of Association. Through
pemegang saham menentukan arah strategis BMHS, the GMS, shareholders determine BMHS’s strategic
seperti mengesahkan kinerja tahunan, menetapkan direction, such as approving the annual performance,
penggunaan laba, serta memutuskan pengangkatan determining the use of profits, and deciding on the
atau pemberhentian anggota Direksi dan Dewan appointment or dismissal of members of the Board of
Komisaris. Directors and Board of Commissioners.
Pelaksanaan Rapat Umum Pemegang Saham 2025 General Meeting of Shareholders Held in 2025
Sepanjang 2025, BMHS menyelenggarakan satu kali In 2025, BMHS held one Annual General Meeting
Rapat Umum Pemegang Saham Tahunan (RUPST) pada of Shareholders (AGM) on May 15, 2025 and one
15 Mei 2025 dan satu kali Rapat Umum Pemegang Extraordinary General Meeting of Shareholders (EGM)
Saham Luar Biasa (RUPSLB) pada 7 Agustus 2025. on August 7, 2025. The AGMS resolutions were ratified
Keputusan RUPST disahkan dalam Akta Nomor 53 in Deed Number 53 dated May 15, 2025, and the EGMS
tanggal 15 Mei 2025 dan keputusan RUPSLB dalam resolutions in Deed Number 41 dated August 7, 2025.
Akta Nomor 41 tanggal 7 Agustus 2025. Kedua akta Both deeds were made before Jose Dima Satria, S.H.,
tersebut dibuat di hadapan Jose Dima Satria, S.H., M.Kn., Notary in Jakarta.
M.Kn., Notaris di Jakarta.
BMHS memastikan seluruh penyelenggaraan RUPS BMHS ensures that all GMS proceedings comply with
memenuhi persyaratan regulasi melalui pengumuman regulatory requirements through announcements
dan undangan, penyampaian agenda dan tata tertib and invitations, delivery of the agendas and meeting
rapat termasuk mekanisme voting, penyediaan surat rules, including voting mechanisms, the provision of
kuasa, serta penyusunan risalah RUPS. Untuk menjaga proxy letters, and the preparation of GMS minutes. To
objektivitas, BMHS menunjuk pihak independen, PT maintain objectivity, BMHS appointed an independent
Datindo Entrycom, dalam penghitungan kuorum dan party, PT Datindo Entrycom, to calculate the quorum
pemungutan suara pada kedua RUPS. and vote counting at both GMS.
Page 105
Laporan Tahunan
Annual Report 105
Rapat Umum Pemegang Saham Tahunan (RUPST)
Annual General Meeting of Shareholders (AGMS)
Tanggal | Date 15 Mei 2025 | May 15, 2025
Tempat | Venue Ruang Auditorium | Auditorium Room, BMHS-Diagnos Tower
6.421.476.300 saham atau 74,64% dari seluruh saham dengan hak suara yang sah
yang telah dikeluarkan oleh BMHS
Kehadiran | Attendance
6,421,476,300 shares or 74.64% of all shares with valid voting rights issued by
BMHS
Pimpinan RUPS | Chair of the GMS Ivan Rizal Sini selaku Komisaris Utama | as President Commissioner
Kehadiran Dewan Komisaris | Board of Commissioners Attendance
Ivan Rizal Sini Komisaris Utama | President Commissioner
Wakil Komisaris Utama dan Komisaris Independen
Wishnutama Kusubandio
Vice President Commissioner and Independent Commissioner
Mesha Rizal Sini
Komisaris | Commissioners
Sunata Tjiterosampurno
Retno L.P. Marsudi
Komisaris Independen | Independent Commissioners
Arianti Anaya
Kehadiran Direksi | Board of Directors Attendance
Agus Heru Darjono Direktur Utama | President Director
Cuncun Wijaya
Direktur | Directors
Emilia Rouli
Mata Acara dan Hasil Keputusan | Agenda and Results of Resolutions
Agenda Rapat 1 | Meeting Agenda 1
Persetujuan dan pengesahan laporan tahunan serta laporan keuangan BMHS termasuk neraca dan perhitungan laba/rugi tahun
buku 2024.
Approval and ratification of BMHS's annual report and financial statements, including the balance sheet and income statement
for the financial year 2024.
Keputusan | Resolution
Menyetujui dan mengesahkan laporan tahunan serta laporan keuangan BMHS termasuk neraca dan perhitungan laba/rugi tahun
buku 2024.
Approved and ratified BMHS's annual report and financial statements, including the balance sheet and calculation of BMHS's
profit/loss for the financial year 2024.
Hasil Pemungutan Suara Setuju | Agree Tidak Setuju | Disagree Abstain
Voting Results 6.271.584.800 0 149.891.500
Realisasi | Realization Terealisasi | Realized
Agenda Rapat 2 | Meeting Agenda 2
Persetujuan penggunaan laba bersih BMHS tahun buku 2024.
Approval of the use of BMHS's net profit of financial year 2024.
Keputusan | Resolution
Menyetujui penggunaan laba bersih BMHS sesuai dengan laporan keuangan yang telah diaudit oleh Kantor Akuntan Publik
Tanubrata Sutanto Fahmi Bambang & Rekan (Member of Firm BDO International), yang akan digunakan sebagai:
1. Dividen yang akan dibagikan kepada Pemegang Saham sebesar Rp0,65 per lembar saham, atas laba bersih konsolidasian tahun
buku 2024 atau sebesar Rp5.592.220.514;
2. Sisa laba bersih BMHS yang akan dicadangkan sebagai laba ditahan.
Approved the use of BMHS's net profit in accordance with the financial statements audited by Tanubrata Sutanto Fahmi Bambang
& Rekan Public Accounting Firm (Member of Firm BDO International), which will be used as:
1. Dividends to be distributed to Shareholders in the amount of Rp0.65 per share, based on the consolidated net profit for the
financial year 2024, or Rp5,592,220,514;
2. The remaining net profit of BMHS to be reserved as retained earnings.
Page 106
106 Governansi Korporat
Corporate Governance
Mata Acara dan Hasil Keputusan | Agenda and Results of Resolutions
Hasil Pemungutan Suara Setuju | Agree Tidak Setuju | Disagree Abstain
Voting Results 6.271.584.800 0 149.891.500
Realisasi | Realization Terealisasi | Realized
Agenda Rapat 3 | Meeting Agenda 3
Penunjukan Kantor Akuntan Publik untuk melakukan audit atas laporan keuangan BMHS tahun buku 2025.
Appointment of a Public Accounting Firm to audit BMHS's financial statements for the 2025 financial year.
Keputusan | Resolution
1. Memberikan wewenang kepada Dewan Komisaris, atas rekomendasi Komite Audit, untuk menunjuk Akuntan Publik dan/
atau Kantor Akuntan Publik yang akan memberikan jasa audit atas informasi keuangan historis tahunan termasuk audit atas
laporan keuangan lain yang dibutuhkan BMHS; dan
2. Memberikan wewenang kepada Dewan Komisaris dan/atau Direksi BMHS untuk melakukan tindakan dan segala pengurusan,
termasuk namun tidak terbatas pada menunjuk Akuntan Publik serta menetapkan besaran honorarium, menandatangani
dokumen-dokumen, dan/atau menunjuk Kantor Akuntan Publik lainnya yang terdaftar di OJK apabila karena satu dan lain hal
Kantor Akuntan Publik tersebut tidak dapat melaksanakan tugasnya.
1. Authorized the Board of Commissioners, upon the recommendation of the Audit Committee, to appoint a Public Accountant
and/or Public Accounting Firm to provide audit services for historical annual financial information, including audits of other
financial reports required by BMHS; and
2. Authorized the Board of Commissioners and/or the Board of Directors of BMHS to take actions and perform all administrative
tasks, including but not limited to appointing a Public Accountant and determining the amount of remuneration, signing of
documents, and/or appointing another Public Accounting Firm registered with Financial Services Authority (OJK) if, for any
reason, the Public Accounting Firm is unable to perform its duties.
Hasil Pemungutan Suara Setuju | Agree Tidak Setuju | Disagree Abstain
Voting Results 6.237.403.400 34.181.400 149.891.500
Realisasi | Realization Terealisasi | Realized
Agenda Rapat 4 | Meeting Agenda 4
Pemberian kewenangan kepada Dewan Komisaris untuk menetapkan gaji dan tunjangan bagi anggota Direksi dan Dewan
Komisaris BMHS untuk kinerja Tahun Buku 2025.
Granting authority to the Board of Commissioners to determine salaries and benefits for members of the Board of Directors and
Board of Commissioners of BMHS for the performance of the Financial Year 2025.
Keputusan | Resolution
Memberikan wewenang dan kuasa kepada Dewan Komisaris BMHS untuk menetapkan gaji dan tunjangan bagi anggota Direksi
serta gaji dan tunjangan bagi anggota Dewan Komisaris untuk tahun buku 2025 dengan kenaikan tidak lebih dari 15% dari gaji dan
tunjangan tahun buku 2024.
Granted authority and power to BMHS's Board of Commissioners to determine the salaries and benefits for members of the
Board of Directors and salaries and benefits for members of the Board of Commissioners for the financial year 2025 with an
increase of no more than 15% of the salary and benefits for the financial year 2024.
Hasil Pemungutan Suara Setuju | Agree Tidak Setuju | Disagree Abstain
Voting Results 6.271.584.800 0 149.891.500
Realisasi | Realization Terealisasi | Realized
Page 107
Laporan Tahunan
Annual Report 107
Rapat Umum Pemegang Saham Luar Biasa (RUPSLB)
Extraordinary General Meeting of Shareholders (EGMS)
Tanggal | Date 7 Agustus 2025 | August 7, 2025
Tempat | Venue Ruang Auditorium | Auditorium Room, BMHS-Diagnos Tower
7.487.854.076 saham atau 87,03% dari seluruh saham dengan hak suara yang sah
yang telah dikeluarkan oleh BMHS.
Kehadiran | Attendance
7,487,854,076 shares or 87.03% of all shares with valid voting rights issued by
BMHS.
Pimpinan RUPS | Chair of the GMS Ivan Rizal Sini selaku Komisaris Utama | as President Commissioner
Kehadiran Dewan Komisaris | Board of Commissioners Attendance
Ivan Rizal Sini Komisaris Utama | President Commissioner
Mesha Rizal Sini Komisaris | Commissioner
Retno L.P. Marsudi
Komisaris Independen | Independent Commissioners
Arianti Anaya
Kehadiran Direksi | Board of Directors Attendance
Agus Heru Darjono Direktur Utama | President Director
Emilia Rouli Direktur | Director
Mata Acara dan Hasil Keputusan | Agenda and Results of Resolutions
Agenda Rapat 1 | Meeting Agenda 1
Persetujuan perubahan susunan pengurus BMHS.
Approval of changes to the composition of BMHS’s Management.
Keputusan | Resolution
1. Menyetujui memberhentikan dengan hormat Tuan Sunata Tjiterosampurno dari jabatannya selaku Komisaris BMHS dengan
ucapan terima kasih dan penghargaan setinggi-tingginya atas dedikasi, waktu serta sumbangsih tenaga dan pikirannya selama
menjabat serta memberikan pembebasan dan pelunasan tanggung jawab sepenuhnya (acquit et decharge) atas tindakan
pengawasan yang telah dilakukan, selama tindakan tersebut sesuai dan tidak menyimpang dari Anggaran Dasar BMHS dan
tercermin dalam Laporan Keuangan BMHS.
Approved to honorably dismiss Mr Sunata Tjiterosampurno from his position as Commissioner of BMHS with gratitude
and highest appreciation for his dedication, time and contribution of energy and thought during his tenure and to grant full
release and discharge of responsibility (acquit et decharge) for supervisory actions that have been carried out, as long as such
actions are in accordance with and do not deviate from BMHS’s Articles of Association and are reflected in BMHS’s Financial
Statements.
2. Menyetujui memberhentikan dengan hormat Tuan Wishnutama Kusubandio dari jabatannya selaku Wakil Komisaris Utama
merangkap Komisaris Independen BMHS dengan ucapan terima kasih dan penghargaan setinggi-tingginya atas dedikasi,
waktu serta sumbangsih tenaga dan pikirannya selama menjabat serta memberikan pembebasan dan pelunasan tanggung
jawab sepenuhnya (acquit et decharge) atas tindakan pengawasan yang telah dilakukan, selama tindakan tersebut sesuai dan
tidak menyimpang dari Anggaran Dasar BMHS dan tercermin dalam Laporan Keuangan BMHS.
Approved to honorably dismiss Mr Wishnutama Kusubandio from his position as Vice President Commissioner and
Independent Commissioner of BMHS with gratitude and highest appreciation for his dedication, time and contribution
of energy and thought during his tenure and to grant full release and discharge of responsibility (acquit et decharge) for
supervisory actions that have been carried out, as long as such actions are in accordance with and do not deviate from BMHS’s
Articles of Association and are reflected in BMHS’s Financial Statements.
3. Menyetujui memberhentikan dengan hormat Tuan Ivan Rizal Sini dari jabatannya selaku Komisaris Utama BMHS dengan
ucapan terima kasih dan penghargaan setinggi-tingginya atas dedikasi, waktu serta sumbangsih tenaga dan pikirannya selama
menjabat serta memberikan pembebasan dan pelunasan tanggung jawab sepenuhnya (acquit et decharge) atas tindakan
pengawasan yang telah dilakukan, selama tindakan tersebut sesuai dan tidak menyimpang dari Anggaran Dasar BMHS dan
tercermin dalam Laporan Keuangan BMHS, serta menyetujui untuk mengangkat kembali Tuan Ivan Rizal Sini selaku Komisaris
Utama BMHS untuk masa jabatan terhitung ditutupnya rapat hingga 7 Agustus 2030.
Approved to honorably dismiss Mr Ivan Rizal Sini from his position as President Commissioner of BMHS with gratitude
and highest appreciation for his dedication, time and contribution of energy and thought during his tenure and to grant full
release and discharge of responsibility (acquit et decharge) for supervisory actions that have been carried out, as long as such
actions are in accordance with and do not deviate from BMHS’s Articles of Association and are reflected in BMHS’s Financial
Statements, and to reappoint Mr. Ivan Rizal Sini as President Commissioner of BMHS for a term of office commencing at the
close of this meeting until August 7, 2030.
Page 108
108 Governansi Korporat
Corporate Governance
Mata Acara dan Hasil Keputusan | Agenda and Results of Resolutions
4. Menyetujui mengangkat Tuan Shubhasish Chattoraj selaku Waki Komisaris Utama BMHS untuk masa jabatan terhitung
ditutupnya rapat hingga 7 Agustus 2030.
Approved the appointment of Mr. Shubhasish Chattoraj as Vice President Commissioner of BMHS for a term of tenure
starting from the closing of the meeting until August 7, 2030.
5. Menyetujui perubahan susunan Dewan Komisaris BMHS, sehingga susunan Direksi dan Dewan Komisaris BMHS adalah
sebagai berikut:
Approved the changes to the composition of BMHS’s Board of Commissioners, thus the composition of BMHS’s Board of
Directors and Board of Commissioners are as follows:
Direksi | Board of Directors
Direktur Utama | President Director Agus Heru Darjono
Direktur | Director Cuncun Wijaya
Direktur | Director Emilia Rouli
Dewan Komisaris | Board of Commissioners
Komisaris Utama | President Commissioner Ivan Rizal Sini
Wakil Komisaris Utama
Shubhasish Chattoraj
Vice President Commissioner
Komisaris | Commissioner Mesha Rizal Sini
Retno L.P. Marsudi
Komisaris Independen | Independent Commissioner
Arianti Anaya
6. Memutuskan memberikan kuasa dan kewenangan kepada Direksi BMHS secara bersama-sama maupun sendiri-sendiri,
dengan hak substitusi, untuk menghadap Notaris dan untuk menyatakan kembali seluruh atau sebagian dari keputusan yang
diambil dalam rapat ini, dan untuk membuat, menandatangani dan menyampaikan semua dokumen terkait dan permohonan
untuk memberitahukan dan mendaftarkan perubahan susunan pengurus BMHS tersebut kepada Menteri Hukum dan Hak
Asasi Manusia Republik Indonesia dan Otoritas yang berwenang, serta mengambil segala sesuatu tindakan pada umumnya
yang diperlukan untuk melaksanakan tujuan tersebut di atas.
Resolved to grant power and authority to the Board of Directors of BMHS jointly and severally, with the right of substitution,
to appear before a Notary and to restate all or part of the Resolutions adopted in this Meeting, and to make, sign and submit
all relevant documents and applications to notify and register the changes in the composition of BMHS’s Management to the
Minister of Law of the Republic of Indonesia and the competent Authority, and to take all actions generally necessary to carry
out the aforementioned purposes.
Hasil Pemungutan Suara Setuju | Agree Tidak Setuju | Disagree Abstain
Voting Results 7.487.854.076 0 0
Realisasi | Realization Terealisasi | Realized
Pelaksanaan Rapat Umum Pemegang Saham 2024 General Meeting of Shareholders Held in 2024
Pada 2024, BMHS melaksanakan Rapat Umum In 2024, BMHS held its Annual General Meeting
Pemegang Saham Tahunan (RUPST) pada 30 Mei of Shareholders (AGM) on May 30, 2024 and an
2024 serta Rapat Umum Pemegang Saham Luar Biasa Extraordinary General Meeting of Shareholders
(RUPSLB) pada 20 Desember 2024. Seluruh keputusan (EGM) on December 20, 2024. All decisions made
yang diambil dalam kedua RUPS tersebut telah at both meetings were implemented in 2024. More
direalisasikan pada tahun 2024. Informasi lebih rinci detailed information regarding the GMS minutes can be
mengenai risalah RUPS dapat diakses pada situs web accessed on BMHS’s website.
BMHS.
Page 109
Laporan Tahunan
Annual Report 109
Dewan Komisaris
Board of Commissioners
Dewan Komisaris merupakan organ pengawasan yang The Board of Commissioners is a supervisory body
bertugas mengawasi arah kebijakan dan pengelolaan tasked with overseeing the direction of BMHS’s policies
BMHS, sekaligus memberikan nasihat kepada Direksi and management, as well as providing advice to the
agar pengelolaan BMHS sejalan dengan Anggaran Board of Directors so that BMHS’s management is in
Dasar. Peran ini sejalan dengan POJK No.33/ accordance with the Articles of Association. This role
POJK.04/2014 tentang Direksi dan Dewan Komisaris is in line with POJK No. 33/POJK.04/2014 concerning
Emiten atau Perusahaan Publik. Pelaksanaan fungsi the Board of Directors and Board of Commissioners of
pengawasan tersebut dipertanggungjawabkan kepada Issuers or Public Companies. The implementation of
pemegang saham melalui RUPS. this supervisory function is accountable to shareholders
through the General Meeting of Shareholders.
Pada 31 Desember 2025, komposisi Dewan Komisaris On December 31, 2025, BMHS’s Board of
BMHS berjumlah lima orang, yang mencakup Komisaris Commissioners’ composition consisted of five members,
Utama, Wakil Komisaris Utama, Komisaris Independen including a President Commissioner, Vice President
dan anggota Komisaris. Komisaris Utama bertanggung Commissioner, Independent Commissioners, and
jawab atas pelaksanaan tugas dan kinerja Dewan member Commissioners. The President Commissioner
Komisaris secara keseluruhan. Tanggung jawab ini is responsible for the overall duties and performance
meliputi memimpin dan mengoordinasikan kegiatan of the Board of Commissioners and includes leading
serta rapat Dewan Komisaris, memimpin jalannya and coordinating the Board of Commissioners’
RUPS, menyampaikan laporan pelaksanaan fungsi activities and meetings, chairing the General Meeting of
pengawasan kepada pemegang saham dalam RUPS, Shareholders, delivering reports on the implementation
serta mewakili Dewan Komisaris dalam hubungan of supervisory functions to shareholders at the General
dengan pihak eksternal. Pembagian tugas dan tanggung Meeting of Shareholders, and representing the Board
jawab pengawasan dilakukan berdasarkan kesepakatan of Commissioners in relations with external parties.
Dewan Komisaris dengan mempertimbangkan The division of supervisory duties and responsibilities
kompetensi, pengalaman, dan bidang keahlian masing- is carried out based on an agreement of the Board of
masing anggota. Pembagian tugas tersebut ditetapkan Commissioners, taking into account the competencies,
dalam Surat Keputusan Dewan Komisaris, termasuk experiences, and areas of expertise of each member.
penugasan sebagai Ketua atau anggota komite The division of duties is stipulated in a Board of
pendukung Dewan Komisaris. Commissioners Decree, and includes appointments
as Chair or members of the Board of Commissioners’
supporting committees.
Tugas dan Tanggung Jawab Dewan Komisaris Board of Commissioners’ Duties and Responsibilities
Dalam menjalankan fungsinya, Dewan Komisaris When carrying out its functions, the Board of
berpedoman pada pedoman kerja yang memuat tugas Commissioners adheres to work guidelines that contain
dan tanggung jawab Dewan Komisaris, antara lain: the Board of Commissioners’ duties and responsibilities,
including:
1. Menelaah dan mengawasi kebijakan pengurusan 1. Reviewing and supervising management policies and
serta pelaksanaannya secara menyeluruh, termasuk their implementation in a comprehensive manner,
kegiatan usaha BMHS, serta memberikan nasihat including BMHS’s business activities, and providing
kepada Direksi; advice to the Board of Directors;
2. Memberikan masukan dan persetujuan atas rencana 2. Providing input and approval on BMHS’s annual work
kerja tahunan BMHS sebelum dimulainya tahun buku, plan before the start of the financial year, as well as
serta memantau pelaksanaan dan pencapaiannya; monitoring its implementation and achievement;
3. Menelaah laporan tahunan yang disusun oleh Direksi 3. Reviewing the annual report prepared by the Board
dan menandatangani laporan tahunan tersebut; of Directors and signing the annual report;
Page 110
110 Governansi Korporat
Corporate Governance
4. Mematuhi Anggaran Dasar dan peraturan 4. Complying with the Articles of Association and
perundang-undangan yang berlaku, serta applicable laws and regulations, as well as applying
menerapkan prinsip profesionalisme, efisiensi, the principles of professionalism, efficiency,
transparansi, kemandirian, akuntabilitas, transparency, independence, accountability,
pertanggungjawaban, dan kewajaran dalam responsibility, and fairness in the performance of
pelaksanaan tugas; duties;
5. Menjalankan fungsi nominasi dan remunerasi sesuai 5. Performing nomination and remuneration functions
dengan ketentuan serta peraturan perundang- in accordance with the provisions in the applicable
undangan yang berlaku; laws and regulations;
6. Memantau kecukupan dan efektivitas penerapan 6. Monitoring the adequacy and effectiveness of
manajemen risiko serta sistem pengendalian internal BMHS’s risk management and internal control
BMHS. systems.
Pedoman dan Tata Tertib Kerja Dewan Komisaris Work Guidelines and Code of Conduct for the Board of
Commissioners
Dewan Komisaris memiliki pedoman kerja dan tata The Board of Commissioners has work guidelines and
tertib yang ditinjau secara berkala guna memastikan rules of procedure that are reviewed periodically to
kesesuaiannya dengan perkembangan regulasi dan ensure their compliance with regulatory developments
dinamika bisnis BMHS. Pedoman kerja tersebut antara and BMHS’s business dynamics. These work guidelines
lain mengatur ruang lingkup tugas dan tanggung regulate, among other things, the scope of duties and
jawab, tata tertib, tata cara rapat, proses pengambilan responsibilities, rules of procedure, meeting procedures,
keputusan, serta hubungan kerja antara Dewan decision-making processes, and the working
Komisaris dan Direksi. Pedoman kerja terakhir dengan relationship between the Board of Commissioners and
Nomor 002-K/DEKOM-BMHS/VIII/ 2021, berlaku the Board of Directors. The latest work guidelines, No.
efektif sejak 2 Agustus 2021. 002-K/DEKOM-BMHS/VIII/2021, became effective on
August 2, 2021.
Komisaris Independen Independent Commissioners
Komisaris Independen berperan memperkuat Independent Commissioners play a role in strengthening
objektivitas pelaksanaan fungsi pengawasan serta the objectivity of supervisory functions and supporting
mendukung penerapan Governansi Korporat. Peran the Corporate Governance implementation. This role
tersebut dijalankan melalui pengawasan yang is carried out through independent supervision to
independen guna melindungi kepentingan seluruh protect the interests of all shareholders and to maintain
pemegang saham dan menjaga keseimbangan a balance between the interests of BMHS and its
antara kepentingan BMHS dengan para pemangku stakeholders.
kepentingan.
Sesuai dengan ketentuan POJK No.33/POJK.04/2014 In accordance with POJK No. 33/POJK.04/2014 and
dan Peraturan Bursa Efek Indonesia (BEI) No. I-A, jumlah Indonesia Stock Exchange (IDX) Regulation No. I-A,
Komisaris Independen paling sedikit harus sebesar 30% the number of Independent Commissioners must be
dari total anggota Dewan Komisaris. Selama periode at least 30% of the total number of members in the
pelaporan, BMHS telah memenuhi ketentuan tersebut. Board of Commissioners, and during the reporting
Komisaris Independen BMHS merupakan anggota period, BMHS complied with this provision. BMHS’s
Dewan Komisaris yang berasal dari luar BMHS dan Independent Commissioners are members of the Board
memenuhi kriteria independensi sehingga mampu of Commissioners coming from outside BMHS, and
menjalankan fungsi pengawasan secara objektif dan meet the criteria of independence so they are able to
bebas dari benturan kepentingan. carry out their supervisory functions objectively and
free from conflicts of interest.
Page 111
Laporan Tahunan
Annual Report 111
Adapun kriteria Komisaris Independen adalah sebagai The criteria for Independent Commissioners are as
berikut: follows:
1. Tidak bekerja atau memiliki kewenangan serta 1. Has not worked for, or had the authority and
tanggung jawab untuk merencanakan, memimpin, responsibility to plan, lead, control, or supervise the
mengendalikan, atau mengawasi kegiatan emiten activities of issuers or public companies within the
atau perusahaan publik dalam enam bulan terakhir, last six months, except in the case of reappointment
kecuali dalam hal pengangkatan kembali sebagai as an Independent Commissioner for the next period;
Komisaris Independen untuk periode berikutnya;
2. Tidak memiliki saham, baik secara langsung maupun 2. Does not own shares, either directly or indirectly, in
tidak langsung, pada emiten atau perusahaan publik; the issuer or public company;
3. Tidak memiliki hubungan afiliasi dengan emiten 3. Has no affiliation with the issuer or public company,
atau perusahaan Publik, anggota Dewan Komisaris, members of the Board of Commissioners, members
anggota Direksi, maupun pemegang saham utama; of the Board of Directors, or majority shareholders;
4. Tidak memiliki hubungan usaha, baik secara langsung 4. Has no business relationship, either directly or
maupun tidak langsung, yang berkaitan dengan indirectly, related to the business activities of the
kegiatan usaha emiten atau perusahaan publik. issuer or public company.
Pernyataan Independensi Komisaris Independen Statement of Independence of Independent
Commissioners
Seluruh Komisaris Independen menyatakan All Independent Commissioners have declared their
komitmennya untuk melaksanakan tugas dan commitment to carry out their duties and responsibilities
tanggung jawab secara profesional, objektif, dan professionally, objectively, and with integrity. This
berintegritas. Komitmen tersebut ditegaskan melalui commitment has been confirmed through the signing
penandatanganan surat pernyataan independensi, of a statement of independence, which states that
yang menyatakan bahwa Komisaris Independen akan Independent Commissioners will act independently in
bertindak independen dalam menjalankan fungsi performing their supervisory functions within BMHS
pengawasan BMHS serta mempertanggungjawabkan and will be accountable to the General Meeting of
pelaksanaannya kepada RUPS sepanjang masa Shareholders for the implementation of these functions
jabatannya. throughout their term of office.
Pelaksanaan Tugas Dewan Komisaris Board of Commissioners’ Implementation of Duties
Dewan Komisaris melaksanakan fungsi pengawasan The Board of Commissioners performs its supervisory
serta pemberian rekomendasi kepada Direksi melalui function and provides recommendations to the Board of
pembahasan yang dilakukan secara berkala, baik Directors through regular discussions, both in internal
dalam rapat internal Dewan Komisaris (Presidium Board of Commissioners meetings (Presidium BoC) and
BoC) maupun rapat bersama Direksi (Presidium BoC- joint meetings with the Board of Directors (Presidium
BoD). Dewan Komisaris dapat mengundang Direktur BoC-BoD). The Board of Commissioners may invite
terkait untuk memperoleh penjelasan, menyampaikan relevant Directors to obtain explanations, provide
arahan dan rekomendasi perbaikan, yang selanjutnya guidance and recommendations for improvement,
dipantau tindak lanjut pelaksanaannya. Selain itu, and subsequently monitor the implementation of
Dewan Komisaris menelaah laporan berkala yang such recommendations. In addition, the Board of
disampaikan oleh Direksi serta memantau realisasi Commissioners will review periodic reports submitted
dan perkembangan pelaksanaan Rencana Kerja dan by the Board of Directors and monitor the realization
Anggaran BMHS (RKAP). and progress of BMHS’s Work Plan and Budget (RKAP).
Page 112
112 Governansi Korporat
Corporate Governance
Rapat Dewan Komisaris Board of Commissioners’ Meetings
Dengan mengacu pada regulasi yang berlaku dan With reference to applicable regulations and
kebijakan rapat dalam pedoman kerja, Dewan meeting policies in the work guidelines, the Board of
Komisaris menyelenggarakan rapat internal Dewan Commissioners holds internal Board of Commissioners
Komisaris (Presidium BoC) secara berkala paling sedikit meetings (Presidium BoC) at least once every two
satu kali dalam dua bulan, serta rapat bersama Direksi months, as well as joint meetings with the Board of
(Presidium BoC–BoD) paling sedikit satu kali dalam Directors (Presidium BoC–BoD) at least once every
empat bulan. Sepanjang 2025, Dewan Komisaris telah four months. In 2025, the Board of Commissioners held
menyelenggarakan 6 kali rapat Presidium BoC–BoD dan 6 BoC–BoD Presidium meetings and 6 BoC Presidium
6 kali rapat Presidium BoC, yang dilaksanakan secara meetings, which were conducted online and offline,
daring maupun luring, dengan tingkat kehadiran sebagai with the following attendance rates:
berikut:
Presidium BoC-BoD Presidium BoC
Jumlah Jumlah Jumlah
Nama | Name Jabatan | Position Jumlah
Rapat Rapat Kehadiran
Kehadiran
Number of Number of Total
Total Attended
Meetings Meetings Attended
Komisaris Utama
Ivan Rizal Sini 6 6 6 6
President Commissioner
Wakil Komisaris Utama
Wishnutama Komisaris Independen
6 2 6 1
Kusubandio*1 Vice President Commissioner
Independent Commissioner
Wakil Komisaris Utama
Shubhasish Chattoraj*2 6 4 6 2
Vice President Commissioner
Mesha Rizal Sini 6 6 6 2
Komisaris
Sunata Commissioners 6 2 6 1
Tjiterosampurno*1
Retno L.P. Marsudi Komisaris Independen 6 6 6 2
Arianti Anaya Independent Commissioners 6 6 6 3
*Keterangan | Notes:
1. Efektif menjabat sampai dengan RUPSLB 7 Agustus 2025 | Effectively served until the EGMS on August 7, 2025
2. Efektif menjabat setelah diangkat dalam RUPSLB 7 Agustus 2025 | Effectively served after being appointed at the EGMS on August 7, 2025
Perbedaan jumlah rapat yang dihadiri oleh masing- The difference in the number of meetings attended by
masing anggota Dewan Komisaris disebabkan oleh each member of the Board of Commissioners is due to
perbedaan masa jabatan selama periode pelaporan. differences in their terms of office during the reporting
Selain menghadiri rapat-rapat tersebut, Dewan period. In addition to attending these meetings, the
Komisaris juga menghadiri RUPS, baik RUPST maupun Board of Commissioners also attended the GMS,
RUPSLB, dengan kehadiran disampaikan pada subbab including the AGMS and EGMS, with attendance
RUPS dalam laporan tahunan ini. Selain melalui reported in the GMS sub-section of this annual report.
mekanisme rapat, Dewan Komisaris juga menyampaikan In addition to meetings, the Board of Commissioners
tanggapan serta memberikan persetujuan dan also submitted responses and provided written
rekomendasi atas usulan Direksi secara tertulis, yang approvals and recommendations to the Board of
disampaikan dalam bentuk surat keputusan dan surat Directors’ proposals in the form of decision letters and
persetujuan. Sepanjang tahun 2025, Dewan Komisaris approval letters. In 2025, the Board of Commissioners
telah menerbitkan sebanyak 8 Surat Keputusan (SK), di issued 8 Decision Letters (SK), including:
antaranya:
Page 113
Laporan Tahunan
Annual Report 113
Nomor Surat Tanggal Perihal
No.
Decree Number Date Subject
Surat Keputusan Dewan Komisaris Tentang
001-K/SK/KOMUT/ 22 Januari 2025 Pemberhentian dan Pengangkatan Ketua Komite Audit
1
BMHS/I/2025 January 22, 2025 Board of Commissioners' Decree on the Dismissal and
Appointment of the Chair of the Audit Committee
Surat Keputusan Dewan Komisaris tentang Persetujuan
Rencana Kerja Anggaran Perusahaan PT Bundamedik Tbk
008-I/SK/KOMUT/BMHS/ 17 Desember 2025
2 Tahun 2025
II/2025 December 17, 2025
Board of Commissioners' Decree on the Approval of the
2025 Work Plan and Budget of PT Bundamedik Tbk
Surat Keputusan Dewan Komisaris Tentang
Pemberhentian dan Pengangkatan Anggota Komite
019-I/SK/KOMUT/BMHS/ 24 Maret 2025 Nominasi dan Remunerasi
3
III/2025 March 24, 2025 Board of Commissioners' Decree on the Dismissal
and Appointment of Members of the Nomination and
Remuneration Committee
Surat Keputusan Pengesahan Piagam Komite Nominasi
020-I/SK/KOMUT/BMHS/ 24 Maret 2025 dan Remunerasi
4
III/2025 March 24, 2025 Decree on the Ratification of the Nomination and
Remuneration Committee Charter
Keputusan Sirkuler Dewan Komisaris terkait Perubahan
Susunan Anggota Komite Audit, Komite GCG &
086-I/SK/KOMUT/BMHS/ 30 Desember 2025 Manajemen resiko
5
XII/2025 December 30, 2025 Board of Commissioners’ Circular Decree on Changes
to the Composition of the Audit Committee, GCG
Committee & Risk Management Committee
Surat Keputusan Pemberhentian dan Pengangkatan
087-I/SK/KOMUT/BMHS/ Komite Audit PT Bundamedik Tbk
6
XII/2025 Decree on the Dismissal and Appointment of the PT
Bundamedik Tbk Audit Committee
Surat Pemberhentian & Pengangkatan Komite GCG &
088-I/SK/KOMUT/BMHS/ 31 Desember 2025 Manajemen Risiko BMHS
7
XII/2025 December 31, 2025 Letter of Dismissal & Appointment of the BMHS GCG &
Risk Management Committee
SK Pemberhentian & Pengangkatan Komite Nominasi &
089-I/SK/KOMUT/BMHS/ Remunerasi
8
XII/2025 Decree on the Dismissal & Appointment of the
Nomination & Remuneration Committee
Peningkatan Kompetensi Competency Development
BMHS menempatkan program peningkatan BMHS considers the Board of Commissioners’
kompetensi Dewan Komisaris sebagai bagian penting competency improvement program to be an
dalam mendukung efektivitas fungsi pengawasan, important part of supporting the effectiveness of its
sesuai Pedoman Tata Kelola. Melalui keikutsertaan supervisory function, in accordance with the Corporate
dalam berbagai seminar, konferensi, dan workshop, Governance Guidelines. By participating in various
Dewan Komisaris memperbarui pengetahuan dan seminars, conferences, and workshops, the Board of
wawasannya, termasuk mengenai perkembangan Commissioners updates its knowledge and insights,
industri pelayanan kesehatan, dinamika regulasi terkini, including developments in the healthcare industry, the
serta topik strategis lainnya yang relevan dengan latest regulatory dynamics, and other strategic topics
kegiatan usaha BMHS. Dewan Komisaris juga aktif relevant to BMHS’s business activities. The Board of
menjadi pembicara dalam berbagai seminar, diskusi Commissioners also actively participates as speakers in
profesional, dan forum industri, berbagi wawasan various seminars, professional discussions, and industry
mengenai teknologi dan inovasi layanan kesehatan, forums, sharing insights on healthcare technology and
tata kelola, manajemen risiko, serta perkembangan innovation, governance, risk management, and industry
industri yang turut memperkuat posisi BMHS dalam developments that strengthen BMHS’s position in
Page 114
114 Governansi Korporat
Corporate Governance
ekosistem layanan kesehatan. Sepanjang 2025, Dewan the healthcare ecosystem. In 2025, the Board of
Komisaris telah mengikuti sejumlah program pelatihan Commissioners participated in a number of training and
dan pengembangan, antara lain: development programs, including:
Tanggal Pelatihan Nama Pelatihan Penyelenggara
No.
Training Date Training Name Organizer
10 Februari 2025 Leaders lnteraction Forum & Empowerment (LIFE)
1 HC Corporate PT Bundamedik Tbk
February 10, 2025 2025
Tim RSPPU RSIA Bunda Jakarta
6 Juli 2025 Workshop Kurikulum RSPPU
2 RSPPU Team at Bunda Jakarta
July 6, 2025 RSPPU Curriculum Workshop
Women and Children Hospital
Fakultas Kedokteran IPB: Pelatihan Hands On sistem
23 Juli 2025 dukungan pembelajaran: LMS, exam, dan IPB Lecture Fakultas Kedokteran IPB
3
July 23, 2025 IPB Faculty of Medicine: Hands-On Training on Learning IPB Faculty of Medicine
Support Systems: LMS, Exams, and IPB Lecture
Undangan pelatihan kebijakan dan pelaksanaan standar
10 September 2025 penjamin mutu internal (SPMI) Fakultas Kedokteran IPB
4
September 10, 2025 Invitation to Training on Policies and Implementation of IPB Faculty of Medicine
Internal Quality Assurance Standards (SPMI)
BMHS melaksanakan program orientasi bagi anggota BMHS conducts orientation programs for newly
Dewan Komisaris yang baru bergabung, yang difasilitasi appointed members to the Board of Commissioners,
oleh Sekretaris Perusahaan. Program ini bertujuan facilitated by the Corporate Secretary. These programs
memberikan pemahaman mengenai lingkup bisnis aim to provide an understanding of BMHS’s business
BMHS, tugas, kewenangan, dan tanggung jawab masing- scope, the duties, authorities, and responsibilities of
masing organ BMHS, serta penerapan prinsip-prinsip each organ of BMHS, as well as the application of GCG
GCG. BMHS telah melaksanakan orientasi bagi Bapak principles. BMHS conducted an orientation for Mr.
Shubhasish Chattoraj pada tanggal 27 Agustus 2025. Shubhasish Chattoraj on August 27, 2025.
Penilaian atas Kinerja Dewan Komisaris Board of Commissioners’ Performance Assessment
BMHS melakukan penilaian kinerja Dewan Komisaris BMHS conducts annual self-assessments of the Board
setiap tahun secara self-assessment, dengan mengacu of Commissioners’ performance that references
pada key performance indicator (KPI) yang telah predetermined key performance indicators (KPIs),
ditetapkan, serta mempertimbangkan faktor-faktor and consider relevant external and internal factors.
eksternal dan internal yang relevan. KPI mencakup KPIs include the duties and functions of the Board of
pelaksanaan tugas dan fungsi Dewan Komisaris, Commissioners, attendance at internal meetings, joint
kehadiran dalam rapat internal, rapat bersama meetings with the Board of Directors, GMS, and other
Direksi, RUPS, dan rapat eksternal lainnya, efektivitas external meetings, the effectiveness of management
pengawasan terhadap manajemen, rekomendasi yang supervision, recommendations given to the Board
diberikan kepada Direksi, serta kepatuhan terhadap of Directors, and compliance with good corporate
praktik governansi korporat yang baik (GCG). governance (GCG) practices.
Page 115
Laporan Tahunan
Annual Report 115
Penilaian atas Kinerja Komite di Bawah Dewan Performance Assessment of Committees under the
Komisaris Board of Commissioners
Dewan Komisaris melakukan penilaian kinerja komite- Every year, the Board of Commissioners assesses the
komite di bawahnya setiap tahun, dengan mengacu performance of its committees, with reference to each
pada KPI masing-masing komite. Penilaian dilakukan committee’s KPIs. These assessments are based on the
berdasarkan pencapaian rencana kerja (on track), achievement of work plans (on track), the quality of
kualitas rekomendasi, serta efektivitas komunikasi recommendations, and the effectiveness of intensive
yang intens dan konstruktif. Dewan Komisaris menilai and constructive communication. The Board of
bahwa seluruh komite telah melaksanakan tugas dan Commissioners assessed that all committees performed
tanggung jawabnya dengan baik, memberikan laporan their duties and responsibilities well, provided reliable
yang andal dan tepat waktu, serta mendukung fungsi and timely reports, and optimally supported the
pengawasan Dewan Komisaris secara optimal. supervisory function of the Board of Commissioners.
Penilaian atas Kinerja Direksi Board of Directors’ Performance Assessment
Dewan Komisaris melakukan penilaian kinerja Direksi The Board of Commissioners assesses the performance
setiap tahun dengan mengacu pada KPI yang telah of the Board of Directors annually by referring to the
ditetapkan, serta mempertimbangkan faktor-faktor established KPIs, while considering relevant external
eksternal dan internal yang relevan, termasuk kondisi and internal factors, including macroeconomic
makroekonomi, dinamika sektor kesehatan, dan kinerja conditions, dynamics in the healthcare sector, and
internal BMHS. Evaluasi mencakup pencapaian target BMHS’s internal performance. These evaluations cover
KPI, efektivitas pelaksanaan strategi bisnis, serta the achievement of KPI targets, the effectiveness
kinerja BMHS secara menyeluruh, termasuk pelayanan of business strategy implementation, and BMHS’s
kesehatan, keuangan, teknologi informasi, sumber daya overall performance, including health services, finance,
manusia, dan unit-unit usaha. Dewan Komisaris menilai information technology, HC, and business units. The
bahwa Direksi telah berhasil mencapai target KPI tahun Board of Commissioners assessed that the Board
2025 secara memuaskan, mencerminkan komitmen of Directors had succeeded in realizing the 2025
tinggi dalam mengelola BMHS dengan prinsip kehati- KPI targets satisfactorily, reflecting a high level of
hatian dan praktik GCG. commitment to managing BMHS with prudence and
GCG practices.
Direksi
Board of Directors
Direksi merupakan organ pengelola BMHS yang The Board of Directors is BMHS’s management body
bertindak mewakili kepentingan BMHS, baik di dalam that acts on behalf of BMHS’s interests, both inside
maupun di luar pengadilan, untuk mencapai tujuan and outside of court, to achieve BMHS’s objectives
BMHS sesuai dengan ketentuan anggaran dasar. Dalam in accordance with the provisions of the articles of
menjalankan fungsinya, Direksi menerapkan prinsip- association. When carrying out its functions, the Board
prinsip governansi korporat dengan memperhatikan of Directors applies corporate governance principles by
keselarasan antara aspek ekonomi, lingkungan, sosial, considering the alignment of economic, environmental,
dan tata kelola guna menciptakan nilai BMHS yang social, and governance aspects to create a sustainable
berkelanjutan. Direksi mempertanggungjawabkan Company value. The Board of Directors is accountable
pelaksanaan fungsinya kepada pemegang saham to the shareholders for the performance of its functions
melalui RUPS. through the General Meeting of Shareholders.
Page 116
116 Governansi Korporat
Corporate Governance
Pada 31 Desember 2025, komposisi Direksi BMHS On December 31, 2025, BMHS’s Board of Directors’
berjumlah tiga orang, yang mencakup Direktur Utama, composition consisted of three people, including the
serta dua Direktur yang membawahi Fungsi Keuangan President Director and two Directors who supervised
dan Sumber Daya Manusia (SDM). Direksi bertanggung the Finance and Human Capital (HC) functions. The
jawab menetapkan kebijakan, strategi, dan target Board of Directors is responsible for determining
kinerja BMHS, serta memastikan implementasinya BMHS’s policies, strategies, and performance targets,
melalui tindakan manajerial yang diperlukan. Dalam as well as ensuring their realization through necessary
pelaksanaan tugasnya, Direksi didukung oleh fungsi- managerial actions. When carrying out its duties, the
fungsi di bawahnya yang terbagi ke dalam dua kelompok Board of Directors is supported by functions reporting
utama, yaitu Fungsi Korporat dan Kelompok Unit to them, which are divided into two main groups,
Bisnis. Fungsi Korporat mencakup Fungsi Keuangan, namely Corporate Functions and Business Unit Groups.
SDM, Digital dan Teknologi, serta Komersial dan The Corporate Functions include Finance, HC, Digital
Pengembangan Bisnis. Sementara Kelompok Unit and Technology, as well as Commercial and Business
Bisnis mencakup seluruh lini usaha yang dimiliki Development. While, the Business Unit Groups cover
BMHS. Struktur ini memungkinkan Direksi menjaga all lines of business owned by BMHS. This structure
efektivitas operasional, kejelasan tanggung jawab, dan enables the Board of Directors to maintain operational
kesinambungan kinerja di seluruh Grup. effectiveness, clarity of responsibilities, and continuity
of performance across the Group.
Tugas dan Tanggung Jawab Direksi Board of Directors’ Duties and Responsibilities
Secara umum, tugas dan tanggung jawab Direksi Overall, the Board of Directors’ duties and
meliputi: responsibilities include:
1. Memimpin dan mengelola BMHS sesuai maksud 1. Leading and managing BMHS in line with its founding
dan tujuan pendiriannya, serta terus mendorong objectives and purposes, as well as continuously
peningkatan efisiensi dan efektivitas kinerja; encouraging improvements in efficiency and
effectiveness of performance;
2. Menguasai, memelihara, dan mengelola seluruh aset 2. Controlling, maintaining, and managing all Company
BMHS untuk kepentingan dan keberlanjutan usaha; assets for the benefit and sustainability of the
business;
3. Menyusun dan menyampaikan rencana kerja dan 3. Preparing and submitting BMHS’s annual work
anggaran tahunan BMHS kepada Dewan Komisaris plan and budget to the Board of Commissioners for
untuk memperoleh persetujuan sebelum dimulainya approval before the start of the next financial year.
tahun buku berikutnya dimulai.
Tugas dan Tanggung Jawab Masing-Masing Anggota Duties and Responsibilities of Each Member of the
Direksi Board of Directors
Piagam Direksi menjadi acuan utama yang mengatur Board of Directors Charter serves as the main reference
secara rinci tugas dan tanggung jawab setiap anggota that regulates in detail the duties and responsibilities of
Direksi. Pembagian tugas tersebut ditetapkan oleh each member of the Board of Directors. The division
RUPS, Dewan Komisaris, atau melalui keputusan of duties is determined by a General Meeting of
Direksi sesuai ketentuan yang berlaku. Setiap anggota Shareholders, the Board of Commissioners, or through
Direksi melaksanakan tugas sesuai kewenangannya, a Board of Directors’ directive in line with applicable
namun pelaksanaan pengurusan BMHS tetap menjadi regulations. Each member of the Board of Directors
tanggung jawab kolektif seluruh Direksi. Adapun tugas performs their duties in accordance with their authority,
dan tanggung jawab Direksi tersebut antara lain: but the management of BMHS remains the collective
responsibility of the entire Board of Directors. The
Board of Directors’ duties and responsibilities include:
Page 117
Laporan Tahunan
Annual Report 117
Direktur Utama President Director
1. Mengendalikan dan mengawasi seluruh operasional 1. Control and supervise all business operations,
bisnis, karyawan, dan kegiatan usaha BMHS, employees, and business activities of BMHS,
termasuk kinerja keuangan, investasi, unit-unit including financial performance, investments,
bisnis, serta kinerja direksi fungsional. business units, and the performance of functional
directors.
2. Mengembangkan dan melaksanakan strategi 2. Develop and instigate business strategies, as
bisnis, serta mengimplementasikan rencana usaha well as comprehensive business plans to support
yang komprehensif untuk mendukung efisiensi operational efficiency and market development.
operasional dan pengembangan pasar.
3. Mendelegasikan tanggung jawab kepada tim 3. Delegate responsibilities to the executive team and
eksekutif dan melakukan pengawasan atas supervising their application, as well as provide
pelaksanaannya, serta memberikan bimbingan dan guidance and motivation to encourage optimal
motivasi untuk mendorong pencapaian kinerja performance.
optimal.
4. Memastikan penerapan budaya kerja BMHS serta 4. Ensure the implementation of BMHS’s work culture
memastikan bahwa seluruh kebijakan dan ketentuan and ensure all applicable policies and all employees
hukum yang berlaku dipatuhi oleh seluruh karyawan. comply with legal provisions.
5. Menjaga kepercayaan dan membangun komunikasi 5. Maintain trust and build good communication
yang baik dengan pemegang saham, mitra bisnis, dan with shareholders, business partners, and other
pemangku kepentingan lainnya. stakeholders.
6. Mengevaluasi laporan yang disampaikan oleh Direksi 6. Evaluate reports submitted by the Board of
dan Sekretaris Perusahaan, menganalisis isu atau Directors and the Corporate Secretary, analyze
kejadian yang berpotensi menimbulkan masalah, issues or events that have the potential to cause
serta memberikan solusi yang diperlukan untuk problems, and provide the necessary solutions to
memastikan keberlanjutan dan pertumbuhan BMHS. ensure BMHS’s sustainability and growth .
Direktur Keuangan Finance Director
1. Berkontribusi dalam pengembangan strategi BMHS, 1. Contribute to the development of BMHS’s strategy,
pengambilan keputusan, serta menyediakan analisis decision-making, and provide financial analysis for
keuangan untuk seluruh kegiatan, rencana, target, all activities, plans, targets, and business directives.
dan arah bisnis.
2. Mengendalikan secara menyeluruh fungsi akuntansi 2. Control BMHS’s overall accounting functions
BMHS serta menyajikan laporan keuangan and present financial reports to the Board of
kepada Dewan Komisaris, Direksi, dan pemangku Commissioners, Board of Directors, and stakeholders
kepentingan secara tepat waktu dan akurat. in a timely and accurate manner.
3. Mengoordinasikan dan mengawasi perencanaan, 3. Coordinate and supervise BMHS’s tax planning,
pelaporan, serta pemenuhan kewajiban perpajakan reporting, and compliance efficiently and accurately,
BMHS secara efisien, akurat, dan memastikan ensuring compliance with regulations in accordance
kepatuhannya terhadap regulasi. sesuai dengan with the provisions of laws and regulations.
ketentuan peraturan perundang-undangan.
4. Bertanggung jawab atas kebijakan pengelolaan kas 4. Responsible for BMHS’s cash management policies,
BMHS, termasuk perencanaan dan pengendalian including cash flow planning and control to maintain
arus kas untuk menjaga posisi kas yang sehat. a healthy cash position.
5. Mengelola kebijakan BMHS terkait struktur modal, 5. Manage BMHS’s policies related to capital structure,
utang, perpajakan, ekuitas, serta tindakan korporasi debt, taxation, equity, and corporate actions such as
seperti pelepasan atau akuisisi aset secara tepat dan divestment or acquisition of assets in a manner that
selaras dengan strategi BMHS. is appropriate and in line with BMHS’s strategy.
Page 118
118 Governansi Korporat
Corporate Governance
Direktur Sumber Daya Manusia Human Capital Director
1. Mengembangkan rencana korporasi terkait 1. Develop corporate plans related to HC management,
pengelolaan SDM, termasuk kebijakan kompensasi, including compensation policies, benefits,
tunjangan, kesehatan dan keselamatan kerja, serta occupational health and safety, and other aspects
aspek lain yang mendukung kesejahteraan karyawan. that support employee welfare.
2. Menyusun strategi evaluasi kinerja, 2. Develop performance evaluation, employment,
ketenagakerjaan, pelatihan, dan pengembangan training, and competency development strategies to
kompetensi untuk mendukung efektivitas support effective HC management across all work
pengelolaan SDM di seluruh unit kerja. units.
3. Memastikan kepatuhan terhadap peraturan 3. Ensure compliance with laws and regulations by
perundang-undangan dengan memantau monitoring the latest regulatory developments
perkembangan regulasi terbaru dan memberikan and providing input to management regarding the
masukan kepada manajemen terkait implikasi implications of specific policies.
kebijakan tertentu.
4. Memfasilitasi dan memantau administrasi program 4. Facilitate and monitor the administration of HC
SDM, termasuk pengelolaan kompensasi, tunjangan, programs, including compensation management,
cuti, tindakan disipliner, penyelesaian perselisihan benefits, leave, disciplinary actions, dispute
dan investigasi, manajemen kinerja dan talenta, resolutions and investigations, performance
produktivitas, program pengakuan dan moral and talent management, productivity, employee
karyawan, serta kesehatan dan keselamatan kerja. recognition and morale programs, and occupational
health and safety.
5. Menetapkan program, strategi, dan proses yang 5. Establish programs, strategies, and processes related
berkaitan dengan paket kompensasi dan tunjangan, to compensation and benefits packages, recruitment,
rekrutmen, manajemen kinerja, keterlibatan performance management, employee engagement,
karyawan, manajemen talenta/pengembangan talent management/organizational development,
organisasi, serta hubungan ketenagakerjaan guna and labor relations to support the achievement of
mendukung pencapaian tujuan organisasi. organizational goals.
6. Menjadi penghubung komunikasi dalam hubungan 6. Act as a liaison for labor relations and building
ketenagakerjaan serta membangun komunikasi yang effective communication with labor unions.
efektif dengan serikat pekerja.
Pedoman Kerja Direksi Board of Directors’ Work Guidelines
Direksi memiliki pedoman kerja atau Piagam Direksi The Board of Directors has a code of conduct or Board
sebagai acuan dalam melaksanakan tugas dan Charter as a reference for carrying out its duties and
tanggung jawabnya. Piagam tersebut mengatur hak, responsibilities. The charter regulates the rights,
wewenang, tugas, tanggung jawab, serta tata tertib authorities, duties, responsibilities, and rules of conduct
yang wajib dipatuhi oleh setiap anggota Direksi. that must be obeyed by each member of the Board of
Seluruh ketentuan dalam Piagam Direksi tercakup Directors. All provisions in the Board of Directors’
dalam Pedoman Tata Kelola. Piagam Direksi ditinjau Charter are included in the Corporate Governance
secara berkala untuk memastikan kesesuaiannya Guidelines. The Board of Directors’ Charter is reviewed
dengan perkembangan regulasi dan kebutuhan periodically to ensure its compliance with regulatory
bisnis BMHS, dengan pembaruan terakhir developments and BMHS’s business needs, with the
ditetapkan melalui Keputusan Direktur Utama latest update stipulated in the President Director’s
No. 044-I/SK/PD/BMHS/XII/2023 tanggal 6 Desember Decree No. 044-I/SK/PD/BMHS/XII/2023 dated
2023 tentang Piagam Direksi. December 6, 2023, concerning the Board of Directors’
Charter.
Page 119
Laporan Tahunan
Annual Report 119
Rapat Direksi Board of Directors’ Meetings
Mengacu pada POJK No.33/POJK.04/2014 yang telah Referring to POJK No.33/POJK.04/2014, which has
diadopsi ke dalam kebijakan rapat Direksi pada pedoman been adopted into the Board of Directors’ meeting
kerja, Direksi mengadakan rapat paling sedikit satu kali policy in the work guidelines, the Board of Directors
setiap bulan dan rapat gabungan bersama Hospital holds meetings at least once every month and joint
Director paling sedikit satu kali dalam empat bulan. meetings with the Hospital Director at least once every
Sepanjang 2025, Direksi telah menyelenggarakan 17 four months. In 2025, the Board of Directors held
kali rapat internal dan 11 kali rapat gabungan dengan 17 internal meetings and 11 joint meetings with the
Hospital Director, dengan tingkat kehadiran sebagai Hospital Director, with the following attendance rates:
berikut:
Tingkat Kehadiran Direksi pada Rapat Direksi
Directors’ Attendance Level at Board of Directors’ Meetings
Rapat Gabungan BOD dengan
Rapat Internal
Hospital Director
Internal Meetings
Nama Jabatan Joint Meetings BOD and Hospital Director
Name Position Jumlah Rapat Jumlah
Jumlah Rapat Jumlah Kehadiran
Number of Kehadiran
Number of Meetings Total Attended
Meetings Total Attended
Direktur Utama
Agus Heru Darjono 17 17 11 11
President Director
Cuncun Wijaya Direktur 17 17 11 11
Emilia Rouli Directors 17 17 11 11
Selain menghadiri rapat-rapat tersebut, Direksi juga In addition to attending these meetings, the Board of
menghadiri RUPS, baik RUPST maupun RUPSLB, Directors also attended the GMS, including the AGMS
dengan kehadiran disampaikan pada subbab RUPS and the EGMS, with attendance reported in the GMS
dalam laporan tahunan ini. sub-chapter in this annual report.
Peningkatan Kompetensi Competency Development
BMHS menempatkan program peningkatan BMHS considers the Board of Directors’ competency
kompetensi Direksi sebagai bagian penting dalam improvement program to be an important part of
mendukung efektivitas fungsi pengelolaan, sesuai supporting the effectiveness of their management
Pedoman Tata Kelola. Melalui keikutsertaan dalam functions, in line with the Corporate Governance
berbagai seminar, konferensi, dan workshop, Direksi Guidelines. Through participation in seminars,
memperbarui pengetahuan dan wawasannya, termasuk conferences, and workshops, the Board of Directors
mengenai perkembangan industri pelayanan kesehatan, updates its knowledge and insights, including
dinamika regulasi terkini, serta topik strategis lainnya developments in the healthcare industry, the latest
yang relevan dengan kegiatan usaha BMHS. Direksi regulatory dynamics, and other strategic topics relevant
juga aktif menjadi pembicara dalam seminar dan to BMHS’s business activities. The Board of Directors
forum industri sebagai bagian dari kontribusi BMHS also actively participates as speakers in seminars and
terhadap pengembangan ekosistem layanan kesehatan. industry forums as part of BMHS’s contribution to the
Sepanjang 2025, Direksi telah mengikuti sejumlah development of the healthcare ecosystem. In 2025, the
program pelatihan dan pengembangan, antara lain: Board of Directors participated in the following training
and development programs:
Page 120
120 Governansi Korporat
Corporate Governance
Tanggal Pelatihan Nama Pelatihan Penyelenggara
No.
Training Date Training Name Organizer
10 Februari 2025 Leaders lnteraction
1 HC Corporate PT Bundamedik Tbk
February 10, 2025 Forum & Empowerment (LIFE) 2025
10 Maret 2025 Training & Workshop ERM (Enterprise Risk
2 BMHS Diklat Indonesia
March 10, 2025 Management)
Workshop Pelatihan Meningkatkan
Analisa Akar Masalah dan Agregasi Root Cause
9 Mei 2025 Analysis (RCA)
3 IMRK
May 9, 2025 Training Workshop on Improving Root Cause
Analysis and Aggregation of Root Cause
Analysis (RCA)
9 Mei 2025 Artificial Intelligent (AI) Utilization at
4 Snowflake
May 9, 2025 Healthcare Industry by Snowflake
27 Oktober 2025
5 Leadership Training HC Corporate PT Bundamedik Tbk
October 27, 2025
BMHS melaksanakan program orientasi bagi anggota BMHS conducts orientation programs for newly
Direksi yang baru bergabung, yang difasilitasi oleh appointed members to the Board of Directors,
Sekretaris Perusahaan. Program ini bertujuan facilitated by the Corporate Secretary. This program
memberikan pemahaman mengenai lingkup bisnis aims to provide an understanding of the scope of BMHS’s
BMHS, tugas, kewenangan, dan tanggung jawab masing- business, the duties, authorities, and responsibilities of
masing organ BMHS, serta penerapan prinsip-prinsip each area of BMHS, as well as the application of GCG
GCG. Pada 2025, BMHS tidak menyelenggarakan principles. In 2025, BMHS did not hold any orientation
program orientasi karena tidak terdapat perubahan programs, as there were no changes in the composition
komposisi Direksi. of the Board of Directors.
Penilaian atas Kinerja Komite di bawah Direksi Performance Assessment of Committees under the
Board of Directors
Direksi menjalankan pengelolaan BMHS dengan In managing BMHS, the Board of Directors is supported
dukungan berbagai organ penunjang yang berada di by Strategic Planning & Business Operations, Internal
bawah koordinasinya, mencakup Strategic Planning Audit, Corporate Secretary, and Procurement
& Business Operations, Internal Audit, Sekretaris Committee. Each supporting body has KPIs that form
Perusahaan, serta Komite Pengadaan. Masing-masing the basis for evaluating the performance of its duties
organ penunjang memiliki KPI yang menjadi dasar and responsibilities. The Board of Directors assesses
evaluasi pelaksanaan tugas dan tanggung jawabnya. the performance of the supporting bodies through
Direksi melakukan penilaian kinerja organ penunjang periodic evaluations based on KPI achievements and
melalui evaluasi berkala berdasarkan pencapaian task implementation competencies. In 2025, the Board
KPI dan kompetensi pelaksanaan tugas. Sepanjang of Directors assessments showed that all supporting
2025, Direksi menilai bahwa seluruh organ penunjang organs had worked optimally within their scope of
telah bekerja secara optimal sesuai ruang lingkup authority, met the established KPIs, and provided
kewenangannya, memenuhi KPI yang ditetapkan, serta effective support for the management of BMHS.
memberikan dukungan yang efektif bagi pengelolaan
BMHS.
Page 121
Laporan Tahunan
Annual Report 121
Nominasi dan Remunerasi Direksi dan Dewan Komisaris
Board of Directors and Board of Commissioners Nomination and Remuneration
BMHS menerapkan prosedur nominasi dan BMHS has implemented nomination and remuneration
remunerasi bagi anggota Direksi dan Dewan Komisaris procedures for members of the Board of Directors and
sebagaimana diatur dalam Pedoman Tata Kelola dan Board of Commissioners as stipulated in the Corporate
Pedoman Kerja Dewan Komisaris. Dewan Komisaris Governance Guidelines and Board of Commissioners
melaksanakan fungsi nominasi dan remunerasi Work Guidelines. The Board of Commissioners carries
dengan mempertimbangkan rekomendasi dari Komite out its nomination and remuneration functions by
Nominasi dan Remunerasi. considering recommendations from the Nomination
and Remuneration Committee.
Prosedur Nominasi Nomination Procedure
Prosedur nominasi mencakup kebijakan nominasi The nomination procedure covers the nomination
serta tahapan proses nominasi, termasuk identifikasi policy and stages of the nomination process, including
kebutuhan, penetapan kriteria, aspek keberagaman identifying needs, setting criteria, diversity aspects, and
komposisi, serta evaluasi kelayakan (fit and proper) evaluating the suitability (fit and proper) of candidates
calon anggota Direksi dan Dewan Komisaris. Dalam for the Board of Directors and Board of Commissioners.
melaksanakan fungsi nominasi, Dewan Komisaris When carrying out its nomination function, the Board of
bertanggung jawab untuk: Commissioners is responsible for:
1. Merekomendasikan komposisi jabatan anggota 1. Recommending the membership composition of the
Direksi dan Dewan Komisaris; Board of Directors and Board of Commissioners;
2. Menetapkan kebijakan serta kriteria pencalonan 2. Establishing nomination policies and criteria in line
sesuai kebutuhan BMHS; with BMHS’s needs;
3. Menyusun kebijakan evaluasi kinerja bagi anggota 3. Formulating performance evaluation policies for
Direksi dan Dewan Komisaris; members of the Board of Directors and Board of
Commissioners;
4. Melakukan penilaian kinerja anggota Direksi dan 4. Assessing the performance of members of the Board
Dewan Komisaris berdasarkan tolok ukur yang telah of Directors and Board of Commissioners based on
ditetapkan; predetermined benchmarks;
5. Memberikan rekomendasi program pengembangan 5. Providing recommendations for competency
kompetensi; development programs;
6. Mengusulkan calon yang memenuhi persyaratan 6. Proposing candidates who meet the requirements to
kepada RUPS. the GMS.
Prosedur, Struktur dan Besaran Remunerasi Procedures, Structure and Amount of Remuneration
Prosedur penetapan remunerasi Direksi dan Dewan The procedure for determining the Board of Directors’
Komisaris dilakukan melalui serangkaian tahapan yang and Board of Commissioners’ remuneration is carried
mencakup evaluasi kinerja tahun berjalan, penilaian out in stages that include an evaluation of the current
kemampuan keuangan BMHS, serta benchmarking year’s performance, an assessment of BMHS’s financial
dengan remunerasi pada industri sejenis. Berdasarkan capabilities, and benchmarking with remuneration in
pertimbangan tersebut, Komite Nominasi dan similar industries. Based on these considerations, the
Remunerasi memberikan rekomendasi besaran Nomination and Remuneration Committee provides
remunerasi kepada Dewan Komisaris. Selanjutnya, recommendations on the amount of remuneration
Dewan Komisaris mengajukan remunerasi tersebut to the Board of Commissioners. Then, the Board
untuk memperoleh persetujuan RUPS. Sesuai keputusan of Commissioners submits the remunerations for
RUPST tahun buku 2024, RUPS memberikan wewenang approval by the GMS. Based on the decision in the
kepada Dewan Komisaris untuk menetapkan gaji dan AGMS for the 2024 financial year, the GMS authorized
tunjangan bagi Direksi dan Dewan Komisaris untuk the Board of Commissioners to determine the salaries
Page 122
122 Governansi Korporat
Corporate Governance
tahun buku 2025, dengan batas kenaikan maksimal and allowances for the Board of Directors and Board
15% dari gaji dan tunjangan tahun buku sebelumnya. of Commissioners for the 2025 financial year, with
a maximum increase of 15% from the salaries and
allowances of the previous financial year.
Struktur remunerasi Direksi dan Dewan Komisaris The remuneration structure for the Board of Directors
terdiri atas gaji, tunjangan, serta insentif atau bonus, and Board of Commissioners consists of salaries,
yang disesuaikan dengan tanggung jawab, ruang benefits, and incentives or bonuses, which are adjusted
lingkup tugas, serta kebijakan remunerasi. BMHS according to each member’s responsibilities, scope of
menyampaikan informasi besaran remunerasi sesuai duties, and the remuneration policies. BMHS discloses
ketentuan yang berlaku. Rincian remunerasi per information on the amount of remuneration in line with
individu anggota Direksi dan Dewan Komisaris tidak applicable regulations. Details of the remuneration for
dipublikasikan karena bersifat konfidensial dan each individual member of the Board of Directors and
berpotensi memengaruhi posisi kompetitif BMHS. Board of Commissioners are not published, as they
Secara keseluruhan, total remunerasi yang diberikan are confidential and could potentially affect BMHS’s
kepada Direksi pada tahun 2025 adalah sebesar competitive position. The total remuneration paid to the
Rp6.953,54 juta sementara remunerasi Dewan Board of Directors in 2025 was IDR 6,953.54 million,
Komisaris sebesar Rp8.419,09 juta. while the remuneration for the Board of Commissioners
was IDR 8,419.09 million.
Hubungan Afiliasi (Dewan Komisaris, Direksi, dan Pemegang
Saham)
Affiliated Relationships (Board of Commissioners, Board of Directors and
Shareholders)
Dewan Komisaris, Direksi, dan pemegang saham BMHS The Board of Commissioners, Board of Directors and
memiliki hubungan afiliasi yang bersifat kekeluargaan, shareholders of BMHS have familial affiliations, but
dan tidak terdapat afiliasi lainnya. Rinciannya sebagai no other forms of affiliation. The details are presented
berikut: below:
Nama Jabatan Sifat Hubungan Kekeluargaan
No.
Name Position Nature of Familial Relationships
Saudara kandung Mesha Rizal Sini, Rito Alam Rizal Sini dan Renobulan Rizal
Komisaris Utama
Sini Suheimi, serta anak kandung Ietje Ika Rizal Sini.
1 Ivan Rizal Sini President
Sibling of Mesha Rizal Sini, Rito Alam Rizal Sini and Renobulan Rizal Sini
Commissioner
Suheimi, and biological children of Ietje Ika Rizal Sini.
Saudara kandung Ivan Rizal Sini, Rito Alam Rizal Sini dan Renobulan Rizal Sini
Komisaris Suheimi, serta anak kandung Ietje Ika Rizal Sini.
2 Mesha Rizal Sini
Commissioner Sibling of Ivan Rizal Sini, Rito Alam Rizal Sini and Renobulan Rizal Sini Suheimi,
and biological children of Ietje Ika Rizal Sini.
Saudara kandung Ivan Rizal Sini, Mesha Rizal Sini dan Renobulan Rizal Sini
Rito Alam Rizal Pemegang Saham Suheimi, serta anak kandung Ietje Ika Rizal Sini.
3
Sini Shareholder Sibling of Ivan Rizal Sini, Mesha Rizal Sini and Renobulan Rizal Sini Suheimi,
and biological children of Ietje Ika Rizal Sini.
Saudara kandung Ivan Rizal Sini, Mesha Rizal Sini dan Rito Alam Rizal Sini,
Renobulan Rizal Pemegang Saham serta anak kandung Ietje Ika Rizal Sini.
4
Sini Suheimi Shareholder Sibling of Ivan Rizal Sini, Mesha Rizal Sini and Rito Alam Rizal Sini, and
biological children of Ietje Ika Rizal Sini.
Page 123
Laporan Tahunan
Annual Report 123
Nama Jabatan Sifat Hubungan Kekeluargaan
No.
Name Position Nature of Familial Relationships
Ibu kandung Ivan Rizal Sini, Mesha Rizal Sini, Rito Alam Rizal Sini dan
Pemegang Saham Renobulan Rizal Sini Suheimi.
5 Ietje Ika Rizal Sini
Shareholder Biological mother of Ivan Rizal Sini, Mesha Rizal Sini, Rito Alam Rizal Sini and
Renobulan Rizal Sini Suheimi.
Seluruh anggota Dewan Komisaris dan Direksi lainnya All other members of the Board of Commissioners
tidak memiliki hubungan afiliasi dengan pemegang and Board of Directors have no affiliated relationships
saham, maupun dengan sesama anggota Dewan with shareholders or fellow members of the Board of
Komisaris dan Direksi. Commissioners and Board of Directors.
Komite Audit
Audit Committee
Komite Audit dibentuk untuk memperkuat efektivitas The Audit Committee was established to strengthen the
fungsi pengawasan Dewan Komisaris. Pembentukan effectiveness of the Supervisory Board’s supervisory
Komite Audit dibentuk melalui Surat Keputusan function. The Audit Committee was established
(SK) Dewan Komisaris No. 016-I/SK/DIRKOM/ based on the Board of Commissioners’ Decree No.
IV/2021 tanggal 5 April 2021 mengenai Pembentukan 016-I/SK/DIRKOM/IV/2021 dated April 5, 2021,
dan Pengangkatan Anggota Komite Audit. Dalam concerning the Formation and Appointment of Audit
menjalankan tugasnya, Komite Audit bertanggung Committee Members. When carrying out its duties,
jawab kepada Dewan Komisaris, dengan kewenangan the Audit Committee is responsible to the Board of
pengangkatan dan pemberhentian anggotanya Commissioners, who has the authority to appoint and
sepenuhnya berada pada Dewan Komisaris. dismiss its members.
Pedoman Kerja Komite Audit Audit Committee Work Guidelines
Komite Audit menjalankan fungsinya berdasarkan The Audit Committee performs its functions based
pedoman kerja atau Piagam Komite Audit yang disusun on the work guidelines or Audit Committee Charter
dengan mengacu pada POJK No. 55/POJK.04/2015 prepared based on POJK No. 55/POJK.04/2015
tentang Pembentukan dan Pedoman Pelaksanaan concerning the Establishment and Work Guidelines for
Kerja Komite Audit. Piagam Komite Audit ditetapkan the Audit Committee. The Audit Committee Charter
oleh Dewan Komisaris pada 5 April 2021 dan terakhir was established by the Board of Commissioners on April
diperbarui pada 26 Januari 2022. Piagam ini mengatur 5, 2021, and was last updated on January 26, 2022.
ketentuan utama mengenai Komite Audit, mencakup This charter regulates the key provisions regarding the
tugas, tanggung jawab, dan wewenang komite, tata cara Audit Committee, including the committee’s duties,
dan prosedur kerja, masa jabatan, penyelenggaraan responsibilities, and authorities, work procedures and
rapat, serta pelaporan kegiatan komite. processes, terms of office, meeting arrangements, and
reporting of committee activities.
Komposisi dan Profil Komite Audit Audit Committee Composition and Profiles
Komite Audit terdiri dari seorang ketua, yang The Audit Committee consists of a chairperson, who is
dijabat oleh Komisaris Independen dan dua orang an Independent Commissioner, and two members, with
anggota, dengan masa jabatan lima tahun, yang dapat a five-year term of office, which can be extended once
diperpanjang satu kali untuk periode berikutnya. Pada for the following period. In 2025, there was a change to
2025, terjadi perubahan susunan Ketua Komite Audit the Audit Committee Chair in line with changes in the
sejalan dengan perubahan komposisi Dewan Komisaris. Board of Commissioners’ composition.
Page 124
124 Governansi Korporat
Corporate Governance
Komposisi Komite Audit
Audit Committee Composition
Nama Jabatan Dasar Pengangkatan Periode Jabatan
Name Position Basis of Appointment Period of Office
SK Pemberhentian dan Pengangkatan Ketua Komite Audit No.001-I/SK/
Ketua KOMUT/BMHS/I/2025 tanggal 22 Januari 2025
Arianti Anaya 2025-2029
Chair Decree on the Dismissal and Appointment of the Audit Committee Chair
No.001-I/SK/KOMUT/BMHS/I/2025 dated January 22, 2025
SK Pembentukan dan Pengangkatan Anggota Komite Audit 087-I/SK/
Albertus Yudha Anggota KOMUT/BMHS/XII/2025 tanggal 31 Desember 2025
2025-2030
Poerwadi Member Decree on the Formation and Appointment of Audit Committee
Members 087-I/SK/KOMUT/BMHS/XII/2025 dated December 31, 2025
SK Pengangkatan Komite Audit Nomor: 001-KEP/KOMUT/XI/2021
Anggota tanggal 1 Desember 2021
Tiwi Setyawati 2021-2026
Member Decision on the Appointment of the Audit Committee No. 001-KEP/
KOMUT/XI/2021 dated December 1, 2021
Profil Komite Audit Audit Committee Profiles
Profil Ketua Komite Audit, Ibu Arianti Anaya telah All other members of the Board of Commissioners The
disampaikan pada bagian Profil Perusahaan Laporan profile of the Audit Committee Chair, Arianti Anaya, can
Tahunan ini. be found in BMHS Profile section of this Annual Report.
Page 125
Laporan Tahunan
Annual Report 125
Marsaulina Olivia Panjaitan
Anggota
Member
Menjabat: 31 Desember 2025 | In office December 31, 2025
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 45 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau memperoleh gelar Dokter dari Fakultas She obtained a Doctor’s degree from the Faculty of
Kedokteran Universitas Sebelas Maret (2005), gelar Medicine, Universitas Sebelas Maret (2005), a Master’s
Magister Administrasi Rumah Sakit dari Universitas degree in Hospital Administration from Universitas
Indonesia (2014), dan gelar Doktor Ilmu Kesehatan Indonesia (2014), and a Doctoral in Public Health
Masyarakat dari Universitas Indonesia (2025). Selain Sciences from Universitas Indonesia (2025). Also
itu, Beliau juga mengikuti pendidikan informal yakni took part in informal education, including the ERMCP
sertifikasi ERMCP yang dikeluarkan oleh Enterprise certification issued by the Enterprise Risk Management
Risk Management Academy (ERMA), Singapura (2018), Academy (ERMA), Singapore (2018), and completed
menyelesaikan program Fellowship ISQua (FISQua) the ISQua Fellowship program (FISQua) in (2022).
pada tahun 2022, pelatihan verifikasi internal audit Internal verification training, coding audit in (2023)
coding CDCAP pada tahun (2023), lulus uji kompetensi CDCAP, and passed the competency test as a surveyor
sebagai surveyor Komisi Akreditasi Rumah Sakit (2025), of the Hospital Accreditation Commission (2025), and
dan memperoleh gelar non degree Certified Hospital obtained the non-degree title of Certified Hospital
Quality Professional (CHQP) tahun 2025. Quality Professional (CHQP) in 2025.
Beliau memulai karier sebagai dokter umum di rumah She started her career as a general practitioner in
sakit dan klinik di Jakarta dan sekitarnya (2005- hospitals and clinics in Jakarta and surrounding areas
2010), mengabdi sebagai dokter PTT di Puskesmas (2005-2010), served as a PTT doctor at Puskesmas
Parmonangan (2007-2008), sebagai Manajer Pelayanan Parmonangan (2007-2008), as Medical Services
Medis di RS Awal Bros Bekasi (2014-2015) dan RSIA Manager at RS Awal Bros Bekasi (2014- 2015) and
Sam Marie Basra (2015-2016), sebagai anggota Komite RSIA Sam Marie Basra (2015-2016), as a member
Audit BPJS, dan dilanjutkan sebagai Komite Manajemen of the BPJS Audit Committee, and continued in the
Risiko Dewan Pengawas BPJS Kesehatan (2016-2019). Risk Management Committee of the BPJS Health
Supervisory Board (2016-2019).
Beliau tidak memiliki rangkap jabatan baik di dalam She does not hold any concurrent positions either inside
maupun di luar BMHS. or outside BMHS.
Page 126
126 Governansi Korporat
Corporate Governance
Tiwi Setyawati
Anggota
Member
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 38 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau meraih gelar Sarjana di bidang Ekonomi She obtained a Bachelor’s degree in Economics from
dari Universitas Sebelas Maret, Solo (2009), dan Universitas Sebelas Maret, Solo (2009), and a Master
Magister Sains Ilmu Ekonomi dari Universitas Gadjah of Science in Economics from Universitas Gadjah
Mada,Yogyakarta (2011). Beliau telah mengikuti Mada, Yogyakarta (2011). In addition, she has also
sejumlah pelatihan tersertifikasi di antaranya: attended a number of certification trainings including:
Perkreditan Corporate dan Commercial Banking Corporate Credit Inducement and Commercial Banking
(2012,2015), Certification ERMAP– ERMCP dan (2012,2015), Certification ERMAP – ERMCP and
Performance Audit (2017), Balance Scorecard in Non- Performance Audit (2017), Balance Scorecard in Non-
Financial Institution (2018), Fellowship ISQua (FISQua) Financial Institution (2018), Fellowship program (2022),
dan Certification in Audit Committee Practices (CACP) ISQua Fellowship (FISQua) and Certification in Audit
(2022), serta Pendidikan Profesi Lanjutan Ikatan Committee Practices (CACP) (2022), and Advanced
Komite Indonesia. Professional Education at the Ikatan Komite Indonesia.
Beliau memulai karier di PT Bank Mandiri (Persero) Tbk She started her career at PT Bank Mandiri (Persero)
hingga tahun 2016 dan selanjutnya menjabat sebagai Tbk until 2016 and then served as a Member of the Risk
Anggota Komite Manajemen Risiko dan Komite Audit Management Committee and Audit Committee on the
pada Dewan Pengawas BPJS Kesehatan RI (2016-2021). BPJS Kesehatan RI Supervisory Board (2016-2021).
Selain itu, pernah menduduki jabatan sebagai Plt Kepala Also held the position of Acting Secretary of the BPJS
Sekretariatan Dewan Pengawas BPJS Kesehatan RI di Kesehatan RI Supervisory Board in 2017. Currently is
tahun 2017. Saat ini Beliau juga masuk menjadi Anggota also a Member of the Small and Medium Enterprises
Bidang Usaha Kecil dan Menengah dalam Asosiasi Sector at Asosiasi Pengusaha Indonesia (APINDO)-
Pengusaha Indonesia (APINDO)-Sulawesi Selatan. South Sulawesi.
Beliau tidak memiliki rangkap jabatan baik di dalam She does not hold any concurrent positions either inside
maupun di luar BMHS. or outside BMHS
Page 127
Laporan Tahunan
Annual Report 127
Albertus Yudha Poerwadi
Anggota
Member
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 59 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau meraih pendidikan Diploma III Akuntansi dari He holds a Diploma III in Accounting from STAN, a
STAN, Sarjana Akuntansi dari Universitas Sumatera Bachelor’s degree in Accounting from the University
Utara, dan Magister Ilmu Ekonomi dari Universitas of North Sumatra, and a Master’s degree in Economics
Syiah Kuala. from Syiah Kuala University.
Memiliki pengalaman panjang di bidang pengawasan He has extensive experience in the fields of oversight
dan tata kelola pemerintahan, antara lain sebagai and public administration, including serving as an
Inspektur Investigasi dan Inspektur IV pada Inspektorat Investigative Inspector and Inspector IV at the
Jenderal Kementerian Kesehatan, BPKP, termasuk Inspectorate General of the Ministry of Health and the
Koordinator Pengawasan dan Kepala Bidang Akuntan State Audit Board (BPKP), as well as holding positions
Negara. Beliau juga memegang berbagai sertifikasi such as Oversight Coordinator and Head of the State
profesional, antara lain Chartered Accountant (CA), Accountant Division. He also holds various professional
Certified Professional Management Accountant certifications, including Chartered Accountant (CA),
(CPMA), Certified Internal Auditor sektor pemerintah, Certified Professional Management Accountant
serta kualifikasi auditor forensik dan auditor internal (CPMA), Certified Internal Auditor for the government
kesehatan serta Dewan Pengawas pada beberapa sector, as well as qualifications as a forensic auditor and
rumah sakit Nasional. internal health auditor, and serves on the Supervisory
Board of several national hospitals.
Saat ini dipercaya sebagai salah satu anggota komite He currently serves as a member of the Audit Committee
Audit di PT Bundamedik Tbk dan memiliki rangkap at PT Bundamedik Tbk and has held the position of
jabatan sebagai Sekretaris Direktorat Jenderal Sumber Secretary of the Directorate General of Health Human
Daya Manusia Kesehatan, Kementerian Kesehatan RI Resources, Ministry of Health of the Republic of
sejak Agustus 2023. Indonesia, since August 2023.
Page 128
128 Governansi Korporat
Corporate Governance
Pernyataan Independensi Komite Audit Audit Committee Statement of Independence
BMHS memastikan bahwa keanggotaan Komite Audit BMHS ensures that the membership of the Audit
memenuhi prinsip independensi sebagaimana diatur Committee complies with the principle of independence
dalam ketentuan tata kelola. Anggota Komite Audit as stipulated in the governance provisions. Members of
berasal dari profesional independen yang memiliki the Audit Committee are independent professionals who
integritas, pengalaman, dan kompetensi yang memadai have integrity, experience, and sufficient competence to
untuk memberikan penelaahan serta rekomendasi provide objective reviews and recommendations to the
secara objektif kepada Dewan Komisaris. Komite Board of Commissioners. The Audit Committee carries
Audit melaksanakan tugas dan tanggung jawabnya out its duties and responsibilities professionally and
secara profesional dan independen, serta senantiasa independently, and always avoids situations that could
menghindari kondisi yang dapat menimbulkan benturan give rise to conflicts of interest.
kepentingan.
Tugas dan Tanggung Jawab Komite Audit Audit Committee’s Duties and Responsibilities
Komite Audit memiliki tugas dan tanggung jawab The Audit Committee’s duties and responsibilities
sebagai berikut: include:
1. Melakukan penelaahan informasi keuangan yang 1. Reviewing financial information to be disclosed
akan dikeluarkan BMHS kepada publik dan/atau by BMHS to the public and/or authorities,
pihak otoritas, antara lain laporan keuangan, including financial reports, projections, and other
proyeksi, dan informasi keuangan lainnya terkait financial information related to BMHS’s financial
dengan informasi keuangan BMHS; information;
2. Melakukan penelaahan atas efektivitas sistem 2. Reviewing the internal control system effectiveness,
pengendalian internal, termasuk telaah pelaksanaan including reviewing the implementation of
pemeriksaan oleh auditor internal dan mengawasi audits by internal auditors, and supervising the
pelaksanaan tindak lanjut Direksi terhadap temuan implementation of follow-up actions by the Board
auditor internal; of Directors on the findings of internal auditors;
3. Melakukan penelaahan terhadap pelaksanaan 3. Reviewing the application of risk management to
manajemen risiko untuk memastikan efektivitas ensure the effectiveness of risk management;
manajemen risiko;
4. Memastikan kepatuhan terhadap peraturan 4. Ensuring compliance with laws and regulations;
perundang-undangan;
5. Memberikan rekomendasi kepada Dewan Komisaris 5. Providing recommendations to the Board of
mengenai penunjukan akuntan atau auditor Commissioners concerning the appointment
eksternal yang didasarkan pada independensi, of external accountants or auditors based
ruang lingkup penugasan, imbalan jasa, dengan on independence, scope of assignment, and
menelaah hasil kerjanya; remuneration, by reviewing their work results;
6. Memberikan pendapat independen dalam hal 6. Providing independent opinions in the event of a
terjadi perbedaan pendapat antara manajemen dan difference of opinion between management and
akuntan atas jasa yang diberikannya; accountants regarding the services provided;
7. Melakukan penelaahan atas pengaduan terkait 7. Reviewing complaints related to BMHS’s accounting
proses akuntansi dan pelaporan keuangan BMHS; and financial reporting processes;
8. Melakukan penelaahan terhadap audit medis; 8. Reviewing medical audits;
9. Melakukan penelaahan dan memberikan saran 9. Reviewing and providing advice to the Board of
kepada Dewan Komisaris terkait dengan adanya Commissioners concerning potential conflicts of
potensi benturan kepentingan BMHS; dan interest within BMHS; and
10. Menjaga kerahasiaan dokumen, data, dan informasi 10. Maintaining the confidentiality of Company
BMHS. documents, data, and information.
Page 129
Laporan Tahunan
Annual Report 129
Pelatihan dan Sertifikasi Komite Audit Audit Committee Training and Certification
Komite Audit mengikuti program pelatihan, The Audit Committee participates in training programs,
pengembangan kompetensi, dan sertifikasi terkait competency development, and certification related
regulasi, audit, pelaporan, dan topik-topik lain yang to regulations, auditing, reporting, and other topics
relevan dengan pelaksanaan tugasnya. Sepanjang 2025, relevant to the performance of its duties. In 2025, the
Komite Audit telah mengikuti beberapa pelatihan, di Audit Committee participated in the following training
antaranya: programs:
Tanggal Pelatihan Nama Pelatihan Penyelenggara
No.
Training Date Training Name Organizer
Sustainability Reporting: Impact & Implementation of
13 September 2025 Ikatan Komite Audit
1 PSPK 1 & 2 for Professionals
September 13, 2025 Indonesia
Pelatihan survei akreditasi calon surveior Akreditasi
16-24 Juni 2025 Rumah Sakit Komisi Akreditasi Rumah
2
June 16-24, 2025 Accreditation survey training for prospective Hospital Sakit
Accreditation surveyors
12 Agustus 2025 Pertemuan Ilmiah Tahunan Nasional (Pitselnas) Komisi Akreditasi Rumah
3
August 12, 2025 National Annual Scientific Meeting (Pitselnas) Sakit
Pelatihan sertifikasi Hospital Quality Professional (CHQP)
13-14 Agustus 2025 Komisi Akreditasi Rumah
4 Hospital Quality Professional (CHQP) certification
August 13-14, 2025 Sakit
training
3-4 Desember 2025
5 Indonesian Hospital Management Summit 2025 IHMS
December 3-4, 2025
Pelaksanaan Rapat Komite Audit Implementation of Audit Committee Meetings
Ketentuan dalam POJK No. 55/POJK.04/2015 Based on the provisions in POJK No. 55/POJK.04/2015
mensyaratkan Komite Audit untuk mengadakan the Audit Committee is required to hold meetings at
rapat sedikitnya satu kali dalam tiga bulan. Ketentuan least once every three months. These provisions have
tersebut telah diadopsi dalam Piagam Komite Audit been adopted in the Audit Committee Charter as
sebagai pedoman penyelenggaraan rapat. Sepanjang guidelines for conducting meetings. In 2025, the Audit
2025, Komite Audit menyelenggarakan 15 rapat, Committee held 15 meetings, with the attendance rates
dengan tingkat kehadiran disajikan sebagai berikut: presented as follows:
Nama Jabatan Jumlah Rapat Jumlah Kehadiran Tingkat Kehadiran (%)
Name Position Number of Meetings Total Attended Attendance Level
Arianti Anaya Ketua | Chair 15 15 100
Marsaulina Olivia
Anggota | Member 15 15 100
Panjaitan
Tiwi Setyawati Anggota | Member 15 15 100
Page 130
130 Governansi Korporat
Corporate Governance
Pelaksanaan Kegiatan Komite Audit Implementation of Audit Committee Activities
Sepanjang 2025, Komite Audit menjalankan fungsi In 2025, the Audit Committee performed its supervisory
pengawasan melalui berbagai aktivitas yang function through activities covering the scope of its
mencerminkan ruang lingkup tugas dan tanggung duties and responsibilities. These activities included
jawabnya. Kegiatan tersebut mencakup penelaahan reviewing reports, providing recommendations, and
laporan, pemberian rekomendasi, hingga koordinasi coordinating directly with business units. The Audit
langsung dengan unit usaha. Kegiatan utama Komite Committee’s main activities included:
Audit meliputi:
1. Menelaah laporan yang ditujukan kepada 1. Reviewed reports addressed to the Board of
Dewan Komisaris, termasuk Laporan Keuangan Commissioners, including Quarterly Consolidated
Konsolidasian Triwulanan, Laporan Hasil Financial Statements, Quarterly Internal Audit
Pemeriksaan Triwulanan Internal Audit (yang Reports (which included significant findings and
mencakup temuan signifikan dan tindak lanjutnya), follow-up actions), and Audit Progress Reports on
serta Laporan Progres Audit atas Laporan Keuangan Annual Financial Statements.
Tahunan.
2. Menelaah dan memberikan rekomendasi atas usulan 2. Reviewed and provided recommendations on
Direksi yang membutuhkan persetujuan tertulis dari proposals from the Board of Directors that require
Dewan Komisaris. written approval from the Board of Commissioners.
3. Menyusun Laporan Hasil Evaluasi Pelaksanaan 3. Prepared the Audit Service Evaluation Report on
Pemberian Jasa Audit atas Laporan Keuangan the 2024 Consolidated Financial Statements, the
Konsolidasian Tahun Buku 2024, Laporan Kegiatan Quarterly Audit Committee Activity Reports, and
Komite Audit Triwulanan, serta Laporan Hasil the Visit Reports.
Kunjungan.
4. Melaksanakan visitasi pengawasan ke unit usaha, 4. Conducted supervisory visits to business units,
rumah sakit, dan klinik. hospitals, and clinics.
5. Menjalin komunikasi dan koordinasi dengan unit- 5. Communicated and coordinated with business units
unit usaha untuk membahas isu-isu yang menjadi to discuss the Audit Committee issues of concern
perhatian dan fokus Komite Audit. and focus.
Komite Nominasi dan Remunerasi
Nomination and Remuneration Committee
Komite Nominasi dan Remunerasi dibentuk untuk The Nomination and Remuneration Committee was
mendukung efektivitas pelaksanaan fungsi nominasi established to support the effectiveness of the Board
dan remunerasi Dewan Komisaris, sebagaimana of Commissioners’ nomination and remuneration
diatur dalam POJK No.34/POJK. 04/2014. Komite functions, as stipulated in POJK No.34/POJK.
ini dibentuk melalui SK Dewan Komisaris No.042-K/ 04/2014. This committee was established through
KOMUT/XI/2021 tanggal 25 November 2021 tentang Board of Commissioners Decree No.042-K/KOMUT/
Pembentukan dan Pengangkatan Anggota Komite XI/2021 dated November 25, 2021 concerning the
Nominasi dan Remunerasi. Dalam menjalankan Formation and Appointment of the Nomination and
tugasnya, Komite Nominasi dan Remunerasi Remuneration Committee Members. In carrying out its
bertanggung jawab kepada Dewan Komisaris, dengan duties, the Nomination and Remuneration Committee
kewenangan pengangkatan dan pemberhentian is responsible to the Board of Commissioners, with the
anggotanya sepenuhnya berada pada Dewan Komisaris. authority to appoint and dismiss its members resting
entirely with the Board of Commissioners.
Page 131
Laporan Tahunan
Annual Report 131
Pedoman Kerja Komite Nominasi dan Remunerasi Nomination and Remuneration Committee Work
Guidelines
Komite Nominasi dan Remunerasi menjalankan The Nomination and Remuneration Committee
fungsinya berdasarkan piagam atau pedoman kerja performs its functions based on the Nomination and
Komite Nominasi dan Remunerasi yang ditetapkan Remuneration Committee charter or work guidelines
oleh Dewan Komisaris BMHS. Piagam ini mengatur determined by BMHS’s Board of Commissioners.
ketentuan utama mengenai Komite Nominasi dan This charter regulates the main provisions regarding
Remunerasi, mencakup tugas, tanggung jawab, dan the Nomination and Remuneration Committee,
wewenang komite, tata cara dan prosedur kerja, masa including the Committee’s duties, responsibilities, and
jabatan, penyelenggaraan rapat, serta pelaporan authorities, work procedures and processes, term of
kegiatan komite. office, meetings, and reporting of committee activities.
Komposisi dan Profil Komite Nominasi dan Nomination and Remuneration Committee
Remunerasi Composition and Profiles
Komite Nominasi dan Remunerasi terdiri atas seorang The Nomination and Remuneration Committee
ketua yang dijabat oleh Komisaris Independen dan consists of a chairperson who is an Independent
anggota yang berasal dari Dewan Komisaris atau pihak Commissioner, and members who are members of the
independen dari luar BMHS. Masa jabatan Komite Board of Commissioners or independent parties from
Nominasi dan Remunerasi selama lima tahun, dan outside BMHS. The Nomination and Remuneration
dapat diangkat kembali untuk periode berikutnya. Pada Committee’s term of office is five years, and members
2025, terjadi perubahan susunan Komite Nominasi dan may be reappointed for the following term. In
Remunerasi, sejalan dengan dinamika susunan Dewan 2025, there were changes to the Nomination and
Komisaris. Remuneration Committee composition, in line with the
dynamics of the Board of Commissioners’ composition.
25 November 2021 – 24 March
Jabatan 2025 24 March 2025 – 24 March 2029 31 Desember 2025 - 31 Desember 2029
Position November 25, 2021 – March 24, March 24, 2025 – March 24, 2029 December 31, 2025 - December 31, 2029
2025
Ketua
Wishnutama Kusubandio Retno L.P. Marsudi Retno L.P. Marsudi
Chair
Ivan Rizal Sini Ivan Rizal Sini Ivan Rizal Sini
Anggota
Ariani Vidya Sofjan Mesha Rizal Sini Mesha Rizal Sini
Member
Sunata Tjiterosampurno
Komposisi Komite Nominasi dan Remunerasi
Nomination and Remuneration Committee Composition
Nama Jabatan Dasar Pengangkatan Periode Jabatan
Name Position Basis of Appointment Period of Office
Retno L.P. Ketua Surat Keputusan Dewan Komisaris Nomor 089-I/SK/
Marsudi Chair KOMUT/BMHS/XII/2025 tanggal 31 Desember 2025 tentang
Pemberhentian dan Pengangkatan Anggota Komite Nominasi dan 31 Desember 2025
Ivan Rizal Sini Remunerasi. – 31 Desember 2029
Anggota Board of Commissioners Decree No. 089-I/SK/KOMUT/BMHS/ December 31, 2025 –
Members XII/2025 dated December 31, 2025 concerning the Dismissal and December 31, 2029
Mesha Rizal Sini Appointment of Members of the Nomination and Remuneration
Committee.
Page 132
132 Governansi Korporat
Corporate Governance
Profil Komite Nominasi dan Remunerasi Nomination and Remuneration Committee Profiles
Profil Ketua Komite dan anggota yang berasal dari The profiles of the Committee Chair and members who
Dewan Komisaris, telah disampaikan pada bagian Profil are members of the Board of Commissioners can be
Perusahaan Laporan Tahunan ini. found in BMHS Profile section of this Annual Report.
Ariani Vidya Sofjan
Anggota
Member
(Menjabat 25 November 2021 – 24 Maret 2025)
(In office November 25, 2021, - March 24, 2025)
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 55 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau meraih gelar Sarjana di bidang Keuangan dari She obtained a Bachelor’s degree in Finance from
Oklahoma State University, Amerika Serikat. Oklahoma State University, United States.
Beliau memulai karier sebagai analis Ekuitas di Deutsche She started her career as an Equity analyst at PT
Morgan Grenfell Asia (1994), kemudian melanjutkan Deutsche Morgan Grenfell Asia (1994). Then continued
karier sebagai Sales Institusi di PT Danareksa (Persero), as Institutional Sales at PT Danareksa (Persero), London,
London, Inggris (1997), dilanjutkan sebagai Vice UK (1997), followed by a position as Vice President of
President - Research di PT Bahana Sekuritas (1999), Research at PT Bahana Sekuritas (1999), and served as
menjabat sebagai Executive Vice President - Head of Executive Vice President and - Head of Research at PT
Research di PT Mandiri Sekuritas (2003). Selanjutnya, Mandiri Sekuritas (2003), she joined Northstar Group
beliau bergabung dengan Northstar Group (2009), (2009), served as Director of PT Delta Dunia Makmur
menjabat sebagai Direktur PT Delta Dunia Makmur Tbk (2009-2022), Commissioner of PT Trimegah Asset
Tbk (2009-2022), Komisaris PT Trimegah Asset Management (since July 2013), and served as Managing
Management (sejak Juli 2013), dan menjabat sebagai Director at PT Nusantara Sugihartana Internasional
Managing Director di PT Nusantara Sugihartana until December 2023.
Internasional hingga Desember 2023.
Saat ini, beliau menjabat sebagai Komisaris Independen Concurrent she also serves as an Independent
di PT Danantara Investment Management (Persero). Commissioner at PT Danareksa (Persero). In addition,
Selain itu, beliau juga menjabat sebagai Komisaris he also serves as an Independent Commissioner at PT
Independen di PT Nusantara Sejahtera Raya Tbk Nusantara Sejahtera Raya Tbk (CNMA).
(CNMA).
Page 133
Laporan Tahunan
Annual Report 133
Pernyataan Independensi Komite Nominasi dan Nomination and Remuneration Committee Statement
Remunerasi of Independence
BMHS menerapkan prinsip independensi dalam BMHS applies the principle of independence in the
pengangkatan Komite Nominasi dan Remunerasi. appointment of the Nomination and Remuneration
Komite Nominasi dan Remunerasi terdiri dari Komisaris Committee. The Nomination and Remuneration
Independen, Komisaris Utama, dan profesional Committee consists of Independent Commissioners,
independen yang memiliki komitmen, integritas, dan President Commissioners, and independent
wewenang yang memadai untuk menjalankan fungsinya professionals who have the commitment, integrity,
secara efektif, profesional, independen, dan terhindar and authority to perform their duties effectively,
dari segala bentuk benturan kepentingan. professionally, independently, and free from any forms
of conflicts of interest.
Tugas dan Tanggung Jawab Komite Nominasi dan Nomination and Remuneration Committee Duties and
Remunerasi Responsibilities
Komite Nominasi dan Remunerasi memiliki tugas dan The Nomination and Remuneration Committee’s duties
tanggung jawab sebagai berikut: and responsibilities include:
Fungsi Nominasi: Nomination Function:
1. Memberikan rekomendasi kepada Dewan Komisaris 1. Provides recommendations to the Board of
mengenai: Commissioners regarding:
a. Komposisi jabatan anggota Direksi dan Dewan a. The Board of Directors and Board of
Komisaris; Commissioners membership composition;
b. Kebijakan dan kriteria yang dibutuhkan dalam b. Policies and criteria required in the nomination
proses Nominasi; dan process; and
c. Kebijakan evaluasi kinerja bagi anggota Direksi c. Performance evaluation policies for members
dan Dewan Komisaris. of the Board of Directors and Board of
Commissioners.
2. Membantu Dewan Komisaris dalam menilai kinerja 2. Assists the Board of Commissioners in assessing the
anggota Direksi dan Dewan Komisaris berdasarkan performance of members of the Board of Directors
tolok ukur yang telah ditetapkan. and Board of Commissioners based on established
benchmarks.
3. Memberikan rekomendasi terkait program 3. Provides recommendations related to the Board of
pengembangan kompetensi bagi anggota Direksi dan Directors’ and Board of Commissioners’ members’
Dewan Komisaris. competency development programs.
4. Memberikan usulan calon anggota Direksi dan 4. Provides proposals for candidates for the Board of
Dewan Komisaris yang memenuhi persyaratan Directors and Board of Commissioners who meet the
untuk disampaikan kepada RUPS melalui Dewan requirements to be submitted to the GMS through
Komisaris. the Board of Commissioners.
Fungsi Remunerasi: Remuneration Function:
1. Memberikan rekomendasi kepada Dewan Komisaris 1. Provides recommendations to the Board of
mengenai struktur, kebijakan dan besaran remunerasi Commissioners regarding the structure, policy, and
bagi anggota Direksi dan Dewan Komisaris. amount of remuneration for members of the Board
of Directors and Board of Commissioners.
2. Membantu Dewan Komisaris dalam menilai 2. Assists the Board of Commissioners in assessing
kesesuaian remunerasi dengan kinerja masing- the appropriateness of remuneration based on
masing anggota Direksi dan Dewan Komisaris. the performance of each member of the Board of
Directors and Board of Commissioners.
Page 134
134 Governansi Korporat
Corporate Governance
Peningkatan Kompetensi Komite Nominasi dan Nomination and Remuneration Committee
Remunerasi Competency Development
Komite Nominasi dan Remunerasi mengikuti program The Nomination and Remuneration Committee
pelatihan dan pengembangan kompetensi, berupa members participate in competency training
seminar, konferensi, workshop terkait industri pelayanan and development programs, including seminars,
kesehatan, perkembangan regulasi terbaru, dan topik- conferences, and workshops related to the healthcare
topik lain yang relevan dengan pelaksanaan tugasnya. industry, the latest regulatory developments, and other
Sepanjang 2025, Komite Nominasi dan Remunerasi topics relevant to the performance of their duties. In
telah mengikuti beberapa pelatihan, di antaranya: 2025, the Nomination and Remuneration Committee
has participated in the following training programs:
Tanggal Pelatihan Nama Pelatihan Penyelenggara
No.
Training Date Training Name Organizer
9 Mei 2025 Artificial Intelligent (AI) Utilization at
1 Snowflake
May 9, 2025 Healthcare Industry
Rapat Komite Nominasi dan Remunerasi Nomination and Remuneration Committee Meetings
Ketentuan dalam Pasal 12 POJK No.34/POJK.04/2014 The provisions of Article 12 in POJK No. 34/
mensyaratkan Komite Nominasi dan Remunerasi untuk POJK.04/2014 require the Nomination and
mengadakan rapat sedikitnya satu kali dalam empat Remuneration Committee hold meetings at least once
bulan. Ketentuan tersebut telah diadopsi dalam Piagam every four months. These provisions have been adopted
Komite Nominasi dan Remunerasi sebagai pedoman in the Nomination and Remuneration Committee
penyelenggaraan rapat. Sepanjang 2025, Komite Charter as guidelines for conducting meetings. In 2025,
Nominasi dan Remunerasi melaksanakan 3 rapat, the Nomination and Remuneration Committee held 3
dengan tingkat kehadiran sebagai berikut: meetings, with the following attendance rates:
Nama Jabatan Jumlah Rapat Jumlah Kehadiran Tingkat Kehadiran (%)
Name Position Number of Meetings Total Attended Attendance Level
Wishnutama Kusubandio*1 3 1 100
Ketua | Chair
Retno L.P. Marsudi*2 3 3 100
Ivan Rizal Sini 3 3 100
Ariani Vidya Sofjan*1 Anggota | 3 1 100
Mesha Rizal Sini*2 Members 3 3 100
Sunata Tjiterosampurno*3 3 2 100
*Keterangan | Notes:
1. Efektif menjabat sampai dengan 24 Maret 2025 | Effectively served until March 24, 2025
2. Efektif menjabat setelah 24 Maret 2025 | Effectively served after March 24, 2025
3. Efektif menjabat 24 Maret 2025- sampai dengan RUPSLB 7 Agustus 2025 | Effectively served from March 24, 2025, until the Extraordinary General
Meeting of Shareholders on August 7, 2025
Pelaksanaan Kegiatan Komite Nominasi dan Nomination and Remuneration Committee
Remunerasi Implementation of Activities
Sepanjang 2025, Komite Nominasi dan Remunerasi In 2025, the Nomination and Remuneration Committee
menjalankan fungsi nominasi dan remunerasi melalui carried out its nomination and remuneration activities
berbagai kegiatan sesuai ruang lingkup tugas dan in accordance with its scope of duties and
tanggung jawabnya, di antaranya: responsibilities, including:
Page 135
Laporan Tahunan
Annual Report 135
1. Menelaah dan menyampaikan rekomendasi terkait 1. Reviewed and provided recommendations
calon anggota Dewan Komisaris dan Direksi yang concerning candidates for the Board of
memenuhi persyaratan kepada Dewan Komisaris Commissioners and Board of Directors who met the
untuk kemudian diajukan dalam RUPS; requirements to the Board of Commissioners to be
submitted to the GMS;
2. Mengkaji data calon Direksi yang berasal dari talent 2. Reviewed data on prospective members for the
pool pejabat satu tingkat di bawah Direksi, serta Board of Directors from the talent pool of officials
mengidentifikasi kandidat potensial untuk posisi one level below the Board of Directors, as well as
Dewan Komisaris; dan identified potential candidates for positions on the
Board of Commissioners; and
3. Menelaah dan merekomendasikan struktur 3. Reviewed and provided recommendations for the
remunerasi bagi Direksi dan Dewan Komisaris, Board of Directors and Board of Commissioners
termasuk komponen gaji atau honorarium, fasilitas remuneration structure, including salaries or
atau tunjangan, serta tantiem. honorariums, facilities or benefits, and bonuses.
Komite GCG dan Manajemen Risiko
GCG and Risk Management Committee
Komite GCG dan Manajemen Risiko dibentuk untuk The GCG and Risk Management Committee was
mendukung efektivitas fungsi pengawasan Dewan established to support the effectiveness of the Board
Komisaris atas penerapan tata kelola dan manajemen of Commissioners’ supervisory function over BMHS’s
risiko BMHS, sebagaimana diatur dalam POJK No.21/ governance implementation and risk management, as
POJK.04/2014 tentang Penerapan Pedoman Tata stipulated in POJK No.21/POJK.04/2014 concerning
Kelola Perusahaan Terbuka. Pembentukan Komite the Implementation of Corporate Governance
GCG dan Manajemen Risiko terakhir ditetapkan Guidelines for Public Companies. The establishment
berdasarkan Surat Keputusan Dewan Komisaris of this Committee was most recently established
Nomor 002-I/SK/KOMUT/BMHS/I/2025 tanggal 22 pursuant to Board of Commissioners Decision No.
Januari 2025 tentang Pengangkatan Komite GCG 002-I/SK/KOMUT/BMHS/I/2025 dated January 22,
dan Manajemen Risiko, yang kemudian diperbarui 2025, regarding the Appointment of the Corporate
melalui Surat Keputusan Nomor 088-I/SK/KOMUT/ Governance and Risk Management Committee, which
BMHS/XII/2025 tanggal 31 Desember 2025. Dalam was subsequently updated by Decision No. 088-I/
menjalankan tugasnya, Komite GCG dan Manajemen SK/KOMUT/BMHS/ XII/2025 dated December 31,
Risiko bertanggung jawab kepada Dewan Komisaris, 2025. In carrying out its duties, the GCG and Risk
dengan kewenangan pengangkatan dan pemberhentian Management Committee is responsible to the Board
anggotanya sepenuhnya berada pada Dewan Komisaris. of Commissioners, with the authority to appoint and
dismiss its members resting entirely with the Board of
Commissioners.
Pedoman Kerja Komite GCG dan Manajemen Risiko GCG and Risk Management Committee Work
Guidelines
Komite GCG dan Manajemen Risiko menjalankan The GCG and Risk Management Committee performs
fungsinya berdasarkan pedoman kerja yang ditetapkan its functions based on the work guidelines established
oleh Dewan Komisaris. Pedoman ini mengatur ketentuan by the Board of Commissioners. These guidelines
utama mengenai Komite GCG dan Manajemen Risiko, regulate the main provisions concerning the GCG and
mencakup tugas, tanggung jawab dan wewenang, tata Risk Management Committee, including its duties,
cara dan prosedur kerja, masa jabatan, rapat, serta responsibilities and authorities, work procedures and
pelaporan kegiatan komite. processes, term of office, meetings, and reporting of
committee activities.
Page 136
136 Governansi Korporat
Corporate Governance
Komposisi dan Profil Anggota Komite GCG dan GCG and Risk Management Committee Composition
Manajemen Risiko and Profiles
Komite GCG dan Manajemen Risiko terdiri The GCG and Risk Management Committee consists
atas seorang ketua yang merupakan Komisaris of a chairperson who is an Independent Commissioner
Independen dan seorang anggota, dengan masa jabatan and one member, with a term of office of 5 years, who
5 tahun, dan dapat diangkat kembali untuk periode may be reappointed for the following period. In 2025,
berikutnya. Pada 2025, terdapat perubahan Ketua there was a change in the GCG and Risk Management
Komite GCG dan Manajemen Risiko sejalan dengan Committee in line with changes in the Board of
perubahan komposisi Dewan Komisaris. Commissioners’ composition.
Jabatan 22 Januari 2025 - 31 Desember 2025 31 Desember 2025-31 Desember 2029
Position January 22, 2025 - December 31, 2025 December 31 2025-December 31, 2029
Ketua | Chair Arianti Anaya Arianti Anaya
Anggota | Member Bernadette Eka A. Wahjoeni Marsaulina Olivia Panjaitan
Komposisi Komite GCG dan Manajemen Risiko
GCG and Risk Management Committee Composition
Nama Jabatan Dasar Pengangkatan Periode Jabatan
Name Position Basis of Appointment Period of Office
SK Pemberhentian dan Pengangkatan Ketua Komite GCG dan
Manajemen Risiko No.002-I/SK/KOMUT/BMHS/I/2025 tanggal 22
Ketua Januari 2025.
Arianti Anaya 2025-2029
Chair Decree on the Dismissal and Appointment of the Chairperson of
the GCG and Risk Management Committee Decree No.002-I/SK/
KOMUT/BMHS/I/2025 dated January 22, 2025.
SK Pembentukan dan Pengangkatan Anggota Komite GCG dan
Manajemen Risiko 088-I/SK/KOMUT/BMHS/XII/2025 tanggal 31
Marsaulina Olivia Anggota Desember 2025.
2025-2029
Panjaitan Member Establishment and Appointment of the Members of the GCG and
Risk Management Committee Decree No. 088-I/SK/KOMUT/BMHS/
XII/2025 dated December 31, 2025.
Profil Komite GCG dan Manajemen Risiko GCG and Risk Management Committee Profiles
Profil Ketua Komite, Arianti Anaya telah disampaikan The profile of the Committee Chair, Arianti Anaya, can
pada bagian Profil Perusahaan Laporan Tahunan ini. be found in BMHS Profile section of this Annual Report.
Page 137
Laporan Tahunan
Annual Report 137
Bernadette Eka A. Wahjoeni
Anggota
Member
(Menjabat sampai dengan 31 Desember 2025)
(In office until December 31, 2025)
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 64 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau meraih gelar Dokter di Fakultas Kedokteran She obtained a Doctor’s degree at the Faculty of
(FK) Universitas Sebelas Maret, Surakarta (1987), Medicine (FK) Universitas Sebelas Maret, Surakarta
dan meraih gelar Magister Manajemen RS dari FK (1987), and holds a Master’s degree in Hospital
Universitas Gadjah Mada, Yogyakarta (2021). Beliau Management from FK Universitas Gadjah Mada,
juga menyelesaikan program Fellowship ISQua (FISQua) Yogyakarta (2021). Also completed the ISQua (FISQua) I
I & II serta Program Specialist FISQua (2020 dan 2021), & II Fellowship program as well as the FISQua Specialist
serta pelatihan verifikasi internal, audit coding CDCAP Program (2020 and 2021), internal verification training,
(2023). audit coding CDCAP (2023).
Beliau memulai karier sebagai Kepala Puskesmas Maga She started her career as Head of the Puskesmas
dan Panyabungan Jahe Dinas Kesehatan Provinsi Maga and Panyabungan Jahe, North Sumatra
Sumatera Utara (1987-1991), Staf hingga Kabid Provincial Health Service (1987-1991), Staff to Head
Pelayanan RS Fatmawati (1991-2008), dan Ketua of Services at RS Fatmawati (1991-2008), and Chair
Komite Keselamatan Pasien Rumah Sakit (KPRS) RS of the Hospital Patient Safety Committee (KPRS) at
Fatmawati (2008-2011). Beliau berkarir di Direktorat RS Fatmawati (2008-2011). Served at Direktorat Bina
Bina Upaya Kesehatan Rujukan, Direktorat Jenderal Upaya Kesehatan Rujukan, Direktorat Jenderal Bina
Bina Upaya Kesehatan, Kementerian Kesehatan Upaya Kesehatan, Republic of Indonesia Ministry of
RI (2011-2016) sebagai Kepala Sub Direktorat RS Health (2011-2016) as Head of the Sub-Directorate of
Pendidikan dan Kepala Sub Direktorat Akreditasi RS dan Teaching Hospitals and Head of the Sub-Directorate of
Sarana Kesehatan Lainnya. Kemudian, Beliau menjabat Accreditation of Hospitals and Other Health Facilities.
sebagai Kepala Sub Direktorat Mutu dan Akreditasi Then, served as Head of the Sub-Directorate of Quality
Pelayanan Kesehatan Rujukan dan Administrator and Accreditation of Referral Health Services and
Kesehatan di Direktorat Mutu dan Akreditasi Pelayanan Health Administrator at the Directorate of Quality and
Kesehatan, Ditjen Pelayanan Kesehatan, Kementerian Accreditation of Health Services, Directorate General
Kesehatan RI (2016-2018). Selain itu Beliau juga of Health Services, Indonesian Ministry of Health
menjabat sebagai Surveyor dan Pembimbing Akreditasi (2016-2018). Also served as Surveyor and Hospital
RS di Komisi Akreditasi Rumah Sakit (2004). Beliau Accreditation Supervisor at Komisi Akreditasi Rumah
juga aktif di organisasi perumahsakitan Asosiasi Rumah Sakit (2004). Is also active in the hospital organization in
Sakit Pendidikan Indonesia (ARSPI) sebagai Sekretaris the Asosiasi Rumah Sakit Pendidikan Indonesia (ARSPI)
Jenderal ARSPI periode 2022-2025. as Secretary General of ARSPI for the (2022-2025)
period.
Beliau tidak memiliki rangkap jabatan baik di dalam She does not hold any concurrent positions either inside
maupun di luar BMHS. or outside BMHS.
Page 138
138 Governansi Korporat
Corporate Governance
Pernyataan Independensi Komite GCG dan GCG and Risk Management Committee Statement of
Manajemen Risiko Independence
BMHS menerapkan prinsip independensi BMHS applies the principle of independence in the
dalam pembentukan dan pelaksanaan tugas formation and implementation of the Risk Management
Komite GCG dan Manajemen Risiko. Komite ini Committee’s duties. This committee consists of
beranggotakan profesional independen yang memenuhi independent professionals who meet the requirements
persyaratan kompetensi dan integritas, sehingga dapat of competence and integrity, so they can carry out their
menjalankan perannya secara objektif dan bebas dari roles objectively and free from conflicts of interest.
benturan kepentingan. Komite GCG dan Manajemen The GCG and Risk Management Committee has no
Risiko tidak memiliki hubungan afiliasi dengan Dewan affiliation with the Board of Commissioners, Board of
Komisaris, Direksi, dan pemegang saham BMHS. Directors, and shareholders of BMHS.
Tugas dan Tanggung Jawab Komite GCG dan GCG and Risk Management Committee Duties and
Manajemen Risiko Responsibilities
Komite GCG dan Manajemen Risiko bertugas melakukan The GCG and Risk Management Committee’s duties
pemantauan dan memberikan nasihat kepada Direksi include monitoring and advising the Board of Directors
terkait penerapan tata kelola dan manajemen risiko di on the implementation of governance and risk
BMHS. Komite menelaah kesesuaian praktik tata kelola management within BMHS. The Committee reviews
dan kecukupan prosedur serta metodologi pengelolaan the appropriateness of governance practices and the
risiko yang diterapkan BMHS, guna memastikan adequacy of BMHS’s risk management procedures and
pengelolaan usaha berada dalam tingkat risiko yang methodologies, to ensure that business management
dapat diterima dan mendukung keberlanjutan BMHS. is within an acceptable level of risk and supports the
sustainability of BMHS.
Peningkatan Kompetensi Komite GCG dan GCG and Risk Management Committee Competency
Manajemen Risiko Development
Komite GCG dan Manajemen Risiko mengikuti program The GCG and Risk Management Committee
pelatihan dan pengembangan kompetensi, berupa participates in competency training and development
seminar, konferensi, workshop terkait industri pelayanan programs, including seminars, conferences, and
kesehatan, perkembangan regulasi terbaru, dan topik- workshops related to the healthcare industry, the latest
topik lain yang relevan dengan pelaksanaan tugasnya. regulatory developments, and other topics relevant
Sepanjang 2025, Komite GCG dan Manajemen Risiko to the performance of their duties. In 2025, the GCG
telah mengikuti beberapa pelatihan, di antaranya: and Risk Management Committee participated in the
following training programs:
Tanggal Pelatihan Nama Pelatihan Penyelenggara
No.
Training Date Training Name Organizer
10-13 Februari 2025
Pelatihan Audit dan Supervisi PPI RS
1 February 10-13, KARS
PPI Hospital Audit and Supervision Training
2025
26-27 Juli 2025 Pelatihan Starkes 2024 Bidang Manajemen
2 KARS
July 26-27, 2025 Starkes 2024 Training in Management
Certified Hospital Management Standard Evaluator Expert
13-14 Agustus 2025 (CHMEE)
3 KARS
August 13-14, 2025 Certified Hospital Management Standard Evaluator Expert
(CHMEE)
Pengembangan Keprofesian Berkelanjutan (WS Teknik Telusur Bid
4-7 Agustus 2025 Manajemen dan Alur Pelayanan di RS Kemenkes-PITSELNAS
4
August 4-7, 2025 Continuing Professional Development (WS Tracking Techniques in IX KARS
Hospital Management and Service Flow)
Page 139
Laporan Tahunan
Annual Report 139
Pelaksanaan Rapat Komite GCG dan Manajemen GCG and Risk Management Committee
Risiko Implementation of Meetings
Pedoman kerja Komite GCG dan Manajemen Risiko The GCG and Risk Management Committee work
mengatur tentang pelaksanaan rapat Komite sedikitnya guidelines stipulate that the Committee must hold at
satu kali dalam 4 bulan. Sepanjang 2025, Komite GCG least one meeting every four months. In 2025, the GCG
dan Manajemen Risiko telah melaksanakan 14 rapat, and Risk Management Committee held 14 meetings,
dengan tingkat kehadiran sebagai berikut: with the following attendance rates:
Nama Jabatan Jumlah Rapat Jumlah Kehadiran Tingkat Kehadiran (%)
Name Position Number of Meetings Total Attended Attendance Level
Arianti Anaya Ketua | Chair 14 14 100
Bernadette Eka A.
Anggota | Member 14 14 100
Wahjoeni
Keterangan: *) Efektif menjabat setelah 31 Desember 2025
Note: *) Effectively served after December 31, 2025
Pelaksanaan Kegiatan Komite GCG dan Manajemen GCG and Risk Management Committee
Risiko Implementation of Activities
Sepanjang 2025, Komite GCG dan Manajemen Risiko In 2025, the GCG and Risk Management Committee
menjalankan fungsi pengawasan melalui berbagai performed its supervisory function through activities in
kegiatan sesuai ruang lingkup tugas dan tanggung accordance with its scope of duties and responsibilities,
jawabnya, di antaranya: including:
1. Menyusun dan menelaah Laporan Profil Risiko, 1. Prepared and reviewed the Risk Profile Report, the
Laporan Kegiatan Komite GCG dan Manajemen GCG and Risk Management Committee Activity
Risiko, Laporan Tata Kelola Terintegrasi, serta Report, the Integrated Governance Report, and the
Laporan Hasil Kunjungan. Visit Results Report.
2. Menelaah dan memberikan rekomendasi kepada 2. Reviewed and provided recommendations to
Dewan Komisaris mengenai aspek risiko atas the Board of Commissioners regarding any risk
berbagai usulan Direksi yang memerlukan aspects in proposals from the Board of Directors
persetujuan Dewan Komisaris, antara lain terkait that required the Board of Commissioners’
perubahan anggaran dasar, penambahan penyertaan approval, including those related to amendments
modal, penjaminan aset perusahaan, usulan to the articles of association, additional capital
pembelian saham, Hospital Bylaws, pedoman tata participation, Company asset guarantees, proposed
kelola pengadaan barang dan jasa, dan RKAP PT share purchases, hospital bylaws, guidelines for the
Bundamedik Tbk Tahun 2025. governance of goods and services procurement, and
the 2025 RKAP Work Plan and Budget (RKAP) of
PT Bundamedik Tbk.
3. Melakukan visitasi pengawasan ke unit-unit usaha, 3. Conducted supervisory visits to business units, as
serta membangun komunikasi dan koordinasi terkait well as established communication and coordination
isu-isu yang menjadi perhatian Komite. regarding issues of concern to the Committee.
4. Berkoordinasi dengan unit-unit kerja BMHS untuk 4. Coordinated with BMHS’s work units to discuss
membahas berbagai isu terkait penerapan GCG dan issues related to the GCG implementation and Risk
Manajemen Risiko. Management.
Page 140
140 Governansi Korporat
Corporate Governance
Sekretaris Perusahaan
Corporate Secretary
Fungsi Sekretaris Perusahaan dibentuk untuk The Corporate Secretary function was established to
memperkuat efektivitas hubungan kerja antara Direksi strengthen the effectiveness of working relationships
dan Dewan Komisaris, mendorong penerapan praktik between the Board of Directors and the Board of
governansi korporat yang baik, serta memastikan Commissioners, to encourage the implementation
terselenggaranya komunikasi yang teratur, transparan, of good governance practices, and to ensure regular,
dan efektif dengan pemegang saham maupun pemangku transparent, and effective communication with
kepentingan lainnya, sesuai dengan ketentuan POJK shareholders and other stakeholders, in accordance
No.35/POJK.04/2014. Sekretaris Perusahaan diangkat with the provisions of POJK No.35/POJK.04/2014. The
dan diberhentikan melalui Keputusan Direksi dan Corporate Secretary is appointed and dismissed by a
bertanggung jawab langsung kepada Direktur Utama. Board of Directors’ decision and reports directly to the
President Director.
Profil Sekretaris Perusahaan
Corporate Secretary Profile
Josephine Tobing
Sekretaris Perusahaan
Corporate Secretary
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 44 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Sekretaris Perusahaan She serves as Corporate Secretary based on the
dengan dasar hukum pengangkatan Surat Keputusan legal basis of appointment of Corporate Secretary
Pengangkatan Sekretaris Perusahaan No. 010-I/SK/ Appointment Decree No. 010-I/SK/DIR/III/2021 dated
DIR/III/2021 tanggal 12 Maret 2021. March 12, 2021.
Beliau memperoleh gelar Sarjana Hukum dari She obtained a Bachelor’s degree in Law from
Universitas Katolik Parahyangan pada 2003 dan gelar Universitas Katolik Parahyangan in (2003), and a
Magister Hukum Kesehatan dari Universitas Katolik Master’s degree in Health Law from Universitas Katolik
Soegijapranata pada 2008. Soegijapranata in (2008).
Beliau memulai karier sebagai Associate di Martin, She started her career as an Associate at Martin,
Ibrahim and Partner Law Firm (2004-2005), dilanjutkan Ibrahim and Partner Law Firm (2004-2005), continued
sebagai Senior Lawyer di STAMP Law Firm (2005- as a Senior Lawyer at STAMP Law Firm (2005-2014),
2014), dan terakhir menjabat sebagai GM Corporate and most recently served as GM Corporate Legal at PT
Legal di PT Bundamedik Tbk (sejak 2014). Bundamedik Tbk (since 2014).
Beliau tidak memiliki rangkap jabatan baik di dalam She does not hold any concurrent positions either inside
maupun di luar BMHS. or outside BMHS.
Page 141
Laporan Tahunan
Annual Report 141
Tugas dan Tanggung Jawab Sekretaris Perusahaan Corporate Secretary’s Duties and Responsibilities
Sekretaris Perusahaan melaksanakan fungsi The Corporate Secretary performs secretarial,
kesekretariatan, komunikasi, kepatuhan, serta aspek communication, compliance, and legal functions,
hukum, termasuk tugas lain yang diberikan oleh including other duties assigned by the President
Direktur Utama. Adapun tugas dan tanggung jawab Director. The Corporate Secretary’s duties and
Sekretaris Perusahaan mencakup: responsibilities include the following:
1. Memantau perkembangan Pasar Modal khususnya 1. Monitors Capital Market developments, particularly
ketentuan dan peraturan perundang-undangan yang applicable laws and regulations.
berlaku.
2. Memberikan masukan kepada Direksi dan Dewan 2. Provides input to the Board of Directors and Board of
Komisaris terkait pemenuhan kewajiban dan Commissioners concerning fulfillment of obligations
kepatuhan terhadap regulasi Pasar Modal. and compliance with Capital Market regulations.
3. Mendukung Direksi dan Dewan Komisaris dalam 3. Supports the Board of Directors and Board
penerapan governansi korporat, yang mencakup: of Commissioners in corporate governance
implementation, which includes:
a. Penyampaian informasi secara terbuka kepada a. Disclosure of information to the public, including
publik, termasuk pemutakhiran informasi pada updating information on BMHS’s website;
situs web BMHS;
b. Penyampaian laporan kepada Otoritas Jasa b. Submitting reports to the Financial Services
Keuangan (OJK) secara tepat waktu; Authority (OJK) in a timely manner;
c. Penyelenggaraan dan pendokumentasian Rapat c. Organizing and documenting the General
Umum Pemegang Saham; Meetings of Shareholders;
d. Penyelenggaraan dan pendokumentasian rapat d. Organizing and documenting Board of Directors
Direksi dan Dewan Komisaris; serta and Board of Commissioners meetings; and
e. Fasilitas program orientasi bagi anggota Direksi e. Facilitating orientation programs for newly
dan Dewan Komisaris yang baru diangkat. appointed members to the Board of Directors and
Board of Commissioners.
4. Bertindak sebagai penghubung antara BMHS dan 4. Acts as a liaison between BMHS and shareholders,
pemegang saham, Otoritas Jasa Keuangan, serta Financial Services Authority (OJK), and other
pemangku kepentingan lainnya; dan stakeholders; and
5. Mewakili BMHS dalam komunikasi dengan otoritas 5. Represents BMHS in communications with capital
pasar modal sesuai kewenangan yang diberikan. market authorities in accordance with the authority
granted.
Peningkatan Kompetensi Competency Development
Sekretaris Perusahaan mengikuti program pelatihan The Corporate Secretary participates in competency
dan pengembangan kompetensi, berupa seminar, training and development programs, including seminars,
konferensi, workshop terkait regulasi tentang pasar conferences, and workshops related to capital market
modal, fungsi sekretaris perusahaan, industri pelayanan regulations, corporate secretary functions, the
kesehatan, dan topik-topik lain yang relevan dengan healthcare industry, and other topics relevant to the
pelaksanaan tugasnya. Sepanjang 2025, Sekretaris performance of their duties. In 2025, the Corporate
Perusahaan telah mengikuti beberapa pelatihan, di Secretary participated in several training programs,
antaranya: including:
Tanggal Pelatihan Nama Pelatihan Penyelenggara
No.
Training Date Training Name Organizer
ESG Disclosure: Peran Corporate Secretary dalam Penyampaian ESG
24 Februari 2025 Metrics melalui SPE-IDXnet
1 ICSA
February 24, 2025 ESG Disclosure: The Role of the Corporate Secretary in Reporting ESG
Metrics via SPE-IDXnet
Page 142
142 Governansi Korporat
Corporate Governance
Tanggal Pelatihan Nama Pelatihan Penyelenggara
No.
Training Date Training Name Organizer
ESG Risk Governance: Peran Corporate Secretary dalam Tata Kelola dan
6 Maret 2025 Pelaporan Risiko ESG
2 ICSA
March 6, 2025 ESG Risk Governance: The Role of the Corporate Secretary in ESG Risk
Governance and Reporting
10 Maret 2025 PT BMHS Diklat
3 Enterprise Risk Management Fundamental
March 10, 2025 Indonesia
Peran Corporate Secretary dalam Mendorong Governansi, Manajemen
17 April 2025 Risiko, dan Kepatuhan (GRK) yang Baik
4 ICSA
April 17, 2025 The Role of the Corporate Secretary in Promoting Good Governance,
Risk Management, and Compliance (GRM)
22 Juli 2025
5 Embracing Diversity, Equality, Inclusion in The Workplace ICSA
July 22, 2025
29 Agustus 2025 A Risk-Based Approach to ESG: Building Resilient, Responsible
6 ICSA
August 29, 2025 Businesses
1 Oktober 2025
7 From Policy to Impact: Best Practice in ESG Journey ICSA
October 1, 2025
29 Oktober 2025 Integrasi Cyber Security dalam Good Corporate Governance (GCG):
8 ICSA
October 29, 2025 Peran Penting Corporate Secretary
13 November 2025
9 IFRS 1 & 2 Update and Practical Insights for Public Companies ICSA
November 13, 2025
18 November 2025 Leadership Coaching Mastermind : Coaching That Ignites Leader’s
10 Coaching Yuk
November 18, 2025 Influence
Masterclass Perlindungan Data Pribadi : ROPA-DPIA, Data Flow dan
19-20 November 2025
Data Transfer
11 November 19–20, Hukumonline
Masterclass on Personal Data Protection: ROPA-DPIA, Data Flow, and
2025
Data Transfer
Kepatuhan ESG bagi Profesional Hukum : Dari Prinsip Hingga
25 November 2025 Implementasi
12 Hukumonline
November 25, 2025 ESG Compliance for Legal Professionals: From Principles to
Implementation
Membangun Sistem Whistleblowing yang Efektif dan Berintegritas
1 Desember 2025 Berbasis ISO 37002:2021
13 ICSA
December 1, 2025 Building an Effective and Ethical Whistleblowing System Based on ISO
37002:2021
Pelaksanaan Kegiatan Sekretaris Perusahaan Corporate Secretary’s Implementation of Activities
Sepanjang 2025, Sekretaris Perusahaan menjalankan In 2025, the Corporate Secretary carried out secretarial
fungsi kesekretariatan dan liaison officer melalui and liaison officer functions through the following
berbagai kegiatan sesuai ruang lingkup tugas dan activities in accordance with their scope of duties and
tanggung jawabnya, di antaranya: responsibilities, including:
1. Mengagendakan serta mengoordinasikan rapat 1. Scheduled and coordinated Board of Commissioners
Dewan Komisaris dan Direksi, termasuk menyiapkan and Board of Directors meetings, including
dokumentasi hasil rapat; documented the meeting results;
2. Mengatur pelaksanaan RUPS sesuai ketentuan yang 2. Arranged GMS in line with applicable regulations and
berlaku dan mempublikasikan agenda serta hasilnya published the agenda and results through BMHS’s
melalui situs web BMHS dan media yang ditetapkan website and media designated by the regulator;
regulator;
3. Menyampaikan keterbukaan informasi kepada OJK 3. Submitted information disclosure to Financial
dan Bursa terkait aksi korporasi, laporan BMHS, dan Services Authority (OJK) and the Stock Exchange
informasi lain yang menjadi perhatian regulator; concerning corporate actions, Company reports, and
other information of interest to regulators;
4. Memfasilitasi komunikasi antara BMHS dengan 4. Facilitated the communication between BMHS
OJK, Bursa, pemegang saham, calon investor, dan and Financial Services Authority (OJK), the Stock
pemangku kepentingan lainnya; Exchange, shareholders, potential investors, and
other stakeholders;
Page 143
Laporan Tahunan
Annual Report 143
5. Mendukung Direksi dalam pengelolaan administrasi 5. Supported the Board of Directors in administrative
dan pemenuhan kewajiban kepatuhan. management and compliance obligations.
Unit Internal Audit
Internal Audit Unit
Unit Internal Audit merupakan fungsi pengawasan The Internal Audit Unit is BMHS’s internal oversight
internal BMHS yang bertugas mendukung efektivitas function that supports the effectiveness of governance,
tata kelola, pengendalian internal, dan manajemen risiko internal control, and risk management across all business
di seluruh unit usaha. Unit Internal Audit bekerja secara units. The Internal Audit Unit works independently
independen untuk memberikan penilaian objektif atas to provide objective assessments of the adequacy of
kecukupan proses bisnis, memfasilitasi penerapan business processes, to facilitate the implementation
manajemen risiko, serta berkoordinasi dengan unit of risk management, and to coordinate with internal
pengawas internal di rumah sakit dan entitas anak guna supervisory units in hospitals and subsidiaries to ensure
memastikan pengawasan berjalan terpadu di seluruh integrated supervision across BMHS’s ecosystem. In
ekosistem BMHS. Seiring dengan perubahan struktur line with organizational restructuring, the Internal
organisasi, unit Internal Audit & Risk Management Audit & Risk Management (IARM) unit was renamed
(IARM) telah disesuaikan menjadi Internal Audit, Internal Audit, in line with the Risk Management
sejalan dengan fungsi Risk Management yang dialihkan function being transferred to the Corporate Secretary
ke Corporate Secretary sejak Desember 2024. in December 2024.
Struktur dan Kedudukan Structure and Position
Unit Kerja Internal Audit dipimpin oleh Kepala Unit The Internal Audit Work Unit is led by the Head of the
Internal Audit PT Bundamedik Tbk yang bertanggung Internal Audit Unit of PT Bundamedik Tbk, who reports
jawab langsung kepada Direktur Utama. Pengangkatan directly to the President Director. The appointment
dan pemberhentian Kepala Unit Internal Audit and dismissal of the Head of the Internal Audit Unit is
dilakukan oleh Direktur Utama dengan persetujuan carried out by the President Director with the approval
Dewan Komisaris. Kepala Unit Kerja Internal Audit of the Board of Commissioners. The Head of the
memimpin Auditor Pelaksana dan bertanggung jawab Internal Audit Work Unit leads the Executive Auditors
atas pelaksanaan audit internal serta pengawasan and is responsible for conducting internal audits and
pengendalian internal di seluruh unit usaha BMHS. supervising internal controls in all Company business
Tugas ini juga mencakup koordinasi dengan Satuan units. These duties also include coordinating with the
Pengawas Internal (SPI) di unit rumah sakit serta dengan Internal Audit Unit (SPI) in the hospital units, and with
unit internal audit pada entitas anak untuk memastikan the internal audit unit in the subsidiaries entities to
pengawasan internal berjalan secara terpadu. ensure that internal supervision is carried out in an
integrated manner.
Unit Kerja Internal Audit terdiri atas satu Kepala Unit The Internal Audit Unit consists of one Head and seven
dan tujuh auditor korporat. Dari tujuh auditor tersebut, corporate auditors. Of the seven auditors, five also
lima auditor juga menjalankan fungsi sebagai Satuan serve as Internal Audit Units (SPI) for hospitals located
Pengawas Internal (SPI) untuk rumah sakit yang in the Greater Jakarta area. For hospitals outside the
berada di wilayah Jabodetabek. Untuk rumah sakit Greater Jakarta area, internal audit is carried out by
di luar Jabodetabek, pengawasan internal dilakukan SPI employees who are specifically assigned to each
oleh pegawai SPI yang ditempatkan khusus di masing- hospital. In addition, three subsidiaries have their own
masing rumah sakit. Selain itu, Tiga entitas anak usaha internal auditors, who remain under the coordination of
memiliki auditor internal masing-masing, yang tetap the Internal Audit Unit.
berada dalam koordinasi Unit Kerja Internal Audit.
Page 144
144 Governansi Korporat
Corporate Governance
Tubagus Adi Satria Prakasa
Kepala Divisi Internal Audit
Head of Internal Audit Division
Warga Negara Indonesia | Indonesian Citizen
Usia | Age: 41 tahun/years
Domisili | Domicile: Jakarta, Indonesia
Beliau menjabat sebagai Kepala Divisi Internal Audit He serves as Head of the Internal Audit Division based
dengan dasar hukum pengangkatan Surat Keputusan on the legal appointment in the Board of Directors
Direksi No. 028-1/SK/DIRUT/VI/2022 tanggal 7 Juni Decree No. 028-1/SK/DIRUT/VI/2022 dated June
2022 tentang Pengangkatan Head of Internal Audit. 7, 2022 concerning the Appointment of the Head of
Internal Audit.
Beliau memperoleh gelar Sarjana Ekonomi dari program He obtained a Bachelor of Economics degree from the
studi Ekonomi Pembangunan Fakultas Ekonomi dari Development Economics study program, Faculty of
Universitas Katolik Parahyangan pada 2005 dan Economics, Universitas Katolik Parahyangan in 2005
gelar Magister Ekonomi dari program MPKP Fakultas and his Master of Economics degree from the MPKP
Ekonomi dari Universitas Indonesia pada 2009. program, Faculty of Economics, Universitas Indonesia
in 2009.
Riwayat jabatan beliau di antaranya sebagai Anggota His career includes being a Member of the Risk
Komite Manajemen Risiko-Dewan Pengawas BPJS Management Committee- of the BPJS Kesehatan RI
Kesehatan RI (2016-2021) dan Koordinator Anggota Supervisory Board (2016-2021) and Coordinator of
Komite Non Dewan Pengawas BPJS Kesehatan (2019- Non-Supervisory Board Committee Members of BPJS
2021). Selanjutnya beliau bergabung di PT Bundamedik Kesehatan (2019-2021). He joined PT Bundamedik Tbk
Tbk sebagai Kepala Divisi Kebijakan, Risiko, dan as Head of the Policy, Risk, and Compliance Division
Kepatuhan (sejak 2021). (since 2021).
Saat ini, beliau memiliki rangkap jabatan sebagai Currently, he holds a concurrent position as Member
Anggota Komite Audit PT Morula Indonesia (sejak of the Audit Committee of PT Morula Indonesia (since
2023). 2023).
Tugas dan Tanggung Jawab Duties and Responsibilities
Unit Kerja Internal Audit menjalankan fungsi The Internal Audit Unit internal supervisory duties and
pengawasan internal, dengan ruang lingkup tugas dan responsibilities include:
tanggung jawab mencakup:
1. Menyusun dan melaksanakan rencana kerja audit 1. Preparing and implementing the annual internal
internal tahunan yang ditetapkan oleh Direktur audit work plan detemined by the President
Utama setelah memperoleh pertimbangan Dewan Director after obtaining consideration from the
Komisaris c.q. Komite Audit selambatnya pada Board of Commissioners c.q. Audit Committee no
Desember sebelum tahun berjalan; later than December before the current year;
Page 145
Laporan Tahunan
Annual Report 145
2. Melakukan pengujian dan evaluasi atas efektivitas 2. Testing and evaluating the effectiveness of
pengendalian internal dan sistem manajemen risiko internal controls and risk management systems in
sesuai dengan kebijakan BMHS; accordance with BMHS’s policies;
3. Mendampingi proses Audit Eksternal (KAP), 3. Providing assistance in the External Audit (KAP)
termasuk tahapan closing secara berkala; process, including the closing stage on a regular
basis;
4. Mereviu laporan keuangan tahunan yang disusun 4. Reviewing the annual financial statements prepared
Direktorat Keuangan sebelum disampaikan kepada by the Finance Directorate before they are
auditor eksternal dan regulator; submitted to external auditors and regulators;
5. Melakukan pemeriksaan dan penilaian secara 5. Conducting periodic reviews and assessments of
berkala atas kecukupan dan efektivitas the adequacy and effectiveness of the controls
pengendalian maupun manajemen risiko di seluruh and risk management in all aspects (finance,
aspek (keuangan, operasional pelayanan, SDM, TI, service operations, HC, IT, commercial, business
komersial, pengembangan usaha, kesekretariatan, development, secretarial, and others);
dan lainnya);
6. Memberikan informasi dan rekomendasi perbaikan 6. Providing objective information and
yang objektif kepada manajemen berdasarkan hasil recommendations for improvements to management
pemeriksaan; based on the results of the examinations;
7. Melaporkan hasil pemeriksaan beserta tindak 7. Reporting the audit results and follow-up
lanjutnya secara berkala (triwulanan) kepada periodically (quarterly) to the President Director,
Direktur Utama, dengan tembusan kepada with a copy to the President Commissioner c.q.
Komisaris Utama c.q. Ketua Komite Audit; Chair of the Audit Committee;
8. Melaporkan kejadian signifikan yang berkaitan 8. Reporting significant events related to the
dengan sistem pengendalian manajemen management control system and identifying the
serta mengidentifikasi kebutuhan perbaikan need for internal control improvements;
pengendalian internal;
9. Memantau, menganalisis, dan melaporkan 9. Monitoring, analyzing, and reporting the
pelaksanaan tindak lanjut rekomendasi yang berasal implementation of follow-up recommendations
dari audit internal maupun audit eksternal; from internal and external audits;
10. Berkoordinasi dengan Komite Audit melalui 10. Cooperating with the Audit Committee through
pertemuan berkala atau insidentil untuk membahas regular or incidental meetings to discuss audit
perkembangan pemeriksaan dan memperoleh developments and to obtain input;
masukan;
11. Memberikan konsultasi kepada unit kerja, unit 11. Providing consultation to work units, business
usaha, dan entitas anak terkait pengendalian units, and subsidiaries concerning internal control,
internal, tata kelola, dan manajemen risiko apabila governance, and risk management if necessary;
diperlukan;
12. Menyusun program evaluasi mutu audit internal 12. Developing an evaluation program on the quality of
yang telah dilakukan; dan internal audits conducted; and
13. Melaksanakan pemeriksaan khusus berdasarkan 13. Conducting special audits based on assignments
penugasan Direktur Utama dengan tetap menjaga from the President Director while maintaining the
independensi auditor internal. independence of internal auditors.
Pedoman Kerja Division Work Guidelines
Unit kerja Internal Audit menjalankan fungsinya The Internal Audit unit performs its functions based
berdasarkan pedoman kerja yang disusun dengan on work guidelines prepared with reference to Law
mengacu pada UU No. 8 Tahun 1995 tentang Pasar No. 8 of 1995 concerning Capital Markets, Law No. 21
Modal, UU No. 21 Tahun 2011 tentang Otoritas Jasa of 2011 concerning Financial Services Authority, and
Keuangan, dan POJK No.56/POJK.04/2015 Tahun POJK No.56/POJK.04/2015 of 2015 concerning the
2015 tentang Pembentukan dan Pedoman Penyusunan Establishment and Guidelines for the Preparation of
Page 146
146 Governansi Korporat
Corporate Governance
Piagam Unit Audit Internal. Pedoman kerja atau Piagam Internal Audit Unit Charters. These work guidelines
Audit Internal tersebut telah mendapat persetujuan or Internal Audit Charter were approved by the
Dewan Komisaris, dan ditetapkan oleh Direksi pada 7 Board of Commissioners and ratified by the Board of
Juni 2022. Pedoman ini memuat ketentuan mengenai Directors on June 7, 2022. These guidelines contain
tugas, tanggung jawab dan wewenang, struktur dan provisions concerning the Internal Audit Unit duties,
kedudukan, kode etik, persyaratan auditor internal, dan responsibilities and authorities, structure and position,
pertanggungjawaban Unit Audit Internal. code of ethics, internal auditor requirements, and
accountability.
Sertifikasi dan Pelatihan Certification and Training
Unit kerja Internal Audit didukung oleh auditor The Internal Audit unit is supported by internal
internal yang memiliki kompetensi sesuai bidangnya auditors who have expertise in their respective fields
dan memenuhi kualifikasi yang dipersyaratkan oleh and meet the qualifications required by regulations.
regulasi. Kepala Unit Internal Audit, Tubagus Adi The Head of the Internal Audit Unit, Tubagus Adi Satria
Satria Prakasa telah mengikuti sertifikasi Enterprise Prakasa, has obtained the Enterprise Risk Management
Risk Management Certified Professional yang diterbitkan Certified Professional certification issued by ERMA and
ERMA dan CRMS. Unit kerja Internal Audit mengikuti CRMS. The Internal Audit unit participates in training
program pelatihan dan pengembangan kompetensi, and competency development programs, including
berupa seminar, konferensi, workshop terkait audit seminars, conferences, and workshops related to
internal dan manajemen risiko, perubahan regulasi, internal audit and risk management, regulatory changes,
industri pelayanan kesehatan, dan topik-topik lain yang the healthcare industry, and other topics relevant to
relevan dengan pelaksanaan tugasnya. Sepanjang 2025, the performance of its duties. In 2025, Internal Audit
Internal Audit telah mengikuti beberapa pelatihan, di participated in the following training programs:
antaranya:
Tanggal Pelatihan Nama Pelatihan Penyelenggara
No.
Training Date Training Name Organizer
Workshop Audit Mutu Internal PT BMHS Diklat
1 23 –24 Juni 2025 | June 23-24, 2025
Internal Quality Audit Workshop Indonesia
2 4 Maret 2025 | March 4, 2025 Business Process Improvement
3 5 Maret 2025 | March 5, 2025 Finance Foundations: Corporate Governance
4 16 Maret 2025 | March 16, 2025 Audit & Due Diligence Foundations
5 24 Maret 2025 | March 24, 2025 ESG Disclosure and Compliance LinkedIn Learning
6 1 Mei 2025 | May 1, 2025 Accounting Foundations: Internal Controls
7 3 Juni 2025 | June 3, 2025 Finance Strategies For Business Leaders
8 8 Juli 2025 | July 8, 2025 Strategic Planning Foundations
Pelaksanaan Rapat dan Kegiatan Divisi Internal Implementation of Internal Audit Division Meetings
Audit and Activities
Unit Kerja Internal Audit secara berkala melaksanakan The Internal Audit Work Unit regularly holds meetings
rapat dengan Dewan Komisaris, Direksi, dan Komite with the Board of Commissioners, Board of Directors,
Audit, untuk membahas penugasan terkait sistem and Audit Committee to discuss assignments related to
pengendalian internal dan manajemen risiko BMHS, BMHS’s internal control and risk management systems,
dengan tingkat kehadiran sebagai berikut: with the following attendance rates:
Page 147
Laporan Tahunan
Annual Report 147
Tingkat Kehadiran
Rapat Jumlah Rapat Jumlah Kehadiran
(%)
Meetings Number of Meetings Total Attended
Attendance Level
Rapat dengan Dewan Komisaris
4 4 100
Meetings with the Board of Commissioners
Rapat dengan Direksi
12 12 100
Meetings with the Board of Directors
Rapat dengan Komite Audit
4 4 100
Meetings with the Audit Committee
Rapat dengan Anggota Audit Internal
12 8 100
Meetings with Internal Audit Members
Rapat dengan Satuan Pengawas Internal Rumah Sakit
12 10 100.
Meetings with Hospital Internal Audit Units
Sepanjang 2025, Unit Kerja Internal Audit telah In 2025, the Internal Audit Work Unit carried out
melaksanakan seluruh program dalam Rencana Kerja all programs in the Internal Audit Work Plan, which
Internal Audit, yang mencakup pemeriksaan rutin, included routine audits, special audits, and compliance
pemeriksaan khusus, dan pemantauan kepatuhan. monitoring. Routine audits were conducted in all
Pemeriksaan rutin dilakukan pada seluruh unit rumah hospital units and subsidiaries of BMHS, covering 8
sakit dan anak usaha BMHS, yang mencakup 8 RS dan hospitals and 7 subsidiaries. In addition, the Internal
7 entitas anak usaha. Selain itu, Unit Kerja Internal Audit Unit also conducted 8 special audits as assigned,
Audit juga melaksanakan 8 pemeriksaan khusus sesuai provided recommendations to the auditees, and
penugasan, serta memberikan rekomendasi kepada monitored their follow-up actions on a regular basis.
auditee dan memantau tindak lanjutnya secara berkala.
Dalam pemantauan kepatuhan, Unit Kerja Internal In monitoring compliance, the Internal Audit Work
Audit melakukan berbagai kegiatan meliputi monitoring Unit conducts other activities including monitoring
inventarisasi persediaan dan kas, penelaahan inventory and cash, reviewing the suitability of assets
kesesuaian aset dalam proses mutasi atau penghapusan, in the transfer or disposal process, monitoring the
pemantauan pengadaan barang dan jasa, serta procurement of goods and services, and conducts annual
inventarisasi aset tahunan. Pemantauan juga mencakup asset inventories. Monitoring also includes following up
tindak lanjut hasil audit, daftar risiko rumah sakit, on audit results, hospital risk lists, and the compliance of
dan kepatuhan unit RS terhadap sistem pengendalian hospital units with internal control systems.
internal.
Untuk memperoleh gambaran mendalam atas isu To gain an in-depth understanding of compliance and
kepatuhan dan pengendalian internal, divisi melakukan internal control issues, the division reviewed several
reviu atas beberapa kajian, termasuk kajian atas studies, including studies on hospital financial operating
prosedur operasional keuangan RS dan kajian terkait procedures and data security. The Internal Audit Unit
keamanan data. Unit Kerja Internal Audit juga also monitored asset inventory across all hospital units,
melaksanakan pemantauan terkait aset opname pada re-socialized the code of ethics, anti-corruption policies,
seluruh unit rumah sakit, menyosialisasikan kembali and the use of the whistleblowing system (WBS), and
kode etik, kebijakan antikorupsi, dan penggunaan followed up on reports of violations received. In addition,
whistleblowing system (WBS), serta menindaklanjuti the division coordinated the collection of integrity pacts
laporan pelanggaran yang diterima. Selain itu, divisi from employees and active vendors throughout 2025.
turut mengoordinasikan pengumpulan pakta integritas
pegawai dan vendor aktif sepanjang 2025.
Page 148
148 Governansi Korporat
Corporate Governance
Sebagai bagian dari penguatan pengendalian internal, As part of strengthening internal control, the Internal
Unit Kerja Internal Audit juga menyusun Pedoman Audit Work Unit also compiled Hospital Internal Control
Sistem Pengendalian Internal (SPI) RS sebagai acuan System (SPI) Guidelines as a reference for implementing
pelaksanaan SPI di seluruh unit RS. Secara keseluruhan, SPI in all hospital units. Overall, the Internal Audit Work
Unit Kerja Internal Audit menjalankan pemantauan, Unit carries out monitoring, analysis, and reporting
analisis, dan pelaporan untuk memastikan kecukupan to ensure the adequacy and effectiveness of BMHS’s
serta efektivitas sistem pengendalian internal BMHS. internal control system.
Sistem Pengendalian Internal
Internal Control System
BMHS menerapkan Sistem Pengendalian Internal BMHS has implemented an Internal Control System
(SPI) di seluruh unit kerja dan jenjang organisasi. SPI (SPI) across all work units and organizational levels.
berfungsi sebagai mekanisme pengawasan The SPI serves as a continuous monitoring mechanism
berkelanjutan untuk melindungi aset BMHS, to protect BMHS’s assets, ensure the availability of
memastikan tersedianya laporan keuangan dan reliable financial and managerial reports, improve
manajerial yang andal, meningkatkan kepatuhan compliance with laws and regulations, and minimize
terhadap peraturan perundang-undangan, potential losses and irregularities. This system is
serta meminimalisasi potensi kerugian maupun designed to identify events that could potentially affect
penyimpangan. Sistem ini dirancang untuk BMHS’s performance, and manage risks to remain
mengidentifikasi kejadian yang berpotensi within tolerance limits (risk appetite) in order to support
memengaruhi kinerja BMHS dan mengelola risiko agar the achievement of BMHS’s objectives.
tetap berada dalam batas toleransi (risk appetite) guna
mendukung pencapaian tujuan BMHS.
Tinjauan atas Efektivitas Sistem Pengendalian Review of the Internal Control System Effectiveness
Internal
Penerapan SPI diintegrasikan ke dalam proses The SPI is integrated into the strategy and operational
penetapan strategi dan operasional di seluruh unit determination processes across all work units with
kerja dengan mengacu pada Kebijakan Internal Control reference to the Internal Control Policy (KICN) as
(KICN) yang tercantum dalam Pedoman Tata Kelola dan stated in the Governance Guidelines and Internal
Piagam Internal Audit. Setiap unit kerja bertanggung Audit Charter. Each work unit is responsible for its
jawab atas penerapan komponen pengendalian internal control components, including management
internal, termasuk pengawasan manajemen, budaya supervision, control culture, risk identification and
pengendalian, identifikasi dan penilaian risiko, aktivitas assessment, control activities and segregation of
pengendalian dan pemisahan fungsi, keandalan sistem duties, reliability of accounting systems, utilization
akuntansi, pemanfaatan teknologi informasi dan of information and communication technology,
komunikasi, serta pemantauan dan tindak korektif atas and monitoring and corrective action on identified
penyimpangan atau kelemahan yang teridentifikasi. deviations or weaknesses.
BMHS turut membangun budaya pengendalian dan BMHS also fosters a culture of control and risk
kesadaran risiko sebagai bagian dari penguatan SPI. Unit awareness as part of strengthening the SPI. The Internal
kerja Internal Audit melakukan audit dan pemantauan Audit unit conducts regular audits and monitoring to
secara berkala untuk menilai efektivitas penerapannya assess the effectiveness of its implementation, and
dan memberikan rekomendasi perbaikan. provides recommendations for improvement.
Pernyataan Direksi dan/atau Dewan Komisaris atas Statement by the Board of Directors and/or Board
Kecukupan Sistem Pengendalian Internal of Commissioners on the Adequacy of the Internal
Control System
Direksi menilai bahwa BMHS telah memiliki Sistem The Board of Directors believes that BMHS has an
Pengendalian Internal yang memadai dan berjalan adequate and effective Internal Control System.
Page 149
Laporan Tahunan
Annual Report 149
efektif. Namun, peningkatan tetap diperlukan seiring However, improvements are still needed in line
pertumbuhan usaha dan meningkatnya kompleksitas with business growth and increasing complexity
peluang maupun risiko. Direksi terus memberikan of opportunities and risks. The Board of Directors
arahan untuk memperkuat budaya sadar risiko dan continues to provide guidance to strengthen a
memastikan bahwa praktik pengendalian internal risk awareness culture and to ensure that internal
diterapkan secara konsisten di seluruh tingkatan control practices are consistently implemented at all
organisasi. organization levels.
BMHS terus meningkatkan efektivitas SPI dengan BMHS continues to improve the effectiveness of its
mengacu pada prinsip-prinsip SPI yang dikembangkan internal control system by referring to the internal
Committee of Sponsoring Organizations of the control principles developed by the Committee of
Treadway Commission (COSO), khususnya pada Sponsoring Organizations of the Treadway Commission
aspek pengendalian, penilaian risiko, dan pemantauan. (COSO), particularly in the areas of control, risk
Peningkatan dilakukan secara berkelanjutan dan assessment, and monitoring. Improvements are made
proporsional terhadap kompleksitas usaha. on an ongoing basis and in proportion to the complexity
of the business.
Sistem Manajemen Risiko
Risk Management System
BMHS terus memperkuat penerapan sistem BMHS continues to strengthen its risk management
manajemen risiko sebagai bagian integral dari systems as an integral part of good corporate
governansi korporat yang baik. Sejalan dengan governance. In line with strengthening the governance
penguatan fungsi governansi, pada 2025 dilakukan functions, in 2025, the risk management function,
perubahan fungsi manajemen risiko yang sebelumnya which was previously under the Internal Audit &
berada di bawah Divisi Internal Audit & Risk Risk Management Division, was transferred to the
Management menjadi berada di bawah Direktorat Corporate Secretary Directorate. Currently, the Risk
Corporate Secretary. Saat ini, fungsi manajemen Management & Sustainability Division under the
risiko dijalankan oleh Divisi Risk Management & Corporate Secretary Directorate carries out the risk
Sustainability yang berada di bawah Direktorat management function. This arrangement is aimed at
Corporate Secretary. Penataan ini bertujuan improving the effectiveness of coordination, integrate
meningkatkan efektivitas koordinasi, integrasi risk management with corporate strategy, and
pengelolaan risiko dengan strategi korporasi, serta strengthen supervision of business and sustainability
penguatan pengawasan terhadap risiko bisnis dan risks.
keberlanjutan.
Sebagai landasan penerapan, BMHS telah menerbitkan As a basis for its implementation, BMHS issued Risk
Pedoman Manajemen Risiko PT Bundamedik Tbk dan Management Guidelines for PT Bundamedik Tbk and
Anak Usaha yang mengacu pada ISO 31000 dalam its Subsidiaries, which refer to ISO 31000 concerning
pengelolaan risiko. Pedoman ini menjadi acuan bagi risk management. These guidelines serve as a reference
seluruh entitas dalam mengidentifikasi, menganalisis, for all entities in identifying, analyzing, controlling,
mengendalikan, serta memantau risiko secara and monitoring risks in a systematic and sustainable
sistematis dan berkelanjutan. manner.
Implementasi manajemen risiko di tingkat Korporat, Risk management at the corporate, business unit, and
Unit Usaha, dan Anak Usaha merupakan tanggung subsidiary levels is the responsibility of Corporate
jawab Corporate Risk Management, yang didukung oleh Risk Management, supported by all work units
seluruh unit kerja dan anak usaha melalui penunjukan and subsidiaries through the appointment of Risk
Risk Champion dari masing-masing unit dan anak usaha. Champions in each unit and subsidiary. Risk Champions
Risk Champion berperan sebagai penghubung dalam act as liaisons during the process of identifying,
Page 150
150 Governansi Korporat
Corporate Governance
proses identifikasi, mitigasi, serta pelaporan risiko di mitigating, and reporting risks within their respective
lingkup operasional masing-masing. operational scopes.
Dalam pelaksanaannya, BMHS melakukan aktivitas For its implementation, BMHS conducts risk
manajemen risiko secara berkelanjutan melalui proses management activities on an ongoing basis through
identifikasi risiko, analisis dan penilaian risiko, serta the processes of risk identification, risk analysis and
monitoring dan evaluasi atas efektivitas pengendalian assessment, as well as monitoring and evaluating the
yang telah diterapkan. Hasil pelaksanaan manajemen effectiveness of the controls implemented. The risk
risiko dilaporkan kepada manajemen sebagai dasar management implementation results are reported to
pengambilan keputusan strategis. management as a basis for strategic decision-making.
Untuk mendukung pengembangan kompetensi dan To support competency development and improve
meningkatkan pemahaman mengenai manajemen understanding of risk management, in 2025 BMHS
risiko, di tahun 2025 BMHS menyelenggarakan organized Enterprise Risk Management (ERM) training
pelatihan dan workshop Enterprise Risk Management and workshops for relevant units. This initiative was part
(ERM) bagi unit terkait. Inisiatif ini merupakan of BMHS’s commitment to building a risk awareness
bagian dari komitmen BMHS dalam membangun culture throughout the organization.
budaya sadar risiko (risk awareness culture) di seluruh
organisasi.
Kerangka kerja dan tata kelola manajemen risiko BMHS BMHS’s risk management framework and governance
juga melibatkan Dewan Komisaris yang menjalankan also involves the Board of Commissioners, which
fungsi risk oversight melalui Komite GCG dan Manajemen performs a risk supervision function through the
Risiko. Direksi bertanggung jawab atas penetapan GCG and Risk Management Committee. The Board of
kebijakan risiko (risk policy) dan pengarahannya. Directors is responsible for establishing and directing
the risk policies.
Jenis Risiko dan Cara Pengelolaannya Types of Risk and How They are Managed
BMHS telah mengidentifikasi risiko utama dan BMHS has identified the following risks and grouped
mengelompokkannya ke dalam tujuh kategori berikut: them into the seven categories:
1. Risiko Tata Kelola 1. Governance Risk
Risiko yang berkaitan dengan tata kelola perusahaan, Risk related to corporate governance resulting from
yang dikarenakan prinsip tata kelola tidak terlaksana non-implementation of good governance principles.
dengan baik. Potensi risiko timbul akibat perubahan Potential risks arise due to changes in health
regulasi/kebijakan/standar kesehatan dan belum regulations/policies/standards and incomplete
lengkapnya pedoman/prosedur/panduan guna guidelines/procedures/guidance for applying
menerapkan prinsip-prinsip tata kelola yang baik comprehensive good governance principles in the
secara menyeluruh dalam pengelolaan BMHS. management of BMHS.
2. Risiko Strategis 2. Strategic Risk
Risiko yang berkaitan dengan pelaksanaan strategi Risk related to the implementation of business
bisnis atau perubahan target yang ditetapkan, antara strategies or changes in targets set including:
lain:
a. Perubahan target dan rencana strategis BMHS; a. Changes in BMHS’s targets and strategic plans;
b. Tidak tercapainya sasaran investasi; b. Failure to achieve investment targets;
c. Ketidakmampuan BMHS dalam persaingan c. BMHS’s inability to compete with competitors;
dengan kompetitor;
d. Kurangnya inovasi atas perubahan market, d. Lack of innovation in market, technology, and
teknologi, dan pelayanan; dan service changes; and
e. Harga saham BMHS bergerak secara fluktuatif e. BMHS’s share price fluctuates and BMHS’s ability
dan kemampuan BMHS dalam membayar dividen. to pay dividends.
Page 151
Laporan Tahunan
Annual Report 151
3. Risiko Hukum atau Kepatuhan 3. Legal or Compliance Risk
Risiko yang berkaitan dengan ketidakpatuhan Risk related to non-compliance with laws,
terhadap undang-undang, peraturan, peraturan regulations, government regulations, and legal
pemerintah, dan badan hukum, termasuk terhadap entities, including standards and policies applicable
standar dan kebijakan yang berlaku di BMHS. to BMHS. Potential risks may arise due to unrenewed
Potensi risiko timbul dikarenakan perizinan/ permits/cooperation agreements and low awareness
perjanjian kerja sama yang belum diperbarui dan of health workers on compliance with laws, policies,
rendahnya kesadaran kepatuhan tenaga kesehatan and procedures set by BMHS.
terhadap hukum, kebijakan, maupun prosedur yang
ditetapkan BMHS.
4. Risiko Operasional 4. Operational Risk
Risiko yang berdampak pada terganggunya Risk related to disruption of service/company
operasional pelayanan/perusahaan yang disebabkan operations caused by inadequate and/or non-
oleh ketidakcukupan dan/atau tidak berfungsinya functioning internal processes, human error, system
proses internal, kesalahan manusia, kegagalan sistem, failure, or external problems that affect corporate
atau adanya masalah eksternal yang mempengaruhi services and operations. Potential operational risks
operasional pelayanan dan operasional korporasi. that may occur may be related to:
Potensi risiko operasional yang mungkin timbul
dapat berkaitan dengan:
a. Penggunaan sistem pada pelayanan dan a. Use of systems in service and managerial matters;
manajerial;
b. Kualitas pemeliharaan sarana dan prasarana; b. Quality of facilities and infrastructure
maintenance;
c. Standardisasi prosedur unit dan anak usaha; c. Standardization of unit and subsidiary procedures;
d. Pelayanan terhadap pasien oleh tenaga d. Services to patients by health workers;
kesehatan;
e. Penggunaan alat kesehatan, farmasi, dan Bahan e. Use of medical devices, pharmaceuticals, and
Habis Pakai; dan Consumables; and
f. Manajemen fasilitas dan keselamatan terutama f. Facility and safety management, especially the
risiko kebakaran, bencana alam, kerusuhan, dan risk of fire, natural disasters, riots, etc.
lain lain.
5. Risiko Finansial 5. Financial Risk
Risiko yang berdampak pada finansial BMHS, Risk related to BMHS’s finances, especially cash
khususnya terhadap arus kas masuk dan keluar yang inflows and outflows that may result in financial
memungkinkan terjadinya kerugian finansial BMHS. losses for BMHS. In this area, the financial risks that
Dalam hal ini, risiko finansial yang mungkin terjadi may occur in BMHS’s activities include:
dalam kegiatan BMHS yakni:
a. Tidak tercapainya target EBITDA/revenue unit/ a. Failure to achieve EBITDA/revenue target for
anak usaha; units/subsidiaries;
b. Ketidakseimbangan arus kas BMHS; b. Imbalance in BMHS’s cash flow;
c. Keterlambatan pembayaran piutang Jaminan c. Delays in the National Health Insurance (JKN),
Kesehatan Nasional (JKN), asuransi swasta, private insurance, guarantor companies, and out-
perusahaan penjamin, serta pasien pembayaran of-pocket expense patient; and
pribadi; dan
d. Pengelolaan keuangan di tingkat unit dan anak d. Financial management at the unit and subsidiary
usaha yang mungkin berpotensi merugikan levels that may potentially harm BMHS.
BMHS.
6. Risiko Reputasi 6. Reputational Risk
Risiko yang berkaitan dengan turunnya tingkat Risk related to the decline in the level of stakeholder
kepercayaan pemangku kepentingan yang trust stemming from negative perceptions of BMHS.
bersumber dari persepsi negatif terhadap BMHS. Potential risks may be related to:
Potensi risiko timbul sehubungan dengan:
Page 152
152 Governansi Korporat
Corporate Governance
a. Kelalaian dalam pelayanan sehingga a. Negligence in service resulting in complaints and
menyebabkan keluhan serta ulasan negatif baik negative reviews either in person, in writing, or on
secara langsung, tertulis, maupun media sosial; social media;
b. Hubungan BMHS dengan pelayanan kesehatan b. BMHS’s relationship with referral health services;
rujukan;
c. Hubungan BMHS dengan asuransi maupun c. BMHS’s relationship with insurance or guarantee
perusahaan penjamin; companies;
d. Tuntutan pasien dan/atau karyawan terhadap d. Claims from patients and/or employees against
BMHS; BMHS;
e. Tingkat kesadaran publik (brand awareness) e. Level of public awareness (brand awareness) of
terhadap keberadaan dan pelayanan unit dan the units and subsidiaries existence and services;
anak usaha; dan and
f. Pelanggaran data, peretasan, atau serangan f. Data breaches, hacks, or cyber attacks that could
dunia maya yang dapat membahayakan informasi compromise sensitive customer information or
sensitif pelanggan atau merusak reputasi. damage reputations.
7. Risiko Medis 7. Medical Risk
Risiko yang timbul akibat tindakan dalam pelayanan Risk arising from actions taken in health services
kesehatan yang berpotensi menimbulkan dampak that can potentially cause medical impacts. Potential
medis. Potensi risiko dikarenakan potensi kesalahan risks may be related to possible errors in patient
pelayanan terhadap pasien, mencakup pemberian care, including administering medication, patient
obat, identifikasi & pembedahan pasien, paparan identification & surgery, exposure to infectious
penyakit menular, maupun risiko yang dapat terjadi diseases, or risks that may occur in food management
dalam pengelolaan makanan di unit usaha. in business units.
Mitigasi Risiko Risk Mitigation
BMHS menerapkan berbagai langkah mitigasi BMHS has determined the mitigation measures
untuk meminimalkan dampak risiko dan menjaga required to minimize the impact of risks and maintain
keberlanjutan operasi. Upaya mitigasi tersebut operational sustainability. These mitigation efforts have
dikelompokkan ke dalam beberapa area utama sebagai been grouped into the following key areas:
berikut:
1. Menyesuaikan diri dan mengantisipasi 1. Adapt and anticipate the development in
perkembangan peraturan dan kebijakan baik dari regulations and policies from the Government and
pemerintah maupun standar yang berlaku, baik applicable international and national standards;
internasional maupun nasional;
2. Melakukan tinjauan dan analisis terhadap regulasi 2. Conduct reviews and analysis of regulations related
yang berkaitan dengan kegiatan usaha untuk to business activities to avoid misinterpretation in
menghindari salah tafsir dalam penerapan regulasi; the application of regulations;
3. Meningkatkan kompetensi dan kolaborasi antar 3. Increase competencies, and collaboration between
unit dan anak usaha dalam menjalankan kegiatan units and subsidiaries when carrying out business
usaha; activities;
4. Meningkatkan mutu pelayanan dengan 4. Improve the quality of services by providing
memberikan pelatihan, meningkatkan sarana training, improving hospital facilities including
rumah sakit termasuk gedung, peralatan medis, dan buildings, medical equipment, and facilities;
fasilitas;
5. Memberikan jasa pelayanan kesehatan yang lebih 5. Provide a wider range of health services with
luas dengan harga dan pelayanan yang kompetitif competitive prices and services through continuous
disertai dengan evaluasi harga dan kualitas secara price and quality evaluation;
kontinuitas;
6. Menciptakan inovasi paket layanan dan 6. Create innovative service packages and
promo, melakukan promosi secara masif serta promotions, conduct massive promotions and use
memanfaatkan media untuk meningkatkan brand media to increase BMHS’s brand awareness;
awareness BMHS;
Page 153
Laporan Tahunan
Annual Report 153
7. Memberikan orientasi dan sosialisasi secara rutin 7. Provide regular orientation and socialization on
mengenai medikolegal dan hukum kesehatan medicolegal and health laws followed by monitoring
secara berkala diikuti dengan melakukan health workers so they continue to comply with
monitoring terhadap tenaga kesehatan sehingga applicable standards and regulations;
terus mematuhi standar dan regulasi yang berlaku;
8. Mengembangkan dan mengoptimalkan Center of 8. Develop and optimize the Center of Excellence;
Excellence;
9. Secara aktif dan secara terus menerus merekrut 9. Actively and continuously recruit reputable
tenaga medis yang mempunyai reputasi baik, medical personnel, create a positive work
menciptakan lingkungan kerja yang positif, environment, create work relationships, and
melakukan ikatan kerja, dan memberikan provide attractive remuneration;
remunerasi yang menarik;
10. Meningkatkan kerja sama dengan pihak lain, 10. Increase cooperation with other parties, such as
khususnya non-BPJS untuk keseimbangan insurance patients, companies, and individuals,
kontribusi pasien BPJS dengan pasien non-BPJS, especially non-BPJS to balance the contribution of
seperti pasien asuransi, perusahaan, dan pribadi; BPJS patients with non-BPJS patients;
11. Membina hubungan yang baik dan memastikan 11. Foster good relationships and ensure information
keterbukaan informasi dengan pemegang saham disclosure transparency with shareholders and
maupun pemangku kepentingan lainnya; other stakeholders;
12. Melakukan pemantauan dan kontrol serta 12. Monitor and control and establish a Board Observer
penempatan Board Observer untuk keputusan- for investment decisions on BMHS’s investments;
keputusan investasi terhadap investasi BMHS;
13. Melakukan pemantauan terhadap perizinan dan 13. Monitor BMHS’s permits and cooperation
perjanjian kerja sama BMHS baik di unit dan anak agreements in units and subsidiaries using a
usaha dengan menggunakan sistem digitalisasi; digitalization system;
14. Terus mengembangkan dan menciptakan standar 14. Continue to develop and create digitally integrated
yang terintegrasi secara digital khususnya antar standards, especially between business units and
unit usaha maupun antar anak usaha; subsidiaries;
15. Mengikuti standar kesehatan dari pemerintah dan 15. Follow Government health standards, and
menerapkan protokol yang memadai, meliputi tata implement adequate protocols, including service
cara pelayanan, proteksi diri, dan cara penanganan procedures, personal protection, and patient
pasien; handling methods;
16. Mengatasi risiko-risiko keuangan dengan 16. Address financial risks by identifying and tracking
melakukan identifikasi dan tracking efisiensi cost efficiency, controlling operational liquidity,
biaya, pengendalian likuiditas operasional, serta and adequately insuring valuable assets;
mengasuransikan sebagian aset dengan nilai yang
memadai;
17. Memberikan orientasi dan sosialisasi secara 17. Provide regular orientation and socialization to
rutin kepada karyawan tentang praktik terbaik employees on cybersecurity best practices to
keamanan siber untuk mencegah serangan phishing prevent phishing attacks or unauthorized access;
atau akses tidak sah; dan and
18. Menjalankan whistleblowing system di lingkup 18. Implement a whistleblowing system within the
Korporasi, Unit Usaha, dan Anak Usaha agar Corporation, Business Units, and Subsidiaries
senantiasa terjalin transparansi dan keterbukaan to ensure transparency and openness regarding
atas potensi pelanggaran yang mungkin ada di potential Company violations.
BMHS.
Tinjauan atas Efektivitas Sistem Manajemen Risiko Review of the Risk Management System Effectiveness
BMHS telah melakukan pemetaan atas seluruh potensi BMHS has mapped all its material risks, both business
risiko material, baik risiko usaha maupun risiko umum, and general risks, by assessing the likelihood and impact
dengan menilai tingkat kemungkinan dan dampak level on BMHS and its subsidiaries. Each identified
Page 154
154 Governansi Korporat
Corporate Governance
terhadap BMHS dan anak usaha. Setiap risiko tersebut risk is followed up with appropriate measures. At
ditindaklanjuti melalui langkah penanganan yang the corporate level, Corporate Risk Management
sesuai. Pada tingkat korporat, Corporate Risk coordinates with Risk Champions to ensure consistent
Management melakukan koordinasi dengan Risk implementation of risk management across all units and
Champion agar penerapan manajemen risiko dapat subsidiaries.
berjalan konsisten di seluruh unit dan anak usaha.
Manajemen memandang bahwa sistem manajemen Management believes that the risk management system
risiko berjalan efektif dan tetap berada dalam batas is effective and remains within controllable limits.
yang dapat dikendalikan. BMHS telah menyelaraskan BMHS has harmonized and implemented a corporate
dan menerapkan sistem manajemen risiko perusahaan risk management system based on the principles of ISO
dengan mengacu pada prinsip-prinsip ISO 31000:2018 31000:2018 as the standard for risk management in
sebagai standar dalam pengelolaan risiko di seluruh all operational activities, as well as conducting ongoing
kegiatan operasional, serta melakukan evaluasi dan evaluations and assessments to improve the quality of
penilaian secara berkelanjutan untuk meningkatkan its implementation over time.
kualitas penerapannya dari waktu ke waktu.
Pernyataan Direksi dan/atau Dewan Komisaris atas Statement by the Board of Directors and/or Board
Kecukupan Sistem Manajemen Risiko of Commissioners on the Adequacy of the Risk
Management System
Dengan telah dilakukan standarisasi pada sistem With the standardization of the risk management
manajemen risiko dan penguatan fungsi manajemen system and the strengthening of the risk management
risiko, Dewan Komisaris dan Direksi menilai bahwa functions, the Board of Commissioners and Board of
sistem manajemen risiko telah dilaksanakan dengan Directors believe that the risk management system
cukup andal. Namun demikian, sistem manajemen risiko has been implemented reliably. However, the risk
perlu terus dikembangkan dan dilakukan pemantauan management system needs to be continuously
agar pelaksanaannya dapat terus berjalan secara efektif developed and monitored to ensure its effective
dan berkelanjutan. Fungsi Corporate Risk Management and sustainable implementation. The Corporate
dan Risk Champion di masing-masing Unit dan Anak Risk Management and Risk Champion functions in
Usaha diharapkan dapat mengoptimalkan perannya each Unit and Subsidiary are expected to optimize
dalam memastikan implementasi manajemen risiko their roles by ensuring the implementation of risk
sehingga risiko prioritas baik keuangan, operasional, management so that priority risks, whether financial,
maupun reputasi dapat ditanganani dengan lebih baik operational, or reputational, can be better handled
melalui langkah penanganan risiko yang komprehensif through comprehensive and targeted risk management
dan tepat sasaran. measures.
Perkara Hukum, Sanksi Administratif, dan Finansial
Legal Cases, Administrative and Financial Sanctions
BMHS mengajukan banding atas perkara hukum yang BMHS filed an appeal against a legal case that arose in
muncul pada 2024 terkait keterlambatan penyampaian 2024 concerning the late submission of an acquisition
notifikasi akuisisi. Pada Juli 2025, Mahkamah Agung notification. In July 2025, the Supreme Court issued
menerbitkan Putusan Kasasi Nomor 849 K/Pdt.Sus- Cassation Decision No. 849 K/Pdt.Sus-KPPU/2025,
KPPU/2025 yang menolak permohonan kasasi BMHS. which rejected BMHS’s cassation petition. Thus, the
Dengan demikian, perkara dimaksud telah berkekuatan case has become final and binding. This case has no
hukum tetap. Perkara ini tidak memberikan dampak material impact on BMHS’s operational activities or
material terhadap kegiatan operasional maupun kondisi financial condition.
keuangan BMHS.
Page 155
Laporan Tahunan
Annual Report 155
Pokok Perkara Banding terkait keterlambatan penyampaian notifikasi akuisisi PT Pintu Ilmu
Subject Matter Appeal related to the late submission of the acquisition notification of PT Pintu Ilmu
Para Pihak BMHS dan KPPU
Parties Company and KPPU
Tahun Timbul
2024
Year of Occurrence
Status 2025 Proses Kasasi telah mendapat putusan berkekuatan hukum tetap
Status 2025 The cassation process has received a final and binding decision
Jenis Perkara Perdata
Type of Case Civil
Dampak Material Tidak berdampak material
Material Impact No material impact
Banding terkait keterlambatan penyampaian notifikasi akuisisi PT Medika Sejahtera
Pokok Perkara Bersama
Subject Matter Appeal related to the late submission of the acquisition notification of PT Medika Sejahtera
Bersama
Para Pihak
PT Morula Indonesia dan KPPU
Parties
Tahun Timbul
2024
Year of Occurrence
Proses Kasasi masih berlangsung di Pengadilan Niaga Jakarta Pusat dan belum mendapat
Status 2025 putusan berkekuatan hukum tetap
Status 2025 The cassation process is still ongoing at the Central Jakarta Commercial Court and no final
and binding decision has been made yet.
Jenis Perkara Perdata
Type of Case Civil
Dampak Material Tidak berdampak material
Material Impact No material impact
Selama tahun pelaporan, BMHS juga menerima During the reporting year, BMHS also received
sanksi administratif terkait kepatuhan pelaporan, administrative sanctions related to reporting
meliputi keterlambatan penyampaian laporan realisasi compliance, including delays in submiting reports on the
penggunaan jasa Akuntan Publik dan Kantor Akuntan realization of the engagement of a Public Accountant
Publik atas audit Laporan Keuangan Tahunan 2023, and a Public Accounting Firm for the audit of the 2023
keterlambatan penyampaian bukti pengumuman Annual Financial Statements, the late submission of
Laporan Keuangan Tahunan 2021, keterlambatan proof of the announcement of the 2021 Annual Financial
penyampaian laporan penunjukan Akuntan Publik dan Statements, delays in reporting the appointment of
Kantor Akuntan Publik untuk audit laporan keuangan a Public Accountant and Public Accounting Firm for
tahunan 2024, serta keterlambatan penyampaian the 2024 annual financial audited, as well as delays in
Laporan Tahunan dan Laporan Keberlanjutan 2024. submitting the 2024 Annual Report and Sustainability
Seluruh sanksi tersebut telah ditindaklanjuti sesuai Report. All of these sanctions have been addressed
ketentuan yang berlaku dan tidak memberikan dampak in accordance with applicable regulations and have
material terhadap kegiatan operasional maupun kondisi not had a material impact on operational activities or
keuangan. financial condition.
Selain perkara tersebut, BMHS, entitas anak, Other than these cases, BMHS, its subsidiaries,
anggota Direksi, dan anggota Dewan Komisaris tidak members of the Board of Directors, and members of the
menghadapi perkara hukum lain yang berdampak Board of Commissioners did not face any other legal
material sepanjang 2025. BMHS juga tidak menerima cases with material impact in 2025. BMHS also did not
sanksi administratif dari Otoritas Jasa Keuangan receive any administrative sanctions from Financial
maupun otoritas lainnya selama tahun pelaporan. Services Authority (OJK) or other authorities during
the reporting year.
Page 156
156 Governansi Korporat
Corporate Governance
Kode Etik
Code of Ethics
BMHS memiliki pedoman internal yang memuat BMHS has internal guidelines that contain the values,
seperangkat nilai, etika bisnis, etika kerja, dan norma business ethics, work ethics, and behavioral norms that
perilaku yang mengikat seluruh insan perusahaan, are binding on all Company personnel, including the
termasuk Dewan Komisaris, Direksi, dan seluruh Board of Commissioners, Board of Directors, and all
karyawan, yang dikenal sebagai Kode Etik BMHS. employees, known as BMHS Code of Ethics. The Code
Kode Etik menjadi acuan dalam menjalankan aktivitas of Ethics serves as a reference for conducting business
usaha dan berinteraksi dengan pemangku kepentingan, activities and interacting with stakeholders, including
baik pemegang saham, pasien, mitra usaha, pemasok, shareholders, patients, business partners, suppliers,
investor, pemerintah, masyarakat, serta media. investors, the government, the community, and the
media.
Pokok-Pokok Kode Etik BMHS Key Points of BMHS’s Code of Ethics
Kode etik berisi prinsip dasar dan komitmen BMHS The code of ethics contains the basic principles and
untuk menciptakan lingkungan dan budaya kerja yang commitments of BMHS to create a professional, safe,
profesional, aman, dan berintegritas, yang mencakup: and ethical work environment and culture, which
includes:
1. Kepatuhan terhadap hukum dan peraturan 1. Compliance with laws and regulations
Mematuhi peraturan perundang-undangan yang Complying with applicable laws and regulations,
berlaku, ketentuan dan prosedur internal, serta internal rules and procedures, and good corporate
prinsip governansi korporat yang baik. governance principles.
2. Integritas dan profesionalisme 2. Integrity and professionalism
Bertindak jujur, bertanggung jawab, menjaga etika Acting honestly, responsibly, maintaining work
kerja, mengupayakan peningkatan nilai pemegang ethics, striving to increase shareholder value, and
saham, serta mengutamakan kualitas pelayanan prioritizing quality of service to patients and other
kepada pasien dan pemangku kepentingan lainnya. stakeholders.
3. Menghormati hak asasi manusia, keberagaman dan 3. Respect for human rights, diversity, and anti-
antidiskriminasi discrimination
Memberikan perlakuan yang adil, kesempatan yang Providing fair treatment, equal opportunities, and
setara, serta memastikan lingkungan kerja bebas ensuring a work environment free from harassment,
dari pelecehan, kekerasan, dan bentuk diskriminasi violence, and other forms of discrimination.
lainnya.
Page 157
Laporan Tahunan
Annual Report 157
4. Keselamatan dan kenyamanan kerja 4. Work safety and comfort
Mematuhi standar keselamatan kerja, menjaga Complying with work safety standards, maintaining
lingkungan kerja yang aman, serta menciptakan a safe working environment, and creating a mutually
suasana kerja yang saling menghargai. respectful work atmosphere.
5. Pencegahan benturan kepentingan 5. Prevention of conflicts of interest
Menghindari tindakan yang dapat memengaruhi Avoiding actions that could affect the objectivity of
objektivitas pengambilan keputusan, termasuk decision-making, including abuse of position, insider
penyalahgunaan jabatan, insider trading, dan segala trading, and all forms of conflicts of interest.
bentuk konflik kepentingan.
6. Antisuap dan antikorupsi 6. Anti-bribery and anti-corruption
Tidak memberikan atau menerima imbalan yang Not giving or receiving rewards related to business
berkaitan dengan transaksi bisnis, sesuai dengan transactions, in accordance with applicable Anti-
Kebijakan Antisuap dan Antikorupsi yang berlaku. Bribery and Anti-Corruption Policies.
7. Pengelolaan aset dan informasi 7. Asset and information management
Menggunakan aset perusahaan secara bertanggung Using Company assets responsibly and maintaining
jawab dan menjaga kerahasiaan data serta informasi the confidentiality of Company data and information
perusahaan dari akses atau penggunaan yang tidak from unauthorized access or use.
sah.
Sosialisasi dan Penegakan Kode Etik Socialization and Enforcement of the Code of Ethics
Sosialisasi dilakukan secara berkala melalui kanal Socialization is carried out periodically through internal
komunikasi internal dan kegiatan edukasi di seluruh communication channels and educational activities at
level, baik Korporasi, Unit Usaha, dan Anak Usaha. all levels, including the Corporation, Business Units, and
Setiap pelanggaran terhadap Kode Etik ditindak sesuai Subsidiaries. Any violation of the Code of Ethics will be
ketentuan perusahaan dan peraturan yang berlaku. dealt with in accordance with Company regulations and
applicable laws.
Program Kepemilikan Saham oleh Karyawan dan/atau
Manajemen
Employees and/or Management Share Ownership Program
BMHS melaksanakan program Management and BMHS has a Management and Employee Stock Option
Employee Stock Option Program (MESOP) sesuai Program (MESOP) in line with the initial public offering
prospektus penawaran umum perdana yang prospectus published on June 29, 2021. Shareholders
diterbitkan tanggal 29 Juni 2021. Pemegang saham approved the issuance of new shares amounting to a
telah menyetujui penerbitan saham baru sebanyak- maximum of 0.29% of the issued and paid-up capital
banyaknya 0,29% dari modal ditempatkan dan disetor after the public offering and bond conversion, or
setelah penawaran umum dan konversi obligasi, atau 25,000,000 shares for the MESOP program. This
25.000.000 lembar saham untuk program MESOP. approval was ratified in Deed No. 5/2021 and BMHS’s
Persetujuan tersebut disahkan dalam Akta No. 5/2021 Board of Directors Decree No. 020-I/SK/DIRKOM/
dan Surat Keputusan Direksi BMHS No. 020-I/SK/ IV/2021 dated April 8, 2021.
DIRKOM/IV/2021 tanggal 8 April 2021.
Tahapan Pelaksanaan Implementation Stages
Program MESOP dilaksanakan dalam dua tahap, The MESOP program was implemented in two stages,
dengan ketentuan: with the following provisions:
1. Tahap pertama, maksimal 90% dari total hak opsi 1. In the first stage, a maximum of 90% of the total
akan diterbitkan paling lambat 90 hari setelah option rights to be issued no later than 90 days after
tanggal pencatatan saham BMHS di BEI. the date of BMHS’s shares being listed on the IDX.
Page 158
158 Governansi Korporat
Corporate Governance
2. Tahap kedua, sisa hak opsi yang belum diterbitkan, 2. In the second stage, the remaining option rights not
paling lambat diterbitkan setelah dua tahun yet issued to be issued no later than two years after
pencatatan saham BMHS di BEI. BMHS’s shares were listed on the IDX.
Kriteria Peserta Participant Criteria
Peserta program MESOP mencakup Komisaris, Direksi, Participants in the MESOP program include
serta karyawan kunci BMHS dan entitas anak yang Commissioners, Directors, and key employees in
memenuhi persyaratan berikut: BMHS and its subsidiaries who meet the following
requirements:
1. Memiliki masa kerja minimal 2 tahun dengan nilai 1. Has a minimum of 2 years of service with a good
performance appraisal baik; performance appraisal scores;
2. Minimal berada pada level Manajer atau setara. 2. Has a minimum position at the Manager level or
Untuk level di bawah Manajer, dapat diusulkan equivalent. For levels below Manager, special
dengan pertimbangan khusus; consideration may be given;
3. Memiliki keahlian kritikal (scarcity of skill set), 3. Possesses critical skills (scarcity of skill set), even if
meskipun masa kerja belum mencapai dua tahun; the length of service has not reached two years;
4. Memiliki potensi dan kapasitas untuk dikembangkan 4. Has the potential and capacity to be developed as a
sebagai pemimpin; leader;
5. Aktif bekerja pada saat pendistribusian opsi serta 5. Is actively working at the time of option distribution
tidak sedang dikenakan sanksi sesuai ketentuan and not currently subject to sanctions in accordance
perusahaan. with Company regulations.
Sejak 2022, BMHS telah melaksanakan program Since 2022, BMHS has implemented the MESOP
MESOP. Pada 2025, BMHS melaksanakan MESOP program. In 2025, BMHS implemented the First Phase
Tahap Pertama dengan jumlah hak opsi sebanyak of MESOP for a total of 22,500,000 share options at
22.500.000 saham dengan harga pelaksanaan Rp863 an exercise price of IDR 863 per share and the Second
per lembar dan MESOP Tahap Kedua dengan jumlah Phase of MESOP for a total of 2,500,000 share options
hak opsi sebanyak 2.500.000 saham dengan harga at an exercise price of IDR 363 per share.
pelaksanaan Rp363 per lembar.
Kebijakan Pengungkapan Kepemilikan Saham Perusahaan oleh
Dewan Komisaris dan/atau Direksi
Board of Commissioners and/or Board of Directors Share Ownership Disclosure
Policy
BMHS menyampaikan daftar pemegang saham serta BMHS discloses a list of shareholders and share
kepemilikan saham oleh anggota Dewan Komisaris ownership by members of the Board of Commissioners
dan Direksi melalui situs web BEI setiap bulan serta and Board of Directors through the IDX website
pada saat terdapat perubahan kepemilikan saham. every month or whenever there is a change in share
Setiap perubahan kepemilikan saham BMHS maupun ownership. Any changes in BMHS’s share ownership
kepemilikan saham oleh anggota Dewan Komisaris or share ownership by members of the Board of
dan Direksi wajib diungkapkan paling lambat tiga Commissioners and Board of Directors must be
hari kerja setelah transaksi terjadi. Pengungkapan disclosed no later than three working days after the
tersebut dikelola oleh Sekretaris Perusahaan dengan transaction occurs. Such disclosures are managed by the
berpedoman pada ketentuan peraturan perundang- Corporate Secretary in accordance with the provisions
undangan yang berlaku. of the applicable laws and regulations.
Page 159
Laporan Tahunan
Annual Report 159
Sistem Pelaporan Pelanggaran
Whistleblowing System
BMHS menyediakan sistem pelaporan pelanggaran BMHS provides a whistleblowing system (WBS) as
(WBS) sebagai sarana bagi karyawan maupun pihak a means for employees and related parties to report
terkait untuk menyampaikan dugaan pelanggaran alleged violations of the Code of Ethics and Company
terhadap Kode Etik dan peraturan perusahaan. Ruang regulations. The reports include actions that could
lingkup laporan mencakup tindakan yang berpotensi potentially harm BMHS, including corruption, fraud,
merugikan perusahaan, termasuk korupsi, kecurangan deception, theft, embezzlement, information leaks,
(fraud), penipuan, pencurian, penggelapan aset, negligence of violations, and other actions that violate
pembocoran informasi, pembiaran atas pelanggaran, the law.
serta tindakan lain yang bertentangan dengan hukum.
Sarana pelaporan dapat diakses melalui beberapa This reporting mechanism can be accessed through
kanal, yaitu email (iarm.corporate@bmhs.co.id), situs several channels, including email (iarm.corporate@
resmi BMHS (bmhs.co.id), surat resmi tertutup, maupun bmhs.co.id), BMHS’s official website (bmhs.co.id),
komunikasi langsung kepada Unit Kerja Internal Audit & sealed official letters, or direct communication with the
SPI RS. BMHS menjamin kerahasiaan identitas pelapor Internal Audit & SPI RS Work Unit. BMHS guarantees
dan isi laporan, serta memberikan perlindungan dari the confidentiality of the whistleblower’s identity and
tindakan pembalasan seperti intimidasi, pemecatan, the content of their report, and provides protection
diskriminasi, atau tindakan merugikan lainnya. from retaliatory actions such as intimidation, dismissal,
discrimination, or other harmful actions.
Pengelolaan dan Tindak Lanjut Pengaduan Management and Follow-up of Complaints
Pengelolaan laporan dilakukan oleh Unit Kerja Internal Report management is carried out by the Internal
Audit. Setiap pengaduan yang masuk akan diverifikasi Audit Work Unit. Every complaint received will be
dan diinvestigasi dengan menjunjung asas itikad baik verified and investigated based on the principles of
dan praduga tak bersalah. Investigasi mendalam good faith and presumption of innocence. In-depth
dilakukan terhadap laporan yang telah terkonfirmasi investigations are carried out on reports that have been
kebenarannya secara sistematis. systematically confirmed to be true.
Page 160
160 Governansi Korporat
Corporate Governance
Alur Sistem Pelaporan Pelanggaran
Whistleblowing System Flowchart
AWAL START Proses process aKHIR eND
Head Internal Audit Internal Audit
Membentuk tim auditor Melakukan pemeriksaan
pelaksana yang dapat lanjutan dengan
berasal dari korporat, Unit mengacu pada prosedur
RS, Anak Usaha dan Tim pemeriksaan khusus.
Mutu.
Internal Audit Conduct follow-up
Form a team of examinations with reference
Menerima laporan secara
implementing auditors that to special examination
verbal/nonverbal melalui
can come from corporate, procedures.
media yang ditentukan secara
hospital units, subsidiaries
sah.
and the Quality Team.
Receive verbal/non-verbal
reports through legally
designated media.
Internal Audit Internal Audit Internal Audit
Laporan yang di valid Melaporkan Melaporkan perkembangan
diajukan secara tertulis perkembangan audit secara audit secara berkala kepada
kepada Head Unit kerja berkala kepada Head Unit Head Unit kerja Internal
Internal Audit untuk kerja Internal Audit Audit
ditindak lanjuti.
Report the progress of the Report the progress of the
Valid reports are submitted audit periodically to the audit periodically to the
in writing to the Head of Head of Internal Audit Unit. Head of Internal Audit Unit.
Internal Audit Unit for
follow-up.
Internal Audit
Menerima dan memverifikasi
laporan/pengaduan.
Ya Yes
Receiving and verifying reports/
complaints.
Valid?
No Tidak Ditindak
lanjuti.
Valid report
Sepanjang 2025, BMHS menerima 20 laporan In 2025, BMHS received 20 complaints through the
pengaduan melalui sistem pelaporan pelanggaran, yang whistleblowing system, all of which were followed up
seluruhnya telah ditindaklanjuti dan diselesaikan sesuai and resolved in accordance with BMHS’s provisions.
ketentuan BMHS.
Page 161
Laporan Tahunan
Annual Report 161
Sosialisasi Sistem Pelaporan Pelanggaran Socialization of the Whistleblowing System
BMHS melakukan sosialisasi sistem pelaporan BMHS regularly socializes its whistleblower reporting
pelanggaran secara berkala, melalui Unit kerja Internal system through the Internal Audit Unit. Socialization is
Audit. Sosialisasi disampaikan melalui berbagai carried out through various communication channels,
kanal komunikasi, termasuk media sosial BMHS, dan including BMHS’s social media, and is implemented at
dilaksanakan di tingkat Korporasi, Unit Usaha, dan Anak the Corporate, Business Unit, and Subsidiary levels
Usaha untuk memastikan seluruh karyawan memahami to ensure all employees understand the available
mekanisme pelaporan yang tersedia. Penerapan sistem reporting mechanisms. The WBS system is expected
WBS diharapkan memperkuat budaya integritas dan to strengthen the culture of integrity and transparency
transparansi di lingkungan BMHS, serta meminimalkan within BMHS, as well as minimize the risk of violations
risiko pelanggaran yang dapat berdampak pada kegiatan that could impact operational activities.
operasional.
Kebijakan Antikorupsi
Anti-Corruption Policy
BMHS menerapkan kebijakan antikorupsi yang menjadi BMHS has an anti-corruption policy that forms part of
bagian dari pedoman tata kelola. Prinsip kejujuran dan its governance guidelines. The principles of honesty
integritas disosialisasikan kepada seluruh karyawan and integrity are socialized to all employees and
dan dituangkan dalam Kode Etik serta peraturan incorporated into the Code of Ethics and internal
internal. Sepanjang periode pelaporan, BMHS telah regulations. During the reporting period, BMHS
melaksanakan sosialisasi kebijakan antikorupsi yang conducted an anti-corruption policy socialization
diikuti oleh karyawan BMHS. Sosialisasi juga dilakukan program, which was attended by BMHS’s employees.
secara berkelanjutan kepada seluruh karyawan melalui Socialization is also carried out continuously to all
berbagai media komunikasi internal, antara lain poster, employees through various internal communication
surat elektronik (surel), artikel, dan portal karyawan, media, including posters, electronic mail (e-mail),
guna memastikan pemahaman dan penerapan prinsip articles, and employee portals, to ensure consistent
antikorupsi secara konsisten. Ketentuan antikorupsi understanding and application of anti-corruption
juga tercantum dalam kebijakan pengadaan yang wajib principles. Anti-corruption provisions are also included
dipatuhi oleh mitra kerja dan pemasok. Pelanggaran in procurement policies that must be complied with
terhadap kebijakan ini dikenakan sanksi sesuai by business partners and suppliers. Violations of
peraturan perusahaan dan ketentuan perundang- these policies are subject to sanctions in accordance
undangan yang berlaku. with Company regulations and applicable laws and
regulations.
Pokok-pokok Kebijakan Antikorupsi BMHS mencakup BMHS’s Anti-Corruption Policy covers the following:
hal-hal berikut:
1. Menjalankan kegiatan usaha secara profesional dan 1. Conducting business activities professionally and
berintegritas sesuai Pedoman Tata Kelola, Kode Etik, with integrity in accordance with the Governance
dan Kebijakan Antikorupsi. Guidelines, Code of Ethics, and Anti-Corruption
Policy.
2. Mencegah dan menghindari seluruh bentuk 2. Preventing and avoiding all forms of corruption
tindakan korupsi sebagaimana dimaksud dalam as referred to in laws and regulations, including:
peraturan perundang-undangan, termasuk: causing financial loss to the state, bribery,
merugikan keuangan negara, penyuapan, embezzlement, extortion, fraud, conflicts of interest,
penggelapan, pemerasan, perbuatan curang, and gratification.
benturan kepentingan, dan gratifikasi.
Page 162
162 Governansi Korporat
Corporate Governance
3. Menjaga independensi setiap organ perusahaan 3. Maintaining the independence of each corporate
dengan melarang transaksi yang menimbulkan body by prohibiting transactions that could give
benturan kepentingan atau keuntungan pribadi, rise to conflicts of interest or personal gain,
larangan memangku jabatan yang berpotensi prohibiting positions that have the potential to
menimbulkan benturan kepentingan, serta larangan give rise to conflicts of interest, and prohibiting the
mewakili perusahaan apabila memiliki kepentingan representation of BMHS if there are interests that
yang bertentangan dengan kepentingan perusahaan. conflict with the interests of BMHS.
4. Melakukan persaingan usaha dan negosiasi secara 4. Conducting business competition and negotiations
jujur dan sah, tanpa tekanan atau praktik yang honestly and legally, without pressure or practices
bertentangan dengan hukum dan etika bisnis. that violate the law and business ethics.
5. Menerapkan sanksi atas pelanggaran kebijakan 5. Applying sanctions for violations of anti-corruption
antikorupsi, mulai dari sanksi administratif sesuai policies, ranging from administrative sanctions in
peraturan perusahaan hingga proses hukum pidana accordance with Company regulations to criminal
apabila terdapat unsur tindak pidana korupsi. proceedings if there are elements of criminal
corruption.
Penerapan Pedoman Tata Kelola Perusahaan Terbuka
Implementation of Public Company Governance Guidelines
BMHS telah mengimplementasikan POJK No.21/ BMHS has implemented POJK No. 21/POJK.04/2015
POJK.04/2015 mengenai Pedoman Tata Kelola concerning Guidelines for Corporate Governance of
Perusahaan Terbuka dan SEOJK No.32/SEOJK.04/2015 Public Companies, and SEOJK No. 32/SEOJK.04/2015
terkait penerapannya. Terdapat sejumlah rekomendasi concerning its implementation. A number of governance
tata kelola yang penerapannya masih diselaraskan recommendations are still being gradually aligned.
secara bertahap. BMHS telah membangun langkah BMHS has taken the initial steps by strengthening its
awal melalui penguatan kapabilitas internal untuk internal capabilities to support future implementation.
mendukung implementasi di masa mendatang.
Prinsip dan Rekomendasi Pernyataan Kepatuhan
Principles and Recommendations Compliance Statement
Aspek 1. Hubungan Perusahaan Terbuka dengan Pemegang Saham dalam Menjamin Hak-Hak Pemegang Saham
Aspect 1. Public Company Relationship with Shareholders in Ensuring Shareholders’ Rights
Prinsip 1: Meningkatkan Nilai Penyelenggaraan Rapat Umum Pemegang Saham (RUPS)
Principle 1: Increasing the Value of General Meeting of Shareholders (GMS).
Perusahaan Terbuka memiliki cara atau prosedur teknis pengumpulan suara
(voting) baik secara terbuka maupun tertutup yang mengedepankan independensi,
Telah dilaksanakan.
1.1 dan kepentingan pemegang saham.
Already implemented.
The Public Company has technical voting methods or procedures, both openly and
privately, that prioritize independence and the interests of shareholders.
Seluruh anggota Direksi dan anggota Dewan Komisaris Perusahaan Terbuka hadir
dalam RUPS Tahunan. Telah dilaksanakan.
1.2
All members of the Board of Directors and the Board of Commissioners of a Public Already implemented.
Company attend the Annual GMS.
Ringkasan risalah RUPS tersedia dalam Situs Web Perusahaan Terbuka paling
sedikit selama satu tahun. Telah dilaksanakan.
1.3
A summary of the GMS minutes is available on the Public Company Website for at Already implemented.
least one year.
Page 163
Laporan Tahunan
Annual Report 163
Prinsip dan Rekomendasi Pernyataan Kepatuhan
Principles and Recommendations Compliance Statement
Prinsip 2: Meningkatkan Kualitas Komunikasi Perusahaan Terbuka dengan Pemegang Saham atau Investor.
Principle 2: Improving the Quality of Public Company Communication with Shareholders or Investors.
Perusahaan Terbuka memiliki suatu kebijakan komunikasi dengan pemegang
Telah dilaksanakan.
2.1 saham atau investor.
Already implemented.
The Public Company has a communication policy with shareholders or investors.
Perusahaan Terbuka mengungkapkan kebijakan komunikasi Perusahaan Terbuka
dengan pemegang saham atau investor dalam Situs Web. Telah dilaksanakan.
2.2
The Public Company discloses the Public Company's communication policy with Already implemented.
shareholders or investors on the Website.
Aspek 2. Fungsi dan Peran Dewan Komisaris
Aspect 2. Functions and Roles of the Board of Commissioners
Prinsip 3: Memperkuat Keanggotaan dan Komposisi Dewan Komisaris.
Principle 3: Strengthening the Membership and Composition of the Board of Commissioners.
Penentuan jumlah anggota Dewan Komisaris mempertimbangkan kondisi
Perusahaan Terbuka. Telah dilaksanakan.
3.1
Determining the number of members of the Board of Commissioners by Already implemented.
considering the conditions of the Public Company.
Penentuan komposisi anggota Dewan Komisaris memperhatikan keberagaman
keahlian, pengetahuan, dan pengalaman yang dibutuhkan. Telah dilaksanakan.
3.2
Determining the composition of members of the Board of Commissioners takes Already implemented.
into account the diversity of expertise, knowledge and experience required.
Prinsip 4: Meningkatkan Kualitas Pelaksanaan Tugas dan Tanggung Jawab Dewan Komisaris.
Principle 4: Improving the Quality of Implementation of Duties and Responsibilities of the Board of Commissioners.
Dewan Komisaris mempunyai kebijakan penilaian sendiri (self- assessment) untuk
menilai kinerja Dewan Komisaris. Telah dilaksanakan.
4.1
The Board of Commissioners has a self-assessment policy to assess the Already implemented.
performance of the Board of Commissioners.
Kebijakan penilaian sendiri (self-assessment) untuk menilai kinerja Dewan
Komisaris, diungkapkan melalui Laporan Tahunan Perusahaan Terbuka. Telah dilaksanakan.
4.2
The self-assessment policy to assess the performance of the Board of Already implemented.
Commissioners is disclosed in the Public Company's Annual Report.
Dewan Komisaris mempunyai kebijakan terkait pengunduran diri anggota Dewan
Komisaris apabila terlibat dalam kejahatan keuangan. Telah dilaksanakan.
4.3
The Board of Commissioners has a policy regarding the resignation of members of Already implemented.
the Board of Commissioners if the said person is involved in a financial crime
Dewan Komisaris atau Komite yang menjalankan fungsi Nominasi dan Remunerasi
menyusun kebijakan suksesi dalam proses Nominasi anggota Direksi. Sedang dalam tahap
4.4 The Board of Commissioners or the Committee that carries out the Nomination pengembangan.
and Remuneration function prepares a succession policy in the Nomination Currently in development stage.
process for members of the Board of Directors.
Aspek 3. Fungsi dan Peran Direksi
Aspect 3. Functions and Roles of the Board of Directors
Prinsip 5: Memperkuat Keanggotaan dan Komposisi Direksi.
Principle 5: Strengthening the Membership and Composition of the Board of Directors.
Penentuan jumlah anggota Direksi mempertimbangkan kondisi Perusahaan
Terbuka serta efektivitas dalam pengambilan keputusan. Telah dilaksanakan.
5.1
Determining the number of members of the Board of Directors considers the Already implemented.
condition of the Public Company and effectiveness in decision making.
Penentuan komposisi anggota Direksi memperhatikan, keberagaman keahlian,
pengetahuan, dan pengalaman yang dibutuhkan. Telah dilaksanakan.
5.2
Determining the composition of members of the Board of Directors takes into Already implemented.
account the diversity of expertise, knowledge and experience required.
Anggota Direksi yang membawahi bidang akuntansi atau keuangan memiliki
keahlian dan/atau pengetahuan di bidang akuntansi. Telah dilaksanakan.
5.3
Members of the Board of Directors in charge of accounting or finance have Already implemented.
expertise and/ or knowledge in the field of accounting.
Page 164
164 Governansi Korporat
Corporate Governance
Prinsip dan Rekomendasi Pernyataan Kepatuhan
Principles and Recommendations Compliance Statement
Prinsip 6: Meningkatkan Kualitas Pelaksanaan Tugas dan Tanggung Jawab Direksi.
Principle 6: Improving the Quality of Implementation of Duties and Responsibilities of the Board of Directors.
Direksi mempunyai kebijakan penilaian sendiri (self-assessment) untuk menilai
Sedang dalam tahap
kinerja Direksi.
6.1 pengembangan.
The Board of Directors has a self-assessment policy to assess the performance of
Currently in development stage.
the Board of Directors.
Kebijakan penilaian sendiri (self-assessment) untuk menilai kinerja Direksi
Sedang dalam tahap
diungkapkan melalui laporan tahunan Perusahaan Terbuka.
6.2 pengembangan.
The self-assessment policy to assess the performance of the Board of Directors is
Currently in development stage.
disclosed in the Public Company's annual report.
Direksi mempunyai kebijakan terkait pengunduran diri anggota Direksi apabila
terlibat dalam kejahatan keuangan. Telah dilaksanakan.
6.3
The Board of Directors has a policy regarding the resignation of members of the Already implemented.
Board of Directors if involved in a financial crime.
Aspek 4. Partisipasi Pemangku Kepentingan
Aspect 4. Stakeholder Participation
Prinsip 7: Meningkatkan Aspek Governansi Korporat melalui Partisipasi Pemangku Kepentingan.
Principle 7: Improving Corporate Governance Aspects through Stakeholder Participation.
Perusahaan Terbuka memiliki kebijakan untuk mencegah terjadinya insider
Telah dilaksanakan.
7.1 trading.
Already implemented.
Public Companies have policies to prevent insider trading.
Perusahaan Terbuka memiliki kebijakan antikorupsi dan anti- fraud. Telah dilaksanakan.
7.2
Public Companies have anti-corruption and anti-fraud policies. Already implemented.
Perusahaan Terbuka memiliki kebijakan tentang seleksi dan peningkatan
kemampuan pemasok atau vendor. Telah dilaksanakan.
7.3
Public Companies have policies regarding the selection and capacity building of Already implemented.
supplier or vendors.
Perusahaan Terbuka memiliki kebijakan tentang pemenuhan hak- hak kreditur. Telah dilaksanakan.
7.4
Public Companies have policies regarding the fulfillment of creditors’ rights. Already implemented.
Perusahaan Terbuka memiliki kebijakan sistem pelaporan pelanggaran. Telah dilaksanakan.
7.5
Public Companies have a whistleblowing system policy. Already implemented.
Perusahaan Terbuka memiliki kebijakan pemberian insentif jangka panjang kepada
Direksi dan karyawan. Telah dilaksanakan.
7.6
Public Companies have a policy of providing long-term incentives to Directors and Already implemented.
employees.
Aspek 5. Keterbukaan Informasi
Aspect 5. Information Disclosure
Prinsip 8: Meningkatkan Pelaksanaan Keterbukaan Informasi.
Principle 8: Improving the Implementation of Information Disclosure.
Perusahaan Terbuka memanfaatkan penggunaan teknologi informasi secara lebih
luas selain Situs Web sebagai media keterbukaan informasi. Telah dilaksanakan.
8.1
Public Companies make broader use of information technology apart from Already implemented.
Websites as a medium for information disclosure.
Laporan Tahunan Perusahaan Terbuka mengungkapkan pemilik manfaat
akhir dalam kepemilikan saham Perusahaan Terbuka paling sedikit 5%, selain
pengungkapan pemilik manfaat akhir dalam kepemilikan saham Perusahaan
Terbuka melalui pemegang saham utama dan pengendali. Telah dilaksanakan.
8.2
The Annual Report of the Public Company discloses the ultimate beneficial owner Already implemented.
in the share ownership of the Public Company of at least 5%, in addition to the
disclosure of the ultimate beneficial owner in the ownership of shares of the Public
Company through the majority and controlling shareholders.
Page 165
Laporan Tahunan
Annual Report 165
Penerapan Pedoman Umum Governansi Korporat Indonesia
(PUGKI) 2021
Implementation of Indonesian Corporate Governance General Guidelines
(PUGKI) 2021
BMHS memperkuat praktik governansi, dengan BMHS has strengthened its governance practices by
menerapkan PUGKI 2021 sebagai salah satu rujukan. implementing PUGKI 2021 as one of its references.
PUGKI dikeluarkan oleh Komite Nasional Kebijakan PUGKI was issued by the National Governance Policy
Governansi (KNKG), sebagai pedoman untuk Committee (KNKG) as a guideline to help companies
membantu Perseroan menjaga kepercayaan publik, maintain public trust, improve the quality of supervision,
meningkatkan kualitas pengawasan, serta memastikan and ensure that business management is conducted
pengelolaan usaha berjalan secara transparan dan in a transparent and responsible manner. PUGKI
bertanggung jawab. PUGKI merangkum delapan summarizes eight governance principles organized
prinsip governansi yang disusun dalam tiga kelompok into three main principle groups, key principles,
prinsip utama beserta panduan dan rekomendasi along with guidelines and recommendations for their
pelaksanaannya. implementation.
Pada 2025, Perseroan melakukan pengukuran In 2025, the Company conducted a measurement
penerapan GCG dengan eksternal assesor sesuai dengan of GCG implementation with an external assessor
indikator PUGKI dengan skor 96,3 kategori Sangat in accordance with PUGKI with a score of 96.3 in
Baik dan Asean Corporate Governance Scorecard the Sangat Baik category and the ASEAN Corporate
(ACGS) dengan hasil 106,50 kategori Leadership Governance Scorecard (ACGS) with a score of 106.50
in Corporate Governance. Selain itu, Perusahaan in the Leadership in Corporate Governance category.
menyelenggarakan BMHS GCG Fest pada Oktober In addition, BMHS held a BMHS GCG Fest in October
2025 yang merupakan agenda rutin dengan bekerja 2025 with a routine agenda for Directorates,
sama lintas Direktorat, Anak Usaha dan Unit Usaha. Subsidiaries, and Business Units. The topics
Topik yang diangkat berkaitan dengan implementasi covered the implementation of Corporate
Governansi Korporat seperti GCG Strategic Planning, Governance, such as GCG Strategic Planning, Anti-
Anti Korupsi, Anti-Fraud, Keterbukaan Informasi, Cyber Corruption, Anti-Fraud, Information Disclosure,
Security, Equity, Diversity & Inclusion, Hospital by Law, Cyber Security, Equity, Diversity & Inclusion,
hingga pelaksanaan Pedoman Pengadaan Barang dan Hospital by Law, and the implementation of the
Jasa di BMHS Group. BMHS Group’s Goods and Services Procurement
Guidelines.
Page 166
166 Governansi Korporat
Corporate Governance
Tanggung Jawab Sosial dan Lingkungan
Social and Environmental Responsibility
BMHS menjalankan kegiatan usaha dengan BMHS conducts its business activities with due
memperhatikan keseimbangan aspek ekonomi, regard to a balance between economic, social,
sosial, lingkungan, dan tata kelola guna memastikan environmental, and governance aspects to ensure
keberlanjutan operasionalnya. Bagi BMHS, tanggung its operational sustainability. For BMHS, social and
jawab sosial dan lingkungan merupakan bagian integral environmental responsibility is an integral part of its
dalam pengelolaan usahanya. Melalui pendekatan business management, and by using an environmental,
lingkungan, sosial, dan tata kelola (LST), yang social, and governance (ESG) approach, aligned with
diselaraskan dengan kerangka IBU, BMHS merancang the IBU framework, BMHS designs and implements
dan melaksanakan berbagai program yang mendukung programs that support employee welfare, quality of
kesejahteraan karyawan, kualitas layanan kesehatan, health services, and sustainable environmental impact
serta pengelolaan dampak lingkungan secara management.
berkelanjutan.
Kerangka IBU terdiri dari tiga pilar yang saling The IBU framework comprises three complementary
melengkapi, yaitu Inisiator yang Adil dan Bertanggung pillars, namely Fair and Responsible Initiators, Beautiful
Jawab, Bumi yang Asri dan Sejahtera, serta Utamakan and Prosperous Earth, and Prioritizing Patient Care.
Pelayanan Pasien. Pilar Inisiator yang Adil dan The Fair and Responsible Initiator pillar reflects
Bertanggung Jawab mencerminkan upaya BMHS BMHS’s efforts to strengthen governance through more
memperkuat tata kelola melalui proses internal yang accountable internal processes, increase supervision
lebih akuntabel, peningkatan efektivitas pengawasan, effectiveness, and operational implementation in line
serta pelaksanaan operasional yang selaras dengan with the principles of integrity and compliance. Through
prinsip integritas dan kepatuhan. Melalui praktik responsible practices, BMHS ensures that operations
yang bertanggung jawab, BMHS memastikan bahwa and decision-making are transparent and support a
operasional dan pengambilan keputusan berjalan secara sustainable performance.
transparan dan mendukung keberlanjutan kinerja.
Pilar Bumi yang Asri dan Sejahtera menjadi landasan The Beautiful and Prosperous Earth pillar is the
pengelolaan dampak lingkungan. Melalui pilar ini, BMHS foundation for managing the environmental impact.
mengarahkan berbagai program untuk menciptakan Through this pillar, BMHS manages programs to create
lingkungan yang lebih sehat dan mendukung kualitas a healthier environment and support the quality of life
hidup masyarakat. Upaya tersebut mencakup in the communities. The efforts made include increasing
peningkatan efisiensi sumber daya, pengelolaan limbah resource efficiency, managing medical waste according
medis sesuai standar, pengurangan emisi dari aktivitas to standards, reducing emissions from operational
operasional, serta penerapan praktik kerja yang activities, and implementing work practices that
meminimalkan risiko lingkungan. minimize environmental risks.
Pilar Utamakan Pelayanan Pasien menempatkan The Patient Service First pillar places the quality of
kualitas layanan kesehatan sebagai inti dari seluruh health services at the core of all of BMHS’s operational
aktivitas operasional BMHS. Melalui pilar ini, BMHS activities. Through this pillar, BMHS endeavors to
berupaya meningkatkan mutu pelayanan secara improve the overall quality of services, including patient
menyeluruh, mulai dari keselamatan pasien, standar safety and clinical standards to the patients’ experience
klinis, hingga pengalaman pasien dalam menerima in receiving services. Efforts taken include the
layanan. Upaya tersebut didukung oleh pengembangan development of health worker competencies, the use
kompetensi tenaga kesehatan, pemanfaatan teknologi of appropriate medical technology, and the provision of
medis yang tepat guna, serta penyediaan fasilitas yang safe and comfortable facilities. This approach ensures
Page 167
Laporan Tahunan
Annual Report 167
aman dan nyaman. Pendekatan ini memastikan bahwa that all services provided reflect the dedication and
setiap layanan yang diberikan mencerminkan dedikasi trust that form the basis of BMHS’s relationship with
dan kepercayaan yang menjadi dasar hubungan BMHS patients and the community. This pillar also includes
dengan pasien dan masyarakat. Pilar ini juga mencakup workforce management as an important part of service
pengelolaan ketenagakerjaan sebagai bagian penting quality. BMHS believes that service quality is greatly
dari mutu pelayanan. BMHS memandang bahwa influenced by the competence, safety, and well being of
kualitas layanan sangat dipengaruhi oleh kompetensi, healthcare professionals and support staff. Therefore,
keselamatan, dan kesejahteraan tenaga kesehatan initiatives are directed at creating a healthy, safe,
maupun karyawan pendukung. Oleh karena itu, berbagai and inclusive work environment, including increasing
inisiatif diarahkan untuk menciptakan lingkungan kerja the capacity of medical personnel, developing talent,
yang sehat, aman, dan inklusif, termasuk peningkatan providing equal development opportunities, and
kapasitas tenaga medis, pengembangan talenta, managing turnover rates in a more measurable
penyediaan kesempatan pengembangan yang setara, manner. BMHS also provides facilities and policies that
serta pengelolaan tingkat turnover secara lebih terukur. support working mothers, such as lactation rooms and
BMHS juga menyediakan fasilitas dan kebijakan yang breastfeeding-friendly work arrangements, in order to
mendukung ibu bekerja, seperti ruang laktasi dan strengthen employee welfare and support the creation
pengaturan kerja yang ramah bagi ibu menyusui, guna of better patient services.
memperkuat kesejahteraan karyawan dan mendukung
terciptanya pelayanan pasien yang lebih baik.
Informasi mengenai strategi, implementasi, serta Information concerning BMHS’s Social and
capaian Tanggung Jawab Sosial dan Lingkungan BMHS Environmental Responsibility strategies,
disampaikan secara lebih lengkap dalam Laporan implementation, and achievements can be found in
Keberlanjutan 2025 PT Bundamedik Tbk, yang more detail in the 2025 Sustainability Report of PT
merupakan bagian yang tidak terpisahkan dari Laporan Bundamedik Tbk, which is an integral part of this
Tahunan ini. Annual Report.
Page 168
168
Surat Pernyataan
Statement
Surat Pernyataan
Dewan Komisaris
Surat Pernyataan
Letter ofDewan
theLetter
Statement Board
Dewandan
ofofthe
Komisaris
Commissioners
Komisaris Board
Direksidan Direksi
danof and Board ofand
Commissioners
Direksi Directors
Board of Directors
Statement Letter of the Board of Commissioners and Board of Directors
Surat Pernyataan Anggota Dewan Komisaris
Surat Pernyataan Anggota Dewan Komisaris
tentang Tanggung Jawab atas Laporan Tahunan
tentang Tanggung Jawab atas Laporan Tahunan
PT Bundamedik Tbk Tahun 2025
PT Bundamedik Tbk Tahun 2025
Statement Letter of the Board of Commissioners Responsibilities
Statement Letter of the Board of Commissioners Responsibilities
on the Annual Report of PT Bundamedik Tbk Year 2025
on the Annual Report of PT Bundamedik Tbk Year 2025
Kami yang bertanda tangan di bawah ini menyatakan We, the undersigned, state that all information in the
Kami yang
bahwa bertanda
semua tangandalam
informasi di bawah ini menyatakan
Laporan Tahunan Annual of PT state
undersigned,
We, theReport that all information
Bundamedik in the
Tbk Year 2025 is
bahwa
PT semua informasi
Bundamedik Tbk Tahun dalam Laporan
2025 telah dimuatTahunan
secara Annual Report
presented in its entirety, and we takeTbk
of PT Bundamedik Year 2025 is
full responsibility
PT Bundamedik
lengkap Tbk Tahun
dan bertanggung 2025
jawab telahatas
penuh dimuat secara
kebenaran presented
for the correctness the we
of and
in its entirety, take fullinresponsibility
contents this Annual
lengkap
isi danTahunan
Laporan bertanggung jawab penuh atas kebenaran
Perseroan.
BMHS. for the correctness of the contents in this Annual
Report.
isi Laporan Tahunan Perseroan. Report.
Demikian pernyataan ini dibuat dengan sebenarnya. Thus this statement is made in all truthfulness.
Demikian pernyataan ini dibuat dengan sebenarnya. Thus this statement is made in all truthfulness.
Jakarta, April 2026
Jakarta, April 2026
Dewan Komisaris | Board of Commissioners
Dewan Komisaris | Board of Commissioners
Ivan Rizal Sini
Ivan RizalUtama
Komisaris Sini
President Commissioner
Komisaris Utama
President Commissioner
Shubhasish Chattoraj Mesha Rizal Sini
Shubhasish
Wakil Chattoraj
Komisaris Utama Mesha Rizal Sini
Komisaris
Vice President
Wakil Commissioner
Komisaris Utama Commissioner
Komisaris
Vice President Commissioner Commissioner
Retno L. P. Marsudi Arianti Anaya
Retno L. P.
Komisaris Marsudi
Independen Arianti Anaya
Komisaris Independen
Komisaris Independen
Independent Commissioner Komisaris Independen
Independent Commissioner
Independent Commissioner Independent Commissioner
Page 169
Laporan Tahunan
Annual Report 169
Surat Pernyataan Anggota Direksi tentang
Tanggung Jawab atas Laporan Tahunan
PT Bundamedik Tbk Tahun 2025
Statement Letter of the Board of Directors Responsibilities
on the Annual Report of PT Bundamedik Tbk Year 2025
Kami yang bertanda tangan di bawah ini menyatakan We, the undersigned, state that all information in the
bahwa semua informasi dalam Laporan Tahunan Annual Report of PT Bundamedik Tbk Year 2025 is
PT Bundamedik Tbk Tahun 2025 telah dimuat secara presented in its entirety, and we take full responsibility
lengkap dan bertanggung jawab penuh atas kebenaran for the correctness of the contents in this Annual
isi Laporan Tahunan BMHS. Report.
Demikian pernyataan ini dibuat dengan sebenarnya. Thus this statement is made in all truthfulness.
Jakarta, April 2026
Direksi | Board of Directors
Agus Heru Darjono
Direktur Utama
President Director
Cuncun Wijaya Emilia Rouli
Direktur Direktur
Director Director
Page 170
170 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
Referensi SEOJK 16/SEOJK.04/2021 tentang Bentuk dan
Isi Laporan Emiten atau Perusahaan Publik
Reference to SEOJK 16/SEOJK.04/2021 regarding the Form and
Content of Reports of Issuers or Public Companies
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Ikhtisar Data Keuangan Penting
Financial Highlights
Ikhtisar data keuangan penting memuat informasi keuangan yang disajikan dalam bentuk
perbandingan selama 3 tahun buku atau sejak memulai usahanya jika Emiten atau Perusahaan
Publik tersebut menjalankan kegiatan usahanya kurang dari 3 tahun, paling sedikit memuat,
1 pendapatan, laba (rugi), jumlah aset, liabilitas, ekuitas, dan rasio-rasio keuangan. 6-7
Financial information is presented in a comparative form over a period of 3 (three) financial years;
if the Issuer or Public Company has been established less than 3 years, the information shall
include at least includes revenue, profit (loss), total assets, liabilities; equity, and financial ratios.
Informasi Saham
Information on Shares
Saham yang telah diterbitkan untuk setiap masa triwulan yang disajikan dalam bentuk
perbandingan selama 2 tahun buku terakhir, paling sedikit memuat:
a. jumlah saham yang beredar;
b. kapitalisasi pasar berdasarkan harga pada bursa efek tempat saham dicatatkan;
c. harga saham tertinggi, terendah, dan penutupan berdasarkan harga pada bursa efek tempat
saham dicatatkan; dan
d. volume perdagangan pada bursa efek tempat saham dicatatkan.
Informasi dalam huruf b), huruf c) dan huruf d) hanya diungkapkan jika sahamnya tercatat di
1 8-9
bursa efek.
Issued shares for each quarter presented in a comparative form of at least 2 financial years at
least include:
a. number of outstanding shares;
b. market capitalization based on the price at the Stock Exchange where the shares are listed;
c. the highest, lowest, and closing share price based on the Stock Exchange where the shares are
listed; and
d. trading volume at the Stock Exchange where the shares are listed.
Dalam hal terjadi aksi korporasi yang menyebabkan terjadinya perubahan pada saham, seperti
pemecahan saham (stock split), penggabungan saham (reverse stock), dividen saham, saham
bonus, perubahan nilai nominal saham, penerbitan efek konversi, serta penambahan dan
2 pengurangan modal, informasi saham sebagaimana dimaksud pada angka 1. 9
In the event of corporate action causes changes in shares such as stock split, reverse stock, stock
dividend, bonus shares, changes in the nominal value of shares, issuance of conversion stock, and
increasing and decreasing interests; information on shares as stated in point 1.
Dalam hal terjadi penghentian sementara perdagangan saham (suspension) dan/atau pembatalan
pencatatan saham (delisting) dalam tahun buku, dijelaskan alasan penghentian sementara
3 perdagangan saham (suspension) dan/atau pembatalan pencatatan saham (delisting) tersebut. 9
In the event of suspension and/or delisting in the financial year, the Issuer or Public Company
shall explain the reasons for the suspension and/or delisting.
Dalam hal penghentian sementara perdagangan saham (suspension) sebagaimana dimaksud
pada angka 3, dan/atau proses pembatalan pencatatan saham (delisting) masih berlangsung
hingga akhir periode Laporan Tahunan, dijelaskan tindakan yang dilakukan untuk menyelesaikan
penghentian sementara perdagangan saham (suspension) dan/atau pembatalan pencatatan
4 9
saham (delisting) tersebut.
In the event that suspension and/or delisting as referred to point 3 is still ongoing until the end of
the Annual Report period, the Issuer or Public Company shall explain the actions taken to resolve
the suspension and/or delisting.
Page 171
Laporan Tahunan
Annual Report 171
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Laporan Direksi
Report of the Board of Directors
Kinerja Emiten atau Perusahaan Publik, paling sedikit memuat:
a. strategi dan kebijakan strategis;
b. peranan Direksi dalam perumusan strategi dan kebijakan strategis;
c. proses yang dilakukan Direksi untuk memastikan implementasi strategi;
d. perbandingan antara hasil yang dicapai dengan yang ditargetkan;
e. kendala yang dihadapi.
1 Performance of Issuer or Public Company, at least includes: 22-26
a. strategies and Strategic Policy:
b. the role of the Board of Directors in the formulation of strategies and strategic policy;
c. processes carried out by the Board of Directors to ensure the implementation of strategies
and strategic policy;
d. comparison between realization and target; and
e. obstacle faced by Issuer or Public Company.
Gambaran tentang prospek usaha Emiten atau Perusahaan Publik.
2 26
Views on business prospect of Issuer or Public Company; and
Penerapan tata kelola Emiten atau Perusahaan Publik.
3 26-29
Implementation of good governance of Issuer or Public Company.
Laporan Dewan Komisaris
Report of the Board of Commissioners
Penilaian terhadap kinerja Direksi mengenai pengelolaan Emiten atau Perusahaan Publik,
termasuk pengawasan Dewan Komisaris dalam perumusan dan implementasi strategi yang
dilakukan oleh Direksi.
1 17-20
Performance evaluation of the Board of Directors regarding management of Issuer or Public
Company, including the supervision of the Board of Commissioners in the formulation and
implementation of strategies for Issuers or Public Company carried out by the Board of Directors.
Pandangan atas prospek usaha yang disusun oleh Direksi.
2 20
Views on business prospect of Issuer or Public Company prepared by the Board of Directors.
Pandangan atas penerapan tata kelola Emiten atau Perusahaan Publik.
3 20-21
Views on the implementation of governance of Issuer or Public Company.
Profil Emiten atau Perusahaan Publik
Profile of Issuer or Public Company
Nama Emiten atau Perusahaan Publik termasuk apabila terdapat perubahan nama, alasan
perubahan, dan tanggal efektif perubahan nama pada tahun buku.
1 28
Name of Issuer or Public Company, including name change, reason of the change, and effective
date of the name change in the financial year.
Akses terhadap Emiten atau Perusahaan Publik termasuk kantor cabang atau kantor perwakilan
yang memungkinkan masyarakat dapat memperoleh informasi mengenai Emiten atau
Perusahaan Publik, meliputi alamat, nomor telepon, alamat surat elektronik, dan alamat situs
2 web. 28
Access to Issuer or Public Company, including branch office or representative office that allows
public to obtain information regarding Issuer or Public Company, including: address; phone
number, email address, and web address.
Riwayat singkat Emiten atau Perusahaan Publik.
3 28-33
Brief history of Issuer or Public Company.
Visi dan misi Emiten atau Perusahaan Publik serta budaya perusahaan (corporate culture) atau
4 nilai-nilai perusahaan. 34-35
Vision and mission of Issuer or Public Company and its corporate culture or values;
Kegiatan usaha menurut anggaran dasar terakhir, kegiatan usaha yang dijalankan pada tahun
buku, serta jenis barang dan/atau jasa yang dihasilkan.
5 36-44
Business activities according to the latest article of association, business activities conducted
within the financial year, and type of goods and/or services.
Page 172
172 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Wilayah operasional Emiten atau Perusahaan Publik; wilayah operasional merupakan wilayah
atau daerah pelaksanaan kegiatan operasional atau jangkauan dari kegiatan operasional
6 perusahaan. 45
Operational area of Issuer or Public Company; operational area is an area or region for carrying
out operational activities or the range of operational activities.
Struktur organisasi Emiten atau Perusahaan Publik dalam bentuk bagan, paling sedikit sampai
dengan struktur satu tingkat di bawah Direksi termasuk komite di bawah Direksi (jika ada) dan
komite di bawah Dewan Komisaris, disertai dengan nama dan jabatan.
7 48
Organizational structure of Issuer or Public Company in the form of a chart, at least until 1 (one)
level below the Board of Directors, including committees under the Board of Directors (if any) and
committees under the Board of Commissioners, along with name and position.
Daftar keanggotaan asosiasi industri baik dalam skala nasional maupun internasional yang
berkaitan dengan penerapan keuangan berkelanjutan.
8 49
A list of industry association memberships on a national and international scale related to the
implementation of sustainable finance.
Profil Direksi, paling sedikit memuat:
a. nama dan jabatan yang sesuai dengan tugas dan tanggung jawab;
b. foto terbaru;
c. usia;
d. kewarganegaraan;
e. riwayat pendidikan dan/atau sertifikasi
f. riwayat jabatan, meliputi informasi:
• dasar hukum pengangkatan;
• rangkap jabatan;
• pengalaman kerja beserta periode waktunya baik di dalam maupun di luar Emiten atau
Perusahaan Publik;
g. hubungan afiliasi dengan anggota Direksi lainnya, anggota Dewan Komisaris, pemegang
saham utama, dan pengendali baik langsung maupun tidak langsung; dan
h. perubahan komposisi anggota Direksi dan alasan perubahannya.
Profile of the Board of Directors, at least includes:
9 58-61
a. name and position in accordance with the duties and responsibilities;
b. recent photograph;
c. age;
d. citizenship;
e. education background and/or certification;
f. position history, including information on:
• legal basis of appointment as a member of the Board of Directors of Issuer or Public
Company;
• concurrent positions;
• work experience and period of service inside and outside Issuer or Public Company;
g. affiliation with other members of the Board of Directors, members of the Board of
Commissioners, major and controlling shareholders, either directly or indirectly to individual
owners.
h. changes in the composition of members of the Board of Directors and the reasons for the
changes.
Page 173
Laporan Tahunan
Annual Report 173
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Profil Dewan Komisaris, paling sedikit memuat:
a. nama dan jabatan;
b. foto terbaru;
c. usia;
d. kewarganegaraan;
e. riwayat pendidikan dan/atau sertifikasi;
f. riwayat jabatan, meliputi informasi:
• dasar hukum pengangkatan sebagai anggota Dewan Komisaris;
• dasar hukum pengangkatan pertama kali sebagai anggota Dewan Komisaris yang
merupakan komisaris independen;
• rangkap jabatan; dan
• pengalaman kerja beserta periode waktunya baik di dalam maupun di luar Emiten atau
Perusahaan Publik;
g. hubungan afiliasi dengan anggota Dewan Komisaris lainnya, pemegang saham utama, dan
pengendali baik langsung maupun tidak langsung;
h. pernyataan independensi komisaris independen dalam hal komisaris independen telah
menjabat lebih dari 2 periode; dan
10 50-57
i. perubahan komposisi anggota Dewan Komisaris dan alasan perubahannya.
Profile of the Board of Commissioners, at least includes:
a. name and position in accordance with the duties and responsibilities;
b. recent photograph;
c. age;
d. citizenship;
e. education background and/or certification;
• position history, including information on:
• legal basis for appointment as a member of the Board of Commissioners;
• concurrent positions;
• work experience and period of service inside and outside Issuer or Public Company;
f. affiliation with other members of the Board of Commissioners, major and controlling
shareholders, either directly or indirectly to individual owners.
g. independence statement of the independent commissioner in the event that the independent
commissioner has served for more than 2 terms; and
h. changes in the composition of members of the Board of Directors and the reasons for the
changes.
Dalam hal terdapat perubahan susunan anggota Direksi dan/atau anggota Dewan Komisaris yang
terjadi setelah tahun buku berakhir sampai dengan batas waktu penyampaian Laporan Tahunan,
susunan yang dicantumkan dalam Laporan Tahunan adalah susunan anggota Direksi dan/atau
anggota Dewan Komisaris yang terakhir dan sebelumnya.
11 In the event that there is a change in the composition of the members of the Board of Directors 50,58
and/or members of the Board of Commissioners that occurs after the financial year ends up to
the deadline for submitting the Annual Report, the composition included in the Annual Report is
the composition of the latest and previous members of the Board of Directors and/or members of
the Board of Commissioners.
Jumlah karyawan menurut jenis kelamin, jabatan, usia, tingkat pendidikan, dan status
ketenagakerjaan (tetap/kontrak) dalam tahun buku.
12 62-66
Number of employees by gender, position, age, education level, and employment status
(permanent/contract) in the financial year.
Page 174
174 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Nama pemegang saham dan persentase kepemilikan pada awal dan akhir tahun buku, yang
terdiri dari informasi mengenai:
a. pemegang saham yang memiliki 5% atau lebih;
b. anggota Direksi dan anggota Dewan Komisaris yang memiliki saham; dan
c. kelompok pemegang saham masyarakat, yaitu kelompok pemegang saham yang masing-
masing memiliki kurang dari 5%.
13 Names of shareholders and percentage of ownership at the beginning and end of the financial 68
year, at least includes information on:
a. shareholders owning 5% or more shares of Issuer or Public Company;
b. members of the Board of Directors and members of the Board of Commissioners who own
shares in Issuers or Public Companies; and
c. public shareholders group who has ownership less than 5% of shares of the Issuer or Public
Company.
Persentase kepemilikan tidak langsung atas saham Emiten atau Perusahaan Publik oleh anggota
Direksi dan anggota Dewan Komisaris pada awal dan akhir tahun buku. Dalam hal seluruh
anggota Direksi dan/atau seluruh anggota Dewan Komisaris tidak memiliki kepemilikan tidak
langsung atas saham Emiten atau Perusahaan Publik, maka diungkapkan mengenai hal tersebut.
14 The percentage of indirect ownership of the shares of the Issuer or Public Company by members 69
of the Board of Directors and members of the Board of Commissioners at the beginning and end
of the financial year. If all members of the Board of Directors and/or the Board of Commissioners
do not have indirect ownership of the shares of the Issuer or Public Company, this matter shall be
disclosed.
Jumlah pemegang saham dan persentase kepemilikan per akhir tahun buku berdasarkan
klasifikasi: kepemilikan institusi lokal; institusi asing; individu lokal; dan individu asing.
15 Number of shareholders and percentage of ownership at the end of the financial year based 69
on the classification: local institution ownership; foreign institution ownership; local individual
ownership; and foreign individual ownership.
Informasi mengenai pemegang saham utama dan pengendali Emiten atau Perusahaan Publik,
baik langsung maupun tidak langsung, sampai kepada pemilik individu, yang disajikan dalam
16 bentuk skema atau bagan. 69
Information on major and controlling shareholders of Issuer or Public Company, either directly or
indirectly, to the individual owners, presented in the form of a scheme or chart.
Nama entitas anak, perusahaan asosiasi, perusahaan ventura bersama dimana Emiten atau
Perusahaan Publik memiliki pengendalian bersama entitas (jika ada), beserta persentase
kepemilikan saham, bidang usaha, total aset, dan status operasi entitas anak, perusahaan
asosiasi, perusahaan ventura bersama. Untuk entitas anak, ditambahkan informasi mengenai
17 70-72
alamat entitas anak tersebut.
Name of subsidiary, associated company, joint venture where Issuer or Public Company has a
jointly controlled entity (if any), along with the percentage of share ownership, line of business,
total assets, and operating status of the subsidiary, associated company, joint venture.
Kronologis pencatatan saham, jumlah saham, nilai nominal, dan harga penawaran dari awal
pencatatan hingga akhir tahun buku serta nama bursa efek dimana saham Emiten atau
Perusahaan Publik dicatatkan, termasuk pemecahan saham (stock split), penggabungan saham
(reverse stock), dividen saham, saham bonus, dan perubahan nilai nominal saham, pelaksanaan
efek konversi, pelaksanaan penambahan dan pengurangan modal (jika ada).
18 72-73
Chronology of share listing, number of shares, par value, and offering price from the beginning of
listing to the end of the financial year as well as the name of the stock exchange where the shares
of the Issuer or Public Company are listed, including stock splits, reverse stock, stock dividend,
bonus shares, and changes in the par value of shares, implementation of conversion stock,
implementation of capital additions and subtractions (if any).
Informasi pencatatan efek lainnya selain efek sebagaimana dimaksud pada angka 18, yang belum
jatuh tempo pada tahun buku paling sedikit memuat nama efek, tahun penerbitan, tingkat suku
bunga/imbal hasil, tanggal jatuh tempo, nilai penawaran, dan peringkat efek (jika ada).
19 72-73
Information on the listing of other securities other than securities as referred to in point 18), that
have not matured within the financial year at least includes name of securities, issuance year,
interest rate/yield, maturity date, offering value, and securities rating (if any).
Page 175
Laporan Tahunan
Annual Report 175
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Informasi penggunaan jasa akuntan publik (AP) dan kantor akuntan publik (KAP) beserta jaringan/
asosiasi/aliansinya meliputi: nama dan alamat; periode penugasan; informasi jasa audit dan/
atau non audit yang diberikan; biaya jasa (fee); dalam hal AP dan KAP beserta jaringan/asosiasi/
aliansinya, yang ditunjuk tidak memberikan jasa non audit, maka diungkapkan mengenai
informasi tersebut.
20 73
Information on the use of public accounting services (AP) and public accounting firms (KAP) and
its networks/associations/alliances include: Name and address; Assignment period; Information
on audit and/or non-audit services provided; audit and/or non-audit fee for each assignment
during the financial year. If the appointed AP and KAP and its network/association/alliance do not
provide non-audit services, then the matter shall be disclosed.
Nama dan alamat lembaga dan/atau profesi penunjang pasar modal selain AP dan KAP.
21 Name and address of capital market supporting institutions and/or professions other than AP and 73
KAP.
Analisis dan Pembahasan Manajemen
Management Discussion and Analysis
Tinjauan operasi per segmen usaha sesuai dengan jenis industri Emiten atau Perusahaan Publik,
paling sedikit mengenai:
a. produksi, yang meliputi proses, kapasitas, dan perkembangannya;
b. pendapatan/penjualan; dan
c. profitabilitas.
1 78-81
Overview of operations per business segment according to the type of industry of Issuer or Public
Company, at least includes:
a. production, including process, capacity, and growth;
b. sales/revenue; and
c. profitability.
Kinerja keuangan komprehensif yang mencakup perbandingan kinerja keuangan dalam 2
tahun buku terakhir, penjelasan tentang penyebab adanya perubahan dan dampak perubahan
tersebut, paling sedikit mengenai:
a. aset lancar, aset tidak lancar, dan total aset;
b. liabilitas jangka pendek, liabilitas jangka panjang, dan total liabilitas;
c. ekuitas;
d. pendapatan/penjualan, beban, laba (rugi), penghasilan komprehensif lain, dan total laba (rugi)
komprehensif; dan
e. arus kas.
2 83-87
Comprehensive financial performance, including comparison of financial performance in the
last 2 (two) financial years, an explanation of the causes of the changes and the impact of these
changes, at least includes:
a. current assets, non-current assets, and total assets;
b. current liabilities, non-current liabilities, and total liabilities;
c. equity;
d. revenue/sales, expenses, profit (loss), other comprehensive income, and total comprehensive
profit (loss); and
e. cash flow.
Kemampuan membayar utang atau kewajiban dengan menyajikan perhitungan rasio yang
3 relevan. 87
Ability to pay debts or liabilities by presenting the relevant ratio calculations.
Tingkat kolektibilitas piutang Emiten atau Perusahaan Publik dengan menyajikan perhitungan
rasio yang relevan.
4 87-88
Collectability level of the Issuer's or Public Company's receivables by presenting the relevant ratio
calculations.
Struktur modal dan kebijakan manajemen atas struktur modal tersebut disertai dasar penentuan
kebijakan dimaksud.
5 88-89
Capital structure and management policy on capital structure along with the basis for determining
the policy.
Page 176
176 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Bahasan mengenai ikatan yang material untuk investasi barang modal dengan penjelasan paling
sedikit memuat:
a. tujuan dari ikatan tersebut;
b. sumber dana yang diharapkan untuk memenuhi ikatan tersebut;
c. mata uang yang menjadi denominasi; dan
d. langkah yang direncanakan Emiten atau Perusahaan Publik untuk melindungi risiko dari posisi
mata uang asing yang terkait.
6 89
Discussion on material commitment for capital goods investment with description, at least
includes:
a. objectives of the commitment;
b. expected source of funds to fulfill the commitment;
c. the denominated currency; and
d. steps planned by Issuer or Public Company to protect the position of related currency from
any risks.
Bahasan mengenai investasi barang modal yang direalisasikan dalam tahun buku terakhir, paling
sedikit memuat:
a. jenis investasi barang modal;
b. tujuan investasi barang modal; dan
7 c. nilai investasi barang modal yang dikeluarkan. 89
Discussion on capital goods investment realized in the latest financial year, at least includes:
a. types of capital goods investment;
b. objectives of capital goods investment; and
c. values of the issued capital goods investment.
Informasi dan fakta material yang terjadi setelah tanggal laporan akuntan (jika ada).
8 90
Material information and facts occurring after the due date of accountant report (if any).
Prospek usaha dari Emiten atau Perusahaan Publik dikaitkan dengan kondisi industri, ekonomi
secara umum dan pasar internasional disertai data pendukung kuantitatif dari sumber data yang
layak dipercaya.
9 90-91
Business prospects of Issuer or Public Company related to the general conditions of industry,
economy, and international market as well as quantitative supporting data from reliable data
sources.
Perbandingan antara target/proyeksi pada awal tahun buku dengan hasil yang dicapai (realisasi),
mengenai:
a. pendapatan/penjualan;
b. laba (rugi);
c. struktur modal; atau
d. hal lainnya yang dianggap penting bagi Emiten atau Perusahaan Publik.
10 91
Comparison between target/projection at the beginning of the financial year and realization,
including:
a. revenue/sales;
b. profit (loss);
c. capital structure; or
d. other matters deemed important to Issuer or Public Company.
Page 177
Laporan Tahunan
Annual Report 177
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Target/proyeksi yang ingin dicapai Emiten atau Perusahaan Publik untuk 1 tahun mendatang,
mengenai:
a. pendapatan/penjualan;
b. laba (rugi);
c. struktur modal;
d. kebijakan dividen; atau
11 e. hal lainnya yang dianggap penting bagi Emiten atau Perusahaan Publik; 92
Target/projection to be achieved by Issuer or Public Company for the following 1 year, including:
a. revenue/sales;
b. profit (loss);
c. capital structure;
d. dividend policy; or
e. other matters deemed important to Issuer or Public Company.
Aspek pemasaran atas barang dan/atau jasa Emiten atau Perusahaan Publik, paling sedikit
mengenai strategi pemasaran dan pangsa pasar.
12 93-95
Marketing aspects of goods and/or services of Issuer or Public Company, at least including
marketing strategy and market share.
Uraian mengenai dividen selama 2 tahun buku terakhir, paling sedikit:
a. kebijakan dividen, antara lain memuat informasi persentase jumlah dividen yang dibagikan
terhadap laba bersih;
b. tanggal pembayaran dividen kas dan/atau tanggal distribusi dividen non kas;
c. jumlah dividen per saham (kas dan/atau non kas); dan
d. jumlah dividen per tahun yang dibayar.
13 95
Description on dividends for the last 2 financial years, at least including:
a. dividend policy, including information on the percentage of total dividends distributed to net
income;
b. date of payment of cash dividends and/or date of distribution of non-cash dividends;
c. amount of dividends per share (cash and/or non-cash); and
d. amount of paid dividends per year.
Realisasi penggunaan dana hasil penawaran umum, dengan ketentuan:
a. dalam hal selama tahun buku, Emiten memiliki kewajiban menyampaikan laporan realisasi
penggunaan dana, maka diungkapkan realisasi penggunaan dana hasil penawaran umum
secara kumulatif sampai dengan akhir tahun buku; dan
b. dalam hal terdapat perubahan penggunaan dana sebagaimana diatur dalam Peraturan
Otoritas Jasa Keuangan mengenai laporan realisasi penggunaan dana hasil penawaran umum,
maka Emiten menjelaskan perubahan tersebut.
14 96
Realization of the use of proceeds from the public offering, provided that:
a. in the event that during the financial year, the Issuer has an obligation to submit a report
on the realization of the use of proceeds, then the realization of the cumulative use of the
proceeds from the public offering shall be disclosed until the end of the financial year; and
b. if there is a change in the use of proceeds as regulated in the Financial Services Authority
Regulation on the report on the realization of the use of the proceeds from the public offering,
the Issuer shall explain the change.
Page 178
178 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Informasi material (jika ada), antara lain mengenai investasi, ekspansi, divestasi, penggabungan/
peleburan usaha, akuisisi, restrukturisasi utang/modal, transaksi material, transaksi afiliasi, dan
transaksi benturan kepentingan, yang terjadi pada tahun buku, paling sedikit memuat:
a. tanggal, nilai, dan objek transaksi;
b. nama pihak yang melakukan transaksi;
c. sifat hubungan afiliasi (jika ada);
d. penjelasan mengenai kewajaran transaksi;
e. pemenuhan ketentuan terkait; dan
f. dalam hal terdapat hubungan afiliasi, selain mengungkapkan informasi sebagaimana
dimaksud dalam huruf (a) sampai dengan huruf (e), Emiten atau Perusahaan Publik juga
mengungkapkan informasi:
• pernyataan Direksi bahwa transaksi afiliasi telah melalui prosedur yang memadai untuk
memastikan bahwa transaksi afiliasi dilaksanakan sesuai dengan praktik bisnis yang
berlaku umum; dan
• peran Dewan Komisaris dan komite audit dalam melakukan prosedur yang memadai;
g. untuk transaksi afiliasi atau transaksi material yang merupakan kegiatan usaha yang
dijalankan dalam rangka menghasilkan pendapatan usaha dan dijalankan secara rutin,
berulang, dan/atau berkelanjutan, ditambahkan penjelasan bahwa transaksi afiliasi
atau transaksi material tersebut merupakan kegiatan usaha yang dijalankan dalam
rangka menghasilkan pendapatan usaha dan dijalankan secara rutin, berulang, dan/atau
berkelanjutan;
h. untuk pengungkapan transaksi afiliasi dan/atau transaksi benturan kepentingan yang
merupakan hasil pelaksanaan transaksi afiliasi dan/atau transaksi benturan kepentingan
yang telah disetujui pemegang saham independen, ditambahkan informasi mengenai tanggal
pelaksanaan RUPS yang menyetujui transaksi afiliasi dan/atau transaksi benturan kepentingan
tersebut;
i. dalam hal tidak terdapat transaksi afiliasi dan/atau transaksi benturan kepentingan, maka
15 96-97
diungkapkan mengenai hal tersebut.
Material information (if any) on investment, expansion, divestment, business merger/
consolidation, acquisition, debt/capital restructuring, material transactions, affiliated transactions,
and conflict of interest transactions, that occur during the financial year, at least includes:
a. date, value, and object of transaction;
b. name of the party making the transaction;
c. nature of affiliated relationship (if any);
d. description on fairness of the transaction;
e. compliance with related provisions; and
f. If there is an affiliated relationship, other than disclosing the information as referred to in
letter (a) to letter (e), the Issuer or Public Company shall also disclose information on:
• statement of the Board of Directors that the affiliate transaction has been through
adequate procedures to ensure that the affiliated transaction is carried out in accordance
with generally accepted business practices;
• role of the Board of Commissioners and the audit committee in carrying out adequate
procedures to ensure that affiliated transactions.
g. as for the routine, repeated, and/or sustainable affiliated or material transactions that are
parts of operational activities conducted to gain revenues, there shall be an added information
stating that those transactions are routine, repeated, and/or sustainable affiliated or material
transactions that are parts of operational activities conducted to gain revenues;
h. as for disclosure of affiliated transactions and/or conflict of interest transactions resulting from
the implementation of affiliated transactions and/or conflict of interest transactions that have
been approved by independent shareholders, additional information regarding the date of
the GMS to approve the affiliated transactions and/or conflict of interest transactions shall be
added;
i. If there is no affiliated transaction and/or conflict of interest transaction, then this matter shall
be disclosed.
Page 179
Laporan Tahunan
Annual Report 179
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Perubahan ketentuan peraturan perundang-undangan yang berpengaruh signifikan terhadap
Emiten atau Perusahaan Publik dan dampaknya terhadap laporan keuangan (jika ada).
16 97-98
Changes in the provisions of laws and regulations that have a significant impact on Issuer or
Public Company and its impact on financial statements (if any).
Perubahan kebijakan akuntansi, alasan dan dampaknya terhadap laporan keuangan (jika ada).
17 98-99
Changes in accounting policies, reasons, and impact on financial statements (if any).
Tata Kelola Emiten atau Perusahaan Publik
Issuer or Public Company Governance
Rapat Umum Pemegang Saham (RUPS), paling sedikit memuat:
a. Informasi mengenai keputusan RUPS pada tahun buku dan 1 tahun sebelum tahun buku
meliputi:
• keputusan RUPS pada tahun buku dan 1 tahun sebelum tahun buku yang direalisasikan
pada tahun buku; dan
• keputusan RUPS pada tahun buku dan 1 tahun sebelum tahun buku yang belum
direalisasikan beserta alasan belum direalisasikan;
b. dalam hal Emiten atau Perusahaan Publik menggunakan pihak independen dalam
pelaksanaan RUPS untuk melakukan perhitungan suara, maka diungkapkan mengenai hal
1 tersebut. 104-108
Issuer or Public Company governance shall at least include a brief description of:
a. Information on GMS resolutions in the financial year and 1 year before the financial year,
including:
• GMS resolution in the financial year and 1 year before the financial year realized in the
financial year; and
• GMS resolutions in the financial year and 1 year before the financial year that have not
been realized and the reasons for not realizing the resolutions;
b. If Issuer or Public Company uses an independent party during the GMS to calculate the votes,
then this matter shall be disclosed.
Direksi, paling sedikit memuat:
a. tugas dan tanggung jawab masing-masing anggota Direksi;
b. pernyataan bahwa Direksi memiliki pedoman atau piagam (charter) Direksi;
c. kebijakan dan pelaksanaan frekuensi rapat Direksi, rapat Direksi bersama Dewan Komisaris,
dan tingkat kehadiran anggota Direksi dalam rapat tersebut termasuk kehadiran dalam RUPS;
d. pelatihan dan/atau peningkatan kompetensi anggota Direksi:
e. penilaian Direksi terhadap kinerja komite yang mendukung pelaksanaan tugas Direksi;
f. dalam hal Emiten atau Perusahaan Publik tidak memiliki komite yang mendukung pelaksanaan
tugas Direksi, maka diungkapkan mengenai hal tersebut.
Board of Directors, at least includes:
2 115-120
a. duties and responsibilities of each member of the Board of Directors;
b. statement that the Board of Directors has Board of Directors Charter;
c. policy and frequency of BOD meetings, meetings of the Board of Directors with the Board of
Commissioners, and attendance rate of members of the Board of Directors in the meeting
including attendance at the GMS;
d. training and/or competency development of members of the Board of Directors:
e. Board of Directors’ appraisal on the performance of the committees supporting the
implementation of the Board of Directors’ duties;
f. If Issuer or Public Company does not have committees to support the implementation of the
duties of the Board of Directors, this matter shall be disclosed.
Page 180
180 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Dewan Komisaris, paling sedikit memuat:
a. tugas dan tanggung jawab Dewan Komisaris;
b. pernyataan bahwa Dewan Komisaris memiliki pedoman atau piagam (charter) Dewan
Komisaris;
c. kebijakan dan pelaksanaan frekuensi rapat Dewan Komisaris, rapat Dewan Komisaris bersama
Direksi dan tingkat kehadiran anggota Dewan Komisaris dalam rapat tersebut termasuk
kehadiran dalam RUPS;
d. pelatihan dan/atau peningkatan kompetensi anggota Dewan Komisaris;
e. penilaian kinerja Direksi dan Dewan Komisaris serta masing-masing anggota Direksi dan
anggota Dewan Komisaris;
f. penilaian Dewan Komisaris terhadap kinerja Komite yang mendukung pelaksanaan tugas
Dewan Komisaris pada tahun buku.
3 Board of Commissioners, at least includes: 109-115
a. duties and responsibilities of the Board of Commissioners;
b. statement that the Board of Commissioners has the Board of Commissioners Manual or
Charter;
c. policy and frequency of Board of Commissioners meetings, joint meetings of the Board of
Commissioners and the Board of Directors and attendance rate of members of the Board of
Commissioners in the meetings, including attendance at the GMS;
d. training and/or competency development of members of the Board of Commissioners:
e. performance appraisal of the Board of Directors and the Board of Commissioners as well as
each member of the Board of Directors and the Board of Commissioners;
f. the Board of Commissioners’ appraisal on the performance of the Committees to support the
implementation of the duties of the Board of Commissioners.
Nominasi dan remunerasi Direksi dan Dewan Komisaris, paling sedikit memuat:
a. prosedur nominasi, meliputi uraian singkat mengenai kebijakan dan proses nominasi anggota
Direksi dan/atau anggota Dewan Komisaris; dan
b. prosedur dan pelaksanaan remunerasi Direksi dan Dewan Komisaris.
Nomination and remuneration of the Board of Directors and the Board of Commissioners shall at
4 121-122
least include:
a. nomination procedure, including a brief description of the nomination policies and processes
of members of the Board of Directors and/or members of the Board of Commissioners; and
b. procedures and implementation of remuneration of the Board of Directors and the Board of
Commissioners.
Dewan pengawas syariah, bagi Emiten atau Perusahaan Publik yang menjalankan kegiatan usaha
berdasarkan prinsip syariah sebagaimana tertuang dalam anggaran dasar (jika ada).
5 N/A
Sharia Supervisory Board, for Issuers or Public Companies that carry out business activities based
on sharia principles as stated in the articles of association.
Komite audit, paling sedikit memuat:
a. nama dan jabatannya dalam keanggotaan komite;
b. usia;
c. kewarganegaraan;
d. riwayat pendidikan;
e. riwayat jabatan;
f. periode dan masa jabatan anggota komite audit;
g. pernyataan independensi komite audit;
h. pelatihan dan/atau peningkatan kompetensi yang telah diikuti dalam tahun buku (jika ada);
i. kebijakan dan pelaksanaan frekuensi rapat komite audit dan tingkat kehadiran anggota komite
audit dalam rapat tersebut; dan
j. pelaksanaan kegiatan komite audit pada tahun buku sesuai dengan yang dicantumkan dalam
pedoman atau piagam (charter) komite audit.
6 123-130
The audit committee, at least includes:
a. name and position in committee membership;
b. age;
c. citizenship;
d. educational background;
e. position history;
f. period and tenure of the audit committee members;
g. independence statement of the audit committee;
h. training and/or competency development attended in the financial year (if any);
i. policy and frequency of audit committee meetings and attendance rate of audit committee
members in the meetings; and
j. implementation of the audit committee’s activities in the financial year in accordance with the
audit committee guidelines or charter.
Page 181
Laporan Tahunan
Annual Report 181
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Komite atau fungsi nominasi dan remunerasi Emiten atau Perusahaan Publik, paling sedikit
memuat:
a. nama dan jabatannya dalam keanggotaan komite;
b. usia;
c. kewarganegaraan;
d. riwayat pendidikan;
e. riwayat jabatan;
f. periode dan masa jabatan anggota komite;
g. pernyataan independensi komite;
h. pelatihan dan/atau peningkatan kompetensi yang telah diikuti dalam tahun buku (jika ada);
i. uraian tugas dan tanggung jawab;
j. pernyataan bahwa telah memiliki pedoman atau piagam (charter);
k. kebijakan dan pelaksanaan frekuensi rapat dan tingkat kehadiran anggota dalam rapat
tersebut;
l. uraian singkat pelaksanaan kegiatan pada tahun buku; dan
m. dalam hal tidak dibentuk komite nominasi dan remunerasi, Emiten atau Perusahaan Publik
cukup mengungkapkan informasi sebagaimana dimaksud dalam huruf (i) sampai dengan
7 huruf (l), mohon dijelaskan alasannya. 130-135
Nomination and remuneration committee or function of Issuer or Public Company, at least
includes:
a. name and position in the committee membership;
b. age;
c. citizenship;
d. educational background;
e. position history;
f. period and tenure of the committee members;
g. independence statement of the committee;
h. training and/or competency development attended in the financial year (if any);
i. description of duties and responsibilities;
j. statement that the committee has guidelines or charter;
k. policy and frequency of meetings and attendance rate of the committee members at the
meeting;
l. brief description of the implementation of activities in the financial year; and
m. in the event that no nomination and remuneration committee is formed, the Issuer or Public
Company as referred to in letter (i) to letter (l), shall disclose the reason.
Komite lain yang dimiliki Emiten atau Perusahaan Publik dalam rangka mendukung fungsi dan
tugas Direksi (jika ada) dan/atau komite yang mendukung fungsi dan tugas Dewan Komisaris.
8 Other committees owned by Issuer or Public Company to support the functions and duties of the 135-139
Board of Directors (if any) and/or committees to support the functions and duties of the Board of
Commissioners.
Sekretaris perusahaan, paling sedikit memuat:
a. nama;
b. domisili;
c. riwayat jabatan;
d. riwayat pendidikan;
e. pelatihan dan/atau peningkatan kompetensi yang diikuti dalam tahun buku; dan
f. uraian singkat pelaksanaan tugas sekretaris perusahaan pada tahun buku.
9 140-143
Corporate secretary, at least includes:
a. name;
b. domicile;
c. position history;
d. educational background;
e. training and/or competency development attended in the financial year; and
f. brief description on the implementation of corporate secretary’s duties in the financial year;
Page 182
182 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Unit audit internal, paling sedikit memuat:
a. nama kepala unit audit internal;
b. riwayat jabatan
c. kualifikasi atau sertifikasi sebagai profesi audit internal (jika ada);
d. pelatihan dan/atau peningkatan kompetensi yang diikuti dalam tahun buku;
e. struktur dan kedudukan unit audit internal;
f. uraian tugas dan tanggung jawab;
g. pernyataan bahwa telah memiliki pedoman atau piagam (charter) unit audit internal; dan
h. uraian singkat pelaksanaan tugas unit audit internal pada tahun buku termasuk kebijakan dan
pelaksanaan frekuensi rapat dengan Direksi, Dewan Komisaris, dan/atau komite audit.
10 Internal audit unit, at least includes: 143-148
a. name of the Internal Audit Unit head;
b. position history;
c. qualification or certification as an internal audit (if any);
d. training and/or competency development attended in the financial year;
e. structure and position of the internal audit unit;
f. description of duties and responsibilities;
g. statement that the internal audit unit has guidelines or charter; and
h. brief description on the implementation of the internal audit unit’s duties in the financial
year, including policy and frequency of meetings with the Board of Directors, Board of
Commissioners, and/or audit committee.
Uraian mengenai sistem pengendalian internal (internal control) yang diterapkan oleh Emiten atau
Perusahaan Publik, paling sedikit memuat:
a. pengendalian keuangan dan operasional, serta kepatuhan terhadap peraturan perundang-
undangan lainnya;
b. tinjauan atas efektivitas sistem pengendalian internal; dan
11 c. pernyataan Direksi dan/atau Dewan Komisaris atas kecukupan sistem pengendalian internal. 148-149
Description on internal control system applied by Issuer or Public Company, at least includes:
a. financial and operational control, as well as compliance with other laws and regulations;
b. review on effectiveness of the internal control system; and
c. statement of the Board of Directors and/or Board of Commissioners on the adequacy of the
internal control system;
Sistem manajemen risiko yang diterapkan oleh Emiten atau Perusahaan Publik, paling sedikit
memuat:
a. gambaran umum mengenai sistem manajemen risiko;
b. jenis risiko dan cara pengelolaannya;
c. tinjauan atas efektivitas sistem manajemen risiko; dan
d. pernyataan Direksi dan/atau Dewan Komisaris atau komite audit atas kecukupan sistem
12 manajemen risiko. 149-154
Risk management system implemented by Issuer or Public Company, at least includes:
a. general description on the risk management system of Issuer or Public Company;
b. types of risks and management methods;
c. review on effectiveness of the risk management system of Issuer or Public Company; and
d. statement of the Board of Directors and/or the Board of Commissioners or the audit
committee on the adequacy of the risk management system.
Perkara hukum yang berdampak material yang dihadapi
oleh Emiten atau Perusahaan Publik, entitas anak, anggota Direksi dan anggota Dewan Komisaris
(jika ada), paling sedikit memuat:
a. pokok perkara/gugatan;
b. status penyelesaian perkara/gugatan; dan
c. pengaruhnya terhadap kondisi Emiten atau Perusahaan Publik.
13 155
Legal proceedings that have a material impact faced by Issuer or Public Company, subsidiaries,
members of the Board of Directors and members of the Board of Commissioners (if any), at least
include:
a. merits of case/lawsuit;
b. status of the case/lawsuit settlement; and
c. impact on the condition of Issuer or Public Company.
Informasi tentang sanksi administratif/sanksi yang dikenakan kepada Emiten atau Perusahaan
Publik, anggota Dewan Komisaris dan anggota Direksi, oleh Otoritas Jasa Keuangan dan otoritas
lainnya pada tahun buku (jika ada).
14 155
Information on administrative sanctions/sanctions imposed on Issuer or Public Company,
members of the Board of Commissioners and members of the Board of Directors, by the Financial
Services Authority and other authorities in the financial year (if any).
Page 183
Laporan Tahunan
Annual Report 183
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Informasi mengenai kode etik Emiten atau Perusahaan Publik meliputi:
• pokok-pokok kode etik;
• bentuk sosialisasi kode etik dan upaya penegakannya; dan
• pernyataan bahwa kode etik berlaku bagi anggota Direksi, anggota Dewan Komisaris, dan
karyawan.
15 156-157
Information on the code of conduct of Issuer or Public Company, including:
• key Principles of Code of conduct;
• the form of dissemination of the code of conduct and its enforcement efforts; and
• statement that the code of conduct applies to members of the Board of Directors, members of
the Board of Commissioners, and employees of Issuer or Public Company.
Uraian singkat mengenai kebijakan pemberian kompensasi jangka panjang berbasis kinerja
kepada manajemen dan/atau karyawan yang dimiliki oleh Emiten atau Perusahaan Publik (jika
ada), antara lain berupa program kepemilikan saham oleh manajemen (management stock
ownership program/MSOP) dan/atau program kepemilikan saham oleh karyawan (employee stock
16 ownership program/ESOP). 157-158
Brief description on the policy of providing long-term performance-based compensation to
management and/or employees owned by Issuer or Public Company (if any), including the
management stock ownership program (MSOP) and/or employee stock ownership program
(ESOP).
Uraian singkat mengenai kebijakan pengungkapan informasi mengenai:
kepemilikan saham anggota Direksi dan anggota Dewan Komisaris paling lambat 3 hari kerja
setelah terjadinya kepemilikan atau setiap perubahan kepemilikan atas saham Perusahaan
Terbuka; dan pelaksanaan atas kebijakan dimaksud.
17 158
Brief description on information disclosure policy regarding:
share ownership of members of the Board of Directors and members of the Board of
Commissioners shall be no later than 3 working days after the occurrence of ownership or any
change in ownership of shares of Public Company; and implementation of the policy.
Uraian mengenai sistem pelaporan pelanggaran (whistleblowing system) di Emiten atau
Perusahaan Publik, paling sedikit memuat:
• cara penyampaian laporan pelanggaran;
• perlindungan bagi pelapor;
• penanganan pengaduan;
• pihak yang mengelola pengaduan; dan
18 • hasil dari penanganan pengaduan. 159-161
Description on whistleblowing system in Issuer or Public Company, at least includes:
• method of submitting a violation report;
• protection for whistleblowers;
• complaint handling;
• the party in charge to manage complaint; and
• result of complaint handling.
Uraian mengenai kebijakan anti korupsi, paling sedikit memuat:
a. program dan prosedur yang dilakukan dalam mengatasi praktik korupsi, balas jasa (kickbacks),
fraud, suap dan/atau gratifikasi dalam Emiten atau Perusahaan Publik; dan
b. pelatihan/sosialisasi anti korupsi kepada karyawan Emiten atau Perusahaan Publik.
Dalam hal Emiten atau Perusahaan Publik tidak memiliki kebijakan anti korupsi, maka dijelaskan
alasan tidak dimilikinya kebijakan dimaksud.
19 161-162
Description on Anti-Corruption Policy of Issuer or Public Company, at least includes:
a. programs and procedures to overcome corruption practices, kickbacks, fraud, bribery and/or
gratuities in Issuer or Public Company; and
b. anti-corruption training/socialization to all employees of Issuer or Public Company.
Dalam hal Emiten atau Perusahaan Publik tidak memiliki kebijakan anti korupsi, maka dijelaskan
alasan tidak dimilikinya kebijakan dimaksud.
Penerapan atas pedoman tata kelola Perusahaan Terbuka bagi Emiten yang menerbitkan efek
bersifat ekuitas atau Perusahaan Publik, meliputi:
a. pernyataan mengenai rekomendasi yang telah dilaksanakan; dan/atau
b. penjelasan atas rekomendasi yang belum dilaksanakan, disertai alasan dan alternatif
pelaksanaannya (jika ada).
10 162-164
implementation of Public Company governance guidelines for Issuer that issues equity securities
or Public Company, including:
a. statement regarding the recommendations that have been realized; and/or
b. description on recommendations that have been realized, along with reasons and alternative
implementations (if any).
Page 184
184 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
URAIAN ISI LAPORAN TAHUNAN HALAMAN
No.
Description of Content of the Annual Report Page
Tanggung Jawab Sosial dan Lingkungan Emiten atau Perusahaan Publik
Social and Environmental Responsibilities of Issuer or Public Company
Informasi yang diungkapkan dalam bagian tanggung jawab sosial dan lingkungan merupakan
Laporan Keberlanjutan (Sustainability Report) sebagaimana dimaksud dalam Peraturan Otoritas
Jasa Keuangan Nomor 51/POJK.03/2017 tentang Penerapan Keuangan Berkelanjutan bagi
Lembaga Jasa Keuangan, Emiten, dan Perusahaan Publik.
1 166-167
Information disclosed in the social and environmental responsibility section is a Sustainability
Report as referred to in the Financial Services Authority Regulation No. 51/POJK.03/2017 on
Implementation of Sustainable Finance for Financial Services Institutions, Issuers, and Public
Companies.
Laporan
Laporan Keberlanjutan sebagaimana dimaksud pada angka 1, harus disusun sesuai Pedoman
Keberlanjutan
Teknis Penyusunan Laporan Keberlanjutan (Sustainability Report) Bagi Emiten dan Perusahaan
PT
Publik sebagaimana tercantum dalam Lampiran II, yang merupakan bagian tidak terpisahkan dari
Bundamedik
Surat Edaran Otoritas Jasa Keuangan ini.
2 Tbk 2025
The Sustainability Report as referred to in point 1) must be prepared in accordance with the
Sustainability
Technical Guidelines for the Preparation of a Sustainability Report for Issuers and Public
Report PT
Companies as stated in Appendix II which is an integral part of this Financial Services Authority
Bundamedik
Circular.
Tbk 2025
Laporan Keuangan Tahunan yang Telah Diaudit
Audited Annual Financial Report
Laporan keuangan tahunan yang dimuat dalam Laporan Tahunan disusun sesuai dengan
standar akuntansi keuangan di Indonesia dan telah diaudit oleh akuntan publik yang terdaftar di
Otoritas Jasa Keuangan. Laporan keuangan tahunan dimaksud memuat pernyataan mengenai
pertanggungjawaban atas laporan keuangan sebagaimana diatur dalam Peraturan Otoritas Jasa
Keuangan mengenai tanggung jawab Direksi atas laporan keuangan atau peraturan perundang-
undangan di sektor pasar modal yang mengatur mengenai laporan berkala perusahaan efek
dalam hal Emiten merupakan perusahaan efek.
1 185-282
The annual financial statements included in the Annual Report shall be prepared in accordance
with Indonesian financial accounting standards and have been audited by a public accountant
registered in the Financial Services Authority. The annual financial report shall contain a
statement regarding the accountability for financial statements as regulated in the Financial
Services Authority Regulation on the Board of Directors’ responsibility for financial reports or
the laws and regulations in the capital market sector regulating the periodic reports of securities
companies in the event that the Issuer is a securities company.
Surat Pernyataan Anggota Direksi dan Anggota Dewan Komisaris tentang Tanggung Jawab atas Laporan Tahunan
Statement Letter of the Board of Directors and f the Board of Commissioners Members on Accountability for Annual
Report
Surat pernyataan anggota Direksi dan anggota Dewan Komisaris tentang tanggung jawab atas
Laporan Tahunan disusun sesuai dengan format Surat Pernyataan Anggota Direksi dan Anggota
Dewan Komisaris tentang Tanggung Jawab atas Laporan Tahunan sebagaimana tercantum dalam
Lampiran I yang merupakan bagian tidak terpisahkan dari Surat Edaran Otoritas Jasa Keuangan
ini.
1 168-169
Statement letter of the Board of Directors and members of the Board of Commissioners Members
on Accountability for Annual Report shall be prepared in accordance with the format of Statement
Letter of the Board of Directors and the Board of Commissioners Members on Accountability
for Annual Report as set forth in Appendix I which is an integral part of this Financial Services
Authority Circular.
Page 185
Laporan Tahunan
Annual Report 185
PT BUNDAMEDIK Tbk
DAN ENTITAS ANAKNYA/ AND ITS SUBSIDIARIES
L A P O R A N K E U A N G A N K O N S O L I D A S I A N/
CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025/
FOR THE YEAR ENDED 31 DECEMBER 2025
DAN/ AND
LAPORAN AUDITOR INDEPENDEN/
INDEPENDENT AUDITOR’S REPORT
Page 186
186 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
LAPORAN KEUANGAN KONSOLIDASIAN CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
DAFTAR ISI CONTENTS
Pernyataan Direksi Director’s Statement
Ekshibit/
Exhibit
Laporan Posisi Keuangan Konsolidasian A Consolidated Statement of Financial Position
Laporan Laba Rugi dan Penghasilan Consolidated Statement of Profit or Loss and
Komprehensif Lain Konsolidasian B Other Comprehensive Income
Laporan Perubahan Ekuitas Konsolidasian C Consolidated Statement of Changes in Equity
Laporan Arus Kas Konsolidasian D Consolidated Statement of Cash Flows
Catatan atas Laporan Keuangan Konsolidasian E Notes to Consolidated Financial Statements
Laporan Auditor Independen Independent Auditors’ Report
Page 187
Laporan Keuangan Financial Report 187
Page 188
188 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian Language
Ekshibit A Exhibit A
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
LAPORAN POSISI KEUANGAN KONSOLIDASIAN CONSOLIDATED STATEMENT OF FINANCIAL POSITION
PER 31 DESEMBER 2025 AS OF 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/ 31 Desember 2025/ 31 Desember 2024/
Notes 31 December 2025 31 December 2024
ASET ASSETS
Aset Lancar Current Assets
Kas dan setara kas 4 826.584.741.908 783.332.056.074 Cash and cash equivalents
Aset keuangan lancar Other current financial
lainnya 5 6.519.211.579 3.262.592.254 assets
Piutang usaha – Pihak ketiga Trade receivables – Third
– Neto 6 161.939.911.962 144.714.255.906 parties – Net
Piutang lain-lain – Neto Other receivables – Net
Pihak berelasi 7,33 25.325.460.858 20.074.879.572 Related parties
Pihak ketiga 7 23.831.602.694 9.970.928.889 Third parties
Persediaan 8 51.620.217.662 47.021.949.525 Inventories
Biaya dibayar di muka dan Prepaid expenses and
uang muka 9 100.933.381.798 69.993.313.658 advances
Pajak dibayar di muka 20a 13.484.587.923 10.510.810.074 Prepaid taxes
Jumlah Aset Lancar 1.210.239.116.384 1.088.880.785.952 Total Current Assets
Aset Tidak Lancar Non-Current Assets
Aset pajak tangguhan 20e 31.691.945.497 25.310.529.957 Deferred tax assets
Taksiran klaim restitusi pajak 20b - 37.511.247 Estimated claim tax refund
Investasi saham 10 83.195.500.000 83.195.500.000 Investment in shares
Aset tetap – Neto 11 2.363.899.139.020 1.934.924.754.148 Property and equipment -Net
Aset hak-guna – Neto 12 147.651.907.371 94.506.359.437 Right-of-use assets – Net
Properti investasi – Neto 13 4.271.939.744 6.581.452.803 Investment properties – Net
Goodwill 14 94.793.507.471 94.793.507.471 Goodwill
Biaya dibayar di muka dan Prepaid expenses and
uang muka – jangka panjang 9 44.571.957.697 78.055.515.818 advances - long-term
Aset tidak lancar lainnya 15 36.114.421.959 40.074.986.915 Other non-current assets
Jumlah Aset Tidak Lancar 2.806.190.318.759 2.357.480.117.796 Total Non-Current Assets
JUMLAH ASET 4.016.429.435.143 3.446.360.903.748 TOTAL ASSETS
Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E See accompanying Notes to Consolidated Financial Statements
terlampir yang merupakan bagian yang tidak terpisahkan dari on Exhibit E which are integral part of the
Laporan Keuangan Konsolidasian secara keseluruhan Consolidated Financial Statements taken as a whole
Page 189
Laporan Keuangan
Financial Report 189
These Consolidated Financial Statements are originally Issued
in Indonesian Language
Ekshibit A/2 Exhibit A/2
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
LAPORAN POSISI KEUANGAN KONSOLIDASIAN CONSOLIDATED STATEMENT OF FINANCIAL POSITION
PER 31 DESEMBER 2025 AS OF 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/ 31 Desember 2025/ 31 Desember 2024/
Notes 31 December 2025 31 December 2024
LIABILITAS DAN EKUITAS LIABILITIES AND EQUITY
Liabilitas Jangka Pendek Current Liabilities
Utang bank jangka pendek 21 445.816.762.935 440.600.262.935 Short-term bank loans
Utang usaha – Pihak Trade payables – Third
ketiga 16 81.660.213.509 30.881.579.952 parties
Utang lain-lain – Pihak Other payables - Third
ketiga 17 23.743.315.736 14.708.865.083 parties
Pendapatan diterima
di muka 18 33.551.746.321 21.248.355.658 Unearned revenues
Beban akrual 19 72.836.181.464 28.573.978.375 Accruals
Utang pajak 20c 18.732.279.932 9.015.649.284 Taxes payables
Liabilitas jangka panjang
yang jatuh tempo dalam Current maturities of
satu tahun long-term liabilities
Utang bank 21 47.931.990.928 3.886.703.167 Bank loans
Sewa 12 21.812.380.174 19.500.574.022 Lease
Jumlah Liabilitas Jangka
Pendek 746.084.870.999 568.415.968.476 Total Current Liabilities
Liabilitas Jangka Panjang Non-Current Liabilities
Liabilitas pajak
tangguhan 20e 1.059.029.647 641.176.357 Deferred tax liabilities
Liabilitas imbalan Post-employment
pasca-kerja 22 34.552.286.808 29.627.155.160 benefit liabilities
Liabilitas jangka panjang –
setelah dikurangi bagian
yang jatuh tempo dalam Long term liabilities –
satu tahun net of current maturities
Utang bank 21 721.891.312.883 646.409.321.168 Bank loans
Sewa 12 118.334.918.295 53.531.597.866 Lease
Jumlah Liabilitas Jangka Total Non-Current
Panjang 875.837.547.633 730.209.250.551 Liabilities
JUMLAH LIABILITAS 1.621.922.418.632 1.298.625.219.027 TOTAL LIABILITIES
Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E See accompanying Notes to Consolidated Financial Statements
terlampir yang merupakan bagian yang tidak terpisahkan dari on Exhibit E which are integral part of the
Laporan Keuangan Konsolidasian secara keseluruhan Consolidated Financial Statements taken as a whole
Page 190
190 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian Language
Ekshibit A/3 Exhibit A/3
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
LAPORAN POSIS! KEUANGAN KONSOLIDASIAN CONSOL/DA TED STATEMENT OF FINANCIAL POSITION
PER 31 DESEMBER 2025 AS OF 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/ 31 Desember 2025/ 31 Desember 2024/
Notes 31 December 2025 31 December 2024
LIABILITAS DAN EKUITAS LIABILITIES AND EQUITY
EKUITAS EQUITY
Ekuitas yang dapat
diatribusikan kepada Equity attributable to
pemilik entitas induk owners of the parent
Modal saham - nilai nominal Share capital - par value
Rp 20 per saham of Rp 20 per shares
Modal dasar - Authorised -
400.000.000.000 saham 400,000,000,000 shares
Modal ditempatkan dan Issued and fully-paid
disetor penuh capital -
8.603.416.176 saham 23 172.068.323.520 172.068.323.520 8,603,416,176 shares
Tambahan modal disetor 24 556.636.429.244 556.675.032.353 Additional paid-in capital
Komponen ekuitas lainnya (2.383.756.076) (2.383.756.076) Other equity component
Penghasilan komprehensif Other comprehensive
lain income
Revaluation surplus of
Surplus revaluasi aset property and
tetap, setelah pajak 11 918.899.732.919 690.499.269.307 equipment, net of tax
Pengukuran kembali Remeasurement of
program imbalan pasti, defined benefit plan,
setelah pajak 22 3.504.855.110 2.227.180.859 net of tax
Rugi yang belum direalisasi Unrealised loss on
atas penurunan nilai incremental profit on
pasar aset keuangan other current
lancar lainnya 5 (10.614.529.136) (10.583.161.120) financial asset
Saldo laba 25 311.803.137.977 304.976.397.170 Retained earnings
Jumlah 1.949.914.193.558 1. 713.479.286.013 To t a l
Kepentingan nonpengendali 26 444.592.822.953 434.256.398.708 Non-controlling interests
JUMLAH EKUITAS 2.394.507.016.511 2.147.735.684.721 TOTAL EQUITY
JUMLAH LIABILITAS DAN TOTAL LIABILITIES
EKUITAS 4.016.429.435.143 3.446.360.903.748 AND EQUITY
Jakarta, 31 Maret 2026/ 31 March 2026
��
Agus Heru Darjono Cuncun Wijaya
Direktur Utama/ President Director Direktur/ Director
Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E See accompanying Notes to Consolidated Financial Statements
terlampir yang merupakan bagian yang tidak terpisahkan dari on Exhibit E which are integral part of the
Laporan Keuangan Konsolidasian secara keseluruhan Consolidated Financial Statements taken as a whole
Page 191
Laporan Keuangan
Financial Report 191
These Consolidated Financial Statements are originally Issued
in Indonesian Language
Ekshibit B Exhibit B
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
LAPORAN LABA RUGI DAN PENGHASILAN CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND
KOMPREHENSIF LAIN KONSOLIDASIAN OTHER COMPREHENSIVE INCOME
UNTUK TAHUN YANG BERAKHIR FOR THE YEAR ENDED
31 DESEMBER 2025 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Catatan/
Notes 2025 2024
PENDAPATAN NETO 27 1.614.340.771.512 1.554.685.010.336 NET REVENUES
BEBAN POKOK PENJUALAN 28 (869.848.305.402) (847.547.994.844) COST OF REVENUES
LABA BRUTO 744.492.466.110 707.137.015.492 GROSS PROFIT
Beban usaha 29 (628.562.924.995) (608.070.432.997) Operating expenses
Penghasilan keuangan 30 22.930.845.594 18.640.836.625 Finance income
Beban keuangan 31 (67.527.392.890) (68.053.448.455) Finance costs
Beban operasi lain - Neto 32 (26.050.344.266) (11.060.239.156) Other operating expenses - Net
LABA SEBELUM PAJAK 45.282.649.553 38.593.731.509 PROFIT BEFORE TAX
Pajak kini 20c (21.742.416.673) (18.096.225.121) Current tax
Pajak tangguhan 20e 6.521.673.752 1.643.320.773 Deferred tax
Pajak periode lalu 20c (388.764.099) (3.245.042.894) Prior years income taxes
Beban pajak penghasilan (15.609.507.020) (19.697.947.242) Income tax expenses
LABA TAHUN BERJALAN 29.673.142.533 18.895.784.267 PROFIT FOR THE YEAR
PENGHASILAN OTHER COMPREHENSIVE
KOMPREHENSIF LAIN INCOME
Pos-pos yang tidak akan Items that will not be
direklasifikasi ke laba rugi: reclassified to profit or loss:
Pengukuran kembali atas Remeasurement of defined
liabilitas imbalan kerja 22 2.581.070.789 (2.004.583.162) benefit liabilities
Pajak penghasilan terkait 20e (558.111.502) 475.975.725 Related income tax
Revaluasi aset tetap 231.142.399.297 - Revaluation on fixed assets
Pos-pos yang akan Items that will be reclassified
direklasifikasi ke laba rugi: to profit or loss:
Rugi yang belum direalisasi Unrealised loss on
atas penurunan nilai pasar decremental profit on
aset keuangan lancar other current financial
lainnya 5 (26.780.676) (2.503.397.606) assets
PENGHASILAN (RUGI) OTHER COMPREHENSIVE
KOMPREHENSIF TAHUN INCOME (LOSS) FOR THE
BERJALAN, Setelah pajak 233.138.577.908 (4.032.005.043) YEAR, Net of Tax
JUMLAH LABA KOMPREHENSIF TOTAL COMPREHENSIVE
PERIODE BERJALAN 262.811.720.441 14.863.779.223 INCOME FOR THE PERIOD
Page 192
192 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
Page 193
These Consolidated Financial Statements are originally Issued
in Indonesian Language
Ekshibit C Exhibit C
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
LAPORAN PERUBAHAN EKUITAS KONSOLIDASIAN CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Ekuitas yang dapat diatribusikan kepada pemilik entitas induk/
Equity attributable to owners of the parent
Penghasilan komprehensif lain/
Other comprehensive income
Laba yang belum
Surplus Pengukuran direalisasi atas
revaluasi aset kembali kenaikan nilai pasar
tetap/ program asset keuangan
Modal ditempatkan Tambahan Revaluation imbalan pasti/ lancer lainnya/ Komponen Kepentingan
dan disetor penuh/ modal disetor/ surplus of Remeasurement Unrealised gain on Ekuitas Lainnya/ nonpengendali/ Jumlah
Issued and fully Additional property and of defined incremental profit Other equity Saldo laba/ Jumlah/ Non-controlling ekuitas/
paid capital paid in capital equipment benefit plan on ot component Retained earnings Total interests Total equity
Balance as at
Saldo 1 Januari 2024 172.068.323.520 437.383.152.743 690.499.269.307 2.475.126.730 (8.079.763.514) (2.383.756.076) 297.850.794.905 1.589.813.147.615 210.222.760.837 1.800.035.908.452 1 January 2024
Setoran modal dari pihak non Paid in capital from non-
pengendali - - - - - - - - 103.638.000.000 293.128.602.500 controlling interests
Difference in equity
Selisih transaksi restructuring
restrukturisasi ekuitas transactions of the
entitas pengendali - 119.291.879.610 - - - - - 119.291.879.610 173.836.722.890 (4.817.913.059) controlling entity
Dividen kas (Catatan 25) - - - - - - (4.817.913.059) (4.817.913.059) - (59.112.692.396) Cash dividends (Note 25)
Dividen kas pada entitas Cash dividends by
anak - - - - - - - - (59.112.692.396) (4.032.005.043) subsidiaries
Other comprehensive
Kerugian komprehensif lain - - - (247.945.871) (2.503.397.606) - - (2.751.343.477) (1.280.661.566) 293.128.602.500 income
Laba tahun berjalan - - - - - - 11.943.515.324 11.943.515.324 6.952.268.943 (4.817.913.059) Profit for the year
Balance as at
Saldo 31 Desember 2024 172.068.323.520 556.675.032.353 690.499.269.307 2.227.180.859 (10.583.161.120) (2.383.756.076) 304.976.397.170 1.713.479.286.013 434.256.398.708 2.147.735.684.721 31 December 2024
Setoran modal dari pihak non Paid in capital from non-
pengendali - - - - - - - - 362.708.000 362.708.000 controlling interests
Difference in equity
Selisih transaksi restructuring
restrukturisasi ekuitas transactions of the
entitas pengendali - (38.603.109) - - - - - (38.603.109) 38.603.109 - controlling entity
Dividen kas (Catatan 25) - - - - - - (5.592.220.514) (5.592.220.514) - (5.592.220.514) Cash dividends (Note 25)
Dividen kas pada entitas Cash dividends by
anak - - - - - - - - (10.810.876.137) (10.810.876.137) subsidiaries
Penghasilan komprehensif Other comprehensive
lain - - 228.400.463.612 1.277.674.251 (31.368.016) - - 229.646.769.847 3.491.808.061 233.138.577.908 income
Laba tahun berjalan - - - - - - 12.418.961.321 12.418.961.321 17.254.181.212 29.673.142.533 Profit for the year
Balance as at
Saldo 31 Desember 2025 172.068.323.520 556.636.429.244 918.899.732.919 3.504.855.110 (10.614.529.136) (2.383.756.076) 311.803.137.977 1.949.914.193.558 444.592.822.953 2.394.507.016.511 31 December 2025
Catatan 23/ Catatan 24/ Catatan 22/ Catatan 5/ Catatan 25/ Catatan 26/
Note 23 Note 24 Note 22 Note 5 Note 25 Note 26
Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E terlampir See accompanying Notes to Consolidated Financial Statements on Exhibit E which are integral part of the
yang merupakan bagian yang tidak terpisahkan dari Consolidated Financial Statements taken as a whole
Financial Report
Laporan Keuangan
Laporan Keuangan Konsolidasian secara keseluruhan
193
Page 194
194 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian Language
Ekshibit D Exhibit D
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
LAPORAN ARUS KAS KONSOLIDASIAN CONSOLIDATED STATEMENT OF CASH FLOWS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2025 2024
CASH FLOWS FROM OPERATING
ARUS KAS DARI AKTIVITAS OPERASI ACTIVITIES
Penerimaan kas dari
pelanggan 1.611.125.750.921 1.525.558.998.211 Receipts from customers
Pembayaran kepada pemasok Payment to suppliers and
dan beban usaha (860.617.479.988) (1.021.599.963.964) operating expenses
Pembayaran kepada pegawai (408.387.618.096) (391.694.842.342) Payment to employees
Penerimaan dari penghasilan
keuangan 22.931.465.736 18.640.836.625 Receipt of finance income
Pembayaran beban keuangan (67.970.680.546) (68.053.448.455) Payment of finance costs
Pembayaran pajak penghasilan (13.665.444.970) (17.811.853.548) Payment of income tax
Pembayaran dari operasi lain
- Neto (32.794.133.363) (11.060.239.156) Other operating expenses - Net
Arus kas bersih dari aktivitas operasi 250.621.859.694 33.979.487.371 Net cash flows from operating activities
ARUS KAS UNTUK AKTIVITAS INVESTASI CASH FLOW FOR INVESTING ACTIVITIES
Perolehan aset tetap (218.905.414.893) (163.412.509.355) Acquisition of property and equipment
Perolehan properti investasi - (10.281.661.136) Acquisition of properties investments
Proceeds from sale of property and
Hasil penjualan aset tetap 1.493.319.558 1.015.362.904 equipment
Additions advanced of acquisition of fixed
Uang muka pembelian aset tetap - (72.612.585.817) assets
Peningkatan investasi saham - (163.412.509.355) Placement of investments shares
Arus kas bersih untuk aktivitas investasi (217.412.095.335) (245.291.393.404) Net cash flows for investing activities
CASH FLOW FROM
ARUS KAS DARI AKTIVITAS PENDANAAN FINANCING ACTIVITIES
Pembayaran liabilitas sewa (98.699.072.459) (23.968.116.240) Payment of lease liabilities
Penerimaan pinjaman bank 178.622.359.690 141.670.889.796 Drawdown of bank loans
Pembayaran pinjaman bank (53.878.580.214) (77.952.817.919) Payment of bank loans
Pembayaran dividen kas (16.403.096.651) (63.930.605.455) Cash dividends paid
Peningkatan modal entitas anak dari pihak Issuance shares of subsidiary to
ketiga 401.311.109 396.766.602.500 non-controlling interests
Arus kas bersih dari aktivitas pendanaan 10.042.921.475 372.585.952.682 Net cash flow from financing activities
NET INCREASE IN
KENAIKAN NETO DALAM KAS DAN SETARA KAS 43.252.685.834 161.274.046.649 CASH AND CASH EQUIVALENTS…
KAS DAN SETARA KAS CASH AND CASH EQUIVALENTS
AWAL TAHUN 783.332.056.074 622.058.009.425 AT BEGINNING OF THE YEAR
KAS DAN SETARA KAS CASH AND CASH EQUIVALENTS
AKHIR TAHUN 826.584.741.908 783.332.056.074 AT END OF THE YEAR
Lihat Catatan atas Laporan Keuangan Konsolidasian pada Ekshibit E See accompanying Notes to Consolidated Financial Statements
terlampir yang merupakan bagian yang tidak terpisahkan dari on Exhibit E which are integral part of the
Laporan Keuangan Konsolidasian secara keseluruhan Consolidated Financial Statements taken as a whole
Page 195
Laporan Keuangan
Financial Report 195
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E Exhibit E
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. UMUM 1. GENERAL
a. Pendirian Perusahaan a. Company Establishment
PT Bundamedik Tbk (“Perusahaan”) didirikan pada PT Bundamedik Tbk (the “Company”) was
tanggal 13 April 1978 berdasarkan Akta No. 21 dari established on 13 April 1978 based on Notarial
notaris Adlan Yulizar, S.H.. Akta pendirian Deed No. 21 of Adlan Yulizar, S.H..
tersebut telah mendapatkan pengesahan The establishment deed had been approved by the
dari Menteri Kehakiman Republik Indonesia Minister of Justice of the Republic of Indonesia in
dengan Surat Keputusan No. Y.A.5/160/18 tanggal its Decision Letter No. Y.A.5/160/18 dated
28 September 1978. 28 September 1978.
Anggaran Dasar Perusahaan mengalami perubahan The Articles of Association has been amended
terakhir dengan Akta No. 41 tanggal 7 Agustus 2025 recently by the notarial deed No. 41 dated 7 August
dari Jose Dima Satria, S.H. M.Kn., notaris di Jakarta, 2025 of Jose Dima Satria, S.H., M.Kn., notary in
mengenai perubahan susunan Dewan Komisaris dan Jakarta, regarding the changed of Board of
Dewan Direksi. Perubahan Akta tersebut telah Commissioners and Board of Directors. This
diterima pemberitahuan Menteri Hukum dan Hak amendment had been received notification Legal
Asasi Manusia Republik Indonesia dengan Surat Body Administration System from Minister of Law
Penerimaan Pemberitahuan No. AHU-AH.01.09- and Human Rights of the Republic of Indonesia in its
0323470 tanggal 11 Agustus 2025. Decision Letter No. AHU-AH.01.09-0323470 dated
11 August 2025.
Sesuai dengan Pasal 3 Anggaran Dasar Perusahaan, According to the Article 3 of the Company’s Articles
kegiatan utama Perusahaan adalah dalam of Association, the Company’s main business
bidang pengelolaan rumah sakit. Perusahaan activities are engaged in hospital management. The
memulai kegiatan operasi komersialnya pada Company strated its commercial operations in year
tahun 1978. 1978.
Perusahaan berdomisili di Jalan Teuku Cik Ditiro The Company is domiciled at Jalan Teuku Cik Ditiro
No. 28, Menteng, Jakarta. No. 28, Menteng, Jakarta.
Entitas induk Perusahaan dan entitas induk terakhir The Company’s parent and ultimate parent of the
dalam Grup adalah PT Bunda Investama Indonesia. Group is PT Bunda Investama Indonesia.
b. Karyawan, Komite Audit, Dewan Komisaris dan b. Employee, Audit Committee, Board of
Direksi Commissioners and Directors
Pada tanggal 31 Desember 2025 dan 2024, susunan As of 31 December 2025 and 2024, the latest
terakhir Dewan Komisaris dan Direksi Perusahaan composition of the Board of Commissioners and
adalah sebagai berikut: Directors of the Company are as follows:
2025 2024
Dewan Komisaris Board of Commissioner
Komisaris Utama : Ivan Rizal Sini Ivan Rizal Sini : President Commissioner
Wakil Komisaris Utama : Shubasish Chattoraj Wishnutama Kusubandio : Vice President Commissioner
Komisaris : Ir. Mesha Rizal Sini Ir. Mesha Rizal Sini : Commissioner
Komisaris : - Sunata Tjiterosampurno : Commissioner
Komisaris Independen : Retno Lestari Priansari Retno Lestari Priansari : Independent Commissioner
Marsudi Marsudi
Komisaris Independen : Arianti Anaya Arianti Anaya : Independent Commissioner
Dewan Direksi Board of Director
Direktur Utama : Agus Heru Darjono Agus Heru Darjono : President Director
Direktur : Emilia Rouli Emilia Rouli : Director
Direktur : Cuncun Wijaya Cuncun Wijaya : Director
Page 196
196 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/2 Exhibit E/2
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
b. Karyawan, Komite Audit, Dewan Komisaris dan b. Employee, Audit Committee, Board of
Direksi (Lanjutan) Commissioners and Directors (Continued)
Perusahaan telah membentuk Komite Audit sesuai The Company has formed the Audit
dengan Peraturan OJK No. 55/POJK.04/2015 tanggal Committee to comply with OJK Rule
29 Desember 2015 dan Peraturan Pencatatan Bursa No. 55/POJK.04/2015 dated 29 December 2015
Efek berdasarkan Surat Keputusan Dewan Komisaris and Listing Rule of Stock Exchange based on
Perusahaan Tentang Pengangkatan Komite Audit Decree of the Board of Commissioners
No. 016-I/SK/DIRKOM/IV/2021 tanggal 5 April 2021 No. 016-I/SK/DIRKOM/IV/2021 dated 5 April 2021
adalah sebagai berikut: are as follows:
31 Desember 2025 dan 2024
31 December 2025 and 2024
Komite Audit Audit Committee
Ketua : Arianti Anaya : Chairman
Anggota : Marsaulina Olivia Panjaitan : Member
Anggota : Tiwi Setyawati : Member
Berdasarkan Surat Keputusan Dewan Komisaris Based on Decree of the Board of Commissioner
No. 009-K/KOMUT/I/2022 tanggal 26 Januari 2022, No. 009-KEP/KOMUT/I/2022 dated 26 January 2022,
Perusahaan mengangkat Tubagus Adi Satria Prakarsa the Company has appointed Tiwi Setyawati as the
sebagai Kepala Unit Internal Audit dan Manajeman Audit Committee Member.
Risiko Perusahaan.
Berdasarkan Surat Keputusan Dewan Komisaris Based on Decree of the Board of Commissioner
No. 001-KEP/KOMUT/XI/2021 tanggal 1 Desember No. 001-KEP/KOMUT/XI/2021 dated 1 December
2021, Perusahaan mengangkat Tiwi Setyawati 2021, the Company has appointed Tiwi Setyawati as
sebagai Anggota Komite Audit Perusahaan. the Audit Committee Member.
Berdasarkan Surat Keputusan Direksi Based on Decree of the Board of Director
No. 010-I/SK/DIR/III/2021 tanggal 12 Maret 2021, No. 010-I/SK/DIR/III/2021 dated 12 March 2021, the
Perusahaan mengangkat Josephine PM Tobing Company has appointed Josephine PM Tobing as the
sebagai Sekretaris Perusahaan. Corporate Secretary.
Pada tanggal 31 Desember 2025 dan 2024, As of 31 December 2025 and 2024, the Company and
Perusahaan dan entitas anaknya masing-masing its subsidiaries employed 1,566 and 1,579
memiliki 1.566 dan 1.579 pegawai tetap. permanent employees, respectively.
c. Penawaran Umum Saham Perusahaan c. Public Offering of the Company’s Shares
Pada tanggal 28 Juni 2021, Perusahaan memperoleh On 28 June 2021, the Company obtained statement
Surat Pemberitahuan Efektif dari Otoritas Jasa effective from the Financial Service Authority (OJK)
Keuangan (OJK) dengan Surat No. S-94/D.04/2021 in his Decision Letter No. S-94/D.04/2021 to offer
dalam rangka penawaran umum sebanyak 620,000,000 of its shares to public with par value of
620.000.000 saham dengan nilai nominal Rp 20 per Rp 20 per share through Indonesia Stock Exchange
saham melalui Bursa Efek Indonesia dengan harga (IDX), at an initial offering price of Rp 340 per
penawaran sebesar Rp 340 per saham. Pada tanggal share. On 6 July 2021, those shares were listed in
6 Juli 2021, seluruh saham telah dicatatkan di Bursa the Indonesian Stock Exchange.
Efek Indonesia.
d. Entitas-Entitas Anak yang Dikonsolidasi d. The Company’s Consolidated Subsidiaries
Selanjutnya Perusahaan dan Entitas Anaknya The Company and Its Subsidiaries will be referred as
disebut sebagai “Grup”. the “Group”.
Page 197
Laporan Keuangan
Financial Report 197
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/3 Exhibit E/3
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
Pada tanggal 31 Desember 2025 dan 2024, As of 31 December 2025 and 2024, the Company has
Perusahaan memiliki kepemilikan langsung dan tidak direct and indirect ownership in the following
langsung pada entitas-entitas anak berikut ini: subsidiaries:
Tahun
beroperasi
komersial/
Year of Persentase Jumlah aset sebelum eliminasi/
kepemilikan/
Entitas anak/ Domisili/ commercial Jenis usaha/ Percentage of Total asset before elimination
ownership
Subsidiary Domicile operations Nature of business 2025 2024 2025 2024
Kepemilikan langsung/
Direct ownership
Konsultan Manajemen Layanan
PT Morula Indonesia dan Teknologi Reproduksi Berbantu/
Entitas anaknya/ and Its Management consultant assissted
Subsidiaries Jakarta 2015 Reproductive Technology Services 47,25% 47,25% 900.118.399.281 832.551.461.797
Rumah Sakit Swasta/
PT Bunda Minang Citra Padang 1995 Hospital 40,00% 40,00% 231.210.371.243 201.624.157.076
PT Citra Ananda Jakarta 2005 Rumah Sakit Swasta/
Hospital 40,00% 40,00% 58.490.188.196 58.072.059.195
PT Bunda Medka Wisesa Jakarta 2017 Hotel/ Hotel 90,00% 90,00% 18.241.667.258 20.508.058.606
Distributor obat dan alat
kesehatan/ Medicine and medical
PT Bunda Global Pharma Jakarta 2017 supplies distributor 65,00% 65,00% 61.280.117.861 51.452.045.252
PT Emergency Response Penyedia Jasa
Indonesia Jakarta 2007 Ambulans/Ambulance Services 60,00% 60,00% 5.578.020.212 7.156.067.217
Layanan klinik USG/
PT Visiscan Indonesia Jakarta 2012 USG Clinic Services 90,00% 90,00% 4.509.592.372 4.509.864.668
Klinik fisioterapi/
PT Sasana Mitra Bunda Jakarta 2012 Physiotherapy Clinic 65,00% 65,00% 4.713.711.484 4.650.734.553
Pendidikan Kesehatan Swasta/
PT BMHS Diklat Indonesia Jakarta 2017 Healthcare Training 90,00% 90,00% 2.010.605.086 838.138.453
PT Prima Dental Medika Jakarta 2010 Klinik gigi/ Dental Clinic 86,67% 86,67% 3.082.030.552 2.706.390.122
Rumah Sakit Swasta/
PT Bunda Medika Dewata Bali 2021 Hospital 99,00% 99,00% 63.762.315.316 62.476.731.205
Rumah Sakit Swasta/
PT Pintu Ilmu Palembang 2002 Hospital 99,00% 99,00% 76.862.409.548 82.120.345.499
Belum
beroperasi/ Rumah Sakit Swasta/
PT Bunda Medika Bekasi Bekasi Dormant Hospital 99,00% 99,00% 2.514.700.148 2.514.700.148
Belum
beroperasi/
PT Bunda Graha Properti Jakarta Dormant Properti / Property 99,00% 99,00% 272.099.324.873 263.826.811.287
Rumah Sakit Swasta/
PT Jolin Sapta Medika Bekasi 2007 Hospital 99,00% 99,00% 60.218.945.242 55.932.497.162
PT Diagnos Laboratorium Laboratorium kesehatan/
Utama Tbk Jakarta 2008 Health laboratories 41,20% 41,20% 318.672.105.755 300.022.257.340
PT Bunda Medika Klinik Jakarta 2023 Klinik / Clinic 99,00% 99,00% 13.548.792.969 12.325.099.265
PT Medika Sejahtera Rumah Sakit Swasta/
Bersama*) Surabaya 2005 Hospital 99,00% 0,00% 90.589.811.495 -
Page 198
198 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/4 Exhibit E/4
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
Tahun
beroperasi
komersial/
Year of Persentase Jumlah aset sebelum eliminasi/
kepemilikan/
Entitas anak/ Domisili/ commercial Jenis usaha/ Percentage of Total asset before elimination
ownership
Subsidiary Domicile operations Nature of business 2025 2024 2025 2024
Kepemilikan tidak langsung/ Indirect
ownership
Konsultan Manajemen Layanan
Teknologi Reproduksi Berbantu/
Management consultant assissted
PT Morula IVF Surabaya Surabaya 2012 Reproductive Technology Services 46,31% 46,31% 86.105.190.428 63.573.534.239
Konsultan Manajemen Layanan
Teknologi Reproduksi Berbantu/
Management consultant assissted
PT Morula IVF Makassar Makassar 2016 Reproductive Technology Services 37,80% 37,80% 28.127.500.628 26.491.415.675
Konsultan Manajemen Layanan
Teknologi Reproduksi Berbantu/
Management consultant assissted
PT Morula IVF Margonda Depok 2016 Reproductive Technology Services 28,35% 28,35% 32.176.983.717 24.792.559.669
Konsultan Manajemen Layanan
Teknologi Reproduksi Berbantu/
Management consultant assissted
PT Morula IVF Bandung Bandung 2016 Reproductive Technology Services 24,10% 24,10% 10.124.858.840 7.898.517.477
Konsultan Manajemen Layanan
Teknologi Reproduksi Berbantu/
Management consultant assissted
PT Morula IVF Pontianak Pontianak 2017 Reproductive Technology Services 28,35% 28,35% 11.753.618.823 9.259.173.159
Konsultan Manajemen Layanan
Teknologi Reproduksi Berbantu/
Management consultant assissted
PT Morula IVF Yogyakarta Yogyakarta 2018 Reproductive Technology Services 33,08% 33,08% 31.810.135.061 24.497.152.715
Konsultan Manajemen Layanan
Teknologi Reproduksi Berbantu/
Management consultant assissted
PT Morula IVF Padang Padang 2021 Reproductive Technology Services 46,78% 46,78% 15.456.979.394 9.829.856.818
Perdangangan besar obat farmasi,
obat tradisional, kosmetik untuk
manusia dan alat laboratorium/
General trading medicine for
pharmaceutical, traditional,
cosmetics for human and
laboratory equipment, pharmacy,
PT Emphi Pharma Sejahtera Jakarta 2021 and medical. 46,31% 46,31% 49.571.012.347 11.313.860.865
Konsultan Manajemen Layanan
Belum Teknologi Reproduksi Berbantu/
beroperasi/ Management consultant assissted
PT Morula IVF Pekanbaru Pekanbaru Dormant Reproductive Technology Services 18,90% 18,90% 4.000.000.000 4.000.000.000
PT Medika Sejahtera Bersama
*) Surabaya 2005 Rumah sakit swasta / Hospital - 47,25% - 87.921.871.491
Belum
beroperasi/
PT Morula Bunda Dewata Bali Dormant Rumah sakit swasta/ Hospital 47,53% 47,53% 102.447.761.368 120.990.974.554
*) Kepemilikan langsung Perusahaan kepada MSB efektif setelah pembelian 8.778 lembar *) The Company’s direct ownership in MSB became effective after purchasing MSB’s shares
saham MSB melalui Morula pada tahun 2025, di mana kepemilikan tidak langsung totalling 8,778 shares through Morula in 2025, in which the Company’s indirect ownership
Perusahaan kepada MSB melalui Morula sebesar 47,25% pada tahun 2024 menjadi in MSB through MI of 47.25% in 2024 became
kepemilikan langsung Perusahaan kepada MSB sebesar 99,99% pada tahun 2025.
Page 199
Laporan Keuangan
Financial Report 199
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/5 Exhibit E/5
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
Kegiatan utama Entitas Anak adalah dalam bidang The Subsidiaries' main business activities in
pelayanan kesehatan yaitu dengan memberikan jasa healthcare services is to provide medical services
pelayanan kesehatan dengan cara memiliki dan through owning and operating hospitals which
mengelola rumah sakit di Jakarta, Bekasi, Depok, are located in Jakarta, Bekasi, Depok, Tangerang,
Tangerang, Padang, Bali, Surabaya, Makassar, Padang, Bali, Surabaya, Makassar, Bandung,
Bandung, Pontianak, Yogyakarta, Pekanbaru dan Pontianak, Yogyakarta, Pekanbaru and Palembang.
Palembang. Seluruh Entitas Anak tersebut memiliki All of these Subsidiaries have hospital operating
izin penyelenggaraan rumah sakit yang diperoleh licenses obtained from the relevant authorities
dari instansi berwenang terkait dan masih berlaku and are still valid on 31 December 2024\5. One of a
pada tanggal 31 Desember 2025. Salah satu entitas subsidiary its scope of activities is engaged in
anak melakukan kegiatan usaha dalam bidang operations of a hotel located in Jakarta.
perhotelan yang terletak di Jakarta.
PT Bunda Minang Citra (40,00%), PT Citra Ananda PT Bunda Minang Citra (40.00%), PT Citra Ananda
(40,00%) PT Diagnos Laboratorium Utama Tbk (40.00%) PT Diagnos Laboratorium Utama Tbk
(41,20%) dan PT Morula Indonesia (47,25%) (41.20%) and PT Morula Indonesia (47,25%), is
dikonsolidasi ke dalam laporan keuangan consolidated into financial statements eventhough
Perusahaan, meskipun kepemilikan saham di bawah the Company’s ownership is under 50%, its because
50% atas kepemilikan Perusahaan, hal tersebut the Company has full controller of above entities.
dikarenakan Perusahaan sebagai pihak pengendali
penuh atas entitas tersebut.
PT BMHS Diklat Indonesia (“BDI”) PT BMHS Diklat Indonesia (“BDI”)
Anggaran Dasar BDI telah mengalami beberapa kali BDI’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 8 tanggal several times, most recently by Deed No. 8 dated
31 Oktober 2024 dari Isadora, S.H., MKn. Notaris di 31 October 2024 of Isadora, S.H., MKn. Notary in
Jakarta terkait dengan perubahan Pasal 3 Anggaran Jakarta to the Decision Statement of the
Dasar Perseroan mengenai Maksud dan Tujuan Extraordinary General Meeting of Shareholders.
Perseroan. Perubahan akta tersebut telah diterima Amendements to the Deed have been received and
dan dicatat di dalam database Sistem Administrasi recorded in the database of the Legal Entity
Badan Hukum, Kementerian dan Hak Asasi Manusia Administration System, Ministry of Law and Human
Republik Indonesia melalui Surat Keputusan Rights of the Republic of Indonesia through Decision
No. AHU-0070967.AH.01.022 tanggal letter No AHU-0070967.AH.01.022 dated
5 November 2024. 5 November 2024.
PT Bunda Medika Wisesa (“BMW”) PT Bunda Medika Wisesa (“BMW”)
Anggaran Dasar BMW telah mengalami beberapa kali BMW’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 23 tanggal several times, most recently by Deed No. 23 dated
26 April 2024, dari Isadora, S.H., MKn. Notaris di 26 April 2024 of Isadora, S.H., MKn. Notary in
Jakarta terkait dengan perubahan susunan dewan Jakarta related to the changes in the composition of
direksi dan komisaris. Perubahan Akta tersebut the board of directors and board of commissioners.
telah diterima dan dicatat di dalam database Sistem Amendments to the Deed have been received and
Administrasi Badan Hukum, Kementerian Hukum recorded in the database of the Legal Entity
dan Hak Asasi Manusia Republik Indonesia melalui Administration System, Ministry of Law and Human
Surat Keputusan No. AHU-AH.01.09-0181727 tanggal Rights of the Republic of Indonesia through Decision
6 Mei 2024. letter No. AHU-AH.01.09-0181727 dated
6 May 2024.
Page 200
200 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/6 Exhibit E/6
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
PT Visiscan Indonesia (“VSI”) PT Visiscan Indonesia (“VSI”)
Anggaran Dasar VSI telah mengalami beberapa kali VSI’s Articles of Association has been amended
perubahan, terakhir dengan Akta Notaris Isadora, several times, most recently with the Notarial Deed
S.H., M.Kn., No. 11 tanggal 30 April 2025, terkait of Isadora S.H., M.Kn., No. 11 dated 30 April 2025,
dengan Pernyataan Keputusan Rapat Umum related to the Decision Statement of the
Pemegang Saham Luar BIasa. Perubahan Akta Extraordinary General Meeting of Shareholders.
tersebut telat diterima dan dicatat di dalam Amendments in the database of the Legal Entity
database Sistem Administrasi Badan Hukum, Administration System, Ministry of Law and Human
Kementrian Hukum dan Hak Asasi Manusia Republik Rights of the Republic of Indonesia through Decision
Indonesia melalui Surat Keputusan letter No. AHU-01.09-0222973 dated 06 May 2025.
No. AHU-01.09-0222973 tanggal
06 Mei 2025.
PT Prima Dental Medika (“PDM”) PT Prima Dental Medika (“PDM”)
Anggaran Dasar PDM telah mengalami beberapa kali PDM’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 17 tanggal several times, most recently by Deed No. 17 dated
26 April 2024 dari Isadora, S.H., M.Kn., Notaris di 26 April 2024 of Isadora, S.H., M.Kn., Notary in
Jakarta terkait dengan perubahan susunan dewan Jakarta related to the changes in the composition of
direksi dan komisaris. Perubahan Akta tersebut the Board of Directors and Board of Commissioners.
telah diterima dan dicatat di dalam database Sistem The amandement has been received and recorded in
Administrasi Badan Hukum, Kementerian Hukum the database of Legal Administration System
dan Hak Asasi Manusia Republik Indonesia melalui Minister of Law and Human Right of the Republic of
Surat Keputusan No. AHU-AH.01.09-0181400 tanggal Indonesia through Decision Letter
06 Mei 2024. No. AHU-AH.01.09-0181400 dated 06 May 2024.
PT Citra Ananda (“CA”) PT Citra Ananda (“CA”)
Anggaran Dasar CA telah beberapa kali mengalami CA’s Articles of Association has been amended
perubahan, yang terakhir adalah akta No. 25 tanggal several times, most recently based on Notarial
26 April 2024 dari Notaris Isadora, S.H., M.Kn., No. 25 dated 26 April 2024 of Isadora, S.H., M.Kn.,
Notaris di Jakarta terkait dengan perubahan Notary in Jakarta related to the changes in the
susunan dewan direksi dan komisaris. Perubahan composition of the Board of Directors and Board of
akta tersebut telah diterima dan dicatat di dalam Commissioners. The amendment has been received
database Sistem Administrasi Badan Republik and recorded in the database of Legal
Indonesia melalui Surat Keputusan Administration Systems Minister of Law and Human
No. AHU-AH.01.09-0181880 tanggal 06 Mei 2024. Rights of the Republic of Indonesia through Decision
Letter No. AHU-AH.01.09-0181880 dated
06 May 2024.
PT Sasana Mitra Bunda (“SMB”) PT Sasana Mitra Bunda (“SMB”)
Anggaran Dasar SMB telah mengalami beberapa kali SMB’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 02 tanggal 03 several times, most recently by Deed No. 02 dated
Mei 2024 dari Isadora, S.H. M.Kn., Notaris di Jakarta 03 May 2024 of Isadora, S.H. M.Kn., Notary in
terkait dengan Pernyataan Keputusan Rapat Umum Jakarta related to the DecisionStatement of the
Pemegang Saham Luar Biasa. Perubahan Akta Extraordinary General Meeting of Shareholders. The
tersebut telah diterima dan dicatat di dalam amendment has been received and recorded in the
database Sistem Administrasi Badan Hukum, database of Legal Administration Systems Minister
Kementerian Hukum dan Hak Asasi Manusia Republik of Law and Human Rights of the Republic of
Indonesia melalui Surat Keputusan No. AHU- Indonesia through Decision Letter No. AHU-
AH.01.03-0109052 tanggal 13 Mei 2024. AH.01.03-0109052 dated 13 May 2024.
Page 201
Laporan Keuangan
Financial Report 201
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/7 Exhibit E/7
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
PT Emergency Response Indonesia (“ERI”) PT Emergency Response Indonesia (“ERI”)
Anggaran Dasar ERI telah mengalami beberapa kali ERI’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 10 tanggal 13 several times, most recently by Deed No. 10 dated
Desember 2024 dari Isadora, S.H., M.Kn., Notaris di 13 December 2024 of Isadora, SH., M.Kn.,Notary in
Jakarta terkait dengan perubahan Pasal 3 Anggaran Jakarta related to the changes in the Article No 3
Dasar Perseroan mengenai Maksud dan Tujuan related to the Scope & Activities of the Company.
Perseroan. Perubahan Akta tersebut telah diterima The amendment has been received and recorded in
dan dicatat di dalam database Sistem Administrasi the database of Legal Administration Systems
Badan Hukum, Kementerian Hukum dan Hak Asasi Minister of Law and Human Rights of the Republic of
Manusia Republik Indonesia melalui Surat Keputusan Indonesia through Decision Letter No. AHU-
No. AHU-0082584.AH.01.02 tanggal 18 Desember 0082584.AH.01.02 dated 18 December 2024.
2024.
PT Bunda Global Pharma (“BGP”) PT Bunda Global Pharma (“BGP”)
Anggaran Dasar BGP telah mengalami beberapa kali BGP’s Articles of Association has been amended
perubahan, terakhir dengan Akta Notaris Isadora, several times, most recently by the Notarial Deed
S.H., M.Kn., No. 29 tanggal 26 April 2024, terkait No. 29 dated 26 April 2024 of Isadora, S.H., M.Kn.,
dengan perubahan susunan dewan direksi dan related to the changes in the composition of the
komisaris. Perubahan Akta tersebut telah diterima Board of Directors and Board of Commissioners. The
dan dicatat di dalam database Sistem Administrasi amendment has been received and recorded in the
Badan Hukum, Kementerian Hukum dan Hak Asasi database of Legal Administration Systems Minister
Manusia Republik Indonesia melalui Surat Keputusan of Law and Human Rights of the Republic of
No. AHU-AH.01.09-0182025 tanggal 06 Mei 2024 Indonesia through Decision Letter No. AHU-
AH.01.09-0182025 dated 06 May 2024.
PT Bunda Medika Dewata (“BMD”) PT Bunda Medika Dewata (“BMD”)
Anggaran Dasar BMD telah mengalami beberapa kali BMD’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 19 tanggal 26 several times, most recently by Deed No. 19 dated
April 2024 dari Isadora, S.H., M.Kn., Notaris di 26 April 2024 of Isadora, S.H., M.Kn., Notary in
Jakarta, terkait dengan perubahan susunan dewan Jakarta, related to the changes in the composition
direksi dan komisaris. Akta perubahan tersebut of the Board of Directors and Board of
telah diterima dan dicatat dalam Sistem Commissioners. The Deed of amendment has been
Administrasi Badan Hukum Kementerian Hukum dan accepted and registered in the Legal Administration
Hak Asasi Manusia Republik Indonesia dengan Surat System of Ministry of Law and Human Rights of the
Keputusan No. AHU-AH.01.09-0181498 tanggal 06 Republic of Indonesia in Decision Letter No. AHU-
Mei 2024. AH.01.09-0181498 dated 06 May 2024.
PT Pintu Ilmu (“PI”) PT Pintu Ilmu (“PI”)
Anggaran Dasar PI telah mengalami beberapa kali PI’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 04 tanggal several times, most recently by Deed No.04 dated
30 Desember 2025 tentang Pernyataan Keputusan 30 December 2025 regarding the Statement Of
Pemegang Saham di Luar Rapat Umum Pemegang Shareholders’ Decisions outside the General Meeting
Saham. Perubahan akta tersebut telah diterima dan of Shareholders. The deed of amendment has been
dicatat di dalam database Sistem Administrasi received and recorded in the database of the Legal
Badan Hukum, Kementerian Hukum dan Hak Asasi Entity Administration System, Ministry of Law and
Manusia Republik Indonesia melalui Surat Human Rights of the Republic of Indonesia through
Keputusan No. AHU-AH.01.03-0018299 tanggal Decree No. AHU-AH.01.03-0018299 dated
22 Januari 2026. 22 January 2026.
Page 202
202 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/8 Exhibit E/8
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
PT Bunda Medika Bekasi (“BMB”) PT Bunda Medika Bekasi (“BMB”)
Anggaran Dasar BMB telah mengalami beberapa kali BMB’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 27 tanggal 26 several times, most recently by Deed No. 27 dated
April 2024 terkait dengan perubahan susunan dewan 26 April 2024 regarding the changes in the
direksi dan komisaris. Perubahan akta tersebut composition of the board of directors and board of
telah diterima dan dicatat di dalam database Sistem commissioners. The deed of amendment has been
Administrasi Badan Hukum, Kementerian Hukum received and recorded in the database of the Legal
dan Hak Asasi Manusia Republik Indonesia melalui Entity Administration System, Ministry of Law and
Surat Keputusan No. AHU-AH.01.09-0181987 tanggal Human Rights of the Republic of Indonesia through
6 Mei 2024. Decree No. AHU-AH.01.09-0181987 dated 6 May
2024.
PT Bunda Minang Citra (“BMC”) PT Bunda Minang Citra (“BMC”)
Anggaran Dasar BMC telah mengalami beberapa kali BMC’s Articles of Association have been
perubahan, terakhir dengan Akta No. 05 tanggal 26 amended several times, most recently by Deed No.
April 2024 dari Isadora, S.H. M.Kn., Notaris di 05 dated 26 April 2024 of Isadora, SH. M.Kn., Notary
Jakarta terkait dengan perubahan direksi dan in Jakarta related to the changes of Board of
komisaris. Perubahan Akta tersebut telah diterima Directors and Board of Commissionairs. The
dan dicatat di dalam database Sistem Administrasi amendment has been received and recorded in the
Badan Hukum, Kementerian Hukum dan Hak Asasi database of Legal Administration Systems Minister
Manusia Republik Indonesia melalui Surat Keputusan of Law and Human Rights of the Republic of
No. AHU-AH.01.09-0180311 tanggal 05 Mei 2024. Indonesia through Decision Letter No. AHU-
AH.01.09-0180311 dated 05 May 2024.
PT Bunda Graha Properti (“BGPP”) PT Bunda Graha Properti (“BGPP”)
Anggaran Dasar BGPP telah beberapa kali BGPP’ s Articles of Association has been amended
mengalami perubahan, yang terakhir adalah akta several times, most recently based on Notarial No.
No. 21 tanggal 26 April 2024 dari Notaris Isadora, 21 dated 26 April 2024 of Isadora, SH., M.Kn. Notary
SH., M.Kn. Notaris di Jakarta terkait dengan in Jakarta related to the changes of Board of
perubahan direksi dan komisaris. Akta perubahan Directors and Board of Commissionairs. The Deed of
tersebut telah diterima dan dicatat dalam Sistem amendment has been accepted and registered in the
Administrasi Badan Hukum Kementrian Hukum dan Legal Administration System of Ministry of Law and
Hak Asasi Manusia Republik Indonesia dengan Surat Human Rights of the Republic of Indonesia in
Keputusan No. AHU-AH.01.09-0181649 tanggal 06 Decision Letter No. AHU-AH.01.09-0181649 dated 06
Mei 2024. May 2024.
PT Jolin Sapta Medika (“JSM”) PT Jolin Sapta Medika (“JSM”)
Anggaran Dasar JSM telah beberapa kali mengalami JSM’s Articles of Association has been amended
perubahan, yang terakhir adalah akta No. 11 tanggal several times, most recently based on Notarial No.
26 April 2024 dari Notaris Isadora, SH., M.Kn. 11 dated 26 April 2024 of Isadora, SH., M.Kn. Notary
Notaris di Jakarta terkait dengan perubahan in Jakarta related to the changes of Board of
susunan dewan direksi dan komisaris. Akta Directors and Board of Commissionairs. The Deed of
perubahan tersebut telah diterima dan dicatat amendment has been accepted and registered in the
dalam Sistem Administrasi Badan Hukum Legal Administration System of Ministry of Law and
Kementrian Hukum dan Hak Asasi Manusia Republik Human Rights of the Republic of Indonesia in
Indonesia dengan Surat Keputusan No. AHU- Decision Letter No. AHU-AH.01.09-0203977 dated 20
AH.01.09-0203977 tanggal 20 Mei 2024. May 2024.
Page 203
Laporan Keuangan
Financial Report 203
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/9 Exhibit E/9
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
PT Bunda Medika Klinik (“BMK”) PT Bunda Medika Klinik (“BMK”)
Anggaran Dasar BMK telah mengalami perubahan BMK’s Articles of Association has been amended
pada akta No. 15 tanggal 26 April 2024 dari Notaris based on Notarial No. 15 dated 26 April 2024 of
Isadora, SH., M.Kn. Notaris di Jakarta terkait dengan Isadora, SH., M.Kn. Notary in Jakarta related to the
perubahan susunan dewan direksi dan komisaris. changes of Board of Directors and Board of
Akta perubahan tersebut telah diterima dan dicatat Commissionairs. The Deed of amendment has been
dalam Sistem Administrasi Badan Hukum Kementrian accepted and registered in the Legal Administration
Hukum dan Hak Asasi Manusia Republik Indonesia System of Ministry of Law and Human Rights of the
dengan Surat Keputusan No. AHU-AH.01.09-0180403 Republic of Indonesia in Decision Letter No. AHU-
tanggal 06 Mei 2024 AH.01.09-0180403 dated 06 May 2024.
PT Medika Sejahtera Bersama (“MSB”) PT Medika Sejahtera Bersama (“MSB”)
Anggaran Dasar MSB telah mengalami beberapa kali MSB articles of Association has been amended based
perubahan, terakhir dengan Akta No. 04 tanggal on Notarial No. 04 dated 30 December 2025 of
30 Desember 2025 tentang Pernyataan Keputusan Isadora, SH., M.Kn. Notary in Jakarta to the
Pemegang Saham di Luar Rapat Umum Pemegang Decision Statement of the Extraordinary General
Saham. Perubahan akta tersebut telah diterima dan Meeting of Shareholders. The Deed of amendment
dicatat di dalam database Sistem Administrasi Badan has been accepted and registered in the Legal
Hukum, Kementerian Hukum dan Hak Asasi Manusia Administration System of Ministry of Law and
Republik Indonesia melalui Surat Human Rights of the Republic of Indonesia in
Keputusan No. AHU-AH.01.03-0019244 tanggal Decision Letter No. AHU-AH.01.03-0019244 dated
23 Januari 2026. 23 January 2026.
PT Morula Indonesia (“Morula”) PT Morula Indonesia (“Morula”)
Anggaran Dasar Morula telah mengalami beberapa Morula’s Articles of Association has been amended
kali perubahan, terakhir dengan Akta No. 02 tanggal several times, most recently by Notarial Deed No. 02
15 Januari 2025, Isadora, S.H., M.Kn. Notaris di dated 15 January 2025 of Isadora, S.H., M.Kn. Notary
Jakarta terkait denganperubahan susunan dewan in Jakarta related to changes in the composition of
komisaris dan direksi. Perubahan Akta tersebut the boards of commissioners & directors. This
telah mendapatkan pengesahan dari Menteri Hukum amendment had been approved by the Minister of
dan Hak Asasi Manusia Republik Indonesia dengan Law and Human Rights of the Republic of Indonesia
Surat Keputusan No. AHU-AH.01.09-0025719 tanggal in its Decision Letter No. AHU-AH.01.09-0025719
22 Januari 2025. dated 22 January 2025.
Berdasarkan Akta No. 04 tanggal 8 November 2024 Based on the Deed No. 04 dated 8 November 2024 of
yang dibuat dihadapan Isadora, S.H., M.Kn., Notaris Isadora, S.H., M.Kn., a notary in Jakarta, the
di Jakarta, Para Pemegang Saham telah menyetujui Shareholders have approved a circular resolution
keputusan sirkuler yang berlaku efektif mulai effective as of 4 November 2024, as follows:
tanggal 4 November 2024 sebagai berikut:
i. Menyetujui, mengesahkan, dan mengadopsi i. Approved, ratifed, and adopted the Share
Program Pemberian Hak Opsi Kepemilikan Ownership Option Grant Program in the
Saham di Morula khusus kepada PT Invitro Company specifically for PT Invitro Investa
Investa Mitra, yang akan dituangkan dalam Mitra, which will be formalized in the form of
bentuk Piagam Program sebagai dasar a Program Charter as the basis for
pelaksanaan program ini yang akan dibuat implementing this program, to be prepared
secara terpisah. separately.
ii. Menyetujui mengeluarkan saham baru Morula ii. Approved the issuance of new shares of the
yang akan dikeluarkan secara bertahap sampai Company, which will be issued gradually up to
dengan maksimal 10.175 lembar saham atau a maximum of 10,175 shares or up to 5% of
sampai dengan 5% dari keseluruhan sama milik Morula’s total shares, in the implementation of
Morula dalam pelaksanaan Program Pemberisan the Share Ownership Option Grant Program for
Hak Opsi Kepemilikan Saham kepada PT Invitro PT Invitro Investa Mitra, in accordance with the
Investa Mitra, sesuai dengan persyaratan yang terms to be stipulated in the Program Charter
akan ditetapkan dalam Piagam Program dan and subject to the approval of all shareholders
mendapatkan persetujuan seluruh pemegang for each new issuance.
saham untuk setiap pengeluaran barunya.
Page 204
204 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/10 Exhibit E/10
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
PT Morula Indonesia (“Morula”) (Lanjutan) PT Morula Indonesia (“Morula”) (Continued)
Berdasarkan Rapat Umum Pemegang Saham Luar Based on the second Extraordinary Shareholder’s
Biasa ke-2 sebagaimana yang tercantum dalam akta General Meeting as stated in notarial deed of Jose
Notaris Jose Dima Satria, S.H., M.Kn., nomor 106 Dima Satria, S.H., M.Kn., No.106 dated 19 July 2024,
tanggal 19 Juli 2024, pemegang saham menyetujui the Shareholders approved an increase in Morula’s
peningkatan modal ditempatkan dan disetor Morula issued and paid-up capital of
sebesar Rp 48.333.000.000 atas kepemilikan saham Rp 48,333,000,000 for the ownership of Jinxin Life
Jinxin Life Asia Healthcare Investment Group Pte. Asia Healthcare Investment Group Pte. Ltd., making
Ltd., menjadikan peningkatan modal ditempatkan the increase in Morula’s issued and paid-up capital
dan disetor Morula yang semula sebesar from the original Rp 145,000,000,000 to
Rp 145.000.000.000 menjadi Rp 193.333.000.000. Rp 193,333,000,000.
Akta Notaris No. 106 ini juga memuat perpindahan This Notary Deed No. 106 also contains the transfer
kepemilikan saham PT Bunda IPITI Investama of ownership of PT Bunda IPITI Investama shares of
sebesar Rp 9.667.000.000 kepada Jinxin Life Asia Rp 9,667,000,000 to Jinxin Life Asia Healthcare
Healthcare Investment Group Pte. Ltd., sebesar Investment Group Pte. Ltd., is Rp 58,000,000,000
Rp 58.000.000.000 dan kepemilikan saham PT Bunda and the share ownership of PT Bunda IPITI Investama
IPITI Investama sebesar Rp 43.983.000.000. shares of Rp 43,983,000,000.
PT Empi Pharma Sejahtera (“EPS”) PT Empi Pharma Sejahtera (“EPS”)
Anggaran dasar EPS telah mengalami perubahan, EPS' articles of association have been amended
terkahir dengan Akta No. 02 tanggal 17 April 2025 several times, most recently by Notarial Deed No. 02
dari, Isadora, S.H., M.Kn. notaris di Jakarta dated April 17, 2025, from Isadora, S.H., M.Kn.,
mengenai perubahan peningkatan modal. Akta notary in Jakarta, regarding changes to the increase
perubahan tersebut telah diterima dan dicatat in capital. The amendment deed has been received
dalam database Sistem Administrasi Badan Hukum and recorded in the database of the Legal Entity
Kementerian Hukum dan Hak Asasi Manusia Republik Administration System of the Ministry of Law and
Indonesia dalam Surat Keputusan Human Rights of the Republic of Indonesia in
No. AHU- 0026224.AH.01.02. Tahun 2025 pada Decision Letter No. AHU-0026224.AH.01.02. Year
tanggal 24 April 2025. 2025 dated 24 April 2025.
PT Morula IVF Surabaya (“MIS”) PT Morula IVF Surabaya (“MIS”)
Anggaran Dasar MIS telah mengalami beberapa kali MIS’ Articles of Association have been amended
perubahan, terakhir dengan Akta No. 08 tanggal several times, most recently by Deed No. 08 dated
26 Maret 2025, dari Isadora, S.H., Mkn, notaris di 26 March 2025, from Isadora, S.H., Mkn, notary in
Jakarta, mengenai perubahan peningkatan modal. Jakarta, regarding changes to the increase in
Akta perubahan tersebut telah diterima dan dicatat capital. The deed of amendment has been received
dalam database Sistem Administrasi Badan Hukum and recorded in the database of the Legal Entity
Kementerian Hukum dan Hak Asasi Manusia Republik Administration System Legal Entity Administration
Indonesia No. AHU-002877.AH.01.02. Tahun 2025 System of the Ministry of Law and Human Rights of
tanggal 9 April 2025. the Republic of Indonesia No. AHU-
002877.AH.01.02. of 2025 dated 9 April 2025.
Page 205
Laporan Keuangan
Financial Report 205
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/11 Exhibit E/11
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
PT Morula IVF Margonda (“MIMG”) PT Morula IVF Margonda (“MIMG”)
Anggaran Dasar MIMG telah mengalami beberapa MIMG’s Articles of Association have been amended
kali perubahan, terakhir dengan Akta No. 01 tanggal several times, most recently by Deed No. 01 dated
10 April 2025, Isadora, S.H., M.Kn., sehubungan April 10, 2025, Isadora, S.H., M.Kn., regarding
dengan perubahan peningkatan modal. Akta changes to the increase in Capital. The amendment
perubahan tersebut telah diterima dan dicatat deed has been received and recorded in the
dalam database Sistem Administrasi Badan Hukum database of the Legal Entity Administration System
Kementerian Hukum dan Hak Asasi Manusia Republik of the Ministry of Law and Human Rights of the
Indonesia No. AHU-AH.01.03-0102797 tanggal Republic of Indonesia No. AHU-AH.01.03-0102797
16 April 2025. dated 16 April 2025.
PT Morula IVF Bandung (“MIB”) PT Morula IVF Bandung (“MIB”)
Anggaran Dasar MIB telah mengalami beberapa kali MIB’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 07 tanggal several times, most recently by Deed No. 07 dated
10 Desember 2024, Isadora, S.H., M.Kn., December 10, 2024, Isadora, S.H., M.Kn., regarding
sehubungan dengan perubahan maksud dan tujuan changes to the board of commissioners and
perusahaan. Akta perubahan tersebut telah directors. The deed of amendment has been
diterima dan dicatat dalam database Sistem received and recorded in the database of the Legal
Administrasi Badan Hukum Kementerian Hukum dan Entity Administration System of the Ministry of Law
Hak Asasi Manusia Republik Indonesia and Human Rights of the Republic of Indonesia
No. AHU-AH.01.09-0289709 tanggal 17 Desember No. AHU-AH.01.09-0289709 dated 17 December
2024. 2024.
PT Morula IVF Pontianak (“MIPT”) PT Morula IVF Pontianak (“MIPT”)
Anggaran Dasar MIPT telah mengalami beberapa kali MIPT’s Articles of Association have been amended
perubahan, terakhir dengan Akta No. 03 tanggal several times, most recently by Deed
14 April 2023, dari Isadora, S.H., M.Kn., sehubungan No. 03 dated 14 April 2023 of Isadora, S.H., M.Kn.,
dengan perubahan dewan komisaris dan direksi. related to the changes of Board Commissionairs and
Akta perubahan tersebut telah diterima dan dicatat Directors. The amendment deed has been received
dalam database Sistem Administrasi Badan Hukum and registered in the database of Legal Entity
Kementerian Hukum dan Hak Asasi Manusia Republik Administration System of the Ministry of Law and
Indonesia No. AHU-AH.01.09-0112705 tanggal Human Rights of the Republic of Indonesia
26 April 2023. No. AHU.AH.01.09-0112705 dated 26 April 2023.
PT Morula IVF Yogyakarta (“MIY”) PT Morula IVF Yogyakarta (“MIY”)
Anggaran Dasar MIY telah mengalami beberapa kali MIY’s Articles of Association have been amended
perubahan, terakhir dengan Akta Notaris No. 01 several times, most recently by Notarial Deed No. 01
tanggal 25 Juni 2025, Isadora, S.H., M.Kn., dated 25 June 2025, Isadora, S.H., M.Kn., in
sehubungan dengan perubahan peningkatan modal. connection with the increase in capital. The Articles
Akta pendirian telah mendapat pengesahan dari of Association have been approved by the Minister
Menteri Hukum dan Hak Asasi Manusia Republik of Law and Human Rights of the Republic of
Indonesia dalam Surat Keputusan No. AHUAH. Indonesia in Decision No. AHU-AH.01.03-0174064
01.03-0174064 tanggal 3 Juli 2025. dated 3 July 2025.
PT Morula IVF Padang (“MIPD”) PT Morula IVF Padang (“MIPD”)
Anggaran Dasar MIPD telah mengalami beberapa kali MIPD’s Articles of Association have been amended
perubahan, terakhir dengan Akta Notaris No. 05 several times, most recently by Notarial Deed No.05
tanggal 20 Maret 2025, Isadora, S.H., M.Kn., dated 20 March 2025, Isadora, S.H., M.Kn., in
sehubungan dengan perubahan peningkatan modal. connection with changes to the increase in capital.
Akta pendirian telah mendapat pengesahan dari The deed of establishment has been approved by the
Menteri Hukum dan Hak Asasi Manusia Republik Minister of Law and Human Rights of the Republic
Indonesia dalam Surat Keputusan No. AHU- of Indonesia in Decision Letter No. AHU-AH.01.03-
AH.01.03-0092874 tanggal 26 Maret 2025. 0092874 dated 26 March 2025.
Page 206
206 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/12 Exhibit E/12
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
1. U M U M (Lanjutan) 1. GENERAL (Continued)
d. Entitas-Entitas Anak yang Dikonsolidasi (Lanjutan) d. The Company’s Consolidated Subsidiaries
(Continued)
PT Morula IVF Pekanbaru (“MIPB”) PT Morula IVF Pekanbaru (“MIPB”)
Anggaran Dasar MIPB telah mengalami beberapa kali MIPB’s Articles of Association have been amended
perubahan, terakhir dengan Akta Notaris No. 27 several times, most recently by Notarial Deed No. 27
tanggal 23 Juni 2022, Isadora, S.H., M.Kn., dated 23 June 2022 of Isadora, S.H., M.Kn, regarding
sehubungan dengan pernyataan keputusan the statements of shareholders. The deed of
pemegang saham. Akta pendirian telah mendapat establishment was approved by the Ministry of Laws
pengesahan dari Menteri Hukum dan Hak Asasi and Human Rights of the Republic of Indonesia in
Manusia Republik Indonesia dalam Surat Keputusan Decision Letter No. AHU-AH.01.09-0034595
No. AHU-AH.01.09-0034595 tanggal 19 Juli 2022. dated 19 July 2022.
PT Morula IVF Makassar (“MIMK”) PT Morula IVF Makassar (“MIMK”)
Anggaran Dasar MIMK telah mengalami beberapa MIMK Articles of Association have been amended
kali perubahan, terakhir dengan Akta No. 33 tanggal several times, most recently by Deed No. 33 dated
16 Juli 2025, Panji Iswandi, S.H., M.Kn., sehubungan 16 July 2025 of Panji Iswandi, S.H., M.Kn., related
dengan perubahan dewan komisaris dan direksi. to the changes of board of commissionairs and
Akta perubahan tersebut telah diterima dan dicatat directors. The amendment deed has been received
dalam database Sistem Administrasi Badan Hukum and registered in the database of Legal Entity
Kementerian Hukum dan Hak Asasi Manusia Republik Administration System of the Ministry of Law and
Indonesia No. AHU-AH.01.09-0312830 tanggal Human Rights of the Republic of Indonesia No. AHU-
17 Juli 2025. AH. 01.09-0312830 tanggal 17 Juli 2025.
PT Morula Bunda Dewata (“MBD”) PT Morula Bunda Dewata (“MBD”)
Anggaran Dasar MBD telah mengalami beberapa kali MBD’s Articles of Association have been amended
perubahahan, terakhir dengan Akta No. 09 tanggal several times, most recently by Notarial Deed No. 09
26 Maret 2025 Isadora, S.H., M.Kn., sehubungan dated 26 March 2025 Isadora, S.H., M.Kn., regarding
dengan perubahan peningkatan modal. Akta changes to capital. The deed of amendment has
perubahan tersebut telah diterima dan dicatat been received and recorded in the database of the
dalam database Sistem Administrasi Badan Hukum Legal Entity Administration System of the Ministry
Kementrian Hukum dan Hak Asasi Manusia Republik of Law and Human Rights of the Republic of
Indonesia dalam Surat Keputusan Indonesia in Decision Letter No. AHU-AH.01.03-
No. AHU-AH.01.03-0096994 tanggal 9 April 2025. 0096994 dated 9 April 2025.
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
Laporan keuangan konsolidasian telah disajikan sesuai The consolidated financial statements have been
dengan Standar Akuntansi Keuangan di Indonesia (SAK) prepared in accordance with Indonesian Financial
yang mencakup Pernyataan (“PSAK”) dan Interpretasi Accounting Standards (“SAK”), which includes
(“ISAK”) yang dikeluarkan oleh Dewan Standar the statements (“PSAK”) and interpretations
Akuntansi Keuangan Ikatan Akuntan Indonesia dan (“ISAK”) issued by the Financial Accounting Standards
Peraturan Nomor VIII.G.7 tentang Pedoman Penyajian Board of Indonesian Institute of Accountants, and
serta Pengungkapan Laporan Keuangan yang diterbitkan Regulation Number VIII.G.7 on Guidelines on Financial
oleh OJK (dahulu Badan Pengawas Pasar Modal dan Statements Presentations and Disclosures issued by the
Lembaga Keuangan (BAPEPAM-LK)) untuk Perusahaan OJK (formerly BAPEPAM-LK) for Publicly Listed
Publik. Company.
Page 207
Laporan Keuangan
Financial Report 207
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/13 Exhibit E/13
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
a. Dasar Penyusunan Laporan Keuangan a. Basis of Preparation of the Consolidated
Konsolidasian Financial Statements
Laporan keuangan konsolidasian disusun berdasarkan The consolidated financial statements are prepared
dasar akrual, kecuali untuk laporan arus kas, disusun on the accrual basis, except for the statements of
berdasarkan konsep biaya historis, kecuali untuk cash flows, and using historical cost concept of
akun tertentu yang diukur berdasarkan pengukuran accounting, except for certain accounts which are
sebagaimana diuraikan dalam kebijakan akuntansi measured on the bases described in the related
masing-masing akun tersebut. accounting policies of each account.
Laporan arus kas konsolidasian disusun dengan The consolidated statements of cash flows have
menggunakan metode langsung dengan been prepared based on the direct method by
mengklasifikasikan arus kas sebagai aktivitas classifying the cash flows on the basis of operating,
operasi, investasi, dan pendanaan. investing, and financing activities.
Transaksi-transaksi yang termasuk dalam laporan Items included in the consolidated financial
keuangan konsolidasian diukur dengan mata uang statements are measured using the currency of
lingkungan ekonomi utama di mana entitas primary economic environment in which the entity
beroperasi (mata uang fungsional). Laporan operates (the functional currency). The
keuangan konsolidasian disajikan dalam Rupiah yang consolidated financial statements are presented in
merupakan mata uang fungsional dan mata uang Rupiah both for functional and presentation
penyajian. currency.
Perubahan atas Pernyataan Standar Akuntansi Changes to Statement of Financial Accounting
Keuangan (“PSAK”) dan Interpretasi Standar Standards ("SFAS") and Interpretations of
Akuntansi Keuangan (“ISAK”) yang berlaku efektif Financial Accounting Standards ("IFAS") effective
pada tahun berjalan in the current year
Penerapan dari revisi standar berikut yang berlaku The adoption of these amended standards, which
efektif mulai 1 Januari 2025 tidak menimbulkan are effective beginning 1 January 2025 did not
perubahan substansial terhadap kebijakan akuntansi result in substantial changes to the Company’s
Perusahaan dan pengaruh yang material atas jumlah accounting policies and had no material impact on
yang dilaporkan atas tahun berjalan atau tahun the amounts reported for the current or prior
sebelumnya, sebagai berikut : financial years, as follows :
- Amendemen PSAK 221 "Pengaruh Perubahan Kurs - Amendment of SFAS 221 "The Effects of
Valuta Asing" - Kekurangan Ketertukaran; Changes in Foreign Exchange Rates" - Lack of
- PSAK 117 "Kontrak Asuransi". Exchangeability;
- Amandemen PSAK 221 “Pengaruh Perubahan Kurs - SFAS 117 "Insurance Contract".
Valuta Asing – Kekurangan Ketertukaran” - Amendment to PSAK 221, “Effects of Changes
in Foreign Exchange Rates”
Penerapan dari revisi standar berikut yang berlaku The adoption of these amended standards, which
efektif mulai 1 Januari 2026 tidak menimbulkan are effective beginning 1 January 2026 did not
perubahan substansial terhadap kebijakan akuntansi result in substantial changes to the Company’s
Perusahaan dan pengaruh yang material atas jumlah accounting policies and had no material impact on
yang dilaporkan tahun berjalan atau tahun the amounts reported for the current or prior
sebelumnya, sebagai berikut : financial years, as follows:
- Amendemen PSAK 109 dan PSAK 107 - Amendment of SFAS 109 and SFAS 107
"Pengungkapan tentang Klasifikasi dan "Classification and Measurement of Financial
Pengukuran Instrumen Keuangan"; Instruments";
- Amendemen PSAK 109 dan PSAK 107 terkait - Amendments to SFAS 109 and SFAS 107 of
Kontrak yang Mengacu pada Listrik Bergantung Contracts Referencing Nature-dependent
Alam. Electricity.
Page 208
208 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/14 Exhibit E/14
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
a. Dasar Penyusunan Laporan Keuangan a. Basis of Preparation of the Consolidated
Konsolidasian (Lanjutan) Financial Statements (Continued)
Penerapan dari standar baru yang berlaku efektif The adoption of the new standar is effective on
1 Januari 2027 dengan penerapan retrospektif 1 January 2027 with retrospective application is
diwajibkan, sehingga informasi komparatif untuk required, and so the comparative information for
tahun yang berakhir 31 Desember 2026 disajikan the financial year ending 31 December 2026 will be
ulang sesuai dengan standar ini: restated accordance with this standard:
- PSAK 118 ”Penyajian dan Pengungkapan dalam - SFAS 118 ”Presentation and Disclosure in
Laporan Keuangan”. Financial Statements”.
Manajemen berpendapat penerapan dari Management believes the adoption of amendment
amandemen dan revisi diatas tidak menimbulkan and revision has no impact on the material
perubahan material atas kebijakan akuntansi Grup accounting policies of the Group and has significant
dan tidak berdampak signifikan pada Laporan on the Financial Statements.
Keuangan.
b. Prinsip-prinsip Konsolidasi b. Principles of Consolidation
Kombinasi bisnis dihitung dengan menggunakan Business combinations are accounted using the
metode akuisisi pada tanggal akuisisi, yaitu tanggal acquisition method as at the acquisition date, which
pengendalian beralih kepada Entitas. Biaya is the date on which control is transferred to the
perolehan termasuk nilai wajar imbalan kontinjensi Entity. The cost of an acquisition includes the fair
pada tanggal akuisisi. Biaya terkait akusisi value of any contingent consideration at the
dibebankan ketika terjadi. Aset, liabilitas dan acquisition date. Acquisition-related costs are
liabilitas kontinjensi dalam suatu kombinasi bisnis expensed as incurred. Assets, liabilities and
diukur pada awalnya sebesar nilai wajar pada contingent liabilities assumed in a business
tanggal akuisisi. Untuk setiap akuisisi, Perusahaan combination are measured initially at their fair
mengakui kepentingan nonpengendali pada pihak value at the acquisition date. On an acquisition-by-
yang diakuisisi baik sebesar nilai wajar atau acquisition basis, the Company recognizes any non-
sebagian proporsional kepentingan nonpengendali controlling interest in the acquire either at fair
atas aset neto pihak yang diakuisisi. value or at non-controlling interest’s proportionate
share of the acquiree’s net assets.
Imbalan yang dialihkan tidak termasuk jumlah yang The consideration transferred does not include
terkait dengan penyelesaian pada hubungan yang amounts related to the settlement of pre-existing
sebelumnya ada. Jumlah tersebut, umumnya diakui relationships. Such amounts are generally
di dalam laporan laba rugi dan penghasilan recognised in profit or loss and other
komprehensif lain. comprehensive income.
Semua imbalan kontinjensi diakui pada nilai wajar Any contingent consideration payable is recognised
pada saat tanggal akuisisi. Apabila imbalan at fair value at the acquisition date. If the
kontinjensi diklasifikasikan sebagai ekuitas, maka contingent consideration is classified as equity, it is
hal tersebut tidak diukur kembali dan not re-measured and settlement is accounted for
penyelesaiannya dicatat di dalam ekuitas. Selain within equity. Otherwise, subsequent changes to
itu, perubahan berikutnya terhadap nilai wajar the fair value of the contingent consideration are
imbalan kontinjensi diakui di laporan laba rugi dan recognised in profit or loss and other
penghasilan komprehensif lain. comprehensive income.
Ketika melakukan akuisisi atas sebuah bisnis, Grup When the Group acquires a business, it assesses the
mengklasifikasikan dan menentukan aset keuangan financial assets acquired and the liabilities assumed
yang diperoleh dan liabilitas keuangan yang diambil for appropriate classification and designation in
alih berdasarkan pada persyaratan kontraktual, accordance with the contractual terms, economic
kondisi ekonomi, dan kondisi terkait lain yang ada circumstances, and pertinent conditions as at the
pada tanggal akuisisi. acquisition date.
Page 209
Laporan Keuangan
Financial Report 209
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/15 Exhibit E/15
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
b. Prinsip-prinsip Konsolidasi (Lanjutan) c. b. Principles of Consolidation (Continued)
Pada tanggal akuisisi, goodwill awalnya diukur pada At acquisition date, goodwill is initially measured
harga perolehan yang merupakan selisih lebih nilai at cost being the excess of the aggregate of the
agregat dari imbalan yang dialihkan dan jumlah consideration transferred and the amount
setiap KNP atas selisih jumlah dari aset recognized for NCI over the net identifiable assets
teridentifikasi yang diperoleh dan liabilitas yang acquired and liabilities assumed. If this
diambil alih. Jika imbalan tersebut kurang dari nilai consideration is lower than the fair value of the net
wajar aset neto entitas anak yang diakuisisi, selisih assets of the subsidiary acquired, the difference is
tersebut diakui dalam laporan laba rugi dan recognized in the consolidated statement of profit
penghasilan komprehensif lain konsolidasian sebagai or loss and other comprehensive income as gain on
keuntungan dari pembelian dengan diskon setelah bargain purchase after previously management
sebelumnya manajemen meninjau kembali assessing the identification and fair value
identifikasi dan pengukuran nilai wajar dari aset measurement of the acquired assets and the
yang diperoleh dan liabilitas yang diambil alih. assumed liabilities.
Setelah pengakuan awal, goodwill diukur pada After initial recognition, goodwill is measured
jumlah tercatat dikurangi akumulasi kerugian at cost less any accumulated impairment losses.
penurunan nilai. Untuk tujuan uji penurunan nilai, For the purpose of impairment testing, goodwill
goodwill yang diperoleh dari suatu kombinasi bisnis, acquired in a business combination is, from
sejak tanggal akuisisi dialokasikan kepada setiap the acquisition date, allocated to each of the
Unit Penghasil Kas (“UPK”) dari Grup yang Group’s Cash-Generating Units (“CGU”) that are
diharapkan akan memberikan manfaat dari sinergi expected to benefit from the combination,
kombinasi tersebut, terlepas dari apakah aset atau irrespective of whether other assets or liabilities
liabilitas lain dari pihak yang diakuisisi ditetapkan of the acquiree are assigned to those CGUs.
atas UPK tersebut.
Jika goodwill telah dialokasikan pada suatu UPK dan If goodwill has been allocated to CGU and certain
operasi tertentu atas UPK tersebut dihentikan, maka operations of which is discontinued, the associated
goodwill yang diasosiasikan dengan operasi yang goodwill with the discontinued operation is included
dihentikan tersebut termasuk dalam jumlah tercatat in the carrying amount when determining the gain
operasi tersebut ketika menentukan keuntungan or loss on disposal. Goodwill discharged is measured
atau kerugian dari pelepasan. Goodwill yang based on the relative value of discontinued
dilepaskan tersebut diukur berdasarkan nilai operations and the portion of the CGU retained.
relatif operasi yang dihentikan dan porsi UPK yang
ditahan.
Kombinasi bisnis entitas sepengendali Business combinations under common control
Kombinasi bisnis entitas sepengendali dicatat Business combinations under common control are
dengan menggunakan metode penyatuan accounted for using the pooling-of-interests
kepentingan, dimana selisih antara jumlah imbalan method, whereby the difference between the
yang dialihkan dengan jumlah tercatat aset neto considerations transferred and the book value of the
entitas yang diakuisisi diakui sebagai bagian dari net assets of the acquiree is recognized as part of
akun "Tambahan Modal Disetor" pada laporan posisi "Additional Paid-in Capital" account in the
keuangan konsolidasian. Dalam menerapkan metode consolidated statement of financial position. In
penyatuan kepentingan tersebut, unsur-unsur applying the said pooling-of-interest method, the
laporan keuangan dari entitas yang bergabung components of the financial statements of the
disajikan seolah-olah penggabungan tersebut telah combining entities are presented as if the
terjadi sejak awal periode entitas yang bergabung combination has occurred since the beginning of the
berada dalam kesepengendalian. period of the combining entity become under
common control.
Page 210
210 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/16 Exhibit E/16
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
b. Prinsip-prinsip Konsolidasi (Lanjutan) c. b. Principles of Consolidation (Continued)
Entitas anak Subsidiaries
Laporan keuangan entitas anak dimasukkan ke The financial statements of subsidiaries are
dalam laporan keuangan konsolidasian sejak tanggal included in the consolidated financial statements
pengendalian dimulai sampai dengan tanggal from the date that control commences until the
pengendalian dihentikan. Kebijakan akuntansi date that control ceases. The accounting policies of
entitas anak diubah apabila dipandang perlu untuk subsidiaries have been changed when necessary to
menyelaraskan kebijakan akuntansi yang diadopsi align them with the policies adopted by the Entity.
oleh Entitas.
Kerugian yang terjadi pada kepentingan Losses applicable to the non-controlling interests in
nonpengendali pada entitas anak dialokasikan a subsidiary are allocated to the non-controlling
kepada kepentingan nonpengendali bahkan apabila interests even if doing so causes the non-controlling
dialokasikan kepada kepentingan nonpengendali interests to have a deficit balance. Non-controlling
tersebut dapat menimbulkan saldo defisit. interests is prsented in the consolidated statement
Kepentingan nonpengendali disajikan di dalam of financial position within equity, separately from
laporan keuangan konsolidasian pada bagian ekuitas, the equity of the owners of the parent.
yang terpisah dari ekuitas pemilik entitas induk.
Setelah terjadi hilangnya pengendalian, Grup Upon the loss of control, the Group derecognises the
menghentikan pengakuan aset dan liabilitas entitas assets and liabilities of the subsidiaries, any non-
anak, semua kepentingan nonpengendali dan controlling interests and the other components of
komponen ekuitas lainnya terkait dengan entitas equity related to the subsidiaries. Any surplus or
anak. Segala surplus atau defisit yang timbul dari deficit arising on the loss of control is recognised in
hilangnya pengendalian, diakui di dalam laporan profit or loss and other comprehensive income.
laba rugi dan penghasilan komprehensif lain.
Apabila Perusahaan masih memiliki bagian di dalam If the Company retains any interest in the previous
entitas anak sebelumnya, maka bagian tersebut subsidiaries, then such interest is measured at fair
diukur pada nilai wajar pada tanggal saat value at the date that control is lost. Subsequently,
pengendalian dihentikan. Selanjutnya, bagian it is accounted for as an equity-accounted investee
tersebut dicatat sebagai investee dengan ekuitas or as an available-for-sale financial asset depending
yang dihitung atau sebagai aset keuangan tersedia on the level of influence retained.
untuk dijual bergantung pada besarnya pengaruh.
Transaksi yang dieliminasi pada konsolidasi Transactions eliminated on consolidation
Saldo dan transaksi antar Grup dan semua Intra-group balances and transactions, and any
pendapatan dan beban yang belum terealisasi yang unrealised income and expenses arising from intra-
timbul dari transaksi antar Grup, dieliminasi di dalam group transactions, are eliminated in preparing the
penyusunan dan penyajian laporan keuangan consolidated financial statements. Unrealised gains
konsolidasian. Laba yang belum terealisasi yang arising from transactions with associates are
timbul dari transaksi dengan entitas asosiasi, eliminated against the investment to the extent of
dieliminasi terhadap investasi dari bagian Grup di the Group’s interest in the investee. Unrealised
dalam investee. Kerugian yang belum terealisasi, losses are eliminated in the same way as unrealised
dieliminasi dengan cara yang sama dengan gains, but only to the extent that there is no
keuntungan yang belum terealisasi, hanya apabila evidence of impairment.
tidak terdapat bukti penurunan nilai.
Transaksi dengan kepentingan nonpengendali Transactions with non-controlling interests are
dihitung sebagai transaksi dengan pemilik dalam accounted for as transactions with owners in their
kapasitasnya sebagai pemilik dan oleh karena itu capacity as owners and therefore no goodwill is
tidak terdapat goodwill yang diakui sebagai hasil recognised as a result of such transactions. The
transaksi tersebut. Penyesuaian kepentingan adjustments to non-controlling interests are based
nonpengendali berdasarkan jumlah proporsional aset on a proportionate amount of the net assets of the
bersih entitas anak. subsidiaries.
Page 211
Laporan Keuangan
Financial Report 211
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/17 Exhibit E/17
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
b. Prinsip-prinsip Konsolidasi (Lanjutan) b. Principles of Consolidation (Continued)
Jika kehilangan pengendalian atas suatu entitas In case of loss of control over a subsidiary, the
anak, maka Grup: Group:
● menghentikan pengakuan aset (termasuk setiap ● derecognises the assets (including goodwill) and
goodwill) dan liabilitas entitas anak; liabilities of the subsidiary;
● menghentikan pengakuan jumlah tercatat setiap ● derecognises the carrying amount of any non-
kepentingan nonpengendali; controlling interest;
● menghentikan pengakuan akumulasi selisih ● derecognises the cumulative translation
penjabaran, yang dicatat di ekuitas, bila ada; differences, recorded in equity, if any;
● mengakui nilai wajar pembayaran yang diterima; ● recognises the fair value of consideration
received;
● mengakui setiap sisa investasi pada nilai ● recognises the fair value of any investment
wajarnya; retained;
● mengakui setiap perbedaan yang dihasilkan ● recognises any surplus or deficit in profit or loss;
sebagai keuntungan atau kerugian dalam laba and
rugi; dan
● mereklasifikasi bagian induk atas komponen yang ● reclassifies the parent’s share of components
sebelumnya diakui sebagai penghasilan previously recognised in other comprehensive
komprehensif ke laporan laba rugi, atau income to profit or loss or retained earnings, as
mengalihkan secara langsung ke saldo laba. appropriate.
c. Transaksi dengan Pihak Berelasi c. Transactions with Related Parties
Pihak-pihak berelasi adalah orang atau entitas yang Related party represents a person or an entity who
terkait dengan entitas pelapor: is related to the reporting entity:
(a) Orang atau anggota keluarga terdekat (a) A person or a close member of the person’s
mempunyai relasi dengan entitas pelapor jika family is related to a reporting entity if that
orang tersebut: person:
(i) memiliki pengendalian atau pengendalian (i) has control or joint control over the
bersama atas entitas pelapor; reporting entity;
(ii) memiliki pengaruh signifikan atas entitas (ii) has significant influence over the reporting
pelapor; atau entity; or
(iii) personil manajemen kunci entitas pelapor (iii) is a member of the key management
atau entitas induk entitas pelapor. personnel of the reporting entity or of a
parent of the reporting entity.
(b) Suatu entitas berelasi dengan entitas pelapor jika (b) An entity is related to a reporting entity if any
memenuhi salah satu hal berikut: of the following conditions applies:
(i) entitas dan entitas pelapor adalah anggota (i) the entity and the reporting entity are
dari grup yang sama (artinya entitas induk, members of the same group (which means
entitas anak, entitas anak berikutnya that each parent, subsidiary and fellow
terkait dengan entitas lain). subsidiary is related to the others).
(ii) satu entitas adalah entitas asosiasi atau (ii) one entity is an associate or joint venture
ventura bersama dari entitas lain (atau of the other entity (or an associate or joint
entitas asosiasi atau ventura bersama yang venture of a member of a group of which
merupakan anggota suatu grup, yang mana the other entity is a member).
entitas lain tersebut adalah anggotanya).
(iii) kedua entitas tersebut adalah ventura (iii) both entities are joint ventures of the same
bersama dari pihak ketiga yang sama. third party.
(iv) satu entitas adalah ventura bersama dari (iv) one entity is a joint venture of a third
entitas ketiga dan entitas yang lain adalah entity and the other entity is an associate
entitas asosiasi dari entitas ketiga. of the third entity.
Page 212
212 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/18 Exhibit E/18
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
c. Transaksi dengan Pihak Berelasi (Lanjutan) c. Transactions with Related Parties (Continued)
(b) Suatu entitas berelasi dengan entitas pelapor jika (b) An entity is related to a reporting entity if any
memenuhi salah satu hal berikut: (lanjutan) of the following conditions applies:
(v) entitas tersebut adalah suatu program (v) the entity is a post-employment benefits
imbalan pasca-kerja untuk imbalan kerja plan for the benefit of employees of either
dari salah satu entitas pelapor atau entitas the reporting entity or an entity related to
yang terkait dengan entitas pelapor. Jika the reporting entity. If the reporting entity
entitas pelapor adalah entitas yang is itself such a plan, the sponsoring
menyelenggarakan program tersebut, maka employers are also related to the reporting
entitas sponsor juga berelasi dengan entitas entity.
pelapor.
(vi) entitas yang dikendalikan atau dikendalikan (vi) the entity is controlled or jointly controlled
bersama oleh orang yang diidentifikasi by a person identified in (a).
dalam huruf (a).
(vii) orang yang diidentifikasi dalam huruf (a)(i) (vii) a person identified in (a)(i) has significant
memiliki pengaruh signifikan atas entitas influence over the entity or is a member of
atau personil manajemen kunci entitas the key management personnel of the
(atau entitas induk dari entitas). entity (or of a parent of the entity).
(viii) entitas atau anggota dari kelompok yang (viii) the entity, or any member of Group of
mana entitas merupakan bagian dari which it is a part, provides key management
kelompok tersebut, menyediakan jasa personal services to the reporting entity or
personal manajemen kunci kepada entitas to the parent of the reporting entity.
pelapor atau kepada entitas induk dari
entitas pelapor.
d. Kas dan Setara Kas d. Cash and Cash Equivalents
Kas terdiri dari kas dan bank. Setara kas adalah Cash consists of cash on hand and cash in banks. Cash
semua investasi yang bersifat jangka pendek dan equivalents are liquid short-term investments which
sangat likuid yang dapat segera dikonversikan can be converted immediately into cash with an
menjadi kas penuh dengan jatuh tempo dalam waktu original maturity of 3 (three) months or less from
3 (tiga) bulan atau kurang sejak tanggal the date of placement, as long as they are not being
penempatannya, dan yang tidak dijaminkan serta pledged as collateral for borrowings nor restricted
tidak dibatasi penggunaannya. to use.
e. Piutang Usaha dan Lain-lain e. Trade and Other Receivables
Piutang usaha dan lain-lain pada awalnya diakui Trade and other receivables are recognised initially
sebesar nilai wajar dan selanjutnya diukur pada at fair value and subsequently measured at
biaya perolehan diamortisasi dengan menggunakan amortised cost using the effective interest method,
metode bunga efektif, kecuali efek diskontonya except where the effect of discounting would
tidak material, setelah dikurangi provisi untuk be immaterial, less provision for receivable
penurunan nilai piutang. impairment.
Provisi untuk penurunan nilai piutang dibentuk pada Provision for receivables impairment is established
saat terdapat bukti objektif bahwa saldo piutang when there is objective evidence that the
tidak dapat ditagih. Piutang ragu-ragu dihapuskan outstanding amounts will not be collective.
pada saat piutang tersebut tidak tertagih. Doubtful accounts are written-off during the period
in which they are determined to be uncollectible.
f. Persediaan f. Inventories
Persediaan dinilai dengan nilai yang terendah antara Inventories are valued at the lower of cost or net
harga perolehan atau nilai realisasi bersih. Metode realizable value. The method used to determine the
yang dipakai untuk menentukan harga perolehan cost is moving average method.
adalah metode rata-rata bergerak (moving average
method).
Page 213
Laporan Keuangan
Financial Report 213
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/19 Exhibit E/19
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
f. Persediaan (Lanjutan) f. Inventories (Contid)
Provisi untuk persediaan usang dan persediaan tidak Provisions for obsolete inventory and unused /
terpakai/ tidak laris ditentukan berdasarkan unquoted supplies are determined based on the
estimasi penggunaan atau penjualan masing-masing estimated use or sale of each type of supply in the
jenis persediaan pada masa mendatang. future.
g. Biaya Dibayar di Muka g. Prepaid Expenses
Biaya dibayar di muka diamortisasi selama masa Prepaid expenses are amortized over their
manfaat masing-masing biaya dengan menggunakan beneficial periods using the straight-line method.
metode garis lurus.
h. Uang Muka h. Advances
Uang muka merupakan pembayaran untuk suatu Advance is a payment for transactions to suppliers
transaksi kepada pemasok atau penyedia jasa atau or service providers or employee of the Group
karyawan Grup sebelum transaksi barang/jasa before goods/services received.
diselesaikan.
i. Aset Tetap i. Property and Equipment
Tanah dan bangunan diukur pada nilai wajar pada Land and buildings are stated at fair value at
tanggal revaluasi dikurangi akumulasi rugi revaluation date less any subsequent accumulated
penurunan nilai setelah tanggal revaluasi. impairments losses.
Pada model biaya, setelah pengakuan sebagai aset, Under the cost model, after recognition as an asset,
aset tetap dicatat pada biaya perolehan dikurangi an item of property and equpment is carried at its
akumulasi penyusutan dan akumulasi rugi penurunan cost less any accumulated depreciation and any
nilai. Sedangkan pada model revaluasi, setelah accumulated impairment losses. Under the
pengakuan sebagai aset, aset tetap yang nilai revaluation model, after recognition as an asset, an
wajarnya dapat diukur secara andal dicatat pada item of property and equipment whose fair value
jumlah revaluasian, yaitu nilai wajar pada tanggal can be measured reliably is carried at a revalued
revaluasi, dikurangi akumulasi penyusutan dan amount, being its fair value at the date of the
akumulasi rugi penurunan nilai setelah tanggal revaluation less any subsequent accumulated
revaluasi. depreciation and subsequent accumulated
impairment losses.
Ketika suatu aset tetap direvaluasi, maka jumlah When a property and equipment is revalued, the
tercatat dari aset tetap tersebut disesuaikan pada carrying amount of property and equipment is
jumlah revaluasiannya. Pada tanggal revaluasi, adjusted to its revalued amount. On revaluation
akumulasi penyusutan dieliminasi terhadap jumlah date, any accumulated depreciation is eliminated
tercatat bruto aset. against the gross carrying amount of the asset.
Penilaian terhadap tanah dan bangunan dilakukan Assessments of land and buildings are conducted by
oleh penilai independen eksternal yang memiliki certified external independent appraisers.
sertifikasi. Penilaian atas aset tersebut dilakukan Assessments of these assets are carried out
secara berkala untuk memastikan bahwa nilai wajar periodically to ensure that the fair value of the
aset yang direvaluasi tidak berbeda secara material assets being revalued does not differ materially
dengan jumlah yang ditentukan dengan from that which would be determined using fair
menggunakan nilai wajar pada akhir periode value at end of the reporting period.
pelaporan.
Jika nilai wajar dari aset yang direvaluasi mengalami If the fair value of the revalued asset changes
perubahan yang signifikan dan fluktuatif, maka perlu significantly and fluctuates, it needs to be revalued
direvaluasi secara tahunan, sedangkan jika nilai annually, whereas if the fair value of the revalued
wajar dari aset yang direvaluasi tidak mengalami asset does not change significantly and fluctuates,
perubahan yang signifikan dan fluktuatif, maka perlu it is necessary to do a revaluation at least once every
dilakukan revaluasi minimal 3 atau 5 tahun sekali. 3 or 5 years.
Page 214
214 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/20 Exhibit E/20
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
i. Aset Tetap (Lanjutan) i. Property and Equipment (Continued)
Kenaikan nilai tercatat yang timbul dari revaluasi The increase in the carrying value arising from the
tanah dicatat sebagai "Selisih bersih revaluasi aset revaluation of land is recorded as "Net difference
tetap" dan disajikan sebagai "Penghasilan asset revaluation" and is presented as "Other
komprehensif lain". Penurunan nilai tercatat yang comprehensive income". Impairment in carrying
timbul dari revaluasi dicatat sebagai beban pada amount arising from revaluation is recorded as an
tahun berjalan. Apabila aset tersebut memiliki saldo expense in the current year. If the asset has a
"Selisih bersih revaluasi aset tetap" yang disajikan balance of "Net difference for property and
sebagai "Penghasilan komprehensif lain", maka equipment revaluation" which is presented as "Other
selisih penurunan nilai tercatat tersebut dibebankan comprehensive income", the difference in
terhadap "Selisih bersih revaluasi aset tetap" dan impairment of the carrying value is charged to "Net
sisanya diakui sebagai beban tahun berjalan. difference in property and equipment revaluation"
and the remainder is recognised as an expense for
the year.
Aset tetap selain tanah dan bangunan dinyatakan Fixed assets other than land and building are stated
berdasarkan biaya perolehan dikurangi akumulasi at cost less accumulated depreciation and
penyusutan dan akumulasi penurunan nilai, jika ada. accumulated impairment losses, if any.
Penyusutan aset tetap selain tanah dihitung dengan Depreciation of property and equipment, except
menggunakan metode garis lurus untuk land are calculated on the straight-line method to
mengalokasikan harga perolehan hingga mencapai allocate their cost to their residual values over their
nilai sisa sepanjang estimasi masa manfaatnya estimated useful lives as follows:
sebagai berikut:
Persentase (Masa manfaat)/
Jenis Aset Tetap Percentage (Useful lifes) Type of Property and Equipment
Bangunan 5% (20 tahun/years) Building
Peralatan medis 6,25% - 25% (4 - 16 tahun/years) Medical equipment
Peralatan kantor 10% - 50% (2 - 10 tahun/years) Office equipment
Mesin dan instalasi 12,5% - 25% (4 - 8 tahun/ years) Machine and installation
Peralatan rumah tangga 20% - 25% (4 - 5 tahun/ years) Household equipment
Kendaraan 12,5% - 20% (4 - 8 tahun/ years) Vehicles
Tanah dan hak atas tanah dinyatakan berdasarkan Land and landrights are stated accordance to fair
nilai wajar tanah dengan menggunakan metode value of the land was determined by using market
perbandingan harga pasar. comparable method.
Estimasi masa manfaat aset tetap ditentukan Estimated useful life of property and equipment are
berdasarkan ekspektasi pemakaian dan pengalaman determined based on expected usage and historical
historis atas aset sejenis. experience on the similar asset.
Masa manfaat, nilai sisa dan metode penyusutan aset The useful lives, residual values and depreciation
tetap ditelaah, jika diperlukan, setidaknya methods of fixed assets are reviewed and adjusted
disesuaikan pada setiap akhir tahun buku. Dampak if appropriate, at the end of each financial year.
dari setiap revisi diakui dalam laba rugi Ketika The effects of any revision are recognized in profit
perubahan terjadi. or loss when the changes arise.
Biaya perolehan awal aset tetap meliputi harga The initial cost of property and equipment consists
perolehan, termasuk bea impor dan pajak pembelian of its purchase price, including import duties and
yang tidak boleh dikreditkan dan biaya-biaya yang taxes and any directly attributable costs in bringing
dapat diatribusikan secara langsung untuk membawa the property and equipment to its working condition
aset ke lokasi dan kondisi yang diinginkan sesuai and location for its intended use.
dengan tujuan penggunaan yang ditetapkan.
Page 215
Laporan Keuangan
Financial Report 215
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/21 Exhibit E/21
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
i. Aset Tetap (Lanjutan) i. Property and Equipment (Continued)
Jumlah tercatat aset tetap dihentikan pengakuannya Carrying amount of property and equipment are
pada saat dilepaskan atau tidak ada manfaat derecognised upon disposal or when no future
ekonomis masa depan yang diharapkan dari economic benefits are expected from its use or
penggunaan atau pelepasannya. Aset tetap yang disposal. When assets are sold or retired, the cost
dijual atau dilepaskan, dikeluarkan dari kelompok and related accumulated depreciation and any
aset tetap berikut akumulasi penyusutan serta impairment loss are removed from the accounts.
akumulasi penurunan nilai yang terkait dengan aset Any gains or loss arising from derecognition of
tetap tersebut. Laba atau rugi yang timbul dari property and equipment calculated as the
penghentian pengakuan aset tetap ditentukan difference between the net disposal proceed, if anys
sebesar perbedaan antara jumlah neto hasil with the carrying amount of the item, is included in
pelepasan, jika ada, dengan jumlah tercatat dari the consolidated statements of profit or loss and
aset tetap tersebut, dan diakui dalam laporan laba other comprehensive income in the year the item is
rugi dan penghasilan komprehensif lain konsolidasian derecognised.
pada tahun terjadinya penghentian pengakuan.
Apabila terdapat indikasi penurunan nilai, nilai Where an indication of impairment exists, the
tercatat aset dinilai dan langsung dicatat terhadap carrying amount of the asset is assessed and written
jumlah terpulihkan apabila nilai tercatat aset down immediately to its recoverable amount if the
tersebut lebih besar dibandingkan dengan jumlah asset's carrying amount is greater than its estimated
terpulihkan yang diestimasi. recoverable amount.
Nilai tercatat aset tetap, umur manfaat, serta The carrying value of property and equipment,
metode penyusutan ditelaah setiap akhir tahun dan useful lives and depreciation method are reviewed
dilakukan penyesuaian apabila hasil telaah berbeda and adjusted if not appropriate, at each financial
dengan estimasi sebelumnya. year end.
Aset dalam Pembangunan Construction in Progress
Aset dalam pembangunan dinyatakan berdasarkan Construction in progress is stated at cost. Costs
biaya perolehan termasuk biaya perolehan tanah dan includes acquisition cost of land and accumulated
akumulasi biaya pembangunan. Saat pembangunan construction costs. When the construction is
tersebut selesai dan siap untuk digunakan, jumlah completed and ready for its intended use, the total
biaya yang terjadi diklasifikasikan ke akun “Aset cost incurred is reclassified to the related “Property
Tetap” sesuai peruntukannya. Penyusutan mulai and Equipment” account. Depreciation is charged
dibebankan pada saat aset tersebut siap digunakan. from the date when assets are ready to use.
j. Penurunan Nilai dari Aset Tetap dan Aset Tidak j. Impairment of Property and Equipment and Other
Lancar Lainnya Non-Current Assets
Aset tetap dan aset tidak lancar lainnya, termasuk Property and equipment and other non-current
aset tak berwujud ditelaah untuk mengetahui assets, include intangible assets are reviewed for
apakah telah terjadi kerugian akibat penurunan nilai impairment losses whenever events or changes in
atau apakah telah terjadi perubahan keadaan yang circumstances indicate that the carrying amount
mengindikasikan bahwa nilai tercatat aset tersebut may not be recoverable. An impairment loss is
tidak dapat diperoleh kembali. Kerugian akibat recognised for the amount by which the carrying
penurunan nilai diakui sebesar selisih antara nilai amount of the asset exceeds its recoverable
tercatat aset dengan nilai yang dapat diperoleh amount, which is the higher of an asset’s net selling
kembali dari aset tersebut. Nilai yang dapat price or value in use. For the purpose of assessing
diperoleh kembali adalah yang lebih tinggi di antara impairment, assets are grouped at the lowest levels
harga jual neto dan nilai pakai aset. Dalam rangka for which there are separately identifiable cash
menguji penurunan nilai, aset dikelompokkan hingga flows.
unit terkecil yang menghasilkan arus kas terpisah.
Page 216
216 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/22 Exhibit E/22
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
k. Aset dan Liabilitas Keuangan k. Financial Assets and Liabilities
Grup telah mengadopsi dan melakukan penerapan Group had performed early adoption and applied on
dini atas PSAK 109 – “Instrumen Keuangan”. PSAK 109 – “Financial Instrument".
Aset Keuangan Financial Assets
Aset keuangan diklasifikasikan ke dalam kategori Financial assets are classified in categories
(i) diukur pada nilai wajar melalui laporan laba rugi, of (i) fair value through profit or loss,
(ii) biaya perolehan diamortisasi, dan (iii) aset (ii) amortised cost, and (iii) fair value through
keuangan yang diukur pada nilai wajar pendapatan other comprehensive income. At initial
komprehensif lain. Pada pengakuan awal, aset measurement, financial assets determined
keuangan diukur pada nilai wajar, ditambah biaya based on fair value, added with transactions
transaksi yang dapat diatribusikan langsung untuk cost attributable direct to financial assets.
aset keuangan yang diukur pada biaya perolehan Management determines the classification of
diamortiasi dan pendapatan komprehensif lain. its financial assets prior initial recognition
Manajemen menentukan klasifikasi aset keuangan based on assessment of businesss model for
tersebut setelah pengakuan awal aset keuangan managing the financial assets or contractual
berdasarkan model bisnis entitas dalam mengelola cashflows give rise to solely payments of principal
aset keuangan atau karakteristik arus kas and interest.
kontraktual hanya dari pembayaran pokok dan bunga
saja.
(i) Aset keuangan yang diukur pada nilai wajar (i) Financial assets at fair value through profit
melalui laporan laba rugi or loss
Aset keuangan yang diukur pada nilai wajar Financial assets at fair value through profit
melalui laporan laba rugi adalah aset keuangan or loss are financial assets classified as held for
yang diperdagangkan. Entitas dapat trading. Entity may determine at initial
menetapkan pilihan yang tidak dapat classification of an uncancellable chosen
dibatalkan pada saat pengakuan awal atas cateogry of financial assets on a certain equity
investasi pada intrumen ekuitas tertentu yang instrument which commonly measured the fair
pada umumnya diukur pada nilai wajar melalui value through profit and loss rise change in the
laba rugi sehingga perubahan nilai wajarnya fair value presented under fair value through
disajikan dalam penghasilan komprehensif lain. other comprehensive income.
Grup tidak memiliki aset keuangan yang diukur Group has no financial assets at fair value
pada nilai wajar melalui laporan laba rugi. through profit or loss.
(ii) Biaya perolehan diamortisasi (ii) Amortised cost
Aset keuangan diukur pada biaya perolehan Financial assets determined under amortised
diamortisasi jika memenuhi kriteria sebagai cost if met criteria as outlined below:
berikut:
a. aset keuangan dikelola dalam bisnis yang a. financial assets held within a business
bertujuan untuk memiliki arus kas whose objective is to hold financial assets
keuangan dalam rangka mendapatkan arus in order to collect contractual cashflows;
kas kontraktual; dan and
b. persyaratan kontraktual aset keuangan b. determining contractual financial assets
yang menimbulkan arus kas yang hanya dari give rise to solely payments of principal and
pembayaran pokok dan bunga. assets.
Pada saat pengakuan awal, instrumen keuangan Financial instruments are initially recognised
diakui pada nilai wajarnya ditambah nilai at fair value plus transaction costs and
transaksi dan selanjutnya diukur pada biaya subsequently measured at amortised cost
perolehan diamortisasi dengan menggunakan using the effective interest rate method.
metode suku bunga efektif.
Page 217
Laporan Keuangan
Financial Report 217
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/23 Exhibit E/23
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
k. Aset dan Liabilitas Keuangan (Lanjutan) k. Financial Assets and Liabilities (Continued)
Aset Keuangan (Lanjutan) Financial Assets (Continued)
(ii) Biaya perolehan diamortisasi (lanjutan) (ii) Amortised cost (continued)
Grup memiliki aset keuangan pada biaya Group’s financial assets at amortised cost include
perolehan yang diamortisasi meliputi kas dan cash and cash equivalents, trade and non-trade
setara kas, piutang usaha dan lain-lain dan receivables and shares investments.
investasi saham.
(iii) Aset keuangan yang diukur pada nilai wajar (iii) Fair value through other comprehensive
pendapatan komprehensif lain income
Aset keuangan yang diukur pada nilai wajar Fair value through other comprehensive
pendapatan komprehensif lain adalah aset income are non-derivative financial assets with
keuangan non-derivative dengan pembayaran fixed or determined payments and fixed
tetap atau telah ditentukan dan jatuh maturities that the management has positive
temponya telah ditetapkan, serta manajemen intention and ability to hold to maturity, other
mempunyai intensi positif dan kemampuan than:
untuk memiliki aset keuangan tersebut hingga
jatuh tempo, kecuali:
a. aset keuangan dikelola dalam model bisnis a. financial assets managed under business
yang tujuannya akan terpenuhi dengan model which its objective is to both collect
mendapatkan arus kas kontraktual dan the contractual cash flows and sell the
menjual aset keuangan; dan financial assets; and
b. persyaratan kontraktual dari aset keuangan b. contractual cash flows characteristics
tersebut memberikan hak pada tanggal resulting rights on certain basic term of
tertentu atas arus kas yang hanya dari cashflows meets the solely payments of
pembayaran pokok dan bunga dari jumlah principal and interest.
pokok terutang.
Grup memiliki aset keuangan yang diukur pada Group has fair value through other
nilai wajar melalui penghasilan komprehensif comprehensive income include other current
lain yaitu asset keuangan lancar lainnya. financial assets.
Penurunan nilai aset keuangan Impairment of financial assets
Aset keuangan dievaluasi terhadap indikator Financial assets are assessed for indicators of
penurunan nilai pada setiap tanggal pelaporan. Aset impairment at each reporting date. Financial assets
keuangan diturunkan nilainya menggunakan basis are impaired using the basis for the accounting of
akuntasi kerugian kredit ekpektasian pada aset expected credit loss (ECLs) on financial assets and
keuangan dan kontraktual, yang bunga contract assets, measuring uses of expected interest
penurunannya dihitung menggunakan suku bunga rate (EIR) of the loss allowance on impairment at a
efektif (SBE) pada cadangan penurunan nilai pada probabilited weighted amount that considers
jumlah probabilita tertimbang yang reasonable and supportable information about past
mempertimbangkan kondisi yang terjadi pada masa events, current conditions, and forecasts of future
lampau, saat sekarang, dan proyeksi atas kondisi economic conditions of the customers. The ECLs are
ekonomi masa depan pelanggan. KKE diperbarui updated at each reporting date to reflect changes in
pada setiap tanggal pelaporan untuk mencerminkan credit risk since initial recognition. ECLs are
perubahan resiko sejak pengakuan awal. KKE calculated for all financial assets in scope,
dihitung untuk semua aset keuangan, terlapas regardless of whether they are overdue or not.
apakah telah jatuh tempo atau tidak.
Page 218
218 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/24 Exhibit E/24
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
k. Aset dan Liabilitas Keuangan (Lanjutan) k. Financial Assets and Liabilities (Continued)
Aset Keuangan (Lanjutan) Financial Assets (Continued)
Pengukuran atas penurunan nilai dimana basis Determining the impairment could whereas basis
pengukuran bergantung pada resiko kredit secara recognition rely on the significant credit risk at
signifikan sejak pengakuan awal adalah sebagai initial recognition may include:
berikut:
(i) Penurunan nilai diakui berdasarkan pengukuran (i) Recognise impairment based on expected losses
kerugian kredit ekspektasian dari peristiwa arising from default events that are expected
default yang diperkirakan akan terjadi untuk to occur over the next 12 (twelve) months; or
12 (dua belas) bulan mendatang; atau
(ii) Pengakuan penurunan berdasarkan kerugian (ii) Recognise impairment based on expected losses
kredit sepanjang umurnya. over the life of the loan.
Penghentian pengakuan aset keuangan Derecognition of financial assets
Grup menghentikan pengakuan aset keuangan jika The Group derecognises a financial asset only when
dan hanya jika hak kontraktual atas arus kas yang the contractual rights to the cash flows from the
berasal dari aset berakhir, atau Grup mentransfer asset expire, or Group transfers the financial asset
aset keuangan dan secara substansial mentransfer and substantially all the risks and rewards of
seluruh risiko dan manfaat atas kepemilikan aset ownership of the asset to another entity.
kepada entitas lain.
Jika Grup tidak mentransfer serta tidak memiliki If Group neither transfers nor retains substantially
secara substansial atas seluruh risiko dan manfaat all the risks and rewards of ownership and continues
kepemilikan serta masih mengendalikan aset yang to control the transferred asset, Group recognise
ditransfer, maka Grup mengakui keterlibatan their retained interest in the asset and an
berkelanjutan atas aset yang ditransfer dan liabilitas associated liability for amounts they may have to
terkait sebesar jumlah yang mungkin harus dibayar. pay. If Group retains substantially all the risks and
Jika Grup memiliki secara substansial seluruh risiko rewards of ownership of a transferred financial
dan manfaat kepemilikan aset keuangan yang asset, Group continue to recognise the financial
ditransfer, Grup masih mengakui aset keuangan dan asset and also recognise a collateralised borrowing
juga mengakui pinjaman yang dijamin sebesar for the proceeds received.
pinjaman yang diterima.
Liabilitas Keuangan Financial Liabilities
Grup mengklasifikasi liabilitas keuangannya dalam The Group classifies its financial liabilities into the
kategori: following categories:
(i) Liabilitas keuangan yang diukur pada nilai (i) Financial liabilities at fair value through
wajar melalui laporan laba rugi profit or loss
Liabilitas keuangan yang diukur pada nilai wajar Financial liabilities at fair value through profit
melalui laporan laba rugi adalah liabilitas or loss are financial liabilities classified as held
keuangan yang diperdagangkan. for trading.
Liabilitas keuangan diklasifikasikan sebagai A financial liability is classified as held for
liabilitas keuangan yang diperdagangkan jika trading if it is acquired principally for the
perolehannya ditujukan untuk dijual atau dibeli purpose of selling or repurchasing it in the
kembali dalam waktu dekat dan terdapat short-term and there is evidence of a recent
adanya kecenderungan ambil untung. actual pattern of profit taking.
Page 219
Laporan Keuangan
Financial Report 219
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/25 Exhibit E/25
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
k. Aset dan Liabilitas Keuangan (Lanjutan) k. Financial Assets and Liabilities (Continued)
Liabilitas Keuangan (Lanjutan) Financial Liabilities (Continued)
Grup mengklasifikasi liabilitas keuangannya dalam The Group classifies its financial liabilities into the
kategori: (Lanjutan) following categories: (Continued)
(ii) Liabilitas keuangan yang diukur dengan biaya (ii) Financial liabilities measured at amortized
perolehan diamortisasi cost
Liabilitas keuangan yang tidak diklasifikasikan Financial liabilities that are not classified
sebagai liabilitas keuangan yang diukur pada as at fair value through profit and loss fall
nilai wajar melalui laporan laba rugi into this category and are measured
diklasifikasikan dalam kategori ini dan diukur at amortized cost. Financial liabilities
pada biaya perolehan diamortisasi. Liabilitas measured at amortized cost are trade and
keuangan yang termasuk adalah utang usaha dan other payables, accruals, bank loans,
lain-lain, beban akrual, utang bank, liabilitas lease liabilities and convertible bonds
sewa dan utang obligasi konversi. payable.
Saling Hapus Instrumen Keuangan Offsetting Financial Instruments
Aset keuangan dan liabilitas keuangan disaling- Financial assets and liabilities are offset and the net
hapuskan dan jumlah netonya dilaporkan pada amount is reported in the financial position when
laporan posisi keuangan ketika terdapat hak yang there is a legally enforceable right to offset the
berkekuatan hukum untuk melakukan saling hapus recognised amounts and there is an intention to
atas jumlah yang telah diakui tersebut dan adanya settle on a net basis, or realize the assets and settle
niat untuk merealisasikan aset dan menyelesaikan the liability simultaneously.
liabilitas secara simultan.
l. Investasi pada Entitas Asosiasi l. Investment in Associate
Investasi Grup pada saham diukur dengan metode Group’s investment in associate is accounted
ekuitas. Entitas asosiasi adalah entitas yang for using the equity method. An associate is
terhadapnya Grup memiliki pengaruh signifikan. an entity over which Group has significant
Pengaruh signifikan adalah kekuasaan untuk influence. Significant influence is the power to
berpartisipasi dalam keputusan kebijakan keuangan participate in the financial and operating
dan operasional investee, tetapi tidak policy decision of the investee, but is not control
mengendalikan atau mengendalikan bersama atas or joint control over those policies.
kebijakan tersebut.
Dalam metode ini, penyertaan awal dicatat sebesar Under this method, the investment in an associate
harga perolehannya yang disesuaikan dengan bagian or a joint venture is initially recognised at cost, and
Grup atas aset bersih entitas asosiasi sejak tanggal adjusted to recognize changes in Group’s share of
akuisisi. net assets of the associates.
Page 220
220 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/26 Exhibit E/26
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
m. Penurunan Nilai Aset Non-Keuangan (tidak m. Impairment of Non-Financial Assets (excluding
termasuk persediaan dan aset pajak tangguhan) inventories and deferred tax assets)
Pengujian penurunan nilai aset non-keuangan Impairment tests on non-financial assets with
dengan menggunakan masa manfaat ekonomi tidak indefinite useful economic life are undertaken
terbatas dilakukan setiap tahun pada akhir periode annually at the financial year end. Other non-
pelaporan keuangan. Aset non-keuangan lain financial assets are subject to impairment tests
dikenakan uji penurunan nilai ketika telah terjadi whenever events or changes in circumstances
atau ada perubahan dalam keadaan yang indicate that their carrying amount may not be
mengindikasikan bahwa nilai tercatat tidak recoverable. Where the carrying value of an asset
terpulihkan. Apabila nilai tercatat aset melebihi exceeds its recoverable amount (i.e. the higher of
jumlah terpulihkan (yaitu mana yang lebih tinggi value in use and fair value less costs to sell), the
antara nilai pakai dan nilai wajar dikurangi biaya asset is written down accordingly.
untuk menjual), maka aset tersebut diturunkan
nilainya.
Apabila tidak mungkin untuk mengestimasi nilai Where it is not possible to estimate the recoverable
terpulihkan dari aset, maka uji penurunan nilai amount of an individual asset, the impairment test
dilakukan pada kelompok terkecil aset dimana aset is carried out on the smallest group of assets to
tersebut merupakan bagian dari kelompok tersebut which it belongs for which there are separately
yang arus kas nya dapat diidentifikasi secara identifiable cash flows; its cash generating units
terpisah; yakni unit penghasil kas. ('CGUs').
Beban penurunan nilai termasuk dalam laba rugi, Impairment charges are included in profit or loss,
kecuali jika beban tersebut membalikkan except to the extent they reverse gains previously
keuntungan yang diakui sebelumnya dalam recognized in other comprehensive income.
penghasilan komprehensif lain.
n. Utang Usaha dan Lain-lain n. Trade and Other Payables
Utang usaha dan lain-lain pada awalnya diakui Trade and other payables are initially recognised at
sebesar nilai wajar dan selanjutnya diukur pada fair value and subsequently measured at amortized
biaya perolehan diamortisasi dengan menggunakan cost using the effective interest method.
metode bunga efektif.
o. Provisi o. Provisions
Provisi diakui apabila Grup mempunyai kewajiban Provisions are recognised when Group have a
hukum atau konstruktif di masa kini sebagai akibat present legal or constructive obligation as a result
dari kejadian di masa lalu; dan besar kemungkinan of past events; it is probable that the outflow of
Grup diharuskan menyelesaikan kewajiban tersebut resources will be required to settle the obligation
dapat diestimasi secara handal. Provisi tidak diakui and the amount can’t be estimated reliably.
untuk kerugian operasi masa depan. Provisions are not recognised for future operating
losses.
Provisi diukur sebesar nilai kini pengeluaran yang Provisions are measured at the present value of the
diharapkan diperlukan untuk menyelesaikan expenditures expected to be required to settle the
kewajiban dengan menggunakan tingkat bunga obligation using a pre-tax rate that reflects current
sebelum pajak yang mencerminkan penilaian pasar market assessments of the time value of money and
atas nilai waktu uang dan risiko yang terkait dengan the risks specific to the obligation. The increase in
kewajiban. Peningkatan provisi karena berjalannya the provision due to the passage of time is
waktu diakui sebagai biaya keuangan. recognised as an interest expense.
Page 221
Laporan Keuangan
Financial Report 221
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/27 Exhibit E/27
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
p. Perpajakan p. Taxation
Pajak Kini dan Pajak Tangguhan Current Tax and Deferred Tax
Beban pajak penghasilan terdiri dari pajak Income tax expenses comprises current and deferred
penghasilan kini dan pajak tangguhan. Pajak diakui income tax. Tax are recognised in the consolidated
dalam laporan laba rugi dan penghasilan statement of profit or loss and other comprehensive
komprehensif lain konsolidasian, kecuali jika pajak income, except to the extent that it relates to item
tersebut terkait dengan transaksi atau kejadian yang recognised in other comprehensive income or
diakui di pendapatan komprehensif lain atau directly in equity.
langsung diakui ke ekuitas.
Beban pajak kini ditentukan berdasarkan laba kena Current tax expense is determined based on the
pajak dalam tahun yang bersangkutan yang dihitung taxable profit for the year, using the tax rates and
berdasarkan tarif pajak dan undang-undang pajak tax laws that have been enacted or substantially
yang berlaku pada tanggal pelaporan. Aset dan enacted at the reporting date. Current tax assets
liabilitas pajak kini diukur sebesar nilai yang and liabilities are measured at the amount expected
diharapkan dapat terpulihkan atau dibayar. to be recovered or paid.
Aset dan liabilitas pajak tangguhan diakui atas Deferred tax assets and liabilities are recognised as
konsekuensi pajak periode mendatang yang timbul a future period tax consequences resulting from
dari perbedaan jumlah tercatat aset dan liabilitas differences of carrying value between assets and
menurut laporan keuangan dengan dasar pengenaan liabilities based on the financial statements with
pajak aset dan liabilitas. Liabilitas pajak tangguhan tax base of assets and liabilities. Deferred tax
diakui untuk semua perbedaan temporer kena pajak liabilities are recognised for all taxable temporary
dan aset pajak tangguhan diakui untuk perbedaan differences and deferred tax assets are recognised
yang boleh dikurangkan, sepanjang besar for deductible differences, when it is probable to be
kemungkinan dapat dimanfaatkan untuk mengurangi used against future taxable income.
laba kena pajak pada masa mendatang.
Pajak tangguhan diukur dengan menggunakan tarif Deferred tax is calculated at the tax rates that have
pajak yang berlaku atau secara substansial telah been enacted or substantially enacted at the
berlaku pada tanggal pelaporan. Pajak tangguhan reporting date. Deferred tax is charged or credited
dibebankan atau dikreditkan dalam laporan laba rugi to the current year’s consolidated statements of
dan penghasilan komprehensif lain konsolidasian profit or loss and other comprehensive income,
tahun berjalan kecuali pajak tangguhan yang except deferred tax which is charged or credited
dibebankan atau dikreditkan langsung ke ekuitas. directly to equity.
Jumlah tercatat aset pajak tangguhan dikaji ulang The carrying amount of deferred tax asset is
pada akhir periode pelaporan dan dikurangi jumlah reviewed at the end of each reporting period and
tercatatnya jika kemungkinan besar laba kena pajak reduced to the extent that it is no longer probable
tidak lagi tersedia dalam jumlah yang memadai that sufficient taxable profits will be available to
untuk mengkompensasikan sebagian atau seluruh allow all or part of the asset to be recovered.
aset pajak tangguhan tersebut.
Peraturan pajak di Indonesia mengatur beberapa Tax regulation in Indonesia determined that certain
jenis penghasilan yang dikenakan pajak yang bersifat taxable income is subject to final tax. Final tax
final. Pajak final yang dikenakan atas nilai bruto applied to the gross value of transactions is applied
transaksi tetap dikenakan walaupun atas transaksi even when the parties carrying the transaction
tersebut pelaku transaksi mengalami kerugian. recognising losses.
Pajak Final Final Tax
Mengacu pada revisi PSAK 212, pajak final tersebut Referring to revised PSAK 212, final tax is no longer
tidak termasuk dalam lingkup yang diatur oleh PSAK governed by PSAK 212. Therefore, the Group has
212. Oleh karena itu, Grup meyajikan beban pajak decided to present all of the final tax arising from
final sehubungan dengan penghasilan yang menjadi revenues subject to final tax as part of operating
obyek pajak final sebagai bagian dari beban usaha. expenses.
Page 222
222 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/28 Exhibit E/28
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
q. Pinjaman q. L o a n s
Pada saat pengakuan awal, pinjaman diakui sebesar Loans are recognised initially at fair value, net of
nilai wajar, dikurangi dengan biaya-biaya transaksi transaction cost incurred. Borrowings are
yang terjadi. Selanjutnya, pinjaman diukur pada subsequently carried at amortised cost.
biaya perolehan diamortisasi.
Pinjaman diklasifikasikan sebagai liabilitas jangka Loans are classified as short-term liabilities unless
pendek kecuali Grup memiliki hak tanpa syarat untuk the Group has the unconditional right to defer
menunda pembayaran liabilitas selama lebih dari payment of liability for more than 12 months after
12 bulan setelah tanggal pelaporan. the date of reporting.
Biaya pinjaman yang dapat diatribusikan secara Borrowing costs that may be directly attributable to
langsung dengan akuisisi atau konstruksi aset the acquisition or construction of a qualifying asset,
kualifikasian (“qualifying asset”), dikapitalisasi are capitalized until the asset is substantially
hingga aset tersebut selesai secara substansial. completed.
r. S e w a r. L e a s e
Grup mengadopdsi dan menerapkan PSAK 116 yang Group has adopted and applied PSAK 116, whereas
mengklasifikasikan pengakuan liabilitas sewa yang set the classification of the recognition of lease
sebelumnya diklasifikasikan sebagai “sewa liabilities in relation to leases which previously was
pembiayaan”. been classified as “consumer financing lease”.
Sebagai Lessee As Lessee
Sebagai penyewa, pada saat dimulainya kontrak, As lessee, at inception of a contract, the Group
Grup menilai apakah kontrak merupakan atau identified whether the contract is or consists a
mengandung sewa. Suatu kontrak merupakan atau lease. A contract is or consist a lease if the contract
mengandung sewa jika kontrak tersebut memberikan provides right to contract the uses of an identified
hak untuk mengendalikan penggunaan aset assets for a period of time in exchange for
identifikasian selama suatu jangka waktu untuk compensation.
dipertukarkan dengan imbalan.
Dalam menilai suatu kontrak memberikan hak In identify a contract provides right to control the
pengendalian penggunaan aset identifikasian, Grup use of an identified assets, the Group assess certain
menilai kondisi berikut: condition:
a. Grup memiliki hak untuk memperoleh seluruh a. Group has rights to substandially obtain all
manfaat ekonomi secara substansial dari economic benefits from the use of the asset
penggunaan aset identifikasian; dan within the period of use; and
b. Grup memiliki hak untuk menentukan b. Group has right to decide the use of an
penggunaan aset identifikasian, yang diperoleh identfdied asset, derived from relevants right to
melalui pengambilan keputusan yang relevan decision-making on how and the purpose of use
atas bagaimana dan tujuan penggunaan aset yang of assets which has determined.
telah ditentukan sebelumnya.
Page 223
Laporan Keuangan
Financial Report 223
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/29 Exhibit E/29
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
r. S e w a (Lanjutan) r. L e a s e (Continued)
Sebagai Lessee (Lanjutan) As Lessee (Continued)
Pada tanggal permulaan atau pada saat penilaian On inception or a reassessment of a contract
kembali kontrak yang mengandung sewa, Grup consisting lease component, Group allocates the
mengalokasikan imbalan dalam kontrak ke masing- compensation in the contract to each component of
masing komponen sewa berdasarkan harga relatif lease based on its own relative price of the
tersendiri dari komponen sewa dan harga agregat component of lease and the its own aggregate
tersendiri dari komponen non-sewa. pricing of component of non-lease.
Pada tanggal permulaan sewa, Grup mengakui aset At commencement lease date, Group recognize
hak-guna dan liabilitas sewa. Aset hak-guna diukur right-of-use assets and a lease liability. Right-of-use
pada biaya perolehan, dimana meliputi jumlah assets are initially measured at cost, which
pengukuran awal liabilitas sewa yang disesuaikan comprises the initial amount of the lease liability
dengan pembayaran sewa yang dilakukan pada atau adjusted for any lease payment made at or before
sebelum tanggal dimulainya sewa. the commencement date.
Aset hak-guna disusutkan menggunakan metode Right-of-use assets are depreciated using the
garis lurus dari tanggal permulaan hingga tanggal straight-line method from the commencement date
yang lebih awal antara akhir umur manfaat aset hak- to the earlier of the end of useful life of the right-
guna atau akhir masa sewa. of-use asset or at the end of lease term.
Liabilitas sewa diukur pada nilai kini pembayaran Lease liability initially measured at the present
sewa yang belum dibayar pada tanggal permulaan, value of the lease payments that are not paid at the
didiskontokan dengan menggunakan suku bunga commencement date, and discounted using the
implisit dalam sewa atau jika suku bunga tersebut interest rate implicit in the lease, or if the rate
tidak dapat ditentukan, maka penggunaan suku connot be readily determined, using incremental
bunga pinjaman inkremental. Pada umumnya, Grup borrowing rate. Generally, Group uses its
menggunakan suku bunga pinjaman inkremental incremental borrowing rate as the discount rate.
sebagai tingkat suku bunga diskonto.
Sebagai penyewa, pembayaran sewa yang termasuk As lessee, lease payment includes in the
dalam pengukuran liabilitas sewa meliputi measurement of the lease liability comprise fixed
pembayaran tetap termasuk pembayaran tetap payment including in substance fixed payments,
secara substansi, pembayaran variabel yang variable lease payments that depend on an index or
tergantung pada indeks atau suku bunga pada a rate at the commencement date, amounts
tanggal permulaan, jumlah yang diperkirakan dapat expected to be payable under a residual value
dibayarkan oleh penyewa dengan jaminan nilai guarantee, the exercise price under a purchase
residual, harga eksekusi opsi beli jika terdapat option with reasonabley certain to exercise, and
kepastian eksekusi opsi tersebut, dan penalti karena penalty on early termination of a lease unless
penghentian awal sewa kecuali terdapat cukup reasonably certain not to early terminate.
kepastian untuk tidak ada penghentian lebih awal.
Pembayaran sewa dialokasikan menjadi bagian Each lease payment is allocated between the
pokok dan biaya keuangan. Biaya keuangan liability and finance cost. The finance cost is charge
dibebankan pada laba rugi selama periode sewa to profit or loss over the lease period so as to
sehingga menghasilkan tingkat suku bunga periodik produce a constant periodic rate of interest on the
yang konstan atas saldo liabilitas untuk setiap remaining balance of the liability for each period.
periode.
Page 224
224 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/30 Exhibit E/30
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
r. S e w a (Lanjutan) r. L e a s e (Continued)
Sebagai Lessee (Lanjutan) As Lessee (Continued)
Jika sewa mengalihkan kepemilikan aset pendasar If the lease transfers ownership of the underlying
kepada Grup pada akhir masa sewa atau jika asset to the Group at the end of the lease term or
biaya perolehan aset hak-guna merefleksikan Grup if the cost of the right-of-use assets reflects that
akan mengeksekusi opsi beli, maka Grup melakukan the Group will exercise a purchase option, the
penyusutan aset hak-guna dari tanggal permulaan Group will depreciate from the commencement date
hingga akhir umur manfaat aset pendasar. Jika to the end of the useful life of the underlying asset.
tidak, maka Grup melakukan penyusutan aset hak- Otherwise, the Group depreciates the right-of-use
guna dari tanggal permulaan hingga tanggal yang assets from the commencement date to the earlier
lebih awal antara akhir umur manfaat aset hak-guna of the end of useful life of the right-use-assets or
atau akhir masa sewa. the end of lease term.
Grup tidak mengakui aset hak-guna dan liabilitas The Group has not to recognize right-of-use assets
sewa untuk sewa jangka pendek yang masa sewa and lease liabilities for short-term leases that have
terdiri dari 12 bulan atau kurang, yang dicatat a lease term of 12 months or less, and recorded as
sebagai sewa dimuka dan dibebankan dengan dasar prepayment lease and amortised over the lease-
garis lurus selama periode sewa. term use a straight-line basis.
Sebagai Lessor As Lessor
Sebagai pesewa, apabila aset disewakan melalui As lessor, when assets are leased out under a finance
sewa pembiayaan, nilai kini pembayaran sewa diakui lease, the present value of the lease payments is
sebagai piutang. Selisih antara nilai piutang bruto recognised as receivable. The difference between
dan nilai kini piutang tersebut diakui sebagai the gross receivables and the present value of the
penghasilan sewa pembiayaan ditangguhkan. receivable is recognised as unearned finance lease
income.
Penghasilan sewa diakui selama masa sewa dengan Lease income is recognised over the term of the
menggunakan metode investasi neto yang lease using the net investment method which reflect
mencerminkan tingkat pengembalian periodik yang a constant periodic rate of return.
konstan.
Apabila aset disewakan melalui sewa operasi, aset When assets are leased out under an operating
disajikan pada laporan posisi keuangan sesuai sifat lease, the assets are presented in the statement of
aset tersebut. Penghasilan sewa diakui sebagai financial position based on the nature of asset.
pendapatan dengan dasar garis lurus selama masa Lease income is recognised over the term of the
sewa. lease on a straight-line basis.
s. Imbalan Pasca-Kerja s. Post-Employment Benefits
Imbalan kerja jangka pendek Short-term employee benefits
Imbalan kerja jangka pendek diakui pada saat Short-term employee benefits which are recognised
terutang kepada karyawan berdasarkan metode when they accrue to the employees.
akrual.
Imbalan pensiun dan imbalan pasca-kerja lainnya Pension benefits and other post-employment
benefits
Grup mengakui imbalan kerja jangka pendek The Group recognised an unfunded employee
berdasarkan metode akrual sesuai dengan Undang- benefits liability in accordance with Omnibus Law
Undang Cipta Kerja No. 11/2020 tanggal No. 11/2020 dated 5 October 2020 and the related
5 Oktober 2020 dan peraturan turunannya. regulations.
Page 225
Laporan Keuangan
Financial Report 225
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/31 Exhibit E/31
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
s. Imbalan Pasca-Kerja (Lanjutan) s. Post-Employment Benefits (Continued)
Imbalan pensiun dan imbalan pasca-kerja lainnya Pension benefits and other post-employment
(Lanjutan) benefits (Continued)
Liabilitas imbalan pasca-kerja merupakan nilai kini The pension post-employment benefits is the
imbalan pasca-kerja pada tanggal pelaporan dan present value of the post-employment benefits at
penyesuaian atas keuntungan atau kerugian the reporting date together with adjustments for
aktuarial. Perhitungan liabilitas imbalan pasca-kerja actuarial gain or losses. The cost of providing post-
menggunakan metode Projected Unit Credit oleh employment benefits obligation is determined using
aktuaris independen. the Projected Unit Credit method by an independent
actuary.
Nilai kini imbalan pasca-kerja ditentukan dengan The present value of the post-employment benefits
mendiskontokan estimasi arus kas di masa depan is determined by discounting the estimated future
dengan menggunakan tingkat bunga obligasi cash outflows using the yield at the reporting date
pemerintah jangka panjang pada tanggal pelaporan of long-term government bonds and that have terms
dan memiliki jangka waktu yang sama dengan to maturity similar to the related pension
liabilitas imbalan pensiun yang bersangkutan. obligation.
Keuntungan atau kerugian aktuaria yang timbul dari Actuarial gains or losses arising from experience
penyesuaian dan perubahan dalam asumsi-asumsi adjustment and changes in actuarial assumptions
aktuarial yang jumlahnya dibebankan atau are charged or credited to equity in other
dikreditkan di penghasilan komprehensif lainnya comprehensive income in the period in which they
sebesar nilai yang timbul pada periode tersebut. arise.
Biaya jasa lalu akan diakui segera dalam laporan laba The past service costs are recognised immediately in
rugi dan penghasilan komprehensif lainnya. statement of profit or loss and other comprehensive
income.
Keuntungan dan kerugian dari kurtailmen atau Gains or losses on the curtailment or settlement of
penyelesaian imbalan pasca-kerja diakui ketika the post-employment benefits are recognised when
kurtailmen atau penyelesaian tersebut terjadi. the curtailment or settlement occurs.
Grup memberikan imbalan pasca-kerja lainnya, The Group also provides other post-employment
seperti uang penghargaan dan uang pisah. Imbalan benefits, such as service pay and separation pay.
berupa uang penghargaan diberikan apabila The service pay benefit vests when the employees
karyawan bekerja hingga mencapai usia pensiun. reach their retirement age. The separation pay
Sedangkan imbalan berupa uang pisah, dibayarkan benefit is paid to employees in the case of voluntary
kepada karyawan yang mengundurkan diri secara resignation, subject to a minimum number of years
sukarela, setelah memenuhi minimal masa kerja of services. These benefits have been accounted for
tertentu. Imbalan ini dihitung dengan menggunakan using the same methodolody to compute post-
metodologi yang sama dengan metodologi yang employment benefits pension plan.
digunakan dalam perhitungan pensiun imbalan
pasca-kerja.
t. Modal Saham t. Share Capital
Modal saham diukur sebesar nilai nominal untuk Share capital is measured at par value for all shares
semua saham yang ditempatkan dan beredar. issued and outstanding.
Biaya tambahan langsung yang berkaitan dengan Incremental costs directly attributable to the
penerbitan saham baru disajikan pada ekuitas issuance of new shares are shown in equity as a
sebagai pengurang, neto setelah pajak, dari jumlah deduction, net of tax, from the proceeds. Any
yang diterima. Selisih lebih antara jumlah yang excess of the proceeds over the par value arising
diterima dengan nilai nominal yang timbul dari from the issuance of shares of stock is credited to
penerbitan saham dikreditkan ke tambahan modal capital paid in exces of par value in the equity.
disetor pada ekuitas.
Page 226
226 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/32 Exhibit E/32
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
u. Laba ditahan u. Retained earnings
Laba ditahan merupakan akumulasi laba atau rugi Retained earnings represent the accumulated net
bersih, setelah dikurangi pembagian dividen dan income or losses, net of any dividend distributions
penyesuaian modal lainnya. Jika akun laba ditahan and other capital adjustments. When the retained
memiliki saldo debit, hal itu disebut "defisit". Defisit earnings account has a debit balance, it is called
bukanlah aset tetapi pengurangan ekuitas. “deficit.” A deficit is not an asset but a deduction
from equity
v. Dividen v. Dividend
Pembagian dividen kepada para pemegang saham The distribution of final dividends to shareholders,
diakui sebagai suatu liabilitas dalam laporan dividends are recognised as liabilities when
keuangan konsolidasian pada periode ketika dividen dividends are approved by stockholders.
tersebut disetujui oleh para pemegang saham. The distribution of dividends to stockholders is
Pembagian dividen diakui sebagai liabilitas ketika recognised as liability when dividends are approved
dividen disetujui bedasarkan rapat direksi sesuai based on the Board of Directors' resolutions refer to
dengan anggaran dasar Grup. articles of association of the Group.
w. Laba per Saham Dasar w. Basic Earnings per Share
Laba per saham dasar dihitung dengan membagi laba Basic earnings per share is computed by dividing
periode berjalan yang dapat diatribusikan kepada profit for the period attributable to equity holders
pemilik dengan rata-rata tertimbang jumlah saham by the weighted average number of outstanding
beredar dalam periode yang bersangkutan. share during the period.
x. Pengakuan Pendapatan dan Beban x. Revenue and Expenses Recognition
Group mengadopsi PSAK 115 yang memperkenalkan The Group adopted PSAK 115, which introduces a
kerangka baru berupa lima-tahapan model untuk new five-step model framework for determining
menentukan bagaimana, berapa dan kapan whether, how much and when the revenue is
pendapatan diakui, sebagai berikut: recognised, as follows:
1. Mengidentifikasi kontrak dengan pelanggan 1. Identify contracts with customers.
2. Mengidentifikasi kewajiban pelaksanaan dalam 2. Identify the performance obligation, in the
kontrak, untuk menyerahkan barang atau jasa contract, to transfer to customer goods or
yang memiliki karakteristik berbeda ke services that are distinct.
pelanggan.
3. Menentukan hanya transaksi, setelah dikurangi 3. Determine the transaction price, net of
diskon, retur, insentif penjualan dan pajak discoutns, returns, sales inventices, and value
pertambahan nilai yang berhak diperoleh suatu added tax, which an entity expects to be
entitas sebagai kompensasi atas diserahkannya entitled to exchange for transferring promised
barang atau jasa yang dijanjikan kepada goods or services to a customer.
pelanggan.
4. Mengalokasi harga transaksi setiap kewajiban 4. Allocate the transaction price to each
pelaksanaan dengan menggunakan dasar harga performace obligation on the basis of the selling
jual dari setiap barang atau jasa yang dijanjikan prices of each goods or services promised in the
di kontrak. contract.
5. Pengakuan pendapatan ketika kewajiban 5. Recognise revenue when performance obligation
pelaksanaan telah dipenuhi ketika barang atau is satisfied by transferring a promised good or
jasa yang dijanjikan diserahkan kepada service to a customer.
pelanggan.
Pendapatan diakui bila besar kemungkinan manfaat Revenue is recognised to the extent that is probable
ekonomi akan diperoleh Grup dan jumlahnya dapat that the economic benefits will flow to the Group
diukur secara andal. and the revenue can be reliably measured.
Page 227
Laporan Keuangan
Financial Report 227
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/33 Exhibit E/33
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
x. Pengakuan Pendapatan dan Beban (Lanjutan) x. Revenue and Expenses Recognition (Continued)
Pendapatan dari penjualan obat dan perlengkapan Revenue from sale of drugs and medical supplies is
medis diakui pada saat barang diserahkan kepada recognised when they are delivered to the patient.
pasien. Pendapatan layanan penunjang medis diakui Revenue from medical support service is recognised
pada saat jasa telah diberikan. Pendapatan kamar when the service is rendered. Revenue from
rawat inap, kamar operasi dan bersalin diakui pada inpatient room, operating and delivery room is
saat kamar digunakan dan pendapatan jasa tenaga recognised when the room is used and revenue from
ahli diakui pada saat jasa diberikan sesuai dengan professional fee's is recognised when the service is
bagian yang menjadi hak Grup. rendered in accordance with portion of the Group's
entitlements.
Uang muka pasien merupakan pembayaran diterima Advance from patients represents payments
di muka dari pasien yang akan diperhitungkan received from patient which will be accounted with
dengan penggunaan obat dan perlengkapan medis the usage of drugs and medical supplies and services
dan jasa yang akan dibebankan kepada pasien yang that will be charged to the related patient.
bersangkutan.
Beban pokok dan beban operasi yang manfaat Costs and expenses are decreases in economic
ekonominya menurun selama periode akuntansi benefits during the accounting period in the form of
dalam bentuk pengeluaran atau penurunan aset atau outflows or decrease of assets or incurrence of
timbulnya liabilitas yang menghasilkan penurunan liabilities that result in decrease in equity, other
ekuitas, selain yang berkaitan dengan distribusi than those relating to distribution to equity
kepada pemegang saham. Biaya dan beban diakui participants. Costs and expenses are recognised
pada saat terjadinya (dasar akrual). when incurred (accrual basis).
y. Klasifikasi Lancar versus Tidak Lancar y. Current versus non-current classification
Grup menyajikan aset dan liabilitas dalam laporan The Group present assets and liabilities in the
posisi keuangan konsolidasian berdasarkan klasifikasi statement of financial position based on
lancar/tak lancar. Suatu aset disajikan lancar bila: current/non-current classification. An asset is
current when it is:
● akan direalisasi, dijual atau dikonsumsi ● expected to be realised or intended to be sold
dalam siklus operasi normal, or consumed in the normal operating cycle,
● untuk diperdagangkan, ● held primarily for the purpose of trading
● akan direalisasi dalam 12 bulan setelah ● expected to be realised within 12 months after
tanggal pelaporan, atau kas atau setara kas the reporting period, or cash or cash equivalent
kecuali yang dibatasi penggunaannya atau akan unless restricted from being exchanged or used
digunakan untuk melunasi suatu liabilitas to settle a liability for at least 12 months after
dalam paling lambat 12 bulan setelah tanggal the reporting period.
pelaporan.
Seluruh aset lain diklasifikasikan sebagai tidak All other assets are classified as non-current.
lancar.
Suatu liabilitas disajikan lancar bila: A liability is current when it is:
● akan dilunasi dalam siklus operasi normal, ● expected to be settled in the normal
operating cycle,
● untuk diperdagangkan, ● held primarily for the purpose of trading,
● akan dilunasi dalam 12 bulan setelah tanggal ● due to be settled within 12 months after the
pelaporan, atau reporting period, or
● tidak ada hak tanpa syarat untuk ● there is no unconditional right to defer the
menangguhkan pelunasannya dalam paling settlement of the liability for at least 12
tidak 12 bulan setelah tanggal pelaporan. months after the reporting period.
Seluruh liabilitas lain diklasifikasikan sebagai tidak All other liabilities are classified as non-current.
lancar.
Page 228
228 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/34 Exhibit E/34
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
z. Klasifikasi instrumen keuangan antara utang dan z. Classification of financial instruments between
ekuitas debt and equity
Aset dan liabilitas pajak tangguhan diklasifikasikan Deferred tax assets and liabilities are classified as
sebagai aset dan liabilitas tidak lancar. non-current assets and liabilities.
Dari perspektif penerbit, instrumen keuangan From the perspective of the issuer, a financial
diklasifikasikan sebagai instrumen utang jika instrument is classified as debt instrument if it
terdapat kewajiban kontraktual untuk: provides for a contractual obligation to:
● menyerahkan uang tunai atau aset keuangan ● deliver cash or another financial asset to
lainnya ke entitas lain; another entity;
● menukar aset keuangan atau liabilitas keuangan ● exchange financial assets or financial liabilities
dengan entitas lain dalam kondisi yang with another entity under conditions that are
berpotensi tidak menguntungkan bagi Grup; potentially unfavorable to the Group; or
atau
● memenuhi kewajiban selain dengan menukar ● satisfy the obligation other than by the
sejumlah uang tunai atau aset keuangan lain exchange of a fixed amount of cash or another
dengan jumlah tetap saham ekuitas sendiri. financial asset for a fixed number of own equity
shares.
Jika Grup tidak memiliki hak tanpa syarat untuk If the Group do not have an unconditional right to
menghindari pengiriman kas atau aset keuangan lain avoid delivering cash or another financial asset to
untuk menyelesaikan kewajiban kontraktualnya, settle its contractual obligation, the obligation
kewajiban tersebut memenuhi definisi liabilitas meets the definition of a financial liability.
keuangan.
aa. Informasi Segmen aa. Segment Information
Segmen operasi dilaporkan dengan cara yang Operating segments are reported in a manner
konsisten dengan pelaporan internal yang diberikan consistent with the internal reporting provided to
kepada pengambil keputusan operasional. chief operating decision-maker. The Chief operating
Pengambil keputusan operasional bertanggung decision-maker is responsible for allocating
jawab untuk mengalokasikan sumber daya, menilai resources, assessing performance of the operating
kinerja segmen operasi dan membuat keputusan segments and making strategic decisions.
strategis.
Pendapatan, beban, hasil, aset dan liabilitas segmen Revenues, expenses, results, assets and liabilities of
termasuk item-item yang dapat diatribusikan segments include items directly attributable to a
langsung kepada suatu segmen serta item-item yang segment as well as items that can be allocated on a
dapat dialokasikan dengan dasar yang sesuai dengan reasonable basis to the segment. Segment is
segmen tersebut. Segmen ditentukan sebelum saldo determined before inter-company balances and
dan transaksi antar perusahaan dieliminasi sebagai transactions are eliminated as part of the
bagian dari proses konsolidasi. consolidation process.
ab. Peristiwa Setelah Tanggal Pelaporan ab. Events after Reporting Period
Peristiwa setelah tanggal pelaporan yang Post year-end events that provide additional
mempengaruhi laporan keuangan konsolidasian Grup information about the Group’s position at end of
di tanggal pelaporan (adjusting events) disajikan reporting period (adjusting events) are reflected in
pada laporan keuangan. Peristiwa setelah tanggal the consolidated financial statements. Post year-
pelaporan yang tidak mempengaruhi laporan end events that are not adjusting events are
keuangan konsolidasian (non adjusting events) Grup disclosed in the notes to consolidated financial
di tanggal pelaporan disajikan pada catatan atas statements when material.
laporan keuangan konsolidasian.
Page 229
Laporan Keuangan
Financial Report 229
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/35 Exhibit E/35
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
2. IKHTISAR KEBIJAKAN AKUNTANSI YANG MATERIAL 2. SUMMARY OF MATERIAL ACCOUNTING POLICIES
(Lanjutan) (Continued)
ac. Pengukuran nilai wajar ac. Fair value measurements
Nilai wajar adalah harga yang akan diterima untuk Fair value is the price that would be received to sell
menjual aset atau dibayarkan untuk mengalihkan an asset or paid to transfer a liability in an orderly
liabilitas dalam transaksi teratur antara pelaku pasar transaction between market participants at the
pada tanggal pengukuran. Pengukuran nilai wajar measurement date. The fair value measurement is
didasarkan pada asumsi bahwa transaksi untuk based on the presumption that the transaction to
menjual aset atau mengalihkan liabilitas terjadi baik sell the asset or transfer the liability takes place
di pasar utama aset atau liabilitas, atau jika tidak either in the principal market for the asset or
ada pasar utama, paling banyak. liability, or in the absence of a principal market, in
the most advantageous market for the asset or
liability.
Nilai wajar dari aktiva atau kewajiban diukur dengan The fair value of an asset or liability is measured
menggunakan asumsi bahwa pelaku pasar akan using the assumptions that market participants
menggunakan ketika harga aset atau kewajiban, would use when pricing the asset or liability,
dengan asumsi bahwa pelaku pasar bertindak dalam assuming that market participants act in their best
kepentingan ekonomi terbaik mereka. economic interest.
Perusahaan dan entitas anak menggunakan teknik The Company and its subsidiaries use valuation
penilaian yang sesuai dengan keadaan dan dimana techniques that are appropriate in the
data yang cukup tersedia untuk mengukur nilai circumstances and for which sufficient data are
wajar, memaksimalkan penggunaan input yang available to measure fair value, maximizing the use
dapat diobservasi yang relevan dan meminimalkan of relevant observable inputs and minimizing the
penggunaan input yang tidak dapat diobservasi. use of unobservable inputs.
Seluruh aset dan liabilitas yang diukur atau All assets and liabilities for which fair value is
diungkapkan nilai wajarnya dalam laporan keuangan measured or disclosed in the consolidated financial
konsolidasian dikategorikan dalam hierarki nilai statements are categorized within the fair value
wajar, yang diuraikan sebagai berikut, berdasarkan hierarchy, described as follows, based on the lowest
input level terendah yang signifikan terhadap level input that is significant to the fair value
pengukuran nilai wajar secara keseluruhan: measurement as a whole:
● Tingkat 1: harga kuotasian (tidak disesuaikan) di ● Level 1: quoted prices (unadjusted) in active
pasar aktif untuk aset atau liabilitas yang markets for identical assets or liabilities;
identik;
● Tingkat 2: input selain harga kuotasian yang ● Level 2: inputs other than quoted prices
termasuk dalam Tingkat 1 yang dapat diobservasi included within Level 1 that are observable for
untuk aset atau liabilitas, baik secara langsung the asset or liability, either directly or
maupun tidak langsung; dan indirectly; and
● Tingkat 3: input untuk aset atau liabilitas yang ● Level 3: inputs for the asset or liability that are
tidak didasarkan pada data pasar yang dapat not based on observable market data.
diobservasi.
Untuk aset dan liabilitas yang diakui dalam laporan For assets and liabilities that are recognized in the
keuangan konsolidasian secara berulang, Perusahaan consolidated financial statements on a recurring
dan Entitas Anak menentukan apakah transfer telah basis, the Company and its subsidiaries determines
terjadi antar level dalam hierarki dengan menilai whether transfers have occurred between levels in
kembali kategorisasi pada setiap akhir periode the hierarchy by re-assessing the categorization at
pelaporan. the end of each reporting period.
Untuk tujuan pengungkapan nilai wajar, Perusahaan For the purpose of fair value disclosures, the
dan Entitas Anak telah menentukan kelas aset dan Company and its subsidiaries has determined classes
liabilitas berdasarkan sifat, karakteristik, dan risiko of assets and liabilities on the basis of the nature,
aset atau liabilitas dan tingkat hierarki nilai wajar. characteristics and risks of the asset or liability and
the level of the fair value hierarchy.
Page 230
230 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/36 Exhibit E/36
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
3. ESTIMASI DAN ASUMSI SIGNIFIKAN 3. SIGNIFICANT ACCOUNTING ESTIMATES AND
ASSUMPTIONS
Penyusunan laporan keuangan konsolidasian Grup The preparation of the Group’s consolidated financial
mengharuskan manajemen untuk membuat estimasi dan statements requires management to make estimates
asumsi yang mempengaruhi jumlah yang dilaporkan dari and assumptions that affect the reported amounts of
pendapatan, beban, aset dan liabilitas, dan revenues, expenses, assets and liabilities, and the
pengungkapan atas liabilitas kontijensi pada akhir disclosure of contingent liabilities at the end of the
periode pelaporan. Ketidakpastian mengenai asumsi dan reporting period. Uncertainty about these assumptions
estimasi tersebut dapat mengakibatkan penyesuaian and estimates could result in outcomes that require
material terhadap nilai tercatat aset dan liabilitas dalam a material adjustment to the carrying amount of the
periode pelaporan berikutnya. asset and liability affected in future periods.
Estimasi dan Asumsi Estimates and Assumptions
Asumsi utama masa depan dan sumber utama estimasi The key assumptions concerning the future and other
ketidakpastian lain pada tanggal pelaporan yang key sources of estimation uncertainty at the reporting
memiliki risiko signifikan bagi penyesuaian yang material date that have a significant risk of causing a material
terhadap nilai tercatat aset dan liabilitas untuk tahun adjustment to the carrying amounts of assets and
berikutnya diungkapkan di bawah ini. liabilities within the next financial year are disclosed
below.
Penyisihan Kerugian Kredit Ekspektasian dan Piutang Allowance for Expected Credit Losses of Trade
Usaha Receivables
Grup menggunakan matriks provisi untuk menghitung Group determines ECL for trade receivables use a
Kerugian Kredit Ekspektasian untuk piutang usaha. Tarif provision matrix. The provision rates are based on days
provisi didasarkan pada hari lewat jatuh tempo untuk past due for grouping of various customer segments
pengelompokkan berbagai segmen pelanggan yang that have similar loss patterns (i.e, by customer type
memiliki pola kerugian yang serupa (yaitu menurut jenis and rating or by product type, and coverage by form of
dan peringkat pelanggan atau jenis produk, dan credit insurance).
pertanggungan kredit lainnya).
Matriks provisi awalnya ditentukan berdasarkan tarif The provision matriks is initially based on the Group’s
default yang diamati secara historis Grup. Grup akan historical observed defaults rates. The Group will
melakukan analisa matriks untuk menyesuaikan calibrate the matrix to adjust the histodical credit loss
pengalaman kerugian kredit historis dengan informasi occurred with forward-looking information, whereas,
berorientasi ke depan, dimana penilaian hubungan the assessment of linked between historical observed
antara tingkat default yang diamati secara historis, default rates, forecast economic conditions and ECL’s is
estimasi kondisi ekonomi dan KKE adalah perkiraan yang significant estimates. The amount of ECL’s is sensitive
signifikan. Jumlah KKE sensitif terhadap perubahan to changes in circumstances and of forecast economic
keadaan dan prakiraan kondisi ekonomi walaupun condition although its may also not represent the
dimungkinkan hal tesebut tidak mewakili default customer’s actual default in future
pelanggan sebenarnya di masa mendatang.
Cadangan Kerugian Penurunan Nilai Persediaan Allowance for Impairment Losses on Inventories
Penyisihan penurunan nilai pasar dan keusangan Allowance for decline in market value and obsolescence
persediaan, jika ada, diestimasi berdasarkan fakta dan of inventories, if any, is estimated based on available
situasi yang tersedia, termasuk namun tidak terbatas facts and circumstances, including but not limited to,
kepada, kondisi fisik persediaan yang dimiliki, harga jual the inventories’ own physical conditions, their market
pasar, estimasi biaya penyelesaian dan estimasi biaya selling prices, estimated costs of completion and
yang timbul untuk penjualan. Provisi dievaluasi kembali estimated costs to be incurred for their sales. The
dan disesuaikan jika terdapat tambahan informasi yang provisions are re-evaluated and adjusted as additional
mempengaruhi jumlah yang diestimasi. Penjelasan lebih information received affects the estimated amount.
rinci diungkapkan dalam Catatan 8. Further details are disclosed in Note 8.
Page 231
Laporan Keuangan
Financial Report 231
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/37 Exhibit E/37
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
3. ESTIMASI DAN ASUMSI SIGNIFIKAN (Lanjutan) 3. SIGNIFICANT ACCOUNTING ESTIMATES AND
ASSUMPTIONS (Continued)
Estimasi dan Asumsi (Lanjutan) Estimates and Assumptions (Continued)
Pajak Tangguhan Deferred Tax
Grup menelaah jumlah tercatat aset pajak tangguhan The Group reviews the carrying amounts of deferred tax
pada setiap akhir tahun keuangan dan mengurangi aset assets at each financial year-end and reduces deferred
pajak tangguhan sejauh tidak lagi dimungkinkan bahwa income tax assets to the extent that it is no longer
laba kena pajak masa depan yang memadai akan probable that sufficient future taxable profits will be
tersedia untuk memungkinkan seluruh atau sebagian available to allow all or part of the deferred income tax
aset pajak penghasilan tangguhan untuk dimanfaatkan. assets to be utilized. Significant management estimates
Estimasi signifikan manajemen diperlukan untuk are required to determine the amount of deferred tax
menentukan jumlah aset pajak tangguhan yang dapat assets that can be recognised, based upon the likely
diakui, berdasarkan kemungkinan waktu dan tingkat laba timing and level of future taxable profits with future
kena pajak masa depan dengan strategi perencanaan tax planning strategies. Further details are disclosed in
pajak masa depan. Rincian lebih lanjut diungkapkan Note 20e.
dalam Catatan 20e.
Penyusutan Aset Tetap Depreciations Property and Equipment
Biaya perolehan aset tetap disusutkan dengan The costs of property and equipment are depreciated
menggunakan metode garis lurus berdasarkan taksiran on a straight-line method over their estimated useful
masa manfaat ekonomisnya. Manajemen mengestimasi lives. Management properly estimates the useful lives
masa manfaat ekonomis aset tetap antara 2 sampai of these property and equipment to be within 2 to 20
dengan 20 tahun. Ini adalah umur yang secara umum years. These are common life expectancies applied in
diharapkan dalam industri dimana Grup menjalankan the industry where the Group conducts its business.
bisnisnya. Perubahan tingkat pemakaian dan Changes in the expected level of usage and
perkembangan teknologi dapat mempengaruhi masa technological development could impact the economic
manfaat ekonomis dan nilai sisa aset, dan karenanya useful lives and the residual values of these assets, and
beban penyusutan masa depan mungkin direvisi. therefore future depreciation charges could be revised.
Penjelasan lebih lanjut diungkapkan dalam Catatan 11. Further details are disclosed in Note 11.
Imbalan Pasca-Kerja Post-Employment Benefits
Penentuan liabilitas imbalan pasca-kerja tergantung The determination of post-employment benefits
pada pemilihan asumsi tertentu yang digunakan oleh liabilities depends on selection of certain assumption
akutaris dalam menghitung jumlah liabilitas tersebut. used by actuary for the calculation of the liability.
Asumsi tersebut termasuk antara lain tingkat diskonto These assumptions include discount rate and rate of
dan kenaikan gaji. Realisasi yang berbeda dari asumsi increase in salaries. Different realization from Group’
Grup diakumulasi dan diamortisasi selama periode assumptions are accumulated and amortized over the
mendatang dan akibatnya akan berpengaruh terhadap future periods and consequently will affect liabilities
jumlah liabilitas yang diakui di masa mendatang. recognised in the future.
Sementara Grup berkeyakinan bahwa asumsi tersebut While the Group believes that its assumptions are
adalah wajar dan sesuai, perbedaan signifikan pada hasil reasonable and appropriate, significant differences in
aktual atau perubahan signifikan dalam asumsi yang the actual results or significant changes in the Group’s
ditetapkan Grup dapat mempengaruhi secara material assumptions may materially affect its estimated
liabilitas diestimasi atas imbalan kerja dan beban employee benefits liability and employee benefits
imbalan kerja. Penjelasan lebih lanjut diungkapkan expense. Further details are disclosed in Note 22.
dalam Catatan 22.
Sewa Leases
Penentuan apakah suatu perjanjian mengandung unsur Determining whether an arrangement is or contains a
sewa membutuhkan pertimbangan yang cermat untuk lease requires careful judgement to assess whether the
menilai apakah perjanjian tersebut memberikan hak arrangement conveys a right to obtain substantially all
untuk mendapatkan secara substantial seluruh manfaat the economic benefits from use of the asset throughout
ekonomi dari penggunaan aset identifikasian dan hak the period of use and right to direct the use of the asset,
untuk mengarahkan menggunakan aset identifikasian, even if the right is not explicitly specified in the
bahkan jika hak tersebut tidak dijabarkan secara arrangement.
eksplisit dalam perjanjian.
Page 232
232 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/38 Exhibit E/38
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
3. PERTIMBANGAN, ESTIMASI DAN ASUMSI SIGNIFIKAN 3. JUDGEMENTS, ESTIMATES AN SIGNIFICANT
(Lanjutan) ASSUMPTIONS (Continued)
Estimasi dan Asumsi (Lanjutan) Estimates and Assumptions (Continued)
Tagihan restitusi pajak Claims for tax refund
Manajemen mempertimbangkan jumlah yang tercatat Management uses judgment that the amounts recorded
pada akun ini dapat dipulihkan dan direstitusi oleh under this account is recoverable and refundable by tax
kantor pajak berdasarkan peraturan pajak yang berlaku. office based on current enacted tax regulation.
Pajak Penghasilan Income Tax
Pertimbangan signifikan dilakukan dalam menentukan Significant judgment is involved in determining the
provisi atas pajak penghasilan badan. Terdapat transaksi provision for corporate income tax. There are certain
dan perhitungan tertentu yang penentuan pajak transactions and computation for which the ultimate
akhirnya adalah tidak pasti dalam kegiatan usaha tax determination is uncertain during the ordinary
normal. Grup mengakui liabilitas atas pajak penghasilan course of business. The Group recognizes liabilities for
badan berdasarkan estimasi apakah akan terdapat expected corporate income tax issues based on
tambahan pajak penghasilan badan. estimates of whether additional corporate income tax
will be due.
4. KAS DAN SETARA KAS 4. CASH AND CASH EQUIVALENTS
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Kas – Rupiah 1.911.294.390 2.655.968.605 Cash on hand – Rupiah
Bank Cash in banks
Rupiah Rupiah
PT Bank Syariah Indonesia Tbk 63.770.180.382 38.396.114.601 PT Bank Syariah Indonesia Tbk
PT Bank Mandiri (Persero) Tbk 62.954.046.234 191.206.300.950 PT Bank Mandiri (Persero) Tbk
PT Bank Rakyat Indonesia (Persero) PT Bank Rakyat Indonesia
Tbk 38.431.412.183 12.756.554.942 (Persero) Tbk
PT Bank Central Asia 34.206.243.088 32.215.109.692 PT Bank Central Asia
PT Bank Negara Indonesia (Persero) PT Bank Negara Indonesia
Tbk 18.177.819.326 10.981.291.718 (Persero) Tbk
PT Bank Capital Indonesia Tbk 11.229.444.457 - PT Bank Capital Indonesia Tbk
PT Bank CIMB Niaga Tbk 3.803.393.548 5.617.292.197 PT Bank CIMB Niaga Tbk
PT Bank China Construction Bank PT Bank China Construction
Indonesia Tbk 1.451.861.589 80.671.006 Bank Indonesia Tbk
PT Bank Mayapada Internasional
PT Bank Mayapada Internasional Tbk 919.855.599 - Tbk
PT Bank Pembangunan Daerah PT Bank Pembangunan Daerah
Sumatera 863.116.468 283.423.500 Sumatera
PT Bank Mega Tbk 552.606.933 416.480.227 PT Bank Mega Tbk
PT Bank Muamalat Indonesia Tbk 454.030.267 455.370.693 PT Bank Muamalat Indonesia Tbk
PT Bank Tabungan Negara PT Bank Tabungan Negara
(Persero) Tbk 399.178.072 397.089.801 (Persero) Tbk
PT Bank Jago Tbk 159.747.045 158.773.343 PT Bank Jago Tbk
PT Bank KB Bukopin Tbk 130.511.136 75.355.770 PT Bank KB Bukopin Tbk
PT Bank HSBC Indonesia 96.800.000 99.600.000 PT Bank HSBC Indonesia
PT Bank Permata Tbk 62.149.751 62.529.080 PT Bank Permata Tbk
PT Bank Pembangunan Daerah Jawa PT Bank Pembangunan Daerah
Timur Tbk 1.995.000 2.380.000 Jawa Timur Tbk
Sub–jumlah 237.664.391.078 293.204.337.520 Sub–total
Page 233
Laporan Keuangan
Financial Report 233
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/39 Exhibit E/39
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
4. KAS DAN SETARA KAS (Lanjutan) 4. CASH AND CASH EQUIVALENTS (Continued)
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Deposito berjangka – Rupiah Time deposit – Rupiah
PT Bank Mandiri (Persero) Tbk 402.000.000.000 409.500.000.000 PT Bank Mandiri (Persero) Tbk
PT Bank Mayapada
PT Bank Mayapada Internasional Tbk 100.000.000.000 - Internasional Tbk
PT Bank Syariah Indonesia Tbk 39.537.437.823 51.294.474.293 PT Bank Syariah Indonesia Tbk
PT Bank Capital Indonesia Tbk 18.000.000.000 - PT Bank Capital Indonesia Tbk
PT Bank Rakyat Indonesia (Persero) PT Bank Rakyat Indonesia
Tbk 17.000.000.000 4.000.000.000 (Persero) Tbk
PT Bank Negara Indonesia (Persero) PT Bank Negara Indonesia
Tbk 7.433.141.809 7.257.044.214 (Persero) Tbk
PT Bank China Construction Bank PT Bank China Construction Bank
Indonesia Tbk 3.038.476.808 2.920.231.442 Indonesia Tbk
PT Bank Mega - 12.500.000.000 PT Bank Mega
Sub–jumlah 587.009.056.440 487.471.749.949 Sub–total
Jumlah kas dan setara kas 826.584.741.908 783.332.056.074 Total cash and cash equivalents
Tingkat suku bunga deposito berjangka per Interest rates on time deposit per
tahun 2,50 – 7,00 % 2,50 – 5,50 % annum
Pada tanggal 31 Desember 2025 dan 2024, terdapat As of 31 December 2025 and 2024, there are time
deposito berjangka yang digunakan sebagai jaminan deposits that are pledged or used as collateral for bank
atas utang bank (Catatan 21). loans (Note 21).
Pada tanggal 31 Desember 2025 dan 2024, seluruh kas As of 31 December 2025 and 2024, all cash and cash
dan setara kas ditempatkan pada pihak ketiga. equivalents are placed with third parties.
5. ASET KEUANGAN LANCAR LAINNYA 5. OTHER CURRENT FINANCIAL ASSETS
Akun ini merupakan penempatan investasi dana pada This account represents placement fund with fund
manajer investasi, PT Atrus Investama, pihak ketiga manager, PT Atrus Investama, third party with
dengan perubahan nilai wajar melalui pendapatan recognition of fair-value through other comprehensive
komprehensif lain. sebagai berikut: income. as follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Investasi yang tersedia untuk dijual 17.000.000.000 17.000.000.000 Securities available for sale
Penambahan investasi tahun Additional Investment in
berjalan 3.283.400.000 - Current Years
Rugi yang belum direalisasi (13.764.188.421) (13.737.407.746) Unrealised loss
Neto 6.519.211.579 3.262.592.254 Net
Rugi yang belum direalisasi per tanggal Unrealised loss as of 31 December 2025 and 2024
31 Desember 2025 dan 2024 masing-masing sebesar amounted to Rp 13,764,188,421 and Rp 13,737,407,746
Rp 13.764.188.421 dan Rp 13.737.407.746 disajikan respectively, are presented as part of “Other
sebagai bagian dari “Penghasilan Komprehensif Lain” Comprehensive Income” in the consolidated statement
pada laporan laba rugi dan penghasilan komprehensif of profit or loss and other comprehensive income.
lain konsolidasian.
Page 234
234 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/40 Exhibit E/40
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
6. PIUTANG USAHA 6. TRADE RECEIVABLES
a. Berdasarkan pelanggan a. By customer
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Perusahaan korporasi 73.630.841.178 60.792.349.219 Corporate
Perusahaan asuransi 66.289.405.612 67.505.259.300 Insurance companies
Individu 8.610.481.624 8.414.368.136 Individual
Kartu kredit 1.026.441.108 1.544.761.114 Credit-cards
Lain-lain 19.962.722.403 10.725.365.751 Others
Sub-jumlah 169.519.891.925 148.982.103.520 Sub-Total
Cadangan kerugian penurunan
nilai (7.579.979.963) (4.267.847.614) Allowance for impairment losses
Neto 161.939.911.962 144.714.255.906 Net
b. Berdasarkan umur b. By age
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Belum jatuh tempo 9.990.279.226 15.110.334.308 Not yet due
Telah jatuh tempo: Past due:
1-30 hari 65.898.071.327 61.458.186.996 1-30 days
31-90 hari 40.681.964.406 29.532.511.980 31-90 days
Lebih dari 90 hari 52.949.576.966 42.881.070.236 More than 90 days
Jumlah 169.519.891.925 148.982.103.520 Total
Cadangan kerugian penurunan
nilai (7.579.979.963) (4.267.847.614) Allowance for impairment losses
Neto 161.939.911.962 144.714.255.906 Net
Perubahan jumlah cadangan penurunan nilai pada The changes in allowance for impairment loss on trade
piutang adalah sebagai berikut: receivables are as follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Saldo awal 4.267.847.614 3.962.120.381 Beginnning balance
Penambahan 3.312.132.349 561.174.970 Additional
Penghapusan - (255.447.737) Written-off
Saldo akhir 7.579.979.963 4.267.847.614 Ending balance
Berdasarkan penilaian status piutang usaha secara Based on review of individual bases of receivable
individual pada tanggal pelaporan, manajemen Grup accounts at the reporting dates, the Group’s
yakin bahwa cadangan penurunan nilai piutang cukup management believes that the allowance for
untuk menutupi kemungkinan kerugian penurunan nilai. impairment losses is sufficient to cover possible losses.
Pada tanggal 31 Desember 2025 dan 2024, tidak ada As of 31 December 2025 and 2024, there
piutang usaha Grup yang diagunkan atau digunakan were no the Group's trade receivables that were
sebagai jaminan untuk pinjaman bank dan pinjaman pledged or used as collateral for bank loan and other
lainnya. borrowing.
Pada tanggal 31 Desember 2025 dan 2024, seluruh As of 31 December 2025 and 2024, all trade receivables
piutang usaha dalam mata uang Rupiah. are denominated in Rupiah.
Page 235
Laporan Keuangan
Financial Report 235
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/41 Exhibit E/41
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
7. PIUTANG LAIN-LAIN 7. OTHER RECEIVABLES
a. Berdasarkan pihak a. By parties
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Pihak berelasi (Catatan 33) 25.325.460.858 20.074.879.572 Related parties (Note 33)
Pihak ketiga Third parties
Piutang karyawan 2.770.669.909 1.839.752.299 Employee receivables
Piutang Dokter 1.604.639.942 1.644.652.484 Doctor receivables
Klinik fertilitas - 169.535.673 Fertility clinic
Lain-lain (di bawah Rp 500
juta) 19.492.709.170 6.353.404.760 Others (below Rp 500 million)
Jumlah 23.868.019.021 10.007.345.216 Total
Cadangan kerugian penurunan Allowance for impairment
nilai (36.416.327) (36.416.327) losses
Sub-jumlah pihak ketiga 23.831.602.694 9.970.928.889 Sub–total third parties
Neto 49.157.063.552 30.045.808.461 Net
b. Berdasarkan umur b. By age
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Belum jatuh tempo 30.880.305.066 9.604.840.823 Not yet due
Telah jatuh tempo: Past due:
1-30 hari 4.013.364.324 1.154.759.583 1-30 days
31-90 hari 5.246.428.927 1.136.631.594 31-90 days
Lebih dari 90 hari 9.053.381.562 18.185.992.788 More than 90 days
Jumlah 49.193.479.879 30.082.224.788 Total
Cadangan kerugian penurunan
nilai (36.416.327) (36.416.327) Allowance for impairment losses
Neto 49.157.063.552 30.045.808.461 Net
Pada tanggal 31 Desember 2025 dan 2024, seluruh As of 31 December 2025 and 2024, all other receivables
piutang lain-lain dalam mata uang rupiah. are denominated in Rupiah.
8. PERSEDIAAN 8. INVENTORIES
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Obat-obatan 38.961.740.700 36.523.484.442 Medicines
Perlengkapan medis 9.418.739.676 7.881.390.095 Medical supplies
Lainnya 3.239.737.286 2.617.074.988 Others
Jumlah 51.620.217.662 47.021.949.525 Total
Manajemen Grup berkeyakinan bahwa seluruh The Group’s management believe that the inventories
persediaan dapat digunakan atau dijual, sehingga tidak can be either used or sold, and therefore an allowance
diperlukan cadangan kerugian penurunan nilai untuk for impairment loss of obsolete stock is not considered
persediaan usang. necessary.
Page 236
236 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/42 Exhibit E/42
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
8. PERSEDIAAN (Lanjutan) 8. INVENTORIES (Continued)
Pada tanggal 31 Desember 2025 dan 2024, tidak ada As of 31 December 2025 and 2024, there were no the
persediaan Grup yang diagunkan atau digunakan sebagai Group's inventories that were pledged or used as
jaminan untuk pinjaman bank dan pinjaman lainnya. collateral for bank loan and other borrowing.
Pada tanggal 31 Desember 2025 dan 2024, persediaan As of 31 December 2025 and 2024, the Group’s
Grup telah diasuransikan terhadap risiko kerugian akibat inventories have been covered by insurance against
bencana alam, kebakaran, kerusuhan, sabotase, the risk of loss due to natural disaster, fire,
pengrusakan dan gangguan bisnis lainnya dengan riots, sabotage, vandalism and other business
total pertanggungan sekitar Rp 6.917.199.956 dan interruption with total coverage of approximately
Rp 5.155.820.885 yang dianggap memadai oleh Rp 6,917,199,956 and Rp 5,155,820,885 respectively,
manajemen untuk menutup kemungkinan kerugian yang which is considered adequate by the management to
timbul dari risiko tersebut. cover possible losses arising from such risks.
9. BIAYA DIBAYAR DIMUKA DAN UANG MUKA 9. PREPAID EXPENSES AND ADVANCES
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Uang muka pembelian 120.705.239.728 135.700.753.450 Purchase advances
Proyek RSPPU 14.051.822.103 - Project RSPPU
Kemitraan 2.915.506.121 3.983.314.913 Partnership
Perjanjian kerjasama 2.735.637.067 3.485.637.067 Cooperation fee
Provisi bank 2.600.266.667 2.599.400.000 Bank provision
Asuransi 1.194.978.775 1.454.933.876 Insurance
Sewa 423.450.100 147.894.554 Rent
Lainnya 878.438.935 676.895.616 Others
Jumlah 145.505.339.496 148.048.829.476 Total
Bagian yang jatuh tempo dalam
satu tahun Current maturities
Uang muka pembelian (92.863.849.826) (61.530.837.633) Purchase advances
Kemitraan - (3.983.314.913) Partnership
Provisi bank (305.800.000) (304.933.333) Bank provision
Asuransi (1.194.978.775) (1.454.933.876) Insurance
Sewa (418.450.099) (147.894.554) Rent
Lainnya (6.150.303.099) (2.571.399.349) Others
Sub-jumlah – Bagian yang jatuh Sub-total – Current maturities
tempo dalam satu tahun (100.933.381.798) (69.993.313.658) portion
Bagian jangka panjang 44.571.957.697 78.055.515.818 Long-term portion
Akun kemitraan merupakan pengadaan fasilitas peralatan Partnership account represents facilities of medical
inseminasi dan peralatan sistem klinik dengan equipment and clinic system placed at the fertilization
penempatan pada klinik-klinik fertilitas dengan clinics includes its medical operator training programs
kemitraan tersebut termasuk pelatihan tenaga kesehatan and amortised over 3 years.
degan masa amortisasi 3 tahun.
Perjanjian kerjasama merupakan entrance fee Cooperation fee are entrance fee PT Diagnos
PT Diagnos Laboratorium Utama Tbk, dengan PT Riau Laboratorium Utama Tbk, with PT Riau Mulia Mitra
Mulia Mitra Medika atau RS Budhi Mulia Pekanbaru. Medika or RS Budhi Mulia Pekanbaru.
Page 237
Laporan Keuangan
Financial Report 237
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/43 Exhibit E/43
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
10. INVESTASI SAHAM 10. INVESTMENT IN SHARES
Presentase
kepemlikan
efektif / Nilai tercatat/ Carrying value
Percentage of
Domisili/ effective 31 Desember 2025/ 31 Desember 2024/
Metode nilai wajar/fair value method Domicile ownership 31 December 2025 31 December 2024
PT Global Sekawan Kreasi Bandung 35.00% 50.000.000.000 50.000.000.000
Klinik Pintar Technologies Pte.Ltd. Singapura 7.57% 21.495.000.000 21.495.000.000
Nalagenetics Pte.Ltd. Jakarta 1.50% 7.194.500.000 7.194.500.000
Asa Ren Pte. Ltd. Singapura 1.27% 4.506.000.000 4.506.000.000
Jumlah/ T o t a l 83.195.500.000 83.195.500.000
Pada tanggal 31 Desember 2025 dan 2024, jumlah As of 31 December 2025 and 2024, provision for
cadangan kerugian nilai atas investasi saham adalah impairment loss on investment in shares is nil.
nihil.
11. ASET TETAP 11. PROPERTY AND EQUIPMENT
2025
Saldo Awal / Penambahan / Pengurangan / Reklasifikasi / Revaluasi / Saldo Akhir /
Beginning Balance Additions Deduction Reclassification Revaluation Ending Balance
Biaya perolehan Costs:
Pemilikan Direct acquisition
langsung
Tanah 1.083.984.425.539 141.634.160.706 - - 229.391.032.360 1.455.009.618.605 Land
Bangunan 565.851.255.032 22.587.812.532 (35.398.873.873) 116.131.557.960 4.713.190.362 673.884.942.013 Buildings
Medical
Peralatan medis 490.158.807.700 25.825.051.180 (278.467.248) - - 515.705.391.632 equipment
Invetaris kantor 119.652.123.909 7.883.100.076 (863.379.174) - - 126.671.844.811 Office equipment
Machine and
Mesin dan instalasi 56.793.382.769 903.445.384 (11.400.000) - - 57.685.428.153 installation
Peralatan rumah Household
tangga 16.948.417.129 812.309.849 (169.657.476) - - 17.591.069.502 equipment
Kendaraan 25.005.624.618 502.473.772 (1.093.859.105) - - 24.414.239.285 Vehicle
Bangunan dalam Construction in
pelaksanaan 200.110.596.444 94.198.094.581 (397.494.209) (116.131.557.960) - 177.779.638.856 progress
2.558.504.633.140 294.346.448.080 (38.213.131.085) - 234.104.222.722 3.048.742.172.857
Akumulasi Accumulated
penyusutan depreciation
Pemilikan Direct acquisition
langsung
Bangunan 148.280.921.498 35.948.779.081 (15.975.462.035) - - 168.254.238.544 Buildings
Medical
Peralatan medis 320.314.652.067 23.150.057.795 (2.248.254.120) - - 341.216.455.742 equipment
Peralatan dan
perlengkapan Office equipment
kantor 81.976.500.346 14.003.724.659 (647.525.622) - - 95.348.139.383 and furniture
Machine and
Mesin dan instalasi 45.140.388.155 4.287.012.851 (4.319.340) - - 49.423.081.666 installation
Peralatan Rumah Household
Tangga 10.551.352.700 2.454.487.941 (1.500.000) - - 13.004.340.641 equipment
Kendaraan 17.316.064.226 1.380.197.013 (1.084.043.378) - - 17.612.217.861 Vehicles
623.579.878.992 81.224.259.340 (19.961.104.495) - - 684.843.033.837
Nilai Tercatat 1.934.924.754.148 2.363.899.139.020 Carrying Amount
Page 238
238 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/44 Exhibit E/44
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. ASET TETAP (Lanjutan) 11. PROPERTY AND EQUIPMENT (Continued)
2024
Saldo Awal / Penambahan / Pengurangan / Reklasifikasi / Saldo Akhir /
Beginning Balance Additions Deduction Reclassification Ending Balance
Biaya perolehan Costs:
Pemilikan langsung Direct acquisition
Tanah 1.072.996.925.539 10.987.500.000 - - 1.083.984.425.539 Land
Bangunan 524.346.792.819 19.976.674.498 (83.250.000) 21.611.037.715 565.851.255.032 Buildings
Peralatan medis 451.174.743.242 39.226.897.244 (2.329.031.681) 2.086.198.895 490.158.807.700 Medical equipment
Invetaris kantor 106.738.111.248 11.648.445.114 (681.620.876) 1.947.188.423 119.652.123.909 Office equipment
Machine and
Mesin dan instalasi 53.822.530.132 1.039.693.187 (26.700.000) 1.957.859.450 56.793.382.769 installation
Peralatan rumah Household
tangga 14.934.795.799 1.560.034.032 (92.725.000) 546.312.298 16.948.417.129 equipment
Kendaraan 23.918.171.025 2.160.025.193 (1.072.571.600) - 25.005.624.618 Vehicle
Bangunan dalam Construction in
pelaksanaan 146.970.197.685 81.288.995.540 - (28.148.596.781) 200.110.596.444 progress
2.394.902.267.489 167.888.264.808 (4.285.899.157) - 2.558.504.633.140
Akumulasi Accumulated
penyusutan depreciation
Pemilikan langsung Direct acquisition
Bangunan 111.615.622.273 36.863.317.956 (11.100.000) (186.918.731) 148.280.921.498 Buildings
Peralatan medis 286.904.241.595 35.211.142.343 (1.800.731.871) - 320.314.652.067 Medical equipment
Peralatan dan
perlengkapan Office equipment
kantor 68.010.098.862 14.590.700.120 (633.433.011) 9.134.375 81.976.500.346 and furniture
Machine and
Mesin dan instalasi 40.402.091.545 4.666.413.052 (21.950.000) 93.833.558 45.140.388.155 installation
Peralatan Rumah Household
Tangga 8.461.653.096 2.098.473.806 (92.725.000) 83.950.798 10.551.352.700 equipment
Kendaraan 16.254.681.629 1.655.184.285 (593.801.688) - 17.316.064.226 Vehicles
531.648.389.000 95.085.231.562 (3.153.741.570) - 623.579.878.992
Nilai Tercatat 1.863.253.878.489 1.934.924.754.148 Carrying Amount
Beban penyusutan aset tetap untuk tahun 2025 dan 2024 Depreciation of property and equipment for the years
yang dibebankan pada kegiatan operasional adalah ended 2025 and 2024 weres charged to operations as
sebagai berikut: follows:
2025 2024
Beban pokok pendapatan 3.207.084.079 9.730.445.461 Cost of revenues
Beban usaha (Catatan 29) 78.017.175.261 85.354.786.101 Operating expenses (Note 29)
Jumlah 81.224.259.340 95.085.231.562 Total
Grup memiliki beberapa bidang tanah yang terletak di Group owns lands located in various locations
beberapa tempat terutama di Jakarta, Depok, dan principally in Jakarta, Depok, and Padang (West
Padang (Sumatera Barat) dengan hak legal berupa hak Sumatera) with legal rights use of land for a period of
guna bangunan yang berjangka waktu 20 sampai dengan 20 to 30 years and will expired in vary period between
30 tahun yang akan jatuh tempo antara tahun 2031 2031 until 2048.
sampai dengan tahun 2048.
Manajemen berpendapat bahwa tidak terdapat masalah Management believes that there will be no issues in the
dengan perpanjangan hak guna bangunan karena seluruh extension of the building use right certificate since
tanah diperoleh secara sah dan didukung dengan bukti lands were acquired legally and are supported by
pemilikan yang memadai. sufficient evidence of ownership.
Page 239
Laporan Keuangan
Financial Report 239
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/45 Exhibit E/45
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. ASET TETAP (Lanjutan) 11. PROPERTY AND EQUIPMENT (Continued)
Tanah, bangunan, dan peralatan rumah sakit milik Grup Land, buildings and hospital equipment of the Group
yang terletak di Jakarta, Depok, Padang, dan Palembang located in Jakarta, Depok, Padang, and Palembang are
dijadikan sebagai jaminan atas utang bank (Catatan 20). pledged as collateral for bank loans (Note 20).
Pada tanggal 31 Desember 2025 dan 2024 aset tetap Grup As of 31 December 2025 and 2024, the Group’s property
telah diasuransikan terhadap risiko kerugian akibat and equipment have been covered by insurance against
bencana alam, kebakaran, kerusuhan, sabotase, the risk of loss due to natural disaster, fire,
pengrusakan, dan gangguan bisnis lainnya dengan total riots, sabotage, vandalism, and other business
pertanggungan sekitar Rp 491.064.268.503 dan interruption with total coverage of approximately
Rp 460.490.309.174 yang dianggap memadai oleh Rp 491,064,268,503 and Rp 460,490,309,174
manajemen untuk menutup kemungkinan kerugian yang respectively, which is considered adequate by the
timbul dari risiko tersebut. management to cover possible losses arising from such
risks.
Surplus revaluasi tanah sebesar Rp 229.391.032.360 dan Revaluation surplus of land amounting to
bangunan sebesar Rp 4.713.190.362. Rp 229,391,032,360 and building amounting to
Rp 4,713,190,362, respectively.
31 Desember 2025/ 31 December 2025
Sebelum revaluasi/ Setelah revaluasi/ After Surplus revaluasi/
Before revaluation revaluation Revaluation Surplus
Tanah 995.236.967.640 1.230.091.000.000 232.952.297.667 Land
Bangunan 421.366.418.223 421.401.433.218 35.014.996 Buildings
Jumlah Total
1.416.603.385.863 1.651.492.433.218 232.987.312.663
Perusahaan The Company
Perusahaan telah melakukan penilaian tanah dan bangunan The Company has appraised its land and building to
untuk mengetahui Nilai Pasar dan Indikasi Nilai determine the Market Value and Liquidation Value
Likuidasi berdasarkan laporan KJPP Nirboyo Indication based on KJPP Nirboyo Adiputro, Dewi
Adiputro, Dewi Apriyanti, dan Rekan (Penilai Apriyanti, and Rekan (Independent Appraisal)
Independen) No. 00252/2.0018-00/PI/05/0496/1/III/2026 report No. 00252/2.0018-00/PI/05/0496/1/III/2026 on 25
pada 25 Maret 2026. March 2026.
PT Morula Indonesia PT Morula Indonesia
Morula telah melakukan penilaian tanah dan untuk Morula has appraised its land and building to determine the
mengetahui Nilai Pasar dan Indikasi Nilai Likuidasi Market Value and Liquidation Value Indication based on
berdasarkan laporan KJPP Teguh Hermawan Yusuf dan KJPP Teguh Hermawan Yusuf and Rekan (Independent
Rekan (Penilai Independen) No. 00257/2.0018- Appraisal) report No. 00257/2.0018-
00/PI/05/0496/1/III/2026 pada 25 Maret 2026. 00/PI/05/0496/1/III/2026 on 25 March 2026.
PT Bunda Minang Citra PT Bunda Minang Citra
BMC telah melakukan penilaian tanah dan bangunan untuk BMC has appraised its land and building to determine the
mengetahui Nilai Pasar dan Indikasi Nilai Likuidasi Market Value and Liquidation Value Indication based on
berdasarkan laporan KJPP Nirboyo Adiputro, Dewi Apriyanti, KJPP Nirboyo Adiputro, Dewi Apriyanti, and Rekan
dan Rekan (Penilai Independen) No. 00253/2.0018- (Independent Appraisal) report No. 00253/2.0018-
00/PI/05/0496/1/III/2026 pada 25 Maret 2026. 00/PI/05/0496/1/III/2026 on 25 March 2026.
PT Citra Ananda PT Citra Ananda
CA telah melakukan penilaian tanah dan bangunan untuk CA has appraised its land and building to determine the
mengetahui Nilai Pasar dan Indikasi Nilai Likuidasi Market Value and Liquidation Value Indication based on
berdasarkan laporan KJPP Nirboyo Adiputro, Dewi Apriyanti KJPP Nirboyo Adiputro, Dewi Apriyanti, and Rekan
dan Rekan (Penilai Independen) No. 00255/2.0018- (Independent Appraisal) report No. 00255/2.0018-
00/PI/05/0496/1/III/2026 pada 25 Maret 2026. 00/PI/05/0496/1/III/2026 on 25 March 2026.
Page 240
240 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/46 Exhibit E/46
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
11. ASET TETAP (Lanjutan) 11. PROPERTY AND EQUIPMENT (Continued)
PT Bunda Global Pharma PT Bunda Global Pharma
BGP telah melakukan penilaian tanah dan bangunan untuk BGP has appraised its land and building to determine the
mengetahui Nilai Pasar dan Indikasi Nilai Likuidasi Market Value and Liquidation Value Indication based on
berdasarkan laporan KJPP Nirboyo Adiputro, Dewi Apriyanti, KJPP Nirboyo Adiputro, Dewi Apriyanti, and Rekan
dan Rekan (Penilai Independen) No. 00256/2.0018- (Independent Appraisal) report No. 00256/2.0018-
00/PI/05/0496/1/III/2026 pada 25 Maret 2026. 00/PI/05/0496/1/III/2026 on 25 March 2026.
PT Bunda Medika Wisesa PT Bunda Medika Wisesa
BMW telah melakukan penilaian bangunan untuk BMW has appraised its building to determine the Market
mengetahui Nilai Pasar dan Indikasi Nilai Likuidasi Value and Liquidation Value Indication based on
berdasarkan laporan KJPP Nirboyo Adiputro, Dewi Apriyanti, KJPP Nirboyo Adiputro, Dewi Apriyanti, and Rekan
dan Rekan (Penilai Independen) No. 00254/2.0018- (Independent Appraisal) report No. 00254/2.0018-
00/PI/05/0496/1/III/2026 pada 25 Maret 2026. 00/PI/05/0496/1/III/2026 on 25 March 2026.
PT Diagnos Laboratorium Utama Tbk PT Diagnos Laboratorium Utama Tbk
Diagnos telah melakukan penilaian bangunan untuk BMW has appraised its building to determine the Market
mengetahui Nilai Pasar dan Indikasi Nilai Likuidasi Value and Liquidation Value Indication based on
berdasarkan laporan KJPP Teguh Hermawan Yusuf dan KJPP Teguh Hermawan Yusuf and Rekan (Independent
Rekan (Penilai Independen) No. 00258/2.0018- Appraisal) report No. 00258/2.0018-
00/PI/05/0496/1/III/2026 pada 25 Maret 2026. 00/PI/05/0496/1/III/2026 on 25 March 2026.
Pada tahun 2025 dan 2024, Grup telah menjual aset tetap In 2025 and 2024, the Group had sold parts of its property
dengan rincian sebagai berikut: and equipment with details as follows:
2025 2024
Harga jual 1.493.319.558 1.015.362.904 Selling price
Nilai tercatat (1.281.171.305) (962.419.493) Carrying amount
Laba atas penjualan aset tetap Gain on sale of property and
(Catatan 32) 212.148.253 52.943.411 equipment (Note 32)
Pada tanggal 31 Desember 2025. tingkat penyelesaian The completion stage of construction in progress as of
bangunan dalam pembangunan adalah sebagai berikut: 31 December 2025. are as follows:
Presentase
penyelesaian/ Estimasi tahun penyelesaian/
Completion percentage Estimated completion year
Pembangunan gedung rumah sakit 30,00% 2026 Hospital building construction
Pembangunan gedung rumah sakit merupakan milik The construction of the hospital building owned by the
Perusahaan di Bekasi. Company in Bekasi.
Page 241
Laporan Keuangan
Financial Report 241
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/47 Exhibit E/47
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
12. ASET HAK-GUNA DAN LIABILITAS SEWA 12. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES
Akun ini merupakan aset hak-guna sebagai berikut This account represent right-of-use assets as follows:
1 Januari/ Penambahan / Pengurangan/ Penyesuaian / 31 Desember/
2025 1 January Additions Deduction Adjustment 31 December 2025
Nilai perolehan Cost:
Bangunan 143.621.020.470 61.527.393.114 (27.343.123.582) - 177.805.290.002 Building
Peralatan Medis - 27.500.000.000 - - 27.500.000.000 Medical Equipment
Kendaraan 10.463.895.863 14.050.252.961 (2.504.182.838) - 22.009.965.986 Vehicle
154.084.916.333 103.077.646.075 (29.847.306.420) - 227.315.255.988
Accumulated
Akumulasi amortisasi amortization
Bangunan 59.040.320.571 35.465.170.560 (23.106.134.284) - 71.399.356.847 Building
Peralatan Medis - 4.124.999.997 - - 4.124.999.997 Medical Equipment
Kendaraan 538.236.325 3.794.175.194 (582.517.312) 389.097.566 4.138.991.773 Vehicle
59.578.556.896 43.384.345.751 (23.688.651.596) 389.097.566 79.663.348.617
Nilai Tercatat 94.506.359.437 147.651.907.371 Carrying Amount
1 Januari/ Penambahan / Pengurangan/ Penyesuaian / 31 Desember/
2024 1 January Additions Deduction Adjustment 31 December 2024
Nilai perolehan Cost:
Bangunan 153.462.960.304 5.699.879.788 (15.541.819.622) - 143.621.020.470 Building
Kendaraan - 10.463.895.863 - - 10.463.895.863 Vehicle
153.462.960.304 16.163.775.651 (15.541.819.622) - 154.084.916.333
Accumulated
Akumulasi amortisasi amortization
Bangunan 50.476.630.176 24.105.510.017 (15.541.819.622) - 59.040.320.571 Building
Kendaraan - 538.236.325 - - 538.236.325 Vehicle
50.476.630.176 24.643.746.342 (15.541.819.622) - 59.578.556.896
Nilai Tercatat 102.986.330.128 94.506.359.437 Carrying Amount
Rincian liabilitas sewa adalah sebagai berikut: The details of lease liabilities are as follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Liabilitas sewa: Lease liabilities:
Bagian jangka pendek 21.812.380.174 19.500.574.022 Current portion
Bagian jangka panjang 118.334.918.295 53.531.597.866 Non-current portion
Jumlah 140.147.298.469 73.032.171.888 Total
Page 242
242 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/48 Exhibit E/48
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
12. ASET HAK-GUNA DAN LIABILITAS SEWA (Lanjutan) 12. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES
(Continued)
Jumlah yang diakui dalam laporan arus kas konsolidasian Amounts recognized in the consolidated statement of
adalah sebagai berikut: cash flows are as follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Jumlah kas keluar untuk: Total cash outflows for:
Pembayaran liabilitas sewa 56.457.929.143 20.365.042.260 Payment of lease liabilities
Pembayaran bunga 42.241.143.316 3.603.073.980 Payment of interest
Jumlah 98.699.072.459 23.968.116.240 Total
Jumlah yang diakui dalam laporan laba rugi dan Amounts recognized in the consolidated statement of
penghasilan komprehensif lain konsolidasian adalah profit or loss and other comprehensive income are as
sebagai berikut: follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Bunga atas liabilitas sewa 42.241.143.316 3.603.073.980 Interest on lease liabilities
Beban usaha (Catatan 29) 43.384.345.751 24.643.746.342 Operating expenses (Note 29)
Beban terkait liabilitas sewa bernilai Expenses related to short-term and
rendah dan jangka pendek (Catatan low value lease liabilities (Note 29)
29) 1.406.228.709 2.844.622.405
Jumlah 87.031.717.776 31.091.442.727 Total
13. PROPERTI INVESTASI 13. INVESTMENT PROPERTIES
1 Januari/ Penambahan / Pengurangan/ 31 Desember/
2025 1 January Additions Deduction 31 December 2025
Bangunan Building
Nilai perolehan 10.281.661.136 - (1.651.661.136) 8.630.000.000 Cost
Akumulasi amortisasi (3.700.208.333) (1.303.158.902) 645.306.979 (4.358.060.256) Accumulated amortization
Nilai tercatat 6.581.452.803 4.271.939.744 Carrying Amount
1 Januari/ Penambahan / Pengurangan/ 31 Desember/
2024 1 January Additions Deduction 31 December 2024
Bangunan Building
Nilai perolehan - 10.281.661.136 - 10.281.661.136 Cost
Akumulasi amortisasi - (3.700.208.333) - (3.700.208.333) Accumulated amortization
Nilai tercatat - 6.581.452.803 Carrying Amount
Akun properti investasi merupakan pengadaan fasilitas Investment properties account represents facilities of
peralatan inseminasi dan peralatan sistem klinik dengan medical equipment and clinic system placed at the
penempatan pada klinik-klinik fertilitas yang berlokasi di fertilization clinic which located in Sumatera, Java,
wilayah Sumatera, Jawa, dan Kalimantan atas PT Morula and Kalimantan of PT Morula Indonesia.
Indonesia.
Page 243
Laporan Keuangan
Financial Report 243
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/49 Exhibit E/49
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
14. GOODWILL 14. GOODWILL
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
PT Morula IVF Surabaya 50.811.634.395 50.811.634.395 PT Morula IVF Surabaya
PT Jolin Sapta Medika 34.679.155.348 34.679.155.348 PT Jolin Sapta Medika
PT Medika Sejahtera Bersama 8.476.711.081 8.476.711.081 PT Medika Sejahtera Bersama
PT Prima Dental Medika 826.006.647 826.006.647 PT Prima Dental Medika
Jumlah 94.793.507.471 94.793.507.471 Total
PT Jolin Sapta Medika PT Jolin Sapta Medika
Pada tanggal 25 Maret 2022, Perusahaan melakukan Dated 25 March 2022, the Company acquired 99.00%
akuisisi sebesar 99,00% saham kepemilikan shares ownership of PT Jolin Sapta Medika, a subsidiary
PT Jolin Sapta Medika, entitas anak dari pemegang from minority interest party. At the efective date of
saham perorangan. Pada tanggal akuisisi terdapat nilai acquisition the fair value identifiable acquired
akuisisi diatas nilai tercatat aset neto yang diakuisisi amounting to Rp 34,679,155,348 was recorded as part
sebesar Rp 34.679.155.348 yang dicatat sebagai of goodwill.
goodwill.
PT Prima Dental Medika PT Prima Dental Medika
Pada tanggal 02 Maret 2022, Perusahaan melakukan Dated 02 March 2022. the Company acquired 40% shares
akuisisi sebesar 40,00% saham kepemilikan ownership of PT Prima Dental Medika become 86.67%
PT Prima Dental Medika menjadi 86,67% kepemilikan, ownership, a subsidiary from minority interest party.
entitas anak dari pemegang saham perseorangan. Pada At the efective date of acquisition the fair value
tanggal akuisisi terdapat nilai akuisisi diatas nilai identifiable acquired amounting to Rp 826,006,647 was
tercatat aset neto yang diakuisisi sebesar recorded as part of goodwill.
Rp 826.006.647 yang dicatat sebagai goodwill.
PT Medika Sejahtera Bersama PT Medika Sejahtera Bersama
Pada tanggal 7 April 2022, PT Morula Indonesia Dated 7 April 2022. PT Morula Indonesia acquired
melakukan akuisisi sebesar 99,99% saham kepemilikan 99.99% shares ownership of PT Medika Sejahtera
PT Medika Sejahtera Bersama, entitas anak dari Bersama, a subsidiary from minority interest party. At
pemegang saham perorangan. Pada tanggal akuisisi the efective date of acquisition the fair value
terdapat nilai akuisisi diatas nilai tercatat aset neto identifiable acquired amounting to Rp 8,476,711,081
yang diakuisisi sebesar Rp 8.476.711.081 yang dicatat was recorded as part of goodwill.
sebagai goodwill.
Pada tanggal 31 Januari 2025, Perusahaan melakukan On 31 January 2025, the Company acquired a 99.99%
akuisisi sebesar 99,99% saham kepemilikan PT Medika equity interest in PT Medika Sejahtera Bersama, a
Sejahtera bersama, entitas anak dari PT Morula subsidiary of PT Morula Indonesia. As of the acquisition
Indonesia. Pada tanggal akuisisi terdapat nilai akuisisi date, the purchase consideration equaled the carrying
sama dengan nilai tercatat aset neto yang diakuisisi. amount of the net assets acquired. No additional
Tidak terdapat perubahan Nilai Goodwill atas transaksi goodwill was recognized. The goodwill arising from the
sebelumnya tetap sebesar Rp 8.476.711.081 yang prior transaction remained unchanged at
dicatat sebagai goodwill Rp 8,476,711,081 and continues to be recognized as
goodwill.
Page 244
244 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/50 Exhibit E/50
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
14. GOODWILL (Lanjutan) 14. GOODWILL (Continued)
PT Morula IVF Surabaya PT Morula IVF Surabaya
Pada tahun 2021, PT Morula Indonesia melakukan In 2021, PT Morula Indonesia acquired additional shares
akuisisi saham PT Morula IVF Surabaya, entitas anak dari of PT Morula IVF Surabaya, a subsidiary from minority
pihak non pengendali. Pada tanggal akuisisi terdapat interest party. At the efective date of acquisition the
biaya perolehan diatas nilai wajar teridentifikasi yang fair value identifiable acquired amounting to
diakuisisi sebesar Rp 50.811.634.395 yang dicatat Rp 50,811,634,395 was recorded as part of goodwill.
sebagai goodwill.
Per tanggal 31 Desember 2021, nilai tercatat goodwill As of 31 December 2021, the carrying amount of
dialokasikan ke unit penghasil kas atas PT Morula IVF goodwill is allocated to the cash generating unit of
Surabaya. PT Morula IVF Surabaya.
Berdasarkan proyeksi keuangan yang disusun manajemen Based on financial projection prepared by management
untuk tahun 2022 – 2026, dihitung arus kas neto yang for years 2022 – 2026 and the net cashflows will be
kemudian didiskontokan dengan tingkat diskonto discounted with an appropriate pretax discount rates
sebelum pajak yang digunakan yaitu sebesar 8,4% - 9,4%. of 8.4% - 9.4% were applied in determining the
Tingkat diskonto ini diestimasi berdasarkan rata-rata recoverable amount. The discount rates were
tertimbang biaya modal yang dialokasikan kepada unit determined based on the weighted average cost of
penghasil kas. capital allocated to cash generating unit.
Tidak ada kerugian penurunan nilai yang diakui pada There was no impairment loss recognized for the years
tahun yang berakhir pada tanggal 31 Desember 2025 dan ended 31 December 2025 and 2024 as the recoverable
2024 karena jumlah terpulihkan dari goodwill lebih tinggi amounts of the goodwill were in excess of their
dari nilai tercatatnya. carrying values.
Nilai tercatat goodwill seluruhnya dialokasikan ke Unit The carrying value of goodwill was all allocated to the
Penghasil Kas (UPK) rumah sakit atau klinik. Cash Generating Unit (CGU) of hospital or clinic.
Sesuai kebijakan akuntansi Grup, goodwill diuji In accordance with the Group’ accounting policy,
penurunan nilainya secara tahunan atau ketika terdapat goodwill is tested for impairment annually and/or
suatu indikasi bahwa nilai tercatatnya mengalami when the circumstances indicate the carrying amount
penurunan nilai. Untuk tujuan pengujian penurunan nilai, may be impaired. For the purpose of assessing
aset dikelompokkan hingga unti terkecil yang impairment, assets are grouped at the lowest level for
menghasilkan arus kas terpisah (UPK). which there are separately identifable cash flows
(CGU).
Asumsi utama yang digunakan dalam perhitungan jumlah The key assumptions used for recoverable amount
terpulihkan pada tanggal 31 Desember 2025 adalah calculations as of 31 December 2025 were as follows:
sebagai berikut:
Persentase/ Percentage
Tingkat pertumbuhan setelah 5 tahun 4.67% Growth rate after five years
Tingkat diskonto setelah pajak (untuk
perhitungan nilai wajar setelah dikurangi Discount rate after tax (fair value less costs
biaya untuk menjual 10.22% of disposal calculation)
Pada tanggal 31 Desember 2025 dan 2024, manajemen As of 31 December 2025 and 2024, the Group’s
Grup berpendapat bahwa tidak ada kejadian atau management was of the opinion that there were no
perubahan keadaan yang mengindikasikan penurunan events or changes in circumstances which would
nilai pada saldo goodwill. indicate impairment in the balance of goodwill.
Page 245
Laporan Keuangan
Financial Report 245
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/51 Exhibit E/51
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
15. ASET TIDAK LANCAR LAINNYA 15. OTHER NONCURRENT ASSETS
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Beban tangguhan 31.492.268.391 30.375.613.694 Deferred charges
Jaminan yang dapat dikembalikan 3.352.839.067 4.102.839.067 Refundable deposit
Uang muka pembelian aset - 48.350.000 Advance on purchase of fixed assets
Lain-lain 1.269.314.502 5.548.184.154 Others
Jumlah 36.114.421.959 40.074.986.915 Total
Beban tangguhan merupakan biaya pembangunan rumah Deferred charges is a capitalised costs of construction
sakit yang dikapitalisasi atas PT Bunda Medika Bekasi, of hospitals on PT Bunda Medika Bekasi, PT Bunda
PT Bunda Medika Dewata, dan PT Morula Bunda Dewata. Medika Dewata, and PT Morula Bunda Dewata.
16. UTANG USAHA – PIHAK KETIGA 16. TRADE PAYABLES – THIRD PARTIES
a. Berdasarkan pemasok a. By vendor
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Pemasok 36.345.471.687 14.576.256.453 Suppliers
Jasa dokter 32.694.903.037 16.244.471.499 Professional doctor fees
Lain-lain (di bawah 500 Juta) 12.619.838.785 60.852.000 Others (each below 500 Millions)
Jumlah 81.660.213.509 30.881.579.952 Total
b. Berdasarkan umur b. By aging
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Belum jatuh tempo 45.067.017.166 17.152.545.656 Not yet due
Telah jatuh tempo: Past due:
1-30 hari 12.892.466.087 6.575.947.174 1-30 days
31-60 hari 2.806.107.196 2.714.778.394 31-60 days
Lebih dari 90 hari 20.894.623.060 4.438.308.728 More than 90 days
Jumlah 81.660.213.509 30.881.579.952 Total
Utang usaha tidak dijaminkan, tidak berbunga memiliki Trade payables are unsecured, non-interest bearing
jangka waktu 30-60 hari. have credit terms of 30-60 days.
Pada tanggal 31 Desember 2025 dan 2024, seluruh utang As of 31 December 2025 and 2024, all trade payables
usaha dalam mata uang rupiah. are denominated in Rupiah.
Page 246
246 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/52 Exhibit E/52
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
17. UTANG LAIN-LAIN – PIHAK KETIGA 17. OTHER PAYABLES – THIRD PARTIES
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Pembelian aset 17.204.374.798 10.817.495.432 Purchase of assets
Lain-lain (di bawah Rp 500 juta) 6.538.940.938 3.891.369.651 Others (below Rp 500 million)
Jumlah 23.743.315.736 14.708.865.083 Total
Pada tanggal 31 Desember 2025 dan 2024, seluruh utang As of 31 December 2025 and 2024, all other payables
lain-lain dalam mata uang rupiah. are denominated in Rupiah.
18. PENDAPATAN DITERIMA DIMUKA 18. UNEARNED REVENUES
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Perawatan 15.684.930.386 14.062.730.595 Treatment
Lain-lain 17.866.815.935 7.185.625.063 Others
Jumlah 33.551.746.321 21.248.355.658 Total
19. BEBAN AKRUAL 19. ACCRUALS
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Gaji dan tunjangan 23.586.366.218 9.261.096.626 Salaries and allowances
Jasa professional 12.179.572.106 4.070.521.079 Professional fees
Alat dan bahan medis 11.404.087.979 5.488.089.645 Medical equipment and material
Obat-obatan dan laboratorium 7.072.818.186 1.705.192.803 Medicine and laboratory
Cadangan manfaat jangka pendek 3.342.838.926 2.948.970.636 Provision of short-term contract
Listrik, air, dan telepon 1.077.538.037 655.524.272 Electricity, water, and telephone
Lain-lain 14.172.960.013 4.444.583.314 Others
Jumlah 72.836.181.464 28.573.978.375 Total
20. PERPAJAKAN 20. TAXATION
a. Pajak Dibayar di Muka a. Prepaid Taxes
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Pajak penghasilan Income taxes
Pasal 21 86.913.349 59.567.109 Article 21
Pasal 23 - 190.250 Article 23
Pasal 25 1.445.405.124 73.222.251 Article 25
Pasal 28a 7.665.365.112 7.665.258.892 Article 28a
Pasal 4(2) 829.170.569 884.000.000 Article 4(2)
Pajak Pertambahan Nilai 3.457.733.769 1.828.571.572 Value Added Tax
Jumlah 13.484.587.923 10.510.810.074 Total
Page 247
Laporan Keuangan
Financial Report 247
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/53 Exhibit E/53
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
20. PERPAJAKAN (Lanjutan) 20. TAXATION (Continued)
b. Taksiran klaim restitusi pajak b. Estimated claim tax refund
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Pajak penghasilan 28a Income taxes article 28a
-Tahun 2022 - 37.511.247 Year 2022 -
Grup, melalui entitas anak, PT Pintu Ilmu memiliki Group, through its subsidiaries, PT Pintu Ilmu has an
taksiran klaim atas lebih bayar pajak penghasilan estimated claim for overpayment of income taxes
tahun 2022 sampai tanggal 31 Desember 2024. fiscal year 2022 until 31 December 2024.
c. Utang Pajak c. Taxes Payable
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Pajak kini Current tax
Perusahaan (Catatan 20d) 464.771.749 1.361.592.977 The Company (Note 20d)
Entitas anak 9.566.395.586 2.924.190.151 Subsidiaries
Pajak Penghasilan Income taxes
Pasal 4(2) 687.746.821 543.287.032 Article 4(2)
Pasal 21 1.525.101.224 1.730.744.808 Article 21
Pasal 22 - 2.481.949 Article 22
Pasal 23 552.406.590 614.467.160 Article 23
Pasal 25 648.304.345 1.447.962.247 Article 25
Pajak pembangunan I - 43.988.136 Development Tax
Pajak Pertambahan Nilai 5.287.553.617 346.934.824 Value Added Tax
Jumlah 18.732.279.932 9.015.649.284 Total
Beban (manfaat) pajak penghasilan Grup adalah Expenses (benefit) income tax of the Group are as
sebagai berikut: follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Pajak kini Current tax
Perusahaan 684.871.220 2.239.653.900 The Company
Entitas anak 21.057.545.453 15.856.571.221 Subsidiaries
21.742.416.673 18.096.225.121
Pajak tangguhan Deferred tax
Perusahaan (934.041.795) (473.758.323) The Company
Entitas anak (5.587.631.957) (1.169.562.450) Subsidiaries
(6.521.673.752) (1.643.320.773)
Pajak periode lalu Prior year income tax
Perusahaan - 2.523.862.122 The Company
Entitas anak 388.764.099 721.180.772 Subsidiaries
388.764.099 3.245.042.894
Jumlah 15.609.507.020 19.697.947.242 Total
Page 248
248 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/54 Exhibit E/54
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
20. PERPAJAKAN (Lanjutan) 20. TAXATION (Continued)
d. Pajak penghasilan d. Income taxes
Beban pajak penghasilan Income tax of expense
Pajak kini Current tax
Rekonsiliasi antara laba sebelum pajak, A reconciliation between profit before taxes,
sebagaimana yang disajikan dalam laporan laba rugi as presented in the consolidated statement of
dan penghasilan komprehensif lain konsolidasian profit or loss and other comprehensive income
dan taksiran laba kena pajak untuk tahun yang and estimated taxable profit for the years ended
berakhir pada tanggal 31 Desember 2025 dan 2024 31 December 2025 and 2024 are as follows:
adalah sebagai berikut:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Laba sebelum pajak menurut Profit before taxes per
laba rugi dan penghasilan consolidated statement of
komprehensif lain profit or loss and other
konsolidasian 45.282.649.553 38.593.731.509 comprehensive income
Eliminasi konsolidasi (44.522.477.111) 70.905.029.634 Consolidated elimination
Laba sebelum pajak Profit before taxes –
penghasilan - Perusahaan 760.172.442 109.498.761.143 The Company
Perbedaan temporer: Temporary differences:
Cadangan kerugian Allowance for impairment
penurunan nilai piutang 504.328.735 171.660.879 losses on receivables
Imbalan pasca kerja 4.076.175.984 1.796.407.960 Post-employment benefits
Provisi 37.100.702 (1.823.010.779) Provision
Liabilitas sewa 4.096.792.924 (2.837.565.656) Lease transaction
Depreciation of property
Penyusutan aset tetap (4.468.753.818) 4.845.954.516 and equipment
4.245.644.527 2.153.446.920
Perbedaan tetap: Permanent differences:
Representasi dan
sumbangan 13.500.000 14.300.000 Entertaint and donation
Beban pajak - 1.095.174.191 Tax expenses
Penjualan dan pemasaran 4.398.342.693 1.015.996.181 Selling and marketing
Penghasilan bunga yang Interest income subjected to
pajaknya bersifat final (9.040.199.534) (8.895.140.003) final tax
Penghasilan sewa yang Net rental income subjected
pajaknya bersifat final (1.872.104.556) (5.926.506.235) to final tax
Pendapatan dividen (4.806.342.757) (90.043.623.020) Dividend income
Lainnya 9.414.037.835 1.267.835.430 Others
(1.892.766.321) (101.471.963.456)
Taksiran laba kena pajak Estimated taxable profit for
tahun berjalan 3.113.050.648 10.180.244.607 the year
Taksiran beban pajak kini 684.871.220 2.239.653.900 Estimated current tax:
Dikurangi pajak dibayar di
muka: Less prepaid income taxes:
Pasal 23 (30.597.520) (108.446.161) Article 23
Pasal 25 (189.501.951) (769.614.762) Article 25
(220.099.471) (878.060.923)
Current tax payables –
Utang pajak kini – Pasal 29 464.771.749 1.361.592.977 Article 29
Page 249
Laporan Keuangan
Financial Report 249
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/55 Exhibit E/55
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
20. PERPAJAKAN (Lanjutan) 20. TAXATION (Continued)
e. Pajak tangguhan e. Deferred tax
Perhitungan pajak penghasilan badan untuk tahun The corporate income tax calculation for the year
2025 adalah suatu perhitungan yang dibuat untuk 2025 was a preliminary estimate made for
tujuan akuntansi dan dapat berubah pada saat accounting purposes and is subject to revision when
Perusahaan menyampaikan Surat Pemberitahuan the Company filed its Annual Corporate Income Tax
Tahunan PPh Badan (SPT) di akhir tahun fiskal. Return (CITR). The corporate income tax calculation
Perhitungan pajak penghasilan badan tahun per for 2024 confirms with the Company’s CITR.
31 Desember 2024 sesuai dengan SPT Perusahaan.
Pendapatan
Komprehensif
Dibebankan ke Lainnya/ Reklasifikasi/
31 Januari Laba (rugi)/ Other Penyesuaian/ 31 Desember
Aset pajak 2025/ January Charged to Comprehensive Reclassification 2025/ December Deferred tax
tangguhan 2025 Income (loss) Income Adjustment 2025 assets
Liabilitas
imbalan Post-employment
pasca-kerja 6.323.558.525 1.678.062.832 (539.719.615) 20.960.731 7.482.862.473 benefit liabilities
Provisi 626.154.820 (23.612.972) - 28.612.456 631.154.304 Provisions
Cadangan Allowance for
kerugian impairment
penurunan losses on
nilai piutang 932.513.555 822.711.785 - - 1.755.225.340 receivables
Aset hak-guna 10.589.376 4.350.785.574 - (2.976.278.329) 1.385.096.621 Right-of-use-asset
Penyusutan 9.158.600.962 (1.613.001.723) - (1.864.183.900) 5.681.415.339 Depreciation
Rugi fiskal 8.259.112.719 5.916.803.565 - 580.275.136 14.756.191.420 Fiscal losses
Jumlah 25.310.529.957 11.131.749.061 (539.719.615) (4.210.613.906) 31.691.945.497 Total
Pendapatan
Komprehensif
Dibebankan ke Lainnya/ Reklasifikasi/
31 Januari Laba (rugi)/ Other Penyesuaian/ 31 Desember
Liabilitas pajak 2025/ January Charged to Comprehensive Reclassification 2025/ December Deferred tax
tangguhan 2025 Income (loss) Income Adjustment 2025 liabilities
Liabilitas imbalan Post employment
pasca-kerja 125.595.673 (7.809.912) (18.391.887) 16.125.644 115.519.518 benefit liabilities
Aset hak guna (201.136.960) (645.741.498) - 268.550.927 (578.327.531) Right of use asset
Penyusutan aset Depreciation of
tetap (565.635.070) (432.047.930) - 401.461.366 (596.221.634) fixed assets
Jumlah (641.176.357) (1.085.599.340) (18.391.887) 686.137.937 (1.059.029.647) Total
Pendapatan
Komprehensif
Dibebankan ke Lainnya/ Reklasifikasi/
31 Januari Laba (rugi)/ Other Penyesuaian/ 31 Desember
Aset pajak 2024/ January Charged to Comprehensive Reclassification 2024/ December Deferred tax
tangguhan 2024 Income (loss) Income Adjustment 2024 assets
Liabilitas Post-employment
imbalan benefit
pasca-kerja 6.167.386.982 536.344.162 578.920.945 (959.093.564) 6.323.558.525 liabilities
Provisi 1.197.592.820 (571.808.450) 370.450 - 626.154.820 Provisions
Cadangan Allowance for
kerugian impairment
penurunan losses on
nilai piutang 881.172.441 51.341.114 - - 932.513.555 receivables
Aset hak-guna 1.746.305.807 (1.923.481.918) - 187.765.487 10.589.376 Right-of-use-asset
Penyusutan 7.615.936.974 867.448.193 - 675.215.795 9.158.600.962 Depreciation
Rugi fiskal 5.022.495.696 3.236.617.023 - - 8.259.112.719 Fiscal losses
Jumlah 22.630.890.720 2.196.460.124 579.291.395 (96.112.282) 25.310.529.957 Total
Page 250
250 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/56 Exhibit E/56
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
20. PERPAJAKAN (Lanjutan) 20. TAXATION (Continued)
e. Pajak tangguhan (Lanjutan) e. Deferred tax (Continued)
Pendapatan
Komprehensif
Dibebankan ke Lainnya/ Reklasifikasi/
31 Januari Laba (rugi)/ Other Penyesuaian/ 31 Desember
Liabilitas pajak 2024/ January Charged to Comprehensive Reclassification 2024/ December Deferred tax
tangguhan 2024 Income (loss) Income Adjustment 2024 liabilities
Liabilitas Post employment
imbalan benefit
pasca-kerja - 26.792.870 (103.315.670) 202.118.473 125.595.673 liabilities
Aset hak guna - (264.167.947) - 63.030.987 (201.136.960) Right of use asset
Penyusutan aset Depreciation of
tetap - (315.764.274) - (249.870.796) (565.635.070) fixed assets
Jumlah - (553.139.351) (103.315.670) 15.278.664 (641.176.357) Total
f. Administrasi pajak di Indonesia f. Tax administration in Indonesia
Berdasarkan peraturan perpajakan yang berlaku. Under the applicable taxation laws. the Group
Grup menghitung. menetapkan dan membayar calculates. establishes and pays for itself
sendiri jumlah pajak yang terhutang the amount of tax payables (self assessment).
(self assessment). Direktorat Jenderal Pajak dapat The Directorate General of Taxes may determine and
menetapkan dan mengubah liabilitas pajak dalam amend tax liability within 5 (five) years from the
batas waktu 5 (lima) tahun sejak tanggal date of the tax payables.
terutangnya pajak.
21. UTANG BANK 21. BANK LOANS
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Utang bank jangka pendek Short-term bank loans
PT Bank Mandiri (Persero) Tbk 445.816.762.935 440.600.262.935 PT Bank Mandiri (Persero) Tbk
Utang bank jangka panjang Long-term bank loans
PT Bank Mandiri (Persero) Tbk 733.230.250.090 637.575.172.118 PT Bank Mandiri (Persero) Tbk
PT Bank Syariah Indonesia Tbk 40.577.688.224 16.758.419.772 PT Bank Syariah Indonesia Tbk
Jumlah 773.807.938.314 654.333.591.890 Total
Biaya provisi bank ortisasi Unamortized bank
yang belum diamortisasi (3.984.634.503) (4.037.567.555) provision cost
Neto 769.823.303.811 650.296.024.335 Net
Dikurangi: Bagian yang jatuh
tempo dalam satu tahun (47.931.990.928) (3.886.703.167) Less : Current maturities
Bagian jangka panjang 721.891.312.883 646.409.321.168 Long-term portion
Page 251
Laporan Keuangan
Financial Report 251
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/57 Exhibit E/57
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
21. UTANG BANK (Lanjutan) 21. BANK LOAN (Continued)
Utang bank jangka pendek Short-term bank loan
PT Bank Mandiri (Persero) Tbk (“Mandiri”) PT Bank Mandiri (Persero) Tbk (“Mandiri”)
Perusahaan The Company
Perusahaan memperoleh fasilitas kredit modal kerja The Company obtained revolving working capital loan
revolving pada tanggal 26 Juli 2023 dari Mandiri dengan facility on 26 July 2023 from Mandiri with maximum
maksimum kredit senilai Rp 392.000.000.000 dengan credit limit of Rp 392,000,000,000 with the aim to
tujuan penggunaan untuk pembiayaan gap cashflow finance cash flow gaps in the context of repayment of
dalam rangka pelunasan fasilitas time revolving back-to- back-to-back time revolving facilities at PT Bank
back di PT Bank Central Asia Tbk. Pinjaman ini Central Asia Tbk. The loan guaranteed with Mandiri
dijaminkan oleh rekening giro dan/atau bilyet deposito current accounts and/or bilyet deposits. This loan has
Mandiri. Pinjaman ini memiliki suku bunga sebesar suku an interest rate of giro interest rate plus 0.6% per
bunga giro ditambah 0,6% per tahun. Perjanjian ini telah annum. This agreement has been renewed on 18 August
diperpanjang pada tanggal 18 Agustus 2025 dengan 2025 with a maturity date of 17 August 2026 and change
jatuh tempo pada tanggal 17 Agustus 2026 dan of maximum credit limit to Rp 442,000,000,000.
perubahan maksimum kredit menjadi senilai
Rp 442.000.000.000.
PT Morula Indonesia (“Morula”) PT Morula Indonesia (“Morula”)
Morula memperoleh fasilitas kredit modal kerja dari Morula obtained working capital credit facility from
Mandiri dengan batas kredit Rp 280.000.000.000 untuk Mandiri with maximum credit limit of
tambahan modal kerja jasa pelayanan kesehatan dengan Rp 280,000,000,000 to fund additional working capital
rincian sebagai berikut: for company’s healthcare service with details as
follows:
a. Fasilitas KMK I a. KMK Facility I
Morula memperoleh fasilitas kredit modal kerja Morula obtained working capital credit facility on
pada tanggal 12 Juli 2023 dari Mandiri dengan batas 12 July 2023 from Mandiri with maximum credit
kredit senilai Rp 30.000.000.000 dan suku bunga limit of Rp 30,000,000,000 and have interest rate
7.25% per tahun. Perjanjian ini telah diperpanjang of 7.25% per annum. This agreement has been
pada tanggal 24 Juli 2025 dengan jatuh tempo pada renewed on 24 July 2025. with a maturity date on
tanggal 25 Juli 2026. 25 July 2026.
b. Fasilitas KMK II b. KMK Facility II
Morula memperoleh fasilitas kredit modal kerja Morula obtained working capital credit facility on
pada tanggal 23 September 2024 dengan batas 23 September 2024 with maximum credit limit of
kredit senilai Rp 250.000.000.000 dan suku bunga Rp 250,000,000,000 and have interest rate of
2.85% per tahun. 2.85% per annum
PT Bunda Global Pharma (“BGP”) PT Bunda Global Pharma (“BGP”)
Perusahaan memperoleh fasilitas kredit agunan surat The Company obtained a credit facility on
berharga pada tanggal 27 September 2025 dari Mandiri 27 September 2025 from Mandiri with maximum credit
dengan maksimum kredit senilai Rp 5.000.000.000 limit of Rp 5,000,000,000 with the aim to additional
dengan tujuan tambahan modal kerja. Pinjaman ini working capital. The loan guaranteed with Mandiri time
dijaminkan oleh surat deposito berjangka Mandiri. deposit. This loan will be matured on
Pinjaman ini akan jatuh tempo pada tanggal 26 September 2026 and bears at the current interest
26 September 2026 dan memiliki suku bunga sebesar rate plus 0.6% per annum.
suku bunga giro ditambah 0,6% per tahun.
Page 252
252 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/58 Exhibit E/58
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
21. UTANG BANK (Lanjutan) 21. BANK LOAN (Continued)
Utang bank jangka panjang Long-term bank loan
PT Bank Mandiri (Persero) Tbk (“Mandiri”) PT Bank Mandiri (Persero) Tbk (“Mandiri”)
Perusahaan The Company
Perusahaan memperoleh fasilitas kredit investasi pada The Company obtained investment credit facility on
tanggal 26 Juli 2023 dari Mandiri dengan maksimum 26 July 2023 from Mandiri with maximum credit limit
kredit senilai Rp 839.950.000.000. Tingkat suku bunga of Rp 839,950,000,000. The credit facility bears
fasilitas kredit ini sebesar 7,25% per tahun dengan interests of 7.25% with details as follows:
rincian sebagai berikut:
a. Fasilitas Term Loan II a. Term Loan II Facility
Kredit investasi dengan limit kredit sebesar The investment credit with a credit limit of
Rp 79.950.000.000 dengan tujuan penggunaan Rp 79,950,000,000 with the aim to finance gap
untuk pembiayaan gap cash flows dalam rangka cash flows to repay the Company’s investment
pelunasan fasilitas kredit investasi Perusahaan di credit facility at PT Bank Central Asia Tbk. This
PT Bank Central Asia Tbk. Jatuh tempo fasilitas ini facility will due at 26 August 2033.
pada tanggal 26 Agustus 2033.
b. Fasilitas Term Loan III b. Term Loan III Facility
Kredit investasi dengan limit kredit sebesar The investment credit with a credit limit of
Rp 150.000.000.000 dengan tujuan penggunaan Rp 150,000,000,000 with the aim to finance gap
untuk pembiayaan gap cash flows dalam rangka cash flows to repay the Company’s investment
pelunasan fasilitas kredit investasi Perusahaan di credit facility at PT Bank Central Asia Tbk. This
PT Bank Central Asia Tbk. Jatuh tempo fasilitas ini facility will due at 26 July 2034.
pada tanggal 26 Juli 2034.
c. Fasilitas Term Loan IV c. Term Loan IV Facility
Kredit investasi dengan limit kredit sebesar The investment credit with a credit limit of
Rp 610.000.000.000 dengan tujuan penggunaan Rp 610,000,000,000 with the aim to finance gap
untuk pembiayaan gap cash flow untuk cash flows to develop hospitals of the Group
pengembangan rumah sakit Grup termasuk akuisisi including the acquisition of hospitals. This facility
rumah sakit. Jatuh tempo fasilitas ini pada tanggal is due at 25 July 2026. The Company has received
25 Juli 2026. Perusahaan telah melakukan the principal disbursement amounted to
pencairan atas fasilitas ini sampai pada tanggal Rp 125,937,499,034 as of 31 December 2024.
31 Desember 2024 sebesar Rp 125.937.499.034.
PT Pintu Ilmu (“PI”) PT Pintu Ilmu (“PI”)
PI memperoleh fasilitas kredit investasi pada tanggal PI obtained investment credit facility on 26 July 2023
26 Juli 2023 dari Mandiri dengan maksimum kredit from Mandiri with maximum credit limit of
senilai Rp 45.000.000.000. Pinjaman ini akan jatuh Rp 45,000,000,000. This loan will be matured on
tempo pada tanggal 25 Juli 2034 dan memiliki suku 25 July 2034 and bears annual interest rate of 7.25%.
bunga sebesar 7,25% per tahun.
Page 253
Laporan Keuangan
Financial Report 253
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/59 Exhibit E/59
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
21. UTANG BANK (Lanjutan) 21. BANK LOAN (Continued)
Utang bank jangka panjang (Lanjutan) Long-term bank loan (Continued)
PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Lanjutan) PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Continued)
PT Morula Indonesia (“Morula”) PT Morula Indonesia (“Morula”)
Morula memperoleh fasilitas kredit investasi pada Morula obtained investment credit facility on
tanggal 26 Juli 2023 dari Mandiri dengan batas kredit 26 July 2023 from Mandiri with maximum credit limit
senilai Rp 420.000.000.000. Tingkat suku bunga fasilitas of Rp 420,000,000,000. The credit facility bears
kredit ini sebesar 7,25% per tahun dengan rincian interests of 7.25% per annum with details as follows:
sebagai berikut:
a. Fasilitas Term Loan I a. Term Loan I Facility
Kredit investasi dengan limit kredit sebesar The investment credit with a credit limit of
Rp 200.000.000.000 dengan tujuan penggunaan Rp 200,000,000,000 with the aim to finance gap
untuk pembiayaan gap cash flows dalam rangka cash flows to repay Morula’s investment credit
pelunasan fasilitas kredit investasi Morula di facility at PT Bank Central Asia Tbk. This facility is
PT Bank Central Asia Tbk. Jatuh tempo fasilitas ini due at 26 August 2033.
pada tanggal 26 Agustus 2033.
b. Fasilitas Term Loan II b. Term Loan II Facility
Kredit investasi dengan limit kredit sebesar The investment credit with a credit limit of
Rp 190.000.000.000 dengan tujuan penggunaan Rp 190,000,000,000 with the aim to finance gap
untuk pembiayaan gap cash flows dalam rangka cash flows to for PT Morula Indonesia and/or its
pengembangan usaha Rumah Sakit atau Klinik subsidiaries in hospital or clinic business
PT Morula Indonesia dan/atau anak Perusahaan. development. This facility is due at 26 August
Jatuh tempo fasilitas ini pada tanggal 26 Agustus 2026.
2026.
PT Medika Sejahtera Bersama (“MSB”) PT Medika Sejahtera Bersama (“MSB”)
MSB memperoleh fasilitas kredit investasi pada tanggal MSB obtained investment credit facility on
26 Juli 2023 dari Mandiri dengan batas kredit senilai 26 July 2023 from Mandiri with maximum credit limit
Rp 45.000.000.000. Tingkat suku bunga fasilitas kredit of Rp 45,000,000,000. The credit facility bears interests
ini sebesar 7,25% per tahun dengan rincian sebagai of 7.25% per annum with details as follows:
berikut:
a. Kredit Investasi – Tranche 1 a. Investment Credit – Tranche 1
Kredit investasi dengan limit kredit sebesar The investment credit with a credit limit of
Rp 25.000.000.000 dengan tujuan penggunaan Rp 25,000,000,000 with the aim to to refinance
untuk pembiayaan kembali aset tanah dan land and buildings. This facility is due at 25 August
bangunan. Jatuh tempo fasilitas ini pada tanggal 2034.
25 Agustus 2034.
b. Kredit Investasi – Tranche 2 b. Investment Credit – Tranche 2
Kredit investasi dengan limit kredit sebesar The investment credit with a credit limit of
Rp 20.000.000.000 dengan tujuan penggunaan Rp 20,000,000,000 with the aim to to finance
untuk pembiayaan renovasi rumah sakit. Jatuh hospital renovation. This facility is due at
tempo fasilitas ini pada tanggal 25 Agustus 2034. 25 August 2034.
Page 254
254 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/60 Exhibit E/60
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
21. UTANG BANK (Lanjutan) 21. BANK LOAN (Continued)
Utang bank jangka panjang (Lanjutan) Long-term bank loan (Continued)
PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Lanjutan) PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Continued)
PT Morula Bunda Dewata (“MBD”) PT Morula Bunda Dewata (“MBD”)
MBD memperoleh fasilitas kredit pada tanggal MBD obtained credit facility on 15 June 2023 from
15 Juni 2023 dari Mandiri dengan batas kredit senilai Mandiri with maximum credit limit of
Rp 80.000.000.000. Tingkat suku bunga 7,25% per tahun Rp 80,000,000,000 The credit facility bears interests of
dengan rincian sebagai berikut: 7.25% per annum with details as follows:
a. Term Loan a. Term Loan
Kredit investasi dengan limit kredit sebesar The investment credit with a credit limit of
Rp 70.000.000.000 dengan tujuan penggunaan Rp 70,000,000,000 with the aim to fund the gap in
untuk pembiayaan arus kas untuk pengembangan cash flow for Morula Bunda Dewata Hospital’s
usaha Rumah Sakit Morula Bunda Dewata Bali. business development. This facility is due at
Jatuh tempo fasilitas ini pada tanggal 15 Juni 2035. 15 June 2035.
b. Bank Garansi b. Bank Guarantee
Bank Garansi dengan limit kredit sebesar The investment credit with a credit limit of
Rp 10.000.000.000 dengan tujuan penggunaan Rp 10,000,000,000 as a collateral (payment bond)
sebagai jaminan pembayaraan (payment bond) for a lease to PT Agung Panorama Propertindo.
atas penyewaan Gedung kepada This facility is due at 15 June 2035.
PT Agung Panorama Propertindo. Jatuh tempo
fasilitas ini pada tanggal 15 Juni 2035.
PT Diagnos Laboratorium Utama Tbk (“DGNS”) PT Diagnos Laboratorium Utama Tbk (“DGNS”)
Berdasarkan akta perjanjian kredit No. 61 tanggal Based on deed of Credit Agreement No. 61 dated 26 July
26 Juli 2023. DGNS memperoleh Kredit Investasi (KI) 2023. DGNS obtained Investment Credit from Mandiri to
Mandiri untuk tujuan pembiayaan pengembangan finance office building and laboratory’s development
gedung kantor dan laboratorium dengan maksimal with credit limit amounting to Rp 50,000,000,000 with
pinjaman sebesar Rp 50.000.000.000 adalah sebagai following:
berikut :
a. Fasilitas Kredit Investasi (KI) Tranche I a. Investment Loan (KI) I Facilities
Kredit Investasi (KI) dengan limit sebesar The investment credit with credit limit amounting
Rp 30.000.000.000 dan Tingkat suku bunga to Rp 30,000,000,000 and flowting rate at 7.25% per
mengambang sebesar 7.25% per tahun dengan jangka annum for a period of 132 months commencing from
waktu 132 bulan terhitung sejak tanggal signing date agreement of 26 July 2023 to 25 July
penandatanganan Perjanjian pada 26 Juli 2023 2034. This facility charges a provision fee at 0.10%
sampai dengan 25 Juli 2034. Fasilitas ini dikenakan and Rp 20,000,000 administrative charges.
biaya provisi sebesar 0,10% dan biaya administrasi
sebesar Rp 20.000.000.
b. Fasilitas Kredit Investasi (KI) Tranche II b. Investment Loan (KI) I Facilities
Kredit Investasi (KI) dengan limit sebesar The investment credit facility with credit limit
Rp 20.000.000.000 dan Tingkat suku bunga amounting to Rp 20,000,000,000 and floating rate at
mengambang sebesar 7,25% per tahun dengan jangka 7.25% per annum for a period of 132 months
waktu 132 bulan terhitung sejak tanggal commencing from signing date agreement of 26 July
penandatanganan Perjanjian pada 26 Juli 2023 2023 to 25 July 2034. This facility charges a provision
sampai dengan 25 Juli 2034. Fasilitas ini dikenakan fee at 0.10% and Rp 20,000,000 administrative
biaya provisi sebesar 0,10% dan biaya administrasi charges.
sebesar Rp 20.000.000.
Page 255
Laporan Keuangan
Financial Report 255
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/61 Exhibit E/61
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
21. UTANG BANK (Lanjutan) 21. BANK LOAN (Continued)
Utang bank jangka panjang (Lanjutan) Long-term bank loan (Continued)
PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Lanjutan) PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Continued)
Jangka waktu availability period dan grace period The availability period and grace period are 12 months
adalah 12 bulan terhitung mulai tanggal starting from the date of signing the credit agreement.
penandatanganan perjanjian kredit.
Perjanjian pinjaman Grup mencakup persyaratan The Group loan agreement includes certain
tertentu antara lain membatasi hak Entitas Anak untuk requirements. including limiting the right of the
mengubah Anggaran Dasar dan susunan Direksi dan Subsidiary to change the Articles of Association and the
Komisaris. menambah utang bank. leasing dan lembaga composition of the Board of Directors and
keuangan lainnya selain utang yang sudah ada dan Commissioners. adding to the debt of banks. leasing and
melakukan pembayaran dividen kepada pemegang other financial institutions in addition to existing debts
saham. Perjanjian tersebut mengharuskan Entitas Anak and making dividend payments to shareholders. The
untuk mempertahankan rasio keuangan tertentu yang Agreement requires the Subsidiary to maintain certain
dihitung berdasarkan laporan keuangan konsolidasian financial ratios calculated under the following
sebagai berikut: consolidated financial statements:
i. Current Ratio > 100%; i. Current Ratio ≥ 100%;
ii. Debt Service Equity Ratio (EBITDA/(Kewajiban ii. Debt Service Equity Ratio (EBITDA/(12 months
pokok selama 12 bulan + bunga) > 100% sejak tahun installment + interest) ≥ 100% starting year 2024;
2024;
iii. Debt Equity Ratio (Interest bearing debt/Equity) iii. Debt Equity Ratio (Interest bearing debt/Equity)
maksimum 4 kali; maximum 4 times;
iv. Ekuitas positif. iv. Positive equity.
Fasilitas utang bank Grup tersebut dijamin dengan The Group’s bank loans facility is guaranteed with the
jaminan sebagai berikut: following guarantees:
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Jakarta. dengan SHGB District. Jakarta City. with SHGB No.498/
No.498/Gondangdia atas nama Perusahaan dengan Gondangdia on behalf of the Company with a total
total seluas 893 m2; area of 893 m2;
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Kota Jakarta. dengan SHGB District. Jakarta City. with SHGB No.1504/
No.1504/Gondangdia atas nama Perusahaan dengan Gondangdia on behalf of the Company with a total
total seluas 575 m2; area of 575 m2;
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Kota Jakarta. dengan SHGB District. Jakarta City. with SHGB No.1541/
No.1541/Gondangdia atas nama Perusahaan dengan Gondangdia on behalf of the Company with a total
total seluas 541 m2; area of 541 m2;
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Kota Jakarta. dengan SHGB District. Jakarta City. with SHGB No.1542/
No.1542/Gondangdia atas nama Perusahaan dengan Gondangdia on behalf of the Company with a total
total seluas 1.273 m2; area of 1.273 m2;
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Kota Jakarta. dengan SHGB District. Jakarta City. with SHGB
No.1305/Gondangdia atas nama Perusahaan dengan No.1305/Gondangdia on behalf of the Company
total seluas 1.005 m2; with a total area of 1.005 m2;
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Kota Jakarta. dengan SHGB District. Jakarta City. with SHGB No.1320 /
No.1320/Gondangdia atas nama PT Morula Indonesia Gondangdia on behalf of PT Morula Indonesia with
dengan total seluas 969 m2; a total area of 969 m2;
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Kota Jakarta. dengan SHGB District. Jakarta City. with SHGB
No.1327/Gondangdia atas nama Perusahaan dengan No.1327/Gondangdia on behalf of the Company
total seluas 971 m2; Tanah dan bangunan di with a total area of 971 m2; Buildings in
Kelurahan Gondangdia. Kecamatan Menteng. Kota Gondangdia Village. Menteng District. Jakarta City.
Jakarta. dengan SHGB No.1329/Gondangdia atas with SHGB No.1329/ Gondangdia on behalf of the
nama Perusahaan dengan total seluas 910 m2; Company with a total area of 910 m2;
Page 256
256 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/62 Exhibit E/62
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
21. UTANG BANK (Lanjutan) 21. BANK LOAN (Continued)
Utang bank jangka panjang (Lanjutan) Long-term bank loan (Continued)
PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Lanjutan) PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Continued)
Fasilitas utang bank tersebut dijamin dengan jaminan Bank loans facility is guaranteed with the following
sebagai berikut: (Lanjutan) guarantees: (Continued)
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Kota Jakarta. dengan SHGB District. Jakarta City. with SHGB
No.1330/Gondangdia atas nama Perusahaan dengan No.1330/Gondangdia on behalf of the Company with
total seluas 350 m2; a total area of 350 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.51/Pondok-Cina atas nama No.51/ Pondok-Cina on behalf of the Company with
Perusahaan dengan total seluas 296 m2; a total area of 296 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.00055/Pondok-Cina atas nama No.00055/Pondok-Cina on behalf of the Company
Perusahaan dengan total seluas 44 m2; with a total area of 44 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.00056/Pondok-Cina atas nama No.00056/Pondok-Cina on behalf of the Company
Perusahaan dengan total seluas 44 m2; with a total area of 44 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.00057/Pondok-Cina atas nama No. 00057/Pondok-Cina on behalf of the Company
Perusahaan dengan total seluas 55 m2; with a total area of 55 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.00058/Pondok-Cina atas nama No.00058/Pondok-Cina on behalf of the Company
Perusahaan dengan total seluas 42 m2; with a total area of 42 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.00059/Pondok-Cina atas nama No.00059/Pondok-Cina on behalf of the Company
Perusahaan dengan total seluas 87 m2; with a total area of 87 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.61/Pondok-Cina atas nama No.61/ Pondok-China on behalf of the Company
Perusahaan dengan total seluas 291 m2; with a total area of 291 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.62/Pondok-Cina atas nama No.62/ Pondok-China on behalf of the Company
Perusahaan dengan total seluas 430 m2; with a total area of 430 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.134/Pondok-Cina atas nama No.134/Pondok-Cina on behalf of the Company with
Perusahaan dengan total seluas 138 m2; a total area of 138 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.135/Pondok-Cina atas nama No.135/ Pondok-Cina on behalf of the Company
Perusahaan dengan total seluas 305 m2; with a total area of 305 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.136/Pondok-Cina atas nama No.136/Pondok-Cina on behalf of the Company with
Perusahaan dengan total seluas 340 m2; a total area of 340 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.137/Pondok-Cina atas nama No.137/Pondok-Cina on behalf of the Company with
Perusahaan dengan total seluas 42 m2; a total area of 42 m2;
Page 257
Laporan Keuangan
Financial Report 257
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/63 Exhibit E/63
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
21. UTANG BANK (Lanjutan) 21. BANK LOAN (Continued)
Utang bank jangka panjang (Lanjutan) Long-term bank loan (Continued)
PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Lanjutan) PT Bank Mandiri (Persero) Tbk (“Mandiri”) (Continued)
Fasilitas utang bank tersebut dijamin dengan jaminan Bank loans facility is guaranteed with the following
sebagai berikut: (Lanjutan) guarantees: (Continued)
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.138/Pondok-Cina atas nama No.138/ Pondok-China on behalf of the Company
Perusahaan dengan total seluas 310 m2; with a total area of 310 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.139/Pondok-Cina atas nama No.139/ Pondok-China on behalf of the Company
Perusahaan dengan total seluas 102 m2; with a total area of 102 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.140/Pondok-Cina atas nama No.140/ Pondok-China on behalf of the Company
Perusahaan dengan total seluas 367 m2; with a total area of 367 m2;
● Tanah dan bangunan di Kelurahan Pondok Cina. ● Land and buildings in Pondok Cina Village. Beji
Kecamatan Beji. Kota Depok. Propinsi Jawa Barat District. Depok City. West Java Province with SHGB
dengan SHGB No.141/Pondok-Cina atas nama No.141/ Pondok-China on behalf of the Company
Perusahaan dengan total seluas 1.373 m2; with a total area of 1.373 m2;
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Kota Jakarta. dengan District. Jakarta City. with SHGB
SHGB No.421/Gondangdia atas nama Ietje Ika S. No.421/Gondangdia on behalf of Ietje Ika S. Rizal
Rizal Sini. Ivan Rizal Sini. Insinyur Mesha Rizal Sini. Sini. Ivan Rizal Sini. Insinyur Mesha Rizal Sini.
Renobulan Rizal Sini Suheimi dan Rito Alam Rizal Sini Renobulan Rizal Sini Suheimi and Rito Alam Rizal
dengan total seluas 90 m2; Sini with a total area of 90 m2;
● Tanah dan bangunan di Kelurahan Gondangdia. ● Land and buildings in Gondangdia Village. Menteng
Kecamatan Menteng. Kota Jakarta. dengan SHGB District. Jakarta City. with SHGB
No.343/Gondangdia atas nama Ietje Ika S. Rizal Sini. No.343/Gondangdia on behalf of Ietje Ika S. Rizal
Ivan Rizal Sini. Insinyur Mesha Rizal Sini. Renobulan Sini. Ivan Rizal Sini. Engineer Mesha Rizal Sini.
Rizal Sini Suheimi dan Rito Alam Rizal Sini dengan Renobulan Rizal Sini Suheimi and Rito Alam Rizal
total seluas 803 m2; Sini with a total area of 803 m2;
● Rumah Sakit BMC. entitas anak. yang terletak di ● BMC Hospital. a subsidiary. located on Jalan
Jalan Proklamasi Nomor 31-37. Ganting Parak Proklamasi Number 31-37. Ganting Parak Gadang.
Gadang. Kecamatan Padang Timur. Kota Padang. East Padang District. Padang City. West Sumatra;
Sumatera Barat;
● 19 Unit Apartemen Atlanta Residence di Jalan ● 19 Atlanta Residence Apartment Units on Jalan
Margonda Raya. No. 28. Kelurahan Pondok Cina. Margonda Raya. No. 28. Pondok Cina Village. Beji
Kecamatan Beji. Depok. atas nama PT Agung Multi District. Depok. on behalf of PT Agung Multi Berjaya
Berjaya yang kemudian akan ditindaklanjuti which subsequently will be transferred on behalf of
baliknama ke atas nama PT Bundamedik Tbk PT Bundamedik Tbk.
● Tanah dan Bangunan Rumah Sakit yang diakuisisi ● Acquired Hospital Land and Buildings and/or
dan/atau saham Rumah Sakit diakuisisi yang akan acquired Hospital shares to be financed by
dibiayai oleh fasilitas Kredit Investasi. investment credit facilities.
● Corporate Guarantee dan Deficit Cashflow ● Corporate Guarantee and Deficit Cashflow
Guarantee atas nama PT Bundamedik Tbk Guarantee on behalf of PT Bundamedik Tbk
PT Bank Syariah Indonesia Tbk (“BSI”) PT Bank Syariah Indonesia Tbk (“BSI”)
PT Bunda Minang Citra (“BMC”) PT Bunda Minang Citra (“BMC”)
Sejak tahun 2019. BMC. entitas anak. mengadakan Since 2019. BMC. the subsidiary entered into a
perjanjian anjak piutang dengan BSI (dahulu PT Bank factoring agreement with BSI (formerly PT Bank Syariah
Syariah Mandiri). berupa fasilitas akad Wakalah bil Mandiri). Wakalah bil Ujroh and Qardh contract
Ujroh dan Qardh. Maskimum nominal fasilitas anjak facilities. The maximum nominal factoring facility is
piutang berdasarkan invoice yang diserahkan oleh BMC based on invoices submitted by the BMC to the Bank.
kepada Bank. Jangka waktu fasilitas akan jatuh tempo The term of the facility will mature no later than 90
tidak lebih dari 90 hari setelah akad disetujui kedua days after the agreement is agreed by both parties.
pihak.
Page 258
258 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/64 Exhibit E/64
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
21. UTANG BANK (Lanjutan) 21. BANK LOAN (Continued)
Utang bank jangka panjang (Lanjutan) Long-term bank loan (Continued)
PT Bank Syariah Indonesia Tbk (“BSI”) (Lanjutan) PT Bank Syariah Indonesia Tbk (“BSI”) (Continued)
PT Bunda Minang Citra (“BMC”) (Lanjutan) PT Bunda Minang Citra (“BMC”) (Continued)
Berikut adalah fasilitas utang bank jangka panjang yang BMC’s long-term bank loans facilities from
dimiliki BMC dari PT Bank Syariah Indonesia Tbk (Dahulu PT Bank Syariah Indonesia Tbk (Formerly PT Bank BNI
PT Bank BNI Syariah) (“BNIS”): Syariah) (“BNIS”) are as follows:
Bank Fasilitas Pinjaman/ Nomor perjanjian/ Jangka Waktu/ Period Maksimum Pinjaman/ Bagi hasil/
Credit facility Agreement number Awal/Start Akhir/End Credit limit Margin sharing
BSI Murabahah PGS/075/2012/MRBH 25/04/12 25/04/19 3.000.000.000 1.907.500.000
Murabahah PGS/041-
I/2014/MRBH/BFM/BNIS 06/03/14 05/10/20 1.395.000.000 793.948.538
Murabahah PGS/041-
II/2014/MRBH/BFM/BNIS 14/03/14 13/03/21 1.860.000.000 1.070.124.169
Murabahah 128/MRB809/88400/X/15 13/10/15 12/09/19 1.036.071.057 310.472.681
Murabahah 147/MRB809/88400/XI/15 20/11/15 19/11/19 441.510.480 132.105.831
Murabahah Investasi/
Investment Murabahah PGS/07/504A/R 25/09/16 25/08/21 834.000.000 314.001.000
Murabahah BNISY/CRD/486/R 25/01/17 25/12/24 15.000.000.000 9.001.521.490
Murabahah Investasi/
Investment Murabahah 009/MRB809/88400/I/17 16/01/17 15/01/25 1.047.776.173 628.760.735
Murabahah Investasi/
Investment Murabahah 044/MRB809/88400/III/17 17/03/17 16/03/25 1.635.543.246 980.265.445
Murabahah Investasi/
Investment Murabahah 091/MRB809/88400/VI/17 19/06/17 18/06/25 1.130.593.399 678.452.783
Murabahah Investasi/
Investment Murabahah 131/MRB809/884000/X/17 19/11/17 18/10/25 1.188.000.000 712.901.454
Murabahah 018/MRB809/81500/II/18 23/03/18 22/12/21 1.188.000.000 712.901.454
Murabahah Investasi/
Investment Murabahah PGS/07/030/R 25/01/18 25/12/22 4.500.000.000 1.608.831.129
Murabahah BNISy/PGS/07/582/R 25/09/18 25/08/23 2.412.922.781 663.125.460
Murabahah Investasi/
Investment Murabahah BNISy/PGS/07/585/R 25/10/18 25/09/25 5.600.000.000 2.209.196.966
Fasilitas utang bank tersebut dijamin dengan jaminan The bank loan facilities is secured by collateral as
sebagai berikut: follows:
● Investasi Terikat Mandiri Syariah (ITSM) sebesar ● Investasi Terikat Mandiri Syariah (ITSM) amounted
Rp 17.000.000.000. to Rp 17,000,000,000.
● Deposito sebesar Rp 273.552.981. ● Deposits amounted to Rp 273,552,981.
Pada tanggal pelaporan keuangan, Grup telah As at reporting date, the Group has fulfilled all the
memenuhi seluruh persyaratan atas utang bank. required covenants of the bank loans.
Page 259
Laporan Keuangan
Financial Report 259
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/65 Exhibit E/65
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
22. IMBALAN PASCA-KERJA 22. POST-EMPLOYMENT BENEFITS
Grup menghitung imbalan pasca-kerja untuk karyawan The Group calculate post-employment benefit for
sesuai dengan UU Cipta Kerja No. 11/2020. Jumlah qualifying employees in accordance with Labor Law
karyawan Grup yang berhak diperhitungkan untuk No. 11/2020. The total number of employees of the
imbalan pasca-kerja tersebut adalah 1.566 dan 1.579 Group entitled to the benefits are 1,566 and 1,579
karyawan masing-masing untuk tahun 2025 dan 2024. employees for 2025 and 2024, respectively. These
Jumlah ini tidak diaudit. figures were unaudited.
Nilai yang termasuk dalam laporan posisi keuangan The amounts included in the consolidated statements of
konsolidasian yang berasal dari Grup sehubungan financial position arising from the Group’s obligation in
dengan liabilitas imbalan pasca-kerja adalah sebagai respect of these post-employment benefits are as
berikut: follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Nilai kini kewajiban yang tidak didanai 34.552.286.808 29.627.155.160 Present value of unfunded obligations
Beban imbalan pasca-kerja yang dibebankan di laporan Amounts charged in the consolidated statements of
laba rugi dan penghasilan komprehensif lain profit or loss and other comprehensive income in
konsolidasian adalah: respect of these post-employment benefits are as
follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Biaya jasa kini 6.564.695.090 4.235.768.217 Current service costs
Biaya bunga 1.965.875.754 1.540.345.263 Interest costs
Biaya terminasi 1.303.577.394 - Termination cost
Biaya jasa lalu 60.080.798 1.917.135.212 Prior service costs
Dampak kurtaimen (38.918.503) (348.065.116) Kurtailment effect
Jumlah 9.855.310.533 7.345.183.576 Total
Mutasi nilai kini liabilitas yang tidak didanai selama The movements in the present value of unfunded
tahun berjalan adalah sebagai berikut: obligations in the current year were as follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Saldo awal 29.627.155.160 25.063.931.536 Beginning balance
Beban tahun berjalan (Catatan 29) 9.855.310.533 7.345.183.576 Current year expenses (Note 29)
Pendapatan komprehensif lain (2.581.070.789) 2.004.583.162 Other comprehensive income
Realisasi pembayaran manfaat (5.099.294.492) (4.786.543.114) Realisation of benefit payment
Penyesuaian 2.750.186.396 - Adjustment
Saldo akhir 34.552.286.808 29.627.155.160 Ending balance
Liabilitas imbalan pasca-kerja tahun 2025 dan 2024 Post-employment benefit liabilities in 2025 and 2024
dicatat berdasarkan perhitungan aktuaris independen are recorded based on an independent actuary
masing-masing oleh Kantor Konsultan Aktuaria Santhi calculation by Kantor Konsultan Aktuaria Santhi Devi
Devi dan Ardianto Handoyo dan Kantor Konsultan and Ardianto Handoyo and Kantor Konsultan Aktuaria
Aktuaria Steven & Mourits dan Kantor Konsultan Aktuaria Steven & Mourits and Kantor Konsultan Aktuaria Budi
Budi Ramdani dan Kantor Konsultan Aktuaria Tubagus Ramdani and Kantor Konsultan Aktuaria Tubagus
Syafrial & Amran Nangasan dengan menggunakan Syafrial & Amran Nangasan, respectively, using the
metode Projected Unit Credit sesuai dengan laporan Projected Unit Credit method in accordance with the
perhitungan Aktuaria. Actuarial calculation report.
Page 260
260 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/66 Exhibit E/66
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
22. IMBALAN PASCA-KERJA (Lanjutan) 22. POST-EMPLOYMENT BENEFITS (Continued)
Berikut adalah asumsi-asumsi akturia yang digunakan The following are the assumptions of acturia used in
dalam menentukan liabilitas imbalan kerja di 2025 dan determining the liability for employee benefits in 2025
2024: and 2024:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Tingkat diskonto 6.25% - 7.13% 6.88% - 7.14% Discount rate
Tingkat kenaikan gaji 4.50% - 5.50% 4.50% - 5.50% Salary increment rate
Tingkat kematian TMI IV (2019) TMI IV (2019) Mortality rate
Usia pensiun normal 59 - 60 59 - 60 Normal retirement age
Sensitivitas imbalan pasca-kerja terhadap asumsi utama The sensitivity of the post-employment benefits to the
adalah: changes in key assumptions:
Perubahan nilai kini Kenaikan gaji/
Diskonto/ kewajiban/ Changes in the Salary Perubahan nilai kini kewajiban/ Changes in the
Discounted present value of liabilities increases present value of liabilities
Digunakan/ be used
Naik 1%/up 1% 1% Turun/ Decrease 3.869.179.982 Naik/ Increase (2.862.626.423)
Turun 1%/down 1% 1% Naik/ Increase (2.951.317.923) Turun/ Decrease 3.827.784.155
Analisis sensitivitas yang disajikan di atas mungkin tidak The sensitivity analysis presented above may not be
mewakili perubahan yang sebenarnya dalam imbalan representative of the actual change in the post-
pasca-kerja mengingat bahwa perubahan asumsi employment benefits as it is unlikely that the change in
terjadinya tidak terisolasi satu sama lain karena assumptions would occur in isolation of one another as
beberapa asumsi tersebut mungkin berkorelasi. some of the assumptions may be correlated.
23. MODAL SAHAM 23. SHARE CAPITAL
Susunan pemegang saham Perusahaan pada tanggal The composition of the Company’s shareholders as of
31 Desember 2025 dan 2024, adalah sebagai berikut: 31 December 2025 and 2024, are as follows:
Ditempatkan dan Disetor Penuh/ Issued and Fully Paid
Persentase
kepemilikan/
Jumlah saham/ percentage of Jumlah/
Pemegang saham Total shares ownership Total Shareholders
PT Bunda Investama Indonesia PT Bunda Investama Indonesia
4.935.430.900 57.37% 98.708.618.000
Akasya Investment Akasya Investment
421.416.176 4.90% 8.428.323.520
Komisaris dan Direksi Commissioner and Director
dr Ivan Rizal Sini. SpOG dr Ivan Rizal Sini. SpOG
278.600.000 3.24% 5.572.000.000
Ir. Mesha Rizal Sini. M. Eng.Sc. Ir. Mesha Rizal Sini. M. Eng.Sc.
278.600.000 3.24% 5.572.000.000
Rito Alam Rizal Sini. S.E. Rito Alam Rizal Sini. S.E.
278.600.000 3.24% 5.572.000.000
Renobulan Rizal Sini Suheimi. S.Psi Renobulan Rizal Sini Suheimi. S.Psi
207.786.000 2.42% 4.155.720.000
Ietje Ika S Rizal Sini Ietje Ika S Rizal Sini
157.865.000 1.83% 3.157.300.000
Masyarakat (masing-masing dibawah 1%) Public (each below 1%)
2.045.118.100 23.76% 40.902.362.000
Jumlah 8.603.416.176 100% 172.068.323.520 Total
Page 261
Laporan Keuangan
Financial Report 261
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/67 Exhibit E/67
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
23. MODAL SAHAM (Lanjutan) 23. SHARE CAPITAL (Continued)
Berdasarkan Akta No. 60 tanggal 9 Maret 2021 dari Jose Based on Notarial Deed No. 60 dated 9 March 2021 of
Dima Satria. S.H., M.Kn, notaris di Jakarta, para Jose Dima Satria, S.H., M.Kn., notary in Jakarta.
pemegang saham menyatakan dan memutuskan antara the shareholders declare and decide par value shares
lain hal-hal sebagai berikut: of the Company the following:
a. Perubahan nilai nominal saham Perusahaan dari a. Changed par value shares of the Company from
semula sebesar Rp 1.000.000 per saham menjadi Rp 1,000,000 into Rp 20 per share;
Rp 20 per saham;
b. Rencana Perusahaan untuk melakukan Penawaran b. The Company's plan to conduct a public offering of
Umum Saham-saham Perdana Perusahaan (IPO); the Company's shares Initial Public Offering (IPO);
c. Pengeluaran saham dalam simpanan atau portepel c. Issuance of the Company’s shares in porteple or
Perusahaan dalam jumlah sebanyak-banyaknya portfolios with maximum number of 620,000,000
620.000.000 saham dengan nilai nominal Rp 20 per shares with nominal value Rp 20 per share
saham (selanjutnya disebut “Saham Baru”) untuk (hereinafter referred to as “New Shares”) to be
ditawarkan kepada masyarakat melalui IPO dengan offered to the public through IPO with due
memperhatikan ketentuan perundang-undangan observance of the prevailing laws and regulations.
yang berlaku termasuk tetapi tidak terbatas pada including but not limited to the Capital Market and
peraturan-peraturan Pasar Modal dan Bursa Efek Indonesia Stock Exchange (IDX) regulations;
Indonesia (BEI);
d. Program Employee Stock Allocation (ESA) dan d. Employee Stock Allocation (ESA) program with
mengalokasikan sebanyak-banyaknya sebesar maximum number of 5,000,000 shares or 0.8%
5.000.000 saham atau 0,8% dari seluruh saham of all shares offered.
yang ditawarkan.
Akta perubahan ini telah disetujui oleh The deed of amendment has been received and
Menteri Hukum dan Hak Asasi Manusia registered by the Minister of Law and Human Rights of
Republik Indonesia dalam surat keputusannya the Republic of Indonesia in his Decision Letter
No. AHU-0046709.AH.01.11.Tahun 2021 tanggal No. AHU-0046709.AH.01.11.Tahun 2021 dated
12 Maret 2021. 12 March 2021.
Manajemen modal Capital management
Grup secara teratur meninjau dan mengelola struktur The Group regularly reviews and manages its capital
permodalannya untuk memastikan struktur dan structure to ensure optimal structure and shareholder
pengembalian pemegang saham yang optimal. dengan returns. taking into consideration the future capital
mempertimbangkan persyaratan modal masa depan requirements of the Company and capital efficiency.
Perusahaan dan efisiensi modal. profitabilitas yang prevailing and projected profitability. projected
berlaku dan proyeksi. arus kas operasi yang operating cash flows. projected capital expenditures
diproyeksikan. pengeluaran modal yang diproyeksikan. and projected strategic investment opportunities. No
dan proyeksi peluang investasi strategis. Tidak ada changes were made in the objectives. policies or
perubahan yang dibuat dalam tujuan. kebijakan atau processes of capital management during the years ended
proses manajemen modal selama tahun yang berakhir 31 December 2025 and 2024.
pada tanggal 31 Desember 2025 dan 2024.
Menurut Undang-Undang Perseroan Terbatas According to Limited Liability Company No. 40/2007.
No. 40/2007. Perusahaan diharuskan untuk membuat The Company is required to reserve at least 20% of the
penyisihan cadangan wajib sekurang-kurangnya 20% issued and fully paid authorized capital of the Company.
dari modal dasar Perusahaan yang ditempatkan dan As of 31 December 2025 and 2024. the Company has not
disetor penuh. Pada tanggal 31 Desember 2025 dan determined its reserves.
2024. Perusahaan belum menempatkan cadangannya.
Page 262
262 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/68 Exhibit E/68
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
24. TAMBAHAN MODAL DISETOR 24. ADDITIONAL PAID-IN CAPITAL
Akun ini terdiri dari: This account represents as follows:
31 Desember 2025/ 31 Desember 2025/
31 December 2025 31 December 2025
Agio saham 1.679.146.625 1.679.146.625 Agio
Selisih nilai transaksi
restrukturisasi entitas Difference transaction value with
sepengendali 137.862.420.330 137.901.023.439 entities under common control
Agio sebagai hasil penawaran Premium on stock from
umum saham perdana 347.302.048.450 347.302.048.450 Initial Public Offering
Pengampunan pajak 69.792.813.839 69.792.813.839 Tax amnesty
Jumlah 556.636.429.244 556.675.032.353 Total
Agio Saham Agio
Akun ini merupakan selisih yang timbul atas penerimaan This account represents difference arised from fund
yang diterima dari Perseroan dan entitas anak dengan received from issuance of share with its par value of
nilai saham yang diterbitkan. paid-in and fully paid capital.
Selisih Nilai Transasksi Restrukturisasi Entitas Difference Transaction Value with Entities Under
Sepengendali Common Control
Akun ini tediri dari selisih yang timbul atas akuisisi This account represents difference arised
kepentingan nonpengendali yang merupakan pihak from acquisition of non-controlling interests
berelasi pada saham PT Morula Indonesia tahun 2020 dan portion whose related party in shares of
tambahan saham PT Diagnos Laboratorium Utama Tbk PT Morula Indonesia in 2020 and addition shares in
tahun 2024. PT Diagnos Laboratorium Utama Tbk in 2024.
Pengampunan Pajak Tax Amnesty
Pada tahun 2017, mengacu pada penerapan PSAK 370 – In 2017, as referred to PSAK 370 Accounting for Tax
Akuntansi Aset dan Liabilitas Pengampunan Pajak. Grup Amnesty Assets and Liability. Group has adjusted
mencatat tambahan modal disetor atas aset additional paid-in capital arised from tax amnesty
pengampunan pajak total sebesar Rp 69.792.813.839. assets totaling Rp 69,792,813,839.
Agio Sebagai Hasil Penawaran Umum Saham Perdana Premium on Stock from Initial Public Offering
Pada Juli 2021, Perusahaan melakukan Penawaran In July 2021, the Company undertook a Public Offering
Umum sebanyak 682.000.000 saham biasa dengan nilai of 682,000,000 ordinary shares with a par value per
nominal sebesar Rp 20 per saham dan harga penawaran share of Rp 20 and offering price of Rp 340 per share to
sebesar Rp 340 per saham kepada masyarakat di the public in Indonesia and convert 421,416,176 shares
Indonesia dan konversi 421.416.176 saham dari obligasi of convertible bond. The Company recorded premium
konversi. Perusahaan mencatat agio sebagai hasil on stock from initial public offering amounting to
penawaran umum saham perdana sebesar Rp 347,302,048,450.
Rp 347.302.048.450.
25. SALDO LABA 25. RETAINED EARNINGS
Dividen Dividends
Berdasarkan Akta Notaris Nomor 53 tanggal 15 Mei 2025 Based on Notarial Deed No. 53 dated 15 May 2025,
mengenai Berita Acara Rapat Umum Pemegang Saham regarding the Minutes of the Annual General Meeting of
Tahunan, para Pemegang Saham Perusahaan telah Shareholders, the Shareholders of the Company have
menyetujui atas deklarasi dividen kas tahun buku 2024 approved the declaration of cash dividends for profit
kepada para pemegang saham sebesar year 2024 to shareholders amounting to
Rp 5.592.220.514. Dividen kas dibayar sepenuhnya pada Rp 5,592,220,514. The cash dividends were fully paid on
18 Juni 2025. 18 June 2025.
Page 263
Laporan Keuangan
Financial Report 263
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/69 Exhibit E/69
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
25. SALDO LABA (Lanjutan) 25. RETAINED EARNINGS (Continued)
Berdasarkan Akta Notaris Nomor 158 tanggal 30 Mei 2024 Based on Notarial Deed No. 158 dated 30 May 2024,
mengenai Berita Acara Rapat Umum Pemegang Saham regarding the Minutes of the Annual General Meeting of
Tahunan, para Pemegang Saham Perusahaan telah Shareholders, the Shareholders of the Company have
menyetujui atas deklarasi dividen kas tahun buku 2023 approved the declaration of cash dividends for profit
kepada para pemegang saham sebesar year 2023 to shareholders amounting to
Rp 4.817.913.058. Dividen kas dibayar sepenuhnya pada Rp 4,817,913,058. The cash dividends were fully paid on
1 Juli 2024. 1 July 2024.
Laba Per Saham Dasar Net Earning Per Share
Rincian perhitungan laba per saham adalah sebagai The details of earnings per share computation are as
berikut: follows:
2025 2024
Laba tahun berjalan yang dapat
diatribusikan kepada pemilik Profit for the year attributable
entitas induk 12.418.961.321 11.943.515.324 to owners of the parent
Jumlah saham yang beredar 7.461.134.368 7.461.134.368 Number of shares
Laba bersih per saham dasar 1.4 1.4 Earnings per share
26. KEPENTINGAN NONPENGENDALI 26. NON-CONTROLLING INTERESTS
31 Desember 2025/ 31 December 2025
Penghasilan
Bagian dari laba Perubahan komprehensif
Saldo Awal / Setoran Modal / rugi / ekuitas lainnya/ lain/ Other Saldo Akhir /
Beginning Issuance of new Share of profit Other equity comprehensive Ending
balance shares or loss movement income Balance
Penyertaan Direct
langsung ownership
Morula 298.478.062.320 - 7.835.390.913 (4.556.642.000) 513.931.867 302.270.743.100 Morula
BMC 94.974.817.204 - 6.674.741.556 (5.400.000.000) 1.077.256.576 97.326.815.337 BMC
BGP 1.459.169.324 - 966.573.063 - (203.489.757) 2.222.252.629 BGP
CA 11.221.343.560 - 331.035.904 - (803.315.857) 10.749.063.607 CA
BMW (71.607.734) - (166.720.490) - 29.915.436 (208.412.788) BMW
PDM 312.607.031 - 64.236.355 (62.878.639) (135.270) 313.829.477 PDM
VSI 450.536.465 - (27.230) - - 450.509.235 VSI
SMB 1.493.940.201 - 443.815.475 (428.647.498) (4.704.060) 1.504.404.120 SMB
BDI (556.147.921) - (236.893.077) - (17.042.433) (810.083.431) BDI
ERI 2.007.078.758 - (329.280.129) - 6.185.689 1.683.984.320 ERI
BMD (210.501.441) - (12.407.577) - 799.501 (222.109.523) BMD
PI 14.351.453 38.603.109 (29.124.746) - (4.663) 23.825.154 PI
BGPP 1.262.572.476 - (44.400.182) - - 1.218.172.293 BGPP
BMB 25.000.000 - - - - 25.000.000 BMB
JSM (38.992.158.035) - 31.239.371 - (1.056.321) (38.961.974.985) JSM
DLU 62.358.959.749 - 1.727.011.761 - 2.893.446.243 66.979.417.753 DLU
BMK 28.375.298 - (147.046) - 21.110 28.249.361 BMK
MSB - - (862.706) - - (862.706) MSB
Jumlah 434.256.398.708 38.603.109 17.795.733.673 (3.135.613.703) (4.362.298.831) 444.592.822.953 Total
Page 264
264 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/70 Exhibit E/70
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
26. KEPENTINGAN NONPENGENDALI (Lanjutan) 26. NON-CONTROLLING INTERESTS (Continued)
31 Desember 2024/ 31 December 2024
Penghasilan
Bagian dari laba Perubahan komprehensif
Saldo Awal / Setoran Modal / rugi / ekuitas lainnya/ lain/ Other Saldo Akhir /
Beginning Issuance of new Share of profit Other equity comprehensive Ending
balance shares or loss movement income Balance
Penyertaan Direct
langsung ownership
Morula 77.066.805.608 103.588.000.000 977.710.448 117.809.442.890 (963.896.626) 298.478.062.320 Morula
BMC 89.857.606.957 - 8.097.586.484 (3.000.000.000) 19.623.763 94.974.817.204 BMC
BGP 4.314.844.471 - (2.656.895.362) - (198.779.785) 1.459.169.324 BGP
CA 11.094.628.117 - 115.216.004 - 11.499.439 11.221.343.560 CA
BMW 121.472.714 - (148.902.843) - (44.177.605) (71.607.734) BMW
PDM 242.916.999 - 69.865.154 - (175.122) 312.607.031 PDM
VSI 450.563.695 - (27.230) - - 450.536.465 VSI
SMB 1.037.843.794 - 535.809.373 (85.412.396) 5.699.430 1.493.940.201 SMB
BDI (446.938.865) - (116.141.311) - 6.932.255 (556.147.921) BDI
ERI 2.302.898.586 - (300.159.768) - 4.339.940 2.007.078.758 ERI
BMD (129.473.120) - (80.892.181) - (136.140) (210.501.441) BMD
PI 12.527.902 50.000.000 (48.176.641) - 192 14.351.453 PI
BGPP 1.262.453.181 - 119.295 - - 1.262.572.476 BGPP
BMB 25.000.000 - - - - 25.000.000 BMB
JSM (39.068.825.561) - 77.335.031 - (667.505) (38.992.158.035) JSM
DLU 62.040.368.603 - 439.496.930 - (120.905.784) 62.358.959.749 DLU
BMK 38.067.756 - (9.674.440) - (18.018) 28.375.298 BMK
Jumlah 210.222.760.837 103.638.000.000 6.952.268.943 114.724.030.494 (1.280.661.566) 434.256.398.708 Total
27. PENDAPATAN NETO 27. NET REVENUES
2025 2024
Rumah Sakit Hospitals
Rawat Inap Inpatient
Obat dan perlengkapan medis 144.330.275.721 142.630.488.000 Drugs and medical supplies
Kamar rawat inap 87.644.208.526 88.187.710.319 Room services
Fasilitas rumah sakit 61.291.576.127 56.399.346.793 Hospital’s facility
Jasa penunjang medis dan Medical support services and
tenaga ahli 201.811.270.208 191.920.976.219 professional fees
Pendapatan administrasi dan Administration income
lainnya 38.408.996.504 45.876.662.372 and others
Kamar operasi dan bersalin 38.107.883.532 35.679.411.271 Operating and maternity room
Rawat Jalan Outpatient
Obat dan perlengkapan medis 270.361.206.222 220.916.177.524 Drugs and medical supplies
Jasa penunjang medis dan Medical support services and
tenaga ahli 262.834.363.614 244.956.389.585 professional fees
Fasilitas rumah sakit 43.700.160.859 44.438.023.971 Hospital’s facility
Pendapatan administrasi dan
lainnya 49.387.120.105 47.490.101.099 Administration income and others
Fertilitas In Vitro In Vitro Fertilization
Fertilisasi dan klinik 520.503.370.204 529.785.137.307 Fertilization and clinic
Hotel 4.971.190.823 5.183.450.111 Hotel
Jumlah 1.723.351.622.445 1.653.463.874.571 Total
Potongan penjualan (109.010.850.933) (98.778.864.235) Sales discount
Neto 1.614.340.771.512 1.554.685.010.336 Net
Page 265
Laporan Keuangan
Financial Report 265
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/71 Exhibit E/71
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
28. BEBAN POKOK PENDAPATAN 28. COST OF REVENUES
2025 2024
Rumah Sakit Hospitals
Tenaga medis 396.966.532.544 368.149.339.874 Medical staff
Layanan penunjang medis Medical support services and
dan lainnya 149.436.971.851 141.364.189.362 others
Obat dan perlengkapan medis 134.642.093.603 129.789.241.147 Drugs and medical supplies
Fertilisasi In Vitro In Vitro Fertilization
Fertilisasi dan klinik 186.728.546.707 205.559.382.713 Fertilization and clinic
Hotel 2.074.160.697 2.685.841.748 Hotel
Jumlah 869.848.305.402 847.547.994.844 Total
29. BEBAN USAHA 29. OPERATING EXPENSES
Akun ini terdiri dari: This account represents as follows:
2025 2024
Penjualan dan pemasaran Selling and marketing
Iklan dan promosi 21.668.465.057 25.315.367.731 Advertising and promotion
Transportasi 3.725.751.792 4.086.086.156 Transportation
Lainnya 9.615.463.824 1.856.113.730 Others
Sub – jumlah 35.009.680.673 31.257.567.617 Sub - total
Umum dan administrasi General and administrative
Gaji dan tunjangan 253.978.217.203 262.097.780.562 Salaries and allowances
Penyusutan dan amortisasi Depreciation and amortization
(Catatan 11) 78.017.175.261 85.354.786.101 (Note 11)
Beban kantor 50.027.210.200 32.238.811.785 Office expenses
Penyusutan aset hak-guna Depreciation right-of-use assets
(Catatan 12) 43.384.485.751 24.643.746.342 (Note 12)
Jasa outsource 35.442.145.614 30.012.550.267 Outsourcing
Jasa profesional 22.930.391.177 27.267.185.590 Professional fees
Listrik dan air 18.805.469.386 18.756.248.821 Electricity and water
Perbaikan dan pemeliharaan 18.384.907.594 19.298.315.836 Repair and maintenance
Kebersihan dan keamanan 10.373.857.726 7.894.985.435 Cleaning and security
Imbalan pasca-kerja Post-employment benefit
(Catatan 22) 9.855.310.533 7.345.183.576 (Note 22)
Telepon dan internet 9.539.239.885 10.099.093.898 Telephone and internet
Perjalanan dinas dan transportasi 7.120.964.139 7.050.244.692 Travel and transportation
Asuransi 3.333.960.837 3.085.131.685 Insurances
Pajak Bumi dan Bangunan 3.062.979.487 2.226.389.071 Land and Property Tax
Sewa (Catatan 12) 1.406.228.709 2.844.622.405 Rent (Note 12)
Amortisasi properti investasi Amortization property investment
(Catatan 13) 1.303.158.902 3.700.208.333 (Note 13)
Pajak dan perijinan 977.150.554 1.692.685.776 Taxes and licenses
Representasi dan sumbangan 229.166.297 315.769.183 Entertain and donation
Pendidikan dan pelatihan 773.785.027 19.634.696.669 Education and training
Lainnya 24.607.440.040 11.254.429.353 Others
Sub-jumlah 593.553.244.322 576.812.865.380 Sub-total
Jumlah 628.562.924.995 608.070.432.997 Total
Page 266
266 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/72 Exhibit E/72
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
30. PENGHASILAN KEUANGAN 30. FINANCIAL INCOME
2025 2024
Penghasilan bunga deposito 19.618.560.043 11.918.212.673 Interest income on time deposits
Penghasilan jasa giro 3.312.285.552 6.722.623.952 Interest income on current accounts
Jumlah 22.930.845.594 18.640.836.625 Total
31. BEBAN KEUANGAN 31. FINANCIAL COSTS
2025 2024
Beban bunga utang bank 60.562.221.147 60.188.756.261 Interest on bank loan
Biaya administrasi bank 3.460.668.470 3.350.324.632 Bank charges
Biaya administrasi kartu kredit 3.504.503.273 4.514.367.562 Credit card charges
Jumlah 67.527.392.890 68.053.448.455 Total
32. PENGHASILAN (BEBAN) OPERASI LAINNYA 32. OTHER OPERATING INCOME (EXPENSES)
2025 2024
Pendapatan komisi 4.546.392.076 - Commisions income
Laba penjualan Gain on sale
aset tetap (Catatan 11) 212.148.253 52.943.411 property and equipment (Note 11)
Beban piutang tak tertagih (3.904.546.042) - Bad debt expense
Lainnya (26.904.338.555) (11.113.182.567) Others
Jumlah (26.050.344.266) (11.060.239.156) Total
33. SALDO DAN TRANSAKSI-TRANSAKSI DENGAN PIHAK 33. BALANCES AND TRANSACTION WITH RELATED PARTIES
BERELASI
Sifat Hubungan dan Transaksi Dengan Pihak-Pihak Nature of Transactions and Relationship With
Berelasi Related Parties
Pihak-pihak berelasi/ Sifat hubungan/ Sifat transaksi
Related parties Nature of relationships Nature of Transaction
PT Bunda Investama Indonesia Entitas induk utama Grup / Ultimate Piutang lain-lain/Other receivables
holding of the Group
PT Bunda Ipiti Investama Manajemen kunci yang sama dan Piutang lain-lain/Other receivables
Pemegang saham Morula/
Same key management and shareholder
of Morula
Kebijakan harga Grup yang berkaitan dengan transaksi The Group’s pricing policies related to transactions
pihak berelasi ditetapkan berdasarkan pada harga yang with related parties are set based on agreed prices.
disepakati kedua pihak.
Transaksi dengan Pihak Berelasi Transaction with Related Parties
Saldo pihak berelasi tidak dijaminkan. tidak dikenakan Related party balances are unsecured. non-interest
bunga dan dibayarkan ketika diminta. kecuali bearing and repayable on demand. unless otherwise
dinyatakan lain. stated.
Page 267
Laporan Keuangan
Financial Report 267
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/73 Exhibit E/73
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
33. SALDO DAN TRANSAKSI-TRANSAKSI DENGAN PIHAK 33. BALANCES AND TRANSACTION WITH RELATED PARTIES
BERELASI (Lanjutan) (Continued)
Saldo dan transaksi–transaksi dengan pihak berelasi Balances and transactions with related parties are as
adalah sebagai berikut: follows:
Piutang lain-lain Other receivables
Persentase dari jumlah asset / Percentage
from total assets
31 Desember 2025/ 31 Desember 2024/ 31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024 31 December 2025 31 December 2024
PT Bunda Investama PT Bunda Investama
0,60% 0,55%
Indonesia 24.112.713.578 18.862.132.292 Indonesia
PT Bunda Ipiti PT Bunda Ipiti
Investama 0,03% 0,04% 1.212.747.280 1.212.747.280 Investama
Jumlah 0,63% 0,59% 25.325.460.858 20.074.879.572 Total
Kompensasi Personel Manajemen Kunci Key Management Personnel Compensation
Personel manajemen kunci Perusahaan adalah anggota Key management personnel of the Company is Boards of
Dewan Komisaris dan Direksi Perusahaan. Imbalan untuk Commissioners and Directors. The compensation
manajemen kunci adalah sebagai berikut: benefits for key managements are as follows:
2025 2024
Imbalan jangka pendek 15.372.629.175 13.990.888.979 Shor-term benefits
34. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN POLICIES
Dalam transaksi normal Perusahaan. secara umum In the normal transactions of the Company.
terekspos risiko keuangan sebagai berikut: generally exposed to financial risk as follows:
a. Risiko tingkat suku bunga a. Interest rate risk
b. Risiko kredit b. Credit risk
c. Risiko likuiditas c. Liquidity risk
Catatan ini menjelaskan mengenai eksposur Perusahaan This note describes the Company exposure to each of
terhadap masing-masing risiko di atas dan pengungkapan the above risks and quantitative disclosures including
secara kuantitatif termasuk seluruh eksposur risiko serta all risk exposures and summarizes the policies and
merangkum kebijakan dan proses-proses yang dilakukan processes undertaken to measure and manage the risks
untuk mengukur dan mengelola risiko yang timbul. that arise. including those related to capital
termasuk yang terkait dengan pengelolaan modal. management.
Direksi Grup bertanggung jawab dalam melaksanakan The Group's Directors are responsible for implementing
kebijakan manajemen risiko keuangan Grup dan secara the Group’s financial risk management policies and the
keseluruhan program manajemen risiko keuangan Grup Company and its subsidiaries' overall financial risk
difokuskan pada ketidakpastian pasar keuangan dan management program is focused on financial market
meminimalisasi potensi kerugian yang berdampak pada uncertainty and minimizing potential losses that may
kinerja keuangan Grup. impact the the Group’s financial performance.
Page 268
268 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/74 Exhibit E/74
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
34. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN (Lanjutan) POLICIES (Continued)
Risiko tingkat suku bunga Interest rate risk
Kebijakan manajemen risiko Grup adalah untuk The Group’s risk management policy is to minimize
meminimalkan eksposur risiko arus kas suku bunga interest rate cash flow risk exposures to changes in
terhadap perubahan suku bunga. Grup memiliki liabilitas interest rates. The Group has lease liabilities and
sewa dan wesel bayar jangka menengah dengan tingkat medium-term notes with fixed interest rates.
bunga tetap. Oleh karena itu. Perusahaan dan entitas Therefore. the Company and its subsidiaries is not
anak tidak terpengaruh oleh perubahan tingkat suku subject to the effect of changes in interest rates.
bunga.
Risiko kredit Credit risk
Risiko kredit merupakan risiko atas kerugian keuangan Credit risk is the risk of financial loss to the Company
Perusahaan jika pelanggan atau pihak lain dari if the customer or other party to the financial
instrumen keuangan gagal memenuhi liabilitas instrument fails to fulfill its contractual
kontraktualnya. Manajemen berpendapat bahwa tidak obligations. Management believes that there is no
terdapat risiko kredit yang terkonsentrasi secara significant concentration of credit risk. The Group’s
signifikan. Grup selalu melakukan pemantauan always monitors the collectibility and reviews of each
kolektibilitas dan penelaahan atas masing-masing customer's receivables on a regular basis to anticipate
piutang pelanggan secara berkala untuk mengantisipasi the possibility of uncollectible receivables and makes
kemungkinan tidak tertagihnya piutang dan melakukan allowances for the results of the review.
pembentukan cadangan dari hasil penelaahan tersebut.
Untuk mengurangi risiko gagal bayar atas penempatan To mitigate the default risk of banks on the Group’s
deposito berjangka pada bank. Grup memiliki kebijakan time deposits. the Company and its subsidiaries has
hanya akan menempatkan deposito berjangka pada bank policies to place its time deposits only in banks with
yang memiliki reputasi yang baik. good reputation.
Tabel di bawah ini menunjukkan risiko kredit maksimum The table below shows the maximum exposure to credit
untuk komponen-komponen dari laporan posisi keuangan risk on the components of the statement of financial
pada 31 Desember 2025 dan 2024: position as of 31 December 2025 and 2024:
2025 2024
Kas dan setara kas 826.584.741.908 783.332.056.074 Cash and cash equivalent
Piutang usaha 161.939.911.962 144.714.255.906 Trade receivables
Piutang lain-lain 49.157.870.887 30.045.808.461 Other receivables
Jumlah 1.037.682.524.757 958.092.120.441 Total
Page 269
Laporan Keuangan
Financial Report 269
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/75 Exhibit E/75
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
34. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN (Lanjutan) POLICIES (Continued)
Risiko kredit (Lanjutan) Credit risk (Continued)
Tabel di bawah ini menyajikan eksposur Grup terhadap The table below presents the Group’s exposure to
risiko kredit dan menunjukkan kualitas kredit aset credit risk and show the credit quality of the assets by
dengan menunjukkan apakah aset tersebut dikenakan indicating whether the assets are subjected to 12-
ECL 12 bulan atau ECL seumur hidup. Aset yang month ECL or lifetime ECL. Assets that are credit-
mengalami penurunan nilai kredit disajikan secara impaired are separately presented.
terpisah.
31 Desember/ December 2025
Aset keuangan pada biaya diamortisasi/
Financial assets at amortized cost
ECL selamany- ECL selamanya-
tidak ada penurunan ada penurunan
nilai/ nilai/
Lifetime ECL- Lifetime ECL-
ECL 12 bulan/ no credit Credit Jumlah/
12-month ECL impaired impaired Total
- - Cash and cash
Kas dan setara kas 826.584.741.908 826.584.741.908 equivalent
Piutang usaha - 161.939.911.962 7.579.979.963 169.519.891.925 Trade receivables
Piutang Lain-lain - 49.157.870.887 36.416.327 49.194.287.214 Other receivables
Jumlah 826.584.741.908 211.097.782.849 7.616.396.290 1.045.298.921.047 Total
31 Desember/ December 2024
Aset keuangan pada biaya diamortisasi/
Financial assets at amortized cost
ECL selamany- ECL selamanya-
tidak ada penurunan ada penurunan
nilai/ nilai/
Lifetime ECL- Lifetime ECL-
ECL 12 bulan/ no credit Credit Jumlah/
12-month ECL impaired impaired Total
Cash and cash
Kas dan setara kas 783.332.056.074 - - 783.332.056.074 equivalent
Piutang usaha - 144.714.255.906 4.267.847.614 148.982.103.520 Trade receivables
Piutang Lain-lain - 30.045.808.461 36.416.327 30.082.224.788 Other receivables
Jumlah 783.332.056.074 174.760.064.367 4.304.263.941 962.396.384.382 Total
Berikut kualitas kredit aset keuangan Grup: The following is the credit quality of the Group’s
financial assets:
31 Desember / December 2025
Level tinggi/ Level menengah/ Level bawah/ Jumlah/
High grade Medium grade Low grade Total
Cash and cash
Kas dan setara kas 826.584.741.908 - - 826.584.741.908 equivalents
Aset keuangan Other current
lancar lainnya 6.519.211.579 - - 6.519.211.579 financial asset
Piutang usaha 9.990.279.226 106.580.035.732 52.949.576.967 169.519.891.925 Trade receivables
Piutang lain-lain 30.880.305.066 9.259.793.252 9.054.189.046 49.194.287.364 Other receivables
Aset tidak lancar Other non-current
lainnya 36.114.421.959 - - 36.114.421.959 assets
Jumlah 910.088.959.738 115.839.828.984 62.003.766.013 1.087.932.554.735 Total
Page 270
270 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/76 Exhibit E/76
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
34. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN (Lanjutan) POLICIES (Continued)
Risiko kredit (Lanjutan) Credit risk (Continued)
Berikut kualitas kredit aset keuangan Grup: (Lanjutan) The following is the credit quality of the Group’s
financial assets: (Continued)
31 Desember / December 2024
Level tinggi/ Level menengah/ Level bawah/ Jumlah/
High grade Medium grade Low grade Total
Kas dan setara kas 783.332.056.074 - - 783.332.056.074 Cash and cash equivalents
Aset keuangan Other current
lancar lainnya 3.262.592.254 - - 3.262.592.254 financial asset
Piutang usaha 15.110.334.308 90.990.698.976 42.881.070.236 148.982.103.520 Trade receivables
Piutang lain-lain 9.604.840.823 2.291.391.177 18.185.992.788 30.082.224.788 Other receivables
Aset tidak lancar lainnya 40.074.986.915 - - 40.074.986.915 Other non-current assets
Jumlah 851.384.810.374 93.282.090.153 61.067.063.024 1.005.733.963.551 Total
Piutang usaha yang dinilai high grade berkaitan dengan Trade receivables assessed as high grade pertains to
piutang dari pembeli yang tidak mengalami gagal bayar; receivable from buyer that had no default in payment;
medium grade adalah piutang dari pembeli yang medium grade pertains to receivable from buyer
memiliki riwayat jatuh tempo 1 sampai 90 hari; dan low who has history of being 1 to 90 days past due;
grade berkaitan dengan piutang dari pembeli yang and low grade pertains to receivable from buyer who
memiliki riwayat jatuh tempo lebih dari 90 hari. Saldo has history of being over 90 days past due. Receivable
piutang dipantau secara teratur untuk memastikan balances are being monitored on a regular basis
pelaksanaan upaya intervensi yang diperlukan tepat to ensure timely execution of necessary intervention
waktu. Grup melakukan investigasi dan evaluasi kredit efforts. The Group perform credit investigation and
untuk setiap pembeli untuk menetapkan kapasitas evaluation of each buyer to establish paying capacity
pembayaran dan kelayakan kredit. Grup akan menilai and creditworthiness. The Group will assess the
kolektibilitas piutang dan memberikan penyisihan collectibility of its receivables and provide a
penyisihan setelah akun tersebut dianggap mengalami corresponding allowance provision once the account is
penurunan nilai. Grup menilai kualitas kredit dari kas considered impaired. The Group assessed the credit
yang tidak dibatasi penggunaannya sebagai kualitas quality of unrestricted cash as high grade since this is
tinggi karena disimpan pada bank terkemuka dengan deposited with reputable banks with low probability of
kemungkinan kebangkrutan yang rendah. insolvency.
Risiko likuiditas Liquidity risk
Risiko kredit untuk aset lancar lainnya dan aset tidak The credit risk for other current assets and other non-
lancar lainnya - jaminan yang dapat dikembalikan current assets - refundable deposits is considered
dianggap dapat diabaikan dikarenakan entitas yang negligible because this was due from entities that are
secara umum memiliki finansial yang stabil. generally financially stable.
Grup mengelola profil likuiditasnya untuk dapat The Group manages its liquidity profile to be able to
mendanai pengeluaran modalnya dan mengelola utang finance its capital expenditures and service its
yang jatuh tempo dengan mengatur kas dan maturing debts by maintaining sufficient cash and the
ketersediaan pendanaan melalui jumlah komitmen availability of funding through an adequate amount of
fasilitas kredit yang cukup. committed credit facilities.
Perusahaan dan Entitas Anak secara reguler The Company and its subsidiaries regularly evaluates
mengevaluasi proyeksi arus kas dan terus-menerus its projected cash flow information and continuously
menilai kondisi pasar keuangan untuk mengidentifikasi assesses conditions in the financial markets for
kesempatan dalam penggalangan dana. opportunities to pursue fundraising initiatives.
Page 271
Laporan Keuangan
Financial Report 271
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/77 Exhibit E/77
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
34. TUJUAN DAN KEBIJAKAN MANAJEMEN RISIKO 34. FINANCIAL RISK MANAGEMENT OBJECTIVES AND
KEUANGAN (Lanjutan) POLICIES (Continued)
Risiko likuiditas (Lanjutan) Liquidity risk (Continued)
Tabel di bawah ini merupakan jadwal jatuh tempo The table below summarizes the maturity periods of
liabilitas keuangan Perusahaan dan Entitas Anak the Company and its subsidiaries’ financial liabilities
berdasarkan pembayaran kontraktual semula yang tidak based on original contractual undiscounted amounts to
didiskontokan: be paid:
31 December 2025/ 31 December 2025
Dalam waktu 1 tahun/ Lebih dari 1 tahun/ Jumlah/
Within 1 year More than 1 year Total
Utang usaha 81.660.213.509 - 81.660.213.509 Trade payables
Utang lain-lain 23.743.315.736 - 23.743.315.736 Other payabales
Beban akrual 72.836.181.463 - 72.836.181.463 Accruals
Liabilitas sewa 21.812.380.174 118.334.918.295 140.147.298.469 Lease liabilities
Jumlah 200.052.090.882 118.334.918.295 118.334.918.295 Total
31 December 2024/ 31 December 2024
Dalam waktu 1 tahun/ Lebih dari 1 tahun/ Jumlah/
Within 1 year More than 1 year Total
Utang usaha 30.881.579.952 - 30.881.579.952 Trade payables
Utang lain-lain 14.708.865.083 - 14.708.865.083 Other payabales
Beban akrual 28.573.978.375 - 28.573.978.375 Accruals
Liabilitas sewa 19.500.574.022 53.531.597.866 73.032.171.888 Lease liabilities
Jumlah 93.664.997.432 53.531.597.866 147.196.595.298 Total
35. MANAJEMEN PERMODALAN 35. CAPITAL MANAGEMENT
Tujuan utama dari pengelolaan modal Grup adalah untuk The main objective of the Group capital management
memastikan bahwa dipertahankannya peringkat kredit is to ensure that it maintains a strong credit rating and
yang kuat dan rasio modal yang sehat agar dapat healthy capital ratios in order to support its business
mendukung kelancaran usahanya dan memaksimalkan and maximize shareholder value.
nilai dari pemegang saham.
Grup mengelola struktur modalnya dan membuat The Group manage its capital structure and make
penyesuaian-penyesuaian sehubungan dengan adjustments with respect to changes in economic
perubahan kondisi ekonomi dan karakteristik dari risiko conditions and the characteristics of its business risks,
usahanya, Agar dapat menjaga dan menyesuaikan in order to maintain and adjust its capital structure.
struktur modalnya. Grup akan menyesuaikan jumlah dari the Group may adjust the amount of dividend payments
pembayaran dividen kepada para pemegang saham atau to shareholders or return capital structure. No changes
tingkat pengembalian modal, tidak ada perubahan have been made in the objectives, policies and
dalam tujuan. kebijakan dan proses dan sama seperti processes as they have been applied in previous years.
penerapan tahun-tahun sebelumnya.
31 December 2025/ 31 December 2024/
31 December 2025 31 December 2024
Pinjaman 1.215.640.066.746 1.090.896.287.270 Debts
Dikurangi : kas dan setara kas (826.584.741.908) (783.332.056.074) Less: Cash and cash equivalents
Pinjaman neto 389.055.324.838 307.564.231.196 Net debt
Jumlah ekuitas (2.394.507.016.511) (2.147.735.684.721) Total equity
Rasio utang terhadap modal (%) -16% -14% Debt to equity (%)
Page 272
272 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/78 Exhibit E/78
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
36. INFORMASI SEGMEN 36. SEGMENTS INFORMATION
31 Desember 2025/ 31 December 2025
Pelayanan
kesehatan/
Healthcare Lainnya/ Eliminasi/
services Others Elimination Total
Pendapatan 1.662.421.301.625 211.180.133.646 (259.260.663.759) 1.614.340.771.512 Revenues
Beban pokok
pendapatan (939.313.766.604) (177.316.835.825) 246.782.297.027 (869.848.305.402) Cost of Revenues
Laba bruto 723.107.535.021 33.863.297.821 (12.478.366.732) 744.492.466.110 Gross profit
Beban usaha (620.736.132.670) (24.556.845.346) 16.730.053.021 (628.562.924.995) Operating expenses
Penghasilan keuangan 22.833.605.960 97.239.634 - 22.930.845.594 Finance income
Beban keuangan (67.298.233.731) (290.540.121) 61.380.962 (67.527.392.890) Finance costs
Penghasilan (beban)
(25.048.656.349) (12.970.598.448) 11.968.910.531 (26.050.344.266) Other income (charges)
operasi lainnya
Laba sebelum pajak 32.858.118.231 (3.857.446.460) 16.281.977.782 45.282.649.553 Profit before tax
Beban pajak
penghasilan (14.664.076.545) (945.430.475) - (15.609.507.020) Income tax expenses
Laba tahun berjalan 18.194.041.686 (4.802.876.935) 16.281.977.782 29.673.142.533 Profit for the year
Penghasilan Other comprehensive
komprehensif lain 234.611.626.618 (1.473.048.710) - 233.138.577.908 income
Jumlah laba
komprehensif pada Total comprehensive
tahun berjalan 252.805.668.304 (6.275.925.645) 16.281.977.782 262.811.720.441 income for the year
Jumlah aset 5.030.918.162.976 387.578.562.815 (1.402.067.290.648) 4.016.429.435.143 Total assets
Jumlah liabilitas 2.114.900.993.357 250.308.423.694 (743.286.998.420) 1.621.922.418.631 Total liabilities
Informasi segmen Other segment
lainnya: information:
Pengeluaran modal 294.221.671.641 84.705.439 - 294.306.377.080 Capital expenditures
Penyusutan dan Depreciation and
amortisasi 72.398.811.838 6.919.818.160 - 79.318.629.998 amortization
31 Desember 2024/ 31 December 2024
Pelayanan
kesehatan/
Healthcare Lainnya/ Eliminasi/
services Others Elimination Total
Pendapatan 1.645.708.325.784 175.347.264.944 (266.370.580.392) 1.554.685.010.336 Revenues
Beban pokok
pendapatan (954.921.020.326) (150.763.167.296) 258.136.192.778 (847.547.994.844) Cost of Revenues
Laba bruto 690.787.305.458 24.584.097.648 (8.234.387.614) 707.137.015.492 Gross profit
Operating expenses
Beban usaha (587.878.271.350) (27.838.006.018) 7.645.844.371 (608.070.432.997)
Finance income
Penghasilan keuangan 18.491.219.751 149.616.874 - 18.640.836.625
Beban keuangan (67.897.527.073) (155.921.382) - (68.053.448.455) Finance costs
Penghasilan (beban)
(8.837.617.927) (5.035.261.011) 2.812.639.782 (11.060.239.156) Other income (charges)
operasi lainnya
Laba sebelum pajak 44.665.108.859 (8.295.473.889) 2.224.096.539 38.593.731.509 Profit before tax
Beban pajak
penghasilan (19.067.980.258) (629.966.984) - (19.697.947.242) Income tax expenses
Laba tahun berjalan 25.597.128.601 (8.925.440.873) 2.224.096.539 18.895.784.267 Profit for the year
Penghasilan Other comprehensive
komprehensif lain (3.117.429.829) (914.575.214) - (4.032.005.043) income
Jumlah laba
komprehensif pada Total comprehensive
tahun berjalan 22.479.698.772 (9.840.016.087) 2.224.096.539 14.863.779.224 income for the year
Page 273
Laporan Keuangan
Financial Report 273
These Consolidated Financial Statements are originally Issued
in Indonesian language
Ekshibit E/79 Exhibit E/79
PT BUNDAMEDIK Tbk DAN ENTITAS ANAKNYA PT BUNDAMEDIK Tbk AND ITS SUBSIDIARIES
CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
36. INFORMASI SEGMEN (Lanjutan) 36. SEGMENTS INFORMATION (Continued)
31 Desember 2024/ 31 December 2024
Pelayanan
kesehatan/
Healthcare Lainnya/ Eliminasi/
services Others Elimination Total
Jumlah aset 4.407.722.937.143 355.648.110.160 (1.317.010.143.555) 3.446.360.903.748 Total assets
Jumlah liabilitas 1.779.350.874.631 215.743.278.220 (696.468.933.824) 1.298.625.219.027 Total liabilities
Informasi segmen Other segment
lainnya: information:
Pengeluaran modal 163.357.162.218 4.531.102.590 - 167.888.264.808 Capital expenditures
Penyusutan dan Depreciation and
amortisasi 95.177.492.806 6.032.997.404 (6.125.258.648) 95.085.231.562 amortization
37. PENGUNGKAPAN TAMBAHAN ATAS ARUS KAS 37. SUPPLEMENTAL DISCLOSURES ON CASH FLOWS
Aktivitas non kas adalah sebagai berikut: Non-cash activities are as follows:
31 Desember 2025/ 31 Desember 2024/
31 December 2025 31 December 2024
Penambahan aset tetap melalui uang muka Addition fixed assets through purchase
pembelian 58.236.656.377 advances
Penambahan aset tetap melalui liabilitas Addition fixed assets through
sewa - 1.063.430.450 lease liabilities
Penambahan aset tetap melalui utang Addition fixed assets through
pembelian aset tetap - 3.412.325.003 liabilities for purchase of fixed assets
Jumlah 58.236.656.377 4.475.755.453 Total
38. PENERBITAN LAPORAN KEUANGAN KONSOLIDASIAN 38. ISSUANCE OF CONSOLIDATED FINANCIAL STATEMENTS
Laporan keuangan konsolidasian ini telah diotorisasi These consolidated financial statements have been
untuk diterbitkan oleh Direksi Perusahaan. selaku pihak authorized to be published by the Director. as the party
yang bertanggung jawab atas penyusunan dan responsible for the preparation and completion of the
penyelesaian laporan keuangan konsolidasian. pada consolidated financial statements on 31 March 2026.
tanggal 31 Maret 2026.
Page 274
274 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
Page 275
Laporan Keuangan Financial Report 275
Page 276
276 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
Page 277
Laporan Keuangan Financial Report 277
Page 278
278 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
IBDO
Halaman 5 Page 5
Tanggung jawab manajemen dan pihak yang Responsibilities of management and those charged
bertanggung jawab atas tata kelola terhadap laporan with governance for the consolidated financial
keuangan konsolidasian (Lanjutan) statements (Continued)
Pihak yang bertanggung jawab atas tata kelola Those charged with governance are responsible for
bertanggung jawab untuk mengawasi proses pelaporan overseeing the Group's financial reporting process.
keuangan Grup.
Tanggung jawab auditor terhadap audit atas laporan Auditors' responsibilities for the audit of the
keuangan konsolidasian consolidated financial statements
Tujuan kami adalah untuk memperoleh keyakinan Our objectives are to obtain reasonable
memadai tentang apakah laporan keuangan assurance about whether the consolidated
konsolidasian secara keseluruhan bebas dari kesalahan financial statements as a whole are free from
penyajian material, baik yang disebabkan oleh material misstatement, whether due to fraud or
kecurangan maupun kesalahan, dan untuk menerbitkan error, and to issue an auditors' report that includes
laporan auditor yang mencakup opini kami. Keyakinan our op1n1on. Reasonable assurance is a high
memadai merupakan suatu tingkat keyakinan tinggi, level of assurance, but is not a guarantee that
namun bukan merupakan suatu jaminan bahwa audit an audit conducted in accordance with Standards on
yang dilaksanakan berdasarkan Standar Audit akan Auditing will always detect a material misstatement
selalu mendeteksi kesalahan penyajian material ketika when it exists. Misstatements can arise from fraud or
hal tersebut ada. Kesalahan penyajian dapat error and are considered material if, individually or in
disebabkan oleh kecurangan maupun kesalahan dan the aggregate, they could reasonably be expected
dianggap material jika, baik secara individual maupun to influence the economic decisions of users
secara agregat, dapat diekspektasikan secara wajar taken on the basis of these consolidated financial
akan mempengaruhi keputusan ekonomi yang diambil statements.
oleh pengguna berdasarkan laporan keuangan
konsolidasian tersebut.
Sebagai bagian dari suatu audit berdasarkan Standar As part of an audit in accordance with Standards on
Audit, kami menerapkan pertimbangan profesional dan Auditing, we exercise professional judgement and
mempertahankan skeptisisme profesional selama audit. maintain professional scepticism throughout the audit.
Kami juga: We also:
• Mengidentifikasi dan menilai risiko kesalahan • Identify and assess the risks of material
penyajian material dalam laporan keuangan misstatement of the consolidated financial
konsolidasian, baik yang disebabkan oleh statements, whether due to fraud or error,
kecurangan maupun kesalahan, mendesain dan design and perform audit procedures
melaksanakan prosedur audit yang responsif responsive to those risks, and obtain audit
terhadap risiko tersebut, serta memperoleh bukti evidence that is sufficient and appropriate to
audit yang cukup dan tepat untuk menyediakan provide a basis for our opinion. The risk of
basis bagi opini kami. Risiko tidak terdeteksinya not detecting a material misstatement
kesalahan penyajian material yang disebabkan resulting from fraud is higher than for one
oleh kecurangan lebih tinggi dari yang disebabkan resulting from error, as fraud may involve
oleh kesalahan, karena kecurangan dapat collusion, forgery, intentional om1ss10ns,
melibatkan kolusi, pemalsuan, penghilangan misrepresentations, or the override of internal
secara sengaja, pernyataan salah, atau control.
pengabaian pengendalian internal.
• Memperoleh suatu pemahaman tentang • Obtain an understanding of internal control
pengendalian internal yang relevan dengan audit relevant to the audit in order to design audit
untuk mendesain prosedur audit yang tepat sesuai procedures that are appropriate in the
dengan kondisinya, tetapi bukan untuk tujuan circumstances, but not for the purpose of
menyatakan opini atas keefektivitasan expressing an opinion on the effectiveness of
pengendalian internal Grup. the Group internal control.
TANUBRATA SUTANTO FAHMI BAMBANG & REKAN
Tanubrata Sutanto Fahrni Bambang & Rekan (Certified Public Accountant), an Indonesian partnership, is a member of BDO International Limited, a UK
company limited by guarantee, and forms part of the international BOO network of Independent member firms.
Page 279
Laporan Keuangan Financial Report 279
Page 280
280 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
Page 281
Laporan
These Financial Statements Keuangan
are originally
281
issued
Financial Report
in Indonesian Language
Ekshibit E Exhibit E
PT HANKING MAKMUR NICKELSMELT PT HANKING MAKMUR NICKELSMELT
CATATAN ATAS LAPORAN KEUANGAN NOTES TO THE FINANCIAL STATEMENTS
UNTUK TAHUN YANG BERAKHIR 31 DESEMBER 2025 FOR THE YEAR ENDED 31 DECEMBER 2025
(Dinyatakan dalam Rupiah, kecuali dinyatakan lain) (Expressed in Rupiah, unless otherwise stated)
Page 282
282 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
Page 283
Laporan Keuangan Financial Report 283
Page 284
284 Referensi SEOJK 16/SEOJK.04/2021
Reference to SEOJK 16/SEOJK.04/2021
Page 285
Laporan Keuangan Financial Report 285
Page 286
2025 Laporan Tahunan Annual Report Jl. Teuku Cik Ditiro No.28 Menteng, Jakarta Pusat, 10350 1-500-799
Names mentioned 219 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Bundamedik Tbk’s
p.2 ×2
unresolved
—
Subsidiaries and Associated Companies
p.4
unresolved
—
Kronologi Pencatatan
p.4
unresolved
org
Chronology of Share and Other Securities
p.4
unresolved
—
Listing
p.4
unresolved
—
Kantor Akuntan Publik
p.4
unresolved
org
Kantor Akuntan Publik Awards
p.4
unresolved
—
Solvency
p.4
unresolved
—
Ikatan yang Material untuk Investasi Barang
p.4
unresolved
person
Issuers
· Sekretaris Perusahaan
p.5
unresolved
org
Indonesia Stock Exchange
p.8 ×6
unresolved
person
Pramono Anung
p.12 ×2
unresolved
org
PT Bundamedik Tbk’s Stunting Prevention Program
p.13
unresolved
org
Bank Indonesia
p.14
unresolved
person
GCG
· Komisaris
p.21
unresolved
person
Adlan Yulizar
· Notaris
p.28 ×3
unresolved
org
Kementerian Kehakiman
p.28
unresolved
org
Ministry of Justice
p.28
unresolved
org
PT Prima
· Director
p.32
unresolved
org
PT Prima Dental
p.32 ×2
unresolved
org
PT Morula Indonesia
p.32 ×12
unresolved
org
PT Visiscan Indonesia
p.32 ×3
unresolved
org
PT Sasana
p.32 ×2
unresolved
org
PT Diagnos Laboratorium Utama. Australia.
p.32
unresolved
org
PT Sasana Mitra Bunda.
p.32 ×2
unresolved
org
PT Bunda Minang Citra.
· Direktur
p.32 ×3
unresolved
org
PT Bunda
p.33 ×19
unresolved
org
PT Bunda Graha
p.33 ×2
unresolved
org
PT Diagnos Committee
p.33
unresolved
org
Laboratorium Utama Tbk
p.33 ×2
unresolved
org
PT Bunda Medika Wisesa.
p.33 ×5
unresolved
org
PT Bunda Medika
p.33 ×6
unresolved
org
Healthcare Investment Group Pte. Ltd.
p.33 ×2
unresolved
org
PT BMHS Diklat Indonesia
p.33 ×4
unresolved
org
PT Pintu Ilmu
p.33 ×7
unresolved
org
PT BMHS Diklat
p.33 ×4
unresolved
org
PT Bunda Global
p.33 ×2
unresolved
org
PT Bunda Medika Wisesa Life Support
p.39
unresolved
person
dr. Farabi
p.47
unresolved
person
Dr. Farabi Clinic
p.47
unresolved
org
PT Diagnos
· President Director
p.48 ×5
unresolved
org
Laboratorium Utama Officer Tbk
p.48 ×2
unresolved
person
Hosp.
· Director
p.48 ×5
unresolved
org
PT Director RSIA
p.48
unresolved
org
PT Daima
p.52
unresolved
org
PT Citra Prima
p.52
unresolved
org
PT Omedata Electric Gajah
p.53
unresolved
org
PT Omedata Electric Gajah Tunggal Group
p.53
unresolved
org
PT PT Bunda Global Pertama
· Direktur
p.53 ×2
unresolved
org
CV Buana Sejahtera
· Direktur
p.53 ×2
unresolved
org
PT Timur Prima
· Direktur
p.53
unresolved
org
PT Timur Prima Utama
p.53
unresolved
org
PT Tenaga Satu Persada
· Komisaris
p.53
unresolved
org
Persada
· Commissioner
p.53 ×2
unresolved
org
PT Tenaga Prima Persada
p.53 ×2
unresolved
org
PT Diagnos Laboratorium
p.53 ×2
unresolved
org
PT Prima Satu Persada
p.53
unresolved
org
PT Agung
p.53
unresolved
org
PT Morula
p.53 ×3
unresolved
org
PT Agung Multi Berjaya
p.53
unresolved
org
PT Vizitrip
p.53
unresolved
org
PT Bunda Minang
p.53 ×2
unresolved
org
PT Vizitrip Global Tour
p.53
unresolved
org
PT Bunda Ipiti
p.53 ×2
unresolved
org
PT Bunda Ipiti Investama
p.53
unresolved
org
PT CRM Bangun Persada
p.53
unresolved
org
PT Daima Citra Prima
p.53 ×3
unresolved
org
PT CRM Bangun CV Bunda Lenen Utama. Beliau
p.53
unresolved
org
Yayasan Yayasan Daima Indonesia
p.53
unresolved
person
Commander CV Bunda Lenen Utama. Currently
· Komisaris
p.53
unresolved
org
Yayasan Daima Indonesia
p.53
unresolved
org
PT Citra Ananda
p.53 ×5
unresolved
org
PT Brandina Kuliner
p.53
unresolved
org
PT Bunda Global Pharma
p.53 ×3
unresolved
org
PT Moosa Genetika Farmindo
p.53
unresolved
org
PT Bunda Medika Bekasi
p.53 ×3
unresolved
org
PT Moosa Genetika
p.53
unresolved
org
PT Bunda Medika Dewata
p.54 ×3
unresolved
org
PT Jolin Sapta Medika
p.54 ×4
unresolved
org
PT Bunda Graha Properti
p.54 ×3
unresolved
org
PT Bunda Medika Klinik
p.54 ×3
unresolved
org
Menteri Luar Negeri
p.54
unresolved
org
Ministry of Foreign Affairs Luar Negeri Indonesia
p.54
unresolved
org
Eksekutif Independen Gurin Energy Pte Ltd
p.55
unresolved
org
Gurin Energy Pte. Ltd.
p.55
unresolved
org
Kementerian Kesehatan
p.55 ×2
unresolved
org
Ministry of Health
p.55 ×2
unresolved
org
Direktorat Jenderal Kefarmasian dan Alat Kesehatan
p.55
unresolved
person
Prof. Dr. dr. I.G. Ng. Ngoerah
p.55
unresolved
org
Ministry of Education
p.55
unresolved
org
PT Pertamina Bina Medika
p.55
unresolved
org
PT Pertamina Bina Medika IHC IHC
p.55
unresolved
person
Executive
· Direktur
p.56
unresolved
—
Kumparan
· Commissioner
p.57 ×2
unresolved
—
Telkomsel
· Chairman
p.57 ×2
unresolved
—
GoTo
· Ketua
p.57
unresolved
org
Minister of Tourism and Creative Economy
p.57
unresolved
org
Menteri Pariwisata
p.57
unresolved
org
Pariwisata
p.57
unresolved
person
Commisioner
· Komisaris
p.57
unresolved
org
PT Danareksa Sekuritas Sekuritas
· Direktur
p.57
unresolved
org
Bank Tabungan Pensiunan Nasional Tbk
p.57 ×2
unresolved
org
Tabungan Pensiunan Nasional Tbk
p.57
unresolved
org
PT Bukit
p.57
unresolved
org
PT Pfizer
p.59
unresolved
org
PT Pfizer Indonesia Indonesia
p.59
unresolved
org
PT Merck Sharp
p.59 ×2
unresolved
org
PT Darya Varia Unilab
p.59
unresolved
org
PT Metro
p.59 ×2
unresolved
org
PT Metro Drug Indonesia- Zuellig Group
p.59
unresolved
org
PT Anugerah Pharmindo Lestari-Zuellig
p.59
unresolved
org
PT Bernofarm Group
p.59
unresolved
org
PT Bernofarm
p.59
unresolved
org
PT Darya
p.59
unresolved
org
Darya–Varia Laboratoria
p.59
unresolved
org
PT Darya-Varia
p.59
unresolved
org
PT Minang Citra
p.59
unresolved
org
PT Prima Dental Medika
p.59 ×2
unresolved
org
PT Emergency
p.59 ×3
unresolved
org
PT Medika
p.59 ×3
unresolved
org
PT Medika Sejahtera Bersama.
p.59 ×4
unresolved
org
PT Honoris Industry
p.60 ×2
unresolved
org
PT Metro Drug Indonesia
p.61
unresolved
org
PT Lafarge Cement
p.61
unresolved
org
PT Lafarge Cement Indonesia
p.61
unresolved
org
Holcim Indonesia Tbk
p.61 ×4
unresolved
org
PT Sodexo
· Director
p.61
unresolved
org
PT Sodexo Indonesia
p.61
unresolved
org
PT Bundamedik Competency Dictionary
p.67
unresolved
org
Ministry of Health Accreditation
p.68
unresolved
org
PT Morula IVF
p.70 ×15
unresolved
org
PT Morula IVF Surabaya
p.70
unresolved
org
PT Prima Dental Indonesia
p.70
unresolved
org
PT Empi
p.70
unresolved
org
Margonda Sejahtera Utama Tbk
p.70
unresolved
org
PT Sasana Husada Citra Medika
p.70
unresolved
org
PT Citra
p.70
unresolved
org
PT Global Sekawan
p.70
unresolved
org
PT Morula Bunda
p.70 ×2
unresolved
org
PT Jolin Sapta
p.70 ×2
unresolved
org
PT Daima Citra Prima Sini Suhelmi
p.70
unresolved
org
PT Sasana Husada Ietje Ika Rizal Sini
p.70
unresolved
—
SIni
p.70
unresolved
org
PT Bunda Ipiti Minang Citra
p.70
unresolved
org
PT Visiscan
p.71
unresolved
org
PT Sasana Mitra
p.71
unresolved
org
PT Diagnos Penunjang Kesehatan
p.71
unresolved
—
Laboratorium
p.71
unresolved
org
Operational Utama Tbk
p.71
unresolved
org
PT Medika Sejahtera
p.72
unresolved
org
PT Empi Pharma
p.72
unresolved
org
Accounting Firm Tanubrata Tanubrata Sutanto Fahmi Bambang & Rekan
p.73
unresolved
org
Sutanto Fahmi Bambang & Rekan
p.73
unresolved
org
BDO International Limited
p.73 ×2
unresolved
org
Tanubrata Sutanto Fahmi Bambang & Rekan
p.73 ×2
unresolved
org
Tanubrata Sutanto Fahmi Bambang
p.73
unresolved
person
Nama Akuntan Publik Susanto Bong
p.73
unresolved
person
CPA
p.73
unresolved
—
Penjamin Pelaksana
· Biro Administrasi Efek
p.73
unresolved
org
Managing Underwriter Makes & Partners
p.73
unresolved
org
PT Datindo Entrycom
p.73 ×2
unresolved
org
PT Ciptadana Sekuritas Menara Batavia
p.73
unresolved
person
K.H. Mas Mansyur
p.73
unresolved
org
Menteri Kesehatan
p.97
unresolved
org
Minister of Health Regulation
p.97
unresolved
org
Financial Services Authority
p.97 ×2
unresolved
person
Jose Dima Satria
p.104 ×2
unresolved
org
Kantor Akuntan Publik Tanubrata Sutanto Fahmi Bambang & Rekan
p.105
unresolved
org
Kantor Akuntan Publik Tanubrata Sutanto Fahmi Bambang
p.105
unresolved
person
Emilia Rouli
· Direktur
p.107 ×2
unresolved
person
Shubhasish Chattoraj
p.108 ×3
unresolved
person
Cuncun Wijaya
· Director
p.108 ×2
unresolved
org
Menteri Hukum dan Hak Asasi Manusia Republik Indonesia dan Otoritas
p.108
unresolved
org
Minister of Law
p.108
unresolved
person
Work Guidelines
· Komisaris
p.110
unresolved
person
Independensi
· Komisaris Independen
p.111
unresolved
person
BoC-BoD
· Direktur
p.111
unresolved
—
Presidium BoC
· Komisaris
p.112
unresolved
person
Wishnutama
· Komisaris Independen
p.112
unresolved
—
Shubhasish Chattoraj*2
· 4
p.112
unresolved
person
Sirkuler
· Komisaris
p.113
unresolved
person
BMHS
· Komisaris
p.114
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.